

```
SQ Sequence 16 BP; 4 A; 5 C; 2 G; 4 T; 0 U; 1 Other;
Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 768 TGATGACATACGTGGC 783
Db 16 TGATGACANATGTGGC 1

RESULT 189
ADF92303
ID ADF92303 standard; DNA; 16 BP.
XX
AC ADF92303;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human cytokeratin 19-related loop F PCR primer - SEQ ID 391.
XX
KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW PCR; loop F.
XX
OS Homo sapiens.
XX
XX WO2003097878-A1.
XX
PD 27-NOV-2003.
XX
PP 20-MAY-2003; 2003WO-JP006256.
XX
PR 21-MAY-2002; 2002JP-00145689.
PR 17-JUN-2002; 2002JP-00175271.
PR 09-JUL-2002; 2002JP-00199759.
XX
PA (SYSM-) SYSMEX CORP.
XX
PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
XX
WPI; 2004-012543/01.
DR
PT LAMP nucleic acid amplification primers for detection of cytokeratin
PT expression as indicator in diagnosis of tumour metastasis.
XX
PS Claim 19; SEQ ID NO 391; 266pp; Japanese.
XX
CC The invention relates to novel nucleic acid amplification primers for the
CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
CC (loop mediated isothermal amplification) method. The primers of the
CC invention may be useful for the detecting cytokeratin 18-20 expression as
CC an indicator for the diagnosis of tumour metastasis, particularly
CC prostate cancer and lymphoma. The amplification using the primers is
CC highly efficient and allows very sensitive detection of tumour
CC metastasis. The current sequence is that of the human CK19-related PCR
CC primer of the invention.
XX
SQ Sequence 16 BP; 0 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 42 GGCCACTGCTTCTGG 56
Db 1 GGCCCTGCTTCTGG 15

RESULT 190
ADR06487
ID ADR06487 standard; DNA; 16 BP.
XX
```

```
AC ADR06487;
XX
DT 21-OCT-2004 (first entry)
XX
DE Murine sequence tag.
XX
KW Identification; gene expression; cell differentiation;
KW stem cell differentiation; murine; ss.
XX
OS Mus musculus.
XX
PN WO2004065553-A2.
XX
PD 05-AUG-2004.
XX
PF 16-JAN-2004; 2004WO-US001482.
XX
PR 16-JAN-2003; 2003US-0440510P.
XX
PA (HEAL-) HEALTH RES INC.
XX
PI Pruitt SC, Maslov A;
XX
XX WPI; 2004-571677/55.
XX
PT Identifying genes expressed during differentiation of a cell, useful,
PT e.g. in research into mechanisms leading to differentiation of stem
PT cells, comprises integrating a cell lineage targeting vector into the
PT genome of a host cell,.
XX
PS Example 6; SEQ ID NO 38; 45pp; English.
XX
CC The present invention relates to a method (M1) for identifying genes
CC expressed during cell differentiation. The method is useful in research
CC into the mechanisms that lead to differentiation of stem cells. Knowledge
CC of these mechanisms is important in understanding embryonic development
CC and homeostasis within somatic tissues, and is also relevance to the
CC therapeutic use of stem cells. The method comprises: integrating into a
CC site in a host cell genome, a cell lineage targeting vector comprising a
CC pair of recombinaase recognition sites flanking one or more
CC polyadenylation sites, a first selectable marker placed downstream or
CC between the two recombinaase recognition sites, a reporter gene placed
CC downstream of the recombinaase recognition sites, and a cell lineage
CC specific gene promoter placed upstream of the recombinaase recognition
CC sites or a cell specific lineage gene placed downstream of the
CC recombinaase recognition sites; amplifying cells generated from the host
CC cell; integrating into the genome of a plurality of the amplified cells,
CC a gene-trap vector comprising a splice acceptor, a type IIS restriction
CC endonuclease cleavage site, one or more polyadenylation sites, a second
CC selectable marker and a splice donor; allowing the cells to differentiate
CC ; isolating cells in which the reporter gene is expressed indicating
CC expression of the cell lineage specific gene; and identifying trapped
CC genes in the isolated cells. The present sequence was used to illustrate
CC the invention.
XX
SQ Sequence 16 BP; 5 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1216 AGGTATGATGAAAGG 1230
Db 1 AGGTATGATGACAGG 15

Search completed: May 13, 2005, 11:26:56
Job time : 4 secs
```

DR WPI; 2003-175124/17.
 XX Novel tumor endothelial marker 7 alpha polypeptide and polynucleotide
 PT useful for diagnosing, preventing and treating e.g. cancer, osteoporosis,
 PT diseases of the lung, heart, kidney and inflammatory diseases.
 XX Example 1; Page 78; 128pp; English.
 PS
 XX The present invention relates to novel murine or human tumour endothelial
 CC marker 7 alpha (TEM7alpha) proteins and polynucleotides encoding such
 CC proteins. Sequences of the inventions are useful for treating, preventing
 CC or ameliorating medical conditions or disorders, especially osteoporosis
 CC or osteoporosis and also for diagnosing a pathological condition or a
 CC susceptibility to a pathological condition. They are useful as surrogate
 CC markers for the treatment or diagnosis of cancer diseases, inflammatory
 CC diseases such as rheumatoid arthritis and inflammatory bowel disease,
 CC myocardial infarction and congestive heart failure, diseases involving
 CC the lung including asthma, bronchospasm and acute respiratory distress
 CC syndrome and diseases involving the kidney including polycystic kidney
 CC disease and acute renal failure. TEM7alpha polypeptides play a role in
 CC the control of angiogenesis in inflammatory diseases. They are also
 CC useful in gene therapy. The present sequence is human TEM7alpha
 CC exon6/intron6 junction DNA. This sequence is used in the exemplification
 CC of the invention
 XX
 SQ Sequence 15 BP; 8 A; 1 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1186 ACTACTCTCTTGTA 1200
 DB 15 ACTACTCTCTTGTA 1
 RESULT 187
 ADF92297
 ID ADF92297 standard; DNA; 15 BP.
 XX
 AC ADF92297;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human cytokeratin 19-related loop F PCR primer - SEQ ID 385.
 XX human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
 KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
 KW PCR; loop F.
 XX
 OS Homo sapiens.
 XX
 PN WO2003097878-A1.
 XX
 PD 27-NOV-2003.
 XX
 PF 20-MAY-2003; 2003WO-JP006256.
 XX
 PR 21-MAY-2002; 2002JP-00145689.
 PR 17-JUN-2002; 2002JP-00175271.
 PR 09-JUL-2002; 2002JP-00199759.
 XX
 PA (SYSM-) SYSMEX CORP.
 XX
 PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
 XX
 DR WPI; 2004-012543/01.
 XX
 XX LAMP nucleic acid amplification primers for detection of cytokeratin
 PT expression as indicator in diagnosis of tumour metastasis.
 XX
 PS Claim 19; SEQ ID NO 385; 266pp; Japanese.

XX The invention relates to novel nucleic acid amplification primers for the
 CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
 CC (loop mediated isothermal amplification) method. The primers of the
 CC invention may be useful for the detecting cytokeratin 18-20 expression as
 CC an indicator for the diagnosis of tumour metastasis, particularly
 CC prostate cancer and lymphoma. The amplification using the primers is
 CC highly efficient and allows very sensitive detection of tumour
 CC metastasis. The current sequence is that of the human CK19-related PCR
 CC primer of the invention.
 XX
 SQ Sequence 15 BP; 1 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 41 AGGCCACTGCTTCTG 55
 DB 1 AGGCCCTGCTTCTG 15
 RESULT 188
 AAH91807/C
 ID AAH91807 standard; DNA; 16 BP.
 XX
 AC AAH91807;
 XX
 DT 09-OCT-2001 (first entry)
 XX
 DE Human inflammatory bowel disease associated polymorphic site #882.
 XX
 KW Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
 KW single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
 KW chromosome 5q31-33; forensic test; gene therapy; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 8
 FT /*tag= a
 FT /note= "SNP, optionally A or C at this position"
 XX
 PN WO200142511-A2.
 XX
 PD 14-JUN-2001.
 XX
 PF 11-DEC-2000; 2000WO-US033632.
 XX
 PR 10-DEC-1999; 99US-0170257P.
 PR 10-APR-2000; 2000US-0196046P.
 XX
 PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
 XX
 PI Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;
 XX
 DR WPI; 2001-367874/38.
 XX
 PT Testing for the presence of polymorphisms associated with inflammatory
 PT bowel disease, using a hybridization assay.
 XX
 PS Claim 1; Page 75; 463pp; English.
 XX
 CC The present invention describes a method for detecting the presence of
 CC polymorphisms associated with inflammatory bowel diseases such as
 CC ulcerative colitis and Crohn's disease. The methods can be used to detect
 CC the presence of genetic polymorphisms associated with inflammatory bowel
 CC disease and correlating their occurrence with disease states. They may be
 CC used in this way for phenotypic correlations, forensics, paternity
 CC testing, medicine and genetic analysis. The present sequence is a
 CC polymorphic site described in the exemplification of the invention
 XX

Best Local Similarity 93.3%; Pred. No. 1e+02; Mismatches 14; Conservative 0; Indels 1; Gaps 0;

QY 1040 AAGTTTCTTTT 1054
 DB 15 AAGTTTCTTTT 1

RESULT 185
 AAH84366/c
 ID AAH84366 standard; cDNA; 15 BP.
 AC AAH84366;
 XX
 DT 21-SEP-2001 (first entry)
 XX
 DE Human cell death protective cDNA clone CNI-00723 ORF51, SEQ:460.
 XX
 KW Cell death protective; apoptosis; necrosis; human; drug screening;
 KW Cell death-associated disorder; central nervous system disorder;
 KW psychiatric disorder; neurological disorder; ischaemia-related disorder;
 KW stroke; cerebral infarction; ischaemic encephalopathy;
 KW neurodegenerative disorder; Alzheimer's disease; Huntington's disease;
 KW Parkinson's disease; infection; meningitis; malaria; trypanosomiasis;
 KW vascular disease; ophthalmological disorder; diabetic retinopathy;
 KW macular degeneration; hypertension; myocardial infarction;
 KW atherosclerosis; respiratory disorder; asthma; transgenic animal;
 KW chronic obstructive pulmonary disease; neoplastic condition; cancer;
 KW benign tumour; anaemia; gastrointestinal disorder; gastritis;
 KW ulcerative colitis; liver disease; biliary cirrhosis; kidney disorder;
 KW glomerulonephritis; cystitis; endometriosis; endocrine disorder;
 KW Grave's disease; Hashimoto's thyroiditis; skin condition; dermatitis;
 KW urticaria; immune disorder; acquired immunodeficiency syndrome; AIDS;
 KW open reading frame; ORF; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200145638-A2.
 XX
 PD 28-JUN-2001.
 XX
 PF 11-DEC-2000; 2000WO-US033547.
 XX
 PR 14-DEC-1999; 99US-00461697.
 XX
 PA (COGE-) COGENT NEUROSCIENCE INC.
 XX
 PI Lo DC, Barney S, Thomas MB, Portbury SD, Puranam K, Katz LC;
 XX
 DR WPI; 2001-390297/41.
 DR P-PSDB; AAG98828.
 XX
 PT Novel protective sequence polynucleotides and polypeptides, used to
 PT identify modulators of their expression and activity, which are used in
 PT to treat central nervous system conditions, diseases and disorders.
 XX
 PS Claim 2; Fig 12AY; 325pp; English.
 XX
 CC Sequences AAH84132-AAH84370 represent human nucleic acid sequences which
 CC protect against cell death (i.e. apoptosis or necrosis). Sequences
 CC AAH84132, AAH84145, AAH84170, AAH84201, AAH84210, AAH84226, AAH84265,
 CC AAH84281, AAH84315 and AAH84367 represent 10 full-length cDNA clones,
 CC while the remaining nucleic acid sequences within the range given above
 CC represent the open reading frames (ORFs) of these cDNA clones. Sequences
 CC AAG98610-AAG98829 represent the polypeptides encoded by the cell death
 CC protective ORFs. The cell death protective cDNA clones are able to
 CC prevent, delay or reverse progression through the apoptotic or necrotic
 CC pathways when injected into a cell predisposed to or undergoing cell
 CC death. The cell death protective nucleic acids and polypeptides can be
 CC used in the diagnosis and treatment of disorders associated with cell
 CC death, and to screen for compounds which modulate their activity or
 CC expression. Such modulators, preferably a small organic molecule, an
 CC antibody, a ribozyme, or an antisense molecule, can also be used to treat

cell death-related diseases. Such diseases include those associated with the central nervous system including psychiatric or neurological disorders, especially ischaemia-related conditions such as strokes, and also includes neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, or Parkinson's disease. The modulators may also be used to treat infections such as meningitis, malaria, or trypanosomiasis; vascular diseases such as ischaemic encephalopathy or cerebral infarction; eye conditions such as diabetic retinopathy or macular degeneration; hypertension; myocardial infarction; atherosclerosis; respiratory conditions such as asthma or chronic obstructive pulmonary disease; neoplastic conditions such as cancers or benign tumours; blood cell or ulcerative colitis; liver conditions such as biliary cirrhosis; kidney disorders such as glomerulonephritis; cystitis; endometriosis; endocrine disorders such as Grave's disease or Hashimoto's thyroiditis; skin conditions such as dermatitis or urticaria; or immune system disorders such as acquired immunodeficiency syndrome (AIDS). The nucleic acids may additionally be used to generate animal models of cell death-associated disorders. The present sequence represents a cell death protective ORF

Sequence 15 BP; 7 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02; Mismatches 14; Conservative 0; Indels 0; Gaps 0;

QY 1561 TTATATAAATACAT 1575
 DB 15 TTATATAAATACAT 1

RESULT 186
 AAD54049/c
 ID AAD54049 standard; DNA; 15 BP.
 XX
 AC AAD54049;
 XX
 DT 17-JUN-2003 (first entry)
 XX
 DE Human TEM7alpha exon6/intron6 junction DNA.
 XX
 KW Human; tumour endothelial marker 7 alpha; TEM7alpha; osteopetrosis;
 KW osteoporosis; cancer; inflammatory disease; inflammatory bowel disease;
 KW rheumatoid arthritis; arrhythmia; congestive heart failure; hypertension;
 KW myocardial infarction; acute respiratory distress syndrome; bronchospasm;
 KW asthma; angiogenesis; polycystic kidney disease; acute renal failure;
 KW angina; gene therapy; osteopathic; cytostatic; nephrotropic; cardiant;
 KW ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT exon 1..9
 FT /*tag= a
 FT /number= 6
 FT /partial
 FT intron 10..15
 FT /*tag= b
 FT /number= 6
 FT /partial
 XX
 PN WO200297110-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 28-MAY-2002; 2002WO-US016639.
 XX
 PR 25-MAY-2001; 2001US-0293852P.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Juan T, Bass MB, Oliner JD;
 XX

PT New nucleic acid encoding a tumor suppressor or marker, used for
PT diagnosis, monitoring progress or treatment, and gene therapy of breast
XX cancer.
PS Example 5; Page 50; 120pp; English.
XX This sequence represents a PCR primer used in a differential display
CC experiment to amplify a human antizuc-1 (AZ-1) DNA fragment sequence
CC (see AA290111). The AZ-1 gene is located on chromosome 10q26, and encodes
CC a protein that acts as a tumour suppressor or marker of malignancy,
CC progression or reversion. The AZ-1 protein is a tumour suppressor, it
CC interacts with E-cadherin and beta-catenin. Detecting low levels of AZ-1
CC nucleotide or amino acid sequences are used to diagnose a breast cell
CC malignancy, also for monitoring disease progression, particularly
CC assessment of therapeutic efficacy. The nucleotide sequence is used in
CC vivo or ex vivo gene therapy, and AZ-1 polypeptides are used for treating
CC or preventing breast cancer. AZ-1 polypeptides are also used to raise
CC specific antibodies, for diagnostic detection of AZ-1. Fragments of the
CC AZ-1 nucleotide sequence are useful as probes or primers for detecting
CC expression of the AZ-1 gene
XX
SQ Sequence 15 BP; 3 A; 0 C; 1 G; 11 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1040 AAGTTTCTTTTCTTTT 1054
DB 1 AAGTTTCTTTTCTTTT 15
RESULT 183
AAF53972
ID AAF53972 standard; DNA; 15 BP.
XX
AC AAF53972;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #4932.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 8; Page 93; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC P45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 5 A; 3 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 241 GGGCACTGGACACA 255
DB 1 GGGCACTGGACACA 15
RESULT 184
AAF77611/C
ID AAF77611 standard; DNA; 15 BP.
XX
AC AAF77611;
XX
DT 29-MAY-2001 (first entry)
XX
DE Modified transcription initiation site Paramyxovirus related oligo #31.
XX
KW Transcription initiation sequence; viral vector; vaccine; therapy; ds.
XX
OS Unidentified.
XX
PN WO200118223-A1.
XX
PD 15-MAR-2001.
XX
PF 06-SEP-2000; 2000WO-JP006051.
XX
PR 06-SEP-1999; 99JP-00252231.
XX
XX (DNAV-) DNAVEC RES INC.
XX
PI Nagai Y, Kato A, Hasegawa M;
XX
XX WPI; 2001-244576/25.
XX
PT Paramyxovirus vectors with modified transcription initiation sequences
PT for increased expression of foreign genes in production of drugs and
PT vaccines.
XX
PS Example 1; Fig 2; 65pp; Japanese.
XX
XX The present invention describes a paramyxovirus vector DNA in which the
CC transcription initiation sequence has been modified to modify the
CC expression of a gene located downstream of the transcription initiation
CC sequence. This is useful in the production of mutant paramyxovirus
CC vectors with elevated gene expression and a more rapid proliferation than
CC the wild-type vector, which can then be used for more efficient
CC production of drug substances and vaccines
XX
SQ Sequence 15 BP; 9 A; 1 C; 1 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;

```

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX DR WPI; 2004-533378/51.
XX
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX
XX PS Disclosure; SEQ ID NO 8637; Opp; English.
XX
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
XX CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX CC defined in the specification, a fragment of at least 8 amino acids of
XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX CC pharmaceutical composition of the invention is useful for treating or
XX CC preventing a disorder associated with decreased expression or activity of
XX CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX CC The present sequence represents a 17-mer nucleotide, used in the
XX CC invention for scanning the sequence represented in ACN63103
XX
XX SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 200 AAATCCAGAAATGCAG 216
XX | ||||| |||||
XX Db 1 AGATCCAGAACTGCAG 17
XX
XX RESULT 181
XX ACN69859
XX ID ACN69859 standard; DNA; 17 BP.
XX
XX AC ACN69859;
XX
XX DT 02-DEC-2004 (first entry)
XX
XX DE Human GDMPLP-1 probe SEQ ID NO:6761.
XX
XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX
XX OS Homo sapiens.
XX
XX PN US2004137589-A1.
XX
XX PD 15-JUL-2004.
XX
XX PF 26-NOV-2003; 2003US-00723361.
XX
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-02600670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.

```

```

XX GUYI/) GU Y.
XX PA JIYI/) JI Y.
XX PA PENN/) PENN S G.
XX PA HANZ/) HANZEL D K.
XX PA RANK/) RANK D.
XX PA CHEN/) CHEN W.
XX PA SHAN/) SHANNON M E.
XX
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX DR WPI; 2004-533378/51.
XX
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX
XX PS Disclosure; SEQ ID NO 6761; Opp; English.
XX
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
XX CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX CC defined in the specification, a fragment of at least 8 amino acids of
XX CC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX CC pharmaceutical composition of the invention is useful for treating or
XX CC preventing a disorder associated with decreased expression or activity of
XX CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX CC The present sequence represents a 17-mer nucleotide, used in the
XX CC invention for scanning the sequence represented in ACN63103
XX
XX SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 506 GTGAGGCTCATGGAGAC 522
XX | ||||| |||||
XX Db 1 GAGGAGCTCTGGAGAC 17
XX
XX RESULT 182
XX AAZ90118
XX ID AAZ90118 standard; DNA; 15 BP.
XX
XX AC AAZ90118;
XX
XX DT 19-MAY-2000 (first entry)
XX
XX DE PCR primer H-T11A used to amplify AZ-1.
XX
XX KW Antizuai-1; AZ-1; human; breast cancer; ss; PCR primer;
XX KW tumour suppressor; malignancy progression marker; malignancy reversion.
XX
XX OS Homo sapiens.
XX
XX PN WO200000503-A1.
XX
XX PD 06-JAN-2000.
XX
XX PF 25-JUN-1999; 99WO-US014482.
XX
XX PR 26-JUN-1998; 98US-0090747P.
XX
XX PA (CHEN/) CHEN H.
XX PA (BISS/) BISSELL M.
XX
XX PI Chen H, Bissell M;
XX
XX DR WPI; 2000-170903/15.
XX

```

CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 874 TTGATGCTGTCACATAC 890
Db 17 TTGATGCTGTCAGCAC 1
RESULT 179
ACN73532/c
ID ACN73532 standard; DNA; 17 BP.
XX
XX
AC ACN73532;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:10434.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
WFI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT

PT function.
XX Disclosure; SEQ ID NO 10434; Opp; English.
PS
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 868 TTGAGTTTTCATGCTGT 884
Db 17 TCGACTTTTCATGCTGT 1
RESULT 180
ACN71735
ID ACN71735 standard; DNA; 17 BP.
XX
XX ACN71735;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:8637.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PF 26-NOV-2003; 2003US-00723361.
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 05-FEB-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor inozyme substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 5 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 CTCCTGCAGGCCACTGC 50
 DB 17 CTCCTGCAGGCCGCGAC 1

RESULT 177
 ADF90161
 ID ADF90161 standard; DNA; 17 BP.

AC ADF90161;
 DT 26-FEB-2004 (first entry)

XX Blocking probe used in Listeria detection.

XX probe; Listeria; ss.

OS Synthetic.

XX WO2003100076-A2.

XX 04-DEC-2003.

XX 13-MAY-2003; 2003WO-US014951.

XX 17-MAY-2002; 2002US-0381132P.

XX (APPL-) APPLERA CORP.

PA (WISC) WISCONSIN ALUMNI RES FOUND.

PI Hyldig-Nielsen JJ, Rigby S, Brehm-Stecher B, Johnson EA;

XX WPI; 2004-035157/03.

XX New PNA probe comprising a probing nucleobase sequence, useful for
 PT detecting, identifying or quantitating Listeria in a sample.

XX Claim 40; SEQ ID NO 35; 47pp; English.

XX The present sequence is that of a blocking probe which can be used with
 CC peptide nucleic acid (PNA) probes of the invention ADF90127-ADF90152 for
 CC detecting, identifying and quantifying Listeria genus organisms or
 CC Listeria monocytogenes in a sample by in situ hybridisation. PNA probes,
 CC probe sets, methods and kits of the invention provide sensitive and
 CC reliable detection, and can be used for determination of Listeria spp. or
 CC Listeria monocytogenes in food, beverages, water, pharmaceutical
 CC products, personal care products, dairy products, environmental samples
 CC and clinical samples.

XX

SQ Sequence 17 BP; 6 A; 1 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 120 CTTAGAAAAATTTTATG 136
 DB 1 CTGAGAAATAATTTTATG 17
 RESULT 178
 ACN73526/c
 ID ACN73526 standard; DNA; 17 BP.
 XX ACN73526;
 XX 02-DEC-2004 (first entry)
 DT Human GDMPLP-1 probe SEQ ID NO:10428.
 DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX Homo sapiens.
 OS US2004137589-A1.
 XX 15-JUL-2004.
 XX 26-NOV-2003; 2003US-00723361.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000861.
 PR 30-JAN-2001; 2001WO-US000862.
 PR 30-JAN-2001; 2001WO-US000863.
 PR 30-JAN-2001; 2001WO-US000864.
 PR 30-JAN-2001; 2001WO-US000865.
 PR 30-JAN-2001; 2001WO-US000866.
 PR 30-JAN-2001; 2001WO-US000867.
 PR 30-JAN-2001; 2001WO-US000868.
 PR 30-JAN-2001; 2001WO-US000869.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.

XX (GUY)/ GU Y.

PA (JIY)/ JI Y.

PA (PENN)/ PENN S G.

PA (HANZ)/ HANZEL D K.

PA (RANK)/ RANK D.

PA (CHEN)/ CHEN W.

PA (SHAN)/ SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX Disclosure; SEQ ID NO 10428; 0pp; English.
 PS The invention relates to a novel polypeptide (I) comprising a sequence
 CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (SI), 95% deviation from (SI) which are conservative substitutions, and

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human NOGO
 CC receptor inozyme substrate sequence.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 7 G; 0 T; 2 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 33 GCTCTGCGAGCGCACTG 49
 |||||
 DB 17 GCTCTGCGAGCGCGCAG 1
 |||||
 RESULT 175
 ADL49415
 ID ADL49415 standard; RNA; 17 BP.
 XX
 AC ADL49415;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #529.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 2948; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 1.1e+02;
 Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
 QY 907 TTTTCTTCAAGACAG 923
 :::: : |||||
 DB 1 UUUUUUUUAAAGACAG 17
 :::: : |||||
 RESULT 176
 ADL46696/c
 ID ADL46696 standard; RNA; 17 BP.
 XX
 AC ADL46696;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor inozyme substrate sequence #129.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor inozyme; substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PF 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 XX
 DR WPI; 2003-058513/05.
 XX
 PT Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 9; SEQ ID NO 229; 317pp; English.

PI Tuijnder M, Telerman A, Amson R;

DR WPI; 2003-250498/25.

PT New nucleic acid sequences associated with tumor suppression, regression, apoptosis or virus resistance are useful to diagnose and treat viral disease, development of tumor cells and cell degeneration.

PS Claim 1; Page 613; 798pp; French.

CC This sequence represents an isolated nucleic acid sequence associated with tumor suppression or regression, apoptosis or virus resistance. The invention relates to these sequences or sequences having at least 80% identity to them, and polypeptides encoded by the sequences or polypeptides having 80% identity to the polypeptide sequences. The invention is used to diagnose or treat viral disease or disease characterized by development of tumor cells or cellular degeneration

XX Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1346 GATCTAACCAATTGAA 1362

DB 1 GATCTCAGCAATTGAA 17

RESULT 173

ADL50557/C
ID ADL50557 standard; RNA; 17 BP.

AC ADL50557;

DT 20-MAY-2004 (first entry)

DE Human PKR substrate sequence #1671.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;

KW substrate; ds.

XX Unidentified.

OS

PN WO200281628-A2.

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 4090; 317pp; English.

PS

XX

CC The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human PKR substrate sequence.

XX Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 14 TGAAGTTTCTCTTAATA 30

DB 17 TGAGGTTTCTCTTGATA 1

RESULT 174

ADL46697/C
ID ADL46697 standard; RNA; 17 BP.

AC ADL46697;

DT 20-MAY-2004 (first entry)

DE Human NOGO receptor inozyme substrate sequence #130.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;

KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;

KW protein kinase PKR; cerebrovascular accident;

KW central nervous system injury; CNS injury; spinal cord injury; cancer;

KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;

KW restenosis; asthma; Crohn's disease; diabetes; obesity;

KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;

KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;

KW allergy; asthma; allergic rhinitis; atopic dermatitis;

KW NOGO receptor inozyme; substrate; ds.

XX Unidentified.

OS

PN WO200281628-A2.

XX 17-OCT-2002.

PD

XX 03-APR-2002; 2002WO-US010512.

PF

XX 05-APR-2001; 2001US-00827395.

PR 29-MAY-2001; 2001US-0294412P.

PR 28-AUG-2001; 2001US-0315315P.

XX (RIBO-) RIBOZYME PHARM INC.

PA

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;

PI WPI; 2003-058513/05.

DR

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 9; SEQ ID NO 230; 317pp; English.

PS

RESULT 170
 ADI50768/c
 ID: ADI50768 standard; DNA; 17 BP.
 XX
 AC ADI50768;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE Human tumour suppression/reversion-related DNA sequence SeqID3271.
 XX
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytostatic; virucide; neuroprotective; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025177-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004523.
 XX
 PR 17-SEP-2001; 2001FR-00011980.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313354/30.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; SEQ ID NO 3271; 30pp; French.
 XX
 CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC neuroleptic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, indentifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 562 GCCTTTGGACCTGGATC 578
 DB 17 GCCTTTGGACCTGGATC 1
 XX
 RESULT 171
 ACC52701
 ID ACC52701 standard; DNA; 17 BP.
 XX
 AC ACC52701;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human tumour suppressor sequence #2482.
 XX
 KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 OS Homo sapiens.
 XX
 PN FR2826373-A1.
 XX
 PD 27-DEC-2002.
 XX
 PF 20-JUN-2001; 2001FR-00008139.
 XX
 PR 20-JUN-2001; 2001FR-00008139.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX
 DR WPI; 2003-250498/25.
 XX
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX
 PS Claim 1; Page 379; 798pp; French.
 XX
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumor suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 720 GTTCCCCACCTACCAAT 736
 DB 1 GATCCCCACCTCCCAAT 17
 XX
 RESULT 172
 ACC53715
 ID ACC53715 standard; DNA; 17 BP.
 XX
 AC ACC53715;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human tumour suppressor sequence #2482.
 XX
 KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 OS Homo sapiens.
 XX
 PN FR2826373-A1.
 XX
 PD 27-DEC-2002.
 XX
 PF 20-JUN-2001; 2001FR-00008139.
 XX
 PR 20-JUN-2001; 2001FR-00008139.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX
 DR WPI; 2003-250498/25.
 XX
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX
 PS Claim 1; Page 379; 798pp; French.
 XX
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumor suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

DE Human tumour suppressor sequence #1468.
 XX
 KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 OS Homo sapiens.
 XX
 PN FR2826373-A1.
 XX
 PD 27-DEC-2002.
 XX
 PF 20-JUN-2001; 2001FR-00008139.
 XX
 PR 20-JUN-2001; 2001FR-00008139.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX
 DR WPI; 2003-250498/25.
 XX
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX
 PS Claim 1; Page 379; 798pp; French.
 XX
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumor suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 720 GTTCCCCACCTACCAAT 736
 DB 1 GATCCCCACCTCCCAAT 17
 XX
 RESULT 172
 ACC53715
 ID ACC53715 standard; DNA; 17 BP.
 XX
 AC ACC53715;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human tumour suppressor sequence #2482.
 XX
 KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 OS Homo sapiens.
 XX
 PN FR2826373-A1.
 XX
 PD 27-DEC-2002.
 XX
 PF 20-JUN-2001; 2001FR-00008139.
 XX
 PR 20-JUN-2001; 2001FR-00008139.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB SA.
 XX
 PI Tuijnder M, Telerman A, Amson R;
 XX
 DR WPI; 2003-250498/25.
 XX
 XX New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX
 PS Claim 1; Page 379; 798pp; French.
 XX
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumor suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 903 GATCTTTTCTTCGAAG 919
 DB 1 GATCTTTTCTTCGAAG 17
 RESULT 168
 ADI52571
 ID ADI52571 standard; DNA; 17 BP.
 AC ADI52571;
 XX
 DT 15-APR-2004 (first entry)
 DE Human tumour suppression/reversion-related DNA sequence SeqID5074.
 XX
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytosolic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025177-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004523.
 XX
 PR 17-SEP-2001; 2001FR-00011980.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313354/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; SEQ ID NO 5074; 30pp; French.
 XX
 CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1346 GATCTAACCAATTGAA 1362
 DB 1 GATCTAACCAATTGAA 17

Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 720 GTTCCCCACCTACCAAT 736
 DB 1 GATCCCCACCTCCCAAT 17
 RESULT 169
 ADI52496
 ID ADI52496 standard; DNA; 17 BP.
 XX
 AC ADI52496;
 XX
 DT 15-APR-2004 (first entry)
 DE Human tumour suppression/reversion-related DNA sequence SeqID4999.
 XX
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytosolic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025177-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004523.
 XX
 PR 17-SEP-2001; 2001FR-00011980.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313354/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; SEQ ID NO 4999; 30pp; French.
 XX
 CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1346 GATCTAACCAATTGAA 1362
 DB 1 GATCTAACCAATTGAA 17

CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and/or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies
 CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

XX Sequence 17 BP; 6 A; 5 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1346 GATCTAACCAATTGAA 1362
 |||||
 Db 1 GATCCAAACCACTTGAA 17

RESULT 166

AD151278
 ID AD151278 standard; DNA; 17 BP.

AC AD151278;

XX 15-APR-2004 (first entry)

XX Human tumour suppression/reversion-related DNA sequence SeqID3781.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytosolic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

XX Disclosure; SEQ ID NO 3781; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC

CC nontropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, indentifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration. The
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 3 A; 2 C; 2 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 903 GATCTTTTCTTCAAAG 919
 |||||
 Db 1 GATCTTTTCTTCAATAG 17

RESULT 167

AD149691

ID AD149691 standard; DNA; 17 BP.

XX AD149691;

XX 15-APR-2004 (first entry)

XX Human tumour suppression/reversion-related DNA sequence SeqID2194.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytosolic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

XX Disclosure; SEQ ID NO 2194; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC nontropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, indentifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The

polypeptide and antibodies.

Disclosure; Page 300; 771pp; French.

The invention relates to the isolation of 6327 nucleotide sequences, fragments of at least 15 consecutive nucleotides of these nucleotides, the sequence having at least 80% identity, after optimal alignment, with the nucleotides, a sequence that hybridizes under stringent conditions with the nucleotides, or the complement, or corresponding RNA, of the nucleotides. The nucleotides are used as probes or primers for detecting, identifying, quantifying and/or amplifying nucleic acids, as in vitro sense and antisense sequences, of nucleotides involved in tumour suppression or reversion, apoptosis and or viral resistance, to produce recombinant polypeptides, and to prepare transgenic animals, as experimental models. The nucleotides (also vectors containing them and cells containing the vectors), the encoded polypeptides and antibodies (Ab) against the polypeptide are useful for prevention and/or treatment of viral infections or diseases characterized by development of tumours or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

Analysis of the expression of the nucleotides can be used for diagnosis and/or prognosis of these diseases. The nucleotides and polypeptides can also be used to screen for their specific interactive molecules, potentially useful for treating diseases associated with abnormal expression of the nucleotides.

Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred NO. 1.1e+02;

Qy 720 GTTCCCCACCTACAAAT 736
 | | | | | | | | | |
 match 15; conservative 0; mismatch 2; indels 0; gaps 0

DD I 5A1CCCCCACC1CCAAAT 17

RESULT 165

1D AUB44351 SCAGUAGU; DNA; 17 bp.
XX
XX
AC ADB44591;
XX

DI 18-DEC-2003 (first entry)
XX XX

DE immunosuppression/reversion associated nucleoside #1919.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW immunosuppression/reversion associated nucleoside #1919.

KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;

XX	diagnosis.
XX	
OS	Homo sapiens.
XX	
PN	WC0203040369-A2.

XX PD 15-MAY-2003.

AA PF 17-SEP-2002; 2002WO-IB004219.

PR 17-SEP-2001; 2001FR-00011981.

PA (MOLE-) MOLECULAR ENGINES LAB.

PI Telerman A, Amson R, Tuijnder M;
yy

DR WPI; 2003-441574/41.
XX '1.

PT New nucleic acid encoding human prostate membrane-specific antigen, useful e.g. for treatment of tumors and viral infection, also related

PT polypeptide and antibodies.
XX

PS Disclosure; Page 606; 771pp; French.
XX

XX OS Mus musculus.
XX PN WO2003025176-A2.
XX XX 27-MAR-2003.
XX PD 17-SEP-2002; 2002WO-IB004210.
XX PF 17-SEP-2001; 2001FR-00011979.
XX PR (MOLE-) MOLECULAR ENGINES LAB.
XX PA Telerman A, Amson R, Tuijnder M;
XX PI WPI; 2003-333167/31.
XX DR New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 693; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC6806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterized by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX CC
XX SQ Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 535 GATGCACAAAGGTGGAT 551
DB 1 GATCACAAGGTGGAT 17
RESULT 162
ADB43853/C
ID ADB43853 standard; DNA; 17 BP.
XX AC ADB43853;
XX XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX XX Tumour suppression/reversion associated nucleotide #4176.
XX DE cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX XX WPI; 2003-441574/41.

PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX PS Disclosure; Page 520; 771pp; French.
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX SQ Sequence 17 BP; 7 A; 3 C; 4 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 562 GCTTTTGACCTGGATC 578
DB 17 GCTTTTGACCTGGATC 1
RESULT 163
ADB39685
ID ADB39685 standard; DNA; 17 BP.
XX AC ADB39685;
XX XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX XX Tumour suppression/reversion associated nucleotide #8.
XX DE cytosstatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX KW primer; probe; tumour suppression; tumour reversion; apoptosis;
XX KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
XX KW diagnosis.
XX OS Homo sapiens.
XX PN WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX XX WPI; 2003-441574/41.

```

Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 260 CCCTGGAGATGATGAC 276
Db 1 CCCTGGAGATGAGAC 17

RESULT 159
ABZ60192/c
ID ABZ60192 standard; RNA; 17 BP.
XX
AC ABZ60192;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNazyme substrate #304.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer; modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 90; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 7 A; 0 C; 0 G; 0 T; 10 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 AAAATACATATATTTT 1583
Db 17 AAAAAATATATATTTT 1

RESULT 160
ABZ64887
ID ABZ64887 standard; RNA; 17 BP.

```

```

XX ABZ64887;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human HER2 DNazyme substrate #344.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer; modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 4; Page 139; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 607 GAGGACGGAATTCGGAC 623
Db 1 GGGGACGAUUCUGAC 17

RESULT 161
ACC68419
ID ACC68419 standard; DNA; 17 BP.
XX
AC ACC68419;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5666.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.

```

CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 261 CCTGGAGATGATGACG 277
DB 1 CCTGGAGATGACG 17

RESULT 157
ADB04816
ID ADB04816 standard; DNA; 17 BP.
AC ADB04816;
XX 20-NOV-2003 (first entry)
DT Human MDZ12 scanning oligonucleotide SEQ ID 5802.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.

XX Homo sapiens.
XX EP1281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 5802; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross

CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 GACAATTCAGACACG 851
DB 1 GACAATTCAGACACG 17

RESULT 158
ADA99700
ID ADA99700 standard; DNA; 17 BP.

XX ADA99700;
XX 20-NOV-2003 (first entry)
DT Human MDZ3 scanning oligonucleotide SEQ ID 689.

XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.

XX Homo sapiens.
XX EP1281758-A2.
XX 05-FEB-2003.
XX 30-JUL-2002; 2002EP-00016874.
XX 02-AUG-2001; 2001US-00922181.
XX (AEOM-) AEOMICA INC.
XX Shannon M, Gu Y, Nguyen C;
XX WPI; 2003-423107/40.
XX New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MDZ3,
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
XX Example 8; SEQ ID NO 689; 103pp; English.

XX The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder
CC associated with decreased or increased expression or activity of MDZ3,
CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.

Sequence 17 BP; 5 A; 5 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.
 XX
 PS Disclosure; Page 296; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 GTTCCCTCCACCTACAAAT 736
 |||||
 Db 1 GATCCCCCACCCTCAAAAT 17

RESULT 155
 ADA99699
 ID ADA99699 standard; DNA; 17 BP.
 XX
 AC ADA99699;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 688.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MD24; MD27; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 FN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX
 XX New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder

PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 688; 103pp; English.
 XX
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
 CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
 CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MDZ3,
 CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 259 ACCCTGGAGATGATGCA 275
 |||||
 Db 1 ACCCTGGAGATGAGACA 17

RESULT 156
 ADA99701
 ID ADA99701 standard; DNA; 17 BP.
 XX
 AC ADA99701;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 690.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 FN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 DR WPI; 2003-423107/40.
 XX
 XX New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 690; 103pp; English.
 XX
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
 CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
 CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MDZ3,
 CC MDZ4, MDZ7 or MDZ12, e.g. cancer.

XX WO2003031621-A2.
 XX 17-APR-2003.
 XX 11-OCT-2002; 2002WO-US032599.
 XX 12-OCT-2001; 2001US-0329000P.
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 XX Zhang J;
 XX WPI; 2003-381720/36.
 XX New GPCR-A-1 nucleic acid and polypeptide, useful for diagnosing,
 PT investigating and/or treating disorders associated with aberrant
 PT expression or activity of GPCR-A-1, such as tumors and cancers.
 XX Example 2; SEQ ID NO 1322; 156pp; English.
 XX The invention describes an isolated nucleic acid encoding a G protein
 CC coupled receptor (GPCR), mutations of which cause cancer, comprising a
 CC 2225 or 1921 base pair sequence, or their degenerate variants, encoding a
 CC 409 residue amino acid sequence, all given in the specification, with or
 CC without conservative amino acid substitutions, or complements of the
 CC sequence of them. The encoding nucleic acid is not more than 100 kb in
 CC length. The methods and compositions of the present invention are useful
 CC for diagnosing, investigating and/or treating disorders associated with
 CC aberrant expression or activity of GPCR-A-1, such as tumors and cancers.
 CC This sequence represents an oligonucleotide used to analyse the gene
 CC encoding human G-protein coupled receptor GPCR-A-1
 XX Sequence 17 BP; 5 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1461 CAGCTTAATAAGTATT 1477
 DB 1 CTGCTCAATAAGTATT 17
 RESULT 153
 ABT34768
 ID ABT34768 standard; DNA; 17 BP.
 XX AC ABT34768;
 XX DT 12-JUN-2003 (first entry)
 XX Tumour suppression related human fukutin oligo SEQ ID No 405.
 DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX Homo sapiens.
 XX OS WO2003025175-A2.
 XX PN WO2003025175-A2.
 XX PD 27-MAR-2003.
 XX PF 17-SEP-2002; 2002WO-IB004208.
 XX PR 17-SEP-2001; 2001FR-00011978.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX Telerman A, Amson R, Tuijnder M;

DR WPI; 2003-313353/30.
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX Disclosure; Page 81; 720pp; French.
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 903 GATCTTTTCTTCAAAG 919
 DB 1 GATCTTTTCTTCAAAG 17
 RESULT 154
 ABT36617
 ID ABT36617 standard; DNA; 17 BP.
 XX AC ABT36617;
 XX DT 12-JUN-2003 (first entry)
 XX Tumour suppression related human fukutin oligo SEQ ID No 2254.
 DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX Homo sapiens.
 XX OS WO2003025175-A2.
 XX PN 27-MAR-2003.
 XX PD 17-SEP-2002; 2002WO-IB004208.
 XX PF 17-SEP-2001; 2001FR-00011978.
 XX PR (MOLE-) MOLECULAR ENGINES LAB.
 XX PA Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-313353/30.
 XX


```

RESULT 150
ACN09806
ID ACN09806 standard; RNA; 17 BP.
XX
AC ACN09806;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Inozyme substrate SEQ ID NO 9809.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 9809; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 7 A; 2 C; 3 G; 0 T; 5 U; 0 Other;
    Query Match 0.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 64.7%; Pred. No. 1.1e+02;
    Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 305 ATCAATTCAGGAATG 321
    ||| :||| |||||
Db 1 AUCAUAUCAGUAGAAUG 17

RESULT 151
ACN05603/c
ID ACN05603 standard; RNA; 17 BP.
XX
AC ACN05603;
XX
DT 22-APR-2004 (first entry)

```

```

XX DE WNV Amberzyme substrate SEQ ID NO 5606.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
PN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 5606; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 2 A; 1 C; 7 G; 0 T; 7 U; 0 Other;
    Query Match 0.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 1.1e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1341 CCAAGGATCTACCAAT 1357
    ||||| ||| |||||
Db 17 CCAAGCATCCAACCAAT 1

RESULT 152
ACD00825
ID ACD00825 standard; DNA; 17 BP.
XX
AC ACD00825;
XX
DT 28-JUL-2003 (first entry)
XX
DE G-protein coupled receptor GPCR-A-1 analysis oligonucleotide #1298.
XX
KW Human; G-protein coupled receptor; GPCR-A-1; cancer; tumour;
KW G-Protein-Agonist; G-Protein-Antagonist; gene therapy; cytostatic; ss.
XX
OS Homo sapiens.

```


PA (THOM/) THOMPSON J.
 XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
 PI Grupe A;
 XX WPI; 2002-217145/27.
 DR Enzymatic polynucleotide that down regulates expression of chloride
 XX channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 PT Claim 4; Page 75; 152pp; English.
 XX The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX
 XX Sequence 17 BP; 10 A; 4 C; 2 G; 0 T; 1 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 484 GACATTTTGGTGGTTT 500
 DB 17 GCCATTTTGGTGGTTT 1
 RESULT 144
 ID ACN07730/C
 XX ACN07730 standard; RNA; 17 BP.
 AC ACN07730;
 XX
 DT 22-APR-2004 (first entry)
 DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7733.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 XX Claim 23; SEQ ID NO 7733; 495pp; English.
 XX The invention relates to nucleic acid molecules that modulate replication
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
 CC treating a condition related to WNV infection e.g. pancreatitis,
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
 CC molecule is selected from the group of ribozymes consisting of
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
 CC nucleic acid molecules further comprise at least five ribose residues, at
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
 CC least three of the 5' terminal nucleotides and a 3' end modification of a
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
 CC in the specification. The present sequence is that of a nucleic acid
 CC molecule of the invention
 XX
 XX Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 761 TCTCTGCTGATGACATA 777
 DB 17 TCTATGCTGATGACACA 1
 RESULT 145
 ID ACN09323
 XX ACN09323 standard; RNA; 17 BP.
 AC ACN09323;
 XX
 DT 22-APR-2004 (first entry)
 DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9326.
 XX
 KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberzyme; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 PR 20-OCT-2000; 2000US-0242411P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 DR WPI; 2002-706994/76.
 XX New nucleic acid molecule that modulates replication of West Nile Virus
 PT (WNV), useful for treating a condition related to WNV infection e.g.
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Novel isolated human testis expressed Patched like protein (HTPL), useful
 PT for identifying agonist and antagonist and specific binding partners, and
 PT for treating subjects having defects in HTPL.
 XX
 XX Example 2; Page 218; 718pp; English.
 XX
 CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention
 XX
 SQ Sequence 17 BP; 9 A; 0 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 GAAAAAATTGATGCAG 1159

DB 1 GAAAAAATTGAGTAG 17

RESULT 142

ID ABK19347/c

XX ABK19347 standard; RNA; 17 BP.

AC ABK19347;

DT 09-APR-2002 (first entry)

DE Human ERG Amberzyme target sequence Seq ID No 1994.

XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.

XX Homo sapiens.

XX WO200188124-A2.

PN 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US015866.

PF 16-MAY-2000; 2000US-00572021.

PR (RIBO-) RIBOZYME PHARM INC.

XX (GLAX) GLAXO GROUP LTD.

PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;

XX

DR WPI; 2002-082995/11.

XX Novel polynucleotide which down regulates expression of Ets-related gene,
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX

PS Claim 4; Page 126; 149pp; English.

XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX

SQ Sequence 17 BP; 7 A; 1 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.1e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1620 ACTCTACTATTAAAGTTT 1636

DB 17 ACTCTACTCTAAAGTTT 1

RESULT 143

ID ABK56577/c

XX ABK56577 standard; RNA; 17 BP.

AC ABK56577;

DT 02-JUL-2002 (first entry)

DE Human CLCA1 gene enzymatic nucleic acid #948.

XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.

XX Homo sapiens.

XX WO200211674-A2.

PN 14-FEB-2002.

XX 09-AUG-2001; 2001WO-US024970.

XX 09-AUG-2000; 2000US-0224383P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (SYNT) SYNTEX USA LLC.

PI Zhang J;
 XX WPI; 2002-479509/51.
 XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
 PT acids encoding the protein, useful for treating subjects having defects
 PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
 PT e.g., liver or bone.
 XX Example 2; Page 266; 418pp; English.
 XX The invention relates to a novel isolated nucleic acid encoding human
 CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
 CC invention has cytostatic activity. The nucleotide may have a use in gene
 CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
 CC monitor a disease caused by altered expression of human KTOM1.
 CC Compositions comprising the nucleic acids, proteins or antibodies may be
 CC used to treat subjects having defects in KTOM1 which can manifest as
 CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
 CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
 CC function. The sequence represents a probe used in the invention to scan
 CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
 XX Sequence 17 BP; 3 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 568 GGACCTGGATCTGGCAT 584
 Db 1 GCACCTGGATTTGGCAT 17
 RESULT 140
 ID ABV79930 standard; DNA; 17 BP.
 XX AC ABV79930;
 XX 03-JAN-2003 (first entry)
 XX Human HTPL scanning oligonucleotide SEQ ID 1176.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX Homo sapiens.
 XX EP1229046-A2.
 XX 07-AUG-2002.
 XX 28-JAN-2002; 2002EP-00001167.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 23-MAY-2001; 2001US-00864761.
 XX 09-OCT-2001; 2001US-0327898P.
 XX (AEOM-) AEOMICA INC.
 XX Zhan J;
 XX WPI; 2002-676582/73.
 XX Novel isolated human testis expressed Patched like protein (HTPL), useful

PT for identifying agonist and antagonist and specific binding partners, and
 PT for treating subjects having defects in HTPL.
 XX Example 2; Page 218; 718pp; English.
 XX The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention
 XX Sequence 17 BP; 9 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1142 TGAAGAAAAATTGATGCA 1158
 Db 1 TGAAGAAAAATTGAGGTA 17
 RESULT 141
 ID ABV79931 standard; DNA; 17 BP.
 XX AC ABV79931;
 XX 03-JAN-2003 (first entry)
 XX Human HTPL scanning oligonucleotide SEQ ID 1177.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX Homo sapiens.
 XX EP1229046-A2.
 XX 07-AUG-2002.
 XX 28-JAN-2002; 2002EP-00001167.
 XX 30-JAN-2001; 2001WO-US000663.
 XX 30-JAN-2001; 2001WO-US000664.
 XX 30-JAN-2001; 2001WO-US000665.
 XX 30-JAN-2001; 2001WO-US000667.
 XX 30-JAN-2001; 2001WO-US000668.
 XX 30-JAN-2001; 2001WO-US000669.
 XX 23-MAY-2001; 2001US-00864761.
 XX 09-OCT-2001; 2001US-0327898P.
 XX (AEOM-) AEOMICA INC.
 XX Zhan J;
 XX WPI; 2002-676582/73.

therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. CC specification data for this patent did not form part of the printed CC specification, but was obtained in electronic format directly from WIPO CC at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 TTTGATGCTGTCACAC 890
DB 17 TTTGATGCTGTCAGC 1

RESULT 138
ABN10442/c

ID ABN10442 standard; DNA; 17 BP.
XX
AC ABN10442;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10434.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 10434; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like

protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. CC specification data for this patent did not form part of the printed CC specification, but was obtained in electronic format directly from WIPO CC at ftp.wipo.int/pub/published_pct_sequence

XX
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 868 TTGAGTTTGTGATGCTGT 884
DB 17 TCGACTTTTGTGATGCTGT 1

RESULT 139
ABQ64120

ID ABQ64120 standard; DNA; 17 BP.
XX
AC ABQ64120;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 833.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX

PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 73; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NIGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NTN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinyzyme (cleaving RNA
 CC with a VGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. the NIGO-
 CC targeting nucleic acid is used to cleave RNA of the NIGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NIGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NIGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NIGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NIGO expression. the present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 908 TTTTCTTCAAGACAGG 924
 DB 17 TGTCTTCAAGACAGG 1
 RESULT 135
 ABN08645
 ID ABN08645 standard; DNA; 17 BP.
 XX
 AC ABN08645;
 XX
 DT 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8637.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 XX

KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 XX Homo sapiens.
 FN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX
 PS Disclosure; SEQ ID NO 8637; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 200 AAATCCACAGAAATGCAG 216
 DB 1 AGATCCAGAACTGCAG 17

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a DNzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.1e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 477 CATGCTGACATTTCGG 493
 DB 1 CAGGGCUGACUUGUGG 17
 RESULT 133
 ID ABK00330 standard; RNA; 17 BP.
 AC ABK00330;
 DT 12-MAR-2002 (first entry)
 DE Human NOGO Hammerhead Ribozyme #330.
 XX
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US004273.
 XX 11-FEB-2000; 2000US-018516P.
 XX 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX Claim 88; Page 71; 200pp; English.
 PS
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The

CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
 CC with a YG motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 8 A; 2 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.1e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 1145 AAAAATGATGACGCT 1161
 DB 1 AAAAUUUAUUGCAGCU 17
 RESULT 134
 ID ABK00480 standard; RNA; 17 BP.
 XX
 AC ABK00480;
 DT 12-MAR-2002 (first entry)
 DE Human NOGO Hammerhead Ribozyme #480.
 XX
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 PN WO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US004273.
 XX 11-FEB-2000; 2000US-0181797P.
 XX 06-MAR-2000; 2000US-018516P.
 XX 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 XX Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 XX
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX Claim 88; Page 71; 200pp; English.
 PS
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The

CC erythropoietin, granulocyte colony stimulating factor protein and
XX interferon alpha
SQ Sequence 17 BP; 6 A; 2 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e-02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914

DB 1 AACAGATATTTTCTT 17

RESULT 131

AAAF03080

ID AAF03080 standard; DNA; 17 BP.

XX AAF03080;

AC AAF03080;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #1375.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;

KW interferon alpha; ss.

XX Homo sapiens.

OS WO2000061729-A2.

PN 19-OCT-2000.

XX 11-APR-2000; 2000WO-US009721.

PR 12-APR-1999; 99US-0129390P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Zwick M, Pavco P, Mcswiggen J;

XX WPI; 2000-647423/62.

DR Enzymatic and antisense nucleic acid inhibition of repressor genes,

PT useful for producing e.g. granulocyte colony stimulating factor protein,
PT interferon alpha and erythropoietin.
XX Claim 37; Page 87; 164pp; English.

XX The present invention relates to enzymatic and antisense nucleic acid

CC molecules that act as inhibitors of the expression of repressor genes
CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
CC factor gene, IRF-2 and/or the CAAAT Displacement Protein (CDP).
CC Inhibition of the repressor removes prevents inhibition (and
CC consequently increases expression of) genes involved in the production of
CC erythropoietin, granulocyte colony stimulating factor protein and
CC interferon alpha

SQ Sequence 17 BP; 5 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.1e-02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 901 AAGATCTTTTCTTCAA 917

DB 1 AAGATATTTTCTTCA 17

RESULT 132

ABK03648

ID ABK03648 standard; RNA; 17 BP.

XX

AC

XX

DT 12-MAR-2002 (first entry)

DE

XX Human CD20 DNazyme #102.

XX

KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
inflammatory arthropathy; central nervous system injury;
cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
Parkinson's disease; ataxia; Huntington's disease;
Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.

OS Synthetic.

PN WO200159103-A2.

XX 16-AUG-2001.

XX 09-FEB-2001; 2001WO-US004273.

XX 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

XX (CHOW/) CHOWRIRA B M.

PI Blatt L, Mcswiggen J, Chowrira BM;

XX WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
constructs, which down regulate expression of a CD20 gene or neurite
growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
central nervous system injury.

PS Claim 30; Page 161; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
expression of a CD20 gene and a nucleic acid molecule which down
regulates expression of a neurite growth inhibitor gene (NOGO). The
nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) or
an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
Furthermore, it may be contacted with a cell to reduce CD20 activity of
the cell and treat a patient having a condition associated with the level
of CD20. The treatment may further comprise the use of one or more
therapies. In particular, the CD20 targeting nucleic acid may be used to
treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
targeting nucleic acid is used to cleave RNA of the NOGO gene in the
presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
nucleic acid may be contacted with a cell to reduce NOGO activity of the
cell and treat a patient having a condition associated with the level of
NOGO. The treatment may further comprise the use of one or more
therapies. In particular, the NOGO-targeting nucleic acid may be used to
treat central nervous system (CNS) injury and cerebrovascular accident

PS Claim 77; Page 71; 148pp; English.

CC The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphorodithioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. CC Because of the high selectivity for targeted RNA, (A) can also be used to correlate inhibition of gene expression with alterations in phenotype, particularly for identification of therapeutic targets, and as research reagents (for RNA, in the same way that restriction endonucleases are used with DNA). The combination of modifications in (A) improves resistance to nucleases, binding affinity and/or activity. AAA23503 to AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their corresponding target sequences. CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent their corresponding target sequences. AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present invention

CC Sequence 17 BP; 2 A; 1 C; 2 G; 12 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1523 GTATCATATAAAATAAAA 1539
|||||
DB 17 GTAACACAAAAATAAAA 1

RESULT 129

AAA25187/c

ID AAA25187 standard; DNA; 17 BP.

XX AAA25187;

AC AAA25187;

DT 19-JUL-2000 (first entry)

XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1685.

DE Oestrogen receptor; c-ras; bcl-2; ribozyme; cleavage;

XX hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;

KW gene expression modification; cancer; phosphorothioate; endonuclease;

XX anticancer; breast cancer; endometrium cancer; ss.

OS Homo sapiens.

XX WO954459-A2.

PN 28-OCT-1999.

XX 19-APR-1999; 99WO-US008547.

PF 20-APR-1998; 98US-0082404P.

PR 23-JUN-1998; 98US-00103636.

XX (RIBO-) RIBOZYME PHARM INC.

PA Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matulic-Adamic J;
XX WPI; 2000-013248/01.

DR New nucleic acids that interact, and optionally cleave, target sequences, PT used to treat cancer.

XX Claim 77; Page 71; 148pp; English.

CC The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphorodithioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. CC Because of the high selectivity for targeted RNA, (A) can also be used to correlate inhibition of gene expression with alterations in phenotype, particularly for identification of therapeutic targets, and as research reagents (for RNA, in the same way that restriction endonucleases are used with DNA). The combination of modifications in (A) improves resistance to nucleases, binding affinity and/or activity. AAA23503 to AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their corresponding target sequences. CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent their corresponding target sequences. AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present invention

CC Sequence 17 BP; 3 A; 1 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1522 TGATCATATAAAATAAAA 1538
|||||
DB 17 TGTACACAAAAATAAAA 1

RESULT 130

AAF03078

ID AAF03078 standard; DNA; 17 BP.

XX AAF03078;

AC AAF03078;

DT 16-FEB-2001 (first entry)

XX Hammerhead ribozyme substrate #1373.

DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;

XX interferon alpha; ss.

KW Homo sapiens.

OS WO2000061729-A2.

PN 19-OCT-2000.

XX 11-APR-2000; 2000WO-US009721.

PF 12-APR-1999; 99US-0129390P.

PR (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
PI WPI; 2000-647423/62.

DR Enzymatic and antisense nucleic acid inhibition of repressor genes. PT useful for producing e.g. granulocyte colony stimulating factor protein, PT interferon alpha and erythropoietin.

XX Claim 37; Page 87; 164pp; English.

CC The present invention relates to enzymatic and antisense nucleic acid molecules that act as inhibitors of the expression of repressor genes encoding the TR2 Orphan Receptor, EAR3/COUP-TF-1, the GATA transcription factor gene, Irf-2 and/or the C/EBP Displacement Protein (CDP). CC Inhibition of the repressors removes inhibition (and consequently increases expression of) genes involved in the production of

CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT.
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4 AAGTTTACAAATGAAGTT 20
DB 17 AAGTTTACAAAGACTT 1
RESULT 127
ID AAA23041 standard; RNA; 17 BP.
AC AAA23041;
XX
DT 19-JUN-2000 (first entry)
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6267.
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
OS Homo sapiens.
XX
XX WO9950403-A2.
PN
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
PI WPI; 1999-591315/50.
DR
XX Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
PS Claim 54; Page 258; 305pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with RNA

CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT.
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 1.1e+02;
Matches 5; Conservative 10; Mismatches 2; Indels 0; Gaps 0;
QY 1037 ATCAAGTTTTTCTTTTT 1053
DB 1 AUCAGUUUUUUUUUUU 17
RESULT 128
ID AAA25186 standard; DNA; 17 BP.
XX
AC AAA25186;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1684.
KW Oestrogen receptor; c-ras; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
XX WO9954459-A2.
PN
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
XX
PR 23-JUN-1998; 98US-00103636.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matlic-Adamic J;
XX WPI; 2000-013248/01.
DR
XX New nucleic acids that interact, and optionally cleave, target sequences,
PT used to treat cancer.
XX

CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 2 G; 0 T; 6 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 1.1e-02;
 Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
 QY 643 AACCTGTTCTCTCACTGC 659
 Db 1 AACUCGUUCCUUAUUGC 17
 RESULT 125
 ID AAA23042 standard; RNA; 17 BP.
 AC AAA23042;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6268.
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS
 XX WO9950403-A2.
 PN
 XX 07-OCT-1999.
 PD
 XX 24-MAR-1999; 99WO-US006507.
 PF
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 PI
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 PS
 XX Claim 54; Page 258; 305pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to
 CC corresponding target sequences; AAA17685 to AAA18386 to AAA19086
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 29.4%; Pred. No. 1.1e+02;
 Matches 5; Conservative 10; Mismatches 2; Indels 0; Gaps 0;
 QY 1038 TCAGTTTTTCTTTT 1054
 Db 1 UCAGUUUUUUUUUUUA 17
 RESULT 126
 ID AAA18827 standard; RNA; 17 BP.
 AC AAA18827;
 XX
 XX 19-JUN-2000 (first entry)
 DT
 DE Human TIE-2 substrate sequence SEQ ID NO:2053.
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS
 XX WO9950403-A2.
 PN
 XX 07-OCT-1999.
 PD
 XX 24-MAR-1999; 99WO-US006507.
 PF
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 PI
 XX WPI; 1999-591315/50.
 DR
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 PS
 XX Claim 56; Page 119; 305pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18386 to AAA19086
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

PT growth factor receptor, useful for inhibiting cell proliferation and for
 PT treating cancers.

PS Claim 5; Page 83; 109pp; English.

CC The present invention describes enzymatic nucleic acid molecules (NAMs)
 CC which specifically cleave RNA derived from an epidermal growth factor
 CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 CC represent specifically claimed target sequence from human EGF-R. AAV98044
 CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
 CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
 CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
 CC expression levels e.g. to inhibit cell proliferation in the prevention or
 CC treatment of cancers. The NAMs can also be used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of EGF-R RNA in a cell

XX Sequence 17 BP; 6 A; 4 C; 1 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.1e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1687 AGTGTCTCTCAACAT 1703

DB 1 AAGUCCUCCUAAAAU 17

RESULT 123

AAV98035/C

ID . AAV98035 standard; RNA; 17 BP.

AC AAV98035;

DT 17-MAR-1999 (first entry)

DE Human EGF-R target sequence nucleotide position 5497.

XX Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
 KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
 KW cancer; genetic drift; detection; mutation; ss.

XX Homo sapiens.

XX WO9833893-A2.

XX 06-AUG-1998.

PF 14-JAN-1998; 98WO-US000730.

PR 31-JAN-1997; 97US-0036476P.

PR 04-DEC-1997; 97US-00985162.

PA (RIBO-) RIBOZYME PHARM INC.

PA (UYAS-) UNIV ASTON.

PI Akhtar S, Fell P, Mcswiggen JA;

XX WPI; 1998-437449/37.

DR Enzymatic nucleic acids - which cleave RNA derived from an epidermal
 PT growth factor receptor, useful for inhibiting cell proliferation and for
 PT treating cancers.

PS Claim 5; Page 85; 109pp; English.

XX The present invention describes enzymatic nucleic acid molecules (NAMs)
 CC which specifically cleave RNA derived from an epidermal growth factor
 CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 CC represent specifically claimed target sequence from human EGF-R. AAV98044
 CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
 CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
 CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR

CC expression levels e.g. to inhibit cell proliferation in the prevention or
 CC treatment of cancers. The NAMs can also be used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of EGF-R RNA in a cell

XX Sequence 17 BP; 2 A; 2 C; 2 G; 0 T; 11 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAATGAAATA 176

DB 17 GAGACAAAATCAATA 1

RESULT 124

AAAZ3189

ID AAZ3189 standard; RNA; 17 BP.

AC AAZ3189;

DT 19-JUN-2000 (first entry)

DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6415.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US006507.

XX 27-MAR-1998; 98US-0079678P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or stability
 of an mRNA encoding an angiogenic factors.

XX Claim 54; Page 267; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
 CC AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,
 CC and AA17168 to AA17560 and AA17623 to AA17684 represent their
 CC corresponding target sequences; AA17685 to AA18385 and AA19087 to
 CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
 CC and AA19155 to AA19222 represent their corresponding target sequences;
 CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
 CC AA21596 to AA21688 represent their corresponding target sequences;
 CC AA21689 to AA22475 and AA23263 to AA23342 represent ribozyme sequences
 CC for integrin subunit beta 3, and AA22476 to AA23262, AA23343 to
 CC AA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or

KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX Mus sp.
XX WO9715662-A2.
XX PD 01-MAY-1997.
XX 25-OCT-1996; 96WO-US017480.
XX 26-OCT-1995; 95US-0005974P.
XX 11-JAN-1996; 96US-00584040.
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR) CHIRON CORP.
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX Claim 4; Page 158; 218pp; English.
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.1e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1679 TGCTCTGTAAGTTGCTT 1695
DB 17 TGCTCTCTTAGTTGCTT 1
RESULT 121
AAX68927
ID AAX68927 standard; RNA; 17 BP.
XX AC AAX68927;
XX 28-JUL-1999 (first entry)
XX Human flt1 VEGF receptor hammerhead ribozyme substrate #222.
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX Homo sapiens.
XX WO9715662-A2.
XX 01-MAY-1997.
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal

PF 25-OCT-1996; 96WO-US017480.
XX 26-OCT-1995; 95US-0005974P.
XX 11-JAN-1996; 96US-00584040.
XX (RIBO-) RIBOZYME PHARM INC.
XX (CHIR) CHIRON CORP.
XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX WPI; 1997-259017/23.
XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
XX rheumatoid arthritis, etc., in a human patient.
XX Claim 4; Page 53; 218pp; English.
XX The present invention describes nucleic acid molecules which modulate the
XX synthesis, expression and/or stability of a mRNA encoding 1 or more
XX receptors of vascular endothelial growth factor (VEGF). A patient
XX (preferably human) having a condition associated with the level of the
XX fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
XX receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
XX angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
XX treated by administering the nucleic acid molecule or the expression
XX vector to the patient. AAX67275 to AAX75752 represent specific examples
XX of nucleic acid molecules from the present invention
XX Sequence 17 BP; 6 A; 3 C; 1 G; 0 T; 7 U; 0 Other;
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 52.9%; Pred. No. 1.1e+02;
XX Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 1666 TACTGGTTAATTACAA 1082
DB 1 UACUCGUUAUUAUCAA 17
RESULT 122
AAV97951
ID AAV97951 standard; RNA; 17 BP.
XX AC AAV97951;
XX 17-MAR-1999 (first entry)
XX Human EGF-R target sequence nucleotide position 5188.
XX Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX Homo sapiens.
XX WO9833893-A2.
XX 06-AUG-1998.
XX 14-JAN-1998; 98WO-US000730.
XX 31-JAN-1997; 97US-0036476P.
XX 04-DEC-1997; 97US-00985162.
XX (RIBO-) RIBOZYME PHARM INC.
XX (UYAS-) UNIV ASTON.
XX Akhtar S, Fell P, Mcswiggen JA;
XX WPI; 1998-437449/37.
XX Enzymatic nucleic acids - which cleave RNA derived from an epidermal

SQ Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.1e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 919 GACAGGTTCTTGGCT 935
 DB 1 GCCAUGUUCUUGGCU 17
 |||:|:|:|:|:
 |||:|:|:|:|:
 RESULT 118
 AAX72925
 ID AAX72925 standard; RNA; 17 BP.
 XX AAX72925;
 XX
 XX 28-JUL-1999 (first entry)
 DT
 DE
 XX
 XX
 XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #358.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 XX Mus sp.
 OS
 XX
 XX W09715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US017480.
 PF
 XX
 XX 26-OCT-1995; 95US-0005974P.
 PR
 XX 11-JAN-1996; 96US-00584040.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX (CHIR) CHIRON CORP.
 PA
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 PI
 XX WPI; 1997-259017/23.
 PD
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PR rheumatoid arthritis, etc., in a human patient.
 PT
 XX
 XX Claim 4; Page 134; 218pp; English.
 PS
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.1e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 919 GACAGGTTCTTGGCT 935
 DB 1 GCCAUGUUCUUGGCU 17
 |||:|:|:|:|:
 |||:|:~|:|:|:~|:
 RESULT 120
 AAX74584/c
 ID AAX74584 standard; RNA; 17 BP.
 XX
 XX AAX74584;
 XX
 XX
 XX 28-JUL-1999 (first entry)
 DT
 DE
 XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #112.
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 XX Mus sp.
 OS
 XX
 XX W09715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US017480.
 PF
 XX
 XX 26-OCT-1995; 95US-0005974P.
 PR
 XX 11-JAN-1996; 96US-00584040.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX (CHIR) CHIRON CORP.
 PA
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 PI
 XX WPI; 1997-259017/23.
 PD
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PR rheumatoid arthritis, etc., in a human patient.
 PT
 XX
 XX Claim 4; Page 134; 218pp; English.
 PS
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.1e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 919 GACAGGTTCTTGGCT 935
 DB 1 GCCAUGUUCUUGGCU 17
 |||:|:~|:|:~|:
 |||:|:~|:~|:~|:
 RESULT 120
 AAX74584/c
 ID AAX74584 standard; RNA; 17 BP.
 XX
 XX AAX74584;
 XX
 XX
 XX 28-JUL-1999 (first entry)
 DT
 DE
 XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #112.
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 XX Mus sp.
 OS
 XX
 XX W09715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US017480.
 PF
 XX
 XX 26-OCT-1995; 95US-0005974P.
 PR
 XX 11-JAN-1996; 96US-00584040.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX (CHIR) CHIRON CORP.
 PA
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 PI
 XX WPI; 1997-259017/23.
 PD
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PR rheumatoid arthritis, etc., in a human patient.
 PT
 XX
 XX Claim 4; Page 134; 218pp; English.
 PS
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 1 A; 5 C; 4 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.1e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 919 GACAGGTTCTTGGCT 935
 DB 1 GCCAUGUUCUUGGCU 17
 |||:|:~|:~|:~|:
 |||:|:~|:~|:~|:
 RESULT 120
 AAX74584/c
 ID AAX74584 standard; RNA; 17 BP.
 XX
 XX AAX74584;
 XX
 XX
 XX 28-JUL-1999 (first entry)
 DT
 DE
 XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #112.
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 XX Mus sp.
 OS
 XX
 XX W09715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US017480.
 PF
 XX
 XX 26-OCT-1995; 95US-0005974P.
 PR
 XX 11-JAN-1996; 96US-00584040.
 PR
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX (CHIR) CHIRON CORP.
 PA
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 PI
 XX WPI; 1997-259017/23.
 PD
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PR rheumatoid arthritis, etc., in a human patient.
 PT
 XX
 XX Claim 4; Page 134; 218pp; English.
 PS
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the

CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.1e+02;
 Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 918 AGACAGGTTCTTCTGCG 934
 |||||: :|||
 Db 1 AGACAGGUAUUCUGCG 17
 RESULT 116
 AAX63966
 ID AAX63966 standard; RNA; 17 BP.
 XX
 AC AAX63966;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 DE Rabbit stromelysin hammerhead target SEQ ID NO:598.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Oryctolagus cuniculus.
 XX
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 XX
 PR 23-DEC-1994; 94US-00363253.
 XX
 PR 23-DEC-1994; 94US-00363254.
 XX
 PR 17-FEB-1995; 95US-00390850.
 XX
 PR 20-APR-1995; 95US-00426124.
 XX
 PR 02-MAY-1995; 95US-00432874.
 XX
 PR 04-MAY-1995; 95US-00434509.
 XX
 PR 07-JUL-1995; 95US-0000951P.
 XX
 PR 07-JUL-1995; 95US-0000974P.
 XX
 PR 07-AUG-1995; 95US-00512861.
 XX
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX
 WPI; 1996-300653/30.
 XX
 DR Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 PS Example 1; Page 155; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance

CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 17 BP; 7 A; 2 C; 4 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 1.1e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 1144 AAAAAATTGATGACG 1160
 |||||: :|||
 Db 1 AGAAAAUUGAUGCUGC 17
 RESULT 117
 AAX71351
 ID AAX71351 standard; RNA; 17 BP.
 XX
 AC AAX71351;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Human KDR VEGF receptor hammerhead ribozyme substrate #363.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 XX
 PR 11-JAN-1996; 96US-00584040.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PA (CHIR) CHIRON CORP.
 XX
 PI Pavco P, McSwiggen J, Stinchcomb D, Escobedo J;
 XX
 WPI; 1997-259017/23.
 XX
 DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 PS Claim 4; Page 108; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

Query Match 0.88; Score 13.8; DB 1; Length 17;

OS	Homo sapiens.	20-JUL-1999	(first entry)	DT
XX	US2004137589-A1.			XX
XX	15-JUL-2004.			DE
PD				XX
XX	26-NOV-2003; 2003US-00723361.			KW
PF				KW
XX	26-MAY-2000; 2000US-0207456P.			KW
XX	21-SEP-2000; 2000US-0234687P.			OS
PR	27-SEP-2000; 2000US-0236359P.			XX
PR	04-OCT-2000; 2000GB-00024263.			XX
PR	30-JAN-2001; 2001WO-US000661.			XX
PR	30-JAN-2001; 2001WO-US000662.			XX
PR	30-JAN-2001; 2001WO-US000663.			XX
PR	30-JAN-2001; 2001WO-US000664.			XX
PR	30-JAN-2001; 2001WO-US000665.			XX
PR	30-JAN-2001; 2001WO-US000666.			XX
PR	30-JAN-2001; 2001WO-US000667.			XX
PR	30-JAN-2001; 2001WO-US000668.			XX
PR	30-JAN-2001; 2001WO-US000669.			XX
PR	30-JAN-2001; 2001WO-US000670.			XX
PR	05-FEB-2001; 2001US-0266860P.			XX
PR	25-MAY-2001; 2001US-00866108.			XX
XX				XX
PA	(GUYI/) GU Y.			XX
PA	(JIYY/) JI Y.			XX
PA	(PENN/) PENN S G.			XX
PA	(HANZ/) HANZEL D K.			XX
PA	(RANK/) RANK D.			XX
PA	(CHEN/) CHEN W.			XX
PA	(SHAN/) SHANNON M E.			XX
XX				XX
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;			PI
XX				PI
XX	WPI; 2004-533378/51.			XX
DR				XX
XX				XX
PT	Novel myosin-like protein-1, useful for treating or preventing disorder			PT
PT	associated with decreased expression or activity of human genome-derived			PT
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle			PT
PT	function.			PT
XX				XX
PS	Disclosure; SEQ ID NO 10430; Opp; English.			PS
XX				XX
CC	The invention relates to a novel polypeptide (I) comprising a sequence			CC
CC	(SI) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully			CC
CC	defined in the specification, a fragment of at least 8 amino acids of			CC
CC	(SI), 95% deviation from (SI) which are conservative substitutions, and			CC
CC	65% identity to (SI). A polypeptide of the invention acts as an agonist or			CC
CC	antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A			CC
CC	pharmaceutical composition of the invention is useful for treating or			CC
CC	preventing a disorder associated with decreased expression or activity of			CC
CC	hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.			CC
CC	The present sequence represents a 17-mer nucleotide, used in the			CC
CC	invention for scanning the sequence represented in ACNG3103			CC
XX				XX
SQ	Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;			SQ
	Query Match 0.8%; Score 14; DB 1; Length 17;			
	Best Local Similarity 100.0%; Pred. No. 1.1e+02;			
	Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	873 TTTTGTGCTGCTCA 886			QY
DB	16 TTTTGTGCTGCTCA 3			DB
RESULT 113				
ID	AAX63973			
XX	AAX63973 standard; RNA; 17 BP.			XX
XX				XX
XX	AAX63973;			XX

20-JUL-1999	(first entry)	20-JUL-1999	(first entry)
Rabbit stromelysin hammerhead target SEQ ID NO:605.		Rabbit stromelysin hammerhead target SEQ ID NO:605.	
Arthritic condition; graft tolerance; immune response; target: cleavage;		Arthritic condition; graft tolerance; immune response; target: cleavage;	
hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;		hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;	
stromelysin; synovial membrane; joint; arthritis; osteoarthritis;		stromelysin; synovial membrane; joint; arthritis; osteoarthritis;	
rheumatoid arthritis; autoimmune disease; allergy; inflammation;		rheumatoid arthritis; autoimmune disease; allergy; inflammation;	
diagnosis; SB.		diagnosis; SB.	
Oryctolagus cuniculus.		Oryctolagus cuniculus.	
WO9618736-A2.		WO9618736-A2.	
20-JUN-1996.		20-JUN-1996.	
22-NOV-1995;	95WO-US015516.	22-NOV-1995;	95WO-US015516.
13-DEC-1994;	94US-00354920.	13-DEC-1994;	94US-00354920.
23-DEC-1994;	94US-00363253.	23-DEC-1994;	94US-00363253.
23-DEC-1994;	94US-00363254.	23-DEC-1994;	94US-00363254.
17-FEB-1995;	95US-00390850.	17-FEB-1995;	95US-00390850.
PR 02-APR-1995;	95US-00426124.	PR 02-APR-1995;	95US-00426124.
PR 04-MAY-1995;	95US-00432874.	PR 04-MAY-1995;	95US-00432874.
PR 07-JUL-1995;	95US-0000951P.	PR 07-JUL-1995;	95US-0000951P.
PR 07-JUL-1995;	95US-0000974P.	PR 07-JUL-1995;	95US-0000974P.
PR 07-AUG-1995;	95US-00512861.	PR 07-AUG-1995;	95US-00512861.
PR 05-OCT-1995;	95US-00541365.	PR 05-OCT-1995;	95US-00541365.
(RIBO-) RIBOZYME PHARM INC.		(RIBO-) RIBOZYME PHARM INC.	
Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;		Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;	
McEwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;		McEwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;	
Karpelsky A, Thompson JD, Modak A, Burgin A;		Karpelsky A, Thompson JD, Modak A, Burgin A;	
WPI; 1996-300653/30.		WPI; 1996-300653/30.	
Enzymatic nucleic acid molecules having a hammer-head motif - used for		Enzymatic nucleic acid molecules having a hammer-head motif - used for	
the treatment of arthritis, induction of graft tolerance or treatment of		the treatment of arthritis, induction of graft tolerance or treatment of	
auto-immune diseases.		auto-immune diseases.	
Example 1; Page 155; 307pp; English.		Example 1; Page 155; 307pp; English.	
The present invention describes a novel enzymatic nucleic acid (ENA)		The present invention describes a novel enzymatic nucleic acid (ENA)	
having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues		having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues	
: (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least		: (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least	
ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's		ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's	
can inhibit collagenase and stromelysin production in the synovial		can inhibit collagenase and stromelysin production in the synovial	
membrane of joints for the treatment or prevention of arthritis.		membrane of joints for the treatment or prevention of arthritis.	
Particularly osteoarthritis or rheumatoid arthritis. The ENA's can also		Particularly osteoarthritis or rheumatoid arthritis. The ENA's can also	
be used to treat antigen presenting cells of a donor to induce tolerance		be used to treat antigen presenting cells of a donor to induce tolerance	
in a recipient to an alloantigen of a donor. They can also be used for		in a recipient to an alloantigen of a donor. They can also be used for	
enhancing graft tolerance or for treating autoimmune disease, and for		enhancing graft tolerance or for treating autoimmune disease, and for	
treating allergies and other inflammatory conditions. The ENA's can also		treating allergies and other inflammatory conditions. The ENA's can also	
be used in diagnosis. Ribozyme therapy impacts on the expression of		be used in diagnosis. Ribozyme therapy impacts on the expression of	
stromelysin without introducing the non-specific effects upon gene		stromelysin without introducing the non-specific effects upon gene	
expression which accompany treatment with retinoids and dexamethasone.		expression which accompany treatment with retinoids and dexamethasone.	
The concentration of ribozyme required to affect a therapeutic treatment		The concentration of ribozyme required to affect a therapeutic treatment	
is lower than that required of antisense molecules, and is highly		is lower than that required of antisense molecules, and is highly	
specific. The present sequence is used in the exemplification of the		specific. The present sequence is used in the exemplification of the	
present invention		present invention	
Sequence 17 BP; 4 A; 3 C; 3 G; 0 T; 7 U; 0 Other;		Sequence 17 BP; 4 A; 3 C; 3 G; 0 T; 7 U; 0 Other;	
Query Match 0.8%; Score 13.8; DB 1; Length 17;		Query Match 0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity 47.1%; Pred. No. 1.1e+02;		Best Local Similarity 47.1%; Pred. No. 1.1e+02;	
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;		Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;	
1186 ACCTACTCTTTGTGTAGA 1202		1186 ACCTACTCTTTGTGTAGA 1202	
: : : : : :		: : : : : :	
1 ACAUACUUCUUGUGGA 17		1 ACAUACUUCUUGUGGA 17	

```

XX OS Homo sapiens.
XX PN WO2003025177-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004523.
XX PR 17-SEP-2001; 2001FR-00011980.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-313354/30.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumours and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; SEQ ID NO 1211; 30pp; French.
XX CC This invention relates to novel isolated nucleic acid sequences involved
XX CC in the phenomena of tumour suppression, tumour reversion, apoptosis
XX CC and/or resistance to viruses. The invention may be useful for the
XX CC development of compounds with a cytostatic, virucide, neuroprotective,
XX CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
XX CC probes and primers for detecting, identifying, quantifying and/or
XX CC amplifying nucleic acid, for example as one component of a gene chip, in
XX CC vitro as antisense reagents and for production of recombinant
XX CC polypeptides. The invention may therefore be useful for preparation of
XX CC pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia. The
XX CC present sequence is that of a nucleic acid sequence of the invention.
XX CC Note: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/publishedpct_sequences
XX SQ Sequence 17 BP; 4 A; 4 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 TGGGAATAAGATC 906
   |||||
DB 14 TGGGAATAAGATC 1

RESULT 111
ACN73527/c
ID ACN73527 standard; DNA; 17 BP.
XX AC ACN73527;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMPLP-1 probe SEQ ID NO:10429.
XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.

```

```

PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX GUYY/) GU Y.
XX JIYY/) JI Y.
XX PENN/) PENN S G.
XX HANZ/) HANZEL D K.
XX RANK/) RANK D.
XX CHEN/) CHEN W.
XX SHANN/) SHANNON M E.
XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX Disclosure; SEQ ID NO 10429; Opp; English.
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
   |||||
DB 17 TTTTGATGCTGTCA 4

RESULT 112
ACN73528/c
ID ACN73528 standard; DNA; 17 BP.
XX AC ACN73528;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMPLP-1 probe SEQ ID NO:10430.
XX KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX KW skeletal muscle function.

```

```

RESULT 108
ADB00378/C
ADB00378 standard; DNA; 17 BP.
XX
XX
AC
ADB00378;
XX
XX
DT 20-NOV-2003 (first entry)
XX
XX
Human MD23 scanning oligonucleotide SEQ ID 1364.
XX
XX
Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX
XX
zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
XX
XX
chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX
XX
developmental disorder; ss.
XX
XX
Homo sapiens.
XX
OS
OS
EP1281758-A2.
XX
XX
PD 05-FEB-2003.
XX
XX
30-JUL-2002; 2002EP-00016874.
XX
XX
02-AUG-2001; 2001US-00922181.
XX
XX
(AEOM-) AEOMICA INC.
XX
XX
Shannon M, Gu Y, Nguyen C;
XX
XX
WPI; 2003-423107/40.
XX
XX
New zinc finger-containing proteins and nucleic acids, useful in
XX
XX
manufacturing a medicament for treating or preventing a disorder
XX
XX
associated with decreased or increased expression or activity of MD23,
XX
XX
MD24, MD27 or MD212, e.g. cancer.
XX
XX
Example 8; SEQ ID NO 1364; 103pp; English.
XX
XX
The present invention relates to novel human zinc finger-containing
XX
XX
proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX
XX
encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX
XX
MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX
XX
15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX
XX
or in manufacturing a medicament for treating or preventing a disorder
XX
XX
associated with decreased or increased expression or activity of MD23,
XX
XX
MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX
XX
acids and proteins are also useful for diagnosing or monitoring a disease
XX
XX
caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX
XX
acids can also be used as probes to detect and characterize gross
XX
XX
alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX
XX
useful in constructing microarrays for measuring gene expression. The
XX
XX
proteins are useful as therapeutic agents for gene therapy or as
XX
XX
vaccines. The present sequence was used to illustrate the invention.
XX
XX
Sequence 17 BP; 6 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX
Query Match 0.8%; Score 14; DB 1; Length 17;
XX
XX
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX
XX
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0
XX
XX
QY 929 TCTGGCTGAAGGTT 942
XX
XX
DB 14 TCTGGCTGAAGGTT 1
XX
XX
RESULT 109
ADB00374/C
ADB00374 standard; DNA; 17 BP.
XX
XX
ADB00374;
XX
XX

```

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10430.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX PN WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US016981.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PR 21-SEP-2000; 2000US-0234687P.
 XX PR 27-SEP-2000; 2000US-0236359P.
 XX PR 04-OCT-2000; 2000GB-00024263.
 XX PR 30-JAN-2001; 2001WO-US000661.
 XX PR 30-JAN-2001; 2001WO-US000662.
 XX PR 30-JAN-2001; 2001WO-US000663.
 XX PR 30-JAN-2001; 2001WO-US000664.
 XX PR 30-JAN-2001; 2001WO-US000665.
 XX PR 30-JAN-2001; 2001WO-US000666.
 XX PR 30-JAN-2001; 2001WO-US000667.
 XX PR 30-JAN-2001; 2001WO-US000668.
 XX PR 30-JAN-2001; 2001WO-US000669.
 XX PR 30-JAN-2001; 2001WO-US000670.
 XX PR 05-FEB-2001; 2001US-0266860P.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX PS Disclosure; SEQ ID NO 10430; 214pp; English.
 XX CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
 CC -1 protein, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 873 TTTTGATGCTGTCA 886

DB 16 TTTTGATGCTGTCA 3
 RESULT 107
 ABT36548/C
 ID ABT36548 standard; DNA; 17 BP.
 XX AC ABT36548;
 XX DT 12-JUN-2003 (first entry)
 XX DE Tumour suppression related human fukutin oligo SEQ ID No 2185.
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 XX human fukutin; ds.
 OS Homo sapiens.
 XX PN WO2003025175-A2.
 XX PD 27-MAR-2003.
 XX PF 17-SEP-2002; 2002WO-IB004208.
 XX PR 17-SEP-2001; 2001FR-00011978.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PI Telerman A, Amson R, Tuijnder M;
 XX WPI; 2003-313353/30.
 XX PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 XX and transfected cells.
 XX PS Disclosure; Page 288; 720pp; French.
 XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 XX related human fukutin oligonucleotide of the invention
 SQ Sequence 17 BP; 11 A; 1 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1580 TTTTTCATTTTGA 1593
 DB 16 TTTTTCATTTTGA 3

Fri May 13 12:26:37 2005

XX PI Blatt L, Mcswiggen J, Chowrira BM;
XX XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX Claim 88; Page 114; 200pp; English.
PS The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (Nogo). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving a an RNA motif) or
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) or
CC an amberyzyme (cleaving RNA with an NGN triplet), a zinyzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The Nogo-
CC targeting nucleic acid is used to cleave RNA of the Nogo gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce Nogo activity of the
CC cell and treat a patient having a condition associated with the level of
CC Nogo. The treatment may further comprise the use of one or more
CC therapies. In particular, the Nogo-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of Nogo expression. The present
CC sequence is a DNzyme molecule of the invention
XX Sequence 17 BP; 10 A; 0 C; 5 G; 0 T; 2 U; 0 Other;
SQ Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 969 TTTAATTCTCTCT 982
DB 14 TTTAATTCTCTCT 1
RESULT 105
ABN10437/C
ID ABN10437 standard; DNA; 17 BP.
XX ABN10437;
AC 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.
DT Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
OS WO200192524-A2.
XX 29-MAY-2002 (first entry)
FN Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.
XX

PD 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
PF 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX (ABOM-) ABOMICA INC.
PA Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 10429; 214pp; English.
PS The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterize and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.1e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 873 TTTTCATGCTGTCA 886
DB 17 TTTTCATGCTGTCA 4
RESULT 106
ABN10438/C
ID ABN10438 standard; DNA; 17 BP.
XX ABN10438;
AC 29-MAY-2002 (first entry)
DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.
XX


```

DE H. pylori strain J99 genome fragment SEQ ID NO:58.
XX ds; stroke: phosphodiesterase 4D; PDE4D.
XX
XX Helicobacter pylori.
OS
XX US2004091865-A1.
XX
XX 13-MAY-2004.
XX
XX 25-SEP-2002; 2002US-00255120.
XX
XX 19-MAR-2001; 2001US-00811352.
XX
XX 04-FEB-2002; 2002US-00067514.
XX
XX (DECO-) DECODE GENETICS EHF.
XX
XX Gretnardottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;
PI WPI; 2004-374932/35.
XX
XX Diagnosing susceptibility to a stroke in an individual comprising
PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.
PT
XX Disclosure; SEQ ID NO 58; 574pp; English.
XX
XX The invention relates to a method of diagnosing susceptibility to a
CC stroke in an individual comprising screening for an at-risk haplotype in
CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC an individual susceptible to stroke (affected) compared to a healthy
CC individual (control), where the at-risk haplotype increases risk of
CC stroke significantly. The composition, methods and kit are useful for
CC diagnosing, predicting of clinical course and treating stroke using
CC polymorphisms in the PDE4D gene. These may also be used in identifying
CC agents that enhance or inhibit PDE4D polypeptide expression or activity.
CC The present sequence represents a fragment of H. pylori strain J99 genome
CC which is not referred to at all in the main body of the specification.
XX
XX Sequence 15 BP; 11 A; 2 C; 1 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 198 AAAAAATCCAGAA 211
Db 1 AAAAAATCCAGAA 14
RESULT 103
ADO49479
ID ADO49479 standard; DNA; 16 BP.
XX
XX ADO49479;
AC
XX 29-JUL-2004 (first entry)
XX
XX H. pylori strain J99 genome fragment SEQ ID NO:102.
DE
XX ds; stroke: phosphodiesterase 4D; PDE4D.
XX
XX Helicobacter pylori.
OS
XX US2004091865-A1.
XX
XX 13-MAY-2004.
XX
XX 25-SEP-2002; 2002US-00255120.
XX
XX 19-MAR-2001; 2001US-00811352.
XX
XX 04-FEB-2002; 2002US-00067514.
XX
XX (DECO-) DECODE GENETICS EHF.
XX

```

```

XX PI Gretnardottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;
XX WPI; 2004-374932/35.
XX
XX Diagnosing susceptibility to a stroke in an individual comprising
PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.
PT
XX Disclosure; SEQ ID NO 102; 574pp; English.
XX
XX The invention relates to a method of diagnosing susceptibility to a
CC stroke in an individual comprising screening for an at-risk haplotype in
CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
CC an individual susceptible to stroke (affected) compared to a healthy
CC individual (control), where the at-risk haplotype increases risk of
CC stroke significantly. The composition, methods and kit are useful for
CC diagnosing, predicting of clinical course and treating stroke using
CC polymorphisms in the PDE4D gene. These may also be used in identifying
CC agents that enhance or inhibit PDE4D polypeptide expression or activity.
CC The present sequence represents a fragment of H. pylori strain J99 genome
CC which is not referred to at all in the main body of the specification.
XX
XX Sequence 16 BP; 11 A; 2 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 197 AAAAAATCCAGAA 210
Db 3 AAAAAATCCAGAA 16
RESULT 104
ABK02203/c
ID ABK02203 standard; RNA; 17 BP.
XX
XX ABK02203;
AC
XX 12-MAR-2002 (first entry)
XX
XX Human NOGO DNAzyme #115.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAzyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX
XX 28-FEB-2000; 2000US-0185516P.
XX
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWIRA B M.

```

CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
 CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.
 XX
 XX Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.2; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.2e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 204 CCAAGAAATGCAGCACTTC 222
 DB 1 CCAAGAAATGCTGTCATTC 19

RESULT 100
 ABZ02308/c
 ID ABZ02308 standard; DNA; 50 BP.

XX ABZ02308;
 AC
 XX 09-JAN-2003 (first entry)
 DT
 DE Human leukocyte gene expression profiling probe SEQ ID NO 2299.

XX T7; leukocyte; gene expression profiling; allograft rejection;
 KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
 KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
 KW ss.

XX Homo sapiens.
 OS
 XX WO200257414-A2.

XX 25-JUL-2002.

XX 22-OCT-2001; 2001WO-US047856.

XX 20-OCT-2000; 2000US-0241994P.

XX 08-JUN-2001; 2001US-0296764P.

XX (BIOC-) BIOCARDIA INC.

XX Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
 PI Ly N, Woodward R, Quertermous T, Johnson F;
 PI WPI; 2002-636525/68.

XX New system for leukocyte expression profiling, diagnosing a disease, or
 PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis
 PT or congestive heart failure, comprises diagnostic oligonucleotides.

XX Claim 1; Page 399; Opp: English.

XX The invention relates to a system for detecting gene expression, which
 CC comprises one or two isolated DNA molecules that detect expression of a
 CC gene, where the gene corresponds to any of 8143 oligonucleotides
 CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
 CC for leukocyte expression profiling. It is particularly useful for
 CC diagnosing a disease, monitoring (rate of) progression of a disease,
 CC predicting therapeutic outcome, determining prognosis for a patient,
 CC predicting disease complications in an individual or monitoring response
 CC to treatment in an individual. The diseases include cardiac allograft
 CC rejection, kidney allograft rejection, liver allograft rejection,
 CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
 CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection

XX Sequence 50 BP; 14 A; 11 C; 8 G; 17 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.2; DB 1; Length 50;
 Best Local Similarity 58.1%; Pred. No. 1.4e+02;
 Matches 25; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1314 TTCTAAACAAATACTACTATTTCTTCCAGGATCTAACCA 1356
 DB 50 TGGCAGAGTAAGTATAATTTCTCAGTCCAGGATGTTAGGAA 8

RESULT 101

AAZ90906

ID AAZ90906 standard; DNA; 15 BP.

XX AAZ90906;

XX 24-MAY-2000 (first entry)

XX Human NR8 gene probe #134.

XX Haemopoietin receptor family; NR8; antibody; diagnosis;
 KW blood formation disorder; fusion protein; probe; ss.

XX Homo sapiens.

XX WO9967290-A1.

XX 29-DEC-1999.

XX 23-JUN-1999; 99WO-JP003351.

XX 24-JUN-1998; 98JP-00214720.

XX 19-OCT-1998; 98JP-00297409.

XX (CHUS) CHUGAI RES INST MOLECULAR MEDICINE INC.

XX Nomura H, Maeda M;

XX WPI; 2000-116933/10.

XX Hemopoietin receptor protein family NR8 used for diagnosis of blood
 PT formation disorders.

XX Example 1; Page 44; 176pp; Japanese.

XX The invention relates to the isolation of sequences encoding human
 CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
 CC were initially searched for comparison on a nucleic acid database with
 CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
 CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-259300 and AAZ90816-
 CC Z90925 represent specific examples of probe sequences used in the search.
 CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
 CC formation disorders. Compounds identified as binding to the proteins are
 CC used for the treatment of such disorders

XX Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 89;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 507 TGGAGCTCATGGAG 520

DB 1 TGGAGCTCATGGAG 14

RESULT 102

ADO49435

ID ADO49435 standard; DNA; 15 BP.

XX ADO49435;

XX 29-JUL-2004 (first entry)

XX

PR 29-MAY-2001; 2001US-0294170P.
 XX (SEQU-) SEQUELLA INC.
 PA (YOUNG/) YOUNG D B.
 PA (STEW/) STEWART G R.
 PA (OGNO/) O'GAORA P C E.
 XX Young DB, Stewart GR, O'gaora PCE;
 XX WPI; 2002-698637/75.
 DR Immunogenic composition of mycobacterial mutants with modified protein
 PT production capabilities, useful for vaccinating and treating infections
 PT in particular mycobacterial diseases such as tuberculosis and Crohn's
 PT disease.
 XX Example 2; Page 22; 59pp; English.
 PS The invention relates to an immunogenic composition of mycobacterial
 CC mutants with modified protein production capabilities. The invention also
 CC relates to methods for the treatment and prevention of infectious
 CC diseases. The methods and compositions of the invention are useful for
 CC vaccinating and treating infections in particular mycobacterial diseases
 CC such as tuberculosis and Crohn's disease. The invention is also used in
 CC gene therapy. The present sequence is a PCR primer used for amplifying
 CC Mycobacterium tuberculosis deltanapr mutant gene. This sequence is used
 CC to illustrate the method of the invention
 XX
 SQ Sequence 18 BP; 5 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. NO. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 623 CTACATTCAGGAGG 638
 DB 16 CTACATTCAGGAGG 1
 RESULT 98
 ABX03799
 ID ABX03799 standard; cDNA; 18 BP.
 AC
 AC ABX03799;
 DT 09-JAN-2003 (first entry)
 XX
 DE DNA encoding secreted protein signal peptide sequence #8.
 XX
 KW Differential display method; leucine-rich motif; transmembrane protein;
 KW secreted protein; secreted protein signal peptide; ss.
 XX
 OS Unidentified.
 XX
 PN WO200259259-A2.
 XX
 PD 01-AUG-2002.
 XX
 PF 23-JAN-2002; 2002WO-IL000071.
 XX
 PR 23-JAN-2001; 2001US-0263158P.
 XX
 PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
 XX
 PI Wrechner DH;
 XX
 XX WPI; 2002-599769/64.
 DR P-PSDB; ABG98328.
 XX
 XX Differential display method for identifying secreted or transmembrane
 PT protein, comprises contacting a DNA with a first primer that hybridizes
 PT to a sequence coding for a leucine-rich motif and with a second
 PT oligonucleotide primer.

XX Disclosure; Fig 2; 37pp; English.
 PS
 XX The invention relates to a differential display comprising contacting
 CC cDNA with a first primer that hybridizes to an oligonucleic sequence
 CC coding for a leucine-rich motif, and with a second oligonucleotide primer
 CC to form a cDNA-hybrid molecule. The method comprises obtaining mRNA from
 CC at least 2 samples, synthesizing cDNA from the RNA of each sample,
 CC contacting the cDNA with a first primer that hybridizes to an
 CC oligonucleic sequence coding for a leucine-rich motif, and with a second
 CC oligonucleotide primer to form cDNA-hybrid molecules, amplifying the cDNA
 CC hybrid molecules, detecting amplified products and comparing the
 CC amplified products from each sample to identify distinctive amplified
 CC products coding for at least one secreted or transmembrane protein. The
 CC method is useful for discovering novel secreted and/or transmembrane
 CC proteins which are important for cell processes and play an important
 CC role in determining its phenotype, and which act as mediators for the
 CC transfer of signals from external environment into the cell itself, thus
 CC modulating gene expression. Sequences ABX03792-ABX03869 represent DNA
 CC encoding secreted protein signal peptide sequences
 XX
 SQ Sequence 18 BP; 1 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. NO. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 30 ACTGCTCTCTGCAGGCC 45
 DB 3 ACTGCTCTCTGCAGGCC 18
 RESULT 99
 ADI53698
 ID ADI53698 standard; DNA; 19 BP.
 XX
 AC ADI53698;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.
 XX
 KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004003098-A1.
 XX
 PD 29-JAN-2004.
 XX
 PF 17-JUL-2003; 2003WO-SE001223.
 XX
 XX 18-JUL-2002; 2002SE-00002253.
 PR 04-SEP-2002; 2002US-0407680P.
 XX
 XX (INDE-) INDEX PHARM AB.
 XX
 PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 XX WPI; 2004-123288/12.
 XX
 PT New compound having a sequence targeted to a nucleic acid encoding
 PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
 PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 PT asthma or psoriasis.
 XX
 PS Claim 7; SEQ ID NO 11; 55pp; English.
 XX The present invention relates to antisense oligonucleotides (ADI53690-
 CC

XX 24-SEP-1997; 97WO-US016828.
 XX
 XX 02-OCT-1996; 96US-00720625.
 XX
 XX (UYNC-) UNIV NORTH CAROLINA.
 XX
 XX Naik UP, Parise LV;
 XX WPI; 1998-240018/21.
 XX
 XX New isolated calcium-integrin binding protein - is expressed in platelets
 PT and activates the fibrinogen receptor, used to develop products for
 PT treating e.g. vascular disorders.
 XX
 XX Example 4; Page 34; 44pp; English.
 XX
 CC This is the nucleotide sequence of the PCR primer used in the
 CC amplification of the human calcium-integrin binding (CIB) protein, that
 CC binds to the integrin alpha IIB cytoplasmic domain. The CIB protein is
 CC expressed in platelets and interacts with the alpha IIB subunit of
 CC integrin alpha IIB- beta 3, to activate the fibrinogen receptor.
 CC Inhibitory compounds can be used to inhibit the activation of the
 CC fibrinogen receptor where it is desired to reduce blood coagulation for
 CC therapeutic, diagnostic or pharmaceutical reasons. The products can be
 CC used for treating vascular disorders, and for isolating or purifying
 CC integrins or fibrinogen. They can also be used for detection and
 CC diagnosis
 XX
 XX Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 781 GGCATTTCAGTCCCTCT 796
 Db 1 GGCATTTCAGTCCCTCT 16
 RESULT 96
 AAV33107
 ID AAV33107 standard; DNA; 18 BP.
 XX
 XX AAV33107;
 AC
 XX 18-NOV-1998 (first entry)
 DT
 XX Stromelysin primer 1.
 DE
 XX Multiplex competitive PCR reaction; MC-PCR; reverse-transcriptase PCR;
 KW RT-PCR; tagging reaction; competitive amplification reaction; primer;
 KW housekeeping gene; Stromelysin; ss.
 KW
 XX Synthetic.
 OS
 OS Homo sapiens.
 XX
 XX WO9835058-A2.
 FN
 XX 13-AUG-1998.
 PD
 XX 27-JAN-1998; 98WO-US001471.
 XX
 XX 07-FEB-1997; 97US-0037841P.
 PR
 XX 18-DEC-1997; 97US-00993731.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Thompson JD;
 FI
 XX WPI; 1998-447252/38.
 DR
 XX Determining relative amounts of different nucleic acids by multiplex
 PT

PT competitive polymerase chain reaction - involves tagging target and
 PT control sequences then amplification with generic primer pair
 PT corresponding to tagging sequences, used e.g. to determine response to
 PT drugs.
 XX

XX Example 1; Page 23; 45pp; English.
 PS

XX The present invention provides a method for determining the relative
 CC amounts of two or more different nucleic acid molecules by using the
 CC multiplex competitive PCR reaction (MC-PCR). A MC-PCR reaction involves a
 CC reverse-transcriptase (RT-PCR) reaction followed by a tagging reaction
 CC and a competitive amplification reaction. The RT-PCR reaction uses a
 CC primer #2 to convert target mRNA into cDNA. Primer #1 in combination with
 CC primer #2 is then used to convert the region of the resulting cDNA to be
 CC amplified during the MC-PCR reaction into a double-stranded molecule.
 CC Primers #3 and #4, nested relative to primers #1 and #2 respectively, are
 CC used as tagging primers in the tagging reaction. A forward tagging primer
 CC has a defined sequence at its 5' end (+TAG sequence) while a reverse
 CC tagging primer has a different defined sequence at its 3' end (-TAG
 CC sequence). The purpose of the tagging reaction is to introduce the two
 CC defined sequences at the correct ends of the sequence to be amplified.
 CC The competitive amplification reaction involves using a single pair of
 CC generic primers, whose sequences are complementary to the +TAG and -TAG
 CC sequences, to amplify the different products generated from the cDNAs
 CC during the tagging step. This amplification reaction is competitive due
 CC to the use of a single primer pair to amplify the different target RNAs.
 CC Probe #5, complementary to the region of target RNA being amplified, is
 CC used to specifically detect the amplified product. The MC-PCR reaction
 CC can amplify one or more target mRNAs in a sample using the primer set #1-
 CC #5 for each target mRNA. In the example given, primers #1, #2, #3, #4 and
 CC probe #5 are the Stromelysin primers 1, 2 (AAV33108), 3a (AAV33109) or 3b
 CC (AAV33110), 4 (AAV33111) and probe 5 (AAV33112) respectively. These
 CC primers/probes were used to illustrate the method of the invention. The
 CC method claims to allow detection of low-abundance mRNA in small samples
 CC (e.g. 10 ng is sufficient) with high precision, and uses housekeeping
 CC genes as controls for RNA input and integrity. Also, a large number of
 CC samples may be processed simultaneously, making the process suitable for
 CC high throughput screening, and does not require continuous monitoring
 XX
 XX Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1012 GCTGCTTATGAATTG 1027
 Db 2 GCTGCTCATGAATTG 17

RESULT 97

AAAD2840/c

ID AAD42840 standard; DNA; 18 BP.

XX AAD42840;

XX 27-DEC-2002 (first entry)

XX M. tuberculosis deltaopr mutant gene amplifying primer, PEX1.

XX Immunogenic; infection; vaccine; mycobacterial disease; tuberculosis;
 KW Crohn's disease; gene therapy; antiinflammatory; antibacterial; PCR;
 KW primer; ss.

XX Mycobacterium tuberculosis.

XX WO200267982-A2.

XX 06-SEP-2002.

XX 20-FEB-2002; 2002WO-US005038.

XX 20-FEB-2001; 2001US-0269801P.

```

XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUY/) GU Y.
XX PA (JIY/) JI Y.
XX PA (PENN/) PENN S G.
XX PA (HANK/) HANZEL D K.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon MB;
XX WPI; 2004-533378/51.
XX PT Novel myosin-like protein-1, useful for treating or preventing disorder
XX PT associated with decreased expression or activity of human genome-derived
XX PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX PT function.
XX PS Disclosure; SEQ ID NO 10433; Opp; English.
XX SC The invention relates to a novel polypeptide (I) comprising a sequence
XX SC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX SC defined in the specification, a fragment of at least 8 amino acids of
XX SC (S1), 95% deviation from (S1) which are conservative substitutions, and
XX SC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX SC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX SC pharmaceutical composition of the invention is useful for treating or
XX SC preventing a disorder associated with decreased expression or activity of
XX SC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX SC The present sequence represents a 17-mer nucleotide, used in the
XX SC invention for scanning the sequence represented in ACN63103
XX SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTTCGCTGTC 885
DB 16 GACTTTTCGCTGTC 1

RESULT 94
AAT86051/c
ID AAT86051 standard; cDNA; 18 BP.
XX AC AAT86051;
XX AC AAT86051;
XX DT 20-NOV-1997 (first entry)
XX DE Primer 1 amplifies cDNA's expressed from V-alpha-1 intron promoter.

```

```

XX Antisense; T-cell receptor; signalling protein; intron; murine;
KW V-alpha-1 gene; cytoplasmic tail; Ig-beta; P8.6; primer; amplify;
KW polymerase chain reaction; PCR; ss.
XX Synthetic.
XX WO9704010-A1.
XX PD 06-FEB-1997.
XX PF 19-JUL-1996; 96WO-US011884.
XX PR 20-JUL-1995; 95US-0001270P.
XX PA (SYNT ) SYNTEX USA INC.
XX PI Webb DR, Maeda T;
XX DR WPI; 1997-132579/12.
XX PT New T-cell receptor V-alpha gene signalling protein - encoded by the
XX PT antisense strand of the V-alpha-1 gene, includes proline-rich region and
XX PT Tyr-X-X-Ile/Leu signal motif.
XX PS Example 4; Page 18; 47pp; English.
XX SC The sequences givne in AAT86051-52 are primers which were used to amplify
XX SC sequences which have been expressed from a sequence in the murine V-alpha
XX SC -1 intron 1. The intronic sequence drives expression of a sequence on the
XX SC antisense strand of the T-cell receptor gene which encodes a signalling
XX SC protein which comprises a proline rich region, a YxxI/L motif and a
XX SC TANYSNI motif. Expression of the signalling element which is found in the
XX SC specifically activated by a regulatory protein sequence is
XX SC intron of the murine V-alpha-1 gene. The encoded protein has a molecular
XX SC weight of 8.6 kD and has a high degree of homology (e.g. 70%) to the
XX SC cytoplasmic tail of Ig-beta. The murine signalling protein P8.6 and its
XX SC homologues, e.g. from human lymphoid cells, can be used to further
XX SC elucidate the role of the T cell receptor V-alpha-1 gene locus in the
XX SC functioning of T cells
XX SQ Sequence 18 BP; 3 A; 3 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 206 AAGAAATGCAGCACTT 221
DB 18 AAGAAATACGCACTT 3

RESULT 95
AAV07215
ID AAV07215 standard; DNA; 18 BP.
XX AC AAV07215;
XX DT 21-AUG-1998 (first entry)
XX DE Calcium-integrin binding protein PCR primer 3.
XX KW Human,calcium-integrin binding protein; CIB; integrin alpha IIb;
XX KW cytoplasmic domain; platelet; alpha IIb-beta-3; fibrinogen receptor;
XX KW inhibition; blood coagulation; vascular disorder; RT-PCR; primer;
XX KW amplification; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9814471-A1.
XX PD 09-APR-1998.

```

PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8638; Opp; English.
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
 PS
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 202 ATCCAGAAATGCAGC 217
 DB 2 ATCCAGAAATGCAGC 17
 |||||
 RESULT 92
 ACN71737
 ID ACN71737 standard; DNA; 17 BP.
 XX
 AC ACN71737;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8639.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 XX 26-NOV-2003; 2003US-00723361.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 8639; Opp; English.
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;
 PS
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 202 ATCCAGAAATGCAGC 217
 DB 1 ATCCAGAAATGCAGC 16
 |||||
 RESULT 93
 ACN73531/c
 ID ACN73531 standard; DNA; 17 BP.
 XX
 AC ACN73531;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:10433.
 XX
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 XX US2004137589-A1.
 PN

PA (MACE/) MACEJACK D.
 XX
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 XX
 XX WPI; 2004-031273/03.
 DR
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX
 PS Claim 1; SEQ ID NO 2114; 198pp; English.
 XX
 CC The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents a HCV DNzyme substrate
 CC sequence.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 99;
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1372 CTACTCCCAACGTATCA 1387
 | : ||||| : |||
 Db 1 CUCCUCCCAACGUUCA 16
 RESULT 90
 ACN73529/c
 ID ACN73529 standard; DNA; 17 BP.
 XX
 AC ACN73529;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:10431.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.

PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 10431; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 871 AGTTTGTGATGCTGTCA 886
 | ||||| |||||
 Db 17 ACTTTGTGATGCTGTCA 2
 RESULT 91
 ACN71736
 ID ACN71736 standard; DNA; 17 BP.
 XX
 AC ACN71736;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:8638.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.

```

PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX
DR WPI; 2003-058513/05.
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 2946; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX
SQ Sequence 17 BP; 4 A; 1 C; 1 G; 0 T; 11 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 99;
Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
Db 1 UUUUUUUUUUAAAGA 16
: : : : :
: : : : :

RESULT 88
ADL49412
ID ADL49412 standard; RNA; 17 BP.
XX
XX
AC ADL49412;
XX
XX
DT 20-MAY-2004 (first entry)
XX
XX
DE Human PKR substrate sequence #526.
XX
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
XX
OS Unidentified.
XX
XX
PN WO200281628-A2.
XX
XX
PD 17-OCT-2002.
XX

```

```

PF 03-APR-2002; 2002WO-US010512.
XX
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
XX
DR WPI; 2003-058513/05.
XX
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX
PS Claim 59; SEQ ID NO 2945; 317pp; English.
XX
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
XX
SQ Sequence 17 BP; 4 A; 0 C; 1 G; 0 T; 12 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 99;
Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
Db 2 UUUUUUUUUUAAAGA 17
: : : : :
: : : : :

RESULT 89
ADL84868
ID ADL84868 standard; RNA; 17 BP.
XX
XX
AC ADL84868;
XX
XX
DT 03-JUN-2004 (first entry)
XX
XX
DE HCV DNazyme substrate sequence #2114.
XX
XX
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX
XX
OS Hepatitis C virus.
XX
XX
PN US2003125270-A1.
XX
XX
PD 03-JUL-2003.
XX
XX
PF 18-DEC-2000; 2000US-00740332.
XX
XX
PR 18-DEC-2000; 2000US-00740332.
XX
XX
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.

```



```
Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1113 CATACATCTTTTGGT 1128
DB 17 CATACATCTTTTGAT 2

RESULT 85
ACCS1404
ID ACC51404 standard; DNA; 17 BP.
XX
AC ACC51404;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #171.
XX
KW ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
KW tumour regression; apoptosis; virus resistance; diagnosis;
KW cellular degeneration.
XX
OS Homo sapiens.
XX
PN FR2826373-A1.
XX
PD 27-DEC-2002.
XX
PF 20-JUN-2001; 2001FR-00008139.
XX
PR 20-JUN-2001; 2001FR-00008139.
XX
PA (MOLE-) MOLECULAR ENGINES LAB SA.
XX
PI Tuijnder M, Telerman A, Anson R;
XX
DR WPI; 2003-250498/25.
XX
PT New nucleic acid sequences associated with tumor suppression, regression,
PT apoptosis or virus resistance are useful to diagnose and treat viral
PT disease, development of tumor cells and cell degeneration.
XX
PS Claim 1; Page 79; 799pp; French.
XX
CC This sequence represents an isolated nucleic acid sequence associated
CC with tumour suppression or regression, apoptosis or virus resistance. The
CC invention relates to these sequences or sequences having at least 80%
CC identity to them, and polypeptides encoded by the sequences or
CC polypeptides having 80% identity to the polypeptide sequences. The
CC invention is used to diagnose or treat viral disease or disease
CC characterized by development of tumour cells or cellular degeneration
XX
SQ Sequence 17 BP; 7 A; 2 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 ACCAAGATAATTCAT 1670
DB 2 ATCAAGATAATTCAT 17

RESULT 86
ACCS1914
ID ACC51914 standard; DNA; 17 BP.
XX
AC ACC51914;
XX
DT 27-JUN-2003 (first entry)
XX
DE Human tumour suppressor sequence #681.

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1559 GATTATATAAATACA 1574
DB 1 GATCATATAAATACA 16

RESULT 87
ADL49413
ID ADL49413 standard; RNA; 17 BP.
XX
AC ADL49413;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #527.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
```

XX Disclosure; Page 165; 771pp; French.

PS The invention relates to the isolation of 6327 nucleotide sequences,

CC fragments of at least 15 consecutive nucleotides of these nucleotides, a

CC sequence having at least 80% identity, after optimal alignment, with the

CC nucleotides, a sequence that hybridizes under stringent conditions with

CC the nucleotides, or the complement, or corresponding RNA, of the

CC nucleotides. The nucleotides are used as probes or primers for detecting,

CC identifying, quantifying and/or amplifying nucleic acids, as in vitro

CC sense and antisense sequences, of nucleotides involved in tumour

CC suppression or reversion, apoptosis and/or viral resistance, to produce

CC recombinant polypeptides, and to prepare transgenic animals, as

CC experimental models. The nucleotides (also vectors containing them and

CC cells containing the vectors), the encoded polypeptides and antibodies

CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours

CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).

CC Analysis of the expression of the nucleotides can be used for diagnosis

CC and/or prognosis of these diseases. The nucleotides and polypeptides can

CC also be used to screen for their specific interactive molecules,

CC potentially useful for treating diseases associated with abnormal

CC expression of the nucleotides.

XX Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 ATCCTTGGACTGAGAA 1717
|||||
DB 2 ATCTTTGGACTGAGAA 17

RESULT 84

AD152546

ID AD152546 standard; DNA; 17 BP.

AC AD152546;

XX

XX 15-APR-2004 (first entry)

DT

DE Human tumour suppression/reversion-related DNA sequence SeqID5049.

XX

XX tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

OS

XX WO2003025177-A2.

PN

XX 27-MAR-2003.

PD

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001FR-00011980.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

PA

XX Telerman A, Amson R, Tuijnder M;

PI

XX WPI; 2003-313354/30.

DR

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 5049; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved

CC

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC nontropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterized by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1103 ATCCCAAGAGCATACA 1118
|||||
DB 2 ATCCCAAGAGCATACA 17

RESULT 84

ACC51264/C

ID ACC51264 standard; DNA; 17 BP.

XX ACC51264;

AC

XX 27-JUN-2003 (first entry)

DT

XX Human tumour suppressor sequence #31.

DE

XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;

KW tumour regression; apoptosis; virus resistance; diagnosis;

KW cellular degeneration.

XX Homo sapiens.

OS

XX FR2826373-A1.

PN

XX 27-DEC-2002.

PD

XX 20-JUN-2001; 2001FR-00008139.

PF

XX 20-JUN-2001; 2001FR-00008139.

PR

XX (MOLE-) MOLECULAR ENGINES LAB SA.

PA

XX Tuijnder M, Telerman A, Amson R;

PI

XX WPI; 2003-250498/25.

DR

XX New nucleic acid sequences associated with tumor suppression, regression,

XX apoptosis or virus resistance are useful to diagnose and treat viral

PT disease, development of tumor cells and cell degeneration.

XX

XX Claim 1; Page 47; 798pp; French.

PS

XX This sequence represents an isolated nucleic acid sequence associated

XX with tumour suppression or regression, apoptosis or virus resistance. The

CC invention relates to these sequences or sequences having at least 80%

CC identity to them, and polypeptides encoded by the sequences or

CC polypeptides having 80% identity to the polypeptide sequences. The

CC invention is used to diagnose or treat viral disease or disease

CC characterized by development of tumour cells or cellular degeneration

XX

XX Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;

SQ

CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCAL in a cell or
 CC tissue. The sequences are useful for reducing CLCAL activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCAL, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCAL RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 2 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 56.2%; Pred. No. 99;
 Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;
 QY 1712 TGAGAAATTATCTTA 1727
 Db 1 UGAGAAUUCUACUA 16
 RESULT 81
 ACD60984
 ID ACD60984 standard; RNA; 17 BP.
 XX
 AC ACD60984;
 XX
 DT 24-SEP-2003 (first entry)
 XX
 DE HCV DNazyme substrate sequence #2114.
 XX
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.
 XX
 OS Hepatitis C virus.
 XX
 FN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PVC/) PAVCO P.
 PA (LEBP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX

DR WPI; 2003-229207/22.
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 XX
 PS Claim 1; Page 271; 387pp; English.
 XX
 CC The present invention relates to nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the HCV
 CC DNazyme or minus strand DNazyme sequences disclosed in the present
 CC invention
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 99;
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
 QY 1372 CTACTCCCAACGTATCA 1387
 Db 1 CUCCUCCACGUACA 16
 RESULT 82
 ADB40821
 ID ADB40821 standard; DNA; 17 BP.
 XX
 AC ADB40821;
 XX
 DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX
 DE Tumour suppression/reversion associated nucleotide #1144.
 XX
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX
 OS Homo sapiens.
 XX
 FN WO2003040369-A2.
 XX
 PD 15-MAY-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004219.
 XX
 PR 17-SEP-2001; 2001FR-00011981.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuljinder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 PT New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.

CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 202 ATCCAAGAAATGCAGC 217
 Db 1 ATCCAAGAACTGCAGC 16
 RESULT 79
 ABK17764/c
 ID ABK17764 standard; RNA; 17 BP.
 XX
 AC ABK17764;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human ERG hammerhead ribozyme target sequence, Seq ID No 411.
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberzyme.
 XX
 OS Homo sapiens.
 XX
 PN WO200188124-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 16-MAY-2001; 2001WO-US015866.
 XX
 XX 16-MAY-2000; 2000US-00572021.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX
 XX Novel polynucleotide which down regulates expression of Ets-related gene,
 XX useful for treating cancer, diabetic retinopathy, macular degeneration,
 XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.
 XX
 XX Claim 4; Page 66; 149pp; English.
 XX
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 XX expression of an Ets-related gene (ERG). (I) is useful for treating
 XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 XX tumour angiogenesis, diabetic retinopathy, macular degeneration,
 XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg²⁺. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention
 XX
 SQ Sequence 17 BP; 7 A; 0 C; 0 G; 0 T; 10 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1555 TAATGATTATATAAAA 1570
 Db 16 TAATTATTATATAAAA 1
 RESULT 80
 ABK55789
 ID ABK55789 standard; RNA; 17 BP.
 XX
 AC ABK55789;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human CLCA1 gene enzymatic nucleic acid #160.
 XX
 KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX
 OS Homo sapiens.
 XX
 PN WO200211674-A2.
 XX
 PD 14-FEB-2002.
 XX
 PF 09-AUG-2001; 2001WO-US024970.
 XX
 XX 09-AUG-2000; 2000US-0224383P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (SYNT) SYNTEX USA LLC.
 XX (THOM/) THOMPSON J.
 XX
 XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
 XX Grupe A;
 XX WPI; 2002-217145/27.
 XX
 XX Enzymatic polynucleotide that down regulates expression of chloride
 XX channel calcium activated gene, useful for treating Chronic obstructive
 XX pulmonary disease (COPD), chronic bronchitis and asthma.
 XX
 XX Claim 4; Page 55; 152pp; English.
 XX
 XX The invention relates to enzymatic nucleic acid molecules that down
 XX regulate expression of chloride channel calcium activated 1 (CLCA1) genes

RESULT 77
ABN08646
ID ABN08646 standard; DNA; 17 BP.
XX
AC ABN08646;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8638.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
PN WO200192524-A2.
XX
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 8638; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX SQ Sequence 17 BP; 6 A; 5 C; 4 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 99;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 202 ATCCAAGAAATGCAGC 217
XX |||||
DB 2 ATCCAAGAACTGCAGC 17
XX
RESULT 78
ABN08647
ID ABN08647 standard; DNA; 17 BP.
XX
AC ABN08647;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8639.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
PN WO200192524-A2.
XX
XX 06-DEC-2001.
XX
PD 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID NO 8639; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule

Fri May 13 12:26:37 2005

chong906-1.rng

XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 10433; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
SQ Best Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 870 GAGTTTGGTCTGTC 885
DB 16 GACTTTTGGTCTGTC 1
RESULT 76
ABN10439/c
ID ABN10439 standard; DNA; 17 BP.
XX AC
XX AC
XX AC
XX 29-MAY-2002 (first entry)
XX DT
XX DE
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10431.
XX

KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX Disclosure; SEQ ID NO 10431; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ Best Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 871 AGTTTGGTCTGTC 886
DB 17 ACTTTTGGTCTGTC 2

CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 2 G; 0 T; 6 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 910 TTCTTCAAGACAGGT 925
 DB 16 TTCTTCAAGAAAGGT 1
 RESULT 74
 ABK01343/c
 ID ABK01343 standard; RNA; 17 BP.
 XX
 AC ABK01343;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Inozyme #613.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BW;
 XX

DR
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 Claim 88; Page 87; 200pp; English.
 CC
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 5 A; 3 C; 3 G; 0 T; 6 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 910 TTCTTCAAGACAGGT 925
 DB 17 TTCTTCAAGAAAGGT 2
 RESULT 75
 ABN10441/c
 ID ABN10441 standard; DNA; 17 BP.
 XX
 AC ABN10441;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10433.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.

KW	B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW	human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW	MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW	inflammatory arthropathy; central nervous system injury;
KW	cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW	chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW	Parkinson's disease; ataxia; Huntington's disease;
KW	Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PN	WO200159103-A2.
XX	
PD	16-AUG-2001.
XX	
XX	09-FEB-2001; 2001WO-US004273.
XX	
XX	11-FEB-2000; 2000US-0181797P.
PR	28-FEB-2000; 2000US-0185516P.
PR	06-MAR-2000; 2000US-0187128P.
XX	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	(BLATY) BLATY L.
PA	(MCSW) MCSWIGGEN J.
PA	(CHOW) CHOWRIRA B M.
XX	
PI	Blatt L, Mcswiggen J, Chowrira BM;
XX	
DR	WPI; 2001-607195/69.
XX	
PT	Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT	constructs, which down regulate expression of a CD20 gene or neurite
PT	growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT	central nervous system injury.
XX	
PS	Claim 88; Page 89; 200pp; English.
XX	
CC	The invention relates to a nucleic acid molecule which down regulates
CC	expression of a CD20 gene and a nucleic acid molecule which down
CC	regulates expression of a neurite growth inhibitor gene (NIGO). The
CC	nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC	DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA motif) or
CC	possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
CC	an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
CC	with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC	of CD20 in the presence of a divalent cation that is preferably Mg ²⁺ .
CC	Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC	the cell and treat a patient having a condition associated with the level
CC	of CD20. The treatment may further comprise the use of one or more
CC	therapies. In particular, the CD20 targeting nucleic acid may be used to
CC	treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
CC	Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, mantle-cell
CC	leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC	lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC	immune thrombocytopaenia, and inflammatory arthropathy. The NIGO-
CC	targeting nucleic acid is used to cleave RNA of the NIGO gene in the
CC	presence of a divalent cation that is preferably Mg ²⁺ . Furthermore, the
CC	nucleic acid may be contacted with a cell to reduce NIGO activity of the
CC	cell and treat a patient having a condition associated with the level of
CC	NIGO. The treatment may further comprise the use of one or more
CC	therapies. In particular, the NIGO-targeting nucleic acid may be used to
CC	treat central nervous system (CNS) injury and cerebrovascular accident
CC	(CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC	chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC	Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC	disease, muscular dystrophy, and/or other neurodegenerative disease
CC	states which respond to the modulation of NIGO expression. The present
CC	sequence is an inozyme of the invention
XX	
SQ	Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 CC
 SQ Sequence 17 BP; 4 A; 3 C; 1 G; 0 T; 9 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 172 AAATATAGTGGAACT 187
 |||||
 Db 17 AAATATAGTGGAACT 2

RESULT 71
 ABK00554
 ID ABK00554 standard; RNA; 17 BP.

XX AC ABK00554;

XX DT 12-MAR-2002 (first entry)

XX DE Human NOGO Hammerhead Ribozyme #554.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
 OS Synthetic.

XX PN WO200159103-A2.

XX PD 16-AUG-2001.

XX PF 09-FEB-2001; 2001WO-US004273.

XX PR 11-FEB-2000; 2000US-0181797P.

XX PR 28-FEB-2000; 2000US-0185516P.

XX PR 06-MAR-2000; 2000US-0187128P.

PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.

PI Blatt L, Mcswiggen J, Chowrira BM;

XX WPI; 2001-607195/69.

XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.

XX Claim 88; Page 74; 200pp; English.

XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA motif) or
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention

XX Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 68.8%; Pred. No. 99;

Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 847 CCACCTCTCTGTGACC 862

|||:|:|:|:|:|

Db 1 CCUGCUCUCUGUGACC 16

RESULT 72

ABK01422
 ID ABK01422 standard; RNA; 17 BP.

XX AC ABK01422;

XX DT 12-MAR-2002 (first entry)

XX DE Human NOGO Inozyme #692.

XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;

sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 5 A; 1 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1265 TTACCAAGAACTTCCA 1280
Db 16 TTACCAAGAACTTCCA 1

RESULT 69
AAA18824/c
ID AAA18824 standard; RNA; 17 BP.
XX
AC AAA18824;
XX
XX 19-JUN-2000 (first entry)
XX
DE Human TIE-2 substrate sequence SEQ ID NO:2050.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
PI WPI; 1999-591315/50.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
XX Claim 56; Page 119; 305pp; English.
XX
XX The present invention describes enzymatic nucleic acid molecules with RNA
CC cleaving activity, which specifically cleave RNA encoded by an aryl
CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
CC and AAA19155 to AAA19222 represent their corresponding target sequences;
CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
CC AAA21596 to AAA21688 represent their corresponding target sequences;
CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
CC AAA23422 represent their corresponding target sequences. The ribozymes of
CC the invention are used for modulating the synthesis, expression and/or
CC stability of an mRNA encoding angiogenic factor, especially ARNT,
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
CC especially used to treat cancer, diabetic retinopathy, age related
CC macular degeneration (ARMD), inflammation, and arthritis, as well as
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
CC integrin subunit alpha-6, or integrin subunit beta-3
XX
SQ Sequence 17 BP; 4 A; 2 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1265 TTACCAAGAACTTCCA 1280
Db 17 TTACCAAGAACTTCCA 2

RESULT 70
AAA23011/c
ID AAA23011 standard; RNA; 17 BP.
XX
AC AAA23011;
XX
XX 19-JUN-2000 (first entry)
XX
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6237.
XX
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
OS Homo sapiens.
XX
PN WO9950403-A2.
XX
PD 07-OCT-1999.
XX
PF 24-MAR-1999; 99WO-US006507.
XX
PR 27-MAR-1998; 98US-0079678P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
PI WPI; 1999-591315/50.
XX
XX Novel ribozymes for modulating the synthesis, expression and/or stability
PT of an mRNA encoding an angiogenic factors.
XX
XX Claim 54; Page 256; 305pp; English.
XX

XX (SYSM-) SYSMEX CORP.
 XX Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
 XX WPI; 2004-012543/01.
 XX LAMP nucleic acid amplification primers for detection of cytokeratin
 XX expression as indicator in diagnosis of tumour metastasis.
 XX Claim 19; SEQ ID NO 390; 266pp; Japanese.
 XX The invention relates to novel nucleic acid amplification primers for the
 XX detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
 XX (loop mediated isothermal amplification) method. The primers of the
 XX invention may be useful for the detecting cytokeratin 18-20 expression as
 XX an indicator for the diagnosis of tumour metastasis, particularly
 XX prostate cancer and lymphoma. The amplification using the primers is
 XX highly efficient and allows very sensitive detection of tumour
 XX metastasis. The current sequence is that of the human CK19-related PCR
 XX primer of the invention.
 XX Sequence 16 BP; 1 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 90;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 41 AGGCCACTGCTTCTGG 56
 ||||| ||||| |||||
 Db 1 AGGCCCTTCTTCTGG 16

RESULT 67
 AAX71309/C
 ID AAX71309 standard; RNA; 17 BP.
 XX
 AC AAX71309;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Human KDR VEGF receptor hammerhead ribozyme substrate #321.
 XX
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 PS Claim 4; Page 106; 218pp; English.
 XX

CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 XX Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 99;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 GAGACTTCCATGCTTT 533
 ||||| ||||| |||||
 Db 17 GAGACTTCCATGCTTT 2

RESULT 68
 AAA18825/C
 ID AAA18825 standard; RNA; 17 BP.
 XX
 AC AAA18825;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:2051.
 XX
 XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 PF 24-MAR-1999; 99WO-US006507.
 XX
 PR 27-MAR-1998; 98US-0079678P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 XX
 XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 XX Claim 56; Page 119; 305pp; English.
 XX
 XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC and AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

Fri May 13 12:26:37 2005

chong906-1.rng

KW male pattern alopecia; acne vulgaris; seborrhoea; female hirsutism;
KW prostatic hypertrophy; ds.
XX Synthetic.
OS Key Location/Qualifiers
PH misc_feature 17..18
FT /*tag= a
FT /note= "2 deoxynucleotide overhang"
XX
XX WO2004063331-A2.
XX
XX 29-JUL-2004.
XX
XX 05-JAN-2004; 2004WO-US000128.
XX
XX 03-JAN-2003; 2003US-0437842P.
XX
XX (GENC-) GENCIA CORP.
XX
XX Kahn S;
XX
XX WPI; 2004-561892/54.
XX
XX Inhibitory nucleic acid that inhibits expression of an androgen signal
transduction pathway protein useful for treating hair loss, comprises a
PT double stranded RNA having a partial sequence encoding a pathway protein
PT in one strand.
XX
XX Claim 11; Page 59; 92pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs),
CC comprising a double stranded RNA, where one strand comprises a partial
CC nucleic acid sequence of an androgen signal transduction pathway protein,
CC and where the double-stranded RNA inhibits translation of mRNA encoding
CC the nucleic acid sequence of the androgen signal transduction pathway
CC protein thereby blocking the androgen signal transduction pathway. The
CC androgen signal transduction pathway protein is chosen from isozymes I
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfate
CC in a mammal which involves contacting several mammal's hair cells with
CC the siRNA, where the siRNA interferes with the translation of mRNA of the
CC androgen signal transduction protein. The siRNAs are useful for treating
CC hyperandrogenic conditions of androgenic alopecia, including male pattern
CC alopecia, acne vulgaris, seborrhoea, and female hirsutism and prostatic
CC hypertrophy. The present sequence is the sense strand for one such siRNA
CC of the invention.
XX
XX Sequence 18 BP; 4 A; 5 C; 4 G; 2 T; 3 U; 0 Other;
SQ
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 418 AAAGCTTCCCAAGTATG 435
DB 18 AAAGCTTCCCAAGCTG 1
RESULT 65
ID ABL91853
XX ABL91853 standard; DNA; 15 BP.
AC ABL91853;
XX
XX 11-JUL-2002 (first entry)
DT
XX Human LipG gene allele specific oligonucleotide primer 32.

XX Human; ss; allele specific oligonucleotide; primer;
KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LipG;
KW drug screening; atherosclerosis; cardiovascular disorder;
KW LipG haplotyping; LipG genotyping.
XX
XX Homo sapiens.
OS
XX WO200216397-A2.
XX
XX 28-FEB-2002.
XX
XX 17-AUG-2001; 2001WO-US026639.
XX
XX 25-AUG-2000; 2000US-0227825P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Duda A, Kazemi A, Kliem SE, Messer C;
XX
XX WPI; 2002-292055/33.
XX
XX Novel genetic variants of Lipase, Endothelial isogenes, useful for
improving efficiency and reliability in drug development for treating
PT diseases associated with LipG activity, e.g. atherosclerosis.
PT
XX
XX Claim 16; Page 14; 134pp; English.
XX
XX The invention comprises the DNA and amino acid sequence of the human
lipase, endothelial (LipG) isogene. Specifically, the invention relates
CC to the discovery of 20 novel polymorphic sites within the LipG gene. The
CC LipG coding sequence and protein are useful for screening drugs that can
CC be used to treat atherosclerosis and other cardiovascular disorders. The
CC LipG coding sequence can also be used to haplotype and genotype the LipG
CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
CC LipG gene allele specific oligonucleotide primers
XX
XX Sequence 15 BP; 3 A; 6 C; 1 G; 4 T; 0 U; 1 Other;
SQ
Query Match 0.8%; Score 14.6; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 76;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 719 TGTTCCTCCCACTACA 733
DB 1 TGTTCCTCCCACTAYA 15
RESULT 66
ID ADF92302
XX ADF92302 standard; DNA; 16 BP.
XX
XX ADF92302;
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human cyokeratin 19-related loop F PCR primer - SEQ ID 390.
DE
XX human; cyokeratin; CK; LAMP; loop mediated isothermal amplification;
KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
KW PCR; loop F.
XX
XX Homo sapiens.
OS
XX WO2003097878-A1.
XX
XX 27-NOV-2003.
XX
XX 20-MAY-2003; 2003WO-JP006256.
XX
XX 21-MAY-2002; 2002JP-00145689.
XX
XX 17-JUN-2002; 2002JP-00175271.
XX
XX 09-JUL-2002; 2002JP-00199759.
XX

DT 26-JAN-2000 (first entry)

DE Human CD40 phosphorothioate antisense oligonucleotide SEQ ID NO:57.

XX Identification: genetic target; gene modulation; human; probe;

KW antisense oligonucleotide; phosphorothioate; PCR primer;

KW nucleotide sequence-based technology; antisense drug discovery;

KW target validation; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9953101-A1.

FN 21-OCT-1999.

XX 13-APR-1999; 99WO-US008268.

PF 13-APR-1999; 98US-0081483P.

XX 28-APR-1999; 98US-00067638.

PR (ISIS-) ISIS PHARM INC.

XX Cowseert LM, Baker BF, Mcneil J, Freier SM, Sasnor HM, Brooks DG;

PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;

XX WPI; 1999-620446/53.

DR Identifying compounds which modulate expression of nucleic acids, used to

PT provide compounds having defined physical, chemical or bioactive

PT properties, e.g. antisense activity.

XX Example 8; Page 78; 264pp; English.

XX A method has been developed of defining a set of compounds that modulate

CC the expression of a target nucleic acid (tNA) sequence via binding of the

CC compounds with the tNA sequence. The method comprises generating a

CC library of virtual compounds in silico according to defined criteria, and

CC evaluating in silico the binding of the virtual compounds with the tNA

CC according to defined criteria. Also described are: (1) a method of

CC defining a set of oligonucleotides (ONs) that modulate the expression of

CC a tNA sequence via binding of the ONs with the tNA sequence comprising

CC generating a library of virtual compounds in silico according to defined

CC criteria, and evaluating in silico the binding of the virtual ONs with

CC the tNA according to defined criteria; and (2) a method of defining a set

CC of compounds that modulate the expression of a tNA sequence via binding

CC of the compounds with the tNA. The methods can be used for the generation

CC and identification of synthetic compounds having defined physical, chemical or bioactive properties. Information gathered from assays of

CC such compounds is used to identify nucleic acid sequences that are

CC tractable to a variety of nucleotide sequence-based technologies, e.g.

CC antisense drug discovery and target validation. AAZ40852 to AAZ41220, and

CC AAY52701 to AAY52706, represent sequences used in the exemplification of

CC the present invention

XX Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

SQ Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 98;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962

DB 18 TGTGAGACCAAGACCTG 1

RESULT 63

AAZ47741/c

ID AAZ47741 standard; DNA; 18 BP.

XX AAZ47741;

AC AAZ47741;

XX 02-MAR-2000 (first entry)

XX Human CD40 antisense oligonucleotide SEQ ID NO:57.

DE Human; CD40; antisense oligonucleotide; phosphorothioate; modulation;

XX expression; immune disease; inflammatory disease; immunomodulatory;

KW anti-inflammatory; anti-arthritis; anti-asthmatic; antiproliferative;

KW anticancer; immuno-suppressive; anti-psoriatic; allograft rejection;

KW hyperproliferative disease; autoimmune disease; rheumatoid arthritis;

KW inflammatory bowel disease; asthma; psoriasis; cancer; tumour; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9957320-A1.

FN 11-NOV-1999.

XX 22-APR-1999; 99WO-US008765.

PF 01-MAY-1998; 98US-00071433.

PR (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowseert LM;

PI WPI; 2000-062158/05.

DR Antisense molecules directed against nucleic acid encoding human CD40,

PT for treating e.g. immune, inflammatory or hyperproliferative diseases.

XX Claim 3; Page 44; 102pp; English.

XX AAZ47685 to AAZ47768 represent phosphorothioate antisense

CC oligonucleotides targeted to human CD40, which can be used to inhibit the

CC expression of human CD40. CD40 is involved in lymphocyte activation,

CC tumour growth and/or angiogenesis. Inhibition of CD40 is used to treat or

CC prevent immune-associated diseases (specifically guest vs. host disease,

CC allograft rejection or autoimmune diseases); inflammation (specifically

CC asthma, rheumatoid arthritis, allograft rejection, inflammatory bowel

CC disease or psoriasis) or hyperproliferation (specifically cancer and

CC tumours). The antisense oligonucleotides are also useful as diagnostic

CC and research reagents. AAZ47769 represents the human CD40 nucleotide

CC sequence. AAZ47770 to AAZ47772 represent human CD40 forward and reverse

CC PCR primers, and a human CD40 PCR probe, respectively. AAZ47773 to

CC AAZ47775 represent other PCR primers and a probe used in the

CC exemplification of the present invention

XX Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

SQ Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 98;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962

DB 18 TGTGAGACCAAGACCTG 1

RESULT 64

ADQ93226/c

ID ADQ93226 standard; RNA; 18 BP.

XX ADQ93226;

AC ADQ93226;

XX 21-OCT-2004 (first entry)

DE 3-alpha-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 802.

XX Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;

KW small interfering RNA; siRNA;

KW androgen signal transduction pathway protein;

KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;

KW hair loss; hyperandrogenic condition; androgenic alopecia;

Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 85;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
 DB 15 TCTGGCTGAAGGTTT 1

RESULT 60
 ADB00376/C
 ID ADB00376 standard; DNA; 17 BP.
 XX
 AC ADB00376;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MDZ3 scanning oligonucleotide SEQ ID 1362.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 WPI; 2003-423107/40.
 XX
 DR New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MDZ3,
 PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX
 PS Example 8; SEQ ID NO 1362; 103pp; English.
 XX
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1. MDZ4 is encoded at chromosome 6p21.3-22.2.
 CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
 CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MDZ3,
 CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 85;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
 DB 16 TCTGGCTGAAGGTTT 2

RESULT 61
 AAV57794
 ID AAV57794 standard; DNA; 18 BP.
 XX
 AC AAV57794;
 XX
 DT 18-NOV-1998 (first entry)
 XX
 DE Human chromosome 18 PCR mapping primer clone 47r.
 XX
 KW Manic-depressive illness; susceptibility; genotype; diagnosis;
 KW chromosomal marker; polymorphic marker; chromosome 18; human;
 KW myo-inositol monophosphatase protein; IMP-18p; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09818963-A1.
 XX
 PD 07-MAY-1998.
 XX
 PF 28-OCT-1997; 97WO-US019381.
 XX
 PR 28-OCT-1996; 96US-0029278P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Detera-Wadleigh SD, Gershon ES, Badner JA, Goldin LR;
 PI Berrettini WH, Yoshikawa T, Sanders AR, Esterling LE;
 XX
 DR WPI; 1998-272247/24.
 XX
 PT New isolated IMP 18p myo-inositol monophosphatase - used to develop
 PT products for determining susceptibility to manic depressive illness and
 PT as targets for preventive and therapeutic treatments.
 XX
 PS Example 5; Page 71; 118pp; English.
 XX
 CC A method has been developed for determining a genotype associated with
 CC increased susceptibility to manic-depressive (MD) illness. The method
 CC comprises determining the genotype of an affected individual with at
 CC least one polymorphic marker localised within the chromosomal region
 CC defined by and including markers D18S843 and D18S869 and determining the
 CC genotype associated with increased susceptibility to MD disorder. The
 CC method can be used for determining susceptibility to MD illness including
 CC bipolar disorder, genetic counselling of individuals from families
 CC affected with MD illness, and aid in the differential diagnosis of MD
 CC illness from other psychiatric pathologies. Products from the present
 CC invention can also be used to obtain modulators of IMP-18p myo-inositol
 CC monophosphatase protein activity and as targets for preventive and
 CC therapeutic treatments. The present sequence represents a PCR primer used
 CC in the mapping of human chromosome 18 for determining the genotype of MD
 CC illness susceptibility, used in an example from the present invention
 XX
 SQ Sequence 18 BP; 2 A; 4 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 98;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 ACTGCTTCTGGAGCTCTT 63
 DB 1 AGTGCTTCTGTAGCTCTT 18

RESULT 62
 AAZ40908/C
 ID AAZ40908 standard; DNA; 18 BP.
 XX
 AC AAZ40908;
 XX

CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX
 XX Sequence 17 BP; 3 A; 5 C; 1 G; 8 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 85;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 298 GATCTCCATCATTC 312
 DB 1 GATCTCCATCATTC 15
 RESULT 58
 ADB00375/c
 ID ADB00375 standard; DNA; 17 BP.
 XX ADB00375;
 XX 20-NOV-2003 (first entry)
 XX Human MD23 scanning oligonucleotide SEQ ID 1361.
 XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
 XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 XX developmental disorder; ss.
 XX Homo sapiens.
 XX EP1281758-A2.
 XX 05-FEB-2003.
 XX 30-JUL-2002; 2002EP-00016874.
 XX 02-AUG-2001; 2001US-00922181.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M, Gu Y, Nguyen C;
 XX WPI; 2003-423107/40.
 XX New zinc finger-containing proteins and nucleic acids, useful in
 XX manufacturing a medicament for treating or preventing a disorder
 XX associated with decreased or increased expression or activity of MD23,
 XX MD24, MD27 or MD212, e.g. cancer.
 XX Example 8; SEQ ID NO 1361; 103pp; English.
 XX The present invention relates to novel human zinc finger-containing
 XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 XX or in manufacturing a medicament for treating or preventing a disorder
 XX associated with decreased or increased expression or activity of MD23,
 XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 XX acids and proteins are also useful for diagnosing or monitoring a disease

CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 XX Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 85;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 929 TCTGCTGAAGGTTT 943
 DB 17 TCTGCTGAAGGTTT 3
 RESULT 59
 ADB00377/c
 ID ADB00377 standard; DNA; 17 BP.
 XX ADB00377;
 XX 20-NOV-2003 (first entry)
 XX Human MD23 scanning oligonucleotide SEQ ID 1363.
 XX Cytostatic; immunostimulant; gene therapy; vaccine; human;
 XX zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 XX developmental disorder; ss.
 XX Homo sapiens.
 XX EP1281758-A2.
 XX 05-FEB-2003.
 XX 30-JUL-2002; 2002EP-00016874.
 XX 02-AUG-2001; 2001US-00922181.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M, Gu Y, Nguyen C;
 XX WPI; 2003-423107/40.
 XX New zinc finger-containing proteins and nucleic acids, useful in
 XX manufacturing a medicament for treating or preventing a disorder
 XX associated with decreased or increased expression or activity of MD23,
 XX MD24, MD27 or MD212, e.g. cancer.
 XX Example 8; SEQ ID NO 1363; 103pp; English.
 XX The present invention relates to novel human zinc finger-containing
 XX proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 XX encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 XX MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 XX 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 XX or in manufacturing a medicament for treating or preventing a disorder
 XX associated with decreased or increased expression or activity of MD23,
 XX MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 XX acids and proteins are also useful for diagnosing or monitoring a disease
 XX caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 XX alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 XX useful in constructing microarrays for measuring gene expression. The
 XX proteins are useful as therapeutic agents for gene therapy or as
 XX vaccines. The present sequence was used to illustrate the invention.
 XX Sequence 17 BP; 7 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 85;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 969 TTTAAATTCCTCCTT 983
 Db 17 TTTAAATTCCTCCTT 3
 RESULT 57
 ABT35046
 ID ABT35046 standard; DNA; 17 BP.
 XX
 AC ABT35046;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 683.
 XX
 KW Cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 FN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuljinder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumours and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; Page 113; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

Qy 507 TGGAGCTCATGGAGACT 523
 Db 18 TGGAGCTCATGGAGACT 2
 RESULT 56
 ID ABK02552/c
 XX ABK02552 standard; RNA; 17 BP.
 AC ABK02552;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NOGO Amberzyme #224.
 XX
 KW Human; ss; antisense therapy; cytotstatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 KW Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 KW constructs, which down regulate expression of a CD20 gene or neurite
 KW growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 KW central nervous system injury.
 XX
 PS Claim 88; Page 135; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
 CC possessing an NCA motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic


```

PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
PA (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 952; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
XX can be used to control ApoB gene expression.
XX
XX Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 93;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
Oy 507 TGGAGCTCATGGAGACT 523
Db 18 TGGAGTTCATGGAGACT 2
XX
RESULT 55
ADNR79085/c
ID ADNR79085 standard; DNA; 19 BP.
XX
AC ADNR79085;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human apolipoprotein B (ApoB) oligonucleotide seqid 3570.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cytostatic; anticoagulant; nootropic; muscula; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;

```

```

KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
XX
XX Homo sapiens.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454285P.
XX 13-MAR-2003; 2003US-0454962P.
XX 13-MAR-2003; 2003US-0455050P.
XX 14-APR-2003; 2003US-0462894P.
XX 17-APR-2003; 2003US-0463772P.
XX 25-APR-2003; 2003US-0465685P.
XX 25-APR-2003; 2003US-0465802P.
XX 09-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 3570; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
XX can be used to control ApoB gene expression.
XX
XX Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.4; DB 1; Length 19;
XX Best Local Similarity 94.1%; Pred. No. 93;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX

```

```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 93;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Query Match 0.9%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 93;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1580 TTTTCAATTTTGAAA 1596
 Db 18 TTTTTCAGTTTGAAGA 2

RESULT 53
 ADR80880/C
 ID ADR80880 standard; DNA; 19 BP.
 XX
 AC ADR80880;
 DT 16-DEC-2004 (first entry)
 DE Human glucose-6-phosphatase oligonucleotide seqid 5379.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 (ALNY-) ALNYLAM PHARM.
 XX
 PA
 XX
 PI Manoharan M, Bumrot D;
 XX
 DR WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX
 PS Example 5; SEQ ID NO 5379; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);

CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that
 CC can be used to control glucose-6-phosphatase gene expression.
 XX
 SQ Sequence 19 BP; 11 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 93;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1044 TTTTCTTTTAAAGATG 1060
 Db 19 TTTTCTTTTCAAGATG 3

RESULT 54
 ADR76467/C
 ID ADR76467 standard; DNA; 19 BP.
 XX
 AC ADR76467;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human apolipoprotein B (apoB) oligonucleotide seqid 952.
 XX
 PR antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 (ALNY-) ALNYLAM PHARM.
 XX
 PA
 XX
 PI Manoharan M, Bumrot D;
 XX
 DR WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX
 PS Example 5; SEQ ID NO 5379; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX
XX Disclosure; SEQ ID NO 10432; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMLP-1, in particular heart
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 77;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 870 GAGTTTTCATGCTGTCA 886
XX 17 GACTTTTGATGCTGTCA 1
XX
XX RESULT 50
XX ACN73530/C
XX ID ACN73530 standard; DNA; 17 BP.
XX
XX ACN73530;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:10432.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX

PD 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUYV/) GU Y.
XX (JIYY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 10432; 0pp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (SI) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (SI), 95% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (SI). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.9%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 77;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 870 GAGTTTTCATGCTGTCA 886
XX 17 GACTTTTGATGCTGTCA 1
XX
XX RESULT 51
XX ADF93537
XX ID ADF93537 standard; RNA; 19 BP.
XX
XX ADF93537;
XX
XX 26-FEB-2004 (first entry)
XX
XX Human TERT transcript target sequence/siNA upper strand, SEQ ID 254.
XX
XX

Fri May 13 12:26:37 2005

chong906-1.rng

XX The invention relates to a compound targeted to a nucleic acid molecule
 CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
 CC is an antisense oligonucleotide that specifically hybridizes with the
 CC nucleic acid and inhibits expression of the polypeptide. The antisense
 CC oligonucleotide comprises at least one modified internucleoside linkage
 CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
 CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
 CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
 CC useful for modulating the expression of the MMP11 polypeptide and in
 CC preparation of a composition for treating hyperproliferative disorders,
 CC e.g. cancer. This sequence represents an antisense oligonucleotide
 CC targeted to DNA encoding the human MMP11 polypeptide of the invention.
 XX
 SQ Sequence 20 BP; 8 A; 3 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 79;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 902 AGATCTTTTCTTCAAG 919
 Db 19 AGCTCTTTTCTTCAAG 2
 RESULT 46
 ID AAX63796 standard; RNA; 17 BP.
 AC AAX63796;
 XX
 XX 20-JUL-1999 (first entry)
 DT Rabbit stromelysin hammerhead target SEQ ID NO:428.
 DE
 DE
 XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 XX Oryctolagus cuniculus.
 OS
 XX WO9618736-A2.
 XX
 XX 20-JUN-1996.
 XX
 XX 22-NOV-1995; 95WO-US015516.
 XX
 XX 13-DEC-1994; 94US-00354920.
 XX 23-DEC-1994; 94US-00363253.
 XX 23-DEC-1994; 94US-00363254.
 XX 17-FEB-1995; 95US-00390850.
 XX 20-APR-1995; 95US-00426124.
 XX 02-MAY-1995; 95US-00432874.
 XX 04-MAY-1995; 95US-00434509.
 XX 07-JUL-1995; 95US-0000951P.
 XX 07-JUL-1995; 95US-0000974P.
 XX 07-AUG-1995; 95US-00512861.
 XX 05-OCT-1995; 95US-00541365.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX
 XX WPI; 1996-300653/30.
 DR
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX

Example 1; Page 153; 307pp; English.

PS The present invention describes a novel enzymatic nucleic acid (ENA)
 XX having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 17 BP; 12 A; 2 C; 1 G; 0 T; 2 U; 0 Other;
 Query Match 0.9%; Score 16; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 66;
 Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 197 AAAAATCCCAAGAAAT 212
 Db 2 AAAAUAUCCCAAGAAU 17
 RESULT 47
 ID ADI28399 standard; DNA; 20 BP.
 AC ADI28399;
 XX
 XX 22-APR-2004 (first entry)
 DT Human neuropeptide Y2 receptor antisense oligonucleotide.
 XX
 DE Human; neuropeptide Y2; antisense; antiangiogenic; ophthalmological;
 KW nephrotropic; antipsoriatic; cardiovascular-gen.; cytostatic; anti-HIV;
 KW receptor; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004002535-A1.
 XX
 XX 08-JAN-2004.
 XX
 XX 17-JUN-2003; 2003WO-FI000487.
 XX
 XX 27-JUN-2002; 2002US-00180967.
 XX (HORM-) HORMOS MEDICAL CORP.
 XX
 XX Koulu M, Tuohimaa J, Pesonen U, Kallio J, Karvonen M;
 PI WPI; 2004-082891/08.
 XX
 XX Use of an agent affecting the neuropeptide Y Y2 receptor, i.e. antisense
 PT oligonucleotide, for treating or preventing a disease or disorder related
 PT to excessive formation of vascular tissue or blood vessels, e.g.
 PT retinopathy or cancer.
 XX
 XX Claim 11; SEQ ID NO 26; 73pp; English.
 PS
 XX The present sequence is that of an antisense oligonucleotide targeted to
 CC human neuropeptide Y2 receptor mRNA ADI28374. It is an example of
 CC neuropeptide Y2 receptor-targeted antisense oligonucleotides of the
 CC invention useful in the treatment or prevention of a disease or disorder
 XX

KW infantile epilepsy; ataxia; ss.
XX Synthetic.
OS WO2004016754-A2.
PN 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
PF 14-AUG-2002; 2002US-0403416P.
XX (PHRA) PHARMACIA CORP.
PA Roberds SL;
XX WPI; 2004-203785/19.
DR New antisense compound targeted to a nucleic acid molecule encoding
XX Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 3692; 417pp; English.
PS The present invention relates to an antisense compound targeted to a
XX nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
XX different regions of the human Nav1.3 RNA.
SQ Sequence 20 BP; 9 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1745 ATTAAGTATATATATTTT 1762
DB 1 ATTAATTATATATATTTT 18
RESULT 44
ADP27276
ID ADP27276 standard; DNA; 20 BP.
XX ADP27276;
AC ADP27276;
XX 26-AUG-2004 (first entry)
DT Human MMP11 DNA antisense oligonucleotide target region #30.
DE Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX Homo sapiens.
OS US2004110152-A1.
XX 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
PF Example 15; SEQ ID NO 57; 76pp; English.

KW infantile epilepsy; ataxia; ss.
XX Synthetic.
OS WO2004016754-A2.
PN 26-FEB-2004.
XX 14-AUG-2003; 2003WO-US025465.
PF 14-AUG-2002; 2002US-0403416P.
XX (PHRA) PHARMACIA CORP.
PA Roberds SL;
XX WPI; 2004-203785/19.
DR New antisense compound targeted to a nucleic acid molecule encoding
XX Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX Claim 4; SEQ ID NO 3692; 417pp; English.
PS The present invention relates to an antisense compound targeted to a
XX nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
XX different regions of the human Nav1.3 RNA.
SQ Sequence 20 BP; 9 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1745 ATTAAGTATATATATTTT 1762
DB 1 ATTAATTATATATATTTT 18
RESULT 44
ADP27276
ID ADP27276 standard; DNA; 20 BP.
XX ADP27276;
AC ADP27276;
XX 26-AUG-2004 (first entry)
DT Human MMP11 DNA antisense oligonucleotide target region #30.
DE Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX Homo sapiens.
OS US2004110152-A1.
XX 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
PF Example 15; SEQ ID NO 57; 76pp; English.

PR 10-DEC-2002; 2002US-00316755.
XX (ISIS-) ISIS PHARM INC.
XX Baker BF, Cowsert LM;
XX WPI; 2004-440341/41.
DR New oligonucleotide compound that inhibits expression of matrix
XX metalloproteinase 11, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX Example 16; SEQ ID NO 202; 76pp; English.
XX The invention relates to a compound targeted to a nucleic acid molecule
CC encoding a matrix metalloproteinase 11 (MMP11) polypeptide. The compound
CC is an antisense oligonucleotide that specifically hybridizes with the
CC nucleic acid and inhibits expression of the polypeptide. The antisense
CC oligonucleotide comprises at least one modified internucleoside linkage
CC i.e. a phosphorothioate linkage, at least one modified sugar moiety,
CC preferably a 2'-O-methoxyethyl sugar moiety, or at least one modified
CC nucleobase comprising a 5-methylcytosine. The antisense compounds are
CC useful for modulating the expression of the MMP11 polypeptide and in
CC preparation of a composition for treating hyperproliferative disorders,
CC e.g. cancer. This sequence represents a human MMP11 DNA antisense
CC oligonucleotide target region of the invention.
XX SQ Sequence 20 BP; 4 A; 5 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 902 AGATCTTTTCTTCAAG 919
DB 2 AGCTCTTTTCTTCAAG 19
RESULT 45
ADP27131/C
ID ADP27131 standard; DNA; 20 BP.
XX ADP27131;
AC ADP27131;
XX 26-AUG-2004 (first entry)
DT Human matrix metalloproteinase 11 DNA antisense oligonucleotide #40.
DE Human; matrix metalloproteinase 11; MMP11; ss; antisense oligonucleotide;
XX phosphorothioate linkage; 2'-O-methoxyethyl sugar moiety;
KW 5-methylcytosine; hyperproliferative disorder; cancer; cytostatic.
XX Homo sapiens.
OS US2004110152-A1.
XX 10-JUN-2004.
PD 10-DEC-2002; 2002US-00316755.
PF 10-DEC-2002; 2002US-00316755.
XX (ISIS-) ISIS PHARM INC.
XX Baker BF, Cowsert LM;
XX WPI; 2004-440341/41.
DR New oligonucleotide compound that inhibits expression of matrix
XX metalloproteinase 11, useful for preparing a composition for treating
PT hyperproliferative disorder, e.g., cancer.
XX Example 15; SEQ ID NO 57; 76pp; English.

ADK76981 standard; DNA; 20 BP.	ADK76981;	20-MAY-2004 (first entry)	Chimeric phosphorothioate oligonucleotide to target Nav1.3 #4315.	Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia; diabetic neuropathy; arthritic pain; migraine headache; infantile epilepsy; ataxia; ss.	Synthetic.	WO2004016754-A2.	26-FEB-2004.	14-AUG-2003; 2003WO-US025465.	14-AUG-2002; 2002US-0403416P.	(PHAA) PHARMACIA CORP.	Roberds SL;	WPI; 2004-203785/19.	New antisense compound targeted to a nucleic acid molecule encoding Nav1.3, useful for treating a disease or condition associated with Nav1.3, e.g. pain, seizure disorder such as childhood seizure disorder, or ataxia.	Claim 4; SEQ ID NO 4315; 417pp; English.	The present invention relates to an antisense compound targeted to a nucleic acid molecule encoding Nav1.3, where the antisense compound specifically hybridizes with and inhibits the expression of Nav1.3. The compound and composition are useful for treating a disease or condition associated with Nav1.3, e.g. pain including but not limited to neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain, diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain, pain from burns, migraine headache, cluster headache, mild-to-moderate headache; seizure disorder such as childhood seizure disorder, including but not limited to neonatal or infantile epilepsy; or ataxia. The present sequence represents a chimeric phosphorothioate oligonucleotide with 2'MOE wings and a deoxy gap. Used during the antisense inhibition of human Nav1.3 expression, the oligonucleotides are designed to target different regions of the human Nav1.3 RNA.	Sequence 20 BP; 7 A; 0 C; 0 G; 13 T; 0 U; 0 Other;	Query Match 0.9%; Score 16.4; DB 1; Length 20; Best Local Similarity 94.4%; Pred. No. 79; Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	QY 1745 ATTAAGTATATATATTTT 1762 	DB 3 ATTAATTATATATATTTT 20 	RESULT 43 ADK76358 ID ADK76358 standard; DNA; 20 BP. XX AC ADK76358; XX 20-MAY-2004 (first entry) XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #3692. XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia; diabetic neuropathy; arthritic pain; migraine headache;
--------------------------------	-----------	---------------------------	---	---	------------	------------------	--------------	-------------------------------	-------------------------------	-------------------------	-------------	----------------------	---	--	---	--	---	-------------------------------------	--------------------------------	---

KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytotactic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
 XX Homo sapiens.
 OS
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465669P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 10-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 XX
 PI Manoharan M, Buncrot D;
 XX
 DR WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 XX
 PS Example 5; SEQ ID NO 5375; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instructions for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that

CC can be used to control glucose-6-phosphatase gene expression.
 XX
 SQ Sequence 19 BP; 11 A; 2 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 72;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1043 TTTTCTTTTAAAGATG 1060
 |||||
 DB 19 TTTTCTTTTCAAGATG 2
 |||||
 RESULT 40
 AAQ39422/c
 ID AAQ39422 standard; DNA; 20 BP.
 XX
 AC AAQ39422;
 XX
 DT 25-MAR-2003 (revised)
 DT 20-MAY-1993 (first entry)
 XX
 DE PCR Primer #2 for mapping EST's to specific chromosome.
 XX
 KW expressed sequence tag; human genome project; chromosome;
 KW human gene sequencing; PCR mapping; somatic cell hybrids;
 KW sublocalisation; gene tagging; tissue typing.
 XX
 OS Synthetic.
 XX
 PN WO9300353-A1.
 XX
 PD 07-JAN-1993.
 XX
 PF 19-JUN-1992; 92WO-US005222.
 XX
 PR 20-JUN-1991; 91US-00716831.
 PR 12-FEB-1992; 92US-00837195.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICE.
 XX
 PI Venter JC, Adams MD;
 XX
 DR WPI; 1993-036325/04.
 XX
 PT Particular expressed sequence tags from human CDNA - corresponds to
 PT transcription prods. of genes, useful for tagging genes, mapping
 PT chromosomes and tissue typing.
 XX
 PS Example 3; Page 42; 199pp; English.
 XX
 CC This PCR primer was used together with AAQ39421 for the PCR mapping of
 CC somatic cell hybrids. This is a method of assigning an EST (expressed
 CC sequence tag) to a particular chromosome. ESTs are markers for human
 CC genes actually transcribed in vivo. Unlike the random genomic DNA
 CC sequence tagged sites (STSs), ESTs point directly to expressed genes. The
 CC use of ESTs could facilitate the tagging of most expressed human genes
 CC within a few years at a fraction of the cost of complete genomic
 CC sequencing. Using these primers and disclosed methods sublocalisation can
 CC be achieved with panels of fragments from specific chromosomes or pools
 CC of large genomic clones in an analogous manner. This PCR primer sequence
 CC was designed from EST00058 by the computer program INTRON (National
 CC Institutes of Mental Health, Bethesda, MD) to minimise the chance of
 CC amplifying through an intron using the assumptions that: 1) introns are
 CC genomic sequences that interrupt the coding and non-coding sequences of
 CC genes. 2) there are consensus sequences for splice junctions. 3) 90% of
 CC the human genes studied have 3' UTR of mRNA not interrupted by introns in
 CC the genomic DNA. This PCR primer localised EST00058 to chromosome 1.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 SQ Sequence 20 BP; 7 A; 6 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.4; DB 1; Length 20;


```

XX PS Claim 12; Page 70; 77pp; English.
XX
CC The synthetic oligomer is capable of forming a triplex at physiological
CC pH with a purine rich target sequence by coupling into the major groove
CC of the duplex. The specific target sequence of this oligomer is the human
CC tumour necrosis factor beginning at nucleotide 1137 contg. a purine rich
CC sequence concd. on one strand of the duplex. The oligomer, and others
CC like it are useful in diagnosis and therapy of diseases characterised by
CC specific DNA duplex targets, e.g. HPV; HER; HIV, hepatitis B, herpes,
CC malignant tumours and inflammation. The triple helices form under mild
CC conditions thus assays may be carried out without subjecting the test
CC specimen to harsh conditions. See also AAQ25452-25501 and AAQ30226-448.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 21 BP; 11 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 77;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1742 AAAATTAAAGTATATATTTT 1761
Db      1 AAAATTATATATATATTTT 20

RESULT 36
AAQ30387
ID AAQ30387 standard; DNA; 21 BP.
XX
AC AAQ30387;
XX
XX 25-MAR-2003 (revised)
XX 07-DEC-1992 (first entry)
XX
DE Oligomer TNF218 for forming triplex with HUMTNFAA target duplex.
XX
XX Tumour necrosis factor; herpes simplex; AIDS; modified; HIV; RSV; HPV;
XX malignancy; hepatitis; inflammation; ss.
XX
XX Synthetic.
XX
XX Key      Location/Qualifiers
FH modified_base 1
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 2
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 3
FT /tag= c
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 4
FT /tag= d
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 7
FT /tag= e
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 9
FT /tag= f
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 11
FT /tag= g
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 13
FT /tag= h

```

```

FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 15
FT /tag= i
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 17
FT /tag= j
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 21
FT /tag= k
FT /mod_base= OTHER
FT /note= "OTHER= N4 N4 ethanocytosine"
XX
XX WO9209705-A1.
XX
XX 11-JUN-1992.
XX
XX 25-NOV-1991; 91WO-US008811.
XX
XX 23-NOV-1990; 90US-00617907.
XX 18-JAN-1991; 91US-00643382.
XX 08-APR-1991; 91US-00683420.
XX 17-APR-1991; 91US-00686544.
XX 17-APR-1991; 91US-00686546.
XX 17-APR-1991; 91US-00686547.
XX 27-SEP-1991; 91US-00766733.
XX
XX (GILE-) GILEAD SCI INC.
XX
XX Froehler B, Krawczyk S, Matteucci MD, Milligan J;
XX WPI; 1992-217083/26.
XX
XX New oligomers contg. modified bases - which form a triplex with G-C
XX doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,
XX herpes malignancy and inflammation.
XX
XX Claim 12; Page 70; 77pp; English.
XX
XX The synthetic oligomer is capable of forming a triplex at physiological
XX pH with a purine rich target sequence by coupling into the major groove
XX of the duplex. The specific target sequence of this oligomer is the human
XX tumour necrosis factor beginning at nucleotide 1137 contg. a purine rich
XX sequence concd. on one strand of the duplex. The oligomer, and others
XX like it are useful in diagnosis and therapy of diseases characterised by
XX specific DNA duplex targets, e.g. HPV; HER; HIV, hepatitis B, herpes,
XX malignant tumours and inflammation. The triple helices form under mild
XX conditions thus assays may be carried out without subjecting the test
XX specimen to harsh conditions. See also AAQ25452-25501 and AAQ30226-448.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 21 BP; 10 A; 1 C; 0 G; 10 T; 0 U; 0 Other;

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 77;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1742 AAAATTAAAGTATATATTTT 1761
Db      1 AAAATTATATATATATTTT 20

RESULT 37
AAQ64428
ID AAQ64428 standard; RNA; 18 BP.
XX
XX AAQ64428;
XX
XX 20-JUL-1999 (first entry)
XX
XX Human stromelysin hairpin target sequence SEQ ID NO:1060.

```

FT modified_base 9 /*tag= f
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 11 /*tag= g
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 13 /*tag= h
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 15 /*tag= i
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 17 /*tag= j
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 21 /*tag= k
FT /mod_base= OTHER
FT /note= "N4N4-ethanocytosine"
XX
XX W09118997-A.
XX
XX 12-DEC-1991.
XX
XX 25-MAY-1990; 90US-00529346.
XX
XX 25-MAY-1990; 90US-00529346.
PR 14-JAN-1991; 91US-00640654.
XX
XX (GILE-) GILEAD SCI INC.
XX
XX Matteucci MD, Krawczyk S;
XX WPI; 1992-007480/01.
XX
XX New sequence-specific non-photo-activated crosslinking agents - bind to
PT the major groove of duplex DNA and are esp. useful for treating latent
PT infections e.g. HIV.
XX
XX Example 4; Page 25; 42pp; English.
XX
XX The sequence is designed to target the Human tumour necrosis factor
CC beginning at nucleotide 1137 and to covalently cross-link to it via the
CC N4N4-ethanocytosine group. See also AAQ20031-Q20038
XX
XX Sequence 21 BP; 10 A; 1 C; 0 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 77;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1742 AAAATTAGTATATATATTT 1761
Db 1 AAAATTATATATATATTT 20
RESULT 35
AAQ30386
ID AAQ30386 standard; DNA; 21 BP.
XX
XX AAQ30386;
XX
XX 25-MAR-2003 (revised)
DT 07-DEC-1992 (first entry)
XX
XX Oligomer TNF217 for forming triplex with HUMTNFAA target duplex.
DE
XX Tumour necrosis factor; herpes simplex; AIDS; modified; HIV; RSV; HPV;

KW malignancy; hepatitis; inflammation; ss.
XX Synthetic.
XX Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 2 /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 3 /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 4 /*tag= d
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 7 /*tag= e
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 9 /*tag= f
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 11 /*tag= g
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 13 /*tag= h
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 15 /*tag= i
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 17 /*tag= j
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
FT modified_base 21 /*tag= k
FT /mod_base= OTHER
FT /note= "OTHER= N6 methyl-8-oxo-2' deoxyadenine"
XX W09209705-A1.
XX 11-JUN-1992.
XX 25-NOV-1991; 91WO-US008811.
XX 23-NOV-1990; 90US-00617907.
PR 18-JAN-1991; 91US-00643382.
PR 08-APR-1991; 91US-00683420.
PR 17-APR-1991; 91US-00686544.
PR 17-APR-1991; 91US-00686546.
PR 17-APR-1991; 91US-00686547.
PR 27-SEP-1991; 91US-00766733.
XX (GILE-) GILEAD SCI INC.
XX Froehler B, Krawczyk S, Matteucci MD, Milligan J;
XX WPI; 1992-217083/26.
XX New oligomers contg. modified bases - which form a triplex with G-C
PT doublet in a DNA duplex, for treating and diagnosing HIV, hepatitis,
XX herpes malignancy and inflammation.

PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 4151; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposcretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1559 GATTATATACATACATAT 1578
DB 20 GATTATATACATACATAT 1

RESULT 33
ADK81657/c
ID ADK81657 standard; DNA; 20 BP.
XX
XX ADK81657;
XX
XX 20-MAY-2004 (first entry)
DT
DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8991.
XX
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
XX diabetic neuropathy; arthritic pain; migraine headache;
XX infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX WO2004016754-A2.
PN
XX 26-FEB-2004.
PD
XX 14-AUG-2003; 2003WO-US025465.
PF
XX 14-AUG-2002; 2002US-0403416P.
PR
XX (PHAA) PHARMACIA CORP.
XX

PI Roberds SL;
XX
DR WPI; 2004-203785/19.
XX
PT New antisense compound targeted to a nucleic acid molecule encoding
PT Nav1.3, useful for treating a disease or condition associated
PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX
PS Claim 4; SEQ ID NO 8991; 417pp; English.
XX
CC The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Nav1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Nav1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Nav1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraine headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Nav1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Nav1.3 RNA.
XX
SQ Sequence 20 BP; 8 A; 1 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1569 AATACATAATATTTTCAAT 1588
DB 20 AATCATAAGATTTTCAAT 1

RESULT 34
AAQ20036
ID AAQ20036 standard; DNA; 21 BP.
XX
XX AAQ20036;
XX
XX 01-APR-1992 (first entry)
DT
DE Cross-linking oligomer 218 for targeting human TNF.
XX
XX deoxyribonucleic acid; major groove; ethanocamino group;
XX aziridinylcytosine; cross-linking group; tumour necrosis factor; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 2 /*tag= b
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 3 /*tag= c
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 4 /*tag= d
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"
FT modified_base 7 /*tag= e
FT /mod_base= OTHER
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"

PT metalloproteinases, growth factors and cell-cycle dependent kinases.
 XX
 PS Example 1; Page 261; 408pp; English.
 XX
 CC The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,
 CC ophthalmological, vulvar, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention
 XX
 XX Sequence 19 BP; 7 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 1.0%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 56;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 901 AAGATCTTTTCTCAAG 919
 DB 19 AAGATCTTTTCTCAAG 1
 RESULT 31
 ABZ88909/C
 ID ABZ88909 standard; DNA; 20 BP.
 XX
 AC ABZ88909;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubinone; antiinflammatory; antiasthmatic;
 KW antiallergic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubinone.

XX
 PS Disclosure; SEQ ID NO 4151; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiseborrheic, antidiabetic, antisickling,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 20 BP; 7 A; 2 C; 2 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 0.9%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 71;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1559 GATTATATAAATACATAAT 1578
 DB 20 GATTATATAAATACATAAT 1
 RESULT 32
 ABD25139/C
 ID ABD25139 standard; DNA; 20 BP.
 XX
 AC ABD25139;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE AI041482-derived oligonucleotide SEQ ID 4151.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to

DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.
 XX Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO2004009098-A1.
 PN 29-JAN-2004.
 PD 17-JUL-2003; 2003WO-SE001223.
 XX 18-JUL-2002; 2002SE-00002253.
 PR 04-SEP-2002; 2002US-0407680P.
 XX (INDE-) INDEX PHARM AB.
 PA Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 PI WPI; 2004-123288/12.
 DR New compound having a sequence targeted to a nucleic acid encoding
 XX metalloproteinase 12 (MMP-12), useful for preparing a composition for
 PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 PT asthma or psoriasis.
 XX Claim 7; SEQ ID NO 11; 55pp; English.
 PS The present invention relates to antisense oligonucleotides (ADI53690-
 CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
 CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.
 XX Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 208 GAAATGCAGCACTTCTGG 226
 DB 19 GAAATGCAGCACTTCTGG 1
 RESULT 29
 ID AAA85022/c
 XX AAA85022 standard; DNA; 19 BP.
 AC AAA85022;
 XX 04-DEC-2000 (first entry)
 DT Cyclin G1 ribozyme binding site #47.
 DE Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
 KW Mammalia.
 XX WO200032765-A2.
 PN 08-JUN-2000.
 PD 06-DEC-1999; 99WO-US028772.
 XX 04-DEC-1998; 98US-0110954P.
 PR

XX (IMMU-) IMMUSOL INC.
 PA Tritz R, Welch PJ, Barber JR, Robbins JM;
 PI WPI; 2000-412314/35.
 DR New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PT PCNA and Cyclin B1.
 XX Disclosure; Page 86; 109pp; English.
 PS The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given in
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells. The
 CC ribozyme is resistant to endonuclease activity and hence is efficient in
 CC restenosis treatment
 XX Sequence 19 BP; 7 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
 SQ Query Match 1.0%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 56;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 901 AAGATCTTTTCTTCAAAG 919
 DB 19 AAGATCTTTTCTTCAAAG 1
 RESULT 30
 ID AAH60184/c
 XX AAH60184 standard; DNA; 19 BP.
 AC AAH60184;
 XX 10-SEP-2001 (first entry)
 DT Cyclin G1 ribozyme binding site SEQ ID NO:2608.
 DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 PN 03-MAY-2001.
 PD 26-OCT-2000; 2000WO-US029500.
 XX 26-OCT-1999; 99US-0161532P.
 PR (IMMU-) IMMUSOL INC.
 XX Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR Treating proliferative skin or eye diseases and scarring, using ribozymes
 PT that cleave RNA encoding cytokines involved in inflammation, matrix

CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.
 XX Sequence 19 BP; 5 A; 1 C; 4 G; 9 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 355 ACCTACAGATCAATAATT 373
 DB 19 ACCTACAGATCAATAATT 1
 |||||
 |||||

RESULT 26
 ADI53696/c
 ID ADI53696 standard; DNA; 19 BP.
 XX
 AC ADI53696;
 XX
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human MMP-12 antisense oligonucleotide, SEQ ID 9.
 XX
 DE Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004009098-A1.
 XX
 XX 29-JAN-2004.
 XX
 XX 17-JUL-2003; 2003WO-SB001223.
 XX
 XX 18-JUL-2002; 2002SE-00002253.
 PR 04-SEP-2002; 2002US-0407680P.
 XX
 XX (INDE-) INDEX PHARM AB.
 XX
 XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 OS Synthetic.
 XX WO2004009098-A1.
 XX
 XX 29-JAN-2004.
 XX
 XX 17-JUL-2003; 2003WO-SB001223.
 XX
 XX 18-JUL-2002; 2002SE-00002253.
 PR 04-SEP-2002; 2002US-0407680P.
 XX
 XX (INDE-) INDEX PHARM AB.
 XX
 XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 XX WPI; 2004-123288/12.
 DR New compound having a sequence targeted to a nucleic acid encoding
 PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
 PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 PT asthma or psoriasis.
 PT
 XX Claim 7; SEQ ID NO 9; 55pp; English.
 XX
 XX The present invention relates to antisense oligonucleotides (ADI53690-
 CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
 CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.
 XX Sequence 19 BP; 3 A; 2 C; 7 G; 7 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 AACCAACGCTGCCAAATC 832
 DB 19 AACCAACGCTGCCAAATC 1
 |||||
 |||||

RESULT 27
 ADI53697/c
 ID ADI53697 standard; DNA; 19 BP.
 XX
 AC ADI53697;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human MMP-12 antisense oligonucleotide, SEQ ID 10.
 XX
 DE Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004009098-A1.
 XX
 XX 29-JAN-2004.
 XX
 XX 17-JUL-2003; 2003WO-SB001223.
 XX
 XX 18-JUL-2002; 2002SE-00002253.
 PR 04-SEP-2002; 2002US-0407680P.
 XX
 XX (INDE-) INDEX PHARM AB.
 XX
 XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 XX WPI; 2004-123288/12.
 DR New compound having a sequence targeted to a nucleic acid encoding
 PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
 PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 PT asthma or psoriasis.
 PT
 XX Claim 7; SEQ ID NO 10; 55pp; English.
 XX
 XX The present invention relates to antisense oligonucleotides (ADI53690-
 CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
 CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.
 XX Sequence 19 BP; 4 A; 2 C; 5 G; 8 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1097 CAATATCCCAAGAGCAT 1115
 DB 19 CAATATCCCAAGAGCAT 1
 |||||
 |||||

RESULT 28
 ADI53698/c
 ID ADI53698 standard; DNA; 19 BP.
 XX
 AC ADI53698;
 XX
 DT 22-APR-2004 (first entry)
 XX


```

OS Synthetic.
FN WO2004009098-A1.
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 13; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 913 TTCAAAGACAGGTTCTTCT 931
Db 19 TTCAAAGACAGGTTCTTCT 1

RESULT 24
ADI53690/c
ID ADI53690 standard; DNA; 19 BP.
XX
AC ADI53690;
XX
XX 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 3.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004009098-A1.
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 5; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 913 TTCAAAGACAGGTTCTTCT 931
Db 19 TTCAAAGACAGGTTCTTCT 1

RESULT 24
ADI53690/c
ID ADI53690 standard; DNA; 19 BP.
XX
AC ADI53690;
XX
XX 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 3.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004009098-A1.
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 5; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

```

```

PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 3; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
SQ Sequence 19 BP; 7 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 751 ACATTTCGCTCTCTGCTG 769
Db 19 ACATTTCGCTCTCTGCTG 1

RESULT 25
ADI53692/c
ID ADI53692 standard; DNA; 19 BP.
XX
AC ADI53692;
XX
XX 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 5.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004009098-A1.
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 5; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

```

```
Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GAGACACCAAGACCAGCTG 964
DB 19 GAGACACCAAGACCAGCTG 1
|||||
RESULT 21
ADIS3701/c
ID ADIS3701 standard; DNA; 19 BP.
XX
AC ADIS3701;
XX
DT 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 14.
XX
XX Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004009098-A1.
XX
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
XX New compound having a sequence targeted to a nucleic acid encoding
XX metalloproteinase 12 (MMP-12), useful for preparing a composition for
XX treating or preventing MMP-12 dependent disorder in a human patient e.g.,
XX asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 14; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADIS3690-
CC ADIS3701) for matrix metalloproteinase 12 (MMP-12; ADIS3688 and
CC ADIS3689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1231 AGACAGATGATGACCCCTG 1249
DB 19 AGACAGATGATGACCCCTG 1
|||||
RESULT 22
ADIS3693/c
ID ADIS3693 standard; DNA; 19 BP.
XX
```

```
XX
AC ADIS3693;
XX
DT 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 6.
XX
XX Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004009098-A1.
XX
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
XX New compound having a sequence targeted to a nucleic acid encoding
XX metalloproteinase 12 (MMP-12), useful for preparing a composition for
XX treating or preventing MMP-12 dependent disorder in a human patient e.g.,
XX asthma or psoriasis.
XX
PS Claim 7; SEQ ID NO 6; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADIS3690-
CC ADIS3701) for matrix metalloproteinase 12 (MMP-12; ADIS3688 and
CC ADIS3689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
SQ Sequence 19 BP; 5 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 512 CTCATGGAGACTTCATGC 530
DB 19 CTCATGGAGACTTCATGC 1
|||||
RESULT 23
ADIS3700/c
ID ADIS3700 standard; DNA; 19 BP.
XX
AC ADIS3700;
XX
DT 22-APR-2004 (first entry)
XX
DE Human MMP-12 antisense oligonucleotide, SEQ ID 13.
XX
XX Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
OS Homo sapiens.
```

```

PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX (INDE-) INDEX PHARM AB.
XX
XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
PI
XX WPI; 2004-123288/12.
DR
XX New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
XX Claim 7; SEQ ID NO 7; 55pp; English.
PS
XX The present invention relates to antisense oligonucleotides (ADIF53690-
CC ADIF53701) for matrix metalloproteinase 12 (MMP-12; ADIF53688 and
CC ADIF53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
XX Sequence 19 BP; 6 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 855 CTGTGACCCCAATTGAGT 873
Db 19 CTGTGACCCCAATTGAGT 1
|||||

RESULT 19
ADIF53695/c
ID ADIF53695 standard; DNA; 19 BP.
XX
XX AC ADIF53695;
XX
XX DT 22-APR-2004 (first entry)
XX
XX DE Human MMP-12 antisense oligonucleotide, SEQ ID 8.
XX
XX KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX PN WO2004009098-A1.
XX
XX PD 29-JAN-2004.
XX
XX DE Human MMP-12 antisense oligonucleotide, SEQ ID 8.
XX
XX KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX PN WO2004009098-A1.
XX
XX PD 29-JAN-2004.
XX
XX PF 17-JUL-2003; 2003WO-SE001223.
XX
XX PR 18-JUL-2002; 2002SE-00002253.
XX PR 04-SEP-2002; 2002US-0407680P.
XX
XX PA (INDE-) INDEX PHARM AB.
XX
XX PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
XX WPI; 2004-123288/12.
XX
XX New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
PT

```

```

XX Claim 7; SEQ ID NO 8; 55pp; English.
XX
XX The present invention relates to antisense oligonucleotides (ADIF53690-
CC ADIF53701) for matrix metalloproteinase 12 (MMP-12; ADIF53688 and
CC ADIF53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
XX Sequence 19 BP; 8 A; 3 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 TAGGACCTACTTCTTTGTA 1200
Db 19 TAGGACCTACTTCTTTGTA 1
|||||

RESULT 20
ADIF53699/c
ID ADIF53699 standard; DNA; 19 BP.
XX
XX AC ADIF53699;
XX
XX DT 22-APR-2004 (first entry)
XX
XX DE Human MMP-12 antisense oligonucleotide, SEQ ID 12.
XX
XX KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
XX Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
XX MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
XX rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
XX OS Homo sapiens.
XX
XX OS Synthetic.
XX
XX PN WO2004009098-A1.
XX
XX PD 29-JAN-2004.
XX
XX PF 17-JUL-2003; 2003WO-SE001223.
XX
XX PR 18-JUL-2002; 2002SE-00002253.
XX PR 04-SEP-2002; 2002US-0407680P.
XX
XX PA (INDE-) INDEX PHARM AB.
XX
XX PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
XX WPI; 2004-123288/12.
XX
XX New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
XX Claim 7; SEQ ID NO 12; 55pp; English.
XX
XX The present invention relates to antisense oligonucleotides (ADIF53690-
CC ADIF53701) for matrix metalloproteinase 12 (MMP-12; ADIF53688 and
CC ADIF53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
XX Sequence 19 BP; 1 A; 6 C; 4 G; 8 T; 0 U; 0 Other;
SQ

```

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; WMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytoskeletal;
KW antipsoriatic; antiseborrheic; antidiabetic; virucide;
KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
PN WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
PI
PI WPI; 2001-300427/31.
DR
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 23; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,
CC dermatological, cytoskeletal, antiseborrheic, antidiabetic, antisickling,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 39;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 781 GGCATTTCAGTCCCTGATGGA 801
Db 1 GGCATTTCAGTCCCTGATGGA 21
RESULT 17
ADI53691/c
ID ADI53691 standard; DNA; 19 BP.
XX
XX ADI53691;
AC
AC 22-APR-2004 (first entry)
DT
DE Human MMP-12 antisense oligonucleotide, SEQ ID 4.
XX
XX Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;

KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
PN WO2004009098-A1.
XX
XX 29-JAN-2004.
XX
XX 17-JUL-2003; 2003WO-SE001223.
XX
XX 18-JUL-2002; 2002SE-0002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
XX (INDE-) INDEX PHARM AB.
PA
PA Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX WPI; 2004-123288/12.
XX
XX New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
XX Claim 7; SEQ ID NO 4; 55pp; English.
XX
XX The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridize with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma.
XX
XX Sequence 19 BP; 4 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 137 GCCTTGAGATAAACAACACT 155
Db 19 GCCTTGAGATAAACAACACT 1
RESULT 18
ADI53694/c
ID ADI53694 standard; DNA; 19 BP.
XX
XX ADI53694;
AC
AC 22-APR-2004 (first entry)
DT
DE Human MMP-12 antisense oligonucleotide, SEQ ID 7.
XX
XX Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX WO2004009098-A1.
PN
XX 29-JAN-2004.
XX
XX 17-JUL-2003; 2003WO-SE001223.
XX

CC invention is useful for determining whether a woman has, or is likely to
 CC develop stress urinary incontinence. The human elastase of the invention
 CC is also useful for treating a woman for stress urinary incontinence and a
 CC disease of undesired elastin degradation (e.g. pelvic organ prolapse,
 CC emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and
 CC inflammatory disease). The present DNA sequence represents a PCR primer
 CC that was used in an example of the invention.
 XX
 SQ Sequence 21 BP; 5 A; 5 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 26;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1015 GCTTATGAAATTCAGCCAGA 1035
 |||||
 DB 21 GCTTATGAAATTCAGCCAGA 1

RESULT 14
 ACC57867/c
 ID ACC57867 standard; DNA; 20 BP.
 XX
 AC ACC57867;
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE Matrix metalloproteinase 12 antisense PCR primer.
 XX
 KW Matrix metalloproteinase 12; MMP-12; human; transcription;
 KW cis-acting element; transcription factor; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003033679-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 17-OCT-2002; 2002WO-US033579.
 XX
 PR 17-OCT-2001; 2001US-0329961P.
 XX
 PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.
 XX
 PI Yokota H, Sun HB;
 XX
 DR WPI; 2003-393526/37.
 XX
 PS Predicting an expression level of a target gene or gene family comprises
 PT experimentally determining the number and type of cis-acting elements
 PT provided in 5' untranslated regulatory regions of the target gene.
 XX
 PS Example 4; Page 36; 78pp; English.

CC The present sequence is an antisense primer for the PCR amplification of
 CC human matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is
 CC obtained using this antisense primer with the sense primer given in
 CC ACC57866. RT-PCR was performed in an example from the invention to
 CC determine expression profiles of MMP genes in human synovial cells in
 CC response to mechanical shear. A model-based analysis was used to identify
 CC the role of transcription factor binding motifs in gene regulation. The
 CC results provide an example of the method of the invention for determining
 CC expression levels of target genes based on sequence elements present in
 CC untranslated regulatory regions
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 CGTGAGGATGTGACTACGC 410
 |||||

DB 20 CGTGAGGATGTGACTACGC 1
 RESULT 15
 ACC57866
 ID ACC57866 standard; DNA; 20 BP.
 XX
 AC ACC57866;
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE Matrix metalloproteinase 12 sense PCR primer.
 XX
 KW Matrix metalloproteinase 12; MMP-12; human; transcription;
 KW cis-acting element; transcription factor; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003033679-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 17-OCT-2002; 2002WO-US033579.
 XX
 PR 17-OCT-2001; 2001US-0329961P.
 XX
 PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.
 XX
 PI Yokota H, Sun HB;
 XX
 DR WPI; 2003-393526/37.
 XX
 PS Predicting an expression level of a target gene or gene family comprises
 PT experimentally determining the number and type of cis-acting elements
 PT provided in 5' untranslated regulatory regions of the target gene.
 XX
 PS Example 4; Page 36; 78pp; English.

CC The present sequence is a sense primer for the PCR amplification of human
 CC matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is obtained
 CC using this sense primer with the antisense primer given in ACC57867. RT-
 CC PCR was performed in an example from the invention to determine
 CC expression profiles of MMP genes in human synovial cells in response to
 CC mechanical shear. A model-based analysis was used to identify the role of
 CC transcription factor binding motifs in gene regulation. The results
 CC provide an example of the method of the invention for determining
 CC expression levels of target genes based on sequence elements present in
 CC untranslated regulatory regions
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 CCATGCTTCTGGAGCTCTT 63
 |||||
 DB 1 CCATGCTTCTGGAGCTCTT 20

RESULT 16
 AAH62035
 ID AAH62035 standard; DNA; 21 BP.
 XX
 AC AAH62035;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE MMP3 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4459.
 XX
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulnery;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;

XX PD 12-DEC-2002.

XX PF 05-JUN-2002; 2002WO-NZ000106.

XX PR 05-JUN-2001; 2001NZ-00512169.

XX PR 17-JUL-2001; 2001NZ-00513016.

XX PR 18-SEP-2001; 2001NZ-00514275.

XX PA (AUCK-) AUCKLAND UNISERVICES LTD.

XX PI Young RP;

XX DR WPI; 2003-140633/13.

XX PT Diagnosing predisposition to and/or severity of chronic obstructive pulmonary disease in smokers/non-smokers, by analyzing polymorphisms in regulatory and/or promoter regions of genes encoding matrix metalloproteinase.

XX PS Example 1; Col 18; 79pp; English.

XX CC The present invention relates to a method of determining a subject's predisposition to or at risk of developing chronic obstructive pulmonary disease (COPD), impaired lung function, morbidity/mortality risk of the disease associated with impaired lung function in smokers/non-smokers. The method involves analysing genetic polymorphisms in regulatory and/or promoter regions of genes encoding matrix metalloproteinase (MMP). The present DNA sequence is a PCR primer used to determine MMP12 (human macrophage elastase) promoter polymorphism. This sequence is used in the amplification of the invention

XX SQ Sequence 21 BP; 3 A; 3 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 65 CCTGTACAGCTCTACAGCC 85
DB 21 CCTGTACAGCTCTACAGCC 1

RESULT 12
ADP44842
ID ADP44842 standard; DNA; 21 BP.
XX AC ADP44842;
XX DT 12-AUG-2004 (first entry)
XX DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #3.
XX KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;
XX KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;
XX KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;
XX KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;
XX KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;
XX MMP-12.
XX OS Homo sapiens.
XX PN WO2004041115-A2.
XX PD 21-MAY-2004.
XX PP 12-JUN-2003; 2003WO-US018696.
XX PR 14-JUN-2002; 2002US-0389094P.
XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX PI Kushner L, Mathrubutham M, Rao SK;

Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary incontinence in woman.

Example 6; SEQ ID NO 9; 54pp; English.

The invention comprises a human elastase that has an optimum pH of about 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the invention is useful for determining whether a woman has, or is likely to develop stress urinary incontinence. The human elastase of the invention is also useful for treating a woman for stress urinary incontinence and a disease of undesired elastin degradation (e.g. pelvic organ prolapse, emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and inflammatory disease). The present DNA sequence represents a PCR primer that was used in an example of the invention.

Sequence 21 BP; 4 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 663 TCACGAGATTGGCCATTTCCTT 683
DB 1 TCACGAGATTGGCCATTTCCTT 21

RESULT 13
ADP44843/c
ID ADP44843 standard; DNA; 21 BP.
XX AC ADP44843;
XX DT 12-AUG-2004 (first entry)
XX DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #4.
XX KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;
XX KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;
XX KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;
XX KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;
XX KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;
XX MMP-12.
XX OS Homo sapiens.
XX PN WO2004041115-A2.
XX PD 21-MAY-2004.
XX PP 12-JUN-2003; 2003WO-US018696.
XX PR 14-JUN-2002; 2002US-0389094P.
XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX PI Kushner L, Mathrubutham M, Rao SK;

Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary incontinence in woman.

Example 6; SEQ ID NO 10; 54pp; English.

The invention comprises a human elastase that has an optimum pH of about 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the

XX DR WPI; 2004-400506/37.

XX PF Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary incontinence in woman.

XX PS Example 6; SEQ ID NO 9; 54pp; English.

XX CC The invention comprises a human elastase that has an optimum pH of about 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the invention is useful for determining whether a woman has, or is likely to develop stress urinary incontinence. The human elastase of the invention is also useful for treating a woman for stress urinary incontinence and a disease of undesired elastin degradation (e.g. pelvic organ prolapse, emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and inflammatory disease). The present DNA sequence represents a PCR primer that was used in an example of the invention.

XX SQ Sequence 21 BP; 4 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 663 TCACGAGATTGGCCATTTCCTT 683
DB 1 TCACGAGATTGGCCATTTCCTT 21

RESULT 13
ADP44843/c
ID ADP44843 standard; DNA; 21 BP.
XX AC ADP44843;
XX DT 12-AUG-2004 (first entry)
XX DE Human matrix metalloproteinase-12 (MMP-12) PCR primer #4.
XX KW human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;
XX KW phenylmethyl-sulfonyl fluoride; stress urinary incontinence;
XX KW undesired elastin degradation disease; pelvic organ prolapse; emphysema;
XX KW abdominal aortic aneurysm; atherosclerosis; pancreatitis;
XX KW inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;
XX MMP-12.
XX OS Homo sapiens.
XX PN WO2004041115-A2.
XX PD 21-MAY-2004.
XX PP 12-JUN-2003; 2003WO-US018696.
XX PR 14-JUN-2002; 2002US-0389094P.
XX PA (NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.
XX PI Kushner L, Mathrubutham M, Rao SK;

Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary incontinence in woman.

Example 6; SEQ ID NO 10; 54pp; English.

The invention comprises a human elastase that has an optimum pH of about 8.5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the

```

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1014 TCGTTATGAATTAAGCCAGAA 1037
Db      ||||| ||||| ||||| ||||| |||||
24 TCGTTATGAATTAAGCCAGAA 1

RESULT 9
ADI53707
ID ADI53707 standard; DNA; 24 BP.
XX
AC ADI53707;
XX
DT 22-APR-2004 (first entry)
XX
DE MMP-12 forward primer, SEQ ID 20.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; matrix metalloproteinase 12; MMP-12;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004009098-A1.
XX
PD 29-JAN-2004.
XX
DE MMP-12 forward primer, SEQ ID 20.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; matrix metalloproteinase 12; MMP-12;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004009098-A1.
XX
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
DR WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Example 1; SEQ ID NO 20; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma. The present sequence is a PCR
CC primer, which was used in an example from the invention.
XX
SQ Sequence 24 BP; 6 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1366 GACTTCCTACTCCACGTATCACC 1389
Db      ||||| ||||| ||||| ||||| |||||
1 GACTTCCTACTCCACGTATCACC 24

RESULT 10
ADI53708/c
ID ADI53708 standard; DNA; 24 BP.
XX

```

```

AC ADI53708;
XX
DT 22-APR-2004 (first entry)
XX
DE MMP-12 reverse primer, SEQ ID 21.
XX
KW Antinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
KW Respiratory; matrix metalloproteinase 12; MMP-12;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease;
KW rheumatoid arthritis; psoriasis; emphysema; asthma; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004009098-A1.
XX
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-SE001223.
XX
PR 18-JUL-2002; 2002SE-00002253.
PR 04-SEP-2002; 2002US-0407680P.
XX
PA (INDE-) INDEX PHARM AB.
XX
PI Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
XX
DR WPI; 2004-123288/12.
XX
PT New compound having a sequence targeted to a nucleic acid encoding
PT metalloproteinase 12 (MMP-12), useful for preparing a composition for
PT treating or preventing MMP-12 dependent disorder in a human patient e.g.,
PT asthma or psoriasis.
XX
PS Example 1; SEQ ID NO 21; 55pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADI53690-
CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
CC ADI53689), which specifically hybridise with the nucleic acid encoding
CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
CC oligonucleotides are useful for preparing a composition for treating or
CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
CC arthritis, psoriasis, emphysema or asthma. The present sequence is a PCR
CC primer, which was used in an example from the invention.
XX
SQ Sequence 24 BP; 7 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1692 GCTTCCTAACATCCTTGACTGAG 1715
Db      ||||| ||||| ||||| ||||| |||||
24 GCTTCCTAACATCCTTGACTGAG 1

RESULT 11
AAD51522/c
ID AAD51522 standard; DNA; 21 BP.
XX
AC AAD51522;
XX
DT 16-APR-2003 (first entry)
XX
DE Hmep2 PCR primer used for MMP12 promoter polymorphism genotyping.
XX
KW Chronic obstructive pulmonary disease; COPD; impaired lung function;
KW morbidity; genetic polymorphism; matrix metalloproteinase; MMP12; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO200299134-A1.

```

CC The present invention describes a method for predicting, diagnosing or
 CC prognosing chronic lung disease by detecting a chronic obstructive
 CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
 CC ACC46777, which encode the COPD related proteins in ABP96779 to
 CC ABP96806). The method is useful for predicting, diagnosing or prognosing
 CC chronic lung disease in a biological sample. The COPD genes and proteins
 CC encoded by them from the present invention (I) can be used for treating
 CC or preventing chronic lung disease in a mammal. (I) can be used in an
 CC animal model for determining the efficacy, toxicity, or side effects of
 CC treatment with (I), and determining the mechanism of action of (I).
 CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used
 CC in an example from the present invention

XX SQ Sequence 25 BP; 4 A; 9 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 980 CCTATGGCCACCTTGCCATCTGG 1004
 DB 1 CCTATGGCCACCTTGCCATCTGG 25

RESULT 7
 ABZ84127
 ID ABZ84127 standard; DNA; 25 BP.
 XX AC ABZ84127;
 XX DT 14-MAY-2003 (first entry)
 XX DE Toxicologically relevant human PCR primer #1286.
 XX KW Toxicologically relevant gene; toxicological response; PCR primer; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO2003016500-A2.
 XX PD 27-FEB-2003.
 XX PF 16-AUG-2002; 2002WO-US026514.
 XX PR 16-AUG-2001; 2001US-0313080P.
 XX PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.
 XX PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schweiser K;
 XX PI Alen P;
 XX DR WPI; 2003-268322/26.
 XX PT Determining a toxicological response to an agent, useful for screening of
 XX PT drugs, comprises comparing the expression profile of one or more human
 XX PT toxic response genes to a reference gene expression profile indicative of
 XX PT toxicity.
 XX PS Claim 1; Page 332; 455pp; English.
 XX CC The present invention describes a method (M1) for determining a
 CC toxicological response to an agent, which comprises comparing the
 CC expression profile of one or more human toxic response genes to a
 CC reference gene expression profile indicative of toxicity, and so
 CC determining the presence of a toxic response to the agent. Also
 CC described: (1) an array comprising one or more polynucleotides selected
 CC from the genes corresponding to the partial sequences given in ABZ82842
 CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues
 CC ; and (2) determining if a gene putatively identified to be a toxic
 CC response gene plays a role on toxic response pathways by determining the
 CC expression profile of the gene after exposure of cells or a human subject

CC to a known toxic pharmaceutical or industrial agent, comprising: (a)
 CC exposing cells to an agent or isolating cells from a human subject who
 CC was exposed to an agent; (b) obtaining the test gene expression profile
 CC for a putatively identified toxic response gene after exposure to a known
 CC toxic pharmaceutical or industrial agent; and (c) comparing the test
 CC profile to the expression profile of a gene with a similar function or
 CC comparing the test profile to the expression profile of that gene after
 CC exposure to other known toxic compounds. The methods are useful for
 CC predicting and determining toxicological responses on a cellular, organ
 CC or system level. The arrays comprising the human genes are useful for
 CC toxicological screening of drugs, pharmaceutical compounds and chemicals

XX SQ Sequence 25 BP; 4 A; 8 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 973 ATTTCTTCTTATGGCCACCTTGC 997
 DB 1 ATTTCTTCTTATGGCCACCTTGC 25

RESULT 8
 ACC46843/C
 ID ACC46843 standard; DNA; 24 BP.
 XX AC ACC46843;
 XX DT 05-JUN-2003 (first entry)
 XX DE Human COPD related gene reverse PCR primer SEQ ID NO:122.
 XX KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;
 XX KW PCR primer; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200297127-A2.
 XX PD 05-DEC-2002.
 XX PF 28-MAY-2002; 2002WO-EP005835.
 XX PR 31-MAY-2001; 2001GB-00013266.
 XX PA (FARB) BAYER AG.
 XX PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;
 XX PI WPI; 2003-140492/13.
 XX PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a
 XX PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.
 XX PS Example 1; Page 212; 214pp; English.
 XX CC The present invention describes a method for predicting, diagnosing or
 XX CC prognosing chronic lung disease by detecting a chronic obstructive
 XX CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
 XX CC ACC46777, which encode the COPD related proteins in ABP96779 to
 XX CC ABP96806). The method is useful for predicting, diagnosing or prognosing
 XX CC chronic lung disease in a biological sample. The COPD genes and proteins
 XX CC encoded by them from the present invention (I) can be used for treating
 XX CC or preventing chronic lung disease in a mammal. (I) can be used in an
 XX CC animal model for determining the efficacy, toxicity, or side effects of
 XX CC treatment with (I), and determining the mechanism of action of (I).
 XX CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used
 XX CC in an example from the present invention

XX SQ Sequence 24 BP; 6 A; 5 C; 3 G; 10 T; 0 U; 0 Other;


```

PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-EP005835.
XX
PR 31-MAY-2001; 2001GB-00013266.
XX
PA (FARB ) BAYER AG.
XX
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;
XX
XX WPI; 2003-140492/13.
XX
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.
XX
PS Example 1; Page 212; 214pp; English.
XX
CC The present invention describes a method for predicting, diagnosing or
CC prognosing chronic lung disease by detecting a chronic obstructive
CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
CC ACC46777, which encode the COPD related proteins in ABP96779 to
CC ABP96806). The method is useful for predicting, diagnosing or prognosing
CC chronic lung disease in a biological sample. The COPD genes and proteins
CC encoded by them from the present invention (I) can be used for treating
CC or preventing chronic lung disease in a mammal. (II) can be used in an
CC animal model for determining the efficacy, toxicity, or side effects of
CC treatment with (I), and determining the mechanism of action of (I).
CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used
CC in an example from the present invention
XX
SQ Sequence 26 BP; 10 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 9.7;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 944 CTGAGAGACCAAGACCAAGTGTAAAT 969
DB 1 CTGAGAGACCAAGACCAAGTGTAAAT 26

RESULT 5
ABZ84121/c
ID ABZ84121 standard; DNA; 26 BP.
XX
AC ABZ84121;
XX
DT 14-MAY-2003 (first entry)
XX
DE Toxicologically relevant human PCR primer #1280.
XX
KW Toxicologically relevant gene; toxicological response; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003016500-A2.
XX
PD 27-FEB-2003.
XX
PF 16-AUG-2002; 2002WO-US026514.
XX
PR 16-AUG-2001; 2001US-0313080P.
XX
PA (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.
XX
PI Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K;
PI Alen P;
XX
DR WPI; 2003-268322/26.
XX
PT Determining a toxicological response to an agent, useful for screening of
PT drugs, comprises comparing the expression profile of one or more human

```

```

PT toxic response genes to a reference gene expression profile indicative of
PT toxicity.
XX
PS Claim 1; Page 332; 455pp; English.
XX
CC The present invention describes a method (M1) for determining a
CC toxicological response to an agent, which comprises comparing the
CC expression profile of one or more human toxic response genes to a
CC reference gene expression profile indicative of toxicity, and so
CC determining the presence of a toxic response to the agent. Also
CC described: (1) an array comprising one or more polynucleotides selected
CC from the genes corresponding to the partial sequences given in ABZ82842
CC to ABZ84784, or their fragments of at least 20 nucleotides, or homologues
CC ; and (2) determining if a gene putatively identified to be a toxic
CC response gene plays a role on toxic response pathways by determining the
CC expression profile of the gene after exposure of cells or a human subject
CC to a known toxic pharmaceutical or industrial agent, comprising: (a)
CC exposing cells to an agent or isolating cells from a human subject who
CC was exposed to an agent; (b) obtaining the test gene expression profile
CC for a putatively identified toxic response gene after exposure to a known
CC toxic pharmaceutical or industrial agent; and (c) comparing the test
CC profile to the expression profile of a gene with a similar function or
CC comparing the test profile to the expression profile of that gene after
CC exposure to other known toxic compounds. The methods are useful for
CC predicting and determining toxicological responses on a cellular, organ
CC or system level. The arrays comprising the human genes are useful for
CC toxicological screening of drugs, pharmaceutical compounds and chemicals
XX
SQ Sequence 26 BP; 11 A; 10 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 1.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 9.7;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1409 GCTGTTTGGTTGTAGAAATGGTGT 1434
DB 26 GCTGTTTGGTTGTAGAAATGGTGT 1

RESULT 6
ACC46841
ID ACC46841 standard; DNA; 25 BP.
XX
AC ACC46841;
XX
DT 05-JUN-2003 (first entry)
XX
DE Human COPD related gene probe SEQ ID NO:120.
XX
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;
KW probe; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO200297127-A2.
XX
PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-EP005835.
XX
PR 31-MAY-2001; 2001GB-00013266.
XX
PA (FARB ) BAYER AG.
XX
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;
XX
DR WPI; 2003-140492/13.
XX
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.
XX
XX Example 1; Page 212; 214pp; English.

```

DT	12-AUG-2004	(first entry)
XX	Human matrix metalloproteinase-12 (MMP-12) PCR primer #1.	
DE	human; human elastase; alpha-1-antitrypsin-1; 10-phenanthroline; EDTA;	
DE	phenylmethyl-sulfonyl fluoride; stress urinary incontinence;	
KW	undesired elastin degradation disease; pelvic organ prolapse; emphysema;	
KW	abdominal aortic aneurysm; atherosclerosis; pancreatitis;	
KW	inflammatory disease; PCR; primer; ss; matrix metalloproteinase-12;	
KW	MMP-12.	
OS	Homo sapiens.	
OS	WO2004041115-A2.	
XX	21-MAY-2004.	
XX	12-JUN-2003; 2003WO-US018696.	
XX	14-JUN-2002; 2002US-0389094P.	
PR	(NSHO-) NORTH SHORE-LONG ISLAND JEWISH RES.	
XX	Kushner L, Mathrubutham M, Rao SK;	
XX	WPI; 2004-400506/37.	
XX	Novel isolated human elastase inhibited by alpha-1-antitrypsin, but not	
PT	by phenylmethyl-sulfonyl fluoride, useful for determining stress urinary	
PT	incontinence in woman.	
XX	Example 6; SEQ ID NO 7; 54pp; English.	
PS	The invention comprises a human elastase that has an optimum pH of about	
CC	8-5, and is inhibited by alpha-1-antitrypsin, 1,10-phenanthroline and	
CC	EDTA, but not phenylmethyl-sulfonyl fluoride. The human elastase of the	
CC	invention is useful for determining whether a woman has, or is likely to	
CC	develop stress urinary incontinence. The human elastase of the invention	
CC	is also useful for treating a woman for stress urinary incontinence and	
CC	disease of undesired elastin degradation (e.g. pelvic organ prolapse,	
CC	emphysema, abdominal aortic aneurysm, atherosclerosis, pancreatitis and	
CC	inflammatory disease). The present DNA sequence represents a PCR primer	
CC	that was used in an example of the invention.	
XX	Sequence 30 BP; 9 A; 10 C; 5 G; 6 T; 0 U; 0 Other;	
XX	Query Match 1.7%; Score 30; DB 1; Length 30;	
XX	Best Local Similarity 100.0%; Pred. No. 4.2;	
XX	Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
Qy	62 TTCCTCTGAACAGCTCTACAGCCTGGAAA 91	
DB	1 TTCCTCTGAACAGCTCTACAGCCTGGAAA 30	
RESULT 4		
ACC46842		
ID	ACC46842 standard; DNA; 26 BP.	
AC	ACC46842;	
XX	05-JUN-2003 (first entry)	
DE	Human COPD related gene forward PCR primer SEQ ID NO:121.	
XX	Human; chronic obstructive pulmonary disease; COPD; chronic lung disease	
KW	PCR primer; ss.	
XX	Homo sapiens.	
OS	Synthetic.	
XX	WO200297127-A2.	
XX		

c 107	14	0.8	17	1	ABT36548	Tumour suppression
c 108	14	0.8	17	1	ADB00378	Human MD23 scannin
c 109	14	0.8	17	1	ADB00378	Human MD23 scannin
c 110	14	0.8	17	1	ADI48708	Human tumour suppressor
c 111	14	0.8	17	1	ADN73527	Human GMMLP-1 prob
c 112	14	0.8	17	1	ADN73528	Human GMMLP-1 prob
c 113	13.8	0.8	17	1	AAK63973	Rabbit stromelysin
c 114	13.8	0.8	17	1	AAK63909	Rabbit stromelysin
c 115	13.8	0.8	17	1	AAK63910	Rabbit stromelysin
c 116	13.8	0.8	17	1	AAK63966	Rabbit stromelysin
c 117	13.8	0.8	17	1	AAK71351	Human KDR VEGF rec
c 118	13.8	0.8	17	1	AAK72925	Mouse flk-1 VEGF r
c 119	13.8	0.8	17	1	AAK75153	Mouse flt-1 VEGF r
c 120	13.8	0.8	17	1	AAK74584	Mouse flt-1 VEGF r
c 121	13.8	0.8	17	1	AAK68927	Human flt1 VEGF r
c 122	13.8	0.8	17	1	AAV97951	Human EGF-R target
c 123	13.8	0.8	17	1	AAV98035	Human EGF-R target
c 124	13.8	0.8	17	1	AAK23189	Integrin subunit b
c 125	13.8	0.8	17	1	AAK23042	Integrin subunit b
c 126	13.8	0.8	17	1	AAK18827	Human TIE-2 subtr
c 127	13.8	0.8	17	1	AAK23041	Integrin subunit b
c 128	13.8	0.8	17	1	AAK25186	Oestrogen receptor
c 129	13.8	0.8	17	1	AAK25187	Oestrogen receptor
c 130	13.8	0.8	17	1	AAK30378	Hammerhead ribozym
c 131	13.8	0.8	17	1	AAK03080	Hammerhead ribozym
c 132	13.8	0.8	17	1	ABK03648	Human CD20 DNzyme
c 133	13.8	0.8	17	1	ABK00330	Human NOGO Hammerh
c 134	13.8	0.8	17	1	ABK00480	Human NOGO Hammerh
c 135	13.8	0.8	17	1	ABN08645	Human GMMLP-1 17-m
c 136	13.8	0.8	17	1	ABN06769	Human GMMLP-1 17-m
c 137	13.8	0.8	17	1	ABN10436	Human GMMLP-1 17-m
c 138	13.8	0.8	17	1	ABN10442	Human GMMLP-1 17-m
c 139	13.8	0.8	17	1	ABQ64120	Human HTPL scannin
c 140	13.8	0.8	17	1	ABV79930	Human HTPL scannin
c 141	13.8	0.8	17	1	ABV79931	Human HTPL scannin
c 142	13.8	0.8	17	1	ABK19347	Human ERG Amberzym
c 143	13.8	0.8	17	1	ABK56577	Human CLCA1 gene e
c 144	13.8	0.8	17	1	ACN07730	WNV minus strand H
c 145	13.8	0.8	17	1	ACN09323	WNV minus strand H
c 146	13.8	0.8	17	1	ACN14538	WNV minus strand A
c 147	13.8	0.8	17	1	ACN07069	WNV Amberzyme subs
c 148	13.8	0.8	17	1	ACN03239	WNV Inozyme subtr
c 149	13.8	0.8	17	1	ACN01009	WNV Hammerhead Rib
c 150	13.8	0.8	17	1	ACN09806	WNV minus strand I
c 151	13.8	0.8	17	1	ACN05603	WNV Amberzyme subs
c 152	13.8	0.8	17	1	ACD00825	G-protein coupled
c 153	13.8	0.8	17	1	ABT34768	Tumour suppression
c 154	13.8	0.8	17	1	ABT36617	Tumour suppression
c 155	13.8	0.8	17	1	ADA99899	Human MD23 scannin
c 156	13.8	0.8	17	1	ADA99701	Human MD23 scannin
c 157	13.8	0.8	17	1	ADB04816	Human MD212 scanni
c 158	13.8	0.8	17	1	ADA99700	Human MD23 scannin
c 159	13.8	0.8	17	1	ABZ60192	Human K-Ras DNzyme
c 160	13.8	0.8	17	1	ABZ64887	Human HER2 DNzyme
c 161	13.8	0.8	17	1	ACG68419	Murine oligonucleo
c 162	13.8	0.8	17	1	ADB43853	Tumour suppression
c 163	13.8	0.8	17	1	ADB39685	Tumour suppression
c 164	13.8	0.8	17	1	ADB41975	Tumour suppression
c 165	13.8	0.8	17	1	ADB44591	Tumour suppression
c 166	13.8	0.8	17	1	ADL51278	Human tumour suppress
c 167	13.8	0.8	17	1	ADL49691	Human tumour suppress
c 168	13.8	0.8	17	1	ADL52571	Human tumour suppress
c 169	13.8	0.8	17	1	ADL52496	Human tumour suppress
c 170	13.8	0.8	17	1	ADL50768	Human tumour suppress
c 171	13.8	0.8	17	1	ACC52701	Human tumour suppress
c 172	13.8	0.8	17	1	ACC53715	Human tumour suppress
c 173	13.8	0.8	17	1	ADL50557	Human PKR subtrac
c 174	13.8	0.8	17	1	ADL46697	Human NOGO recepto
c 175	13.8	0.8	17	1	ADL49415	Human PKR subtrac
c 176	13.8	0.8	17	1	ADL46696	Human NOGO recepto
c 177	13.8	0.8	17	1	ADP90161	Blocking probe use
c 178	13.8	0.8	17	1	ACN73526	Human GMMLP-1 prob
c 179	13.8	0.8	17	1	ACN73532	Human GMMLP-1 prob
180	13.8	0.8	17	1	ACN71735	Human GMMLP-1 prob
181	13.8	0.8	17	1	ACN69859	Human GMMLP-1 prob
182	13.4	0.8	15	1	AAZ90118	PCR primer H-T1A
183	13.4	0.8	15	1	AAF53972	IGF-I oligonucleot
c 184	13.4	0.8	15	1	AAF77611	Modified transcrip
c 185	13.4	0.8	15	1	AAH84366	Human cell death p
c 186	13.4	0.8	15	1	AAH84366	Human TEM7alpha ex
c 187	13.4	0.8	15	1	AAH84366	Human cytokeatin
c 188	13.4	0.8	15	1	AAH91807	Human inflammatory
c 189	13.4	0.8	16	1	ADP92303	Human cytokeatin
190	13.4	0.8	16	1	ADP06487	Murine sequence ta
RESULT 1						
ABZ02308						
ID	ABZ02308	standard; DNA; 50 BP.				
XX	XX					
AC	ABZ02308;					
XX	XX					
DT	09-JAN-2003	(first entry)				
XX	XX					
DE	Human leukocyte gene expression profiling probe SEQ ID NO 2299.					
XX	XX					
KW	T7; leukocyte; gene expression profiling; allograft rejection;					
KW	atherosclerosis; congestive heart failure; systemic lupus erythematosus;					
KW	rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;					
KW	ss.					
XX	Homo sapiens.					
OS	WO200257414-A2.					
XX	XX					
PN	25-JUL-2002.					
XX	XX					
PF	22-OCT-2001; 2001WO-US047856.					
XX	XX					
PR	20-OCT-2001; 2000US-0241994P.					
PR	08-JUN-2001; 2001US-0296764P.					
XX	XX					
PA	(BIOC-) BIOCARDIA INC.					
XX	XX					
PI	Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;					
PI	Ly N, Woodward R, Quertemous T, Johnson F;					
XX	XX					
DR	WPI; 2002-636525/68.					
XX	XX					
PT	New system for leukocyte expression profiling, diagnosing a disease, or					
PT	monitoring (the rate of) progression of a disease, e.g. atherosclerosis					
PT	or congestive heart failure, comprises diagnostic oligonucleotides.					
PS	Claim 1; Page 399; Opp; English.					
XX	XX					
CC	The invention relates to a system for detecting gene expression, which					
CC	comprises one or two isolated DNA molecules that detect expression of a					
CC	gene, where the gene corresponds to any of 8143 oligonucleotides					
CC	(ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful					
CC	for leukocyte expression profiling. It is particularly useful for					
CC	diagnosing a disease, monitoring (rate of) progression of a disease,					
CC	predicting therapeutic outcome, determining prognosis for a patient,					
CC	predicting disease complications in an individual or monitoring response					
CC	to treatment in an individual. The diseases include cardiac allograft					
CC	rejection, kidney allograft rejection, liver allograft rejection,					
CC	atherosclerosis, congestive heart failure, systemic lupus erythematosus,					
CC	rheumatoid arthritis, osteoarthritis or cytomegalovirus infection					
XX	XX					
SQ	Sequence 50 BP; 14 A; 11 C; 8 G; 17 T; 0 U; 0 Other;					
Query Match	2.8%; Score 50; DB 1; Length 50;					
Best Local Similarity	100.0%; Pred. No. 0.04;					
Matches	50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:26:51 ; Search time 3 Seconds
(Without alignments)
4.037 Million cell updates/sec

Title: US-10-619-906-1
Perfect score: 1778
Sequence: 1 tagaagttacaatgaagtt.....tttggctcaataaaattg 1778

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 188 seqs, 3406 residues

Total number of hits satisfying chosen parameters: 376

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 190 summaries

Database : rng1.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	2.8	50	1	AB202308 Human leukocyte ge
2	30	1.7	30	1	ADP44841 Human matrix metal
3	30	1.7	30	1	ADP44840 Human matrix metal
4	26	1.5	26	1	ACC46842 Human COPD related
5	26	1.5	26	1	AB284121 Toxicologically re
6	25	1.4	25	1	ACC46841 Human COPD related
7	25	1.4	25	1	AB284127 Toxicologically re
8	24	1.3	24	1	ACC46843 Human COPD related
9	24	1.3	24	1	ADI53707 MMP-12 forward pri
10	24	1.3	24	1	ADI53708 MMP-12 reverse pri
11	21	1.2	21	1	ADP44842 Hmep2 PCR primer u
12	21	1.2	21	1	ADP44843 Human matrix metal
13	21	1.2	21	1	ACC57867 Matrix metalloprot
14	20	1.1	20	1	ACC57866 MMP3 hairpin/hamme
15	20	1.1	20	1	AAH62035 Human MMP-12 antis
16	19.4	1.1	19	1	ADI53691 Human MMP-12 antis
17	19	1.1	19	1	ADI53694 Human MMP-12 antis
18	19	1.1	19	1	ADI53695 Human MMP-12 antis
19	19	1.1	19	1	ADI53699 Human MMP-12 antis
20	19	1.1	19	1	ADI53701 Human MMP-12 antis
21	19	1.1	19	1	ADI53693 Human MMP-12 antis
22	19	1.1	19	1	ADI53700 Human MMP-12 antis
23	19	1.1	19	1	ADI53690 Human MMP-12 antis
24	19	1.1	19	1	ADI53692 Human MMP-12 antis
25	19	1.1	19	1	ADI53696 Human MMP-12 antis
26	19	1.1	19	1	ADI53697 Human MMP-12 antis
27	19	1.1	19	1	ADI53698 Human MMP-12 antis
28	19	1.1	19	1	AAH60184 Cyclin G1 ribozyme
29	17.4	1.0	19	1	AAH60184 Cyclin G1 ribozyme
30	17.4	1.0	19	1	ABZ88909 Human oligonucleot
31	16.8	0.9	20	1	ABZ88909 Human oligonucleot
32	16.8	0.9	20	1	ADK81657 Al041482-derived o
33	16.8	0.9	20	1	Chimeric phosphoro

34	16.8	0.9	21	1	AAQ20036 Cross-linking olig
35	16.8	0.9	21	1	AAQ30386 Oligomer TNF217 fo
36	16.8	0.9	21	1	AAQ30387 Oligomer TNF218 fo
37	16.4	0.9	18	1	AAZ64428 Human strumelysin
38	16.4	0.9	19	1	AAZ71398 Human biallelic ma
39	16.4	0.9	19	1	ADR80876 Human glucose-6-ph
40	16.4	0.9	20	1	AAQ39422 PCR Primer #2 for
41	16.4	0.9	20	1	ADK76164 Chimeric phosphoro
42	16.4	0.9	20	1	ADK76981 Chimeric phosphoro
43	16.4	0.9	20	1	ADK76358 Chimeric phosphoro
44	16.4	0.9	20	1	ADP27276 Human Mpl1 DNA an
45	16.4	0.9	20	1	ADP27131 Human matrix metal
46	16	0.9	20	1	AAZ63796 Rabbit strumelysin
47	16	0.9	20	1	ADI28399 Human neuropeptide
48	16	0.9	20	1	ADI28398 Human neuropeptide
49	15.4	0.9	17	1	ABN10440 Human GDMPL-1 17-m
50	15.4	0.9	17	1	ACN73530 Human GDMPL-1 17-m
51	15.4	0.9	19	1	ADF93537 Human TERT transcr
52	15.4	0.9	19	1	ADF93791 Human TERT siNA lo
53	15.4	0.9	19	1	ADR80880 Human glucose-6-ph
54	15.4	0.9	19	1	ADR76467 Human apolipoprote
55	15.4	0.9	19	1	ADR79085 Human apolipoprote
56	15	0.8	17	1	ABK02552 Human NCOG Amberzy
57	15	0.8	17	1	ABT35046 Tumour suppression
58	15	0.8	17	1	ADB00375 Human MD23 scannin
59	15	0.8	17	1	ADB00377 Human MD23 scannin
60	15	0.8	17	1	ADB00376 Human MD23 scannin
61	14.8	0.8	18	1	AAV57794 Human chromosome 1
62	14.8	0.8	18	1	AAZ40908 Human CD40 phospho
63	14.8	0.8	18	1	AAZ47741 Human CD40 antise
64	14.8	0.8	18	1	ADQ93226 3-alpha-hydroxyste
65	14.6	0.8	15	1	ABL91853 Human LiFG gene al
66	14.4	0.8	16	1	ADF92302 Human cytokerafin
67	14.4	0.8	17	1	AAZ71309 Human KDR VEGF rec
68	14.4	0.8	17	1	AAA18825 Human TIE-2 substr
69	14.4	0.8	17	1	AAA18824 Human TIE-2 substr
70	14.4	0.8	17	1	AAA23011 Integrin subunit b
71	14.4	0.8	17	1	ABK00554 Human NCOG Hammerh
72	14.4	0.8	17	1	ABK01422 Human NCOG Inozyme
73	14.4	0.8	17	1	ABK00479 Human NCOG Hammerh
74	14.4	0.8	17	1	ABK01343 Human NCOG Inozyme
75	14.4	0.8	17	1	ABN10441 Human GDMPL-1 17-m
76	14.4	0.8	17	1	ABN10439 Human GDMPL-1 17-m
77	14.4	0.8	17	1	ABN08646 Human GDMPL-1 17-m
78	14.4	0.8	17	1	ABN08647 Human GDMPL-1 17-m
79	14.4	0.8	17	1	ABK17764 Human ERG hammethe
80	14.4	0.8	17	1	ABK55789 Human CLCA1 gene e
81	14.4	0.8	17	1	ACD60984 HCV DNazyme substr
82	14.4	0.8	17	1	ADB40821 Tumour suppression
83	14.4	0.8	17	1	ADI52546 Human tumour suppr
84	14.4	0.8	17	1	ACC51264 Human tumour suppr
85	14.4	0.8	17	1	ACC51404 Human tumour suppr
86	14.4	0.8	17	1	ACC51914 Human tumour suppr
87	14.4	0.8	17	1	ADL49413 Human PKR substrat
88	14.4	0.8	17	1	ADL49412 Human PKR substrat
89	14.4	0.8	17	1	ADI84868 HCV DNazyme substr
90	14.4	0.8	17	1	ACN73529 Human GDMPL-1 17-m
91	14.4	0.8	17	1	ACN71736 Human GDMPL-1 17-m
92	14.4	0.8	17	1	ACN71737 Human GDMPL-1 17-m
93	14.4	0.8	17	1	ACN73531 Human GDMPL-1 17-m
94	14.4	0.8	18	1	AAZ86051 Primer 1 amplifies
95	14.4	0.8	18	1	AAV07215 Calcium-integrin b
96	14.4	0.8	18	1	AAV33107 Stromelysin primer
97	14.4	0.8	18	1	AAZ42840 M. tuberculosis de
98	14.4	0.8	18	1	ADI53698 DNA encoding secre
99	14.2	0.8	19	1	ADI53699 Human MMP-12 antis
100	14.2	0.8	50	1	ABZ02308 Human leukocyte ge
101	14	0.8	15	1	AAZ90906 Human NR8 gene pro
102	14	0.8	15	1	ADO49435 H. pylori strain J
103	14	0.8	16	1	ADO49479 H. pylori strain J
104	14	0.8	17	1	ABK02203 Human NCOG DNazyme
105	14	0.8	17	1	ABN10437 Human GDMPL-1 17-m
106	14	0.8	17	1	ABN10438 Human GDMPL-1 17-m

THIS PAGE BLANK (USPTO)

Fri May 13 12:26:36 2005

FEATURES FT /organism='Unknown'.
source Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
||| |||||
Db 16 TTTGTTTTTAAAGA 1

Search completed: May 13, 2005, 11:25:04
Job time : 3 secs

1

ORGANISM unclassified.
unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Ksieich,K., Matulic-Adamic,J., Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.B. and Wolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Genes
Patent: EP 1260586-A 5545 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .15
/organism="unclassified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1572 ACATAATATTTT 1584
|||||
Db 14 ACATAATATTTT 2
RESULT 147
AR002582/c
LOCUS AR002582 16 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 23 from patent US 5741706.
ACCESSION AR002582
VERSION AR002582.1 GI:3964136
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Leavitt,M.C., Tritz,R., Duarte,E., Barber,J. and Yu,M.
TITLE Anti-HIV ribozymes
JOURNAL Patent: US 5741706-A 23 21-APR-1998;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 21 TCTTCTAATACTG 33
|||||
Db 16 TCTTCTAATACTG 4
RESULT 148
A88311/c
LOCUS A88311 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 459 from Patent WO9833904.
ACCESSION A88311
VERSION A88311.1 GI:6736881
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 459 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source
1. .16
/organism="unclassified"

/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1043 TTTTCTTTTAAAGA 1058
|||||
Db 16 TTGTGTTTTTAAAGA 1
RESULT 149
A90278/c
LOCUS A90278 16 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 459 from Patent EP0856579.
ACCESSION A90278
VERSION A90278.1 GI:6738792
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 459 05-AUG-1998;
BIOGNOSTIK GES (DE)
FEATURES
source
1. .16
/organism="unclassified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1043 TTTTCTTTTAAAGA 1058
|||||
Db 16 TTGTGTTTTTAAAGA 1
RESULT 150
AR002566/c
LOCUS AR002566 16 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 7 from patent US 5741706.
ACCESSION AR002566
VERSION AR002566.1 GI:3964120
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Leavitt,M.C., Tritz,R., Duarte,E., Barber,J. and Yu,M.
TITLE Anti-HIV ribozymes
JOURNAL Patent: US 5741706-A 7 21-APR-1998;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 89;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 794 TGTATGAGACCCAAA 809
|||||
Db 16 TGTATGAGACCCCAA 1
RESULT 151
AR435857/c
LOCUS AR435857 16 bp RNA linear PAT 18-DEC-2003

LOCUS AR156872 15 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 29 from patent US 6242427.
ACCESSION AR156872
VERSION AR156872.1 GI:15125576
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Methods of inhibiting phagocytosis
JOURNAL Patent: US 6242427-A 29 05-JUN-2001;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 142
LOCUS I77892 15 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 599 from patent US 5693532.
ACCESSION I77892
VERSION I77892.1 GI:3014046
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.
TITLE Respiratory syncytial virus ribozymes
JOURNAL Patent: US 5693532-A 599 02-DEC-1997;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1572 ACATAATATTTT 1584
Db 14 ACATAATATTTT 2

RESULT 143
LOCUS AR180094 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 162 from patent US 6333152.
ACCESSION AR180094
VERSION AR180094.1 GI:20222127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 162 25-DEC-2001;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1572 ACATAATATTTT 1584
Db 14 ACATAATATTTT 2

RESULT 143
LOCUS AR180094 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 162 from patent US 6333152.
ACCESSION AR180094
VERSION AR180094.1 GI:20222127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 162 25-DEC-2001;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1572 ACATAATATTTT 1584
Db 14 ACATAATATTTT 2

RESULT 143
LOCUS AR180094 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 162 from patent US 6333152.
ACCESSION AR180094
VERSION AR180094.1 GI:20222127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 162 25-DEC-2001;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="unassigned DNA"

LOCUS AR412066 15 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 25 from patent US 6638764.
ACCESSION AR412066
VERSION AR412066.1 GI:40164615
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Methods of inhibiting phagocytosis
JOURNAL Patent: US 6638764-A 25 28-OCT-2003;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 145
LOCUS AR412070 15 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 29 from patent US 6638764.
ACCESSION AR412070
VERSION AR412070.1 GI:40164619
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Schreiber,A.D. and Park,J.-G.
TITLE Methods of inhibiting phagocytosis
JOURNAL Patent: US 6638764-A 29 28-OCT-2003;
FEATURES
source
Location/Qualifiers
1..15
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 146
LOCUS AX638406 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 5545 from Patent EP1260586.
ACCESSION AX638406
VERSION AX638406.1 GI:28474020
KEYWORDS
SOURCE unidentified

Db 2 CATGACAAATAGTGG 16

RESULT 136

AR328342

LOCUS AR328342 16 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 5744 from patent US 6566127.

ACCESSION AR328342

VERSION AR328342.1 GI:33714150

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 5744 20-MAY-2003;

FEATURES

source Location/Qualifiers

1..16

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred.No. 75;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1596 ACTCTAATGTGCAAT 1610

Db 2 ACTCTAATGTGCAAT 16

RESULT 137

AR436137

LOCUS AR436137 16 bp RNA linear PAT 18-DEC-2003

DEFINITION Sequence 396 from patent US 6656731.

ACCESSION AR436137

VERSION AR436137.1 GI:40199221

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.

TITLE Nucleic acid catalysts with endonuclease activity

JOURNAL Patent: US 6656731-A 396 02-DEC-2003;

FEATURES

source Location/Qualifiers

1..16

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred.No. 75;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1643 AGTTACCTTCAAGC 1657

Db 2 AGTTACCTTCAAGC 16

RESULT 138

AR028986/c

LOCUS AR028986/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 25 from patent US 5858981.

ACCESSION AR028986

VERSION AR028986.1 GI:5940959

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Schreiber,A.D. and Park,J.-G.

TITLE Method of inhibiting phagocytosis

JOURNAL Patent: US 5858981-A 25 05-JUN-2001;

FEATURES

source Location/Qualifiers

1..15

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred.No. 77;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487

Db 14 GGCATGGCTGACA 2

RESULT 139

AR028990/c

LOCUS AR028990/c 15 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 29 from patent US 5858981.

ACCESSION AR028990

VERSION AR028990.1 GI:5940963

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Schreiber,A.D. and Park,J.-G.

TITLE Method of inhibiting phagocytosis

JOURNAL Patent: US 5858981-A 29 12-JAN-1999;

FEATURES

source Location/Qualifiers

1..15

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred.No. 77;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487

Db 14 GGCATGGCTGACA 2

RESULT 140

ARI56868/c

LOCUS ARI56868/c 15 bp DNA linear PAT 08-AUG-2001

DEFINITION Sequence 25 from patent US 6242427.

ACCESSION ARI56868

VERSION ARI56868.1 GI:15125572

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Schreiber,A.D. and Park,J.-G.

TITLE Methods of inhibiting phagocytosis

JOURNAL Patent: US 6242427-A 25 05-JUN-2001;

FEATURES

source Location/Qualifiers

1..15

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred.No. 77;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487

Db 14 GGCATGGCTGACA 2

RESULT 141

ARI56872/c

BD067891
LOCUS BD067891 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
ACCESSION BD067891
VERSION JP 2001511003-A/731.
KEYWORDS unidentifed
SOURCE unclassified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 731 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS Unidentifed
PN JP 2001511003-A/731
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17 /organism='Unidentified'.
FEATURES
source Location/Qualifiers
1..17 /organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1687 AAGTTCCTCTCTACAT 1703
|||||
Db 1 AAGTTCCTCTCTAAAAA 17

RESULT 133
BD067975/C
LOCUS BD067975 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.
ACCESSION BD067975
VERSION BD067975.1 GI:22613578
KEYWORDS JP 2001511003-A/815.
SOURCE unidentifed
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 815 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS Unidentifed
PN JP 2001511003-A/815
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC

CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17 /organism='Unidentified'.
FEATURES
source Location/Qualifiers
1..17 /organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAAATGAAATA 176
|||||
Db 17 GAGACAAAATCAATA 1

RESULT 134
AR560062
LOCUS AR560062 15 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 28 from patent US 6753154.
ACCESSION AR560062
VERSION AR560062.1 GI:53970361
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Chen,H.-M. and Bissell,M.
TITLE Human AZU-1 gene, variants thereof and expressed gene products
JOURNAL Patent: US 6753154-A 28 22-JUN-2004;
FEATURES
source Location/Qualifiers
1..15 /organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 69;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1040 AAGTTTTCCTTTTA 1054
|||||
Db 1 AAGTTTTCCTTTTA 15

RESULT 135
I71540
LOCUS I71540 16 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 8 from patent US 5681943.
ACCESSION I71540
VERSION I71540.1 GI:3007675
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Letsinger,R.Lewis. and Gryaznov,S.M.
TITLE Method for covalently linking adjacent oligonucleotides
JOURNAL Patent: US 5681943-A 8 28-OCT-1997;
FEATURES
source Location/Qualifiers
1..16 /organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 75;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1057 GATGACAAATCTCG 1071
|||||

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels

QY 1346 GATCTAACCAATTGAA 1362
|||||
Db 1 GATCCAACCACTTTGAA 17

RESULT 132

```
ACCESSION AX737681
VERSION AX737681.1 GI:30516969
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3271 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 562 GCTTTTGACCTGGATC 578
Db 17 GCTTTTGAACCTTGATC 1
RESULT 124
LOCUS AX738191 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3781 from Patent WO03025177.
ACCESSION AX738191
VERSION AX738191.1 GI:30517479
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3781 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 903 GATCTTTTCTTCAAG 919
Db 1 GATCTTTTCTTCAAG 17
RESULT 125
LOCUS AX739409 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4999 from Patent WO03025177.
ACCESSION AX739409
VERSION AX739409.1 GI:30518706
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
ACCESSION AX737681
VERSION AX737681.1 GI:30516969
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4999 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 720 GTTCCCCCACCCTACAAAT 736
Db 1 GATCCCCCACCCTCAAAAT 17
RESULT 127
LOCUS AX745357 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 1322 from Patent WO03031621.
ACCESSION AX745357
VERSION AX745357.1 GI:30724024
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Zhang,J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 1322 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
Location/Qualifiers
```

Fri May 13 12:26:36 2005

chong906-1.rge

```

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 GACAAATTCAGAACACG 851
Db 1 GACAAATTCAGAACACG 17

RESULT 119
AX727979          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
Sequence 5666 from Patent WO03025176.
ACCESSION
AX727979
VERSION
AX727979.1 GI:30507322
KEYWORDS
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025176-A 5666 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 535 GATGCAAAAGGTGGAAT 551
Db 1 GATGCAAAAGGTGGAAT 17

RESULT 120
AX728771          17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION
Sequence 405 from Patent WO03025175.
ACCESSION
AX728771
VERSION
AX728771.1 GI:30508114
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 405 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 903 GATCTTTTCTTCAAG 919
Db 1 GATCTTTTCTTCAAG 17

RESULT 123
AX737681/c
LOCUS
DEFINITION
Sequence 3271 from Patent WO03025177.

```

```

VERSION      AX674037.1  GI:29332385
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or resistance to viruses and their use as
              medicines
JOURNAL      Patent: WO/03004526-A 2482 16-JAN-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1346 GATCTAACCAATTGAA 1362
      ||||| ||||| |||||
Db 1 GATCTCAGCAATTGAA 17

RESULT 115
AX687956
LOCUS      AX687956      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 688 from Patent EP1281758.
ACCESSION  AX687956
VERSION     AX687956.1  GI:29410654
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 688 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES     source
              1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 ACCCTGGAGATGATGCA 275
      ||||| ||||| |||||
Db 1 ACCCTGGAGATGAGACA 17

RESULT 116
AX687957
LOCUS      AX687957      17 bp      DNA      linear      PAT 01-APR-2003
DEFINITION Sequence 689 from Patent EP1281758.
ACCESSION  AX687957
VERSION     AX687957.1  GI:29410655
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.

```

```

TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 689 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES     source
              1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 260 CCCTGGAGATGATGCAC 276
      ||||| ||||| |||||
Db 1 CCCTGGAGATGAGACAC 17

RESULT 117
AX687958
LOCUS      AX687958      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 690 from Patent EP1281758.
ACCESSION  AX687958
VERSION     AX687958.1  GI:29410656
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 690 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES     source
              1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 261 CCTGGAGATGATGCACG 277
      ||||| ||||| |||||
Db 1 CCTGGAGATGAGACAG 17

RESULT 118
AX693070
LOCUS      AX693070      17 bp      DNA      linear      PAT 31-MAR-2003
DEFINITION Sequence 5802 from Patent EP1281758.
ACCESSION  AX693070
VERSION     AX693070.1  GI:29416034
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE        Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
              mdz12
JOURNAL      Patent: EP 1281758-A 5802 05-FEB-2003;
              Aeomica, Inc. (US)
FEATURES     source
              1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 568 GGACCTGGATTCGCAT 584
Db 1 GCACCTGGATTCGCAT 17

RESULT 110
AX499869
LOCUS AX499869 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1176 from Patent EP1229046.
ACCESSION AX499869
VERSION AX499869.1 GI:23382162
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Zhan, J.
AUTHORS Human testis expressed patched like protein
TITLE Patent: EP 1229046-A 1176 07-AUG-2002;
JOURNAL Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1142 TGAATAAAATTGATGCA 1158
Db 1 TGAATAAAATTGAGGTA 17

RESULT 111
AX499870
LOCUS AX499870 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1177 from Patent EP1229046.
ACCESSION AX499870
VERSION AX499870.1 GI:23382163
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Zhan, J.
AUTHORS Human testis expressed patched like protein
TITLE Patent: EP 1229046-A 1177 07-AUG-2002;
JOURNAL Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 GAAAAAATTGATGACG 1159
Db 1 GAAAAAATTGAGGTAG 17
```

```
RESULT 112
AX579110/c
LOCUS AX579110 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 948 from Patent WO0211674.
ACCESSION AX579110
VERSION AX579110.1 GI:27648312
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
AUTHORS Method and reagent for the inhibition of calcium activated chloride
TITLE channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 948 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 484 GACATTTTGGTGTGTTT 500
Db 17 GCCATTTTGGTGTGTTT 1

RESULT 113
AX673023
LOCUS AX673023 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1468 from Patent WO03004526.
ACCESSION AX673023
VERSION AX673023.1 GI:29331371
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telerman, A., Amson, R. and Tuijnder, M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1468 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 720 GTTCCCCACCTTCAAAAT 736
Db 1 GATCCCCACCTTCAAAAT 17

RESULT 114
AX674037
LOCUS AX674037 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 2482 from Patent WO03004526.
ACCESSION AX674037
```



```

ACCESSION AX214888
VERSION AX214888.1 GI:15524931
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 330 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1145 AAAAAATTGATCAGCT 1161
DB 1 AAAAAATTGATCAGCT 17
RESULT 106
AX215038/
LOCUS AX215038 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 480 from Patent WO0159103.
ACCESSION AX215038
VERSION AX215038.1 GI:15525081
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 480 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 908 TTTTCTTCAAGACAGG 924
DB 17 TTTTCTTCAAGAGAGG 1
RESULT 107
AX218206
LOCUS AX218206 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3648 from Patent WO0159103.
ACCESSION AX218206
VERSION AX218206.1 GI:15528267
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
PATENT: WO 0159103-A 3648 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1620 ACTCTACTTAAAGTTT 1636
DB 17 ACTCTACTTAAAGTTT 1
RESULT 109
AX475675
LOCUS AX475675 17 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 896 from Patent WO224750.
ACCESSION AX475675
VERSION AX475675.1 GI:22214960
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhang, J.
TITLE Human kidney tumor overexpressed membrane protein 1
JOURNAL Patent: WO 0224750-A 896 28-MAR-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"

```

```

SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Akhtar, S., Fell, P. and McSwiggen, J.A.
TITLE       Enzymatic nucleic acid treatment of diseases of conditions related
            to levels of epidermal growth factor receptors
JOURNAL     Patent: US 623962-A 815 23-SEP-2003;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match.      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAATAAATCAATA 176
Db 17 GAGACAAATAAATCAATA 1

RESULT 101
AR463084 AR463084 17 bp DNA linear PAT 20-FEB-2004
LOCUS    Sequence 6761 from patent US 6686188.
DEFINITION
ACCESSION AR463084
VERSION   AR463084.1 GI:42698141
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 6761 03-FEB-2004;
FEATURES  Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 GTGAGCTCATGGAGAC 522
Db 1 GAGGAGCTCTGGAGAC 17

RESULT 102
AR464960 AR464960 17 bp DNA linear PAT 20-FEB-2004
LOCUS    Sequence 8637 from patent US 6686188.
DEFINITION
ACCESSION AR464960
VERSION   AR464960.1 GI:42700017
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 8637 03-FEB-2004;
FEATURES  Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 TTTGATGCTGTCCTACTAC 890
Db 17 TTTGATGCTGTCAGCAC 1

RESULT 104
AR466757 AR466757 17 bp DNA linear PAT 20-FEB-2004
LOCUS    Sequence 10434 from patent US 6686188.
DEFINITION
ACCESSION AR466757
VERSION   AR466757.1 GI:42701814
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE     Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL   Patent: US 6686188-A 10434 03-FEB-2004;
FEATURES  Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 868 TTGAGTTTTTGATGCTGT 884
Db 17 TCGACTTTTGATGCTGT 1

RESULT 105
AX214888 AX214888 17 bp RNA linear PAT 07-SEP-2001
LOCUS    Sequence 330 from Patent WO0159103.
DEFINITION
```

Query Match 0.8%: Score 13.8: DB 1: Length 17:

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 74;		
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	527	ATGCTTTTCATGCAAA	543	
DB	17	ATGCTTTTCATGTA	1	
RESULT 93				
AR322820				
LOCUS	AR322820		17 bp	RNA
DEFINITION	Sequence 222 from patent US 6566127.			linear
ACCESSION	AR322820			
VERSION	AR322820.1	GI:33708628		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.			
TITLE	Method and reagent for the treatment of diseases or conditions			
JOURNAL	related to levels of vascular endothelial growth factor receptor			
FEATURES	Patent: US 6566127-A 222 20-MAY-2003;			
	Location/Qualifiers			
source	1..17			
	/organism="unknown"			
	/mol_type="unassigned RNA"			
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 74;		
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	1066	TACTGGTTAATTAGCAA	1082	
DB	1	TACTCGTTAATTATCAA	17	
RESULT 94				
AR324466				
LOCUS	AR324466		17 bp	RNA
DEFINITION	Sequence 1868 from patent US 6566127.			linear
ACCESSION	AR324466			
VERSION	AR324466.1	GI:33710274		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	1 (bases 1 to 17)			
AUTHORS	Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.			
TITLE	Method and reagent for the treatment of diseases or conditions			
JOURNAL	related to levels of vascular endothelial growth factor receptor			
FEATURES	Patent: US 6566127-A 1868 20-MAY-2003;			
	Location/Qualifiers			
source	1..17			
	/organism="unknown"			
	/mol_type="unassigned RNA"			
Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 74;		
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;
QY	919	GACAGGTTCTTCGGCT	935	
DB	1	GCCATGTTCTTCGGCT	17	
RESULT 95				
AR325741/c				
LOCUS	AR325741		17 bp	RNA
DEFINITION	Sequence 3143 from patent US 6566127.			linear
ACCESSION	AR325741			
VERSION	AR325741.1	GI:33711549		


```

RESULT 80
LOCUS      I37592
DEFINITION Sequence 605 from patent US 5612215.
ACCESSION  I37592
VERSION     I37592.1 GI:2085552
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
TITLE       Stromelysin targeted ribozymes
JOURNAL     Patent: US 5612215-A 605 18-MAR-1997;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1186 ACCTACTCTTTCTGTAGA 1202
Db      1 ACATACTCTTTGTGGA 17

RESULT 81
LOCUS      I54288/c
DEFINITION Sequence 2029 from patent US 5646042.
ACCESSION  I54288
VERSION     I54288.1 GI:2475491
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myb targeted ribozymes
JOURNAL     Patent: US 5646042-A 2029 08-JUL-1997;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1571 TACATAATATTTTCAA 1587
Db      17 TACATAATACTTTCAA 1

RESULT 82
LOCUS      I54290/c
DEFINITION Sequence 2031 from patent US 5646042.
ACCESSION  I54290
VERSION     I54290.1 GI:2475493
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myb targeted ribozymes
JOURNAL     Patent: US 5646042-A 2031 08-JUL-1997;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1571 TACATAATATTTTCAA 1587
Db      17 TACATAATACTTTCAA 1

```

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1570 ATACATAATATTTTCA 1586
Db      17 ATACATAATACTTTCA 1

RESULT 83
LOCUS      I54678
DEFINITION Sequence 2419 from patent US 5646042.
ACCESSION  I54678
VERSION     I54678.1 GI:2475881
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE       C-myb targeted ribozymes
JOURNAL     Patent: US 5646042-A 2419 08-JUL-1997;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      416 GGAAAGCTTTCCAACTA 432
Db      1 GGAAAGCTCTCCAAGAA 17

RESULT 84
LOCUS      I94378
DEFINITION Sequence 541 from patent US 5731295.
ACCESSION  I94378
VERSION     I94378.1 GI:3938848
KEYWORDS   .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
            Stinchcomb,D.T.
TITLE       Method of reducing stromelysin RNA via ribozymes
JOURNAL     Patent: US 5731295-A 541 24-MAR-1998;
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      908 TTTTCTTCAAGACAGG 924
Db      1 TGTCTTTAAAGACAGG 17

RESULT 85
LOCUS      I94379
DEFINITION Sequence 542 from patent US 5731295.

```



```

Db      1  AAGATATTTTCTTCCA 17

RESULT 73
LOCUS   CQ622021                17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION
Sequence 6761 from Patent WO0192524.
ACCESSION CQ622021
VERSION   CQ622021.1  GI:41672239
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE    Myosin-like gene expressed in human heart and muscle
JOURNAL  Patent: WO 0192524-A 6761 06-DEC-2001;
        Aeomica, Inc. (US)
FEATURES
         Location/Qualifiers
            1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      506  GTGGAGCTCATGGAGAC 522
Db      1  GAGGAGCTCTGGAGAC 17

RESULT 74
LOCUS   CQ623897                17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION
Sequence 8637 from Patent WO0192524.
ACCESSION CQ623897
VERSION   CQ623897.1  GI:41674115
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1  Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
Shannon, M.E.
TITLE    Myosin-like gene expressed in human heart and muscle
JOURNAL  Patent: WO 0192524-A 8637 06-DEC-2001;
        Aeomica, Inc. (US)
FEATURES
         Location/Qualifiers
            1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      200  AAATCCAAGAAATGCAG 216
Db      1  AGATCCAAGAACTGCAG 17

RESULT 75
LOCUS   CQ625688/c              17 bp      DNA      linear      PAT 02-FEB-2000
DEFINITION
Sequence 10428 from Patent WO0192524.
ACCESSION CQ625688

```


C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FT Location/Qualifiers
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1037 ATCAAGTTTTTCTTTT 1053
|||||

Db 1 ATCAAGTTTTTCTTTT 17

RESULT 69
BD203242
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD203242.1 GI:33013012
VERSION
JP 2002509721-A/6268.
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL
Patent: JP 2002509721-A 6268 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/6268
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FT Location/Qualifiers
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1038 TCAAGTTTTTCTTTT 1054
|||||

Db 1 TCAAAGTTTTTATTTTA 17

RESULT 70
BD203389
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD203389.1 GI:33013159
VERSION
JP 2002509721-A/6415.
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL
Patent: JP 2002509721-A 6415 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/6415
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
/organism='Homo sapiens (human)'.
FT Location/Qualifiers
1..17
/organism='Homo sapiens'
/mol_type='genomic RNA'
/db_xref='taxon:9606'

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 643 AACTGTTCCTCACTGC 659
|||||

Db 1 AACTGTTCCTCACTGC 17

RESULT 71
BD255276
LOCUS
DEFINITION
Regulation of repressor genes using nucleic acid molecules.
ACCESSION
BD255276
VERSION
BD255276.1 GI:33065046
KEYWORDS
JP 2002541795-A/3069.
SOURCE
unidentified
ORGANISM
unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Blatt L., Zwick M., Pavco,P. and Mcswiggen,J.
TITLE
Regulation of repressor genes using nucleic acid molecules
JOURNAL
Patent: JP 2002541795-A 3069 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/3069
PD 10-DEC-2002
PF 11-APR-2000 JP 2000611654

```

source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1571 TACATAAATATTTTCA 1587
|||||
Db 17 TACATAAATATTTTCA 1

RESULT 65
AR047238/c
LOCUS AR047238 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2031 from patent US 5817796.
ACCESSION AR047238
VERSION AR047238.1 GI:5968703
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
AUTHORS C-myb ribozymes having 2'-5'-linked adenylylate residues
TITLE Patent: US 5817796-A 2031 06-OCT-1998;
JOURNAL Location/Qualifiers
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1570 ATACATAAATATTTTCA 1586
|||||
Db 17 ATACATAAATATTTTCA 1

RESULT 66
AR047626
LOCUS AR047626 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2419 from patent US 5817796.
ACCESSION AR047626
VERSION AR047626.1 GI:5969091
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 17)
Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
AUTHORS C-myb ribozymes having 2'-5'-linked adenylylate residues
TITLE Patent: US 5817796-A 2419 06-OCT-1998;
JOURNAL Location/Qualifiers
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 416 GGAAAGCTTTCCTCAAGTA 432
|||||
Db 1 GGAAAGCTTTCCTCAAGTA 17

RESULT 67
BD199027/c
LOCUS BD199027 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning

```

```

molecule participating in vasculogenic response.
BD199027
BD19027.1 GI:33008797
JP 2002509721-A/2053.
Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
AUTHORS Method and reagent for treating diseases or conditions concerning
TITLE molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 2053 02-APR-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/2053
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1. .17
/organism="Homo sapiens (human)".

FEATURES
source
1. .17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 AAGTTTACATGAAGTT 20
|||||
Db 17 AAGTTTACATGAAGTT 1

RESULT 68
BD203241
LOCUS BD203241 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION BD203241
VERSION BD203241.1 GI:33013011
KEYWORDS JP 2002509721-A/6267.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
AUTHORS Method and reagent for treating diseases or conditions concerning
TITLE molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 6267 02-APR-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/6267
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC

```

Db 17 CTGGCTGAAGGTTT 4

RESULT 60
LOCUS AX688632/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1364 from Patent EP1281758.
ACCESSION AX688632
VERSION AX688632.1 GI:29411334
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 1364 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 929 TCTGGCTGAAGTTT 942
Db 14 TCTGGCTGAAGTTT 1

RESULT 61
LOCUS AX730551/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2185 from Patent WO03025175.
ACCESSION AX730551
VERSION AX730551.1 GI:30509894
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL Patent: WO 03025175-A 2185 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1580 TTTTTCAAATTTGA 1593
Db 16 TTTTTCAAATTTGA 3

RESULT 62
LOCUS AX735621/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1211 from Patent WO03025177.
ACCESSION AX735621

AX735621.1 GI:30514898
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 1211 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 893 TGGGAATAGATC 906
Db 14 TGGGAATAGATC 1

RESULT 63
LOCUS A11108 17 bp DNA linear PAT 03-DEC-1993
DEFINITION Oligonucleotide L1.
ACCESSION A11108
VERSION A11108.1 GI:490958
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 17)
AUTHORS Ikehara,M. and Kida,M.
TITLE Synthetic gene for human lysozyme
JOURNAL Patent: EP 0181634-A 52 21-MAY-1986;
Takeda Chemical Industries, Ltd
FEATURES
source Location/Qualifiers
1..17
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 933 GCTGAAGGTTTCTGAGA 949
Db 17 GATGAAGGTTTTCGAGA 1

RESULT 64
LOCUS AR047236/c 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2029 from patent US 5817796.
ACCESSION AR047236
VERSION AR047236.1 GI:5968701
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylyate residues
JOURNAL Patent: US 5817796-A 2029 06-OCT-1998;
FEATURES Location/Qualifiers

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10430 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 873 TTTTGATGCTGTCA 886
Db 16 TTTTGATGCTGTCA 3
RESULT 56
LOCUS AR466752/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10429 from patent US 6686188.
ACCESSION AR466752
VERSION AR466752.1 GI:42701809
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10429 03-FEB-2004;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 873 TTTTGATGCTGTCA 886
Db 17 TTTTGATGCTGTCA 4
RESULT 57
LOCUS AR466753/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10430 from patent US 6686188.
ACCESSION AR466753
VERSION AR466753.1 GI:42701810
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10430 03-FEB-2004;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

```

```

/mol_type="genomic DNA"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 873 TTTTGATGCTGTCA 886
Db 16 TTTTGATGCTGTCA 3
RESULT 58
LOCUS AX216761/c 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2203 from Patent WO0159103.
ACCESSION AX216761
VERSION AX216761.1 GI:15526822
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2203 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 969 TTTAATTTCTTCCT 982
Db 14 TTTAATTTCTTCCT 1
RESULT 59
LOCUS AX688628/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1360 from Patent EP1281758.
ACCESSION AX688628
VERSION AX688628.1 GI:29411330
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
mdz12
JOURNAL Patent: EP 1281758-A 1360 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 930 CTGGCTGAAGGTTT 943
Db 14 CTGGCTGAAGGTTT 943

```

```

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1103 ATCCCAAGAGCATACA 1118
|||||
Db 2 ATCCCAAGAGCATACA 17

RESULT 51
LOCUS AX757823 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 1144 from Patent WO03040369.
ACCESSION AX757823
VERSION AX757823.1 GI:32252439
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 1144 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 ATCCTTGACTGAGAA 1717
|||||
Db 2 ATCCTTGACTGAGAA 17

RESULT 52
LOCUS AR157063 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 8 from patent US 6242587.
ACCESSION AR157063
VERSION AR157063.1 GI:15125767
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Naik,U.P. and Patise,L.V.
TITLE DNA molecules encoding a calcium-integrin binding protein
JOURNAL Patent: US 6242587-A 8 05-JUN-2001;
FEATURES
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTTCAGTCCCTGT 796
|||||
Db 1 GGCATTTCAGTCCCTGT 16

source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 CTACACATTCAGGAGG 638
|||||
Db 16 CTACATATTCAGGAGG 1

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 CTACACATTCAGGAGG 638
|||||
Db 16 CTACATATTCAGGAGG 1

RESULT 54
LOCUS CQ625689 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10429 from Patent WO0192524.
ACCESSION CQ625689
VERSION CQ625689.1 GI:41675907
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10429 06-DEC-2001;
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
|||||
Db 17 TTTTGATGCTGTCA 4

RESULT 55
LOCUS CQ625690 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10430 from Patent WO0192524.
ACCESSION CQ625690
VERSION CQ625690.1 GI:41675908
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens

```

KEYWORDS Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Thompson, J., Mcswigen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
Patent: WO 0211674-A 160 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1712 TCAGAAATCTACTTA 1727
|||||
Db 1 TGAGAAATCTACTTA 16

RESULT 47
AX671586/c
LOCUS
DEFINITION
Sequence 31 from Patent WO03004526.
AX671586
ACCESSION
AX671586.1 GI:29329934
VERSION
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 31 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1113 CACATCTCTTTGGT 1128
|||||
Db 17 CACATCTCTTTGGT 2

RESULT 48
AX671726
LOCUS
DEFINITION
Sequence 171 from Patent WO03004526.
AX671726
ACCESSION
AX671726.1 GI:29330074
VERSION
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 31 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1559 GATTATATAAATACA 1574
|||||
Db 1 GATCATATAAATACA 16

RESULT 50
AX739459
LOCUS
DEFINITION
Sequence 5049 from Patent WO03025177.
AX739459
ACCESSION
AX739459.1 GI:30518756
VERSION
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03025177-A 5049 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 171 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1655 AGCAAGATATTTCTAT 1670
|||||
Db 2 ATCAAGATATTTCTAT 17

RESULT 49
AX672236
LOCUS
DEFINITION
Sequence 681 from Patent WO03004526.
AX672236
ACCESSION
AX672236.1 GI:29330584
VERSION
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 681 16-JAN-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1559 GATTATATAAATACA 1574
|||||
Db 1 GATCATATAAATACA 16

RESULT 50
AX739459
LOCUS
DEFINITION
Sequence 5049 from Patent WO03025177.
AX739459
ACCESSION
AX739459.1 GI:30518756
VERSION
KEYWORDS
Homo sapiens (human)
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1 Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03025177-A 5049 27-MAR-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAGAAGCAGGT 925
Db 16 TTCTTCAAGAAGGT 1

RESULT 42
AX215112          17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION
Sequence 554 from Patent WO0159103.
ACCESSION
AX215112
VERSION
AX215112.1 GI:15525155
KEYWORDS
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 554 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 847 CCAGCTCTCTGTGACC 862
Db 1 CCTGCTCTCTGTGACC 16

RESULT 43
AX215901/c
LOCUS
DEFINITION
Sequence 1343 from Patent WO0159103.
ACCESSION
AX215901
VERSION
AX215901.1 GI:15525944
KEYWORDS
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 1343 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAGAAGCAGGT 925
Db 17 TTCTTCAAGAAGGT 2

RESULT 44
AX215980          17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION
Sequence 1422 from Patent WO0159103.
ACCESSION
AX215980
VERSION
AX215980.1 GI:15526023
KEYWORDS
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 1422 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 847 CCAGCTCTCTGTGACC 862
Db 2 CCTGCTCTCTGTGACC 17

RESULT 45
AX422075/c
LOCUS
DEFINITION
Sequence 411 from Patent WO0188124.
ACCESSION
AX422075
VERSION
AX422075.1 GI:21525457
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
REFERENCE
1
AUTHORS
Jarvis, T., von Carlowitz, I., McSwiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 411 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1555 TAATGATTATATAAAA 1570
Db 16 TAATTATTATATAAAA 1

RESULT 46
AX578322
LOCUS
DEFINITION
Sequence 160 from Patent WO0211674.
ACCESSION
AX578322
VERSION
AX578322.1 GI:27647524
```

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10431 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 871 AGTTTGGATGCTGCTCA 886
 Db 17 ACTTTTGATGCTGCTCA 2

RESULT 40
 AR466756/c
 LOCUS AR466756 17 bp DNA linear PAT 20-FEB-2004
 DEFINITION Sequence 10433 from patent US 6686188.
 ACCESSION AR466756
 VERSION AR466756.1 GI:42701813
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10433 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAGAAATGCAGC 217
 Db 2 ATCCAGAACTGCAGC 17

RESULT 38
 AR464962
 LOCUS AR464962 17 bp DNA linear PAT 20-FEB-2004
 DEFINITION Sequence 8639 from patent US 6686188.
 ACCESSION AR464962
 VERSION AR464962.1 GI:42700019
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 8639 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAGAAATGCAGC 217
 Db 1 ATCCAGAACTGCAGC 16

RESULT 39
 AR466754/c
 LOCUS AR466754 17 bp DNA linear PAT 20-FEB-2004
 DEFINITION Sequence 10431 from patent US 6686188.
 ACCESSION AR466754
 VERSION AR466754.1 GI:42701811
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 17)

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10431 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGGATGCTGCTC 885
 Db 16 GACTTTTGATGCTGCTC 1

RESULT 41
 AX215037/c
 LOCUS AX215037 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 479 from Patent WO0159103.
 ACCESSION AX215037
 VERSION AX215037.1 GI:15525080
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 479 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)
 FEATURES Location/Qualifiers
 source 1. .17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"


```

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
REFERENCE     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS      Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE        Myosin-like gene expressed in human heart and muscle
JOURNAL      Patent: WO 0192524-A 8639 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      202 ATCCAAGAAATGCAGC 217
Db      1 ATCCAAGAACTGCAGC 16

RESULT 33
LOCUS      CQ625691
DEFINITION Sequence 10431 from Patent.W00192524.
ACCESSION  CQ625691
VERSION    CQ625691.1 GI:41675909
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 10431 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
             source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      871 AGTTTGTGATGCTGTC 886
Db      17 ACTTTGTGATGCTGTC 2

RESULT 34
LOCUS      CQ625693
DEFINITION Sequence 10433 from Patent W00192524.
ACCESSION  CQ625693
VERSION    CQ625693.1 GI:41675911
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
              Shannon, M.E.
TITLE      Myosin-like gene expressed in human heart and muscle

JOURNAL      Patent: WO 0192524-A 10433 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES     Location/Qualifiers
             source
             1..17
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      871 AGTTTGTGATGCTGTC 886
Db      17 ACTTTGTGATGCTGTC 2

RESULT 35
LOCUS      ARI88571/c
DEFINITION Sequence 4059 from patent US 6346398.
ACCESSION  ARI88571
VERSION    ARI88571.1 GI:20234536
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL    Patent: US 6346398-A 4059 12-FEB-2002;
Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
             source
             1..17
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      518 GAGACTTCCATGCTTT 533
Db      17 GAGACTTCGATGCTTT 2

RESULT 36
LOCUS      AR324424/c
DEFINITION Sequence 1826 from patent US 6566127.
ACCESSION  AR324424
VERSION    AR324424.1 GI:33710232
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unknown.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL    Patent: US 6566127-A 1826 20-MAY-2003;
Aeomica, Inc. (US)
FEATURES   Location/Qualifiers
             source
             1..17
               /organism="unknown"
               /mol_type="unassigned RNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 62;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      518 GAGACTTCCATGCTTT 533
Db      17 GAGACTTCGATGCTTT 2

```

JOURNAL
 COMMENT
 QY 1265 TTACCAAGAACTTCCA 1280
 Db 17 TTACCAAGAACTTCCA 2

RESULT 29
 BD199025/c
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

BD199025
 Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
 BD199025 1 GI:33008795
 BD199025.1 GI:33008795
 JP 2002509721-A/2051.
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 17)
 Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
 Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
 Patent: JP 2002509721-A 2051 02-APR-2002;
 RIBOZYME PHARMACEUTICALS INC
 OS Homo sapiens (human)
 PN JP 2002509721-A/2051
 PD 02-APR-2002
 PF 24-MAR-1999 JP 2000541291
 PR 27-MAR-1998 US 60/079678
 PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
 PI JAMES A MCSWIGGEN
 PC C12N15/00,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
 A61P29/00,
 PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
 C12N5/00
 CC Method and reagent for treating diseases or conditions CC
 concerning molecule
 CC participating in vasculogenic response
 FH Key Location/Qualifiers
 FT source 1..17
 FT /organism='Homo sapiens (human)'.
 FEATURES
 source
 1..17
 /organism='Homo sapiens'
 /mol_type='genomic RNA'
 /db_xref='taxon:9606'
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 172 AAATATAGTGGAACT 187
 Db 17 AAATATAGTGGAACT 2

RESULT 31
 CO623898
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

CO623898
 Sequence 8638 from Patent WO0192524.
 CO623898
 CO623898.1 GI:41674116
 Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1
 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
 Shannon,M.E.
 Myosin-like gene expressed in human heart and muscle
 Patent: WO 0192524-A 8638 06-DEC-2001;
 Aeomica, Inc. (US)
 Location/Qualifiers
 1..17
 /organism='Homo sapiens'
 /mol_type='unassigned DNA'
 /db_xref='taxon:9606'
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 62;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 202 ATCCAAGAACTGCAGC 217
 Db 2 ATCCAAGAACTGCAGC 17

RESULT 32
 CO623899
 LOCUS
 DEFINITION
 ACCESSION
 VERSION

CO623899
 Sequence 8639 from Patent WO0192524.
 CO623899
 CO623899.1 GI:41674117

```

/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 945 TGAGAGACCAAGACCAG 962
Db 18 TGTGAGACCAAGACCTG 1

RESULT 26
LOCUS AR233564 18 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 193 from patent US 6458532.
ACCESSION AR233564
VERSION AR233564.1 GI:27276155
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Detera-Wadleigh,S.D., Yoshikawa,T., Sanders,A.R. and Esterling,L.E.
TITLE Polynucleotides encoding IMP.18p myo-inositol monophosphatase and methods of detecting said polynucleotides
JOURNAL Patent: US 6458532-A 193 01-OCT-2002;
FEATURES
source Location/Qualifiers
    source 1..18
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 46 ACTGCTTCTGAGCTCTT 63
Db 1 AGTGCTTCTGTAGCTCTT 18

RESULT 27
ATHS20245 18 bp DNA linear PLN 29-MAR-2003
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone 017F02.
DEFINITION
ACCESSION AJ520245
VERSION AJ520245.1 GI:26788481
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepintec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE 2
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).

FEATURES
source Location/Qualifiers
    source 1..18
    /organism="Arabidopsis thaliana"
    /mol_type="genomic DNA"
    /cultivar="Wassiliewskaja"
    /db_xref="taxon:3702"
    /clone="017F02"
    /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
    misc_feature 1..18
    /note="T-DNA flanking sequence
    left border"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1035 AAATCAAGTTTCTTTT 1052
Db 1 AAATCATGATTTCTTTT 18

RESULT 28
BD199024/c 17 bp RNA linear PAT 17-JUL-2003
LOCUS Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.
DEFINITION
ACCESSION BD199024
VERSION BD199024.1 GI:33008794
KEYWORDS JP 2002509721-A/2050.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Meswiggen,J.A.
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 2050 02-APR-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/2050
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Homo sapiens (human)'

FEATURES
source Location/Qualifiers
    source 1..17
    /organism="Homo sapiens"
    /mol_type="genomic RNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Fri May 13 12:26:36 2005

```

RESULT 22
AX729049 AX729049 17 bp DNA linear PAT 08-MAY-2003
LOCUS Sequence 683 from Patent WO03025175.
DEFINITION
ACCESSION AX729049
VERSION AX729049.1 GI:30508392
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1.
Telerman,A., Amson,R. and Tuijnder,M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 683 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 GATCTCCATCATTC 312
|||||
Db 1 GATCTCCATCATTC 15

RESULT 23
AR138047/c AR138047 18 bp DNA linear PAT 16-JUN-2001
LOCUS Sequence 57 from patent US 6197584.
DEFINITION
ACCESSION AR138047
VERSION AR138047.1 GI:14479556
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
1 (bases 1 to 18)
Bennett,C.Frank. and Cowsert,L.M.
AUTHORS
TITLE Antisense modulation of CD40 expression
JOURNAL Patent: US 6197584-A 57 06-MAR-2001;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962
|||||
Db 18 TGTGAGACCAAGACCCTG 1

RESULT 24
BD226598/c BD226598 18 bp DNA linear PAT 17-JUL-2003
LOCUS Antisense modulation of CD40 expression.
DEFINITION
ACCESSION BD226598
VERSION BD226598.1 GI:33036368
KEYWORDS JP 2002513593-A/57.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 18)
Bennett,C.F. and Cowsert,L.M.
AUTHORS

Antisense modulation of CD40 expression
Patent: JP 2002513593-A 57 14-MAY-2002;
ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002513593-A/57
PD 14-MAY-2002
PF 22-APR-1999 JP 2000547271
PR 01-MAY-1998 US 09/071433
PI C. FRANK BENNETT, LEX M COWSERT
PC C12N15/09,A61K9/10,A61K45/00,A61K48/00,A61P11/06, PC
A61P17/06,
PC A61P29/00,A61P35/00,A61P37/02,A61P37/06,A61P43/00,C12P19/34,
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of CD40 expression
FH Key Location/Qualifiers
FT source 1..18
/organism='Unidentified'.
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962
|||||
Db 18 TGTGAGACCAAGACCCTG 1

RESULT 25
BD250503/c BD250503 18 bp DNA linear PAT 17-JUL-2003
LOCUS Identification of genetic targets for modulation by
DEFINITION oligonucleotides and generation of oligonucleotides for gene
modulation.
ACCESSION BD250503
VERSION BD250503.1 GI:33060273
KEYWORDS JP 2002511276-A/57.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1 (bases 1 to 18)
Cowsert,L.M., Baker,B.F., Mcneil,J., Freier,S.M., Sasamor,H.M.,
Brooks,D.G., Ohasi,C., Wyatt,J.R., Borchers,A.H. and Vikkars,T.A.
AUTHORS Identification of genetic targets for modulation by
oligonucleotides and generation of oligonucleotides for gene
modulation
TITLE
JOURNAL Patent: JP 2002511276-A 57 16-APR-2002;
ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002511276-A/57
PD 16-APR-2002
PF 13-APR-1999 JP 2000543647
PR 13-APR-1998 US 60/081483,28-APR-1998 US 09/067638
PI LEX M COWSERT,BRENDA F BAKER,JOHN MCNEIL,SUSAN M FRIER,HENRI PI
M SASMOR.
PI DOUGLAS G BROOKS,CARA OHASI,JACQUELINE R WYATT,ALEXANDER H PI
BORCHERS,
PI TIMOTHY A VIKKARS
PC C12N15/09,C07B61/00,C07B61/00,C12Q1/68,G06F17/30,G06F17/50, PC
C12N15/00
CC Antisense Oligonucleotide
FH Key Location/Qualifiers
FT source 1..18
/organism='Artificial Sequence'.
Location/Qualifiers
1..18

```

```

FEATURES
  source
    Wa Pharm AB (SE)
    Location/Qualifiers
      1..17
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="PCR primer"

Query Match
  Best Local Similarity 0.9%; Score 15.4; DB 1; Length 17;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAGAAATGCAG 216
Db 17 AGATCCAGAAATGCAG 1

RESULT 18
AX217110/c
LOCUS AX217110 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2552 from Patent WO0159103.
ACCESSION AX217110
VERSION AX217110.1 GI:15527171
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens
  REFERENCE
    1
    Blatt L., McSwiggen J. and Chowrira B.M.
    Method and reagent for the modulation and diagnosis of cd20 and
    nogo gene expression
  JOURNAL
    Patent: WO 0159103-A 2552 16-AUG-2001;
    RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
    McSwiggen, James (US); Chowrira, Bharat M. (US)
  FEATURES
    source
      Location/Qualifiers
        1..17
          /organism="synthetic construct"
          /mol_type="unassigned RNA"
          /db_xref="taxon:32630"
          /note="Nucleic Acid"

Query Match
  Best Local Similarity 0.8%; Score 15; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCTT 983
Db 17 TTTAATTTCTTCCTT 3

RESULT 19
AX688629/c
LOCUS AX688629 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1361 from Patent EP1281758.
ACCESSION AX688629
VERSION AX688629.1 GI:29411331
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens (human)
  REFERENCE
    1
    Shannon, M., Gu, Y. and Nguyen, C.T.
    Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
    mdz12
  JOURNAL
    Patent: EP 1281758-A 1361 05-FEB-2003;
    Aeomica, Inc. (US)
  FEATURES
    source
      Location/Qualifiers
        1..17
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 15; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
Db 15 TCTGGCTGAAGGTTT 1

RESULT 20
AX688630/c
LOCUS AX688630 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1362 from Patent EP1281758.
ACCESSION AX688630
VERSION AX688630.1 GI:29411332
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens (human)
  REFERENCE
    1
    Shannon, M., Gu, Y. and Nguyen, C.T.
    Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
    mdz12
  JOURNAL
    Patent: EP 1281758-A 1362 05-FEB-2003;
    Aeomica, Inc. (US)
  FEATURES
    source
      Location/Qualifiers
        1..17
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 15; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
Db 16 TCTGGCTGAAGGTTT 2

RESULT 21
AX688631/c
LOCUS AX688631 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1363 from Patent EP1281758.
ACCESSION AX688631
VERSION AX688631.1 GI:29411333
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens (human)
  REFERENCE
    1
    Shannon, M., Gu, Y. and Nguyen, C.T.
    Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
    mdz12
  JOURNAL
    Patent: EP 1281758-A 1363 05-FEB-2003;
    Aeomica, Inc. (US)
  FEATURES
    source
      Location/Qualifiers
        1..17
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 15; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
Db 15 TCTGGCTGAAGGTTT 1

Query Match
  Best Local Similarity 0.8%; Score 15; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 929 TCTGGCTGAAGGTTT 943
Db 15 TCTGGCTGAAGGTTT 1

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 AAAAATCCAGAAAT 212
|||||
Db 2 AAAAATCCAGAAAT 17

RESULT 13
LOCUS A73892/c 17 bp DNA linear PAT 15-OCT-1999
DEFINITION Sequence 19 from Patent WO9404674.
ACCESSION A73892
VERSION A73892.1 GI:6064263
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Wikberg,J. and Chhajlani,V.
TITLE HUMAN MELANOCYTE STIMULATING HORMONE RECEPTOR
JOURNAL Patent: WO 9404674-A 19 03-MAR-1994;
WIKBERG JARL (SE); CHHAJLANI VIJAY (SE)
FEATURES Location/Qualifiers
source 1..17
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAGAAATGCAG 216
|||||
Db 17 AGATCCAGAAATGCAG 1

RESULT 14
LOCUS CQ625692/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10432 from Patent WO0192524.
ACCESSION CQ625692
VERSION CQ625692.1 GI:41675910
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10432 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTTCAGCTGTCA 886
|||||
Db 17 GACTTTTTCAGCTGTCA 1

RESULT 15
LOCUS AR228318/c 17 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 19 from patent US 6448032.
ACCESSION AR228318
VERSION AR228318.1 GI:27267097
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Wikberg,J. and Chhajlani,V.
TITLE Human melanocyte stimulating hormone receptor polypeptide and DNA
JOURNAL Patent: US 6448032-A 19 10-SEP-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAGAAATGCAG 216
|||||
Db 17 AGATCCAGAAATGCAG 1

RESULT 16
LOCUS AR466755/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10432 from patent US 6686188.
ACCESSION AR466755
VERSION AR466755.1 GI:42701812
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10432 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTTCAGCTGTCA 886
|||||
Db 17 GACTTTTTCAGCTGTCA 1

RESULT 17
LOCUS AX316540/c 17 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 19 from Patent EP1160322.
ACCESSION AX316540
VERSION AX316540.1 GI:17899699
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Wikberg,J. and Chhajlani,V.
TITLE Human melanocyte stimulating hormone receptors
JOURNAL Patent: EP 1160322-A 19 05-DEC-2001;

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin G1 ribozyme binding site"

Query Match
  1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 31;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 901 AAGATCTTTTCTTCAAAG 919
Db 19 AAGATCTTTTACTTCAAG 1

RESULT 8
LOCUS I38057 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 1070 from patent US 5612215.
ACCESSION I38057
VERSION I38057.1 GI:2086047
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 1070 18-MAR-1997;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match
  0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 38;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 782 GCATTCACTCCCTGTATG 799
Db 1 GCATTCACTCCCTGTATG 18

RESULT 9
LOCUS I94907 18 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 1070 from patent US 5731295.
ACCESSION I94907
VERSION I94907.1 GI:3939377
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 1070 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match
  0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 38;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 782 GCATTCACTCCCTGTATG 799
Db 1 GCATTCACTCCCTGTATG 18

RESULT 10
LOCUS AR294019/c 19 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 5754 from patent US 6537751.
ACCESSION AR294019
VERSION AR294019.1 GI:31681303
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
          disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 5754 25-MAR-2003;
FEATURES Location/Qualifiers
          source
            1..19
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match
  0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 41;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1190 ACTTCTTTGTAGATAACC 1207
Db 18 ACTTCTTTGCAGATACC 1

RESULT 11
LOCUS I37415 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 428 from patent US 5612215.
ACCESSION I37415
VERSION I37415.1 GI:2085375
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 428 18-MAR-1997;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match
  0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 197 AAAAAATCCAAGAAAT 212
Db 2 AAAAAATCCAAGAAAT 17

RESULT 12
LOCUS I94265 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 428 from patent US 5731295.
ACCESSION I94265
VERSION I94265.1 GI:3938735
KEYWORDS
SOURCE Unknown.
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 428 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
```

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1014 TGCTTATGAATTCGAGCCAGAA 1037
 Db 24 TGCTTATGAATTCGAGCCAGAA 1

RESULT 4
 LOCUS BD167388 20 bp DNA linear PAT 17-JAN-2003
 DEFINITION Transgenic rabbits expressing human MMP-12.
 ACCESSION BD167388
 VERSION BD167388.1 GI:27873200
 KEYWORDS JP 2002209472-A/1.
 SOURCE unidentified
 ORGANISM unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Watanabe, T. and Fan, J.
 TITLE Transgenic rabbits expressing human MMP-12
 JOURNAL Patent: JP 2002209472-A 1 30-JUL-2002;
 COMMENT JAPAN SCIENCE AND TECHNOLOGY CORP

OS Artificial Sequence
 PN JP 2002209472-A/1
 PD 30-JUL-2002
 PF 18-JAN-2001 JP 2001010673
 PI TERUO WATANABE,JIANGLIN FAN
 PC A01K67/027,C12N15/09,C12Q1/02,C12Q1/37,C12Q1/68,G01N33/15, PC
 G01N33/50,
 PC G01N33/68//C12N9/50, (C12Q1/37,C12R1:91), (C12Q1/68,C12R1:91),
 PC C12N15/00
 CC Description of Artificial Sequence:Sense Primer FH Key
 FT source 1..20
 FT Location/Qualifiers
 FT source 1..20
 FT /organism="unidentified"
 FT /mol_type="genomic DNA"
 FT /db_xref="taxon:32644"

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 584 TTGGAGGGATGCACATTTTC 603
 Db 1 TTGGAGGGATGCACATTTTC 20

RESULT 5
 LOCUS BD167389/c 20 bp DNA linear PAT 17-JAN-2003
 DEFINITION Transgenic rabbits expressing human MMP-12.
 ACCESSION BD167389
 VERSION BD167389.1 GI:27873201
 KEYWORDS JP 2002209472-A/2.
 SOURCE unidentified
 ORGANISM unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Watanabe, T. and Fan, J.
 TITLE Transgenic rabbits expressing human MMP-12
 JOURNAL Patent: JP 2002209472-A 2 30-JUL-2002;
 COMMENT JAPAN SCIENCE AND TECHNOLOGY CORP

OS Artificial Sequence
 PN JP 2002209472-A/2
 PD 30-JUL-2002
 PF 18-JAN-2001 JP 2001010673
 PI TERUO WATANABE,JIANGLIN FAN
 PC A01K67/027,C12N15/09,C12Q1/02,C12Q1/37,C12Q1/68,G01N33/15, PC
 G01N33/50,
 PC G01N33/68//C12N9/50, (C12Q1/37,C12R1:91), (C12Q1/68,C12R1:91),

PC C12N15/00
 CC Description of Artificial Sequence:Antisense Primer FH Key
 FT source 1..20
 FT Location/Qualifiers
 FT source 1..20
 FT /organism="unidentified"
 FT /mol_type="genomic DNA"
 FT /db_xref="taxon:32644"

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 15;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1243 GACCTGGTTATCCCAACT 1262
 Db 20 GACCTGGTTATCCCAACT 1

RESULT 6
 LOCUS AX133241 21 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 4459 from Patent WO0130362.
 ACCESSION AX133241
 VERSION AX133241.1 GI:14139551
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 REFERENCE 1 Robbins,J.M. and Tritz,R.
 AUTHORS Ribozyme therapy for the treatment of proliferative skin and eye diseases
 TITLE Patent: WO 0130362-A 4459 03-MAY-2001;
 JOURNAL IMMUSOL, INC. (US)
 FT source 1..21
 FT Location/Qualifiers
 FT source 1..21
 FT /organism="Homo sapiens"
 FT /mol_type="unassigned DNA"
 FT /db_xref="taxon:9606"
 FT /note="MMP-3 ribozyme recognition site"

Query Match 1.1%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 20;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTGATCCCTGTATGGA 801
 Db 1 GGCATTGATCCCTGTATGGA 21

RESULT 7
 LOCUS AX131390/c 19 bp DNA linear PAT 15-MAY-2001
 DEFINITION Sequence 2608 from Patent WO0130362.
 ACCESSION AX131390
 VERSION AX131390.1 GI:14137695
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 REFERENCE 1 Robbins,J.M. and Tritz,R.
 AUTHORS Ribozyme therapy for the treatment of proliferative skin and eye diseases
 TITLE Patent: WO 0130362-A 2608 03-MAY-2001;
 JOURNAL IMMUSOL, INC. (US)
 FT source 1..19
 FT Location/Qualifiers
 FT source 1..19
 FT /organism="Homo sapiens"


```
107 13.8 0.8 17 1 AX218206
c 108 13.8 0.8 17 1 AX423658
109 13.8 0.8 17 1 AX475675
110 13.8 0.8 17 1 AX499869
111 13.8 0.8 17 1 AX499870
112 13.8 0.8 17 1 AX579110
113 13.8 0.8 17 1 AX673023
114 13.8 0.8 17 1 AX674037
115 13.8 0.8 17 1 AX687956
116 13.8 0.8 17 1 AX687957
117 13.8 0.8 17 1 AX687958
118 13.8 0.8 17 1 AX693070
119 13.8 0.8 17 1 AX727979
120 13.8 0.8 17 1 AX728771
121 13.8 0.8 17 1 AX730620
122 13.8 0.8 17 1 AX736604
123 13.8 0.8 17 1 AX737681
124 13.8 0.8 17 1 AX738191
125 13.8 0.8 17 1 AX739409
126 13.8 0.8 17 1 AX739484
127 13.8 0.8 17 1 AX745357
128 13.8 0.8 17 1 AX756687
129 13.8 0.8 17 1 AX758977
c 130 13.8 0.8 17 1 AX760855
131 13.8 0.8 17 1 AX761593
132 13.8 0.8 17 1 BD067891
133 13.8 0.8 17 1 BD067975
134 13.4 0.8 15 1 AR560062
135 13.4 0.8 16 1 I71540
136 13.4 0.8 16 1 AR328342
c 137 13.4 0.8 16 1 AR436137
138 13 0.7 15 1 AR028986
c 139 13 0.7 15 1 AR028990
c 140 13 0.7 15 1 AR156868
c 141 13 0.7 15 1 AR156872
c 142 13 0.7 15 1 I77892
c 143 13 0.7 15 1 AR180094
c 144 13 0.7 15 1 AR412066
c 145 13 0.7 15 1 AR412070
c 146 13 0.7 15 1 AX638406
c 147 13 0.7 16 1 AR002582
c 148 12.8 0.7 16 1 AR8311
c 149 12.8 0.7 16 1 A90278
c 150 12.8 0.7 16 1 AR002566
c 151 12.8 0.7 16 1 AR435857
152 12.8 0.7 16 1 AX268349
153 12.8 0.7 16 1 AX405167
c 154 12.8 0.7 16 1 AX796642
c 155 12.8 0.7 16 1 BD065824

ALIGNMENTS
RESULT 1
AX663746 26 bp DNA linear PAT 22-MAR-2003
LOCUS
DEFINITION Sequence 121 from Patent WO02097127.
ACCESSION AX663746
VERSION AX663746.1 GI:29163926
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and
Kroegel,C.
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis
and treatment of chronic lung disease
JOURNAL Patent: WO 02097127-A 121 05-DEC-2002;
Bayer Aktiengesellschaft (DE)
FEATURES
source
1. .26
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="L23808 reverse primer"

Query Match 1.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.6;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 944 CTGAGACACCAAGACCAGTGTAAAT 969
Db 1 CTGAGACACCAAGACCAGTGTAAAT 26

RESULT 2
AX663745 25 bp DNA linear PAT 22-MAR-2003
LOCUS
DEFINITION Sequence 120 from Patent WO02097127.
ACCESSION AX663745
VERSION AX663745.1 GI:29163925
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and
Kroegel,C.
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis
and treatment of chronic lung disease
JOURNAL Patent: WO 02097127-A 120 05-DEC-2002;
Bayer Aktiengesellschaft (DE)
FEATURES
source
1. .25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="L23808 probe"

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 980 CCTTATGGCCAACTTCCCATCTGG 1004
Db 1 CCTTATGGCCAACTTCCCATCTGG 25

RESULT 3
AX663747/c 24 bp DNA linear PAT 22-MAR-2003
LOCUS
DEFINITION Sequence 122 from Patent WO02097127.
ACCESSION AX663747
VERSION AX663747.1 GI:29163927
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
AUTHORS Oellers,N., Gehrman,M., Kallabis,H., Hall,R., Schulze,T. and
Kroegel,C.
TITLE Genes and proteins for prevention, prediction, diagnosis, prognosis
and treatment of chronic lung disease
JOURNAL Patent: WO 02097127-A 122 05-DEC-2002;
Bayer Aktiengesellschaft (DE)
FEATURES
source
1. .24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="L23808 reverse primer"

Query Match 1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 6;
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:25:01 ; Search time 3 Seconds
(without alignments)
3.141 Million cell updates/sec

Title: US-10-619-906-1
Perfect score: 1778
Sequence: 1 tagaagtttacaatgaagttt.....ttttggtcaataaaattg 1778

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 155 seqs, 2650 residues
Total number of hits satisfying chosen parameters: 310

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 155 summaries

Database : rgel.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	1.5	26	1	ACCESSION:AX663746
2	25	1.4	25	1	ACCESSION:AX663745
3	24	1.3	24	1	ACCESSION:AX663747
4	20	1.1	20	1	ACCESSION:BD167388
5	20	1.1	20	1	ACCESSION:BD167389
6	19.4	1.1	21	1	ACCESSION:AX133241
7	17.4	1.0	19	1	ACCESSION:AX133190
8	16.4	0.9	18	1	ACCESSION:AX133190
9	16.4	0.9	18	1	ACCESSION:AX133190
10	16.4	0.9	19	1	ACCESSION:AX133190
11	16	0.9	17	1	ACCESSION:AX133190
12	16	0.9	17	1	ACCESSION:AX133190
13	15.4	0.9	17	1	ACCESSION:AX133190
14	15.4	0.9	17	1	ACCESSION:AX133190
15	15.4	0.9	17	1	ACCESSION:AX133190
16	15.4	0.9	17	1	ACCESSION:AX133190
17	15.4	0.9	17	1	ACCESSION:AX133190
18	15	0.8	17	1	ACCESSION:AX133190
19	15	0.8	17	1	ACCESSION:AX133190
20	15	0.8	17	1	ACCESSION:AX133190
21	15	0.8	17	1	ACCESSION:AX133190
22	15	0.8	17	1	ACCESSION:AX133190
23	14.8	0.8	18	1	ACCESSION:AX133190
24	14.8	0.8	18	1	ACCESSION:AX133190
25	14.8	0.8	18	1	ACCESSION:AX133190
26	14.8	0.8	18	1	ACCESSION:AX133190
27	14.8	0.8	18	1	ACCESSION:AX133190
28	14.4	0.8	17	1	ACCESSION:AX133190
29	14.4	0.8	17	1	ACCESSION:AX133190
30	14.4	0.8	17	1	ACCESSION:AX133190
31	14.4	0.8	17	1	ACCESSION:AX133190
32	14.4	0.8	17	1	ACCESSION:AX133190
33	14.4	0.8	17	1	ACCESSION:AX133190

C 34	14.4	0.8	17	1	CQ625693
C 35	14.4	0.8	17	1	AR188571
C 36	14.4	0.8	17	1	AR324424
C 37	14.4	0.8	17	1	AR464961
C 38	14.4	0.8	17	1	AR464962
C 39	14.4	0.8	17	1	AR466754
C 40	14.4	0.8	17	1	AR466756
C 41	14.4	0.8	17	1	AX215037
C 42	14.4	0.8	17	1	AX215112
C 43	14.4	0.8	17	1	AX215901
C 44	14.4	0.8	17	1	AX215980
C 45	14.4	0.8	17	1	AX22075
C 46	14.4	0.8	17	1	AX578322
C 47	14.4	0.8	17	1	AX6711586
C 48	14.4	0.8	17	1	AX6711726
C 49	14.4	0.8	17	1	AX672236
C 50	14.4	0.8	17	1	AX739459
C 51	14.4	0.8	17	1	AX757823
C 52	14.4	0.8	18	1	AR157063
C 53	14.4	0.8	18	1	AR339863
C 54	14	0.8	17	1	CQ625689
C 55	14	0.8	17	1	CQ625690
C 56	14	0.8	17	1	AR466752
C 57	14	0.8	17	1	AR466753
C 58	14	0.8	17	1	AX216761
C 59	14	0.8	17	1	AX688628
C 60	14	0.8	17	1	AX688632
C 61	14	0.8	17	1	AX730551
C 62	14	0.8	17	1	AX735621
C 63	13.8	0.8	17	1	AX11108
C 64	13.8	0.8	17	1	AR047236
C 65	13.8	0.8	17	1	AR047238
C 66	13.8	0.8	17	1	AR047626
C 67	13.8	0.8	17	1	BD199027
C 68	13.8	0.8	17	1	BD203241
C 69	13.8	0.8	17	1	BD203242
C 70	13.8	0.8	17	1	BD203389
C 71	13.8	0.8	17	1	BD252276
C 72	13.8	0.8	17	1	BD252278
C 73	13.8	0.8	17	1	CQ622021
C 74	13.8	0.8	17	1	CQ623897
C 75	13.8	0.8	17	1	CQ625688
C 76	13.8	0.8	17	1	CQ625694
C 77	13.8	0.8	17	1	137528
C 78	13.8	0.8	17	1	137529
C 79	13.8	0.8	17	1	137585
C 80	13.8	0.8	17	1	137592
C 81	13.8	0.8	17	1	154288
C 82	13.8	0.8	17	1	154290
C 83	13.8	0.8	17	1	154678
C 84	13.8	0.8	17	1	194378
C 85	13.8	0.8	17	1	194379
C 86	13.8	0.8	17	1	194435
C 87	13.8	0.8	17	1	194442
C 88	13.8	0.8	17	1	AR186189
C 89	13.8	0.8	17	1	AR188613
C 90	13.8	0.8	17	1	AR190187
C 91	13.8	0.8	17	1	AR191846
C 92	13.8	0.8	17	1	AR192415
C 93	13.8	0.8	17	1	AR322820
C 94	13.8	0.8	17	1	AR324466
C 95	13.8	0.8	17	1	AR325741
C 96	13.8	0.8	17	1	AR326284
C 97	13.8	0.8	17	1	AR328170
C 98	13.8	0.8	17	1	AR362733
C 99	13.8	0.8	17	1	AR402391
C 100	13.8	0.8	17	1	AR402475
C 101	13.8	0.8	17	1	AR463084
C 102	13.8	0.8	17	1	AR464960
C 103	13.8	0.8	17	1	AR466751
C 104	13.8	0.8	17	1	AR466757
C 105	13.8	0.8	17	1	AX214888
C 106	13.8	0.8	17	1	AX215038

R. Site2: NotI 5' Seq Primer M13P Normalised library constructed from pooled ovaries. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, www.ark-genomics.org.

FEATURES

source

1..14
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone="C0003273 I16"
/tissue_type="ovary"
/clone_lib="CSEQRAN19"
/note="Vector: pBlueScript11(KS+); Site_1: EcoRI; Site_2: NotI; Single pass sequencing; Normalised library constructed from pooled ovaries"

Query Match 0.6%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred No. 9.6;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 CTACACATTCAGG 635

Db 13 CTGCACATTCAGG 1

Search completed: May 13, 2005, 11:34:01
Job time : 1 secs

0.88; Score 14; DB 1; Length 17;

Contact: Andreas.Breit@uni-koeln.de
 Genomics and Bioinformatics
 Roslin Institute
 Roslin, Midlothian, EH25 9PS, UNITED KINGDOM
 Single pass sequencing. Bases called and trimmed with phred
 v0.020425.c. Vector identified by cross match with the -minscore 20
 and -mismatch 12 options. Vector: pBlueScriptII (KS) R. SiteI: EcoRI

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:34:00 ; Search time 0.001 Seconds
(without alignments)
497.840 Million cell updates/sec

Title: US-10-619-906-1
Perfect score: 1778
Sequence: 1 tagaagtttaaatgaagtt.....tttgggtcaataaaattg 1778

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 8 seqs, 140 residues
Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 8 summaries

Database: rst1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	17.8	1.0	21	AG187907	ACCESSION:AG187907
C 2	14.8	0.8	18	BZ424714	ACCESSION:BZ424714
C 3	14.8	0.8	18	BZ424774	ACCESSION:BZ424774
C 4	14.8	0.8	18	BZ425093	ACCESSION:BZ425093
C 5	14.8	0.8	18	BZ425186	ACCESSION:BZ425186
C 6	14.8	0.8	17	AW246518	ACCESSION:AW246518
C 7	12.8	0.7	16	AL037434	ACCESSION:AL037434
C 8	11.4	0.6	14	AJ649806	ACCESSION:AJ649806

ALIGNMENTS

RESULT 1
AG187907/c 21 bp DNA linear GSS 06-MAR-2004
LOCUS Pan troglodytes DNA, clone: RP43-061C06.T7, genomic survey
DEFINITION sequence.
ACCESSION AG187907
VERSION AG187907.1 GI:45220076
KEYWORDS GSS.
SOURCE Pan troglodytes (chimpanzee)
ORGANISM Pan troglodytes
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.
1
Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J., Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.
BAC end sequences of Library RP-43
Unpublished
2 (bases 1 to 21)
Park, H., Kim, Y., Kim, S., Han, Y., Woo, T., Park, K., Eun, C.J., Hoon, S.T., Chu, M., Kim, H., Joo, S., Kim, C., Song, W. and Yoo, H.

TITLE Direct Submission
JOURNAL Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC); Sz, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
(E-mail:redstone@mail.krribb.re.kr, URL:http://phs.grc.krribb.re.kr/, Tel:82-42-866-7181, Fax:82-42-860-4409)
Clones are derived from the chimpanzee BAC library RP-43 This BAC end was generated during the R&D process and may have higher chance of clone tracking errors.
PRIMERS

Sequencing: T7

LIBRARY
Vector : pBACE3.6
R.Site 1 : EcoRI
R.Site 2 : EcoRI

FEATURES
source
1. .21
Location/Qualifiers
/organism="Pan troglodytes"
/mol_type="genomic DNA"
/db_xref="taxon:9598"
/clone="RP43-061C06.T7"
/sex="male"
/cell_type="lymphocytes"
/clone_lib="RP-43 Chimpanzee Male BAC Library"

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 0.48;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 194 AGGAAAAATCCAGAAATGC 214

DB 21 AGGAAAAATATAAGAAATGC 1

RESULT 2

BZ424714

LOCUS

DEFINITION

ACCESSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE Integrating transcriptional and metabolite profiles to direct the engineering of lovastatin-producing strains
JOURNAL Unpublished (2002)
COMMENT Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
Location/Qualifiers
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone library"
/note="Vector: pZBrOTM-2; Site 1: Sau3A; Site 2: BamHI; Sau3A genomic fragments ligated into BamHI digested"

BZ424714 18 bp DNA linear GSS 13-DEC-2002
100018520-2995 Aspergillus terreus random genomic DNA clone library
Aspergillus terreus genomic, genomic survey sequence.

BZ424714 GI:26666169
GSS.
Aspergillus terreus
Aspergillus terreus
Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
Eurotiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
1 (bases 1 to 18)
Askenazi, M., Driggers, E.M., Holtzman, D.A., Norman, T.C., Iverson, S., Zimmer, D.P., Boers, M.E., Blomquist, P.R., Martinez, E.J., Monreal, A.W., Feibelman, T.P., Mayorga, M.E., Maxon, M.E., Sykes, K., Tobin, J., Cordero, E., Salama, S.R., Trueheart, J., Royer, J.C. and Madden, K.T.

TITLE Integrating transcriptional and metabolite profiles to direct the engineering of lovastatin-producing strains
JOURNAL Unpublished (2002)
COMMENT Contact: Zimmer DP
Microbia, Inc.
One Kendall Square Building 1400 W, Cambridge, MA 02139, USA
Tel: 617-621-8322
Fax: 617-
Email: dzimmer@microbia.com
Class: plasmid ends.
Location/Qualifiers
1. .18
/organism="Aspergillus terreus"
/mol_type="genomic DNA"
/strain="ATCC 20542 (A. terreus Thom, anamorph)"
/db_xref="taxon:33178"
/lab_host="Escherichia coli"
/clone_lib="Aspergillus terreus random genomic DNA clone library"
/note="Vector: pZBrOTM-2; Site 1: Sau3A; Site 2: BamHI; Sau3A genomic fragments ligated into BamHI digested"

```
; ORGANISM: Homo sapiens
US-09-922-261-460

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1561 TTATATAAATACAT 1575
Db 15 TTATATAAATACAT 1

RESULT 633
US-10-138-674-5744
; Sequence 5744, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5744
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5744

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1596 ACTCTAATTGTCAT 1610
Db 2 ACUCUAUUGUCAU 16

RESULT 634
US-10-287-949A-5744
; Sequence 5744, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5744
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5744

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 3.5e+02;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1596 ACTCTAATTGTCAT 1610
Db 2 ACUCUAUUGUCAU 16

RESULT 635
US-10-712-672-1831
; Sequence 1831, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1831
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1831

Query Match      0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 46.7%; Pred. No. 3.5e+02;
Matches 7; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1582 TTTCATTTTCAAAA 1596
Db 1 UUCAGUUUUGAAAA 15

Search completed: May 13, 2005, 11:31:07
Job time : 13 secs
```

APPLICANT: KATZ, LAWRENCE C.
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CONDITIONS DISORDERS. OR DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM.

; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1625
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1625

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914
DB 17 AAAAAAGAGCTTTTCTT 1

RESULT 626
US-10-724-270-304/c
; Sequence 304, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBH02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 304
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-724-270-304

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 AAAATACATAATATTTT 1583
DB 17 AAAAAATATAATATTTT 1

RESULT 627

US-10-724-270-4999
; Sequence 4999, Application US/10724270
; Publication No. US20050080031A1

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBH02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4999
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-4999

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 607 GAGGACGGAATTCGGAC 623
DB 1 GGGGACGGAUUCUGAC 17

RESULT 628

US-10-751-736-10774/c
; Sequence 10774, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; Cancers

```
, PRIORITY NUMBER: PCT/US01/006654
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/006659
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/006655
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/006658
, PRIOR FILING DATE: 2001-01-30
, Remaining Prior Application data removed
, NUMBER OF SEQ ID NOS: 15755
, SOFTWARE: Acomica Sequence Listing Engine
, SEQ ID NO 8637
, LENGTH: 17
, TYPE: DNA
, ORGANISM: Homo sapiens
US-10-723-361-8637
```

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 3.6e+02;		
Matches 15:	Conservative	0;	Mismatches 2;	Indels 0;
				Gaps 0;

Qy 200 AAATCCAAGAAATGCAG 216
| | | | | | | | | |
pb 1 AGATCCAAGAACTGCAG 17

```

RESULT 623
US-10-723-361-10428/c
, Sequence 10428, Application US/10723361
, Publication No. US20040137589A1
, GENERAL INFORMATION:
, APPLICANT: GU, Yizhong
, APPLICANT: JI, Yonggang
, APPLICANT: PENN, Sharron G.
, APPLICANT: HANZEL, David K.
, APPLICANT: RANKZ, David R.
, APPLICANT: CHEN, Wensheng
, APPLICANT: SHANNON, Mark
, TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLY
, FILE REFERENCE: PB0105
, CURRENT APPLICATION NUMBER: US/10/723,361
, CURRENT FILING DATE: 2003-11-25
, PRIOR APPLICATION NUMBER: US 09/866,108
, PRIOR FILING DATE: 2001-05-25
, PRIOR APPLICATION NUMBER: US 60/207,456
, PRIOR FILING DATE: 2000-05-26
, PRIOR APPLICATION NUMBER: GB 24263.6
, PRIOR FILING DATE: 2000-10-04
, PRIOR APPLICATION NUMBER: US 60/236,359
, PRIOR FILING DATE: 2000-09-27
, PRIOR APPLICATION NUMBER: PCT/US01/006656
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00667
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00664
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00669
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00665
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00668
, PRIOR FILING DATE: 2001-01-30
, PRIOR APPLICATION NUMBER: PCT/US01/00664
, PRIOR FILING DATE: 2001-01-30
, Remaining Prior Application data removed
, NUMBER OF SEQ ID NOS: 15755
, SOFTWARE: Acemica Sequence Listing Engine
, SEQ ID NO 10428
, LENGTH: 17
, TYPE: DNA
, ORGANISM: Homo sapiens
US-10-723-361-10428

```

Query Match	0.8%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%	Pred. No. 3.6e+02;		

	Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	874	TTT	GAT	GCT	GTC	ACT	ATC	890		
Db	17	TTT	GAT	GCT	GTC	AGC	AC	1		

```

RESULT 624
US-10-723-361-10434/C
, Sequence 10434, Application US/10723361
, Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wenheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10723,
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,10
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,451
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,355
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/0066
PRIOR FILING DATE: 2001-01-30
Remaining prior application data removed
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aemica Sequence Listing Eng
SEQ ID NO 10434
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-10434

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 868 TTGAGTTTGTGCTGT 884
| | | | | | | |
nb 17 TCGACTTTGTGCTGT 1

RESULT 625
US-10-712-633-1625/c
; Sequence 1625, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Glad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MO

```

: APPLICANT: Stinchcomb, Dan
: TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
: FILE REFERENCE: MEH800-882-C (400/Q19)
: CURRENT APPLICATION NUMBER: US/10/712,672
: CURRENT FILING DATE: 2003-11-13
: PRIOR APPLICATION NUMBER: US/09/653,225
: PRIOR FILING DATE: 2000-08-31
: PRIOR APPLICATION NUMBER: 60/197,769
: PRIOR FILING DATE: 2000-04-14
: PRIOR APPLICATION NUMBER: 60/150,713
: PRIOR FILING DATE: 1999-08-31
: NUMBER OF SEQ ID NOS: 586
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 81
: LENGTH: 17
: TYPE: RNA
: ORGANISM: Homo sapiens
: US-10-712-672-81

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0

Qy 43 GCCACTGCTTCTGGAGC 59
||| | : : | | |
Db 1 GCCCGUUGUUGGAGC 17

RESULT 620
US-10-712-672-82
; Sequence 82, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBHB00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/553,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 82
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-82

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 3.6e+02;
Matches 10: Conservative 5; Mismatches 2; Indels 0; Gaps 0;
```

Qy 44 CCACTGCTTCTGGAGCT 60
|||:::||||:
Dp 1 CCCUGUUUCUGGAGCU 17

RESULT 621
US-10-723-361-6761
Sequence 6761, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
;

```

; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File wrapper or PALM
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-6761

```

Query Match	0.8%	Score 13.8	DB 1	Length 17
Best Local Similarity	88.2%	Pred. No. 3.6e+02		
Matches 15	Conservative	0	Mismatches 2	Indels 0
Gaps 0				

QY 506 GTGGAGCTCATGGAGAC 522
Db 1 GAGGAGCTCCTGGAGAC 17

RESULT 622
US-10-723-361-8637
; Sequence 8637, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN SKELETAL MUSCLE
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30


```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3686
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3686

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 ATGCTTTTGATGCGCAA 543
DB 17 ATGCTTTTGATGCGTAA 1

RESULT 611
US-10-138-674-5572/c
; Sequence 5572, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-5572

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 TGATGAAGGACAGACAGA 1237
DB 17 TTATGAAGGACAGACA 1

RESULT 612
US-10-138-674-8308/c
; Sequence 8308, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
```

```
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8308
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8308

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 898 AATAAGATCTTTTCTT 914
DB 17 AAAAAGAGCTTTTCTT 1

RESULT 613
US-10-287-949A-222
; Sequence 222, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-222

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1066 TACTGGTTAATTAGCAA 1082
DB 1 UACUCGUUAUUUACAA 17

RESULT 614
US-10-287-949A-1868
; Sequence 1868, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1868
```

QY	1066	TACTGGTTAATTACAA	1082
		: : :: : :	
Db	1	UACUCGUAAUAUCAA	17

RESULT 608

US-10-138-674-1868

; Sequence 1868, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1868

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-1868

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	52.9%;	Pred. No. 3.6e+02;		
Matches	9;	Conservative	6;	Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTCTGGCT 935

||| ||:|:|:|:|

Db 1 GCCAUGUUCUUCUGGCU 17

RESULT 609

US-10-138-674-3143/c

; Sequence 3143, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3143

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus musculus

US-10-138-674-3143

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 3.6e+02;		
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAAGTTGCTT 1695

||||| |

Db 17 TGCTCTCTTAGTTGCTT 1

RESULT 610

US-10-138-674-3686/c

; Sequence 3686, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 3143

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Mus musculus

US-10-138-674-3143

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	88.2%;	Pred. No. 3.6e+02;		
Matches	15;	Conservative	0;	Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAAGTTGCTT 1695

||||| |

Db 17 TGCTCTCTTAGTTGCTT 1

; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 529
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-529

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.6e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 907 TTTTCTTCAAGACAG 923
DB 1 UUUUUUUUAAAGACAG 17

RESULT 602

US-10-156-306-3602/c
; Sequence 3602, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 14 TGAAGTTTCTTCTAATA 30
DB 17 TGAGGTTTCTTCTGATA 1

RESULT 603

US-10-238-700-304/c
; Sequence 304, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 304
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-304

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 AAAATACATAATATTTT 1583
DB 17 AAAAAATATAATATTTT 1

RESULT 604

US-10-430-882-229/c
; Sequence 229, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-229

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 CTCCTGAGCGCCACTGC 50
DB 17 CTCCTGAGCGCCGAGC 1

RESULT 605

US-10-430-882-230/c
; Sequence 230, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 230

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1177
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-060-756A-1177

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1143 GAAAAAAATTGATGCAG 1159
        |||||
Db       1 GAAAAAAATTGAGGTAG 17

RESULT 600
US-10-163-552-344
; Sequence 344, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to levels
; TITLE OF INVENTION: HER2
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 344
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-163-552-344

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 3.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      607 GAGGACGAATTCGTGCAC 623
        |||||
Db       1 GGGGACGAATTCUGCAC 17

RESULT 601
US-10-156-306-529
; Sequence 529, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28

```



```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.6e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1687 AAGTGTGCTCTCAACAT 1703
DB 1 AAGUUCUUCUCAAUAU 17

RESULT 593
US-09-848-754A-815/c
; Sequence 815, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-815

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAATCAATA 176
DB 17 GAGACAAAATCAATA 1

RESULT 594
US-09-848-754A-2380/c
; Sequence 2380, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2380
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2380

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 532 TTTGATGGCAAGGTGG 548
DB 17 TTGGATGGCACAGGTGG 1

RESULT 595
US-09-780-164-947
; Sequence 947, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
```

```
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 947
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-947

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 477 CATGGCTGACATTTTGG 493
DB 1 CAGGGCUGACAUUGUGG 17

RESULT 596
US-09-827-395A-229/c
; Sequence 229, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Gene Expression
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 229
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-229

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 34 CTCCTGCAGGCGCACTGC 50
DB 17 CTCCTGCAGGCGCCGAGC 1

RESULT 597
US-09-827-395A-230/c
; Sequence 230, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor Gene Expression
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aescica Sequence Listing Engine
; SEQ ID NO 10434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10434

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 868 TTGACTTTTGATGCTGT 884
Db 17 TCGACTTTTGATGCTGT 1

RESULT 589
US-09-780-533A-330
; Sequence 330, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 330
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-330

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 3.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1145 AAAAATTTGATGCTGT 1161
Db 1 AAAAUUUAUACAGCU 17

RESULT 590
US-09-780-533A-480/c
; Sequence 480, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00, 878-A (400/011)

; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 480
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-480

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 908 TTTTCTTCAAGACAGG 924
Db 17 TGTCTTCAAGAAAGG 1

RESULT 591
US-09-927-046-948/c
; Sequence 948, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloric
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-948

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 484 GACATTTTGGTGTGTTT 500
Db 17 GCCATTTTGGTGTGTTT 1

RESULT 592
US-09-848-754A-731
; Sequence 731, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 731
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-731

; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8637
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8637

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 200 AAATCCAAGAAATGCAG 216
Db 1 AGATCCAAGAACTGCAG 17

RESULT 587
US-09-866-108-10428/c
; Sequence 10428, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 874 TTTGATGCTGTCTACTAC 890
Db 17 TTTGATGCTGTCTAGCAC 1

RESULT 588
US-09-866-108-10434/c
; Sequence 10434, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663


```
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGCA 886
DB 17 TTTTGATGCTGCA 4

RESULT 581
US-09-866-108-10430/c
; Sequence 10430, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10430

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGCA 886
DB 16 TTTTGATGCTGCA 3

RESULT 582
US-09-780-533A-2203/c
; Sequence 2203, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MSBH00, 878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2203
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2203

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCT 982
DB 14 TTTAATTTCTTCCT 1

RESULT 583
US-10-723-361-10429/c
; Sequence 10429, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AND
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10429
```

```
; Sequence 2299, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; FILE REFERENCE: 506612000120
; CURRENT APPLICATION NUMBER: US/10/131,827
; PRIOR FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2299
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-2299
```

```
Query Match 0.8%; Score 14.2; DB 1; Length 50;
Best Local Similarity 58.1%; Pred. No. 5.1e+02;
Matches 25; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 1314 TTCTAAAAACAATACTACTATTCTTCCAGGATCTAACCA 1356
Db 50 TGCAGAGTAAGTATATTTCTCAGTCCAGGATGTAGGAA 8
```

```
RESULT 578
US-10-255-120-58
; Sequence 58, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
; FILE REFERENCE: Jim Zeeger Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/255,120
; CURRENT FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 903
; SOFTWARE: Proprietary
; SEQ ID NO 58
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Helicobacter pylori, strain J99 complete genome.
; FEATURE:
; LOCATION: (104076)...(104091)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 92
US-10-255-120-58
```

```
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 198 AAAAAATCCAGAAA 211
Db 1 AAAAAATCCAGAAA 14
```

```
RESULT 579
US-10-255-120-102
; Sequence 102, Application US/10255120
; Publication No. US20040091865A1
; GENERAL INFORMATION:
; APPLICANT: Feldmann, Richard J.; Global Determinants, Inc.
; TITLE OF INVENTION: Helicobacter pylori, strain J99 complete genome.
; FILE REFERENCE: Jim Zeeger Law Offices - 703-684-8333
; CURRENT APPLICATION NUMBER: US/10/255,120
; CURRENT FILING DATE: 2002-11-19
```

```
; NUMBER OF SEQ ID NOS: 903
; SOFTWARE: Proprietary
; SEQ ID NO 102
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Helicobacter pylori, strain J99 complete genome.
; FEATURE:
; LOCATION: (170536)...(170551)
; OTHER INFORMATION: Chromosome = 1 Strand = negative ConnectronObjectNumber = 157
US-10-255-120-102
```

```
Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 197 AAAAAATCCAGAA 210
Db 3 AAAAAATCCAGAA 16
```

```
RESULT 580
US-09-866-108-10429/C
; Sequence 10429, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10429
```

```
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTC 885
DB 16 GACTTTTGTGCTGTC 1

RESULT 573
US-10-079-136-14/c
; Sequence 14, Application US/10079136
; Publication No. US20020172885A1
; GENERAL INFORMATION:
; APPLICANT: Stewart, Graham
; APPLICANT: O'Gaora, Peadar
; TITLE OF INVENTION: Methods and Compositions for Therapeutic Intervention in Infectio
; TITLE OF INVENTION: Disease
; FILE REFERENCE: 19626-0211 (45454-270653)
; CURRENT APPLICATION NUMBER: US/10/079,136
; CURRENT FILING DATE: 2002-06-04
; PRIOR APPLICATION NUMBER: US 60/269,801
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: US 60/294,170
; PRIOR FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
US-10-079-136-14

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 CTACATTCAGGAGG 638
DB 16 CTACATATTCAGGAGG 1

RESULT 574
US-10-807-963-14/c
; Sequence 14, Application US/10807963
; Publication No. US20040219159A1
; GENERAL INFORMATION:
; APPLICANT: Stewart, Graham
; APPLICANT: O'Gaora, Peadar
; APPLICANT: Young, Douglas
; TITLE OF INVENTION: Methods and Compositions for Therapeutic Intervention in Infectio
; TITLE OF INVENTION: Disease
; FILE REFERENCE: 19626-0211 (45454-270653)
; CURRENT APPLICATION NUMBER: US/10/807,963
; CURRENT FILING DATE: 2004-03-24
; PRIOR APPLICATION NUMBER: US 60/269,801
; PRIOR FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: US 60/294,170
; PRIOR FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
US-10-807-963-14

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.4e+02;
```

```
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 CTACATTCAGGAGG 638
DB 16 CTACATATTCAGGAGG 1

RESULT 575
US-10-619-906-11
; Sequence 11, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
US-10-619-906-11

Query Match 0.8%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 204 CCAAGAAATGCAGCACTTC 222
DB 1 CCAAGAACTGCTGCATTTC 19

RESULT 576
US-10-751-736-10931/c
; Sequence 10931, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10931
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10931

Query Match 0.8%; Score 14.2; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 4.9e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 205 CAAGAAATGCAGCACTTCT 223
DB 19 CAAGAAGTGTGCACTTCT 1

RESULT 577
US-10-131-827-2299/c
```

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8639

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      202 ATCCAGAAATCGAGC 217
Db      1 ATCCAGAAATCGAGC 16

RESULT 571
US-10-723-361-10431/c
; Sequence 10431, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8639

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      202 ATCCAGAAATCGAGC 217
Db      1 ATCCAGAAATCGAGC 16

RESULT 571
US-10-723-361-10431/c
; Sequence 10431, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: HANZEL, David R.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8639
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10431

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      871 AGTTTCATGCTGTCA 886
Db      17 ACTTTGATGCTGTCA 2

RESULT 572
US-10-723-361-10433/c
; Sequence 10433, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10433

Query Match          0.8%; Score 14.4; DB 1; Length 17;
```


Fri May 13 12:26:37 2005

```

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1372 CTAATCCACGATCA 1387
   1 CUCCUCCACGUAUCA 16
   1:|||||:|:|
   1:|||||:|:|

RESULT 563
US-10-156-306-526
; Sequence 526, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 526
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-526

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 3e+02;
Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
   2 UUUUUUUUUUAAAGA 17
   :|:|:|:|:|
   :|:|:|:|:|

RESULT 564
US-10-156-306-527
; Sequence 527, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 527
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-527

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 3e+02;
Matches 5; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TTTTCTTTTAAAGA 1058
   1 UUUUUUUUUUAAAGA 16
   :|:|:|:|:|
   :|:|:|:|:|

RESULT 565
US-10-138-674-1826/c
; Sequence 1826, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```

; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-1826

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 GAGACTTCATGCTTT 533
   17 GAGACTTCATGCTTT 2
   |||||:|:|:|
   |||||:|:|:|

RESULT 566
US-10-287-949A-1826/c
; Sequence 1826, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1826
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-1826

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 GAGACTTCATGCTTT 533
   17 GAGACTTCATGCTTT 2
   |||||:|:|:|
   |||||:|:|:|

RESULT 567
US-10-712-672-382
; Sequence 382, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31

```

```
; APPLICANT: Haebeli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1343
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-09-780-533A-1343

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 910 TTCTTCAAAGACAGGT 925
Db 17 TTCTTCAAAGAAAGGT 2

RESULT 559
US-09-780-533A-1422
; Sequence 1422, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haebeli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1422
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1422

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 847 CCAGCTCTCTGTGACC 862
Db 2 CCUGCUCUCUGUGACC 17

RESULT 560
US-09-927-046-160
; Sequence 160, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
```

```
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 160
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-160

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 3e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1712 TGAGAAATTATCTTA 1727
Db 1 UGAGAAAUUCUACUUA 16

RESULT 561
US-09-740-332-2114
; Sequence 2114, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-2114

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1372 CTACTCCAAACGTATCA 1387
Db 1 CUCCUCCACCGUAUCA 16

RESULT 562
US-09-817-879-2114
; Sequence 2114, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2114
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2114
```

Best Local Similarity 93.8%; Pred. No. 3e+02; DB 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 871 AGTTTGTGCTGTCA 886
DB 17 ACTTTTGATGCTGTCA 2

RESULT 555
US-09-866-108-10433/c
; Sequence 10433, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aromica Sequence Listing Engine
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; DB 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 870 GAGTTTGTGCTGTGC 885
DB 16 GACTTTTGATGCTGTGC 1

RESULT 556
US-09-780-533A-479/c

; Sequence 479, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-479

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; DB 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1;

QY 910 TTCTTCAAGACAGGT 925
DB 16 TTCTTCAAGACAGGT 1

RESULT 557
US-09-780-533A-554
; Sequence 554, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBHB00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 554
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-554

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 3e+02; DB 1; Indels 0; Gaps 0;
Matches 11; Conservative 4; Mismatches 1;

QY 847 CCAGCTCTCTGTGACC 862
DB 1 CCUGCUCUCUGUGACC 16

RESULT 558
US-09-780-533A-1343/c
; Sequence 1343, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8638
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8638

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217
DB 2 ATCCAAGAACTGCAGC 17

RESULT 553
US-09-866-108-8639
; Sequence 8639, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-03-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;

; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8639

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 ATCCAAGAAATGCAGC 217
DB 1 ATCCAAGAACTGCAGC 16

RESULT 554
US-09-866-108-10431/c
; Sequence 10431, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Mismatch 0; Mismatches 2; Indels 0; Gaps 0;

```

; APPLICANT: Freier, Susan M.
; APPLICANT: Sasnor, Henri M.
; APPLICANT: Brooks, Douglas G.
; APPLICANT: Ohashi, Cara
; APPLICANT: Wyatt, Jacqueline R.
; APPLICANT: Borchers, Alexander
; APPLICANT: Vickers, Timothy A.
; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR
; TITLE OF INVENTION: MODULATION BY OLIGONUCLEOTIDES AND
; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION
; FILE REFERENCE: ISIS-4503
; CURRENT APPLICATION NUMBER: US/10/388,263
; CURRENT FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 947
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-388-263-57

```

```

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 945 TGAGAGACCAAGACCAG 962
DB 18 TGTGAGACCAAGACCTG 1

```

```

RESULT 547
US-10-698-689-57/c
; Sequence 57, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-57

```

```

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 945 TGAGAGACCAAGACCAG 962
DB 18 TGTGAGACCAAGACCTG 1

```

```

RESULT 548
US-10-698-689-221
; Sequence 221, Application US/10698689
; Publication No. US20040186071A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, C. Frank
; APPLICANT: Cowsett, Lex M.
; APPLICANT: Malik, Leila
; APPLICANT: Siwkowski, Andrew
; APPLICANT: Eldrup, Anne B.
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD40 EXPRESSION
; FILE REFERENCE: ISIS-5315
; CURRENT APPLICATION NUMBER: US/10/698,689
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: PCT/US03/31166
; PRIOR FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 10/261,382
; PRIOR FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: US 09/067,638
; PRIOR FILING DATE: 1998-04-28
; PRIOR APPLICATION NUMBER: US 60/081,483
; PRIOR FILING DATE: 1998-04-13
; NUMBER OF SEQ ID NOS: 248
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-698-689-221

```

```

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 945 TGAGAGACCAAGACCAG 962
DB 1 TGTGAGACCAAGACCTG 18

```

```

RESULT 549
US-10-830-475-57/c
; Sequence 57, Application US/10830475
; Publication No. US20040197814A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Brenda F. Baker
; APPLICANT: John McNeil
; APPLICANT: Susan M. Freier
; APPLICANT: Henri M. Sasnor
; APPLICANT: Douglas G. Brooks
; APPLICANT: Cara Ohashi
; APPLICANT: Jacqueline R. Wyatt
; APPLICANT: Alexander Borchers
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Identification of Genetic
; Targets for Modulation By Oligonucleotides and
; Generation of Oligonucleotides for Gene
; Modulation
; NUMBER OF SEQUENCES: 112
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: WOODCOCK WASHBURN KURTZ
; STREET: 1 LIBERTY PLACE 46TH FLOOR
; CITY: PHILADELPHIA
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; COMPUTER: IBM
; OPERATING SYSTEM: PC-Windows NT

```

FILE REFERENCE: 38-10(52679)A
 CURRENT APPLICATION NUMBER: US/09/969,373
 PRIOR FILING DATE: 2001-10-02
 PRIOR APPLICATION NUMBER: US 09/754,853
 PRIOR FILING DATE: 2001-01-05
 PRIOR APPLICATION NUMBER: US 09/760,427
 PRIOR FILING DATE: 2001-01-13
 PRIOR APPLICATION NUMBER: US 09/855,768
 PRIOR FILING DATE: 2001-05-15
 NUMBER OF SEQ ID NOS: 4593
 SEQ ID NO 2034
 LENGTH: 18
 TYPE: DNA
 ORGANISM: Glycine max
 US-09-969-373-2034

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 105 ATTGGTGAGAGTACTT 122
 |||||
 DB 18 ATTGGTGGAGATGCTT 1

RESULT 544
 US-10-116-325-57/c

Sequence 57, Application US/10116325
 Publication No. US20030113739A1
 GENERAL INFORMATION:
 APPLICANT: Cowsert, Lex M.
 APPLICANT: Baker, Brenda F.
 APPLICANT: McNeil, John
 APPLICANT: Freier, Susan M.
 APPLICANT: Sasnor, Henri M.
 APPLICANT: Brooks, Douglas G.
 APPLICANT: Ohashi, Cara
 APPLICANT: Wyatt, Jacqueline R.
 APPLICANT: Borchers, Alexander
 APPLICANT: Vickers, Timothy A.
 TITLE OF INVENTION: Identification of Genetic Targets For Modulation By Oligonucleotides
 FILE REFERENCE: IS185026
 CURRENT APPLICATION NUMBER: US/10/116,325
 CURRENT FILING DATE: 2002-04-04
 PRIOR APPLICATION NUMBER: 09/067,638
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/081,483
 PRIOR FILING DATE: 1998-04-13
 NUMBER OF SEQ ID NOS: 112
 SOFTWARE: Patent version 3.1
 SEQ ID NO 57
 LENGTH: 18
 TYPE: DNA
 ORGANISM: Artificial Sequence
 OTHER INFORMATION: No. US20030113739A1e1 Sequence
 US-10-116-325-57

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962
 |||||
 DB 18 TGTGAGACCAAGACCTG 1

RESULT 545
 US-10-251-598-193
 Sequence 193, Application US/10251598
 Publication No. US20030170669A1
 GENERAL INFORMATION:

APPLICANT: Detera-Wadleigh, Sevilla D.
 Gershon, Elliot S.
 Badner, Judith A.
 Goldin, Lynn R.
 Berrettini, Wade H.
 Yoshikawa, Takeo
 Sanders, Alan R.
 Esterling, Lisa E.
 TITLE OF INVENTION: Chromosomal Markers and Diagnostic Tests for Manic-Depressive Illness
 NUMBER OF SEQUENCES: 197
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Townsend and Townsend and Crew LLP
 STREET: Two Embarcadero Center, Eighth Floor
 CITY: San Francisco
 STATE: CA
 COUNTRY: USA
 ZIP: 94111-3834
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FastSeq for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10/251,598
 FILING DATE: 19-Sep-2002
 CLASSIFICATION: <Unknown>
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US/09/091,952
 FILING DATE: 19-Apr-1999
 APPLICATION NUMBER: US 60/029,278
 FILING DATE: 28-Oct-1996
 APPLICATION NUMBER: PCT/US97/19381
 FILING DATE: 28-Oct-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: Smith, Timothy L.
 REGISTRATION NUMBER: 35,367
 REFERENCE/DOCKET NUMBER: 015280-297100US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 576-0200
 TELEFAX: (415) 576-0300
 TELEX: <Unknown>
 INFORMATION FOR SEQ ID NO: 193:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA
 FEATURE:
 NAME/KEY: -
 LOCATION: 1...18
 OTHER INFORMATION: Clone 47 reverse primer
 SEQUENCE DESCRIPTION: SEQ ID NO: 193:
 US-10-251-598-193
 Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 3e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 46 ACTGCTCTCGAGCTCTT 63
 |||||
 DB 1 AGTGCTCTCTAGCTCTT 18
 RESULT 546
 US-10-388-263-57/c
 Sequence 57, Application US/10388263
 Publication No. US20030228597A1
 GENERAL INFORMATION:
 APPLICANT: Cowsert, Lex M.
 APPLICANT: Baker, Brenda F.
 APPLICANT: McNeil, John


```
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 10432
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-10432

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTCA 886
DB 17 GACTTTGTGCTGTCA 1

RESULT 541
US-09-780-533A-2552/c
; Sequence 2552, Application US/09780533A
; Publication No. US2003006011A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggan, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2552
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2552

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCTT 983
DB 17 TTTAATTTCTTCCTT 3

FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Acomica Sequence Listing Engine
SEQ ID NO 10432
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-10432

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTCA 886
DB 17 GACTTTGTGCTGTCA 1

RESULT 541
US-09-780-533A-2552/c
; Sequence 2552, Application US/09780533A
; Publication No. US2003006011A1
; GENERAL INFORMATION:
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggan, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2552
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2552

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 969 TTTAATTTCTTCCTT 983
DB 17 TTTAATTTCTTCCTT 3
```

```
RESULT 542
US-09-067-638B-57/c
; Sequence 57, Application US/09067638B
; Patent No. US20020028923A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowseert
; APPLICANT: Brenda F. Baker
; APPLICANT: John McNeil
; APPLICANT: Susan M. Freier
; APPLICANT: Henri M. Saemor
; APPLICANT: Douglas G. Brooks
; APPLICANT: Cara Ohashi
; APPLICANT: Jacqueline R. Wyatt
; APPLICANT: Alexander Borchers
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Identification of Genetic
; TITLE OF INVENTION: Targets for Modulation By Oligonucleotides and
; TITLE OF INVENTION: Generation of Oligonucleotides for Gene
; TITLE OF INVENTION: Modulation
; NUMBER OF SEQUENCES: 112
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: WOODCOCK WASHBURN KURTZ
; ADDRESSEE: MACKIEWICZ & NORRIS LLP
; STREET: 1 LIBERTY PLACE 46TH FLOOR
; CITY: PHILADELPHIA
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; COMPUTER: IBM
; OPERATING SYSTEM: PC-Windows NT
; SOFTWARE: WORD PERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/067,638B
; FILING DATE: 28-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/081,483
; FILING DATE: 13-APR-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-2960
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 57:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-067-638B-57

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962
DB 18 TGTGAGACCAAGACCTG 1

RESULT 543
US-09-969-373-2034/c
; Sequence 2034, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Eifertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
```

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 314 GGGAAATGCCAGGGGGGCC 332
Db 19 GGGAAATGCCAGGAGGCC 1

RESULT 538
US-09-866-108-10432/c
; Sequence 10432, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTCA 886
Db 17 GACTTTTGTGCTGTCA 1

RESULT 539
US-10-052-545-19/c
; Sequence 19, Application US/10052545

; Publication No. US20020142392A1
; GENERAL INFORMATION:
; APPLICANT: Human Melanocyte stimulating hormone receptor
; TITLE OF INVENTION: Human Melanocyte stimulating hormone receptor
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Ave., N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/052,545
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/387,805
; FILING DATE: 21-FEB-95
; APPLICATION NUMBER: PCT/DK93/00273
; FILING DATE: 20-AUG-93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 1046/92
; FILING DATE: 21-AUG-92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 1118/92
; FILING DATE: 10-SEP-92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DK 0528/93
; FILING DATE: 05-MAY-93
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 1102.0160000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-10-052-545-19

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAAGAAATGCAG 216
Db 17 AGATCCAAGAAATGCAG 1

RESULT 540
US-10-723-361-10432/c
; Sequence 10432, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-462-039-25

Query Match          0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

QY 486 CATTGTGGTGGTTT 501
    |||||
Db 2 CATTGTGGTGGTTT 17

RESULT 535
US-10-462-039-26
; Sequence 26, Application US/10462039
; Publication No. US20040254131A1
; GENERAL INFORMATION:
; APPLICANT: Hormos Medical Corporation
; APPLICANT: Koulou, Markku
; APPLICANT: Tuohimaa, Jukka
; APPLICANT: Pesonen, Ullamari
; APPLICANT: Kallio, Jaana
; APPLICANT: Karvonen, Matti
; TITLE OF INVENTION: Method for Prevention or Treatment of Diseases or Disorders Related to Excessive Formation of Vascular Tissue or Blood Vessels
; FILE REFERENCE: 2630-123
; CURRENT APPLICATION NUMBER: US/10/462,039
; CURRENT FILING DATE: 2003-06-16
; PRIOR APPLICATION NUMBER: US 60/
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-462-039-26

Query Match          0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 16; Conservative 0;

QY 486 CATTGTGGTGGTTT 501
    |||||
Db 5 CATTGTGGTGGTTT 20

RESULT 536
US-10-830-569-140
; Sequence 140, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-447

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 140
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-830-569-140

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.5e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 314 GCGAATGCCAGGGGCC 332
    |||||
Db 1 GCGAAGUGCCAGGAGGCC 19

RESULT 537
US-10-830-569-447/c
; Sequence 447, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 447
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-447

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.5e+02;
```

```
RESULT 530
US-10-316-755-57/c
; Sequence 57, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-755-57

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 902 AGATCTTTTCTTCAAG 919
Db 19 AGCTCTTTTCTTCAAG 2

RESULT 531
US-10-316-755-202
; Sequence 202, Application US/10316755
; Publication No. US20040110152A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: MODULATION OF MATRIX METALLOPROTEINASE 11 EXPRESSION
; FILE REFERENCE: RTS-0381
; CURRENT APPLICATION NUMBER: US/10/316,755
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 277
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-755-202

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 2.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 902 AGATCTTTTCTTCAAG 919
Db 2 AGCTCTTTTCTTCAAG 19

RESULT 532
US-10-751-736-10777/c
; Sequence 10777, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AML00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10777
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10777

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 204 CCAAGAAATGCAGCACTTCTT 224
Db 21 CCAAGAGTGTGCACTTCTT 1

RESULT 533
US-10-751-736-10930/c
; Sequence 10930, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AML00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.8e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 205 CAAGAAATGCAGCACTTCTTG 225
Db 21 CCAAGAGTGTGCACTTCTTG 1

RESULT 534
US-10-462-039-25
; Sequence 25, Application US/10462039
; Publication No. US20040254131A1
; GENERAL INFORMATION:
; APPLICANT: Hormos Medical Corporation
; APPLICANT: Koulou, Markku
; APPLICANT: Tuohimaa, Jukka
; APPLICANT: Pesonen, Ullamari
; APPLICANT: Kallio, Jaana
; APPLICANT: Karvonen, Matti
; TITLE OF INVENTION: Method for Prevention or Treatment of Diseases or Disorders Relate
; FILE REFERENCE: 2630-123
; CURRENT APPLICATION NUMBER: US/10/462,039
; CURRENT FILING DATE: 2003-06-16
; PRIOR APPLICATION NUMBER: US 60/
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 42
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
```

```
Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1208 AGTATTGGAGGTATGATGAA 1227
Db 2 AATACTGGAGGTATGATGAA 21

RESULT 526
US-10-751-736-8707
; Sequence 8707, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8707
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8707

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1208 AGTATTGGAGGTATGATGAA 1227
Db 1 AATACTGGAGGTATGATGAA 20

RESULT 527
US-10-751-736-10057
; Sequence 10057, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10057
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10057

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1402 AGCAATAGCTGGTTGGTTG 1421
Db 2 AGCAATAGCTGGTTTAATTG 21
```

```
RESULT 528
US-10-751-736-10162
; Sequence 10162, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10162
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10162

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1395 ACTGAAAAGCAATAGCTGGT 1414
Db 2 ATTGAAGAGCAATAGCTGGT 21

RESULT 529
US-10-349-143-5754/c
; Sequence 5754, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5754
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURES:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-6628 for SEQ 1820,
US-10-349-143-5754

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1190 ACTTCTTTGTAGATAACC 1207
Db 18 ACTTCTTTGCAGATACC 1
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10054
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10054

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1398 GAAAAGCAATAGCTGTTT 1416
      ||| ||||| ||||| |||||
Db      1 GAAGAGCAATAGCTGTTT 19

RESULT 524
US-10-751-736-8698
; Sequence 8698, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8698
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8698

Query Match      0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1186 ACCTACTCTTTGTAGATAA 1205
      ||| ||||| ||||| |||||
Db      2 ACCTACTCTTTGTGCTAA 21

RESULT 525
US-10-751-736-8704
; Sequence 8704, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8704
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8704
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10012
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10012

Query Match      1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1185 GACCTACTCTTTGTAGA 1202
      ||| ||||| ||||| |||||
Db      1 GACCTACTCTTTGTAGA 18

RESULT 522
US-10-751-736-10058
; Sequence 10058, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10058
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10058

Query Match      1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.8e+02;
Matches 10; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY      1403 GCAATAGCTGTTGTTGTTT 1423
      ||| ||||| ||||| |||||
Db      1 GCAAAAGCUGGUUAAUUGUU 21

RESULT 523
US-10-751-736-10054
; Sequence 10054, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

	: : : : : : :	
Db	1 UAGACCUUCUUGUA 19	
RESULT 517		
US-10-751-736-9562		
; Sequence 9562, Application US/10751736		
; Publication No. US20040265230A1		
; GENERAL INFORMATION:		
; APPLICANT: Wyeth		
; APPLICANT: Martinez, Robert		
; APPLICANT: Brown, Eugene		
; APPLICANT: Liu, Wei		
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON		
; FILE REFERENCE: AM100927 (031896-002000)		
; CURRENT APPLICATION NUMBER: US/10/751,736		
; CURRENT FILING DATE: 2003-01-06		
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000		
; PRIOR FILING DATE: 2003-01-06		
; NUMBER OF SEQ ID NOS: 54873		
; SOFTWARE: PatentIn version 3.2		
; SEQ ID NO 9562		
; LENGTH: 21		
; TYPE: DNA		
; ORGANISM: homo sapiens		
US-10-751-736-9562		
Query Match	1.0%; Score 18.4; DB 1; Length 21;	
Best Local Similarity	95.0%; Pred. No. 1.5e+02;	
Matches	19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	1183 AGGACTTCTTTGTAGA 1202	
Db	1 AAGACTTCTTTGTAGA 20	
RESULT 518		
US-10-751-736-10009		
; Sequence 10009, Application US/10751736		
; Publication No. US20040265230A1		
; GENERAL INFORMATION:		
; APPLICANT: Wyeth		
; APPLICANT: Martinez, Robert		
; APPLICANT: Brown, Eugene		
; APPLICANT: Liu, Wei		
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON		
; FILE REFERENCE: AM100927 (031896-002000)		
; CURRENT APPLICATION NUMBER: US/10/751,736		
; CURRENT FILING DATE: 2003-01-06		
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000		
; PRIOR FILING DATE: 2003-01-06		
; NUMBER OF SEQ ID NOS: 54873		
; SOFTWARE: PatentIn version 3.2		
; SEQ ID NO 10009		
; LENGTH: 21		
; TYPE: DNA		
; ORGANISM: homo sapiens		
US-10-751-736-10009		
Query Match	1.0%; Score 18.4; DB 1; Length 21;	
Best Local Similarity	95.0%; Pred. No. 1.5e+02;	
Matches	19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
Qy	1183 AGGACTTCTTTGTAGA 1202	
Db	2 AAGACTTCTTTGTAGA 21	
RESULT 519		
US-10-751-736-10163		
; Sequence 10163, Application US/10751736		

	PRIOR FILING DATE:	2003-01-06		
	NUMBER OF SEQ ID NOS:	54873		
	SOFTWARE:	Patentin version 3.2		
	SEQ ID NO	11453		
	LENGTH:	21		
	TYPE:	RNA		
	ORGANISM:	RNai		
	US-10-751-736-11453			
	Query Match	1.1%; Score 19; DB 1; Length 21;		
	Best Local Similarity	73.7%; Pred. No. 1.2e+02;		
	Matches	14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;		
QY	606 TGAGGACGAATTCGGACT 624			
DB	: ::: :			
	UGAGGACGAUUCUGGACU 19			
	RESULT 513			
	US-10-751-736-11456			
	; Sequence 11456, Application US/10751736			
	; Publication No. US20040265230A1			
	; GENERAL INFORMATION:			
	; APPLICANT: Wyeth			
	; APPLICANT: Martinez, Robert			
	; APPLICANT: Brown, Eugene			
	; APPLICANT: Liu, Wei			
	; TITLE OF INVENTION: CANCERS			
	; FILE REFERENCE: AM100927 (031896-002000)			
	; CURRENT APPLICATION NUMBER: US/10/751,736			
	; CURRENT FILING DATE: 2003-01-06			
	; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
	; PRIOR FILING DATE: 2003-01-06			
	; NUMBER OF SEQ ID NOS: 54873			
	; SOFTWARE: Patentin version 3.2			
	; SEQ ID NO 11456			
	; LENGTH: 21			
	; TYPE: RNA			
	; ORGANISM: RNai			
	US-10-751-736-11456			
	Query Match	1.1%; Score 19; DB 1; Length 21;		
	Best Local Similarity	78.9%; Pred. No. 1.2e+02;		
	Matches	15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		
QY	609 GGAGCAATTCTGCATA 627			
DB	: ::: :			
	GAGCGAUUCUGGUACA 19			
	RESULT 514			
	US-10-751-736-11468			
	; Sequence 11468, Application US/10751736			
	; Publication No. US20040265230A1			
	; GENERAL INFORMATION:			
	; APPLICANT: Wyeth			
	; APPLICANT: Martinez, Robert			
	; APPLICANT: Brown, Eugene			
	; APPLICANT: Liu, Wei			
	; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
	; FILE REFERENCE: AM100927 (031896-002000)			
	; CURRENT APPLICATION NUMBER: US/10/751,736			
	; CURRENT FILING DATE: 2003-01-06			
	; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
	; PRIOR FILING DATE: 2003-01-06			
	; NUMBER OF SEQ ID NOS: 54873			
	; SOFTWARE: Patentin version 3.2			
	; SEQ ID NO 11468			
	; LENGTH: 21			
	; TYPE: RNA			
	; ORGANISM: RNai			
	US-10-751-736-11468			
	Query Match	1.1%; Score 19; DB 1; Length 21;		
	Best Local Similarity	78.9%; Pred. No. 1.2e+02;		
	Matches	15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;		
QY	609 GGAGCAATTCTGCATA 627			
DB	: ::: :			
	GAGCGAUUCUGGUACA 19			
	US-10-751-736-11468			
	Sequence 11468, Application US/10751736			
	Publication No. US20040265230A1			
	GENERAL INFORMATION:			
	APPLICANT: Wyeth			
	APPLICANT: Martinez, Robert			
	APPLICANT: Brown, Eugene			
	APPLICANT: Liu, Wei			
	TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
	FILE REFERENCE: AM100927 (031896-002000)			
	CURRENT APPLICATION NUMBER: US/10/751,736			
	CURRENT FILING DATE: 2003-01-06			
	PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
	PRIOR FILING DATE: 2003-01-06			
	NUMBER OF SEQ ID NOS: 54873			
	SOFTWARE: Patentin version 3.2			
	SEQ ID NO 11468			
	LENGTH: 21			
	TYPE: RNA			
	ORGANISM: RNai			
	US-10-751-736-11468			
	Query Match	1.1%; Score 19; DB 1; Length 21;		
	Best Local Similarity	57.9%; Pred. No. 1.2e+02;		
	Matches	11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;		
QY	1182 TAGGACCTTCTTTGTGTA 1200			


```
US-10-751-736-11438
; Sequence 11438, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11438
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11438

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      389 ACCGTGAGGATGTTGACTA 407
Db      1 ACCGUGAGGAGUGUGACUA 19

RESULT 509
US-10-751-736-11441
; Sequence 11441, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11441
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11441

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      396 CGAGTTGACTACGCAATC 414
Db      1 GGAUGUGACUACGCAATC 19

RESULT 510
US-10-751-736-11444
; Sequence 11444, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
```

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11444
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11444

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      399 TGTGTACTACGCAATCCGG 417
Db      1 UGUUGACUACGCAAUCCGG 19

RESULT 511
US-10-751-736-11450
; Sequence 11450, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11450
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11450

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      594 TGCACATTTGATGAGGAC 612
Db      1 UGCACAUUUCGAGGAC 19

RESULT 512
US-10-751-736-11453
; Sequence 11453, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11402

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 CACCTGACATGACCGTGA 395
DB 1 CACCGACAUGAACCGUGA 19

RESULT 504
US-10-751-736-11408
; Sequence 11408, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11408
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11408

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 429 AGTATGGAGTAATGTACC 447
DB 1 AGAUGGAGUAUGUUAACC 19

RESULT 505
US-10-751-736-11411
; Sequence 11411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11411
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11411

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 461 GCAAGATTACACAGGCAT 479
DB 1 GCAAGAUAUACACAGGCAU 19

RESULT 506
US-10-751-736-11426
; Sequence 11426, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11426
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11426

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 656 CTGCTGTTACGACATTCG 674
DB 1 CUGCUGUUCACGAGAUUGG 19

RESULT 507
US-10-751-736-11435
; Sequence 11435, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11435
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11435

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 384 CATGAACCGTGAGGATGT 402
DB 1 CAUGAACCGUGAGGAUGU 19

RESULT 508
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11381
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11381

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      390 CCGTGAGGATGTGACTAC 408
Db      1 CCGUGAGGAUGUUGACUAC 19

RESULT 500
US-10-751-736-11387
; Sequence 11387, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11387
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11387

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      457 TTCAGCAAGATTACACAG 475
Db      1 UUCAGCAAGAUUACACAG 19

RESULT 501
US-10-751-736-11393
; Sequence 11393, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11393
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11393

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 85.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy      810 AGAGAACCAACGCTTGCCA 828
Db      1 AGAGAACCAACGCUUGCCA 19

RESULT 502
US-10-751-736-11399
; Sequence 11399, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11399
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11399

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      816 CCAACGCTTGCCAAATCCT 834
Db      1 CCAACGCTUUGCCAAAUCCU 19

RESULT 503
US-10-751-736-11402
; Sequence 11402, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11402
; LENGTH: 21
```

Fri May 13 12:26:37 2005

```
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1332 CTATTCTTCCAAGACT 1350
DB 1 CUUUUUCUCCAGGAUCU 19

RESULT 495
US-10-751-736-11339
; Sequence 11339, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11339
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11339

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1335 TTCTTCTCAAGATCTAAC 1353
DB 1 UUUUUCUCCAGGAUCUAC 19

RESULT 496
US-10-751-736-11351
; Sequence 11351, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11351
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11351

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1486 TTTCGTATGCTCTCAGTCT 1504
DB 1 UUUUGUAUGUCCUCCAGUGU 19
```

```
RESULT 497
US-10-751-736-11363
; Sequence 11363, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11363
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11363

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1644 GTTACTTCAAGCAAGAT 1662
DB 1 GUUACCUCAAGCAAGAU 19

RESULT 498
US-10-751-736-11378
; Sequence 11378, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11378
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11378

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1724 CTTACTTCTGGCATACTA 1742
DB 1 CUUACUUCUGGCAUACUA 19

RESULT 499
US-10-751-736-11381
; Sequence 11381, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

; NUMBER OF SEQ ID NOS: 54873

Query Match 1.18:

Query Match

APPLICANT: Liu, Wei

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11267
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11267

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 179 GTGGAACCTTAATGAAGA 197
|:|||||:|:|:|:|:|:|:|:|:|
Db 1 GUGGAACCUAUAUGAAGA 19

RESULT 482
US-10-751-736-11270
; Sequence 11270, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11270
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11270

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 371 ATTACACACCTGACATGAA 389
|:|||||:|:|:|:|:|:|:|:|:|
Db 1 AUUACACACCUGACAUGAA 19

RESULT 483
US-10-751-736-11273
; Sequence 11273, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11273
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11273

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 371 ATTACACACCTGACATGAA 389
|:|||||:|:|:|:|:|:|:|:|:|
Db 1 AUUACACACCUGACAUGAA 19

RESULT 484
US-10-751-736-11276
; Sequence 11276, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11276
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11276

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 408 CGCAATCCGGAAGCTTTC 426
|:|||||:|:|:|:|:|:|:|:|:|
Db 1 CGCAAUCCGGAAGCUUUC 19

RESULT 485
US-10-751-736-11291
; Sequence 11291, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11291
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11291

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 732 CAATATGTCGACATCAAC 750
|:|||||:|:|:|:|:|:|:|:|:|
```

```

; Sequence 11237, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11237
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11237

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1362 ATATGACTTCTTCTACGCCAA 1380
Db 1 AUAAGACUCCUACGUCAAC 19

RESULT 478
US-10-751-736-11240
; Sequence 11240, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11240
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11240

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1368 CTTCTCTACTCCCAACGATC 1386
Db 1 CUUCCUACUCCACGUCAUC 19

RESULT 479
US-10-751-736-11258
; Sequence 11258, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11258
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11258

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 106 TTGTGTCGAGAGATACTTAG 124
Db 1 UUUGUGAGAGAUACUUG 19

RESULT 480
US-10-751-736-11264
; Sequence 11264, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11264
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11264

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 148 AACAACTTCCAGTGACAA 166
Db 1 AACAAACUCCAGUGACAA 19

RESULT 481
US-10-751-736-11267
; Sequence 11267, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06

```



```
; ORGANISM: RNAi
US-10-751-736-11222

Query Match
  1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1217 GGTATGATGAAGGAGACA 1235
Db 1 GGUAUGAAGGAGGAGACA 19

RESULT 473
US-10-751-736-11225
; Sequence 11225, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11225
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11225

Query Match
  1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1224 TGAAGGAGACAGATGATG 1242
Db 1 UGAAAGGAGACAGAUAG 19

RESULT 474
US-10-751-736-11228
; Sequence 11228, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11228
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11228

Query Match
  1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

; ORGANISM: RNAi
US-10-751-736-11223
; Sequence 11231, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11231
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11231

Query Match
  1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1265 TTACCAAGACTTCCAAGG 1283
Db 1 UUACCAAGACUCCAGG 19

RESULT 476
US-10-751-736-11234
; Sequence 11234, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11234
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11234

Query Match
  1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1302 TGCAGCTTCTATTCTAAA 1320
Db 1 UGCAGCTTCTATTCTAAA 19

RESULT 477
US-10-751-736-11237
```

;	PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000		
;	PRIOR FILING DATE: 2003-01-06		
;	NUMBER OF SEQ ID NOS: 54873		
;	SOFTWARE: PatentIn version 3.2		
;	SEQ ID NO 11216		
;	LENGTH: 21		
;	TYPE: RNA		
;	ORGANISM: RNA1		
US-10-751-736-11216			
Query Match	1.1%;	Score 19; DB 1; Length 21;	
Best Local Similarity	57.9%;	Pred. No. 1.2e+02;	
Matches 11; Conservative	8; Mismatches	0; Indels	0; Gaps 0;
Qy	1187 CCTACTCTCTTTGTAGATAA	1205	
	:::		
Db	1 CCUACUUCUUGAUAUA	19	
RESULT 471			
US-10-751-736-11219			
;	Sequence 11219, Application US/10751736		
;	Publication No. US20040265230A1		
;	GENERAL INFORMATION:		
;	APPLICANT: Wyeth		
;	APPLICANT: Martinez, Robert		
;	APPLICANT: Brown, Eugene		
;	APPLICANT: Liu, Wei		
;	TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON		
;	TITLE OF INVENTION: CANCERS		
;	FILE REFERENCE: AM100927 (031896-002000)		
;	CURRENT APPLICATION NUMBER: US/10/751,736		
;	CURRENT FILING DATE: 2003-01-06		
;	PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000		
;	PRIOR FILING DATE: 2003-01-06		
;	NUMBER OF SEQ ID NOS: 54873		
;	SOFTWARE: PatentIn version 3.2		
;	SEQ ID NO 11219		
;	LENGTH: 21		
;	TYPE: RNA		
;	ORGANISM: RNA1		
US-10-751-736-11219			
Query Match	1.1%;	Score 19; DB 1; Length 21;	
Best Local Similarity	68.4%;	Pred. No. 1.2e+02;	
Matches 13; Conservative	6; Mismatches	0; Indels	0; Gaps 0;
Qy	1203 TRACCAGTATTGGAGGTAT	1221	
	:::		
Db	1 UAACCAUAUUGGAGGUUA	19	
RESULT 472			
US-10-751-736-11222			
;	Sequence 11222, Application US/10751736		
;	Publication No. US20040265230A1		
;	GENERAL INFORMATION:		
;	APPLICANT: Wyeth		
;	APPLICANT: Martinez, Robert		
;	APPLICANT: Brown, Eugene		
;	APPLICANT: Liu, Wei		
;	TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON		
;	TITLE OF INVENTION: CANCERS		
;	FILE REFERENCE: AM100927 (031896-002000)		
;	CURRENT APPLICATION NUMBER: US/10/751,736		
;	CURRENT FILING DATE: 2003-01-06		
;	PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000		
;	PRIOR FILING DATE: 2003-01-06		
;	NUMBER OF SEQ ID NOS: 54873		
;	SOFTWARE: PatentIn version 3.2		
;	SEQ ID NO 11222		
;	LENGTH: 21		
;	TYPE: RNA		

Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 623 CTACACATTGAGGCGAC 641
|:|||||:|||||
Db 1 CUACACAUCAGGAGCGAC 19

RESULT 464

US-10-751-736-11171
; Sequence 11171, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11171
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11171

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 705 TCCAAAGGCTGTATGTTTC 723
:|||||:|:|:|
Db 1 UCCAAAGGCGUGAUGUUC 19

RESULT 465

US-10-751-736-11183
; Sequence 11183, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11183
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11183

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 813 GAACCAACGCTTGCCAAAT 831
|||||:|:|:|
Db 1 GAACCAACGCGUCCCAAU 19

RESULT 466

US-10-751-736-11195
; Sequence 11195, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11195
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11195

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 938 AGGTTTCTGAGAGACCAAA 956
|:|:|:|:|:|:|
Db 1 AGGUUUCUGAGAGACCAAA 19

RESULT 467

US-10-751-736-11198
; Sequence 11198, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11198
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11198

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 948 GAGACCAAGACCGAGTTT 966
|:|:|:|:|:|:|
Db 1 GAGACCAAGACCGAGUUT 19

RESULT 468

US-10-751-736-11207
; Sequence 11207, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11150
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11150

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 609 GGACGAATTCGGACTACA 627
Db 1 GGACGAUAUUCUGGACUACA 19

RESULT 462
US-10-751-736-11156
; Sequence 11156, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11156
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11156

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 615 ATTCGGACTACATTCACA 633
Db 1 AUUCUGGACUACACAUUCA 19

RESULT 463
US-10-751-736-11159
; Sequence 11159, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11159
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11159

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11144
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11144

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 594 TGCACATTCGATGAGGAC 612
Db 1 UGCACAAUUCUGGAGGAC 19

RESULT 460
US-10-751-736-11147
; Sequence 11147, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11147
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11147

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 606 TGAGGACGAATTCGGACT 624
Db 1 UGAGGACGAUAUUCUGGACU 19

RESULT 461
US-10-751-736-11150
; Sequence 11150, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11150
```

```
RESULT 455
US-10-751-736-11129
; Sequence 11129, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11129
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11129

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      455  AATTCAGCAAGATTAAAC 473
Db      1  AAUUCAGCAAGAUAAAC 19
      ||:|||||:|||||
      ||:|||||:|||||

RESULT 456
US-10-751-736-11132
; Sequence 11132, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11132
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11132

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      467  TTAACACAGGCGATGCTGA 485
Db      1  UUAACACAGGCAUGGCUGA 19
      ||:|||||:|||||
      ||:|||||:|||||

RESULT 457
US-10-751-736-11138
; Sequence 11138, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11138
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11138

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      537  TGGCAAAAGGTGGATCCTA 555
Db      1  UGGCAAAAGGUGGAAUCCUA 19
      ||:|||||:|||||
      ||:|||||:|||||

RESULT 458
US-10-751-736-11141
; Sequence 11141, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11141
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11141

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy      571  CCTCGATCTGCGATTGGAG 589
Db      1  CCUGGAUCUGGCAUUGGAG 19
      ||:|||||:|||||
      ||:|||||:|||||

RESULT 459
US-10-751-736-11144
; Sequence 11144, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; GENERAL INFORMATION:
```

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11108

LENGTH: 21

TYPE: RNA

ORGANISM: RNAI

US-10-751-736-11108

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 73.7%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 ATCAATAATTACACACCTG 382

Db 1 AUCAAUAUACACACCCUG 19

RESULT 451

US-10-751-736-11111

Sequence 11111, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

TITLE OF INVENTION: CANCERS

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11111

LENGTH: 21

TYPE: RNA

ORGANISM: RNAI

US-10-751-736-11111

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 73.7%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 384 CATGAACCGTGAGGATTT 402

Db 1 CAUGAACCGUGAGGAUGU 19

RESULT 452

US-10-751-736-11114

Sequence 11114, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

TITLE OF INVENTION: CANCERS

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11114

LENGTH: 21

TYPE: RNA

ORGANISM: RNAI

US-10-751-736-11114

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 73.7%; Pred. No. 1.2e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 389 ACCGTGAGGATGTCCTA 407

Db 1 ACCGUGAGGAGUGUACUA 19

RESULT 453

US-10-751-736-11117

Sequence 11117, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

TITLE OF INVENTION: CANCERS

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11117

LENGTH: 21

TYPE: RNA

ORGANISM: RNAI

US-10-751-736-11117

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 73.7%; Pred. No. 1.2e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 396 GGATGTTGACTACGCAATC 414

Db 1 GGAUGUGUACUACGCAUC 19

RESULT 454

US-10-751-736-11120

Sequence 11120, Application US/10751736

Publication No. US20040265230A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Martinez, Robert

APPLICANT: Brown, Eugene

APPLICANT: Liu, Wei

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

TITLE OF INVENTION: CANCERS

FILE REFERENCE: AM100927 (031896-002000)

CURRENT APPLICATION NUMBER: US/10/751,736

CURRENT FILING DATE: 2003-01-06

PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

PRIOR FILING DATE: 2003-01-06

NUMBER OF SEQ ID NOS: 54873

SOFTWARE: PatentIn version 3.2

SEQ ID NO 11120

LENGTH: 21

TYPE: RNA

ORGANISM: RNAI

US-10-751-736-11120

Query Match 1.1%; Score 19; DB 1; Length 21;

Best Local Similarity 73.7%; Pred. No. 1.2e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 399 TGTGACTACGCAATCCGG 417

Db 1 UGUUGACUACGCAUCCGG 19

```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11099
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11090

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 146 TAAACAACTTCAGTGAC 164
Db 1 UAAACAACTUCGAGGAC 19

RESULT 447
US-10-751-736-11099
; Sequence 11099, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11099
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11099

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 272 TGCACGCACCTCGATGG 290
Db 1 UGCACGCACCCUGAUGG 19

RESULT 448
US-10-751-736-11102
; Sequence 11102, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11102
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11102

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 341 GGAACATTATATCACCTA 359
Db 1 GGAACCAUAUAUACCUA 19

RESULT 449
US-10-751-736-11105
; Sequence 11105, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11105
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11105

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 344 AACATTATATCACCTACAG 362
Db 1 AACAUUAUACCUACAG 19

RESULT 450
US-10-751-736-11108
; Sequence 11108, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

Fri May 13 12:26:37 2005

chong906-1.rnpb

US-10-751-736-11054

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 1271 AGAAGTTCAGGAATCGG 1289
DB 1 AGAACUCCAGGAUCCG 19

RESULT 442

US-10-751-736-11060
; Sequence 11060, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11060
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11060

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
QY 1406 ATAGCTGGTTGTGTGTTA 1424
DB 1 AUAGCGUUGUUGUUGUA 19

RESULT 443

US-10-751-736-11081
; Sequence 11081, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11081
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11081

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
QY 17 AGTTTCTTCTAATACTGCT 35

DB 1 AGUUUCUUAUACUGCU 19

RESULT 444

US-10-751-736-11084
; Sequence 11084, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11084
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11084

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 71 ACAGCTCTACAAGCCTGGA 89
DB 1 ACAGCUCUACAGCCUGGA 19

RESULT 445

US-10-751-736-11087
; Sequence 11087, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11087
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11087

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 144 GATAAACCAACTTCAGTG 162
DB 1 GAUAAACAAACUCCAGUG 19

RESULT 446

US-10-751-736-11090
; Sequence 11090, Application US/10751736


```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11030
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11030

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 917 AAGACAGGTTCTTCGGCT 935
Db      1 AAGACAGGTCUUCUGGCU 19

RESULT 438
US-10-751-736-11036
; Sequence 11036, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11036
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11036

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 991 ACCGTGCCATCTGGCATG 1009
Db      1 ACCUGCCAUCCUGGCAUUG 19

RESULT 439
US-10-751-736-11048
; Sequence 11048, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11048
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11048

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GTATTGGAGGTATCATGAA 1227
Db      1 GUAUUGGAGGUUGAUGAA 19

RESULT 440
US-10-751-736-11051
; Sequence 11051, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11051
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11051

Query Match          1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1259 AACTGATTACCAAGACTT 1277
Db      1 AACUGAUUACCAAGACUU 19

RESULT 441
US-10-751-736-11054
; Sequence 11054, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11054
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
```

Fri May 13 12:26:37 2005

```

US-10-751-736-11021
; Sequence 11021, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11021
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11021

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      829 AATCTGACAAATTCAGAAC 847
Db      1 AAUCCUGACAAUUCUGAAC 19

RESULT 436
US-10-751-736-11027
; Sequence 11027, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11027
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11027

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      844 GAACCAAGCTCTGTGACC 862
Db      1 GAACCAAGCTCTGTGACC 19

RESULT 437
US-10-751-736-11030
; Sequence 11030, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
US-10-751-736-11015
; Sequence 11015, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11015
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11015

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy      754 TTTCGCTCTCTGCTGATG 772
Db      1 UUUGGCCUCUCUGUGAUG 19

RESULT 434
US-10-751-736-11018
; Sequence 11018, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11018
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11018

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      819 ACGTTGCCAAATCTGTGAC 837
Db      1 ACGUUGCCAAUUCUGAC 19

RESULT 435

```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10958
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10958

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 429 AGTATGGAGTAATGTACC 447
Db 1 AGAUGGAGUAUGUACC 19

RESULT 429

US-10-751-736-10961
; Sequence 10961, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10961
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10961

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 461 GCAAGATTAAACACAGGCAT 479
Db 1 GCAAGAUUAACACAGGCAU 19

RESULT 430

US-10-751-736-10988
; Sequence 10988, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10988
; LENGTH: 21

; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10988

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 656 CTGCTGTTACGAGATTGG 674
Db 1 CUGCUGUUCACGAGAUUGG 19

RESULT 431

US-10-751-736-10991
; Sequence 10991, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10991
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10991

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 666 CGAGATTGGCCATTCCTTA 684
Db 1 CGAGAUUGGCCAUUCCUUA 19

RESULT 432

US-10-751-736-11000
; Sequence 11000, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11000
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11000

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

; APPLICANT: Liu, Wei
 ; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
 ; TITLE OF INVENTION: CANCERS
 ; FILE REFERENCE: AM100927 (031896-002000)
 ; CURRENT APPLICATION NUMBER: US/10/751,736
 ;

```
; SEQ ID NO 10886
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10886

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1261 CTGATTACCAAGACTTCC 1279
DB 1 CUGAUUACCAAGACUCC 19

RESULT 420
US-10-751-736-10901
; Sequence 10901, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Martinez, Robert
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10901
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10901

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1407 TAGCTGGTTGCTGTAG 1425
DB 1 UAGCUGUUGGUGUAG 19

RESULT 421
US-10-751-736-10919
; Sequence 10919, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10919
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10919

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1689 GTTGCTTCTAACATCCTT 1707
DB 1 GUUGCUCCUACCAUCCUU 19

Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1689 GTTGCTTCTAACATCCTT 1707
DB 1 GUUGCUCCUACCAUCCUU 19

RESULT 422
US-10-751-736-10928
; Sequence 10928, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10928
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10928

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 47 CTGCTTGTGGAGCTCTCC 65
DB 1 CUGCTUCUGGAGCUCUCC 19

RESULT 423
US-10-751-736-10931
; Sequence 10931, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10931
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10931

Query Match
Best Local Similarity 1.1%; Score 19; DB 1; Length 21;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 207 AGAAATGCAGCACTTCTTG 225
DB 1 AGAAUUGCAGCACUCCUUG 19
```

Fri May 13 12:26:37 2005

```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10862
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10862

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1012 GCTGCTTATGAATTCAG 1030
DB 1 GCUGCUUAUGAAUUGAAG 19

RESULT 416
US-10-751-736-10874
; Sequence 10874, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10874
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10874

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1088 GACCAGAGCCAAATATCC 1106
DB 1 GACCAGAGCCAAAUUCC 19

RESULT 417
US-10-751-736-10877
; Sequence 10877, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

```

```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10877
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10877

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1206 CCAGTATTGGAGGTATGAT 1224
DB 1 CCAGAUUGGAGGUAUGAU 19

RESULT 418
US-10-751-736-10883
; Sequence 10883, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10883
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10883

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1260 ACTGATTACCAAGACTTC 1278
DB 1 ACUGAUUACCAAGAACUUC 19

RESULT 419
US-10-751-736-10886
; Sequence 10886, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2

```

```
Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTCAGAACCGCTCTCTGT 858
Db 1 UUCAGAACCGACUCUCUGU 19

RESULT 411
US-10-751-736-10847
; Sequence 10847, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10847
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10847

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 918 AGACAGGTTCTTCTGCGTG 936
Db 1 AGACAGGUUCUUCUGGCGU 19

RESULT 412
US-10-751-736-10850
; Sequence 10850, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10850
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10850

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 919 GACAGGTTCTTCTGCTGA 937
Db 1 GACAGGUUCUUCUGGCGUGA 19

RESULT 413
US-10-751-736-10853
; Sequence 10853, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10853
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10853

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGTTCGTGAGAGACCAAG 957
Db 1 GGUUCUGAGAGACCAAG 19

RESULT 414
US-10-751-736-10859
; Sequence 10859, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10859
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10859

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 992 CCTTGCCATCTGCCATTGA 1010
Db 1 CCUUGCCAUCUGGCAUGA 19

RESULT 415
US-10-751-736-10862
; Sequence 10862, Application US/10751736
; Publication No. US20040265230A1
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10826
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10826

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      810 AGAGACCAACGCTTGCCCA 828
Db      1 AGAGACCAACGCTTGCCCA 19

RESULT 407
US-10-751-736-10832
; Sequence 10832, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10832
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10832

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      816 CCAACGCTTGCCCAATCCT 834
Db      1 CCAACGCTTGCCCAAUCCU 19

RESULT 408
US-10-751-736-10838
; Sequence 10838, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10838
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10838

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      830 ATCTGACAAATTCAGAAC 848
Db      1 AUCCUGACAAUUCAGAAC 19

RESULT 409
US-10-751-736-10841
; Sequence 10841, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10841
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10841

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      831 TCCTGACAAATTCAGAACCA 849
Db      1 UCCUGACAAUUCAGAACCA 19

RESULT 410
US-10-751-736-10844
; Sequence 10844, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10844
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10844
```


QY 457 TTCAGCAAGATTACACAG 475
:::|||||:::|||||
DB 1 UUCAGCAAGUAUACACAG 19

RESULT 402

US-10-751-736-10802
; Sequence 10802, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10802
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10802

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 465 GATTAAACACAGCATGGCT 483
:::|||||:::|||||
DB 1 GAUUAACACAGCAUGGCU 19

RESULT 403

US-10-751-736-10808
; Sequence 10808, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10808
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10808

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 616 TTCAGCAATACATTCAG 634
:::|||||:::|||||
DB 1 UUCUGACUAACACAUUCAG 19

RESULT 404

US-10-751-736-10814

; Sequence 10814, Application US/10751736
; Publication No. US20040265230A1

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10814
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10814

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.2e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 645 CTTGTTCTCTCACTGCTGT 663
:::|||||:::|||||
DB 1 CUUGUCCUACUGUGUU 19

RESULT 405

US-10-751-736-10823
; Sequence 10823, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10823
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10823

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.2e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 750 CACATTTGGCCTCTGCT 768
|||:::|||||:::|||||
DB 1 CACAUUUGCCUCUCUGCU 19

RESULT 406

US-10-751-736-10826
; Sequence 10826, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10781
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10781

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 369 CCGTACACCTGACATG 387
Db 1 UUAUACACCCUGACAUG 19

RESULT 398
US-10-751-736-10784
; Sequence 10784, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10784
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10784

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 372 TTACACACCTGACATGAAC 390
Db 1 UUAACACCCUGACAUGAAC 19

RESULT 399
US-10-751-736-10787
; Sequence 10787, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10787
; LENGTH: 21
; TYPE: RNA

; ORGANISM: RNAi
US-10-751-736-10787

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 390 CCGTGAGGATGTGTGACTAC 408
Db 1 CCGUGAGGAGUUGUACUAC 19

RESULT 400
US-10-751-736-10793
; Sequence 10793, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10793
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10793

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 420 AGCTTTCCAGTATGAGT 438
Db 1 AGCUUCCAGUUGGAGU 19

RESULT 401
US-10-751-736-10799
; Sequence 10799, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10799
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10799

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
RESULT 393
US-10-751-736-10010
; Sequence 10010, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10010
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10010

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCTACTTCTTTGTAGAT 1203
      |||||:||||:||||:||||:
DB 2 GACCUACUUCUUGUAGAU 20

RESULT 394
US-10-751-736-10760
; Sequence 10760, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10760
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10760

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 72 CAGCTCTACAGCCCTGGAA 90
      |||||:||||:||||:||||:
DB 1 CAGCUACACAGCCUGAA 19

RESULT 395
US-10-751-736-10763
; Sequence 10763, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10763
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10763

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.2e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 96 TAATGTGCTATTGTGTGAG 114
      |||||:||||:||||:||||:
DB 1 UAAUGUGCUAUUGUGAG 19

RESULT 396
US-10-751-736-10769
; Sequence 10769, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10769
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10769

Query Match      1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 149 ACAAACTTCAGTCACAAA 167
      |||||:||||:||||:||||:
DB 1 ACAAACTTCAGTCACAAA 19

RESULT 397
US-10-751-736-10781
; Sequence 10781, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
```

```

; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
US-0619-906-11

```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19: Conservative 0; Mismatches 0; Indels

Qy 208 GAAATGCAGCACTTCTTGG 226
pb 19 GAAATGCAGCACTTCTTGG 1

```

RESULT 389
US-10-619-906-12/c
, Sequence 12, Application US/10619906
, Publication No. US20040087533A1
, GENERAL INFORMATION:
, APPLICANT: Index Pharmaceuticals
, TITLE OF INVENTION: New Compound
, FILE REFERENCE: 50299
, CURRENT APPLICATION NUMBER: US/10/6
, CURRENT FILING DATE: 2003-07-16
, NUMBER OF SEQ ID NOS: 23
, SOFTWARE: PatentIn version 3.1
, SEQ ID NO 12
, LENGTH: 19
, TYPE: DNA
, ORGANISM: Artificial
, FEATURE:
, NAME/KEY: misc_feature
, LOCATION: (1)..(19)
, OTHER INFORMATION: SEQ ID NO. 12,
US-10-619-906-12

```

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels

Qy 946 GAGAGACCAAGACCAAGTG 964
|||
Db 19 GAGAGACCAAGACCAAGTG 1

```

RESULT 390
US/10-619-906-13/c
; Sequence 13, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 13, antisense
US-10-619-906-13

```

Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%;	Pred. No. 95;		

	Matches	19;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
Qy	913	TTCAAAGACAGGTTCTTCT	931							
Dh	19	TTCAAAGACAGGTTCTTCT	1							

```

RESULT 391
US-10-619-906-14/c
; Sequence 14, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 14, antisense oligonucleotide
US-10-619-906-14

```

Query Match	1.1%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%;	Pred. No. 95;		
Matches 19;	Conservative	0;	Mismatches	0;
Indels	0;	Gaps	0;	

Qy 1231 AGACAGATGATGGACCCTG 1249
|||
Dh 19 AGACAGATGATGGACCCTG 1

```

RESULT 392
US-10-872-063-160
; Sequence 160, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRIANT, John L.
; APPLICANT: BRYANT, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; TITLE OF INVENTION: Recurrence
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 160
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-160

```

Query Match	1.1%	Score 19;	DB 1;	Length 19;
Best Local Similarity	100.0%	Pred. No. 95;		
Matches 18. Conservative	0;	Mismatches	0;	Gaps 0;

Qy 816 CCAACGCTTGCCAAATCCT 834

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 512 CTCATGGAGACTTCATGCG 530
DB 19 CTCATGGAGACTTCATGCG 1

RESULT 384

US-10-619-906-7/c
; Sequence 7, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 7, antisense oligonucleotide
US-10-619-906-7

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 855 CTGTGACCCCAATTGAGT 873
DB 19 CTGTGACCCCAATTGAGT 1

RESULT 385

US-10-619-906-8/c
; Sequence 8, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 8, antisense oligonucleotide
US-10-619-906-8

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 TAGGACCTACTCTTTGTA 1200
DB 19 TAGGACCTACTCTTTGTA 1

RESULT 386

US-10-619-906-9/c

; Sequence 9, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 9, antisense oligonucleotide
US-10-619-906-9

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 AACCAACGCTTGCCAAATC 832
DB 19 AACCAACGCTTGCCAAATC 1

RESULT 387

US-10-619-906-10/c
; Sequence 10, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO. 10, antisense oligonucleotide
US-10-619-906-10

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1097 CAAATTATCCCAAGAGCAT 1115
DB 19 CAAATTATCCCAAGAGCAT 1

RESULT 388

US-10-619-906-11/c
; Sequence 11, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11

Fri May 13 12:26:37 2005

```

; Sequence 11465, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11465
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11465

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e-02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      774 CATACGTGGCATTCACTGCTCT 794
DB      1 CAUACGGGCAUUCAGUCCUU 21

RESULT 380
US-10-619-906-3/c
; Sequence 3, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.3, antisense oligonucleotide
US-10-619-906-3

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      751 ACATTTCGCTCTCTGCTG 769
DB      19 ACATTTCGCTCTCTGCTG 1

RESULT 381
US-10-619-906-4/c
; Sequence 4, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23

```

```

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.4, antisense oligonucleotide
US-10-619-906-4

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      137 GCCTTGAGATAAACAACT 155
DB      19 GCCTTGAGATAAACAACT 1

RESULT 382
US-10-906-5/c
; Sequence 5, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.5, antisense oligonucleotide
US-10-619-906-5

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      355 ACCTACAGATCAATAATT 373
DB      19 ACCTACAGATCAATAATT 1

RESULT 383
US-10-619-906-6/c
; Sequence 6, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.6, antisense oligonucleotide
US-10-619-906-6

```



```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11345
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11345

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 52.4%; Pred. No. 1.1e+02;
Matches 11; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 1409 GCTGGTTTGGTTGTAGAAAT 1429
Db 1 GCUGGUUGUGUUGAUAU 21

RESULT 371
US-10-751-736-11354
; Sequence 11354, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11354
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11354

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1493 TGTCTCAGTGATCCACTACT 1513
Db 1 UGUCCUCAGUGUACCAUAU 21

RESULT 372
US-10-751-736-11357
; Sequence 11357, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11357
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11357

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1506 CCACTACTTAGAGATATGTAT 1526
Db 1 CCACUACUAGAGUAUGUAU 21

RESULT 373
US-10-751-736-11360
; Sequence 11360, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11360
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11360

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1602 ATTGTCCATTCTTGCTTGACT 1622
Db 1 AUUGUCCAUUCUUGCUUGUAU 21

RESULT 374
US-10-751-736-11366
; Sequence 11366, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11366
; LENGTH: 21
; TYPE: RNA
```


Matches	12;	Conservative	8;	Mismatches	1;	Indels	0;	Gaps	0;
Qy	685	GGTCTTGCCCAATCTAGTGAT	705						
Db	1	GGUCUUGGCCCAUCUAGUGUU	21						
RESULT 366									
US-10-751-736-11288									
Sequence 11288, Application US/10751736									
Publication No. US20040265230A1									
GENERAL INFORMATION:									
APPLICANT: Wyeth									
APPLICANT: Martinez, Robert									
APPLICANT: Brown, Eugene									
APPLICANT: Liu, Wei									
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON									
TITLE OF INVENTION: CANCERS									
FILE REFERENCE: AM100927 (031896-002000)									
CURRENT APPLICATION NUMBER: US/10/751,736									
CURRENT FILING DATE: 2003-01-06									
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000									
PRIOR FILING DATE: 2003-01-06									
NUMBER OF SEQ ID NOS: 54873									
SOFTWARE: Patent in version 3.2									
SEQ ID NO 11288									
LENGTH: 21									
TYPE: RNA									
ORGANISM: RNAi									
US-10-751-736-11288									
Query Match 1.1%; Score 19.4; DB 1; Length 21;									
Best Local Similarity 66.7%; Pred. No. 1.1e+02;									
Matches	14;	Conservative	6;	Mismatches	1;	Indels	0;	Gaps	0;
Qy	701	GTGATCCAAAGCGTGTAATGT	721						
Db	1	GUGAUCCAAGGCGUGUAAUU	21						
RESULT 367									
US-10-751-736-11318									
Sequence 11318, Application US/10751736.									
Publication No. US20040265230A1									
GENERAL INFORMATION:									
APPLICANT: Wyeth									
APPLICANT: Martinez, Robert									
APPLICANT: Brown, Eugene									
APPLICANT: Liu, Wei									
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON									
TITLE OF INVENTION: CANCERS									
FILE REFERENCE: AM100927 (031896-002000)									
CURRENT APPLICATION NUMBER: US/10/751,736									
CURRENT FILING DATE: 2003-01-06									
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000									
PRIOR FILING DATE: 2003-01-06									
NUMBER OF SEQ ID NOS: 54873									
SOFTWARE: Patent in version 3.2									
SEQ ID NO 11318									
LENGTH: 21									
TYPE: RNA									
ORGANISM: RNAi									
US-10-751-736-11318									
Query Match 1.1%; Score 19.4; DB 1; Length 21;									
Best Local Similarity 66.7%; Pred. No. 1.1e+02;									
Matches	14;	Conservative	6;	Mismatches	1;	Indels	0;	Gaps	0;
Qy	1201	GATAACCAAGTATTCGAGGTAT	1221						
Db	1	GAUAAACCAAGUAGGAGGUU	21						

```

RESULT 368
US-10-751-736-11327
; Sequence 11327, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11327
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11327

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy    1221 TGATGAAGGACAGACAGATGAT 1241
Db          :||:|||:|||:|||:|||:|||:

RESULT 369
US-10-751-736-11342
; Sequence 11342, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11342
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11342

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy    1365 TGACTTCTTACTCCAAGGTAT 1385
Db          :|||:|||:|||:|||:|||:|||:

RESULT 370
US-10-751-736-11345
; Sequence 11345, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11252
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11252

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 31 CTGCTCCTGCGAGGCACTGCT 51
Db 1 CUGCUCCUGAGCCACAGUU 21

RESULT 362
US-10-751-736-11255
; Sequence 11255, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11255
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11255

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 98 ATGTGCTATTGTGAGAGAT 118
Db 1 AUGUGCUUUUGUGAGAGUU 21

RESULT 363
US-10-751-736-11261
; Sequence 11261, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11261
```

```
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11261

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 135 TGGCCTTGAGATAAACAACT 155
Db 1 UGGCCUUGAGUAAACAAAUU 21

RESULT 364
US-10-751-736-11282
; Sequence 11282, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11282

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 626 CACATTCAGGAGGCACAACT 646
Db 1 CACAUCAGGAGGCACAAAUU 21

RESULT 365
US-10-751-736-11285
; Sequence 11285, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11285
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11285

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
```

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11246
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11246

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 52.4%; Pred. No. 1.1e+02;
Matches 11; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 1717 AATTACTTACTTCTGGCAT 1737
   |||::|||::|||::|||::
Db 1 AAUUAUACUACUUCUGGCUU 21

RESULT 360
US-10-751-736-11249
; Sequence 11249, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11249
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11249

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 28 ATACTGCTCTCGAGGCCACT 48
   |||::|||::|||::|||::
Db 1 AUACUGUCUCCUGCAGGCCAUU 21

RESULT 361
US-10-751-736-11252
; Sequence 11252, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11249
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11249

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1023 AATTGAAGCCAGAAATCAAGT 1043
   |||::|||::|||::|||::
Db 1 AAUUGAGCCAGAAUACUAAU 21

RESULT 359
US-10-751-736-11246
; Sequence 11246, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11192
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11192

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 921 CAGGTTCTTCTGGCTGAAGGT 941
   |||::|||::|||::|||::
Db 1 CAGGUUCUUCUGGUGAAGU 21

RESULT 358
US-10-751-736-11210
; Sequence 11210, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11210
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11210

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1023 AATTGAAGCCAGAAATCAAGT 1043
   |||::|||::|||::|||::
Db 1 AAUUGAGCCAGAAUACUAAU 21

RESULT 359
US-10-751-736-11246
; Sequence 11246, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11192
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11192
```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11069
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11069

Query Match
; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1509 CTACTAGAGATATGATCAT 1529
Db 1 CUACUAGAGAUUGUACUU 21

RESULT 353
US-10-751-736-11135
; Sequence 11135, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11135
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11135

Query Match
; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 511 GCTCATGGAGACTTCATGCT 531
Db 1 GCUCAGGAGACUUCUACU 21

RESULT 354
US-10-751-736-11162
; Sequence 11162, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11162
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11162
```

```

Query Match
; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 637 GGCACAACTGTTCTCCTACT 657
Db 1 GGCACAACTGUUCUCCAUU 21

RESULT 355
US-10-751-736-11165
; Sequence 11165, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11165
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11165

Query Match
; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 669 GATTGGCATTCTTAGTCT 689
Db 1 GAUUGGCAUUCUUGU 21

RESULT 356
US-10-751-736-11180
; Sequence 11180, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11180
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11180

Query Match
; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 774 CATACGTGGCATTGCTCCT 794
Db 1 CAUUGGCAUUCUUGU 21
```

```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10997
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-110997

Query Match          1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 696 TTCTAGTGATCAACAAAGGCTGT 716
DB 1 UUCUAGUGAUGCAACAAAGGCUUU 21

RESULT 349
US-10-751-736-11003
; Sequence 11003, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11003
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11003

Query Match          1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 734 AATATGTGCACATCAACACAT 754
DB 1 AAUUGUGACAUCAACACUU 21

RESULT 350
US-10-751-736-11039
; Sequence 11039, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11039
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11039

Query Match          1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 1.1e+02;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1000 TCTGGCATTGAAGCTGCTTAT 1020
DB 1 UCUGGCAUUGAAGCTGCUUUU 21

RESULT 351
US-10-751-736-11063
; Sequence 11063, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11063
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11063

Query Match          1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1484 TATTGTCTATGCTCCTCAGTGT 1504
DB 1 UAUUUGCUAUGUCCUCAGUUU 21

RESULT 352
US-10-751-736-11069
; Sequence 11069, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

US-10-751-736-10904

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 1597 CTCCTAATGTCCTCTGCT 1617

DB 1 CUCUAAUUGUCCAUUCUGGUU 21

RESULT 344

US-10-751-736-10910
; Sequence 10910, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10910
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10910

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1642 TAGTTACCTTCAAGCAAGAT 1662

DB 1 UAGUUAUCCUCAAAGCAAGU 21

RESULT 345

US-10-751-736-10925
; Sequence 10925, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10925
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10925

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 42 GGCCACTGCTTCTGGAGCTCT 62

DB 1 GGCCACUGCUUGGAGGUU 21

RESULT 346

US-10-751-736-10949
; Sequence 10949, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10949
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10949

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.1e+02;
Matches 16; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 379 CCTGACATGAACCGTGAGAT 399

DB 1 CCUGACUAGAACCGUGAGUU 21

RESULT 347

US-10-751-736-10952
; Sequence 10952, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10952
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10952

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 386 TGAACCGTGAGGATGTTGACT 406

DB 1 UGAACCGUGAGGUGUUAU 21

RESULT 348

US-10-751-736-10997
; Sequence 10997, Application US/10751736

```

; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10856
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10856

Query Match
Best Local Similarity 52.4%; Score 19.4; DB 1; Length 21;
Matches 11; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 974 TTCTTCTTATGCGCAACT 994
Db 1 UUUUUUUUUAUGGCAACUU 21

RESULT 340
US-10-751-736-10880
; Sequence 10880, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10880
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10880

Query Match
Best Local Similarity 81.0%; Score 19.4; DB 1; Length 21;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1228 AGGACGACGATGACCCCT 1248
Db 1 AGGACGACGAUGGACCCU 21

RESULT 341
US-10-751-736-10892
; Sequence 10892, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

```

```

; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10892
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10892

Query Match
Best Local Similarity 61.9%; Score 19.4; DB 1; Length 21;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1363 TATGACTTCTACTCCAACT 1383
Db 1 UAUGACUUCUACUCCAAUU 21

RESULT 342
US-10-751-736-10895
; Sequence 10895, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10895
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10895

Query Match
Best Local Similarity 57.1%; Score 19.4; DB 1; Length 21;
Matches 12; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1402 AGCAATAGCTGTTGGTTGT 1422
Db 1 AGCAUAGCUGUUGGUUUU 21

RESULT 343
US-10-751-736-10904
; Sequence 10904, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10904
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi

```

Fri May 13 12:26:37 2005

```

US-10-751-736-10829
; Sequence 10829, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 10829
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10829

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.1e+02;
Matches 17; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      811 GAGAACCAACGCTTGCCAAAT 831
DB      1 GAGAACCAACGCTTGCCAAAU 21

RESULT 338
US-10-751-736-10835
; Sequence 10835, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 10835
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10835

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      820 CGCTTGCCAAATCCTGCAAT 840
DB      1 CGCUUCCAAUCCUGACAUU 21

RESULT 339
US-10-751-736-10856
; Sequence 10856, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene

```

```

US-10-751-736-10790
; Sequence 10790, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 10790
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10790

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY      413 TCCGGAAGCTTCCCAAGTAT 433
DB      1 UCCGGAAGCUUCCAGAUU 21

RESULT 336
US-10-751-736-10796
; Sequence 10796, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 10796
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10796

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY      421 GCTTCCCAAGTATGAGTAAT 441
DB      1 GCUUCCAAUAGUAGAUU 21

RESULT 337

```


; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11471
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11471

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 815 ACCAAGCGTGGCAAACTCT 834
DB 1 ACCAAGCGUUGCAAAUCCU 20

RESULT 331

US-10-751-736-11477
; Sequence 11477, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11477
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11477

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 952 CCAAGACGAGTGTAAATTT 971
DB 1 CCAAGACGAGUGUUAUUU 20

RESULT 332

US-10-751-736-10754
; Sequence 10754, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10754
; LENGTH: 21

; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10754

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 1.1e+02;
Matches 10; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 18 GTTTCCTCTAATAGTCTCT 38
DB 1 GUUUCUUAUAUCGUCUU 21

RESULT 333

US-10-751-736-10775
; Sequence 10775, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10775
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10775

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.1e+02;
Matches 15; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 203 TCCAGAAATGCGACACTTCT 223
DB 1 UCCAGAAAUUGAGCACUUUU 21

RESULT 334

US-10-751-736-10778
; Sequence 10778, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10778
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10778

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 1.1e+02;
Matches 14; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 11459
LENGTH: 21
TYPE: RNA
ORGANISM: RNai
US-10-751-736-11459

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 671 TTGGCCATTCTTAGGTCCTT 690
DB 1 UUGGCCAUUCCUAGGUCUU 20

RESULT 329
US-10-751-736-11462
Sequence 11462, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 11462
LENGTH: 21
TYPE: RNA
ORGANISM: RNai
US-10-751-736-11462

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 744 CATCAACACATTTCGCTCT 763
DB 1 CAUCAACAUAUUGCCUCU 20

RESULT 330
US-10-751-736-11471
Sequence 11471, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736

US-10-751-736-11420
Sequence 11420, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 11420
LENGTH: 21
TYPE: RNA
ORGANISM: RNai
US-10-751-736-11420

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 600 TTTCGATGAGGAGCAATTC 619
DB 1 UUCUGAUGAGGAGCAUAUCU 20

RESULT 327
US-10-751-736-11432
Sequence 11432, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 11432
LENGTH: 21
TYPE: RNA
ORGANISM: RNai
US-10-751-736-11432

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCAACACATTTCGCTCT 765
DB 1 UCAACACAUAUUGCCUCU 20

RESULT 328
US-10-751-736-11459
Sequence 11459, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth

```
; SEQ ID NO 11369
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11369

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1688 AGTTGCTTCTCAACATCCTT 1707
Db 1 AGUUGCUCCUACAUCCUU 20

RESULT 322
US-10-751-736-11375
; Sequence 11375, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11375
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11375

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1722 TACTTACTTCTGCGTAACT 1741
Db 1 UACUUAUUCUGGCAUAACU 20

RESULT 323
US-10-751-736-11390
; Sequence 11390, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11390
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11390

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1688 AGTTGCTTCTCAACATCCTT 1707
Db 1 AGUUGCUCCUACAUCCUU 20

RESULT 322
US-10-751-736-11414
; Sequence 11414, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11414
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11414

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 464 AGATTAAACACAGCGATGCGT 483
Db 1 AGAUUAAACACAGCGAUGGCU 20

RESULT 325
US-10-751-736-11417
; Sequence 11417, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11417
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11417

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 598 CATTTCGATGAGGACGAATT 617
Db 1 CAUUUGAUGAGGACGAUAU 20
```

```

; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11315
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11315

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1191 CTTCTTGTAGATAACCACT 1210
DB      1 CUUCUUGUGAGUAACCAGU 20

RESULT 318
US-10-751-736-11321
; Sequence 11321, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11321
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11321

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1205 ACCAGTATGAGGTATGAT 1224
DB      1 ACCAGUAUUGGAGGUAUGAU 20

RESULT 319
US-10-751-736-11333
; Sequence 11333, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

```

```

; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11333
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11333

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY      1329 CTACTATTCTTCCAAGGAT 1348
DB      1 CUACUAUUUCUCCAAAGGAU 20

RESULT 320
US-10-751-736-11348
; Sequence 11348, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11348
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11348

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY      1479 TTGCATATTTCCTATGTCCT 1498
DB      1 UUGCAUAUUGCUAUGUCCU 20

RESULT 321
US-10-751-736-11369
; Sequence 11369, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2

```

```
Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 771 TCACATACGTGCGCATTTCAGT 790
DB 1 UGACAUACGUGGCAUUCAGU 20

RESULT 313
US-10-751-736-11186
; Sequence 11186, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Martinez, Robert
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11186
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11186

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 815 ACCAACGCTTGCCAAATCCT 834
DB 1 ACCAACGCTTGCCAAAUCCU 20

RESULT 314
US-10-751-736-11189
; Sequence 11189, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11189
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11189

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 837 CAATTCAAGACGACTCTCT 856
DB 1 CAATTCAAGACGACTCTCT 856

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1184 GGACCTACTCTTTGTAGAT 1203
DB 1 GGACCUACUUCUUGUAGAU 20

RESULT 317
US-10-751-736-11315
; Sequence 11315, Application US/10751736
; Publication No. US20040265230A1
```

```
Db 1 CAUUCAGACACGACUCUCU 20

RESULT 315
US-10-751-736-11204
; Sequence 11204, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11204
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11204

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 952 CCAAAGACGAGTGTAAATTT 971
DB 1 CCAAAGACGAGUGUUAUUU 20

RESULT 316
US-10-751-736-11312
; Sequence 11312, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11312
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11312

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1184 GGACCTACTCTTTGTAGAT 1203
DB 1 GGACCUACUUCUUGUAGAU 20

RESULT 317
US-10-751-736-11315
; Sequence 11315, Application US/10751736
; Publication No. US20040265230A1
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11126
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11126

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 419 AAGCTTTCGAAGTATGAGT 438
Db 1 AAGCUUCCAAAGUAGGAGU 20

RESULT 309
US-10-751-736-11153
; Sequence 11153, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11153
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11153

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 612 CGAAUUCUGGACUACAUU 631
Db 1 CGAAUUCUGGACUACAUU 20

RESULT 310
US-10-751-736-11168
; Sequence 11168, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11168
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11168
```

```
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 671 TTGGCCATTCCTTAGGTCTT 690
Db 1 UUGGCCAUUCCUAGGUCUU 20
```

```
RESULT 311
US-10-751-736-11174
; Sequence 11174, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11174
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11174
```

```
Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 744 CATCAACACATTTCGCTCT 763
Db 1 CAUCACACAUUUGCCUCU 20
```

```
RESULT 312
US-10-751-736-11177
; Sequence 11177, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11177
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11177
```

```
QY 1501 GTGTACCACTACTTACAGAT 1520
      :|||:||||:||||:
Db 1 GUGUACCAUACUAGAGAU 20

RESULT 304
US-10-751-736-11075
; Sequence 11075, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11075
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11075

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAGTTGCTTCT 1698
      :|||:||||:||||:
Db 1 UGCUCUGUAGUUGCUCCU 20

RESULT 305
US-10-751-736-11078
; Sequence 11078, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11078
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11078

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1703 TCCTTGGACTGAGAAATAT 1722
      :|||:||||:||||:
Db 1 UCCUUGGACUGAGAAAUAU 20

RESULT 306
US-10-751-736-11093
; Sequence 11093, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11093
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11093

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 267 GATGATGCACGCACCTCGAT 286
      :|||:||||:||||:
Db 1 GAUGAUGCACGCACCCUGAU 20

RESULT 307
US-10-751-736-11096
; Sequence 11096, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11096
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11096

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 269 TGATGCACGCACCTCGATGT 288
      :|||:||||:||||:
Db 1 UGAUGCACGCACCCUGAU 20

RESULT 308
US-10-751-736-11126
; Sequence 11126, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
```

		; ORGANISM: RNAi			
		US-10-751-736-11042			
Query Match		1.1%; Score 20; DB 1; Length 21;			
Best Local Similarity		60.0%; Pred. No. 89;			
Matches		12; Conservative		0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	
				0; Indels	
				0; Gaps	


```
RESULT 295
US-10-751-736-10982
; Sequence 10982, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10982
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10982

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 641 CAACCTGCTTCTCACTGCT 660
Db 1 CAACUUGUCCUCACUGCU 20

RESULT 296
US-10-751-736-10994
; Sequence 10994, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10994
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10994

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

Qy 678 TTCCTTAGCTTGTGCCATT 697
Db 1 UUCUUGGUCUUGGCCAUU 20

RESULT 297
US-10-751-736-11006
; Sequence 11006, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11006
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11006

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 746 TCAACACATTTCGCCTCTCT 765
Db 1 UCAACACAUUUGCCUCUCU 20

RESULT 298
US-10-751-736-11009
; Sequence 11009, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11009
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11009

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;
Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

Qy 749 ACACATTCGCCTCTCTGCT 768
Db 1 ACACAUUUGCCUCUCUCU 20

RESULT 299
US-10-751-736-11012
; Sequence 11012, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10964

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 464 AGATTAAACACAGGCGATGGCT 483
DB 1 AGAUUAACACAGGCGAUGGCU 20

RESULT 291
US-10-751-736-10967
; Sequence 10967, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10967
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10967

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 598 CATTTCGATGAGGACGAATT 617
DB 1 CAUUCGAGGAGGACGAUU 20

RESULT 292
US-10-751-736-10970
; Sequence 10970, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10970
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10970

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 89;

```

```

Matches 13; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 600 TTTTCGATGAGGACGAATTCT 619
DB 1 UUUUGAUGAGGACGAUUUCU 20

RESULT 293
US-10-751-736-10973
; Sequence 10973, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10973
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10973

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 628 CATTGAGGAGGACAAACTT 647
DB 1 CAUUCGAGGAGGACAAACUU 20

RESULT 294
US-10-751-736-10979
; Sequence 10979, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10979
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10979

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 634 GGAGGCACAAACTTGTCTCT 653
DB 1 GGAGGCACAAACUUGUUCU 20

```

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10916
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10916

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 0; Indels 0; Gaps 0;

QY 1676 GCATGCTCTGTAGTTGCTT 1695
DB 1 GCAUGCUCUGAAGUUGCUU 20

RESULT 287
US-10-751-736-10922
; Sequence 10922, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10922
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10922

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 70.0%; Pred. No. 89;
Matches 14; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1701 CATCCTTGACTGAGAAAT 1720
DB 1 CAUCCUGGACUGAGAAAU 20

RESULT 288
US-10-751-736-10940
; Sequence 10940, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10940
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10940

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 362 GAATCAATAATTACACACT 381
DB 1 GAUCCAAUAUACACACCU 20

RESULT 289
US-10-751-736-10955
; Sequence 10955, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10955
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10955

Query Match          1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 412 ATCCGAAAGCTTCCAAAGT 431
DB 1 AUCCGAAAGCUUCCAAAGU 20

RESULT 290
US-10-751-736-10964
; Sequence 10964, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10964
```

Fri May 13 12:26:37 2005

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 0; Indels 0; Gaps 0;

QY 644 ACTTGTCTCTACTCTCTCT 663
DB 1 ACUUGUCCACACUCGUGU 20

RESULT 282
US-10-751-736-10871
; Sequence 10871, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10871
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10871

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1083 TTTAAGACGACGACCAAT 1102
DB 1 UUUAGACGACGACCAAUU 20

RESULT 283
US-10-751-736-10889
; Sequence 10889, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10889
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10889

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 1298 TTGATGAGTCTTCTATCT 1317
DB 1 UUGAUGCAGCUCUUAUUCU 20

RESULT 284

US-10-751-736-10907
; Sequence 10907, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10907
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10907

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 89;
Matches 10; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 1603 TTGTCCATTCTTGCTGACT 1622
DB 1 UUGUCCAUCUCUGCUGACU 20

RESULT 285

US-10-751-736-10913
; Sequence 10913, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10913
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10913

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 89;
Matches 11; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1665 TTCTATTGAGCAGTCCTCT 1684
DB 1 UUCUUAUUUGAAGCAGCUCU 20

RESULT 286

US-10-751-736-10916
; Sequence 10916, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:

; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-36

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 391 CQTGAGGATGTTGACTACGC 410
Db 20 CQTGAGGATGTTGACTACGC 1

RESULT 278

US-10-751-736-10757
; Sequence 10757, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10757
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10757

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 89;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 29 TACTGCTCTGCAGGCCACT 48
Db 1 UACUGCUCCUGCAGGCCACU 20

RESULT 279

US-10-751-736-10766
; Sequence 10766, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10766
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10766

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 99 TGTGCTATTTGCTGAGAGAT 118
Db 1 UGUGCUAUUUGUGAGAGAU 20

RESULT 280

US-10-751-736-10772
; Sequence 10772, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10772
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10772

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 89;
Matches 16; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 202 ATCCAAGAAATGCAGCACTT 221
Db 1 AUCCAAGAAAUCCAGCACUU 20

RESULT 281

US-10-751-736-10811
; Sequence 10811, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10811
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10811

Fri May 13 12:26:37 2005

chong906-1.rnpb

```
US-10-719-900-879471
Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1241 TGGACCTGTTATCCCAACTGAT 1265
      ||||| ||||| ||||| |||||
Db 1 TGGACCTGCTTACCCCAAGCTGAT 25

RESULT 273
US-10-719-900-908158
; Sequence 908158, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 908158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-908158

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1197 TGTAGATAACCACTATTTGGAGGTAT 1221
      ||||| ||||| ||||| |||||
Db 1 TGTGGATAAACAGTACTGGAGGTAT 25

RESULT 274
US-10-719-900-967442/c
; Sequence 967442, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 967442
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-967442

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 161 TGACAAAATGAATATAGTGGAAA 185
      ||||| ||||| ||||| |||||
Db 25 TGACAAGATGAATCTATTGGAAA 1

RESULT 275
US-10-809-189-125366
; Sequence 125366, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125366

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1276 TTCCAAGGATCGGCGCTAAATTTG 1300
      ||||| ||||| ||||| |||||
Db 1 TTCCAGGAATCAAGCTAAATTTG 25

RESULT 276
US-10-274-095-35
; Sequence 35, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-35

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 44 CCACCTGCTTCTGGAGCTCTT 63
      ||||| ||||| ||||| |||||
Db 1 CCACCTGCTTCTGGAGCTCTT 20

RESULT 277
US-10-274-095-36/c
; Sequence 36, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
```

```

US-10-751-736-11479
; Sequence 11479, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11479
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11479

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 TACACACCTGACATGAACCGT 393
DB 1 TACACACCTGACATGAACCGT 21

RESULT 269
US-10-751-736-11482
; Sequence 11482, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11482
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11482

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1180 TATAGGACCTACTTCTTTGTA 1200
DB 1 TATAGGACCTACTTCTTTGTA 21

RESULT 270
US-10-719-900-174230
; Sequence 174230, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1

```

```

; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174230
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174230

Query Match          1.2%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1290 GCCTAAAATTGATGCAGTCTTCTA 1313
DB 2 GCCTAAAATTGATGCAGTCTTCTA 25

RESULT 271
US-10-809-189-127779
; Sequence 127779, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-127779

Query Match          1.1%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTTCAGTCCCTGTATGGAG 802
DB 3 GGCATTTCATCCCTGTATGGAG 24

RESULT 272
US-10-719-900-879471
; Sequence 879471, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 879471
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

```

Fri May 13 12:26:37 2005

; TYPE: DNA		1.2%; Score 21; DB 1; Length 21;	
; ORGANISM: homo sapiens		Best Local Similarity 100.0%; Pred. No. 65;	
US-10-751-736-11467		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Query Match			
; Sequence 11473, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11470			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11470			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11473, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11473			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11473			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11473, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11473			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11473			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11473, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11473			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11473			

; TYPE: DNA		1.2%; Score 21; DB 1; Length 21;	
; ORGANISM: homo sapiens		Best Local Similarity 100.0%; Pred. No. 65;	
US-10-751-736-11467		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Query Match			
; Sequence 11473, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11470			
; LENGTH: 21			
; TYPE: RNA			
; ORGANISM: RNAi			
US-10-751-736-11474			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 76.2%; Pred. No. 65;		Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11476, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11476			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11476			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11476, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11476			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11476			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11476, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11476			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11476			
Query Match		1.2%; Score 21; DB 1; Length 21;	
Best Local Similarity 100.0%; Pred. No. 65;		Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
; Sequence 11476, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; TITLE OF INVENTION: CANCERS			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: Patentin version 3.2			
; SEQ ID NO 11476			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11476			

RESULT 2


```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11455
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11455

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 607 GAGGACGAATTCGACTACA 627
DB 1 GAGGACGAATTCGACTACA 21

RESULT 260
US-10-751-736-11458
; Sequence 11458, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11458
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11458

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 GATTGGCCATTCCTTAGGTCT 689
DB 1 GATTGGCCATTCCTTAGGTCT 21

RESULT 261
US-10-751-736-11461
; Sequence 11461, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11461
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11461

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 GACATCAACACATTTGCGCTC 762
DB 1 GACATCAACACATTTGCGCTC 21

RESULT 262
US-10-751-736-11464
; Sequence 11464, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11464
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11464

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 772 GACATACGTGGCATTTCAGTCC 792
DB 1 GACATACGTGGCATTTCAGTCC 21

RESULT 263
US-10-751-736-11467
; Sequence 11467, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11467
; LENGTH: 21
```

```

Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GATGTTGACTACGCAATCCGG 417
DB 1 GATGTTGACTACGCAATCCGG 21

RESULT 255
US-10-751-736-11446
; Sequence 11446, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11446
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11446

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 GACTACGCAATCCGGAAGCT 423
DB 1 GACTACGCAATCCGGAAGCT 21

RESULT 256
US-10-751-736-11447
; Sequence 11447, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11447
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11447

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 405 CTACGCAATCCGGAAGCTTT 425
DB 1 CUACGCAUCCGGAAGCUUU 21

```

```

RESULT 257
US-10-751-736-11449
; Sequence 11449, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11449
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11449

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 GATGCACATTCGATGAGGAC 612
DB 1 GATGCACATTCGATGAGGAC 21

RESULT 258
US-10-751-736-11452
; Sequence 11452, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11452
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11452

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GATGAGGACGAATTCGGACT 624
DB 1 GATGAGGACGAATTCGGACT 21

RESULT 259
US-10-751-736-11455
; Sequence 11455, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

```

Query Match 1.2%; Score 21; DB 1; Length 21;

b	1	CATTTCGATGAGGACGAATTC	21
RESULT 246			
US-10-751-736-11422			
; Sequence 11422, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11422			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11422			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 65;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	641	CAAACTGTTCCTCACTGCTG	661
DB	1	CAAACTGTTCCTCACTGCTG	21
RESULT 247			
US-10-751-736-11423			
; Sequence 11423, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11423			
; LENGTH: 21			
; TYPE: RNA			
; ORGANISM: RNA1			
US-10-751-736-11423			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 57.1%; Pred. No. 65;			
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;			
QY	643	AACCTGTTCCTCACTGCTGT	663
DB	1	AACUUGUUCUCACUGUGUU	21
RESULT 248			
US-10-751-736-11425			
; Sequence 11425, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11423			
; LENGTH: 21			
; TYPE: RNA			
; ORGANISM: RNA1			
US-10-751-736-11423			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 57.1%; Pred. No. 65;			
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;			
QY	643	AACCTGTTCCTCACTGCTGT	663
DB	1	AACUUGUUCUCACUGUGUU	21
RESULT 249			
US-10-751-736-11428			
; Sequence 11428, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11428			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11428			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 65;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	654	CACTGCTGTTCAAGGCTTGG	674
DB	1	CACTGCTGTTCAAGGCTTGG	21
RESULT 250			
US-10-751-736-11431			
; Sequence 11431, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11428			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11428			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 65;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	694	CATTCTAGTGTCCAAAGGCT	714
DB	1	CATTCTAGTGTCCAAAGGCT	21
RESULT 250			
US-10-751-736-11431			
; Sequence 11431, Application US/10751736			
; Publication No. US20040265230A1			
; GENERAL INFORMATION:			
; APPLICANT: Wyeth			
; APPLICANT: Martinez, Robert			
; APPLICANT: Brown, Eugene			
; APPLICANT: Liu, Wei			
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON			
; FILE REFERENCE: AM100927 (031896-002000)			
; CURRENT APPLICATION NUMBER: US/10/751,736			
; CURRENT FILING DATE: 2003-01-06			
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000			
; PRIOR FILING DATE: 2003-01-06			
; NUMBER OF SEQ ID NOS: 54873			
; SOFTWARE: PatentIn version 3.2			
; SEQ ID NO 11428			
; LENGTH: 21			
; TYPE: DNA			
; ORGANISM: homo sapiens			
US-10-751-736-11428			
Query Match 1.2%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 65;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	694	CATTCTAGTGTCCAAAGGCT	714
DB	1	CATTCTAGTGTCCAAAGGCT	21

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11407
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11407

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 462 CAAGATTAAACACAGGCATGCC 482
DB 1 CAAGATTAAACACAGGCATGCC 21

RESULT 244
US-10-751-736-11416
; Sequence 11416, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11416
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11416

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 596 CACATTCGATGAGGACGAAT 616
DB 1 CACATTCGATGAGGACGAAT 21

RESULT 245
US-10-751-736-11419
; Sequence 11419, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11419
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11419

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 598 CATTTCGATGAGGACGAATTC 618
DB 1 CATTTCGATGAGGACGAATTC 618
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11407
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11407

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 427 CAAGTATGAGTAATGTTACC 447
DB 1 CAAGTATGAGTAATGTTACC 21

RESULT 242
US-10-751-736-11410
; Sequence 11410, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11410
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11410

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 459 CAGCAAGATTAAACACAGGCAT 479
DB 1 CAGCAAGATTAAACACAGGCAT 21

RESULT 243
US-10-751-736-11413
; Sequence 11413, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11413
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11413
```

Fri May 13 12:26:37 2005

```
; Sequence 11395, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11395
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11395

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      809 AAGAGAACCAACGCTTGCCAA 829
Db      1 AAGAGAACCAACGCTTGCCAA 21

RESULT 238
US-10-751-736-11398
; Sequence 11398, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11398
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11398

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      814 AACCAACGCTTGCCAAATCCT 834
Db      1 AACCAACGCTTGCCAAATCCT 21

RESULT 239
US-10-751-736-11401
; Sequence 11401, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11401
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11401

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      375 CACACCTGACATGACCGTGA 395
Db      1 CACACCTGACATGACCGTGA 21

RESULT 240
US-10-751-736-11404
; Sequence 11404, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11404
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11404

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      384 CATGAACCGTGAGGATGTGA 404
Db      1 CATGAACCGTGAGGATGTGA 21

RESULT 241
US-10-751-736-11407
; Sequence 11407, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11407
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11407

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; ORGANISM: homo sapiens
US-10-751-736-11380

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 388 AACCGTGAGGATGTTGACTAC 408
Db 1 AACCGTGAGGATGTTGACTAC 21

RESULT 233
US-10-751-736-11383
; Sequence 11383, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11383
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11383

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 AAGCTTTCACAGTATGGAGTA 439
Db 1 AAGCTTTCACAGTATGGAGTA 21

RESULT 234
US-10-751-736-11386
; Sequence 11386, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11386
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11386

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 AATTCAGCAAGATTAAACAG 475
Db 1 AATTCAGCAAGATTAAACAG 21

RESULT 235
US-10-751-736-11389
; Sequence 11389, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11389
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11389

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 642 AAACCTTGTTCTCCTCACTGCTGT 662
Db 1 AAACCTTGTTCTCCTCACTGCTGT 21

RESULT 236
US-10-751-736-11392
; Sequence 11392, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11392
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11392

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 808 AAAGAGAACCAACGCTTGCCA 828
Db 1 AAAGAGAACCAACGCTTGCCA 21

RESULT 237
US-10-751-736-11395
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11371
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11371

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1698 TAACATCCTTGACTGAGAAA 1718
Db 1 TAACATCCTTGACTGAGAAA 21

RESULT 229
US-10-751-736-11372
; Sequence 11372, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11372
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Rna1
US-10-751-736-11372

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 65;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1700 ACATCCTTGACTGAGAAATT 1720
Db 1 ACAUCCUUGGACUGAGAAUU 21

RESULT 230
US-10-751-736-11374
; Sequence 11374, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11374
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11374

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 TATACTTACTTCTGGCATAAC 1740
Db 1 TATACTTACTTCTGGCATAAC 21

RESULT 231
US-10-751-736-11377
; Sequence 11377, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11377
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11377

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1722 TACTTACTTCTGGCATAACTA 1742
Db 1 TACTTACTTCTGGCATAACTA 21

RESULT 232
US-10-751-736-11380
; Sequence 11380, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11380
; LENGTH: 21
; TYPE: DNA
```



```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1504 TACCACACTTAGAGATATGT 1524
      |||||
Db 1 TACCACACTTAGAGATATGT 21

RESULT 224
US-10-751-736-11359
; Sequence 11359, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11359
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11359

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1600 TAATTGTCCATCTTGGCTTGA 1620
      |||||
Db 1 TAATTGTCCATCTTGGCTTGA 21

RESULT 225
US-10-751-736-11362
; Sequence 11362, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11362
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11362

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1642 TAGTTACCTTCAAGCAAGAT 1662
      |||||
Db 1 TAGTTACCTTCAAGCAAGAT 21
```

```
RESULT 226
US-10-751-736-11365
; Sequence 11365, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11365
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11365

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1668 TATTTGAAGCATGCTCTGTAA 1688
      |||||
Db 1 TATTTGAAGCATGCTCTGTAA 21

RESULT 227
US-10-751-736-11368
; Sequence 11368, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11368
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11368

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1686 TAAGTTGCTTCTTAACATCCT 1706
      |||||
Db 1 TAAGTTGCTTCTTAACATCCT 21

RESULT 228
US-10-751-736-11371
; Sequence 11371, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```



```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11332
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11332

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1333 TATTCTTCCCAAGGATCTTAC 1353
Db 1 TATTCTTCCCAAGGATCTTAC 21

RESULT 218
US-10-751-736-11341
; Sequence 11341, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11341
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11341

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1363 TATGACTTCTCTACTCCAAGT 1383
Db 1 TATGACTTCTCTACTCCAAGT 21

RESULT 219
US-10-751-736-11344
; Sequence 11344, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)

```

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11332
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11332

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1337 TACTACTATTCTTCCCAAGGA 1347
Db 1 TACTACTATTCTTCCCAAGGA 21

RESULT 216
US-10-751-736-11335
; Sequence 11335, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11335
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11335

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TACTATTCTTCTCCCAAGGATCT 1350
Db 1 TACTATTCTTCTCCCAAGGATCT 21

RESULT 217
US-10-751-736-11338
; Sequence 11338, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:

```

Fri May 13 12:26:37 2005

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11317
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11317

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1199 TAGATAACCAAGTATTGGAGGT 1219
Db 1 TAGATAACCAAGTATTGGAGGT 21

RESULT 211
US-10-751-736-11320
; Sequence 11320, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11320
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11320

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 TAACCAAGTATTGGAGGTATGA 1223
Db 1 TAACCAAGTATTGGAGGTATGA 21

RESULT 212
US-10-751-736-11323
; Sequence 11323, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11323
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11323
```

```
Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1210 TATTGGAGGTATGATGAAGG 1230
Db 1 TATTGGAGGTATGATGAAGG 21

RESULT 213
US-10-751-736-11326
; Sequence 11326, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11326
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11326

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1219 TATGATGAAGGAGACAGATG 1239
Db 1 TATGATGAAGGAGACAGATG 21

RESULT 214
US-10-751-736-11329
; Sequence 11329, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11329
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11329

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1266 TACCAAGAACTTCCAAGGAAT 1286
Db 1 TACCAAGAACTTCCAAGGAAT 21
```

```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11305
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11305

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1085 TAAGACCAGAGCAAAATTATC 1105
DB 1 TAAGACCAGAGCAAAATTATC 21

RESULT 207
US-10-751-736-11308
; Sequence 11308, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11308
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11308

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1180 TATAGGACCTACTTCTTTGTGA 1200
DB 1 TATAGGACCTACTTCTTTGTGA 21

RESULT 208
US-10-751-736-11311
; Sequence 11311, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11311
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11311

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 TAGGACCTACTTCTTTGTAGA 1202
DB 1 TAGGACCTACTTCTTTGTAGA 21

RESULT 209
US-10-751-736-11314
; Sequence 11314, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11314
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11314

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1189 TACTTCTTTGTAGATAACCAG 1209
DB 1 TACTTCTTTGTAGATAACCAG 21

RESULT 210
US-10-751-736-11317
; Sequence 11317, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

```
US-10-751-736-11290
Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 730 TACAATATGTCGACATCAAC 750
|||||
Db 1 TACAATATGTCGACATCAAC 21

RESULT 202
US-10-751-736-11293
; Sequence 11293, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11293
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11293

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 736 TATGTCGACATCAACACATTT 756
|||||
Db 1 TATGTCGACATCAACACATTT 21

RESULT 203
US-10-751-736-11296
; Sequence 11296, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11296
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11296

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 TAATTTCTTCTTATGCCAA 991
|||||
Db 1 TAATTTCTTCTTATGCCAA 21

US-10-751-736-11299
Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 983 TATGCCCAACCTTGCCTCATCTG 1003
|||||
Db 1 TATGCCCAACCTTGCCTCATCTG 21

RESULT 205
US-10-751-736-11302
; Sequence 11302, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11302
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11302

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1077 TAGCAATTTAAGACCAGAGCC 1097
|||||
Db 1 TAGCAATTTAAGACCAGAGCC 21

RESULT 206
US-10-751-736-11305
; Sequence 11305, Application US/10751736
```

; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11279
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11279

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 470 ACACAGGCATGCTGACATTT 490
DB 1 ACACAGGCAUGCUGACAUUU 21

RESULT 198

US-10-751-736-11281
; Sequence 11281, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11281
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11281

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 624 TACACATTCAGGAGGCACAAA 644
DB 1 TACACATTCAGGAGGCACAAA 21

RESULT 199

US-10-751-736-11284
; Sequence 11284, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11284
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11284

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 683 TAGGTCCTTGGCCATCTTAGTG 703
DB 1 TAGGTCCTTGGCCATCTTAGTG 21

RESULT 200

US-10-751-736-11287
; Sequence 11287, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11287
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11287

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 699 TAGTGATCCAAAGGCTGTAAT 719
DB 1 TAGTGATCCAAAGGCTGTAAT 21

RESULT 201

US-10-751-736-11290
; Sequence 11290, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11290
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

```
QY 177 TAGTGGAACTTAATGAAGGA 197
| | | | | | | | | | | | | | |
Db 1 TAGTGGAACTTAATGAAGGA 21

RESULT 193
US-10-751-736-11269
; Sequence 11269, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11269

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 369 TAATTACACACCTGACATGAA 389
| | | | | | | | | | | | | | |
Db 1 TAATTACACACCTGACATGAA 21

RESULT 194
US-10-751-736-11272
; Sequence 11272, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11272
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11272

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 373 TACACACCTGACATGAACCGT 393
| | | | | | | | | | | | | | |
Db 1 TACACACCTGACATGAACCGT 21

RESULT 195
US-10-751-736-11275
; Sequence 11275, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11275
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11275

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 406 TAGCGAATCCGGAAGCTTTC 426
| | | | | | | | | | | | | | |
Db 1 TAGCGAATCCGGAAGCTTTC 21

RESULT 196
US-10-751-736-11278
; Sequence 11278, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11278
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11278

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 TAACACAGCATGGCTGACAT 488
| | | | | | | | | | | | | | |
Db 1 TAACACAGCATGGCTGACAT 21

RESULT 197
US-10-751-736-11279
; Sequence 11279, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
```



```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11254
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11254

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 96 TAATGTGCTATTGTGTGAGAG 116
|||||
Db 1 TAATGTGCTATTGTGTGAGAG 21

```

RESULT 189

```

US-10-751-736-11257
; Sequence 11257, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11257
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11257

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 104 TATTTGGTGAGAGACTTAG 124
|||||
Db 1 TATTTGGTGAGAGACTTAG 21

```

RESULT 190

```

US-10-751-736-11260
; Sequence 11260, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11260
; LENGTH: 21

```

```

; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11260
Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 133 TATGGCCTTGAGATAAACA 153
|||||
Db 1 TATGGCCTTGAGATAAACA 21

```

RESULT 191

```

US-10-751-736-11263
; Sequence 11263, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11263
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11263

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 146 TAAACAAACTTCCAGTGACAA 166
|||||
Db 1 TAAACAAACTTCCAGTGACAA 21

```

RESULT 192

```

US-10-751-736-11266
; Sequence 11266, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11266
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11266

```

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```
RESULT 184
US-10-751-736-11243
; Sequence 11243, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11243
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11243

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 61.9%; Pred. No. 65;
Matches 13; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1675 AGCATGCTCTGTAAGTTGCTT 1695
DB 1 AGCAUGCUCUGAAGUGCUU 21

RESULT 185
US-10-751-736-11245
; Sequence 11245, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11245
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11245

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1715 GAAATTATCTTACTTCTGCG 1735
DB 1 GAAATTATCTTACTTCTGCG 21

RESULT 186
US-10-751-736-11248
; Sequence 11248, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11248
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11248

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 26 TAATAGTCTCTCTGCGGCCA 46
DB 1 TAATAGTCTCTCTGCGGCCA 21

RESULT 187
US-10-751-736-11251
; Sequence 11251, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11251
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11251

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 29 TACTGCTCTCTGCGGCCACTG 49
DB 1 TACTGCTCTCTGCGGCCACTG 21

RESULT 188
US-10-751-736-11254
; Sequence 11254, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
```

```
; SEQ ID NO 11230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11230

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11230
1263 GATTACCAAGAACTTCCCAAGG 1283
|||||
Db 1 GATTACCAAGAACTTCCCAAGG 21

RESULT 180
US-10-751-736-11233
; Sequence 11233, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11233
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11233

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11233
1300 GATCGAGTCTTCTATTCTAAA 1320
|||||
Db 1 GATCGAGTCTTCTATTCTAAA 21

RESULT 181
US-10-751-736-11236
; Sequence 11236, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11236
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11236

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11236
1360 GATATGACTTCTCTACTCCAA 1380
|||||
Db 1 GATATGACTTCTCTACTCCAA 21

RESULT 182
US-10-751-736-11239
; Sequence 11239, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11239
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11239

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11242
1366 GACTTCTCTACTCCAACTATC 1386
|||||
Db 1 GACTTCTCTACTCCAACTATC 21

RESULT 183
US-10-751-736-11242
; Sequence 11242, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11242
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11242

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

US-10-751-736-11242
1673 GAAGCATGCTCTGTAAATTGC 1693
|||||
Db 1 GAAGCATGCTCTGTAAATTGC 21
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11218
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11218

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1201 GATAACCACTATGGAGGTAT 1221
Db 1 GATAACCACTATGGAGGTAT 21

RESULT 176
US-10-751-736-11221
; Sequence 11221, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11221
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11221

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1215 GAGGTATGATGAAGGAGACA 1235
Db 1 GAGGTATGATGAAGGAGACA 21

RESULT 177
US-10-751-736-11224
; Sequence 11224, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11224
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11224

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1222 GATGAAGGAGACAGATGATG 1242
Db 1 GATGAAGGAGACAGATGATG 21

RESULT 178
US-10-751-736-11227
; Sequence 11227, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11227
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11227

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1225 GAAAGGAGACAGATGATGAC 1245
Db 1 GAAAGGAGACAGATGATGAC 21

RESULT 179
US-10-751-736-11230
; Sequence 11230, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

QY 1021 GAAATTGAAGCCAGAAATCAA 1041

```

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. NO. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1185  GACCTACTTCTTTGTAGATAA 1205
          |||||
Db      1      GACCTACTTCTTTGTAGATAA 21

RESULT 175
US-10-751-736-11218
; Sequence 11218, Application US/10751736
; Publication No. US20040265230A1

```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11194
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11194

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 936 GAAGGTTTCTGAGAGACCAAA 956
Db 1 GAAGGTTTCTGAGAGACCAAA 21

RESULT 167
US-10-751-736-11197
; Sequence 11197, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11197
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11197

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 946 GAGAGACCAAGACCAAGTGT 966
Db 1 GAGAGACCAAGACCAAGTGT 21

RESULT 168
US-10-751-736-11200
; Sequence 11200, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11200
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11200

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 948 GAGACCAAGACCAAGTGTAA 968
Db 1 GAGACCAAGACCAAGTGTAA 21

RESULT 169
US-10-751-736-11201
; Sequence 11201, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11201
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11201

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 950 GACCAAGACCAAGTGTAAAT 970
Db 1 GACCAAGACCAAGTGTAAAU 21

RESULT 170
US-10-751-736-11203
; Sequence 11203, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11203
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11203
```

QY 772 GACATACGTGGCAATTCAGTCC 792
|||||
DB 1 GACATACGTGGCAATTCAGTCC 21

RESULT 162

US-10-751-736-11182
; Sequence 11182, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11182
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11182

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 835 GACAAATTCAGAACCAAGCTCTC 855
|||||
DB 1 GACAAATTCAGAACCAAGCTCTC 21

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 811 GAGAACCAACGCTTGCCAAAT 831
|||||
DB 1 GAGAACCAACGCTTGCCAAAT 21

RESULT 163

US-10-751-736-11185
; Sequence 11185, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11185
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11185

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 813 GAACCAACGCTTGCCAAATCC 833
|||||
DB 1 GAACCAACGCTTGCCAAATCC 21

RESULT 164

US-10-751-736-11188

; Sequence 11188, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11188
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11188

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 835 GACAAATTCAGAACCAAGCTCTC 855
|||||
DB 1 GACAAATTCAGAACCAAGCTCTC 21

RESULT 165

US-10-751-736-11191
; Sequence 11191, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11191
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11191

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 919 GACAGGTTCTTCGCTGAAG 939
|||||
DB 1 GACAGGTTCTTCGCTGAAG 21

RESULT 166

US-10-751-736-11194
; Sequence 11194, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11167
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11170

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 GATTGGCCATTCTTAGGTCT 689
DB 1 GATTGGCCATTCTTAGGTCT 21

RESULT 158
US-10-751-736-11170
; Sequence 11170, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11170
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11170

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 703 GATCCAAAGGCTGTAATGTTCT 723
DB 1 GATCCAAAGGCTGTAATGTTCT 21

RESULT 159
US-10-751-736-11173
; Sequence 11173, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11173
; LENGTH: 21
; TYPE: DNA

; ORGANISM: homo sapiens
US-10-751-736-11173

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 742 GACATCAACACATTTCGCCTC 762
DB 1 GACATCAACACATTTCGCCTC 21

RESULT 160
US-10-751-736-11176
; Sequence 11176, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11176
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11176

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 GATGACATACGTGGCATTTCAG 789
DB 1 GATGACATACGTGGCATTTCAG 21

RESULT 161
US-10-751-736-11179
; Sequence 11179, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11179
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11179

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
RESULT 153
US-10-751-736-11155
; Sequence 11155, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11155
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11155

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 613 GAATTCGACATTCACATTCAC 633
Db 1 GAATTCGACATTCACATTCAC 21

RESULT 154
US-10-751-736-11158
; Sequence 11158, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11158
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11158

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 621 GACTACACATTCAGGAGGCAC 641
Db 1 GACTACACATTCAGGAGGCAC 21

RESULT 155
US-10-751-736-11161
; Sequence 11161, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11161
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11161

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 GAGGCACAACTTGTTCTCTCA 655
Db 1 GAGGCACAACTTGTTCTCTCA 21

RESULT 156
US-10-751-736-11164
; Sequence 11164, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11164
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11164

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 667 GAGATTGCCATTCCTTAGGT 687
Db 1 GAGATTGCCATTCCTTAGGT 21

RESULT 157
US-10-751-736-11167
; Sequence 11167, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11140

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 569 GACCTGGATCTGGCATTGGAG 589
DB 1 GACCTGGATCTGGCATTGGAG 21

RESULT 149
US-10-751-736-11143
; Sequence 11143, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 11143
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11143

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 GATGCACATTTCCGATGAGGAC 612
DB 1 GATGCACATTTCCGATGAGGAC 21

RESULT 150
US-10-751-736-11146
; Sequence 11146, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 11146
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11146

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 GATGAGGACGAATTCGGACT 624
DB 1 GATGAGGACGAATTCGGACT 21

RESULT 151
US-10-751-736-11149
; Sequence 11149, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 11149
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11149

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 607 GAGGACGAATTCGGACTACA 627
DB 1 GAGGACGAATTCGGACTACA 21

RESULT 152
US-10-751-736-11152
; Sequence 11152, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 11152
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11152

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 610 GACGAATTCGGACTACACAT 630
DB 1 GACGAATTCGGACTACACAT 21

```
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11128
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11128

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 453 GAAATTCAGCAGATTAAAC 473
Db 1 GAAATTCAGCAGATTAAAC 21

RESULT 145
US-10-751-736-11131
; Sequence 11131, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11131
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11131

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 465 GATTAACACAGCGATGGCTGA 485
Db 1 GATTAACACAGCGATGGCTGA 21

RESULT 146
US-10-751-736-11134
; Sequence 11134, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
```

```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11134
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11134

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 509 GAGCTCATGGAGACTTCCATG 529
Db 1 GAGCTCATGGAGACTTCCATG 21

RESULT 147
US-10-751-736-11137
; Sequence 11137, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11137
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11137

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 535 GATGCAAGGTGGATCCTTA 555
Db 1 GATGCAAGGTGGATCCTTA 21

RESULT 148
US-10-751-736-11140
; Sequence 11140, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11140
```

```
Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 GAGGATGTTGACTACGCAATC 414
DB 1 GAGGATGTTGACTACGCAATC 21

RESULT 140
US-10-751-736-11119
; Sequence 11119, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11119
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11119

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 397 GATGTTGACTACGCAATCCGG 417
DB 1 GATGTTGACTACGCAATCCGG 21

RESULT 141
US-10-751-736-11122
; Sequence 11122, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11122
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11122

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 GACTACGCAATCCGGAAGCT 423
DB 1 GACTACGCAATCCGGAAGCT 21
```

```
RESULT 142
US-10-751-736-11123
; Sequence 11123, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11123
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11123

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 405 CTACGCAATCCGGAAGCTTT 425
DB 1 CUACGCAAUCCGGAAGCUUU 21

RESULT 143
US-10-751-736-11125
; Sequence 11125, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11125
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11125

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GAAAGCTTTCCCAAGTATGGAG 437
DB 1 GAAAGCTTTCCCAAGTATGGAG 21

RESULT 144
US-10-751-736-11128
; Sequence 11128, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
```

```
; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873
; SOFTWARE:  PatentIn version 3.2
; SEQ ID NO 11104
; LENGTH:  21
; TYPE:  DNA
; ORGANISM:  homo sapiens
US-10-751-736-11104

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      342  GAAACATTATATCACTACAG 362
Db      1    GAAACATTATATCACTACAG 21

RESULT 136
US-10-751-736-11107
; Sequence 11107, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873
; SOFTWARE:  PatentIn version 3.2
; SEQ ID NO 11107
; LENGTH:  21
; TYPE:  DNA
; ORGANISM:  homo sapiens
US-10-751-736-11107

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      362  GAATCAATAATTACACACCTG 382
Db      1    GAATCAATAATTACACACCTG 21

RESULT 137
US-10-751-736-11110
; Sequence 11110, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873

; TITLE OF INVENTION:  CANCERS
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873
; SOFTWARE:  PatentIn version 3.2
; SEQ ID NO 11110
; LENGTH:  21
; TYPE:  DNA
; ORGANISM:  homo sapiens
US-10-751-736-11110

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      382  GACATGACCGTGAGGATGTT 402
Db      1    GACATGACCGTGAGGATGTT 21

RESULT 138
US-10-751-736-11113
; Sequence 11113, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873
; SOFTWARE:  PatentIn version 3.2
; SEQ ID NO 11113
; LENGTH:  21
; TYPE:  DNA
; ORGANISM:  homo sapiens
US-10-751-736-11113

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      387  GAACCGTGAGGATGTTGACTA 407
Db      1    GAACCGTGAGGATGTTGACTA 21

RESULT 139
US-10-751-736-11116
; Sequence 11116, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION:  COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE:  AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER:  US/10/751,736
; CURRENT FILING DATE:  2003-01-06
; PRIOR APPLICATION NUMBER:  US Provisional Application 60/438,000
; PRIOR FILING DATE:  2003-01-06
; NUMBER OF SEQ ID NOS:  54873
; SOFTWARE:  PatentIn version 3.2
; SEQ ID NO 11116
; LENGTH:  21
; TYPE:  DNA
; ORGANISM:  homo sapiens
US-10-751-736-11116
```

RESULT 133
US-10-751-736-11098
: Sequence 11098, Application US/10751736

RESULT 135
US-10-751-736-11104
; Sequence 11104, Application US/10751736
; Publication No. US2004026520A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND M

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11077
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11077

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1701 CATCCTTGACTGAGAAATTA 1721
Db 1 CATCCTTGACTGAGAAATTA 21

RESULT 127
US-10-751-736-11080
; Sequence 11080, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11080
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11080

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 15 GAAGTTTCTTCTAAATCTGCT 35
Db 1 GAAGTTTCTTCTAAATCTGCT 21

RESULT 128
US-10-751-736-11083
; Sequence 11083, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11083
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11083

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 142 GAGATAAACAACTTCCAGTG 162
Db 1 GAGATAAACAACTTCCAGTG 21

RESULT 130
US-10-751-736-11089
; Sequence 11089, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11089
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11089

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 144 GATAAACAACTTCCAGTGAC 164
Db 1 GATAAACAACTTCCAGTGAC 164

RESULT 129
US-10-751-736-11086
; Sequence 11086, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11086
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11086

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 69 GAACAGCTCTACAAGCCTGGA 89
Db 1 GAACAGCTCTACAAGCCTGGA 21

RESULT 129
US-10-751-736-11086
; Sequence 11086, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11086
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11086

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 144 GATAAACAACTTCCAGTGAC 164
Db 1 GATAAACAACTTCCAGTGAC 164
```

US-10-751-736-11068
; Sequence 11068, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11068
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11068
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1507 CACTACTTAGAGATATGATC 1527
Db 1 CACTACTTAGAGATATGATC 21
RESULT 123
US-10-751-736-11071
; Sequence 11071, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11071
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11071
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1608 CATTCTTGCTTGACTCTACTA 1628
Db 1 CATTCTTGCTTGACTCTACTA 21
RESULT 124
US-10-751-736-11072
; Sequence 11072, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11072
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11072
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 47.6%; Pred. No. 65;
Matches 10; Conservative 11; Mismatches 0; Indels 0; Gaps 0;
QY 1610 TTCTTGCTTGACTCTACTATT 1630
Db 1 UUCUUGCUUGACUCUACUAAU 21
RESULT 125
US-10-751-736-11074
; Sequence 11074, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11074
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11074
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 CATGCTCTGTAAGTTGCTTCC 1697
Db 1 CATGCTCTGTAAGTTGCTTCC 21
RESULT 126
US-10-751-736-11077
; Sequence 11077, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000


```
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11053

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1269 CAAGAAGTCTCCAGGAATCGG 1289
      |||||
Db 1 CAAGAAGTCTCCAGGAATCGG 21

RESULT 118
US-10-751-736-11056
; Sequence 11056, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11056
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11056

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1342 CAAGGATCTTACCAATTGAA 1362
      |||||
Db 1 CAAGGATCTTACCAATTGAA 21

RESULT 119
US-10-751-736-11059
; Sequence 11059, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11059
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11059

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1404 CAATAGCTGGTTGGTTGTTA 1424
      |||||
Db 1 CAATAGCTGGTTGGTTGTTA 21

RESULT 120
US-10-751-736-11062
; Sequence 11062, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11062
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11062

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1482 CATATTGCTATGTCCTCAGT 1502
      |||||
Db 1 CATATTGCTATGTCCTCAGT 21

RESULT 121
US-10-751-736-11065
; Sequence 11065, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11065
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11065

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1499 CAGTGTAACCACTACTTAGAGA 1519
      |||||
Db 1 CAGTGTAACCACTACTTAGAGA 21

RESULT 122
```

Fri May 13 12:26:37 2005

```

; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11044
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11044

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1080 CAATTTAAGACGAGCCAA 1100
DB      1 CAATTTAAGACGAGCCAA 21

RESULT 114
US-10-751-736-11045
; Sequence 11045, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11045
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11045

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 65;
Matches 16; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      1082 ATTAAAGACGAGCCAAATT 1102
DB      1 AUUUAAGACGAGCCAAAUU 21

RESULT 115
US-10-751-736-11047
; Sequence 11047, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11053
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11053

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1257 CAAACTGATTACCAAGAACTT 1277
DB      1 CAAACTGATTACCAAGAACTT 21

RESULT 117
US-10-751-736-11053
; Sequence 11053, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11053
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11053

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1257 CAAACTGATTACCAAGAACTT 1277
DB      1 CAAACTGATTACCAAGAACTT 21

```

```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11047
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11047

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1207 CAGTATTGGAGGTATGATGAA 1227
DB      1 CAGTATTGGAGGTATGATGAA 21

RESULT 116
US-10-751-736-11050
; Sequence 11050, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11050
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11050

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1257 CAAACTGATTACCAAGAACTT 1277
DB      1 CAAACTGATTACCAAGAACTT 21

RESULT 117
US-10-751-736-11053
; Sequence 11053, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11053
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11053

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1257 CAAACTGATTACCAAGAACTT 1277
DB      1 CAAACTGATTACCAAGAACTT 21

```

```
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 CAGGTTCTTCTGCTGAAGGT 941
DB 1 CAGGTTCTTCTGCTGAAGGT 21

RESULT 109
US-10-751-736-11033
; Sequence 11033, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11033
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11033

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 923 GGTCTTCTGCTGAAGTTT 943
DB 1 GGUUCUUCUGGUGAAGGUU 21

RESULT 110
US-10-751-736-11035
; Sequence 11035, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11035
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11035

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 989 CAACCTTGCCATCTGCGATTG 1009
DB 1 CAACCTTGCCATCTGCGATTG 21

Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 CAGGTTCTTCTGCTGAAGGT 941
DB 1 CAGGTTCTTCTGCTGAAGGT 21

RESULT 111
US-10-751-736-11038
; Sequence 11038, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11038
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11038

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 998 CATCTGGCATTGAAGCTGCTT 1018
DB 1 CATCTGGCATTGAAGCTGCTT 21

RESULT 112
US-10-751-736-11041
; Sequence 11041, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11041
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11041

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1005 CATTGAAGCTGCTTATGAAT 1025
DB 1 CATTGAAGCTGCTTATGAAT 21

RESULT 113
US-10-751-736-11044
; Sequence 11044, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

Query Match	1.2%	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-11026				
Query Match	1.2%;	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
US-10-751-736-11026				
SEQ ID NO 11026				

```
Dbb 1 CATCAACACATTTCGCTCTC 21

RESULT 100
US-10-751-736-11008
; Sequence 11008, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11008
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11008

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 747 CAACACATTTCGCTCTCTGC 767
Db 1 CAACACATTTCGCTCTCTGC 21

RESULT 101
US-10-751-736-11011
; Sequence 11011, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11011
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11011

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CACATTTCGCTCTCTCTGTA 770
Db 1 CACATTTCGCTCTCTCTGTA 21

RESULT 102
US-10-751-736-11014
; Sequence 11014, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11014
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11014

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 752 CATTTCGCTCTCTCTGCTGATG 772
Db 1 CATTTCGCTCTCTCTGCTGATG 21

RESULT 103
US-10-751-736-11017
; Sequence 11017, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11017
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11017

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 817 CAACGCTTGCCAAATCCTGAC 837
Db 1 CAACGCTTGCCAAATCCTGAC 21

RESULT 104
US-10-751-736-11020
; Sequence 11020, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11020
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11020

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 817 CAACGCTTGCCAAATCCTGAC 837
Db 1 CAACGCTTGCCAAATCCTGAC 21
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10993

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 726 CACCTACAAATATGTCGACAT 746
Db 1 CACCTACAAATATGTCGACAT 21

RESULT 98
US-10-751-736-11002
; Sequence 11002, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11002
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11002

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 732 CAAATATGTCGACATCAACAC 752
Db 1 CAAATATGTCGACATCAACAC 21

RESULT 99
US-10-751-736-11005
; Sequence 11005, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11005
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11005

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 744 CATCAACATTTCCCTCTC 764
Db 1 CATCAACATTTCCCTCTC 764
```

```

; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10993

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 676 CATTCTTAGTCTTGGCCAT 696
Db 1 CATTCTTAGTCTTGGCCAT 21

RESULT 96
US-10-751-736-10996
; Sequence 10996, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10996
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10996

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 694 CATTCTAGTATCCAAAGGCT 714
Db 1 CATTCTAGTATCCAAAGGCT 21

RESULT 97
US-10-751-736-10999
; Sequence 10999, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10999
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10999
```

```
; Sequence 10984, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10984
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10984

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 CAAACTTGTTCTCCTACTGCTG 661
DB 1 CAAACTTGTTCTCCTACTGCTG 21

RESULT 92
US-10-751-736-10985
; Sequence 10985, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10985
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10985

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 643 AACTTGTTCTCCTACTGCTGTT 663
DB 1 AACUUGUUCUCCACUGCUGUU 21

RESULT 93
US-10-751-736-10987
; Sequence 10987, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10987
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10987

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 CACTGCTGTTCCAGAGATTGG 674
DB 1 CACTGCTGTTCCAGAGATTGG 21

RESULT 94
US-10-751-736-10990
; Sequence 10990, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10990
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10990

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 664 CACGAGATTGGCCATTCTCTTA 684
DB 1 CACGAGATTGGCCATTCTCTTA 21

RESULT 95
US-10-751-736-10993
; Sequence 10993, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10993
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10993

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; ORGANISM: homo sapiens
US-10-751-736-10972

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 626 CACATTCAGGAGGCACAACT 646
Db 1 CACATTCAGGAGGCACAACT 21

RESULT 87
US-10-751-736-10975
; Sequence 10975, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10975
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10975

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 628 CATTGAGGAGGCACAACTTG 648
Db 1 CATTGAGGAGGCACAACTTG 21

RESULT 88
US-10-751-736-10976
; Sequence 10976, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10976
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10976

Query Match
Best Local Similarity 71.4%; Score 21; DB 1; Length 21;
Matches 15; Conservative 6; Mismatches 6; Indels 0; Gaps 0;

; ORGANISM: homo sapiens
US-10-751-736-10972

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 630 TTCAGGAGGCACAACTTGT 650
Db 1 UUCAGGAGGCACAACTUGUU 21

RESULT 89
US-10-751-736-10978
; Sequence 10978, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10978
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10978

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 632 CAGGAGGCACAACTTGTTC 652
Db 1 CAGGAGGCACAACTTGTTC 21

RESULT 90
US-10-751-736-10981
; Sequence 10981, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10981
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10981

Query Match
Best Local Similarity 100.0%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 639 CACAACTTGTTCCTCACTGC 659
Db 1 CACAACTTGTTCCTCACTGC 21

RESULT 91
US-10-751-736-10984
```



```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10960
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10960

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 459 CAGCAAGATTACACAGGCAT 479
Db 1 CAGCAAGATTACACAGGCAT 21

RESULT 83
US-10-751-736-10963
; Sequence 10963, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10963
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10963

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 462 CAAGATTAAACACAGCATGGC 482
Db 1 CAAGATTAAACACAGCATGGC 21

RESULT 84
US-10-751-736-10966
; Sequence 10966, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
```

```
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10966
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10966

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 596 CACATTCGATGAGGACGAAT 616
Db 1 CACATTCGATGAGGACGAAT 21

RESULT 85
US-10-751-736-10969
; Sequence 10969, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10969
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10969

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 598 CATTTCGATGAGGACGAATTC 618
Db 1 CATTTCGATGAGGACGAATTC 21

RESULT 86
US-10-751-736-10972
; Sequence 10972, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10972
; LENGTH: 21
; TYPE: DNA
```

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 375 CACACTGACATGACCGTGA 395
DB 1 CACACTGACATGACCGTGA 21

RESULT 78
US-10-751-736-10948
; Sequence 10948, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10948
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10948

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 377 CACCTGACATGACCGTGAGG 397
DB 1 CACCTGACATGACCGTGAGG 21

RESULT 79
US-10-751-736-10951
; Sequence 10951, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10951
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10951

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 384 CATGAACCGTGAGGATGTGA 404
DB 1 CATGAACCGTGAGGATGTGA 21

RESULT 80

US-10-751-736-10954
; Sequence 10954, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10954
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10954

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 410 CAATCGGAAGCTTTCCAG 430
DB 1 CAATCGGAAGCTTTCCAG 21

RESULT 81

US-10-751-736-10957
; Sequence 10957, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10957
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10957

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 427 CAAGTATGAGTATGTTACC 447
DB 1 CAAGTATGAGTATGTTACC 21

RESULT 82

US-10-751-736-10960
; Sequence 10960, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert

; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10933
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10933

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 CACGCACCTCGATGGAGTC 294
Db 1 CACGCACCTCGATGGAGTC 21

RESULT 74

US-10-751-736-10936
; Sequence 10936, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10936
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10936

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 346 CATTATATCACCCTACAGATC 366
Db 1 CATTATATCACCCTACAGATC 21

RESULT 75

US-10-751-736-10939
; Sequence 10939, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10939

; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10939

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 360 CAGAATCAATAATTACACACC 380
Db 1 CAGAATCAATAATTACACACC 21

RESULT 76

US-10-751-736-10942
; Sequence 10942, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10942
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10942

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 366 CAATAATTACACCTGACAT 386
Db 1 CAATAATTACACCTGACAT 21

RESULT 77

US-10-751-736-10945
; Sequence 10945, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10945
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10945

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10921
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10921

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1699 AACATCCTTGGACTGAGAAAT 1719
DB 1 AACATCCTTGGACTGAGAAAT 21

RESULT 70
US-10-751-736-10924
; Sequence 10924, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10924
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10924

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 CAGGCCACTGCTTCTGGAGCT 60
DB 1 CAGGCCACTGCTTCTGGAGCT 21

RESULT 71
US-10-751-736-10927
; Sequence 10927, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10927
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10927

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 205 CAAGAAATGCAGCACTTCTTG 225
DB 1 CAAGAAATGCAGCACTTCTTG 21

RESULT 73
US-10-751-736-10933
; Sequence 10933, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 CACTGCTTCTGGAGCTTCTCC 65
DB 1 CACTGCTTCTGGAGCTTCTCC 21

RESULT 72
US-10-751-736-10930
; Sequence 10930, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10930
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10930

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 205 CAAGAAATGCAGCACTTCTTG 225
DB 1 CAAGAAATGCAGCACTTCTTG 21

RESULT 73
US-10-751-736-10933
; Sequence 10933, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10927
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10927

```

Query Match	1.2%	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1663	AATTCTATTGAGCATGCTC	1683	
Db	1	AATTCTATTGAGCATGCTC	21	
RESULT 67				
US-10-751-736-10915				
Sequence 10915, Application US/10751736				
Publication No. US20040265230A1				
GENERAL INFORMATION:				
APPLICANT: Wyeth				
APPLICANT: Martinez, Robert				
APPLICANT: Brown, Eugene				
APPLICANT: Liu, Wei				
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON				
TITLE OF INVENTION: CANCERS				
FILE REFERENCE: AM100927 (031896-002000)				
CURRENT APPLICATION NUMBER: US/10/751,736				
CURRENT FILING DATE: 2003-01-06				
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000				
PRIOR FILING DATE: 2003-01-06				
NUMBER OF SEQ ID NOS: 54873				
SOFTWARE: PatentIn version 3.2				
SEQ ID NO 10915				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-10915				
Query Match	1.2%	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1674	AAGCATGCTCTGTAAGTTGCT	1694	
Db	1	AAGCATGCTCTGTAAGTTGCT	21	
RESULT 68				
US-10-751-736-10918				
Sequence 10918, Application US/10751736				
Publication No. US20040265230A1				
GENERAL INFORMATION:				
APPLICANT: Wyeth				
APPLICANT: Martinez, Robert				
APPLICANT: Brown, Eugene				
APPLICANT: Liu, Wei				
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON				
TITLE OF INVENTION: CANCERS				
FILE REFERENCE: AM100927 (031896-002000)				
CURRENT APPLICATION NUMBER: US/10/751,736				
CURRENT FILING DATE: 2003-01-06				
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000				
PRIOR FILING DATE: 2003-01-06				
NUMBER OF SEQ ID NOS: 54873				
SOFTWARE: PatentIn version 3.2				
SEQ ID NO 10918				
LENGTH: 21				
TYPE: DNA				
ORGANISM: homo sapiens				
US-10-751-736-10918				
Query Match	1.2%	Score 21;	DB 1;	Length 21;
Best Local Similarity	100.0%;	Pred. No. 65;		
Matches	21;	Conservative	0;	Mismatches 0; Indels 0; Gaps 0;
Qy	1687	AAGTGTCTTCCTAACATCCTT	1707	
Db	1	AAGTGTCTTCCTAACATCCTT	21	

```
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10897
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10897

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 AAGCAATAGCTGGTTGGTTG 1421
Db 1 AAGCAATAGCTGGTTGGTTG 21

RESULT 61
US-10-751-736-10898
; Sequence 10898, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10898
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-10898

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 57.1%; Pred. No. 65;
Matches 12; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 1403 GCAATAGCTGGTTGGTTGTT 1423
Db 1 GCAUAGCUGGUUGGUUGU 21

RESULT 62
US-10-751-736-10900
; Sequence 10900, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10900
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10900

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1405 AATAGCTGGTTGGTTGTTAG 1425
Db 1 AATAGCTGGTTGGTTGTTAG 21

RESULT 63
US-10-751-736-10903
; Sequence 10903, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10903
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10903

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1595 AACTCTAATTGTCATTCTTG 1615
Db 1 AACTCTAATTGTCATTCTTG 21

RESULT 64
US-10-751-736-10906
; Sequence 10906, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

```
US-10-751-736-10882
Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1258 AAACGTGATTACCAAGAACTTCC 1278
Db 1 AAACGTGATTACCAAGAACTTCC 21

RESULT 56
US-10-751-736-10885
; Sequence 10885, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10885
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10885

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1259 AACTGATTACCAAGAACTTCC 1279
Db 1 AACTGATTACCAAGAACTTCC 21

RESULT 57
US-10-751-736-10888
; Sequence 10888, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10888
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10888

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1296 AATTGATGAGTCTTCTATTCC 1316
Db 1 AATTGATGAGTCTTCTATTCC 21

US-10-751-736-10891
; Sequence 10891, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10891
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10891

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1361 AATATGACTTCTCTACTCCAAC 1381
Db 1 AATATGACTTCTCTACTCCAAC 21

RESULT 59
US-10-751-736-10894
; Sequence 10894, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10894
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10894

Query Match          1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1400 AAAGCAATAGCTGCTTTGGTT 1420
Db 1 AAAGCAATAGCTGCTTTGGTT 21

RESULT 60
US-10-751-736-10897
; Sequence 10897, Application US/10751736
```

```
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10870
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10870

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 AATTTAAGACGACGACCAAT 1101
Db 1 AATTTAAGACGACGACCAAT 21

RESULT 52
US-10-751-736-10873
; Sequence 10873, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10873
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10873

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1086 AAGACGACGACGACCAATATCC 1106
Db 1 AAGACGACGACGACCAATATCC 21

RESULT 53
US-10-751-736-10876
; Sequence 10876, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
```

```
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10876
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10876

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1204 AACGAGTATTGGAGGTATGAT 1224
Db 1 AACGAGTATTGGAGGTATGAT 21

RESULT 54
US-10-751-736-10879
; Sequence 10879, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10879
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10879

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1226 AAAGGACAGACAGATGATGACC 1246
Db 1 AAAGGACAGACAGATGATGACC 21

RESULT 55
US-10-751-736-10882
; Sequence 10882, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10882
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
```


RESULT 49

Fri May 13 12:26:37 2005

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10849
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10849

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 917 AAGACAGGTTCTTCGGCTGA 937
Db 1 AAGACAGGTTCTTCGGCTGA 21

RESULT 43

US-10-751-736-10852
; Sequence 10852, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10852
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10852

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 937 AAGGTTTCTGAGAGACCAAG 957
Db 1 AAGGTTTCTGAGAGACCAAG 21

RESULT 44

US-10-751-736-10855
; Sequence 10855, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10855
; LENGTH: 21

; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10855

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 972 AATTCTCTCTTATGCCAAC 992
Db 1 AATTCTCTCTTATGCCAAC 21

RESULT 45

US-10-751-736-10858
; Sequence 10858, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10858
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10858

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 AACCTGCCATCTGGCATTGA 1010
Db 1 AACCTGCCATCTGGCATTGA 21

RESULT 46

US-10-751-736-10861
; Sequence 10861, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10861
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10861

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
RESULT 38
US-10-751-736-10837
; Sequence 10837, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10837
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10837

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      828 AATCTGACAAATTCAGAACCC 848
Db      1 AATCTGACAAATTCAGAACCC 21

RESULT 39
US-10-751-736-10840
; Sequence 10840, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10840
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10840

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      829 AATCTGACAAATTCAGAACCA 849
Db      1 AATCTGACAAATTCAGAACCA 21

RESULT 40
US-10-751-736-10843
; Sequence 10843, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10843
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10843

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      838 AATTCAGAACCCAGCTCTCTGT 858
Db      1 AATTCAGAACCCAGCTCTCTGT 21

RESULT 41
US-10-751-736-10846
; Sequence 10846, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10846
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10846

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      916 AAAGACAGGTTCTTCTGGCTG 936
Db      1 AAAGACAGGTTCTTCTGGCTG 21

RESULT 42
US-10-751-736-10849
; Sequence 10849, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
```

```
; SEQ ID NO 10822
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10822

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 748 AACACATTGCGCTCTGCT 768
Db 1 AACACATTGCGCTCTGCT 21

RESULT 34
US-10-751-736-10825
; Sequence 10825, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10825
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10825

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 808 AAGAGAACCAACGCTTGCCA 828
Db 1 AAGAGAACCAACGCTTGCCA 21

RESULT 35
US-10-751-736-10828
; Sequence 10828, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10828
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10828

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 809 AAGAGAACCAACGCTTGCCA 829
Db 1 AAGAGAACCAACGCTTGCCA 21

RESULT 36
US-10-751-736-10831
; Sequence 10831, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10831
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10831

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 814 AACCAACGCTTGCCAAATCCT 834
Db 1 AACCAACGCTTGCCAAATCCT 21

RESULT 37
US-10-751-736-10834
; Sequence 10834, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10834
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10834

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 818 AACGCTTGCCAAATCCTGACA 838
Db 1 AACGCTTGCCAAATCCTGACA 21
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10816
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10816

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 733 AAATATGTCGACATCAACACA 753
Db 1 AAATATGTCGACATCAACACA 21

RESULT 30
US-10-751-736-10817
; Sequence 10817, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10817
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10817

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 65;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 735 ATATGTCGACATCAACACATT 755
Db 1 AAUUGCGACAUCAACACAUU 21

RESULT 31
US-10-751-736-10819
; Sequence 10819, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
```

```
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10819
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10819

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 734 AATATGTCGACATCAACACAT 754
Db 1 AATATGTCGACATCAACACAT 21

RESULT 32
US-10-751-736-10820
; Sequence 10820, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10820
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10820

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 65;
Matches 14; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 736 TATGTCGACATCAACACATTT 756
Db 1 UAUGUCGACAUCAACACAUU 21

RESULT 33
US-10-751-736-10822
; Sequence 10822, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

Db 1 AATTCTGGACTACACATTGAG 21

RESULT 27

US-10-751-736-10810

; Sequence 10810, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE OF INVENTION: CANCERS

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 10810

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-10810

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 642 AAACCTGTTCTCCTCACTGCTGT 662

Db 1 AAACCTGTTCTCCTCACTGCTGT 21

RESULT 28

US-10-751-736-10813

; Sequence 10813, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE OF INVENTION: CANCERS

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 10813

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-10813

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 643 AAACCTGTTCTCCTCACTGCTGT 663

Db 1 AAACCTGTTCTCCTCACTGCTGT 21

RESULT 29

US-10-751-736-10816

; Sequence 10816, Application US/10751736

; Publication No. US20040265230A1

Db 1 AATTCTGGACTACACATTGAG 21

Qy 614 AATTCTGGACTACACATTGAG 634

Db 1 AATTCTGGACTACACATTGAG 21

Qy 469 AACACAGCGCATGGTGACATT 489

Db 1 AACACAGCGCATGGTGACATT 21

RESULT 25

US-10-751-736-10805

; Sequence 10805, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE OF INVENTION: CANCERS

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 10805

; LENGTH: 21

; TYPE: RNA

; ORGANISM: RNAi

US-10-751-736-10805

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 71.4%; Pred. No. 65;

Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 471 CACAGGCATGGTGACATT 491

Db 1 CACAGGCATGGTGACATT 21

RESULT 26

US-10-751-736-10807

; Sequence 10807, Application US/10751736

; Publication No. US20040265230A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert

; APPLICANT: Brown, Eugene

; APPLICANT: Liu, Wei

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON

; FILE OF INVENTION: CANCERS

; FILE REFERENCE: AM100927 (031896-002000)

; CURRENT APPLICATION NUMBER: US/10/751,736

; CURRENT FILING DATE: 2003-01-06

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000

; PRIOR FILING DATE: 2003-01-06

; NUMBER OF SEQ ID NOS: 54873

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 10807

; LENGTH: 21

; TYPE: DNA

; ORGANISM: homo sapiens

US-10-751-736-10807

Query Match 1.2%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 65;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 614 AATTCTGGACTACACATTGAG 634

Db 1 AATTCTGGACTACACATTGAG 21

Qy 614 AATTCTGGACTACACATTGAG 634

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10792
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10792

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 418 AAGCTTTCCAAAGTATGGAGT 438
Db 1 AAGCTTTCCAAAGTATGGAGT 21

RESULT 21
US-10-751-736-10795
; Sequence 10795, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10795
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10795

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 419 AAGCTTTCCAAAGTATGGAGTA 439
Db 1 AAGCTTTCCAAAGTATGGAGTA 21

RESULT 22
US-10-751-736-10798
; Sequence 10798, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10798
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10798

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 455 AATTCAGCAAGATTAAACACAG 475
Db 1 AATTCAGCAAGATTAAACACAG 21

RESULT 23
US-10-751-736-10801
; Sequence 10801, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10801
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10801

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 463 AAGATTAAACACAGCGCATGGCT 483
Db 1 AAGATTAAACACAGCGCATGGCT 21

RESULT 24
US-10-751-736-10804
; Sequence 10804, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10804
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10804
```

Qy 206 AAGAAATGCACACTTCTTGG 226
Db 1 AAGAAATGCACACTTCTTGG 21

RESULT 16
US-10-751-736-10780
; Sequence 10786, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10786
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10786

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 388 AACCGTGAGGATGTTGACTAC 408
Db 1 AACCGTGAGGATGTTGACTAC 21

RESULT 19
US-10-751-736-10789
; Sequence 10789, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10789
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10789

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 AATCCGGAAGCTTTCCAAGT 431
Db 1 AATCCGGAAGCTTTCCAAGT 21

RESULT 20
US-10-751-736-10792
; Sequence 10792, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

Qy 206 AAGAAATGCACACTTCTTGG 226
Db 1 AAGAAATGCACACTTCTTGG 21

RESULT 16
US-10-751-736-10780
; Sequence 10780, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10780
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10780

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 367 AATAATTACACCTGACATG 387
Db 1 AATAATTACACCTGACATG 21

RESULT 17
US-10-751-736-10783
; Sequence 10783, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10783

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 370 AATTACACCTGACATGAAC 390
Db 1 AATTACACCTGACATGAAC 21

RESULT 18
US-10-751-736-10786

; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10765
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10765

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 97 AATGTGCTATTGGTGAGAGA 117
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AATGTGCTATTGGTGAGAGA 21

RESULT 12
US-10-751-736-10768
; Sequence 10768, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10768
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10768

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 147 AAACAACCTCCAGTGACAAA 167
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AAACAACCTCCAGTGACAAA 21

RESULT 13
US-10-751-736-10771
; Sequence 10771, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10771
; LENGTH: 21
; TYPE: DNA

; ORGANISM: homo sapiens
US-10-751-736-10771

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 200 AATCCAAGAAATCGACACT 220
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AATCCAAGAAATCGACACT 21

RESULT 14
US-10-751-736-10774
; Sequence 10774, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10774
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10774

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 AATCCAAGAAATCGACACT 221
| | | | | | | | | | | | | | | | | | | | | |
Db 1 AATCCAAGAAATCGACACT 21

RESULT 15
US-10-751-736-10777
; Sequence 10777, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10777
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10777

Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10759
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10759

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      70 AACAGCTCTACAAGCCTGGAA 90
Db      1 AACAGCTCTACAAGCCTGGAA 21

RESULT 10.
US-10-751-736-10762
; Sequence 10762, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10762
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10762

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      94 AATAATGCTATTGGTGAG 114
Db      1 AATAATGCTATTGGTGAG 21

RESULT 11.
US-10-751-736-10765
; Sequence 10765, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10759
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10759
```

```

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10753
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10753

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      16 AAGTTTCTCTAATACTGCTC 36
Db      1 AAGTTTCTCTAATACTGCTC 21

RESULT 8.
US-10-751-736-10756
; Sequence 10756, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10756
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10756

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      27 AATACTGCTCTGAGGCCAC 47
Db      1 AATACTGCTCTGAGGCCAC 21

RESULT 9.
US-10-751-736-10759
; Sequence 10759, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: SEQ ID NO. 20; MMP-12 forward primer
US-10-619-906-20

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1366 GACTTCCTACTCCACGATACACC 1389
Db 1 GACTTCCTACTCCACGATACACC 24

RESULT 3
US-10-619-906-21/c
; Sequence 21, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 21
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: SEQ ID NO. 21; MMP-12 reverse primer
US-10-619-906-21

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1692 GCTTCCTAACATCCTTGGACTGAG 1715
Db 24 GCTTCCTAACATCCTTGGACTGAG 1

RESULT 4
US-10-872-063-161/c
; Sequence 161, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soomnyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-161
```

```
Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 870 GAGTTTGTGATGCTGTCTCACTACCGT 893
Db 24 GAGTTTGTGATGCTGTCTCACTACCGT 1

RESULT 5
US-10-872-063-162
; Sequence 162, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soomnyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; TITLE OF INVENTION: Recurrence
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 162
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-162

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 845 AACCAGCTCTCTGTGACCCCAATT 868
Db 1 AACCAGCTCTCTGTGACCCCAATT 24

RESULT 6
US-10-719-900-174229
; Sequence 174229, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174229
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174229

Query Match      1.3%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 65;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1290 GCCTAAATTTGATGCAGTCTTCTA 1313
Db 2 GCCTAAATTTGATGCAGTCTTCTA 25
```


399	19	1.1	21	1	US-10-751-736-10787	Sequence 10787, A	472	19	1.1	21	1	US-10-751-736-11222	Sequence 11222, A
400	19	1.1	21	1	US-10-751-736-10793	Sequence 10793, A	473	19	1.1	21	1	US-10-751-736-11225	Sequence 11225, A
401	19	1.1	21	1	US-10-751-736-10799	Sequence 10799, A	474	19	1.1	21	1	US-10-751-736-11228	Sequence 11228, A
402	19	1.1	21	1	US-10-751-736-10802	Sequence 10802, A	475	19	1.1	21	1	US-10-751-736-11231	Sequence 11231, A
403	19	1.1	21	1	US-10-751-736-10808	Sequence 10808, A	476	19	1.1	21	1	US-10-751-736-11234	Sequence 11234, A
404	19	1.1	21	1	US-10-751-736-10814	Sequence 10814, A	477	19	1.1	21	1	US-10-751-736-11237	Sequence 11237, A
405	19	1.1	21	1	US-10-751-736-10823	Sequence 10823, A	478	19	1.1	21	1	US-10-751-736-11240	Sequence 11240, A
406	19	1.1	21	1	US-10-751-736-10826	Sequence 10826, A	479	19	1.1	21	1	US-10-751-736-11258	Sequence 11258, A
407	19	1.1	21	1	US-10-751-736-10832	Sequence 10832, A	480	19	1.1	21	1	US-10-751-736-11264	Sequence 11264, A
408	19	1.1	21	1	US-10-751-736-10838	Sequence 10838, A	481	19	1.1	21	1	US-10-751-736-11267	Sequence 11267, A
409	19	1.1	21	1	US-10-751-736-10841	Sequence 10841, A	482	19	1.1	21	1	US-10-751-736-11270	Sequence 11270, A
410	19	1.1	21	1	US-10-751-736-10844	Sequence 10844, A	483	19	1.1	21	1	US-10-751-736-11273	Sequence 11273, A
411	19	1.1	21	1	US-10-751-736-10847	Sequence 10847, A	484	19	1.1	21	1	US-10-751-736-11276	Sequence 11276, A
412	19	1.1	21	1	US-10-751-736-10850	Sequence 10850, A	485	19	1.1	21	1	US-10-751-736-11291	Sequence 11291, A
413	19	1.1	21	1	US-10-751-736-10853	Sequence 10853, A	486	19	1.1	21	1	US-10-751-736-11294	Sequence 11294, A
414	19	1.1	21	1	US-10-751-736-10859	Sequence 10859, A	487	19	1.1	21	1	US-10-751-736-11297	Sequence 11297, A
415	19	1.1	21	1	US-10-751-736-10862	Sequence 10862, A	488	19	1.1	21	1	US-10-751-736-11300	Sequence 11300, A
416	19	1.1	21	1	US-10-751-736-10874	Sequence 10874, A	489	19	1.1	21	1	US-10-751-736-11303	Sequence 11303, A
417	19	1.1	21	1	US-10-751-736-10877	Sequence 10877, A	490	19	1.1	21	1	US-10-751-736-11306	Sequence 11306, A
418	19	1.1	21	1	US-10-751-736-10883	Sequence 10883, A	491	19	1.1	21	1	US-10-751-736-11309	Sequence 11309, A
419	19	1.1	21	1	US-10-751-736-10886	Sequence 10886, A	492	19	1.1	21	1	US-10-751-736-11324	Sequence 11324, A
420	19	1.1	21	1	US-10-751-736-10901	Sequence 10901, A	493	19	1.1	21	1	US-10-751-736-11330	Sequence 11330, A
421	19	1.1	21	1	US-10-751-736-10919	Sequence 10919, A	494	19	1.1	21	1	US-10-751-736-11336	Sequence 11336, A
422	19	1.1	21	1	US-10-751-736-10928	Sequence 10928, A	495	19	1.1	21	1	US-10-751-736-11339	Sequence 11339, A
423	19	1.1	21	1	US-10-751-736-10931	Sequence 10931, A	496	19	1.1	21	1	US-10-751-736-11351	Sequence 11351, A
424	19	1.1	21	1	US-10-751-736-10934	Sequence 10934, A	497	19	1.1	21	1	US-10-751-736-11363	Sequence 11363, A
425	19	1.1	21	1	US-10-751-736-10937	Sequence 10937, A	498	19	1.1	21	1	US-10-751-736-11378	Sequence 11378, A
426	19	1.1	21	1	US-10-751-736-10943	Sequence 10943, A	499	19	1.1	21	1	US-10-751-736-11381	Sequence 11381, A
427	19	1.1	21	1	US-10-751-736-10946	Sequence 10946, A	500	19	1.1	21	1	US-10-751-736-11387	Sequence 11387, A
428	19	1.1	21	1	US-10-751-736-10958	Sequence 10958, A	501	19	1.1	21	1	US-10-751-736-11393	Sequence 11393, A
429	19	1.1	21	1	US-10-751-736-10961	Sequence 10961, A	502	19	1.1	21	1	US-10-751-736-11399	Sequence 11399, A
430	19	1.1	21	1	US-10-751-736-10988	Sequence 10988, A	503	19	1.1	21	1	US-10-751-736-11402	Sequence 11402, A
431	19	1.1	21	1	US-10-751-736-10991	Sequence 10991, A	504	19	1.1	21	1	US-10-751-736-11408	Sequence 11408, A
432	19	1.1	21	1	US-10-751-736-10991	Sequence 10991, A	505	19	1.1	21	1	US-10-751-736-11411	Sequence 11411, A
433	19	1.1	21	1	US-10-751-736-11015	Sequence 11015, A	506	19	1.1	21	1	US-10-751-736-11426	Sequence 11426, A
434	19	1.1	21	1	US-10-751-736-11018	Sequence 11018, A	507	19	1.1	21	1	US-10-751-736-11435	Sequence 11435, A
435	19	1.1	21	1	US-10-751-736-11021	Sequence 11021, A	508	19	1.1	21	1	US-10-751-736-11438	Sequence 11438, A
436	19	1.1	21	1	US-10-751-736-11027	Sequence 11027, A	509	19	1.1	21	1	US-10-751-736-11441	Sequence 11441, A
437	19	1.1	21	1	US-10-751-736-11030	Sequence 11030, A	510	19	1.1	21	1	US-10-751-736-11444	Sequence 11444, A
438	19	1.1	21	1	US-10-751-736-11036	Sequence 11036, A	511	19	1.1	21	1	US-10-751-736-11450	Sequence 11450, A
439	19	1.1	21	1	US-10-751-736-11048	Sequence 11048, A	512	19	1.1	21	1	US-10-751-736-11453	Sequence 11453, A
440	19	1.1	21	1	US-10-751-736-11051	Sequence 11051, A	513	19	1.1	21	1	US-10-751-736-11456	Sequence 11456, A
441	19	1.1	21	1	US-10-751-736-11054	Sequence 11054, A	514	19	1.1	21	1	US-10-751-736-11468	Sequence 11468, A
442	19	1.1	21	1	US-10-751-736-11060	Sequence 11060, A	515	19	1.1	21	1	US-10-751-736-11480	Sequence 11480, A
443	19	1.1	21	1	US-10-751-736-11081	Sequence 11081, A	516	19	1.1	21	1	US-10-751-736-11483	Sequence 11483, A
444	19	1.1	21	1	US-10-751-736-11084	Sequence 11084, A	517	18.4	1.0	21	1	US-10-751-736-9562	Sequence 9562, Ap
445	19	1.1	21	1	US-10-751-736-11087	Sequence 11087, A	518	18.4	1.0	21	1	US-10-751-736-10009	Sequence 10009, Ap
446	19	1.1	21	1	US-10-751-736-11090	Sequence 11090, A	519	18.4	1.0	21	1	US-10-751-736-10163	Sequence 10163, A
447	19	1.1	21	1	US-10-751-736-11099	Sequence 11099, A	520	18	1.0	21	1	US-10-751-736-9563	Sequence 9563, Ap
448	19	1.1	21	1	US-10-751-736-11102	Sequence 11102, A	521	18	1.0	21	1	US-10-751-736-10012	Sequence 10012, A
449	19	1.1	21	1	US-10-751-736-11105	Sequence 11105, A	522	17.8	1.0	21	1	US-10-751-736-10058	Sequence 10058, A
450	19	1.1	21	1	US-10-751-736-11108	Sequence 11108, A	523	17.4	1.0	21	1	US-10-751-736-10054	Sequence 10054, A
451	19	1.1	21	1	US-10-751-736-11110	Sequence 11110, A	524	16.8	0.9	21	1	US-10-751-736-8698	Sequence 8698, Ap
452	19	1.1	21	1	US-10-751-736-11114	Sequence 11114, A	525	16.8	0.9	21	1	US-10-751-736-8704	Sequence 8704, Ap
453	19	1.1	21	1	US-10-751-736-11117	Sequence 11117, A	526	16.8	0.9	21	1	US-10-751-736-8707	Sequence 8707, Ap
454	19	1.1	21	1	US-10-751-736-11120	Sequence 11120, A	527	16.8	0.9	21	1	US-10-751-736-10057	Sequence 10057, A
455	19	1.1	21	1	US-10-751-736-11129	Sequence 11129, A	528	16.8	0.9	21	1	US-10-751-736-10162	Sequence 10162, A
456	19	1.1	21	1	US-10-751-736-11132	Sequence 11132, A	529	16.4	0.9	21	1	US-10-349-143-5754	Sequence 5754, Ap
457	19	1.1	21	1	US-10-751-736-11138	Sequence 11138, A	530	16.4	0.9	20	1	US-10-316-755-57	Sequence 57, Appl
458	19	1.1	21	1	US-10-751-736-11141	Sequence 11141, A	531	16.4	0.9	20	1	US-10-316-755-202	Sequence 202, Appl
459	19	1.1	21	1	US-10-751-736-11144	Sequence 11144, A	532	16.2	0.9	21	1	US-10-751-736-10777	Sequence 10777, A
460	19	1.1	21	1	US-10-751-736-11147	Sequence 11147, A	533	16.2	0.9	21	1	US-10-751-736-10930	Sequence 10930, A
461	19	1.1	21	1	US-10-751-736-11150	Sequence 11150, A	534	16	0.9	20	1	US-10-462-039-25	Sequence 25, Appl
462	19	1.1	21	1	US-10-751-736-11156	Sequence 11156, A	535	16	0.9	20	1	US-10-462-039-26	Sequence 26, Appl
463	19	1.1	21	1	US-10-751-736-11159	Sequence 11159, A	536	15.8	0.9	19	1	US-10-830-569-140	Sequence 140, Appl
464	19	1.1	21	1	US-10-751-736-11171	Sequence 11171, A	537	15.8	0.9	19	1	US-10-830-569-447	Sequence 447, Appl
465	19	1.1	21	1	US-10-751-736-11183	Sequence 11183, A	538	15.4	0.9	17	1	US-09-866-108-10432	Sequence 10432, A
466	19	1.1	21	1	US-10-751-736-11195	Sequence 11195, A	539	15.4	0.9	17	1	US-10-052-545-19	Sequence 19, Appl
467	19	1.1	21	1	US-10-751-736-11198	Sequence 11198, A	540	15.4	0.9	17	1	US-10-723-361-10432	Sequence 10432, A
468	19	1.1	21	1	US-10-751-736-11207	Sequence 11207, A	541	15	0.8	17	1	US-09-780-533A-2552	Sequence 2552, Ap
469	19	1.1	21	1	US-10-751-736-11213	Sequence 11213, A	542	14.8	0.8	18	1	US-09-067-638B-57	Sequence 57, Appl
470	19	1.1	21	1	US-10-751-736-11216	Sequence 11216, A	543	14.8	0.8	18	1	US-09-969-373-2034	Sequence 2034, Ap
471	19	1.1	21	1	US-10-751-736-11219	Sequence 11219, A	544	14.8	0.8	18	1	US-10-116-325-57	Sequence 57, Appl

253	21	1.2	21	1	US-10-751-736-11440	Sequence 11440, A	326	20	1.1	21	1	US-10-751-736-11420	Sequence 11420, A
254	21	1.2	21	1	US-10-751-736-11443	Sequence 11443, A	327	20	1.1	21	1	US-10-751-736-11432	Sequence 11432, A
255	21	1.2	21	1	US-10-751-736-11446	Sequence 11446, A	328	20	1.1	21	1	US-10-751-736-11459	Sequence 11459, A
256	21	1.2	21	1	US-10-751-736-11447	Sequence 11447, A	329	20	1.1	21	1	US-10-751-736-11462	Sequence 11462, A
257	21	1.2	21	1	US-10-751-736-11449	Sequence 11449, A	330	20	1.1	21	1	US-10-751-736-11471	Sequence 11471, A
258	21	1.2	21	1	US-10-751-736-11452	Sequence 11452, A	331	20	1.1	21	1	US-10-751-736-11477	Sequence 11477, A
259	21	1.2	21	1	US-10-751-736-11455	Sequence 11455, A	332	19.4	1.1	21	1	US-10-751-736-10754	Sequence 10754, A
260	21	1.2	21	1	US-10-751-736-11458	Sequence 11458, A	333	19.4	1.1	21	1	US-10-751-736-10775	Sequence 10775, A
261	21	1.2	21	1	US-10-751-736-11461	Sequence 11461, A	334	19.4	1.1	21	1	US-10-751-736-10778	Sequence 10778, A
262	21	1.2	21	1	US-10-751-736-11467	Sequence 11467, A	335	19.4	1.1	21	1	US-10-751-736-10796	Sequence 10796, A
263	21	1.2	21	1	US-10-751-736-11470	Sequence 11470, A	336	19.4	1.1	21	1	US-10-751-736-10829	Sequence 10829, A
264	21	1.2	21	1	US-10-751-736-11473	Sequence 11473, A	337	19.4	1.1	21	1	US-10-751-736-10835	Sequence 10835, A
265	21	1.2	21	1	US-10-751-736-11474	Sequence 11474, A	338	19.4	1.1	21	1	US-10-751-736-10856	Sequence 10856, A
266	21	1.2	21	1	US-10-751-736-11476	Sequence 11476, A	339	19.4	1.1	21	1	US-10-751-736-10880	Sequence 10880, A
267	21	1.2	21	1	US-10-751-736-11479	Sequence 11479, A	340	19.4	1.1	21	1	US-10-751-736-10892	Sequence 10892, A
268	21	1.2	21	1	US-10-751-736-11482	Sequence 11482, A	341	19.4	1.1	21	1	US-10-751-736-10895	Sequence 10895, A
269	21	1.2	21	1	US-10-751-736-11483	Sequence 11483, A	342	19.4	1.1	21	1	US-10-751-736-10904	Sequence 10904, A
270	20.8	1.2	25	1	US-10-719-900-127230	Sequence 127230, A	343	19.4	1.1	21	1	US-10-751-736-10910	Sequence 10910, A
271	20.4	1.1	25	1	US-10-809-189-127779	Sequence 127779, A	344	19.4	1.1	21	1	US-10-751-736-10925	Sequence 10925, A
272	20.2	1.1	25	1	US-10-719-900-908158	Sequence 908158, A	345	19.4	1.1	21	1	US-10-751-736-10949	Sequence 10949, A
273	20.2	1.1	25	1	US-10-719-900-967442	Sequence 967442, A	346	19.4	1.1	21	1	US-10-751-736-10952	Sequence 10952, A
274	20.2	1.1	25	1	US-10-809-189-125366	Sequence 125366, A	347	19.4	1.1	21	1	US-10-751-736-10957	Sequence 10957, A
275	20.2	1.1	25	1	US-10-274-095-35	Sequence 35, Appl	348	19.4	1.1	21	1	US-10-751-736-11003	Sequence 11003, A
276	20	1.1	20	1	US-10-274-095-36	Sequence 36, Appl	349	19.4	1.1	21	1	US-10-751-736-11039	Sequence 11039, A
277	20	1.1	20	1	US-10-751-736-10757	Sequence 10757, A	350	19.4	1.1	21	1	US-10-751-736-11063	Sequence 11063, A
278	20	1.1	21	1	US-10-751-736-10766	Sequence 10766, A	351	19.4	1.1	21	1	US-10-751-736-11069	Sequence 11069, A
279	20	1.1	21	1	US-10-751-736-10772	Sequence 10772, A	352	19.4	1.1	21	1	US-10-751-736-11135	Sequence 11135, A
280	20	1.1	21	1	US-10-751-736-10811	Sequence 10811, A	353	19.4	1.1	21	1	US-10-751-736-11162	Sequence 11162, A
281	20	1.1	21	1	US-10-751-736-10871	Sequence 10871, A	354	19.4	1.1	21	1	US-10-751-736-11165	Sequence 11165, A
282	20	1.1	21	1	US-10-751-736-10889	Sequence 10889, A	355	19.4	1.1	21	1	US-10-751-736-11180	Sequence 11180, A
283	20	1.1	21	1	US-10-751-736-10907	Sequence 10907, A	356	19.4	1.1	21	1	US-10-751-736-11192	Sequence 11192, A
284	20	1.1	21	1	US-10-751-736-10913	Sequence 10913, A	357	19.4	1.1	21	1	US-10-751-736-11210	Sequence 11210, A
285	20	1.1	21	1	US-10-751-736-10916	Sequence 10916, A	358	19.4	1.1	21	1	US-10-751-736-11246	Sequence 11246, A
286	20	1.1	21	1	US-10-751-736-10922	Sequence 10922, A	359	19.4	1.1	21	1	US-10-751-736-11249	Sequence 11249, A
287	20	1.1	21	1	US-10-751-736-10932	Sequence 10932, A	360	19.4	1.1	21	1	US-10-751-736-11252	Sequence 11252, A
288	20	1.1	21	1	US-10-751-736-10940	Sequence 10940, A	361	19.4	1.1	21	1	US-10-751-736-11255	Sequence 11255, A
289	20	1.1	21	1	US-10-751-736-10955	Sequence 10955, A	362	19.4	1.1	21	1	US-10-751-736-11261	Sequence 11261, A
290	20	1.1	21	1	US-10-751-736-10964	Sequence 10964, A	363	19.4	1.1	21	1	US-10-751-736-11282	Sequence 11282, A
291	20	1.1	21	1	US-10-751-736-10967	Sequence 10967, A	364	19.4	1.1	21	1	US-10-751-736-11285	Sequence 11285, A
292	20	1.1	21	1	US-10-751-736-10970	Sequence 10970, A	365	19.4	1.1	21	1	US-10-751-736-11288	Sequence 11288, A
293	20	1.1	21	1	US-10-751-736-10973	Sequence 10973, A	366	19.4	1.1	21	1	US-10-751-736-11318	Sequence 11318, A
294	20	1.1	21	1	US-10-751-736-10979	Sequence 10979, A	367	19.4	1.1	21	1	US-10-751-736-11327	Sequence 11327, A
295	20	1.1	21	1	US-10-751-736-10982	Sequence 10982, A	368	19.4	1.1	21	1	US-10-751-736-11342	Sequence 11342, A
296	20	1.1	21	1	US-10-751-736-10994	Sequence 10994, A	369	19.4	1.1	21	1	US-10-751-736-11345	Sequence 11345, A
297	20	1.1	21	1	US-10-751-736-11006	Sequence 11006, A	370	19.4	1.1	21	1	US-10-751-736-11354	Sequence 11354, A
298	20	1.1	21	1	US-10-751-736-11009	Sequence 11009, A	371	19.4	1.1	21	1	US-10-751-736-11357	Sequence 11357, A
299	20	1.1	21	1	US-10-751-736-11012	Sequence 11012, A	372	19.4	1.1	21	1	US-10-751-736-11360	Sequence 11360, A
300	20	1.1	21	1	US-10-751-736-11024	Sequence 11024, A	373	19.4	1.1	21	1	US-10-751-736-11366	Sequence 11366, A
301	20	1.1	21	1	US-10-751-736-11042	Sequence 11042, A	374	19.4	1.1	21	1	US-10-751-736-11384	Sequence 11384, A
302	20	1.1	21	1	US-10-751-736-11057	Sequence 11057, A	375	19.4	1.1	21	1	US-10-751-736-11396	Sequence 11396, A
303	20	1.1	21	1	US-10-751-736-11066	Sequence 11066, A	376	19.4	1.1	21	1	US-10-751-736-11405	Sequence 11405, A
304	20	1.1	21	1	US-10-751-736-11075	Sequence 11075, A	377	19.4	1.1	21	1	US-10-751-736-11429	Sequence 11429, A
305	20	1.1	21	1	US-10-751-736-11078	Sequence 11078, A	378	19.4	1.1	21	1	US-10-751-736-11465	Sequence 11465, A
306	20	1.1	21	1	US-10-751-736-11093	Sequence 11093, A	379	19.4	1.1	21	1	US-10-751-736-11465	Sequence 11465, A
307	20	1.1	21	1	US-10-751-736-11096	Sequence 11096, A	380	19	1.1	19	1	US-10-619-906-3	Sequence 3, Appl
308	20	1.1	21	1	US-10-751-736-11126	Sequence 11126, A	381	19	1.1	19	1	US-10-619-906-4	Sequence 4, Appl
309	20	1.1	21	1	US-10-751-736-11132	Sequence 11132, A	382	19	1.1	19	1	US-10-619-906-5	Sequence 5, Appl
310	20	1.1	21	1	US-10-751-736-11153	Sequence 11153, A	383	19	1.1	19	1	US-10-619-906-6	Sequence 6, Appl
311	20	1.1	21	1	US-10-751-736-11168	Sequence 11168, A	384	19	1.1	19	1	US-10-619-906-7	Sequence 7, Appl
312	20	1.1	21	1	US-10-751-736-11174	Sequence 11174, A	385	19	1.1	19	1	US-10-619-906-8	Sequence 8, Appl
313	20	1.1	21	1	US-10-751-736-11177	Sequence 11177, A	386	19	1.1	19	1	US-10-619-906-9	Sequence 9, Appl
314	20	1.1	21	1	US-10-751-736-11186	Sequence 11186, A	387	19	1.1	19	1	US-10-619-906-10	Sequence 10, Appl
315	20	1.1	21	1	US-10-751-736-11189	Sequence 11189, A	388	19	1.1	19	1	US-10-619-906-11	Sequence 11, Appl
316	20	1.1	21	1	US-10-751-736-11204	Sequence 11204, A	389	19	1.1	19	1	US-10-619-906-12	Sequence 12, Appl
317	20	1.1	21	1	US-10-751-736-11312	Sequence 11312, A	390	19	1.1	19	1	US-10-619-906-13	Sequence 13, Appl
318	20	1.1	21	1	US-10-751-736-11315	Sequence 11315, A	391	19	1.1	19	1	US-10-619-906-14	Sequence 14, Appl
319	20	1.1	21	1	US-10-751-736-11321	Sequence 11321, A	392	19	1.1	19	1	US-10-619-906-15	Sequence 15, Appl
320	20	1.1	21	1	US-10-751-736-11333	Sequence 11333, A	393	19	1.1	19	1	US-10-619-906-16	Sequence 16, Appl
321	20	1.1	21	1	US-10-751-736-11348	Sequence 11348, A	394	19	1.1	21	1	US-10-751-736-10010	Sequence 10010, A
322	20	1.1	21	1	US-10-751-736-11369	Sequence 11369, A	395	19	1.1	21	1	US-10-751-736-10760	Sequence 10760, A
323	20	1.1	21	1	US-10-751-736-11375	Sequence 11375, A	396	19	1.1	21	1	US-10-751-736-10763	Sequence 10763, A
324	20	1.1	21	1	US-10-751-736-11390	Sequence 11390, A	397	19	1.1	21	1	US-10-751-736-10769	Sequence 10769, A
325	20	1.1	21	1	US-10-751-736-11414	Sequence 11414, A	398	19	1.1	21	1	US-10-751-736-10781	Sequence 10781, A
326	20	1.1	21	1	US-10-751-736-11417	Sequence 11417, A	399	19	1.1	21	1	US-10-751-736-10784	Sequence 10784, A

107	21	1.2	21	1	US-10-751-736-11029	Sequence 11029, A	180	21	1.2	21	1	US-10-751-736-11233	Sequence 11233, A
108	21	1.2	21	1	US-10-751-736-11032	Sequence 11032, A	181	21	1.2	21	1	US-10-751-736-11236	Sequence 11236, A
109	21	1.2	21	1	US-10-751-736-11033	Sequence 11033, A	182	21	1.2	21	1	US-10-751-736-11239	Sequence 11239, A
110	21	1.2	21	1	US-10-751-736-11035	Sequence 11035, A	183	21	1.2	21	1	US-10-751-736-11242	Sequence 11242, A
111	21	1.2	21	1	US-10-751-736-11038	Sequence 11038, A	184	21	1.2	21	1	US-10-751-736-11243	Sequence 11243, A
112	21	1.2	21	1	US-10-751-736-11041	Sequence 11041, A	185	21	1.2	21	1	US-10-751-736-11245	Sequence 11245, A
113	21	1.2	21	1	US-10-751-736-11044	Sequence 11044, A	186	21	1.2	21	1	US-10-751-736-11248	Sequence 11248, A
114	21	1.2	21	1	US-10-751-736-11045	Sequence 11045, A	187	21	1.2	21	1	US-10-751-736-11251	Sequence 11251, A
115	21	1.2	21	1	US-10-751-736-11047	Sequence 11047, A	188	21	1.2	21	1	US-10-751-736-11254	Sequence 11254, A
116	21	1.2	21	1	US-10-751-736-11050	Sequence 11050, A	189	21	1.2	21	1	US-10-751-736-11257	Sequence 11257, A
117	21	1.2	21	1	US-10-751-736-11053	Sequence 11053, A	190	21	1.2	21	1	US-10-751-736-11260	Sequence 11260, A
118	21	1.2	21	1	US-10-751-736-11056	Sequence 11056, A	191	21	1.2	21	1	US-10-751-736-11263	Sequence 11263, A
119	21	1.2	21	1	US-10-751-736-11059	Sequence 11059, A	192	21	1.2	21	1	US-10-751-736-11266	Sequence 11266, A
120	21	1.2	21	1	US-10-751-736-11062	Sequence 11062, A	193	21	1.2	21	1	US-10-751-736-11269	Sequence 11269, A
121	21	1.2	21	1	US-10-751-736-11065	Sequence 11065, A	194	21	1.2	21	1	US-10-751-736-11272	Sequence 11272, A
122	21	1.2	21	1	US-10-751-736-11068	Sequence 11068, A	195	21	1.2	21	1	US-10-751-736-11275	Sequence 11275, A
123	21	1.2	21	1	US-10-751-736-11071	Sequence 11071, A	196	21	1.2	21	1	US-10-751-736-11278	Sequence 11278, A
124	21	1.2	21	1	US-10-751-736-11072	Sequence 11072, A	197	21	1.2	21	1	US-10-751-736-11279	Sequence 11279, A
125	21	1.2	21	1	US-10-751-736-11074	Sequence 11074, A	198	21	1.2	21	1	US-10-751-736-11281	Sequence 11281, A
126	21	1.2	21	1	US-10-751-736-11077	Sequence 11077, A	199	21	1.2	21	1	US-10-751-736-11284	Sequence 11284, A
127	21	1.2	21	1	US-10-751-736-11080	Sequence 11080, A	200	21	1.2	21	1	US-10-751-736-11287	Sequence 11287, A
128	21	1.2	21	1	US-10-751-736-11083	Sequence 11083, A	201	21	1.2	21	1	US-10-751-736-11290	Sequence 11290, A
129	21	1.2	21	1	US-10-751-736-11086	Sequence 11086, A	202	21	1.2	21	1	US-10-751-736-11293	Sequence 11293, A
130	21	1.2	21	1	US-10-751-736-11089	Sequence 11089, A	203	21	1.2	21	1	US-10-751-736-11296	Sequence 11296, A
131	21	1.2	21	1	US-10-751-736-11092	Sequence 11092, A	204	21	1.2	21	1	US-10-751-736-11299	Sequence 11299, A
132	21	1.2	21	1	US-10-751-736-11095	Sequence 11095, A	205	21	1.2	21	1	US-10-751-736-11302	Sequence 11302, A
133	21	1.2	21	1	US-10-751-736-11098	Sequence 11098, A	206	21	1.2	21	1	US-10-751-736-11305	Sequence 11305, A
134	21	1.2	21	1	US-10-751-736-11101	Sequence 11101, A	207	21	1.2	21	1	US-10-751-736-11308	Sequence 11308, A
135	21	1.2	21	1	US-10-751-736-11104	Sequence 11104, A	208	21	1.2	21	1	US-10-751-736-11311	Sequence 11311, A
136	21	1.2	21	1	US-10-751-736-11107	Sequence 11107, A	209	21	1.2	21	1	US-10-751-736-11314	Sequence 11314, A
137	21	1.2	21	1	US-10-751-736-11110	Sequence 11110, A	210	21	1.2	21	1	US-10-751-736-11317	Sequence 11317, A
138	21	1.2	21	1	US-10-751-736-11113	Sequence 11113, A	211	21	1.2	21	1	US-10-751-736-11320	Sequence 11320, A
139	21	1.2	21	1	US-10-751-736-11116	Sequence 11116, A	212	21	1.2	21	1	US-10-751-736-11323	Sequence 11323, A
140	21	1.2	21	1	US-10-751-736-11119	Sequence 11119, A	213	21	1.2	21	1	US-10-751-736-11326	Sequence 11326, A
141	21	1.2	21	1	US-10-751-736-11122	Sequence 11122, A	214	21	1.2	21	1	US-10-751-736-11329	Sequence 11329, A
142	21	1.2	21	1	US-10-751-736-11125	Sequence 11125, A	215	21	1.2	21	1	US-10-751-736-11332	Sequence 11332, A
143	21	1.2	21	1	US-10-751-736-11128	Sequence 11128, A	216	21	1.2	21	1	US-10-751-736-11335	Sequence 11335, A
144	21	1.2	21	1	US-10-751-736-11131	Sequence 11131, A	217	21	1.2	21	1	US-10-751-736-11338	Sequence 11338, A
145	21	1.2	21	1	US-10-751-736-11134	Sequence 11134, A	218	21	1.2	21	1	US-10-751-736-11341	Sequence 11341, A
146	21	1.2	21	1	US-10-751-736-11137	Sequence 11137, A	219	21	1.2	21	1	US-10-751-736-11344	Sequence 11344, A
147	21	1.2	21	1	US-10-751-736-11140	Sequence 11140, A	220	21	1.2	21	1	US-10-751-736-11347	Sequence 11347, A
148	21	1.2	21	1	US-10-751-736-11143	Sequence 11143, A	221	21	1.2	21	1	US-10-751-736-11350	Sequence 11350, A
149	21	1.2	21	1	US-10-751-736-11146	Sequence 11146, A	222	21	1.2	21	1	US-10-751-736-11353	Sequence 11353, A
150	21	1.2	21	1	US-10-751-736-11149	Sequence 11149, A	223	21	1.2	21	1	US-10-751-736-11356	Sequence 11356, A
151	21	1.2	21	1	US-10-751-736-11152	Sequence 11152, A	224	21	1.2	21	1	US-10-751-736-11359	Sequence 11359, A
152	21	1.2	21	1	US-10-751-736-11155	Sequence 11155, A	225	21	1.2	21	1	US-10-751-736-11362	Sequence 11362, A
153	21	1.2	21	1	US-10-751-736-11158	Sequence 11158, A	226	21	1.2	21	1	US-10-751-736-11365	Sequence 11365, A
154	21	1.2	21	1	US-10-751-736-11161	Sequence 11161, A	227	21	1.2	21	1	US-10-751-736-11368	Sequence 11368, A
155	21	1.2	21	1	US-10-751-736-11164	Sequence 11164, A	228	21	1.2	21	1	US-10-751-736-11371	Sequence 11371, A
156	21	1.2	21	1	US-10-751-736-11167	Sequence 11167, A	229	21	1.2	21	1	US-10-751-736-11374	Sequence 11374, A
157	21	1.2	21	1	US-10-751-736-11170	Sequence 11170, A	230	21	1.2	21	1	US-10-751-736-11377	Sequence 11377, A
158	21	1.2	21	1	US-10-751-736-11173	Sequence 11173, A	231	21	1.2	21	1	US-10-751-736-11380	Sequence 11380, A
159	21	1.2	21	1	US-10-751-736-11176	Sequence 11176, A	232	21	1.2	21	1	US-10-751-736-11383	Sequence 11383, A
160	21	1.2	21	1	US-10-751-736-11179	Sequence 11179, A	233	21	1.2	21	1	US-10-751-736-11386	Sequence 11386, A
161	21	1.2	21	1	US-10-751-736-11182	Sequence 11182, A	234	21	1.2	21	1	US-10-751-736-11389	Sequence 11389, A
162	21	1.2	21	1	US-10-751-736-11185	Sequence 11185, A	235	21	1.2	21	1	US-10-751-736-11392	Sequence 11392, A
163	21	1.2	21	1	US-10-751-736-11188	Sequence 11188, A	236	21	1.2	21	1	US-10-751-736-11395	Sequence 11395, A
164	21	1.2	21	1	US-10-751-736-11191	Sequence 11191, A	237	21	1.2	21	1	US-10-751-736-11398	Sequence 11398, A
165	21	1.2	21	1	US-10-751-736-11194	Sequence 11194, A	238	21	1.2	21	1	US-10-751-736-11401	Sequence 11401, A
166	21	1.2	21	1	US-10-751-736-11197	Sequence 11197, A	239	21	1.2	21	1	US-10-751-736-11404	Sequence 11404, A
167	21	1.2	21	1	US-10-751-736-11200	Sequence 11200, A	240	21	1.2	21	1	US-10-751-736-11407	Sequence 11407, A
168	21	1.2	21	1	US-10-751-736-11203	Sequence 11203, A	241	21	1.2	21	1	US-10-751-736-11410	Sequence 11410, A
169	21	1.2	21	1	US-10-751-736-11206	Sequence 11206, A	242	21	1.2	21	1	US-10-751-736-11413	Sequence 11413, A
170	21	1.2	21	1	US-10-751-736-11209	Sequence 11209, A	243	21	1.2	21	1	US-10-751-736-11416	Sequence 11416, A
171	21	1.2	21	1	US-10-751-736-11212	Sequence 11212, A	244	21	1.2	21	1	US-10-751-736-11419	Sequence 11419, A
172	21	1.2	21	1	US-10-751-736-11215	Sequence 11215, A	245	21	1.2	21	1	US-10-751-736-11422	Sequence 11422, A
173	21	1.2	21	1	US-10-751-736-11218	Sequence 11218, A	246	21	1.2	21	1	US-10-751-736-11425	Sequence 11425, A
174	21	1.2	21	1	US-10-751-736-11221	Sequence 11221, A	247	21	1.2	21	1	US-10-751-736-11428	Sequence 11428, A
175	21	1.2	21	1	US-10-751-736-11224	Sequence 11224, A	248	21	1.2	21	1	US-10-751-736-11431	Sequence 11431, A
176	21	1.2	21	1	US-10-751-736-11227	Sequence 11227, A	249	21	1.2	21	1	US-10-751-736-11434	Sequence 11434, A
177	21	1.2	21	1	US-10-751-736-11230	Sequence 11230, A	250	21	1.2	21	1	US-10-751-736-11437	Sequence 11437, A
178	21	1.2	21	1	US-10-751-736-11233	Sequence 11233, A	251	21	1.2	21	1	US-10-751-736-11440	Sequence 11440, A
179	21	1.2	21	1	US-10-751-736-11236	Sequence 11236, A	252	21	1.2	21	1	US-10-751-736-11443	Sequence 11443, A

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:30:53 ; Search time 11 Seconds
(without alignments)
4.138 Million cell updates/sec

Title: US-10-619-906-1
Perfect score: 1778
Sequence: 1 tagaagtttaacaagaatt.....tttggctcaataaattg 1778

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 625 seqs, 12799 residues
Total number of hits satisfying chosen parameters: 1250

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 635 summaries

Database : rnpbl.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	2.8	50	1	US-10-131-827-2299
2	24	1.3	24	1	Sequence 2299, Ap
3	24	1.3	24	1	Sequence 1019, Ap
4	24	1.3	24	1	Sequence 161, Ap
5	24	1.3	24	1	Sequence 162, Ap
6	22.4	1.3	25	1	Sequence 174229
7	21	1.2	21	1	US-10-719-900-174229
8	21	1.2	21	1	Sequence 10753, A
9	21	1.2	21	1	Sequence 10756, A
10	21	1.2	21	1	Sequence 10759, A
11	21	1.2	21	1	Sequence 10762, A
12	21	1.2	21	1	Sequence 10765, A
13	21	1.2	21	1	Sequence 10768, A
14	21	1.2	21	1	Sequence 10771, A
15	21	1.2	21	1	Sequence 10774, A
16	21	1.2	21	1	Sequence 10777, A
17	21	1.2	21	1	Sequence 10780, A
18	21	1.2	21	1	Sequence 10783, A
19	21	1.2	21	1	Sequence 10786, A
20	21	1.2	21	1	Sequence 10789, A
21	21	1.2	21	1	Sequence 10792, A
22	21	1.2	21	1	Sequence 10795, A
23	21	1.2	21	1	Sequence 10798, A
24	21	1.2	21	1	Sequence 10801, A
25	21	1.2	21	1	Sequence 10804, A
26	21	1.2	21	1	Sequence 10807, A
27	21	1.2	21	1	Sequence 10810, A
28	21	1.2	21	1	Sequence 10813, A
29	21	1.2	21	1	Sequence 10816, A
30	21	1.2	21	1	Sequence 10817, A
31	21	1.2	21	1	Sequence 10819, A
32	21	1.2	21	1	Sequence 10820, A
33	21	1.2	21	1	Sequence 10822, A

34	21	1.2	21	1	US-10-751-736-10825	Sequence 10825, A
35	21	1.2	21	1	US-10-751-736-10828	Sequence 10828, A
36	21	1.2	21	1	US-10-751-736-10831	Sequence 10831, A
37	21	1.2	21	1	US-10-751-736-10834	Sequence 10834, A
38	21	1.2	21	1	US-10-751-736-10837	Sequence 10837, A
39	21	1.2	21	1	US-10-751-736-10840	Sequence 10840, A
40	21	1.2	21	1	US-10-751-736-10843	Sequence 10843, A
41	21	1.2	21	1	US-10-751-736-10846	Sequence 10846, A
42	21	1.2	21	1	US-10-751-736-10849	Sequence 10849, A
43	21	1.2	21	1	US-10-751-736-10852	Sequence 10852, A
44	21	1.2	21	1	US-10-751-736-10855	Sequence 10855, A
45	21	1.2	21	1	US-10-751-736-10858	Sequence 10858, A
46	21	1.2	21	1	US-10-751-736-10861	Sequence 10861, A
47	21	1.2	21	1	US-10-751-736-10864	Sequence 10864, A
48	21	1.2	21	1	US-10-751-736-10867	Sequence 10867, A
49	21	1.2	21	1	US-10-751-736-10868	Sequence 10868, A
50	21	1.2	21	1	US-10-751-736-10870	Sequence 10870, A
51	21	1.2	21	1	US-10-751-736-10873	Sequence 10873, A
52	21	1.2	21	1	US-10-751-736-10876	Sequence 10876, A
53	21	1.2	21	1	US-10-751-736-10879	Sequence 10879, A
54	21	1.2	21	1	US-10-751-736-10882	Sequence 10882, A
55	21	1.2	21	1	US-10-751-736-10885	Sequence 10885, A
56	21	1.2	21	1	US-10-751-736-10888	Sequence 10888, A
57	21	1.2	21	1	US-10-751-736-10891	Sequence 10891, A
58	21	1.2	21	1	US-10-751-736-10894	Sequence 10894, A
59	21	1.2	21	1	US-10-751-736-10897	Sequence 10897, A
60	21	1.2	21	1	US-10-751-736-10898	Sequence 10898, A
61	21	1.2	21	1	US-10-751-736-10900	Sequence 10900, A
62	21	1.2	21	1	US-10-751-736-10903	Sequence 10903, A
63	21	1.2	21	1	US-10-751-736-10906	Sequence 10906, A
64	21	1.2	21	1	US-10-751-736-10909	Sequence 10909, A
65	21	1.2	21	1	US-10-751-736-10912	Sequence 10912, A
66	21	1.2	21	1	US-10-751-736-10915	Sequence 10915, A
67	21	1.2	21	1	US-10-751-736-10918	Sequence 10918, A
68	21	1.2	21	1	US-10-751-736-10921	Sequence 10921, A
69	21	1.2	21	1	US-10-751-736-10924	Sequence 10924, A
70	21	1.2	21	1	US-10-751-736-10927	Sequence 10927, A
71	21	1.2	21	1	US-10-751-736-10930	Sequence 10930, A
72	21	1.2	21	1	US-10-751-736-10933	Sequence 10933, A
73	21	1.2	21	1	US-10-751-736-10936	Sequence 10936, A
74	21	1.2	21	1	US-10-751-736-10939	Sequence 10939, A
75	21	1.2	21	1	US-10-751-736-10942	Sequence 10942, A
76	21	1.2	21	1	US-10-751-736-10945	Sequence 10945, A
77	21	1.2	21	1	US-10-751-736-10948	Sequence 10948, A
78	21	1.2	21	1	US-10-751-736-10951	Sequence 10951, A
79	21	1.2	21	1	US-10-751-736-10954	Sequence 10954, A
80	21	1.2	21	1	US-10-751-736-10957	Sequence 10957, A
81	21	1.2	21	1	US-10-751-736-10960	Sequence 10960, A
82	21	1.2	21	1	US-10-751-736-10963	Sequence 10963, A
83	21	1.2	21	1	US-10-751-736-10966	Sequence 10966, A
84	21	1.2	21	1	US-10-751-736-10969	Sequence 10969, A
85	21	1.2	21	1	US-10-751-736-10972	Sequence 10972, A
86	21	1.2	21	1	US-10-751-736-10975	Sequence 10975, A
87	21	1.2	21	1	US-10-751-736-10978	Sequence 10978, A
88	21	1.2	21	1	US-10-751-736-10981	Sequence 10981, A
89	21	1.2	21	1	US-10-751-736-10984	Sequence 10984, A
90	21	1.2	21	1	US-10-751-736-10987	Sequence 10987, A
91	21	1.2	21	1	US-10-751-736-10990	Sequence 10990, A
92	21	1.2	21	1	US-10-751-736-10993	Sequence 10993, A
93	21	1.2	21	1	US-10-751-736-10996	Sequence 10996, A
94	21	1.2	21	1	US-10-751-736-10999	Sequence 10999, A
95	21	1.2	21	1	US-10-751-736-11002	Sequence 11002, A
96	21	1.2	21	1	US-10-751-736-11005	Sequence 11005, A
97	21	1.2	21	1	US-10-751-736-11008	Sequence 11008, A
98	21	1.2	21	1	US-10-751-736-11011	Sequence 11011, A
99	21	1.2	21	1	US-10-751-736-11014	Sequence 11014, A
100	21	1.2	21	1	US-10-751-736-11017	Sequence 11017, A
101	21	1.2	21	1	US-10-751-736-11020	Sequence 11020, A
102	21	1.2	21	1	US-10-751-736-11023	Sequence 11023, A
103	21	1.2	21	1	US-10-751-736-11026	Sequence 11026, A
104	21	1.2	21	1		
105	21	1.2	21	1		
106	21	1.2	21	1		

THIS PAGE BLANK (USPTO)

ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
FILING DATE: 17-Jul-2000
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: McSwiggen, Jim
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 240052.419C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 64:
US-09-618-166-64
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 13 ATGAAGTTTCTTCT 26
Db 1 AAGAAGTTTCTTCT 14
RESULT 100
US-09-689-012-5
Sequence 5, Application US/09689012
Patent No. 6670135
GENERAL INFORMATION:
APPLICANT: Spriggs, Melanie K.
TITLE OF INVENTION: NOVEL SEMAPHORIN POLYPEPTIDES
FILE REFERENCE: 2634-US
CURRENT APPLICATION NUMBER: US/09/689,012
CURRENT FILING DATE: 2000-10-12
PRIOR APPLICATION NUMBER: PCT/US99/09831
PRIOR FILING DATE: 1999-05-05
PRIOR APPLICATION NUMBER: US 60/085,497
PRIOR FILING DATE: 1998-05-14
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn version 3.1
SEQ ID NO 5
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PRIMER
US-09-689-012-5
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1329 CTACTATTTCTTCC 1342
Db 2 CTACTACTTCTTCC 15
RESULT 101
US-09-685-664B-4101/C
Sequence 4101, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH00-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
CURRENT FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/594,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 4101
LENGTH: 15
TYPE: RNA
ORGANISM: Homo sapiens
US-09-685-664B-4101
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1562 TATATAAATACAT 1575
Db 14 TATACAAAATACAT 1
Search completed: May 13, 2005, 11:28:24
Job time : 2 secs

```
; Patent No. 6528639
; GENERAL INFORMATION:
; APPLICANT: USMAN, NASSIM
; APPLICANT: BEIGELMAN, LEONID
; APPLICANT: MCSWIGGEN, JAMES
; APPLICANT: KARPEISKI, ALEX
; TITLE OF INVENTION: BASE MODIFIED ENZYMATIC NUCLEIC ACIDS
; FILE REFERENCE: MBH00-810-F
; CURRENT APPLICATION NUMBER: US/09/034,113
; CURRENT FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 07/963,322
; PRIOR FILING DATE: 1992-10-15
; PRIOR APPLICATION NUMBER: 08/149,210
; PRIOR FILING DATE: 1993-11-08
; PRIOR APPLICATION NUMBER: 08/435,521
; PRIOR FILING DATE: 1995-05-05
; PRIOR APPLICATION NUMBER: 09/034,113
; PRIOR FILING DATE: 1998-03-03
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 11
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target of
; OTHER INFORMATION: Hammerhead Ribozyme to Site C (HHC).
US-09-034-113-11

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 910 TTCTTCRAAGACAG 923
Db 14 TTCTTCRAAGACAG 1

RESULT 97
US-08-431-048F-148/c
; Sequence 148, Application US/08431048F
; Patent No. 6531596
; GENERAL INFORMATION:
; APPLICANT: ST. GEORGE-HYSLOP, PETER H
; ROMMENS, JOHANNA M
; FRASER, PAUL E
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
; NUMBER OF SEQUENCES: 155
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARRY & DARRY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: N.Y.
; COUNTRY: U.S.A.
; ZIP: 10022-7513
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/431,048F
; FILING DATE: 28-Apr-1995
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: FEHLNER, PAUL F.
; REGISTRATION NUMBER: 35135
; REFERENCE/DOCKET NUMBER: 1034/0F808
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-527-7700
; TELEFAX: 212-527-6237
; INFORMATION FOR SEQ ID NO: 148:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 148:
US-08-431-048F-148

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 473 CAGGCATGGCTGAC 486
Db 14 CAGGCATGGATGAC 1

RESULT 98
US-09-371-772B-4101/c
; Sequence 4101, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4101
; LENGTH: 15
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4101

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1562 TATATAAAATACAT 1575
Db 14 TATACAAAATACAT 1

RESULT 99
US-09-618-166-64
; Sequence 64, Application US/09618166
; Patent No. 6583112
; GENERAL INFORMATION:
; APPLICANT: Fu, Ying-Hui
; Yu, Chang-En
; Oshima, Junko
; Mulligan, John T.
; Schellenberg, Gerald D.
; TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
; WERNER'S SYNDROME
; NUMBER OF SEQUENCES: 209
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed Intellectual Property Law Group
; STREET: 701 Fifth Avenue, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
```

;; PRIOR APPLICATION DATA: 0.7%; Score 12.4; DB 1; Length 15;
;; APPLICATION NUMBER: 08/585,684
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/078
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 93:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-038-073-93

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 652 CTCACCTGCTGTCA 665
Db 1 CUCACUUCUGUCCA 14

RESULT 94
US-08-584-040-8445/c
; Sequence 8445, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8445:

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-8445

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1562 TATATAAATACAT 1575
Db 14 TATACAAATACAT 1

RESULT 95
US-09-593-312-12/c
; Sequence 12, Application US/09593312
; Patent No. 6514699
; GENERAL INFORMATION:
; APPLICANT: O'Neill, Roger A.
; APPLICANT: Chen, Jer-Kang
; APPLICANT: Chiesa, Claudia
; APPLICANT: Fry, George
; TITLE OF INVENTION: Multiplex Polynucleotide Capture
; TITLE OF INVENTION: Methods and Compositions
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PE Applied Biosystems
; STREET: 850 Lincoln Centre Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/593,312
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/873,437
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bortner, Scott R.
; REGISTRATION NUMBER: 34,298
; REFERENCE/DOCKET NUMBER: 4294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-638-6245
; TELEFAX: 415-638-6071
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-593-312-12

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 15 GAAGTTTCTTCTAA 28
Db 15 GAAGTTTCTTCTAA 2

RESULT 96
US-09-034-113-11/c
; Sequence 11, Application US/09034113

QY 13 ATGAAGTTTCTTCT 26
| | | | | | | | | |
Db 1 AAGAAGTTTCTTCT 14

RESULT 91

US-08-873-437-12/c
; Sequence 12, Application US/08873437
; Patent No. 6124092
; GENERAL INFORMATION:
; APPLICANT: O'Neill, Roger A.
; APPLICANT: Chen, Jer-Kang
; APPLICANT: Chiesa, Claudia
; APPLICANT: Fry, George
; TITLE OF INVENTION: Multiplex Polynucleotide Capture
; TITLE OF INVENTION: Methods and Compositions
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PE Applied Biosystems
; STREET: 850 Lincoln Centre Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/873,437
; FILING DATE: 12-JUN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/027,832
; FILING DATE: 04-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bortner, Scott R
; REGISTRATION NUMBER: 34,298
; REFERENCE/DOCKET NUMBER: 4294
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-638-6245
; TELEFAX: 415-638-6071
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-873-437-12

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 15 GAAGTTTCTTCTAA 28
| | | | | | | | | |
Db 15 GAAGTTTCTTCTAA 2

RESULT 92

US-09-038-073-92
; Sequence 92, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-038-073-92

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 652 CTCACGCTGCTTCA 665
| | | | | | | | | |
Db 2 CUCACUUCUGUUA 15

RESULT 93

US-09-038-073-93
; Sequence 93, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-93
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
APPLICANT: Parimoo, S.
APPLICANT: Prouty, S.
TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/832,021
CURRENT FILING DATE: 1997-04-02
NUMBER OF SEQ ID NOS: 64
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 17
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-17

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1043 TTTTCTCTTTTAAA 1056
Db 2 TTTTCTCTTTTAAA 15

RESULT 90
US-08-781-891-64
Sequence 64, Application US/08781891
Patent No. 6090620
GENERAL INFORMATION:
APPLICANT: Fu, Ying-Hui
APPLICANT: Yu, Chang-En
APPLICANT: Oshima, Junko
APPLICANT: Mulligan, John T.
APPLICANT: Schellengerg, Gerald D.
TITLE OF INVENTION: GENE AND GENE PRODUCTS RELATED TO
TITLE OF INVENTION: WERNER'S SYNDROME
NUMBER OF SEQUENCES: 209
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/781,891
FILING DATE: 27-DEC-1996
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: No. 6090620tenburg Ph.D., Carol
REGISTRATION NUMBER: 39,317
REFERENCE/DOCKET NUMBER: 240052.419
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 64:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-781-891-64

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1043 TTTTCTCTTTTAAA 1056
Db 14 TTTTCTCTTTTAAA 1

RESULT 89
US-08-832-021-17
Sequence 17, Application US/08832021
Patent No. 6045398
GENERAL INFORMATION:
APPLICANT: Combates, N.
APPLICANT: Pardinas, J.
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/863,639A
CURRENT FILING DATE: May 28, 1997
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Joseph E. Mueth
REGISTRATION NUMBER: 20,532
REFERENCE/DOCKET NUMBER: 11859-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (626) 795-6321
TELEFAX: (626) 795-4000
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
US-08-863-639A-8

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1043 TTTTCTCTTTTAAA 1056
Db 14 TTTTCTCTTTTAAA 1

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1043 TTTTCTCTTTTAAA 1056
Db 14 TTTTCTCTTTTAAA 1

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1043 TTTTCTCTTTTAAA 1056
Db 14 TTTTCTCTTTTAAA 1

```

; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-1145

```

```

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 910 TTCCTCAAGACAG 923
Db 14 TTCCTCAAGACAG 1

```

```

RESULT 86
US-08-585-684B-92
; Sequence 92, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-1145

```

```

; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-92

```

```

Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 57.1%; Pred. No. 40;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 652 CTCACCTGCTGTCA 665
Db 2 CUCACUCUGUUA 15

```

```

RESULT 87
US-08-585-684B-93
; Sequence 93, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs

```

```
US-08-319-492B-165
Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 42.9%; Pred. No. 40;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1467 AATAAGTATTTATT 1480
||: ||: ||: ||: ||:
Db 1 AAUAGUAAUUUU 14

RESULT 83
US-08-334-847-279/c
; Sequence 279, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 279:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-334-847-279

Query Match      0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 40;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1570 ATACATAATATTTT 1583
||||| ||||| |||||
Db 14 ATACATAATATTTAT 1

RESULT 85
US-08-435-634-1145/c
; Sequence 1145, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California

US-08-334-847-528/c
; Sequence 528, Application US/08334847
; Patent No. 5693532
```



```
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc difference
; LOCATION: one-of(6, 9, 11, 13, 15)
; OTHER INFORMATION: /note= "These positions are T,
; OTHER INFORMATION: 5-(1-propynyl)-2'-deoxyuridine (pdu), or other suitable
; OTHER INFORMATION: pyrimidines."
; FEATURE:
; NAME/KEY: misc difference
; LOCATION: replace(8, "")
; OTHER INFORMATION: /note= "This position is
; OTHER INFORMATION: 7-substituted deazapurine nucleomonomer."
; FEATURE:
; NAME/KEY: misc difference
; LOCATION: one-of(1, 2, 3, 4, 5, 7, 10, 12, 14)
; OTHER INFORMATION: /note= "These positions are
; OTHER INFORMATION: 2'-deoxyadenosine."
; US-08-479-248-9
;
; Query Match 0.7%; Score 12.4; DB 1; Length 15;
; Best Local Similarity 86.7%; Pred. No. 40;
; Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; Qy 1570 ATACATATATTTT 1584
; Db 15 ATATATATATTTT 1
;
; RESULT 81
; US-08-390-850-1145/c
; Sequence 1145, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRIIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
```

```
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-1145
;
; Query Match 0.7%; Score 12.4; DB 1; Length 15;
; Best Local Similarity 92.9%; Pred. No. 40;
; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
; Qy 910 TTCTTCAAGACAG 923
; Db 14 TTCTTCAAGACAG 1
;
; RESULT 82
; US-08-319-492B-165
; Sequence 165, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994
; PRIOR APPLICATION DATA:
; APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 165:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

Two

;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: US 60/059,473
;; PRIOR FILING DATE: 1997-09-22
;; NUMBER OF SEQ ID NOS: 1208
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 116
;; LENGTH: 16
;; TYPE: RNA
;; ORGANISM: Homo sapiens
US-09-479-005A-116

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 40;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 AAATACATAATATTTT 1583
DB 16 AAAATATAATATTTT 1

RESULT 78
PCT-US91-03056-1/c
; Sequence 1, Application PC/TUS9103056
; GENERAL INFORMATION:
; APPLICANT: Vakharia, Vikram
; TITLE OF INVENTION: SPECIFIC DNA AND RNA SEQUENCES
; TITLE OF INVENTION: ASSOCIATED WITH US IBDV VARIANTS, VECTOR CARRYING DNA
; TITLE OF INVENTION: SEQUENCES, HOST CARRYING CLONED VECTOR, DEDUCED AMINO ACID
; TITLE OF INVENTION: SEQUENCES, VACCINE AND METHOD OF VACCINATION
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Viviana Anzel, Ph.D.
; STREET: 112 East Pecan, 2000 NBC Bank Plaza
; CITY: San Antonio
; STATE: Texas
; COUNTRY: USA
; ZIP: 78205
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03056
; FILING DATE: 19910718
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/514,202
; FILING DATE: 14-MAY-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Anzel Ph.D., Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: U-0125.02
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/554-5325
; TELEFAX: 512/226-8395
; TELEX: 762609
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: both
; TOPOLOGY: linear
; PUBLICATION INFORMATION:
; AUTHORS: Hudson, P. J.
; JOURNAL: Nucleic Acids Res.
; VOLUME: 14
; PAGES: 5001-5012
; DATE: 1986
PCT-US91-03056-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 40;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 553 CTAGCCCATGCTTTTG 568
DB 16 CTAGCCCATGCAATG 1

RESULT 79
US-09-867-915-10
; Sequence 10, Application US/09867915
; Patent No. 6521747
; GENERAL INFORMATION:
; APPLICANT: Genaisance Pharmaceuticals, Inc.
; APPLICANT: Anastasio, Alison E.
; APPLICANT: Finkel, Kevin
; APPLICANT: Koshy, Beena
; APPLICANT: Lee, Helen H.
; TITLE OF INVENTION: HAPLOTYPES OF THE AGTR1 GENE
; FILE REFERENCE: AGTR1-1136test
; CURRENT APPLICATION NUMBER: US/09/867,915
; CURRENT FILING DATE: 2001-05-30
; PRIOR APPLICATION NUMBER: 60/228,542
; PRIOR FILING DATE: 2000-08-28
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-867-915-10

Query Match 0.7%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 36;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1709 GACTGAGAAATTA 1721
DB 3 GACTGAGAAATKA 15

RESULT 80
US-08-479-248-9/c
; Sequence 9, Application US/08479248
; Patent No. 5594121
; GENERAL INFORMATION:
; APPLICANT: FROHLER, BRIAN
; APPLICANT: MATTEUCCI, MARK
; TITLE OF INVENTION: ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX
; TITLE OF INVENTION: FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: GILEAD SCIENCES INC.
; STREET: 353 Lakeside Drive
; CITY: Foster City
; STATE: CA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/479,248
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MUENCHAU, DARYL
; REGISTRATION NUMBER: 36,616
; REFERENCE/DOCKET NUMBER: 160.1C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 574-3000
; TELEFAX: (415) 573-4899

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
; FEATURE:
; NAME/KEY: -
; LOCATION: 1..16
; OTHER INFORMATION: /note= "HIV target sequence for
; OTHER INFORMATION: anti-2345 GUA ribozyme target site"
US-08-719-593-23
```

```
Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 21 TCTTCTAATACGTG 33
DB 16 TCTTCTAATACGTG 4
```

```
RESULT 75
US-08-753-147-183/c
; Sequence 183, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/753,147
FILING DATE:
CLASSIFICATION: 435
```

```
ATTORNEY/AGENT INFORMATION:
NAME: Sheiness, Diana K.
REGISTRATION NUMBER: 35,356
REFERENCE/DOCKET NUMBER: VMRC-1-9714
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 743-4387
TELEFAX: (206) 224 0779
```

```
INFORMATION FOR SEQ ID NO: 183:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-753-147-183
```

```
Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1639 AAATAGTTACCTT 1651
DB 16 AAATAGTTACCTT 4
```

```
RESULT 76
US-08-719-593-7/c
; Sequence 7, Application US/08719593
; Patent No. 5741706
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley Carl
; APPLICANT: Duarte, Elizabeth
; APPLICANT: Tritz, Richard
; APPLICANT: Barber, Jack R.
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: No. 5741706el Anti-HIV Ribozymes
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
```

```
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
```

```
APPLICATION NUMBER: US/08/719,593
FILING DATE: No. 5741706 yet assigned
CLASSIFICATION: 435
```

```
ATTORNEY/AGENT INFORMATION:
NAME: Weber, Kenneth A.
REGISTRATION NUMBER: 31,677
REFERENCE/DOCKET NUMBER: 016556-000810US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
```

```
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA (genomic)
FEATURE:
NAME/KEY: -
LOCATION: 1..16
OTHER INFORMATION: /note= "HIV target sequence for vif
OTHER INFORMATION: ribozyme 5251 target site"
US-08-719-593-7
```

```
Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 40;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 794 TGTATGGAGACCCAAA 809
DB 16 TGTATGCAGACCCAAA 1
```

```
RESULT 77
US-09-479-005A-116/c
; Sequence 116, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
```

RESULT 72
US-09-811-492-25/c
; Sequence 25, Application US/09811492
; Patent No. 6638764
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/811,492
; FILING DATE: 19-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION NUMBER: US 08/657,884
; FILING DATE: 07-JUN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-811-492-25
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2
|||||
RESULT 74
US-08-719-593-23/c
; Sequence 23, Application US/08719593
; Patent No. 5741706
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley Carl
; APPLICANT: Duarte, Elizabeth
; APPLICANT: Tritz, Richard
; APPLICANT: Barber, Jack R.
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: No. 5741706el Anti-HIV Ribozymes
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/719,593
; FILING DATE: No. 5741706 yet assigned
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Weber, Kenneth A.
; REGISTRATION NUMBER: 31,677
; REFERENCE/DOCKET NUMBER: 016556-000810US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 23:
US-08-719-593-23/c
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2
|||||
RESULT 73
US-09-811-492-29/c
; Sequence 29, Application US/09811492
; Patent No. 6638764
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
US-09-811-492-25
Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2
|||||

```
Query Match          0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 69
US-09-158-980-25/c
; Sequence 25, Application US/09158980
; Patent No. 6242427
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,980
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-158-980-25
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-158-980-25

Query Match          0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 70
US-09-158-980-29/c
; Sequence 29, Application US/09158980
; Patent No. 6242427
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
```

```
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/158,980
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/657,884
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-09-158-980-29

Query Match          0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 71
US-09-081-646-162/c
; Sequence 162, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 162
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-081-646-162

Query Match          0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TTTTGTAGTTCA 1457
Db 15 TTTTGTAGTTCA 3
```

chong906-1.rni

Fri May 13 12:26:37 2005

```

; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Rod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: NO. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 599:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-334-847-599

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGCATGGCTGACA 487
Db 14 GGCATGGCTGACA 2

RESULT 68
US-08-657-884-29/c
; Sequence 29, Application US/08657884
; Patent No. 5858981
; GENERAL INFORMATION:
; APPLICANT: SCHREIBER, ALAN D.
; APPLICANT: PARK, JONG-GU
; TITLE OF INVENTION: METHODS OF INHIBITING PHAGOCYTOSIS
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHVE P.C.
; STREET: 1100 NORTH GLEBE ROAD, 8TH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-657-884-29

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/657,884
; FILING DATE: 07-JUN-1996
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WILSON, MARY J.
; REGISTRATION NUMBER: 32,955
; REFERENCE/DOCKET NUMBER: 555-46
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-657-884-29

```

;/ TITLE OF INVENTION: PRODUCTS
;/ FILE REFERENCE: 2960.44 (HV)
;/ CURRENT APPLICATION NUMBER: US/09/344,624
;/ CURRENT FILING DATE: 1999-06-25
;/ EARLIER APPLICATION NUMBER: 60/090,747
;/ EARLIER FILING DATE: 1998-06-26
;/ NUMBER OF SEQ ID NOS: 29
;/ SOFTWARE: PatentIn Ver. 2.0
;/ SEQ ID NO 28
;/ LENGTH: 15
;/ TYPE: DNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-344-624-28

Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 25;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1040 AAGTTTCTTTT 1054
|||||
Db 1 AAGTTTCTTTT 15

RESULT 63
US-08-436-145-8
; Sequence 8, Application US/08436145
; Patent No. 5681943
; GENERAL INFORMATION:
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Gryaznov, Sergei M.
; TITLE OF INVENTION: METHOD OF FORMING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Reising, Ethington, Barnard & Perry
; STREET: P.O. Box 4390
; CITY: Troy
; STATE: Michigan
; COUNTRY: USA
; ZIP: 48099
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,145
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kohn, Kenneth I.
; REGISTRATION NUMBER: 30,955
; REFERENCE/DOCKET NUMBER: P-323 (NW)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (810) 689-3500
; TELEFAX: (810) 689-4071
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-436-145-8

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 31;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1057 GATGACAAATAGTGG 1071
|||||
Db 2 GATGACAAATAGTGG 16

RESULT 64
US-09-371-772B-5744
; Sequence 5744, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5744
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5744

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 53.3%; Pred. No. 31;
Matches 8; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

Qy 1596 ACTCTAATTGTCAT 1610
|||||
Db 2 ACUCUAAUGUCAAU 16

RESULT 65
US-09-479-005A-396
; Sequence 396, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 396
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-396

Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 31;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy 1643 AGTTCCTTCAAGC 1657
|||||
Db 2 AGUUAACCUAGAAGC 16

RESULT 66
US-08-334-847-599/c
; Sequence 599, Application US/08334847

/ Remaining Prior Application data removed - See File Wrapper or PALM.

/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 10428
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108A-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 874 TTGTGATGCTGCTACTAC 890
Db 17 TTGTGATGCTGCTAGCAC 1

RESULT 55

/ Sequence 10434, Application US/09866108A
/ Patent No. 6686188

/ GENERAL INFORMATION:

/ APPLICANT: GU, Yizhong

/ APPLICANT: JI, Yonggang

/ APPLICANT: PENN, Sharron G.

/ APPLICANT: HANZEL, David K.

/ APPLICANT: RANK, David R.

/ APPLICANT: CHEN, Wensheng

/ APPLICANT: SHANNON, Mark

/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

/ FILE REFERENCE: AEMICA-7

/ CURRENT APPLICATION NUMBER: US/09/866,108A

/ CURRENT FILING DATE: 2001-05-25

/ PRIOR APPLICATION NUMBER: US 60/207,456

/ PRIOR FILING DATE: 2000-05-26

/ PRIOR APPLICATION NUMBER: GB 24263.6

/ PRIOR FILING DATE: 2000-10-04

/ PRIOR APPLICATION NUMBER: US 60/236,359

/ PRIOR FILING DATE: 2000-09-27

/ PRIOR APPLICATION NUMBER: PCT/US01/00666

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00667

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00664

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00669

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00665

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00668

/ PRIOR FILING DATE: 2001-01-30

/ PRIOR APPLICATION NUMBER: PCT/US01/00663

/ PRIOR FILING DATE: 2001-01-30

/ Remaining Prior Application data removed - See File Wrapper or PALM.

/ NUMBER OF SEQ ID NOS: 15755

/ SOFTWARE: Aecomica Sequence Listing Engine

/ Patent No. 6686188

/ SEQ ID NO 10434

/ LENGTH: 17

/ TYPE: DNA

/ ORGANISM: Homo sapiens

US-09-866-108A-10434

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 868 TTGACTTTTGATGCTGT 884
Db 17 TCGACTTTTGATGCTGT 1

RESULT 56

US-09-685-664B-222

/ Sequence 222, Application US/09685664B

/ Patent No. 6818447

/ GENERAL INFORMATION:

/ APPLICANT: Ribozyme Pharmaceuticals, Inc.

/ APPLICANT: Pavco, Pam

/ APPLICANT: McSwiggen, Jim

/ APPLICANT: Stinchcomb, Dan

/ APPLICANT: Escobedo, Jaime

/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

/ FILE REFERENCE: MBHB00-876-K (400/021)

/ CURRENT APPLICATION NUMBER: US/09/685,664B

/ CURRENT FILING DATE: 2000-10-10

/ PRIOR APPLICATION NUMBER: US 60/005,974

/ PRIOR FILING DATE: 1995-10-26

/ PRIOR APPLICATION NUMBER: US 08/584,040

/ PRIOR FILING DATE: 1996-01-08

/ PRIOR APPLICATION NUMBER: US 09/371,772

/ PRIOR FILING DATE: 1999-08-10

/ NUMBER OF SEQ ID NOS: 8231

/ SOFTWARE: PatentIn version 3.0

/ SEQ ID NO 222

/ LENGTH: 17

/ TYPE: RNA

/ ORGANISM: Homo sapiens

US-09-685-664B-222

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;

Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1066 TACTGTTTAATTAGCAA 1082
Db 1 UACCGUUAUUUACAA 17

RESULT 57

US-09-685-664B-1868

/ Sequence 1868, Application US/09685664B

/ Patent No. 6818447

/ GENERAL INFORMATION:

/ APPLICANT: Ribozyme Pharmaceuticals, Inc.

/ APPLICANT: Pavco, Pam

/ APPLICANT: McSwiggen, Jim

/ APPLICANT: Stinchcomb, Dan

/ APPLICANT: Escobedo, Jaime

/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

/ FILE REFERENCE: MBHB00-876-K (400/021)

/ CURRENT APPLICATION NUMBER: US/09/685,664B

/ CURRENT FILING DATE: 2000-10-10

/ PRIOR APPLICATION NUMBER: US 60/005,974

/ PRIOR FILING DATE: 1995-10-26

/ PRIOR APPLICATION NUMBER: US 08/584,040

/ PRIOR FILING DATE: 1996-01-08

/ PRIOR APPLICATION NUMBER: US 09/371,772

/ PRIOR FILING DATE: 1999-08-10

/ NUMBER OF SEQ ID NOS: 8231

/ SOFTWARE: PatentIn version 3.0

/ SEQ ID NO 1868

/ LENGTH: 17

/ TYPE: RNA

/ ORGANISM: Homo sapiens

US-09-685-664B-1868

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;

Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 919 GACAGGTTCTCTCGCT 935

```
RESULT 52
US-09-866-108A-6761
; Sequence 6761, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6761

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 GTGGAGCTCATGGAGAC 522
Db 1 GAGGAGCTCTGGAGAC 17

RESULT 53
US-09-866-108A-8637
; Sequence 8637, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6761
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6761

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 506 GTGGAGCTCATGGAGAC 522
Db 1 GAGGAGCTCTGGAGAC 17

RESULT 54
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8637
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8637

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 200 AAATCCCAAGAAATGCAG 216
Db 1 AGATCCCAAGAACTGCAG 17

RESULT 54
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
```

```
; FILE REFERENCE: MBHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5572
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5572

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1221 TGATGAAGGACAGACA 1237
DB 17 TTATGAAGGACAGACA 1

RESULT 50
US-09-401-063-731
; Sequence 731, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 731:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-815

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAATCAAATA 176
DB 17 GAGACAAAATCAAATA 1

RESULT 51
US-09-401-063-815/c
; Sequence 815, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 815:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-401-063-815

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAATCAAATA 176
DB 17 GAGACAAAATCAAATA 1
```

Fri May 13 12:26:37 2005

```

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 222
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-222

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1066 TACTGTTCTTAATTAGCAA 1082
Db 1 UACUCGUUAUAUCA 17

RESULT 46
US-09-371-772B-1868
; Sequence 1868, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1868
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1868

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 919 GACAGGTTCTTCTCGCT 935
Db 1 GCCAUGUUCUUCUGGCU 17

RESULT 47
US-09-371-772B-3143/c
; Sequence 3143, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

```

```

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3143
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3143

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1679 TGCTCTCTTAAGTTGCTT 1695
Db 17 TGCTCTCTTAAGTTGCTT 1

RESULT 48
US-09-371-772B-3686/c
; Sequence 3686, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3686
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3686

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 527 ATGCTTTTGTGATGGCAA 543
Db 17 ATGCTTTTGTGATGGTAAA 1

RESULT 49
US-09-371-772B-5572/c
; Sequence 5572, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5675

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 919 GACAGGTTCTCTGGCT 935
||| :||:|:|:|:
DB 1 GCCAUGUUCUGGCU 17

RESULT 43

US-08-584-040-7334/c
; Sequence 7334, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TOPOLOGY: linear

INFORMATION FOR SEQ ID NO: 7334:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7334

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1679 TGCTCTGTAAGTTGCTT 1695
||||| :||:|:|:|:
DB 17 TGCTCTCTTAGTTGCTT 1

RESULT 44

US-08-584-040-7903/c
; Sequence 7903, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TOPOLOGY: linear
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7903

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 527 ATGCTTTTGATGGCAAA 543
||||| :||:|:|:|:
DB 17 ATGCTTTTGATGGTAAA 1

RESULT 45

US-09-371-772B-222
; Sequence 222, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1677:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1677

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1066 TACTGTTAATTAGCAA 1082
Db 1 UACUCGUAAUUAUCAA 17

RESULT 41
US-08-584-040-4101
Sequence 4101, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974

FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4101:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4101

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 31;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 919 GACAGGTTCTTCGGCT 935
Db 1 GCCAUGUUCUUGGCU 17

RESULT 42
US-08-584-040-5675
Sequence 5675, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5675:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

QY 416 GGAAGCTTCCAACTA 432
 |||||: :||| |
 DB 1 GGAAGCUCUCCAAGAA 17

RESULT 38
 US-08-985-162-731
 ; Sequence 731, Application US/08985162
 ; Patent No. 6057156
 ; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Fell, Patricia
 ; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSEQ for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/985,162
 ; FILING DATE: 04 December 1997
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 731:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-985-162-731

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 31;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1687 AAGTTGCTTCTTAACAT 1703
 ||||: |||: |||:
 DB 1 AAGUUCUCCUCAAUAU 17

RESULT 39
 US-08-985-162-815/c
 ; Sequence 815, Application US/08985162
 ; Patent No. 6057156
 ; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT

; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSEQ for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/985,162
 ; FILING DATE: 04 December 1997
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 815:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-985-162-815

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 31;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 GTGACAAAATGAAATA 176
 |||||: |||||:
 DB 17 GAGACAAAATCAAATA 1

RESULT 40
 US-08-584-040-1677
 ; Sequence 1677, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Favco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 ; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 ; TITLE OF INVENTION: GROWTH FACTOR
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066

INFORMATION FOR SEQ ID NO: 2029:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2029

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1571 TACATAAATATTTTCA 1587
|||||
Db 17 TACATAAATATTTTCA 1

RESULT 36
US-08-435-628-2031/c
Sequence 2031, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2031:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-435-628-2031

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1570 ATACATAAATATTTTCA 1586
|||||
Db 17 ATACATAAATATTTTCA 1

RESULT 37
US-08-435-628-2419
Sequence 2419, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2419:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2419

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; TELECOMMUNICATION INFORMATION:
; REFERENCE/DOCKET NUMBER: 211/084
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 598:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-598

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 31;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1144 AAAAAAATGTGACGAC 1160
DB 1 AGAAAAUUGAUGCUG 17

RESULT 34
US-08-435-634-605
; Sequence 605, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 605:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-605

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 31;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1186 ACCTACTTCCTTTGTAGA 1202
DB 1 ACUACUCUCUUGUGGA 17

RESULT 35
US-08-435-628-2029/c
; Sequence 2029, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

chong906-1.rni

Fri May 13 12:26:37 2005

```

; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-541

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 31;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 908 TTTTCTTCAAGACAGG 924
Db 1 UGUUCUUUAAAGACAGG 17

RESULT 32
US-08-435-634-542
; Sequence 542, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-435-634-541

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 31;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 918 AGACAGGTTCTTCTGGC 934
Db 1 AGACAGGUUUUUCUGGC 17

RESULT 33
US-08-435-634-598
; Sequence 598, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

RESULT 29
US-08-373-124A-2031/c
; Sequence 2031, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2031:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-2031

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1570-ATACATAATTTTCA 1586
DB 17 ATACATAAATACTTTCA 1

RESULT 30
US-08-373-124A-2419
; Sequence 2419, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale

; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2419:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-2419
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 416 GGAAGCTTTTCCAAGTA 432
DB 1 GGAAGCTTCCCAAGTA 17
RESULT 31
US-08-435-634-541
; Sequence 541, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 598:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-598

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 31;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1186 ACCTACTTCTTTCTAGA 1202
DB 1 ACAUACUUCUUGUGGA 17
|||||:|:|:|:|:|

RESULT 28
US-08-373-124A-2029/c
Sequence 2029, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2029:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2029

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 31;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1571 TACATAATATTTTCAA 1587
DB 17 TACATAATAACTTTCAA 1
|||||:|:|:|:|:|

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 598:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-598

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 31;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1144 AAAAAAATGTGACGAC 1160
DB 1 AGAAAAUUGAUGCUC 17
|||||:|:|:|:|:|

RESULT 27
US-08-390-850-605
Sequence 605, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 605:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-605

ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 541:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-541

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 31;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 908 TTTTCTTCAAGACAGG 924
DB 1 UGUUCUUUAAAGACAGG 17

RESULT 25
US-08-390-850-542
Sequence 542, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 542:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-542

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 31;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 918 AGACAGGTTCTTCGGC 934
DB 1 AGACAGGUUUUCUGGC 17

RESULT 26
US-08-390-850-598
Sequence 598, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA primer"
US-08-720-625-8

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 28;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTGCTCCTGT 796
Db 1 GGCATTGCTCCTGT 16

RESULT 22
US-09-866-108A-10429/c
Sequence 10429, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR FILING DATE: 2000-10-04
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 10429
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
Db 17 TTTTGATGCTGTCA 4

RESULT 23
US-09-866-108A-10430/c
Sequence 10430, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR FILING DATE: 2000-10-04
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 10429
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
Db 17 TTTTGATGCTGTCA 4

RESULT 24
US-08-390-850-541
Sequence 541, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

Sequence 10430, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR FILING DATE: 2000-10-04
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aeomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 10430
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-10430

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
Db 16 TTTTGATGCTGTCA 3

RESULT 24
US-08-390-850-541
Sequence 541, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
Db 16 TTTTGATGCTGTCA 3

RESULT 24
US-08-390-850-541
Sequence 541, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 873 TTTTGATGCTGTCA 886
Db 17 TTTTGATGCTGTCA 4

NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 24;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 871 ACTTTTGATGCTGTC 886
| | | | | | | | | |
Db 17 ACTTTTGATGCTGTC 2

RESULT 19

US-09-866-108A-10433/c
; Sequence 10433, Application US/09866108A
; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Weneheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: ACOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 10433

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-10433

Query Match

Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTC 885
| | | | | | | | | |
Db 16 GACTTTGTGCTGTC 1

RESULT 20

US-09-685-664B-1826/c

; Sequence 1826, Application US/09685664B

; Patent No. 6818447

; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

; FILE REFERENCE: MEHB00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1826

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-1826

Query Match

Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 518 GAGACTTCCATGCTTT 533
| | | | | | | | | |
Db 17 GAGACTTCCATGCTTT 2

RESULT 21

US-08-720-625-8

; Sequence 8, Application US/08720625

; Patent No. 6242587

; GENERAL INFORMATION:

; APPLICANT: Naik, Ulhas P.

; TITLE OF INVENTION: CALCIUM-INTEGRIN BINDING PROTEIN

; NUMBER OF SEQUENCES: 10

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Bell, Seltzer, Park & Gibson

; STREET: P.O. Drawer 34009

; CITY: Charlotte

; STATE: No. 6242587th Carolina

; COUNTRY: USA

; ZIP: 28234

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/720,625

; FILING DATE:

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Sibley, Kenneth D.

; REGISTRATION NUMBER: 31,665

; REFERENCE/DOCKET NUMBER: 5470-138

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 919-420-2200

; TELEFAX: 919-881-3175

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 base pairs

Fri May 13 12:26:37 2005

chong906-1.rni

```

US-09-866-108A-8638
; Sequence 8638, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8638
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8638

```

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 24;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 202 ATCCAAGAAATGCAGC 217
||| ||||| |||||
Db 2 ATCCAAGAAATGCAGC 17

```

```

RESULT 17
US-09-866-108A-8639
; Sequence 8639, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6

```

```

; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8639
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8639

```

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 24;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 202 ATCCAAGAAATGCAGC 217
||| ||||| |||||
Db 1 ATCCAAGAAATGCAGC 16

```

```

RESULT 18
US-09-866-108A-10431/c
; Sequence 10431, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

```



```

, STATE: CA
, COUNTRY: USA
, ZIP: 94111-3834
, COMPUTER READABLE FORM:
, MEDIUM TYPE: Diskette
, COMPUTER: IBM Compatible
, OPERATING SYSTEM: DOS
, SOFTWARE: FastSeq for Windows Version 2.0
, CURRENT APPLICATION DATA:
, APPLICATION NUMBER: US/09/091.952A
, FILING DATE: 19-Apr-1999
, CLASSIFICATION: <Unknown>
, PRIOR APPLICATION DATA:
, APPLICATION NUMBER: US 60/029,278
, FILING DATE: 28-OCT-1996
, APPLICATION NUMBER: PCT/US97/19381
, FILING DATE: 28-OCT-1997
, ATTORNEY/AGENT INFORMATION:
, NAME: Smith, Timothy L.
, REGISTRATION NUMBER: 35,367
, REFERENCE/DOCKET NUMBER: 015280-297100US
, TELECOMMUNICATION INFORMATION:
, TELEPHONE: (415) 576-0200
, TELEFAX: (415) 576-0300
, TELEX: <Unknown>
, INFORMATION FOR SEQ ID NO: 193:
, SEQUENCE CHARACTERISTICS:
, LENGTH: 18 base pairs
, TYPE: nucleic acid
, STRANDEDNESS: single
, TOPOLOGY: linear
, MOLECULE TYPE: DNA
, FEATURE:
, NAME/KEY: -
, LOCATION: 1...18
, OTHER INFORMATION: Clone 47 reverse primer
, SEQUENCE DESCRIPTION: SEQ ID NO: 193:
, US-09-091-952A-193

Query Match 0.8%; Score 14.8; DB 1;
Best Local Similarity 88.9%; Pred. No. 24;
Matches 16; Conservative 0; Mismatches 2;

QY 46 ACTGCTTCTGAGCTCTT 63
Db 1 AGTGCTTCTGTAGCTCTT 18
|||||
|||||

RESULT 14
US-08-584-040-4059/c
Sequence 4059, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

chong906-1.rni

Fri May 13 12:26:37 2005

; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.
 ; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; Patent No. 6686188
 ; SEQ ID NO 10432
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-09-866-108A-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 15;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 GAGTTTGTGCTGTCTCA 886
 DB 17 GACTTTGTGCTGTCTCA 1

RESULT 12
 US-09-071-433-57/c
 ; Sequence 57, Application US/09071433A
 ; Patent No. 6197584
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett, C. Frank
 ; APPLICANT: Cowsett, Lex M
 ; TITLE OF INVENTION: Antisense Modulation of CD40 Expression
 ; FILE REFERENCE: RTS-0002
 ; CURRENT APPLICATION NUMBER: US/09/071.433A
 ; CURRENT FILING DATE: 1998-05-01
 ; NUMBER OF SEQ ID NOS: 91
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 57
 ; LENGTH: 18
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; US-09-071-433-57

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 24;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 945 TGAGAGACCAAGACCAG 962
 DB 18 TGTGAGACCAAGACCCTG 1

RESULT 13
 US-09-091-952A-193
 ; Sequence 193, Application US/09091952A
 ; Patent No. 6458532
 ; GENERAL INFORMATION:
 ; APPLICANT: Detera-Wadleigh, Sevilla D.
 ; Gershon, Elliot S.
 ; Badner, Judith A.
 ; Goldin, Lynn R.
 ; Berrettini, Wade H.
 ; Yoshikawa, Takeo
 ; Sanders, Alan R.
 ; Esterling, Lisa E.
 ; TITLE OF INVENTION: Chromosomal Markers and Diagnostic Tests for Manic-Depressive Illness
 ; NUMBER OF SEQUENCES: 197
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Townsend and Crew LLP
 ; STREET: Two Embarcadero Center, Eighth Floor
 ; CITY: San Francisco

; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/387.805
 ; FILING DATE: 21-FEB-95
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/DK93/00273
 ; FILING DATE: 20-AUG-93
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: DK 1046/92
 ; FILING DATE: 21-AUG-92
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: DK 1118/92
 ; FILING DATE: 10-SEP-92
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: DK 0528/93
 ; FILING DATE: 05-MAY-93
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Cimbala, Michele A.
 ; REGISTRATION NUMBER: 33,851
 ; REFERENCE/DOCKET NUMBER: 1102.0160000
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202)371-2600
 ; TELEFAX: (202) 371-2540
 ; INFORMATION FOR SEQ ID NO: 19:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (synthetic)
 ; US-08-387-805-19

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 15;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 200 AAATCCAAGAAATGCAG 216
 DB 17 AGATCCAAGAAATGCAG 1

RESULT 11
 US-09-866-108A-10432/c
 ; Sequence 10432, Application US/09866108A
 ; Patent No. 6686188
 ; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: ACOMICA-7
 ; CURRENT APPLICATION NUMBER: US/09/866.108A
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6
 ; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665
 ; PRIOR FILING DATE: 2001-01-30

US-08-390-850-428
; Sequence 428, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 428:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-428
Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 11;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Oy 197 AAAAAATCCAAGAAAT 212
Db 2 AAAAAAUCCAAGAAU 17
RESULT 9
US-08-435-634-428
; Sequence 428, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS

US-08-387-805-19/c
; Sequence 19, Application US/08387805
; Patent No. 6448032
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Human Melanocyte stimulating hormone receptor
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Ave., N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
US-08-435-634-428
Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 11;
Matches 14; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Oy 197 AAAAAATCCAAGAAAT 212
Db 2 AAAAAAUCCAAGAAU 17
RESULT 10
US-08-387-805-19/c
; Sequence 19, Application US/08387805
; Patent No. 6448032
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Human Melanocyte stimulating hormone receptor
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Ave., N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1070:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-1070

Query Match 0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 11;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 782 GCATTGAGTCCCTGTATG 799
DB 1 GCAUUCAGUCCCUCAUG 18

RESULT 6
US-08-435-634-1070
Sequence 1070, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESS: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1070:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-1070

Query Match 0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 11;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 782 GCATTGAGTCCCTGTATG 799
DB 1 GCAUUCAGUCCCUCAUG 18

RESULT 7

US-09-422-978-5754/c
Sequence 5754, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 5754
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1...19
OTHER INFORMATION: upstream amplification primer 99-6628 for SEQ 1820,
US-09-422-978-5754

Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 13;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1190 ACTTCTTTGTAGATAACC 1207
DB 18 ACTTCTTTGCAGATAACC 1

RESULT 8

```
RESULT 1
US-09-396-196G-127779
; Sequence 127779, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 127779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-127779

Query Match      1.1%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 5;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTGAGTCCCTGATGGAG 802
DB 3 GGCATTGAGTCCCTGATGGAG 24

RESULT 2
US-09-396-196G-125366
; Sequence 125366, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125366

Query Match      1.1%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 5.5;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1276 TTCCAGGAATCGGCGCTAAATTG 1300
DB 1 TTCCAGGAATCAAGCCTAAATTG 25

RESULT 3
US-09-696-791-4459
; Sequence 4459, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 4459
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: WMP-3 ribozyme recognition site
US-09-696-791-4459

Query Match      1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.5;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 781 GGCATTGAGTCCCTGATGGA 801
DB 1 GGCATTGAGTCCCTGATGGA 21

RESULT 4
US-09-696-791-2608/c
; Sequence 2608, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patent in Ver. 2.0
; SEQ ID NO 2608
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin G1 ribozyme binding site
US-09-696-791-2608

Query Match      1.0%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 8.3;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 901 AAGATCTTTTCTTCAAAG 919
DB 19 AAGATCTTTTCTTCAAAG 1

RESULT 5
US-08-390-850-1070
; Sequence 1070, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 11:28:21 ; Search time 1 Seconds
(without alignments)

5.946 Million cell updates/sec

Title: US-10-619-906-1

Perfect score: 1778
Sequence: i tagaagttacaatgaagtt.....tttgggtcaataaaattg 1778

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 101 seqs, 1672 residues

Total number of hits satisfying chosen parameters: 202

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 101 summaries

Database : rni1.seq1*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	20.4	1.1	25	1	US-09-396-1960-127779
2	20.2	1.1	25	1	US-09-396-1960-125366
3	19.4	1.1	21	1	US-09-696-791-4459
4	17.4	1.0	19	1	US-09-696-791-2608
5	16.4	0.9	18	1	US-08-390-850-1070
6	16.4	0.9	18	1	US-08-435-634-1070
7	16.4	0.9	19	1	US-09-422-978-5754
8	16	0.9	17	1	US-08-390-850-428
9	16	0.9	17	1	US-08-435-634-428
10	15.4	0.9	17	1	US-08-387-805-19
11	15.4	0.9	17	1	US-09-866-108A-10432
12	14.8	0.8	18	1	US-09-071-433-57
13	14.8	0.8	18	1	US-09-091-952A-193
14	14.4	0.8	17	1	US-08-584-040-4059
15	14.4	0.8	17	1	US-09-371-772B-1826
16	14.4	0.8	17	1	US-09-866-108A-8638
17	14.4	0.8	17	1	US-09-866-108A-8639
18	14.4	0.8	17	1	US-09-866-108A-10431
19	14.4	0.8	17	1	US-09-866-108A-10433
20	14.4	0.8	17	1	US-09-866-108A-1826
21	14.4	0.8	18	1	US-08-720-625-8
22	14	0.8	17	1	US-09-866-108A-10429
23	14	0.8	17	1	US-09-866-108A-10430
24	13.8	0.8	17	1	US-08-390-850-541
25	13.8	0.8	17	1	US-08-390-850-542
26	13.8	0.8	17	1	US-08-390-850-598
27	13.8	0.8	17	1	US-08-390-850-605
28	13.8	0.8	17	1	US-08-373-124A-2029
29	13.8	0.8	17	1	US-08-373-124A-2031
30	13.8	0.8	17	1	US-08-373-124A-2419
31	13.8	0.8	17	1	US-08-435-634-541
32	13.8	0.8	17	1	US-08-435-634-542
33	13.8	0.8	17	1	US-08-435-634-598

34	13.8	0.8	17	1	US-08-435-634-605	Sequence 605, App
35	13.8	0.8	17	1	US-08-435-628-2029	Sequence 2029, App
36	13.8	0.8	17	1	US-08-435-628-2031	Sequence 2031, App
37	13.8	0.8	17	1	US-08-435-628-2419	Sequence 2419, App
38	13.8	0.8	17	1	US-08-985-162-731	Sequence 731, App
39	13.8	0.8	17	1	US-08-985-162-815	Sequence 815, App
40	13.8	0.8	17	1	US-08-584-040-1677	Sequence 1677, App
41	13.8	0.8	17	1	US-08-584-040-4101	Sequence 4101, App
42	13.8	0.8	17	1	US-08-584-040-5675	Sequence 5675, App
43	13.8	0.8	17	1	US-08-584-040-7334	Sequence 7334, App
44	13.8	0.8	17	1	US-08-584-040-7903	Sequence 7903, App
45	13.8	0.8	17	1	US-09-371-772B-222	Sequence 222, App
46	13.8	0.8	17	1	US-09-371-772B-1868	Sequence 1868, App
47	13.8	0.8	17	1	US-09-371-772B-3143	Sequence 3143, App
48	13.8	0.8	17	1	US-09-371-772B-3686	Sequence 3686, App
49	13.8	0.8	17	1	US-09-371-772B-5572	Sequence 5572, App
50	13.8	0.8	17	1	US-09-401-063-731	Sequence 731, App
51	13.8	0.8	17	1	US-09-401-063-815	Sequence 815, App
52	13.8	0.8	17	1	US-09-866-108A-6761	Sequence 6761, App
53	13.8	0.8	17	1	US-09-866-108A-8637	Sequence 8637, App
54	13.8	0.8	17	1	US-09-866-108A-10428	Sequence 10428, A
55	13.8	0.8	17	1	US-09-866-108A-10434	Sequence 10434, A
56	13.8	0.8	17	1	US-09-685-664B-222	Sequence 222, App
57	13.8	0.8	17	1	US-09-685-664B-1868	Sequence 1868, App
58	13.8	0.8	17	1	US-09-685-664B-3143	Sequence 3143, App
59	13.8	0.8	17	1	US-09-685-664B-3686	Sequence 3686, App
60	13.8	0.8	17	1	5182195-67	Patent No. 5182195
61	13.4	0.8	15	1	US-09-461-697-460	Sequence 460, App
62	13.4	0.8	15	1	US-09-344-624-28	Sequence 28, App
63	13.4	0.8	16	1	US-08-436-145-8	Sequence 8, Appli
64	13.4	0.8	16	1	US-09-371-772B-5744	Sequence 5744, App
65	13.4	0.8	16	1	US-09-479-005A-396	Sequence 396, App
66	13	0.7	15	1	US-08-334-847-599	Sequence 599, App
67	13	0.7	15	1	US-08-657-884-25	Sequence 25, Appl
68	13	0.7	15	1	US-08-657-884-29	Sequence 29, Appl
69	13	0.7	15	1	US-09-158-980-25	Sequence 25, Appl
70	13	0.7	15	1	US-09-158-980-29	Sequence 29, Appl
71	13	0.7	15	1	US-09-081-646-162	Sequence 162, App
72	13	0.7	15	1	US-09-811-492-25	Sequence 25, Appl
73	13	0.7	15	1	US-09-811-492-29	Sequence 29, Appl
74	13	0.7	16	1	US-08-719-593-23	Sequence 23, Appl
75	13	0.7	16	1	US-08-753-147-183	Sequence 183, App
76	12.8	0.7	16	1	US-08-719-593-7	Sequence 7, Appli
77	12.8	0.7	16	1	US-09-479-005A-116	Sequence 116, App
78	12.8	0.7	16	1	PCT-US91-03056-1	Sequence 1, Appli
79	12.6	0.7	15	1	US-08-867-915-10	Sequence 10, Appli
80	12.4	0.7	15	1	US-08-479-248-9	Sequence 9, Appli
81	12.4	0.7	15	1	US-08-390-850-1145	Sequence 1145, App
82	12.4	0.7	15	1	US-08-319-492B-165	Sequence 165, App
83	12.4	0.7	15	1	US-08-334-847-279	Sequence 279, App
84	12.4	0.7	15	1	US-08-435-634-1145	Sequence 528, App
85	12.4	0.7	15	1	US-08-334-847-279	Sequence 1145, App
86	12.4	0.7	15	1	US-08-585-684B-92	Sequence 92, Appli
87	12.4	0.7	15	1	US-08-585-684B-93	Sequence 93, Appli
88	12.4	0.7	15	1	US-08-863-639A-8	Sequence 8, Appli
89	12.4	0.7	15	1	US-08-832-021-17	Sequence 17, Appl
90	12.4	0.7	15	1	US-08-781-891-64	Sequence 64, Appl
91	12.4	0.7	15	1	US-08-873-437-12	Sequence 12, Appl
92	12.4	0.7	15	1	US-09-038-073-92	Sequence 92, Appl
93	12.4	0.7	15	1	US-09-038-073-93	Sequence 93, Appl
94	12.4	0.7	15	1	US-08-584-040-8445	Sequence 8445, App
95	12.4	0.7	15	1	US-09-593-312-12	Sequence 12, Appl
96	12.4	0.7	15	1	US-09-034-113-11	Sequence 11, Appl
97	12.4	0.7	15	1	US-08-431-048F-148	Sequence 148, App
98	12.4	0.7	15	1	US-09-371-772B-4101	Sequence 4101, App
99	12.4	0.7	15	1	US-09-618-166-64	Sequence 64, Appl
100	12.4	0.7	15	1	US-09-689-012-5	Sequence 5, Appli
101	12.4	0.7	15	1	US-09-685-664B-4101	Sequence 4101, App

ALIGNMENTS

THIS PAGE BLANK (USPTO)

Fax: 801 585 7177
 Email: ddum@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0082 row: P column: 18
 Seq primer: CGTTGTAAACGACGGCCACT
 Class: plasmid ends
 High quality sequence stop: 24.

FEATURES

Location/Qualifiers
 1..24
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0082P18"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

source

Query Match 0.7%; Score 12.2; DB 1; Length 24;
 Best Local Similarity 82.4%; Pred. No. 34;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Query Match 0.7%; Score 12.2; DB 1; Length 24;

Best Local Similarity 82.4%; Pred. No. 34;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1713 CATGTTTGTTCCTTT 1729

Db 4 CTTTTCCTTTCTTT 20

RESULT 27

AJ739036 12 bp mRNA linear EST 07-OCT-2004
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE

EST.
 AJ739036.1 GI:53904414
 Gallus gallus (chicken)

ORGANISM

Gallus gallus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
 Phasianinae; Gallus.

1 (bases 1 to 12)

REFERENCE

AWDwell, R.B., Kierzek, A.M., Arakawa, H., Bezzubov, Y., Zaim, J.,
 Fiedler, P., Kutter, S., Blagodatki, A., Kostovska, D., Koter, M.,
 Plachy, J., Carninci, P., Hayashizaki, Y. and Buerstedde, J.M.

Full-length cDNAs from bursal lymphocytes to facilitate gene

function analysis

Unpublished (2004)

JOURNAL

CONTACT: Caldwell RB
 GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
 Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

FEATURES

Location/Qualifiers
 1..12
 /organism="Gallus gallus"
 /mol_type="mRNA"
 /db_xref="taxon:9031"

source

/clone="16p11r3"
 /cell_type="bursal lymphocyte"
 /dev_stage="2-3 weeks old"
 /clone_lib="rikeni"
 /note="CB inbred strain"

Query Match 0.7%; Score 12; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 14;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAA 1760

Db 1 AAAAAAAAAA 12

RESULT 28

AJ656714 15 bp mRNA linear EST 28-JUN-2004
 LOCUS
 DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE

Sus scrofa (pig)
 Sus scrofa
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.

1 (bases 1 to 15)
 Anderson, S.I., Finlayson, H.A. and Archibald, A.L.
 Development of cDNA and EST resources for studying reproduction and
 embryo development in pigs and cattle

JOURNAL

Unpublished (2004)

COMMENT

Contact: Anderson SI

Genomics and Bioinformatics

Roslin Institute

Roslin, Midlothian, EH25 9PS, UNITED KINGDOM

Single pass sequencing. Bases called and trimmed with phred

v0.020425.c. Vector identified by cross-match with the -minscore 20

and -minmatch 12 options. Vector: pBlueScriptII(SK+) R. Site1: EcoRI

R. Site2: NotI 5' Seq Primer M13F Normalised library constructed

from pooled early embryos, from 8- cell stage to blastocysts.

Clones available from UK Centre for Functional Genomics in Farm

Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS,

www.arkgenomics.org.

Location/Qualifiers

1..15

source

/organism="Sus scrofa"

/mol_type="mRNA"

/db_xref="taxon:9823"

/clone="C0005194.F04"

/tissue_type="embryo"

/clone_lib="KN277"

/note="Vector: pBlueScriptII(SK+); Site 1: EcoRI; Site 2:

NotI; Single pass sequencing. Normalised library

constructed from pooled early embryos, from 8-cell stage

to blastocysts."

to blastocysts."

Query Match 0.7%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 22;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 155 TCCTAAAGAAA 166

Db 1 TCCTAAAGAAA 12

Search completed: May 13, 2005, 12:26:21

Job time : 1 secs


```

/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="RIGM gene trap library"
/notes="Vector: pLip1"

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 26;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1575 TTTTTCACATTCATTCATCTTA 1598
||||| ||| ||| ||| |||
Db 3 TTTTTCATTTTTCATTTTTCATTTTA 26

RESULT 24
CF301021
LOCUS
DEFINITION
Oryza sativa (japonica cultivar-group) cDNA clone 7LEAF--05-L10, mRNA
sequence.
CF301021
CF301021.1 GI:33672782
EST.
SOURCE
Oryza sativa (japonica cultivar-group)
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 14)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
of Bioscience and Genetics Institute, GreenGene Biotech Inc.; Division
Genomics and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES
source
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-L10"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 0.7%; Score 12.4; DB 1; Length 14;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
||||| ||| ||| |||
Db 1 AAAAAAAAAAAAAA 14

RESULT 25
CV091538
LOCUS
DEFINITION
CV091538 28 bp mRNA linear EST 26-AUG-2004
NAIL03_R cDNA non acclimated Bluecrop library Vaccinium corymbosum

/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="RIGM gene trap library"
/notes="Vector: pLip1"

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 26;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1575 TTTTTCACATTCATTCATCTTA 1598
||||| ||| ||| ||| |||
Db 3 TTTTTCATTTTTCATTTTTCATTTTA 26

RESULT 24
CF301021
LOCUS
DEFINITION
Oryza sativa (japonica cultivar-group) cDNA clone 7LEAF--05-L10, mRNA
sequence.
CF301021
CF301021.1 GI:33672782
EST.
SOURCE
Oryza sativa (japonica cultivar-group)
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE
1 (bases 1 to 14)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
of Bioscience and Genetics Institute, GreenGene Biotech Inc.; Division
Genomics and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
FEATURES
source
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-L10"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/notes="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 0.7%; Score 12.4; DB 1; Length 28;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1715 TGTTCGTTTCTTTTAAATAATT 1737
||||| ||| ||| ||| |||
Db 4 TTTTTCATTTTTCATTTTTCATTTT 26

RESULT 26
AZ814559
LOCUS
DEFINITION
2M0082P18F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0082P18 F, genomic survey sequence.
ACCESSION
AZ814559
VERSION
AZ814559.1 GI:12984467
KEYWORDS
Mus musculus (house mouse)
SOURCE
Mus musculus
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D. Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606

```

Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: W. Douglas Figg, Ph.D., Paul H. Duray, M.D.,
Rodrigo F. Chuqui, M.D., Michael R. Emmert-Buck, M.D., Ph.D.
CDNA Library Preparation: David B. Krizman, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA Sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www-bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality
Seq primer: -40ml3 fwd. ET from Amersham
High quality sequence stop: 1.

Location/Qualifiers
1. .16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:1253890"
/sex="male"
/tissue_type="metastatic prostate bone lesion"
/lab_host="DH10B"
/clone_lib="NCI CGAP Pr12"
/note="Vector: PAMP10; mRNA made from metastatic prostate
lesion of the bone, cDNA made by oligo-dT priming.
Non-directionally cloned. Size-selected on agarose gel,
average insert size 600 bp. Library made by D. Krizman,
NIH."

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 20;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1764
Db 16 AAAAAAAAAAACAA 1

RESULT 23
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

CW020478 26 bp mRNA linear GSS 28-SEP-2004
GC0745 TIGEM gene trap library Mus musculus CDNA clone A015.B4,
mRNA sequence.
CW020478 GI:52789738
GSS.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 26)
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di
Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
tagging genes with cassette-exchange sites
Unpublished (2004)
Contact: TIGEM
107

TIGEM
Via P. Castellino, 111, 80131 NAPOLI, ITALY
Tel: +390816132205
Fax: +390815790919
Email: cobellis@tigem.it
Sequence tag generated by 5' RACE of total RNA from gene trap ES
cell line. ES cell lines harboring insertion mutation of target
gene are available upon request from TIGEM. Annotation information
available from TIGEM
Class: Gene Trap.
Location/Qualifiers
1. .26
/organism="Mus musculus"

FEATURES
source

QY 1575 TTTTTCACCTTCATCTATCTCTAAATTTT 1603
Db 1 TTTTTCACCTTCATCTATCTCTAAATTTT 29

RESULT 22
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

AA937877 16 bp mRNA linear EST 30-APR-1998
nw90e06.s1 NCI CGAP Pr12 Homo sapiens cDNA clone IMAGE:1253890
similar to TR:Q35989 Q35989 CYTOCHROME C OXIDASE SUBUNIT 1 i, mRNA
sequence.
AA937877 GI:3095988
AA937877.1 Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 16)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

QY 1565 TTTTAGGAAGTTT 1577
Db 2 TTTTAGGAAGTTT 14

RESULT 21
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

CW020481 30 bp mRNA linear GSS 28-SEP-2004
GC0748 TIGEM gene trap library Mus musculus CDNA clone A015.C10,
mRNA sequence.
CW020481 GI:52789741
GSS.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 30)
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di
Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
tagging genes with cassette-exchange sites
Unpublished (2004)
Contact: TIGEM
107

TIGEM
Via P. Castellino, 111, 80131 NAPOLI, ITALY
Tel: +390816132205
Fax: +390815790919
Email: cobellis@tigem.it
Sequence tag generated by 5' RACE of total RNA from gene trap ES
cell line. ES cell lines harboring insertion mutation of target
gene are available upon request from TIGEM. Annotation information
available from TIGEM
Class: Gene Trap.
Location/Qualifiers
1. .30
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.C10"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/note="Vector: pFLIPI"

Query Match 0.7%; Score 13; DB 1; Length 30;
Best Local Similarity 65.5%; Pred. No. 29;
Matches 19; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1575 TTTTTCACCTTCATCTATCTCTAAATTTT 1603
Db 1 TTTTTCACCTTCATCTATCTCTAAATTTT 29

RESULT 22
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE

AA937877 16 bp mRNA linear EST 30-APR-1998
nw90e06.s1 NCI CGAP Pr12 Homo sapiens cDNA clone IMAGE:1253890
similar to TR:Q35989 Q35989 CYTOCHROME C OXIDASE SUBUNIT 1 i, mRNA
sequence.
AA937877 GI:3095988
AA937877.1 Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 16)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),

<p> Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H. Large-scale Sequencing Analysis of Rice ESTs Unpublished (2003) Contact: Nahm B.H. Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University Yongin, Kyeonggi, Korea Tel: 82 31 330 6193 Fax: 82 31 321 6355 Email: bhnahm@ggbio.com, bhnahm@bio.myongji.ac.kr. </p>	<p> /lab_host="DH10B (Life Technology)" /clone_lib="Barley EST endosperm library" /note="vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor." </p>
<p> TITLE JOURNAL COMMENT </p>	<p> /clone_lib="Barley EST endosperm library" /note="vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the barley cultivar Himalaya. cDNA was synthesised from pooled 10, 12, and 15 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor." </p>
<p> FEATURES source </p>	<p> Query Match 0.7%; Score 13.4; DB 1; Length 31; Best Local Similarity 64.5%; Pred. No. 28; Matches 20; Conservative 0; Mismatches 11; Indels 0; Gaps 0; </p>
<p> QY 1749 AAAAAAAAAAAAAA 1763 </p>	<p> QY 1571 GAATCTTTTTCATTCATTCATTCATTAATT 1601 </p>
<p> Db 1 AAAAAAAAAAAAAA 15 </p>	<p> Db 31 GAATCTTTTTCATTCATTCATTCATTAATT 1 </p>
<p> RESULT 19 CV057897/c </p>	<p> RESULT 20 AJ588201 </p>
<p> LOCUS DEFINITION </p>	<p> LOCUS DEFINITION </p>
<p> ACCESSION VERSION KEYWORDS SOURCE ORGANISM </p>	<p> ACCESSION VERSION KEYWORDS SOURCE ORGANISM </p>
<p> REFERENCE AUTHORS TITLE JOURNAL COMMENT </p>	<p> REFERENCE AUTHORS TITLE JOURNAL COMMENT </p>
<p> FEATURES source </p>	<p> FEATURES source </p>
<p> Query Match 0.7%; Score 13.4; DB 1; Length 15; Best Local Similarity 93.3%; Pred. No. 15; Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0; </p>	<p> Query Match 0.7%; Score 13; DB 1; Length 14; Best Local Similarity 100.0%; Pred. No. 15; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0; </p>

TITLE
JOURNAL
COMMENT

Pongo pygmaeus mRNA (Koehler, K., Beyer, A., Mewes, H.W., et al.)
Unpublished (2004)
Contact: MIPS

1749 AAAAAAAAAAAAAA 1764
|||||
2 AAAAAAAAAAAAAA 16

RESULT 16
CR786609 16 bp mRNA linear EST 01-OCT-2004
LOCUS
DEFINITION
DKFZ468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
Further information about the clone and the sequencing project is
available at <http://mips.gsf.de/projects/cdna/>.

FEATURES
source
1..16
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZ468C2031"
/tissue_type="heart"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1764
Db 1 AAAAAAAAAAAAAA 16

RESULT 16
CR786609 16 bp mRNA linear EST 01-OCT-2004
LOCUS
DEFINITION
DKFZ468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
Further information about the clone and the sequencing project is
available at <http://mips.gsf.de/projects/cdna/>.

FEATURES
source
1..16
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZ468C2031"
/tissue_type="heart"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

Query Match 0.8%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 8.6;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1764
Db 1 AAAAAAAAAAAAAA 16

RESULT 16
CR786609 16 bp mRNA linear EST 01-OCT-2004
LOCUS
DEFINITION
DKFZ468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
Further information about the clone and the sequencing project is
available at <http://mips.gsf.de/projects/cdna/>.

FEATURES
source
1..16
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZ468C2031"
/tissue_type="heart"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1763 AAAAAAAAAAAAAA 1776
Db 1 AAAAAAAAAAAAAA 14

RESULT 18
CR291030 15 bp mRNA linear EST 14-AUG-2003
LOCUS
DEFINITION
14ROOT--01-E19.g1 Rice root plasmid cDNA library (14ROOT) Oryza
sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA
sequence.
Accession
CR291030.1 GI:33660063
VERSION
CR291030
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Rukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 15)
REFERENCE
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

TITLE
JOURNAL
COMMENT

Pongo pygmaeus mRNA (Koehler, K., Beyer, A., Mewes, H.W., et al.)
Unpublished (2004)
Contact: MIPS

1749 AAAAAAAAAAAAAA 1763
|||||
2 AAAAAAAAAAAAAA 16

RESULT 17
CR789161 15 bp mRNA linear EST 01-OCT-2004
LOCUS
DEFINITION
DKFZ468J1632_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
Further information about the clone and the sequencing project is
available at <http://mips.gsf.de/projects/cdna/>.

FEATURES
source
1..15
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZ468J1632"
/tissue_type="heart"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/note="Vector: pSport1_Sfi; Site_1: SfilA; Site_2: SfilB"

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1763 AAAAAAAAAAAAAA 1776
Db 1 AAAAAAAAAAAAAA 14

RESULT 18
CR291030 15 bp mRNA linear EST 14-AUG-2003
LOCUS
DEFINITION
14ROOT--01-E19.g1 Rice root plasmid cDNA library (14ROOT) Oryza
sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA
sequence.
Accession
CR291030.1 GI:33660063
VERSION
CR291030
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Rukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 15)
REFERENCE
Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into cells chemically-competent E. coli XL10-Gold (Stratagene) and selected for ampicillin resistance."

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.8%; Pred. No. 9.5;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
|||||
DB 21 AAAAAAAAAAGAAAGAAAAA 1

RESULT 10
CV066327/c
LOCUS
DEFINITION
WHEAT EST endospERM library Triticum aestivum cDNA clone
WHEAT32e2 5' similar to Unknown Function, mRNA sequence.

ACCESSION
CV066327
VERSION
CV066327.1 GI:51529504
KEYWORDS
EST.
SOURCE
Triticum aestivum (bread wheat)
ORGANISM
Triticum aestivum

REFERENCE
AUTHORS
Ali, S. Holloway, B. and Taylor, W. C.
TITLE
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis

JOURNAL
COMMENT
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 35.

FEATURES
source
1..35
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WHEAT32e2"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endospERM library"
/notes="Vector: ZiploX; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZiploX vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.0%; Score 17.4; DB 1; Length 35;
Best Local Similarity 68.6%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1569 AGGAACCTTTTTCACCTTCATCTATTCTTAATTTT 1603
|||||
DB 35 AGGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 1

RESULT 12
CV064759/c
LOCUS
DEFINITION
WHEAT EST endospERM library Triticum aestivum cDNA clone
WHEAT498 5' similar to Unknown Function, mRNA sequence.

ACCESSION
CV064759
VERSION
CV064759.1 GI:51527936
KEYWORDS
EST.
SOURCE
Triticum aestivum (bread wheat)
ORGANISM
Triticum aestivum

REFERENCE
AUTHORS
Ali, S. Holloway, B. and Taylor, W. C.
TITLE
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis

RESULT 11
CV066718/c
LOCUS
DEFINITION
WHEAT EST endospERM library Triticum aestivum cDNA clone
WHEAT7d3 5' similar to Unknown Function, mRNA sequence.

ACCESSION
CV066718
VERSION
CV066718.1 GI:51529895
KEYWORDS
EST.
SOURCE
Triticum aestivum (bread wheat)
ORGANISM
Triticum aestivum

REFERENCE
AUTHORS
Ali, S. Holloway, B. and Taylor, W. C.
TITLE
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis

JOURNAL
COMMENT
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry,
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 36.

FEATURES
source
1..36
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WHEAT7d3"
/tissue_type="endospERM"
/dev_stage="developing endospERM tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endospERM library"
/notes="Vector: ZiploX; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endospERM tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endospERM using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZiploX vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.0%; Score 17.4; DB 1; Length 36;
Best Local Similarity 68.8%; Pred. No. 21;
Matches 24; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1569 AGGAACCTTTTTCACCTTCATCTATTCTTAATTTT 1603
|||||
DB 36 AGGAATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT 2

RESULT 12
CV064759/c
LOCUS
DEFINITION
WHEAT EST endospERM library Triticum aestivum cDNA clone
WHEAT498 5' similar to Unknown Function, mRNA sequence.

ACCESSION
CV064759
VERSION
CV064759.1 GI:51527936
KEYWORDS
EST.
SOURCE
Triticum aestivum (bread wheat)
ORGANISM
Triticum aestivum

REFERENCE
AUTHORS
Ali, S. Holloway, B. and Taylor, W. C.
TITLE
Normalisation of cereal endospERM EST libraries for structural and functional genomic analysis

```

/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.B4"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/lab_lib="TIGEM gene trap library"
/notes="Vector: pFLIP1"

Query Match      1.2%; Score 21.8; DB 1; Length 26;
Best Local Similarity 92.0%; Pred. No. 5;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
DB 25 AACATATAAAAAAAAAAAAAAAAA 1

RESULT 8
AZ814559/c
LOCUS      24 bp      DNA      linear      GSS 20-FEB-2001
DEFINITION clone UUGC2M0082P18 F, genomic survey sequence.
ACCESSION  AZ814559
VERSION     AZ814559.1  GI:112984467
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
REFERENCE  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 24)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0082 row: P column: 18
Seq primer: CGTTGTAACGACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 24.
Location/Qualifiers
1..24
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0082P18"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: FWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (gi|4732114|gb|AF129072.1), a copy-number

of pMD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match      1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 8.6;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAAGAAAGAAAAAGAAAAA 1

RESULT 9
AZ597932/c
LOCUS      21 bp      DNA      linear      GSS 13-DEC-2000
DEFINITION clone UUGC1M0412D23 F, genomic survey sequence.
ACCESSION  AZ597932
VERSION     AZ597932.1  GI:11720122
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
REFERENCE  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS   Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0412 row: D column: 23
Seq primer: CGTTGTAACGACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1..21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0412D23"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: FWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (gi|4732114|gb|AF129072.1), a copy-number

```

Db 30 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 4

RESULT 5
CV057897
LOCUS
DEFINITION
CV057897 31 bp mRNA linear EST 24-AUG-2004
BNEL32a8 Barley EST endosperm library Hordeum vulgare subsp.
vulgare cDNA clone BNEL32a8 5' similar to Unknown Function, mRNA
sequence.
CV057897
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Hordeum vulgare subsp. vulgare
Hordeum vulgare subsp. vulgare
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Pooideae; Triticeae; Hordeum.
1 (bases 1 to 31)
Ali, S., Holloway, B. and Taylor, W.C.
Normalisation of cereal endosperm EST libraries for structural and
functional genomic analysis
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 31.
Location/Qualifiers
1. .31
/organism="Hordeum vulgare subsp. vulgare"
/mol_type="mRNA"
/cultivar="Himalaya"
/sub_species="vulgare"
/db_xref="taxon:112509"
/clones="BNEL32a8"
/tissue_type="endosperm"
/dev_stages="developing endosperm tissue 10, 12, 15 dpa
(days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Barley EST endosperm library"
/note="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA
was prepared from endosperm tissues of the Barley cultivar
Himalaya. cDNA was synthesised from pooled 10, 12, and 15
dpa endosperm using Not I-oligo(dT)18 primer/adaptor
(Pharmacia Biotech), and then ligated to the Sal I-Not I
site of Ziplox vector (Life Technology) after adding a
Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan
Ali and Bill Taylor."

Query Match 1.5%; Score 27; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1775
Db 1 AAAAAAAAAAAAAAAAAAAAAAAAAAAAA 27

RESULT 6
CV091538/c
LOCUS
DEFINITION
CV091538 28 bp mRNA linear EST 26-AUG-2004
NAL103 R cDNA non acclimated Bluecrop library Vaccinium corymbosum
cDNA 3', mRNA sequence.
CV091538
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Vaccinium corymbosum
Vaccinium corymbosum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
asterids; Ericales; Ericaceae; Vaccinioideae; Vaccinieae;
Vaccinium.
1 (bases 1 to 28)
Dhanaraj, A.L., Alkharouf, N.W., Beard, H.S., Chouikha, I.B.,
Matthews, B.F. and Rowland, L.J.
Monitoring gene expression changes during cold acclimation of
blueberry (Vaccinium corymbosum L.) using a cDNA microarray
Unpublished (2004)
Contact: Rowland, L.J.
Fruit Lab
US Department of Agriculture (USDA), ARS, PSI
Bldg 010A, 10300 Baltimore avenue, BARC West, Beltsville, MD
20705-2350, USA
Tel: 301-504-6654
Fax: 301-504-5653
Email: rowlandj@ba.ars.usda.gov.
Location/Qualifiers
1. .28
/organism="Vaccinium corymbosum"
/mol_type="mRNA"
/cultivar="Bluecrop"
/db_xref="taxon:69266"
/tissue_type="Flower plants"
/dev_stages="Mature plants"
/note="lib=cDNA non acclimated Bluecrop library"
/clone_lib="cDNA non acclimated Bluecrop library"
/note="Vector: pBluescript SK-; cDNA clones from Vaccinium
corymbosum cv. Bluecrop, RNA for preparation of library
was extracted from flower buds collected in the fall from
non acclimated plants"

Query Match 1.4%; Score 24.4; DB 1; Length 28;
Best Local Similarity 89.3%; Pred. No. 2.8;
Matches 25; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1739 AAGAAAGTGAAGAAAAAAAAAAAAAAAAAAAA 1766
Db 28 ANAAAAAGTNAAAAAAAAAAAAAAAAAAAAA 1

RESULT 7
CV020478/c
LOCUS
DEFINITION
CV020478 26 bp mRNA linear GSS 28-SEP-2004
GC0745 TIGEM gene trap library Mus musculus cDNA clone A015.B4,
mRNA sequence.
CV020478
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 26)
Cobellis, G., Nicolaus, G., Marra, E., Barbarisi, M., Sardiello, M., Di
Giorgio, F.P., Iovino, N., Zollo, M., Ballabio, A. and Cortese, R.
Tagging genes with cassette-exchange sites
Unpublished (2004)
Contact: TIGEM
107
TIGEM
Via P. Castellino, 111, 80131 NAPOLI, ITALY
Tel: +390816132205
Fax: +390815790919
Email: cobellis@tigem.it
Sequence tag generated by 5' RACE of total RNA from gene trap ES
cell line. ES cell lines harboring insertion mutation of target
gene are available upon request from TIGEM. Annotation information
available from TIGEM
Class: Gene Trap.
Location/Qualifiers
1. .26
/organism="Mus musculus"
/mol_type="mRNA"


```

functional genomic analysis
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 36.
Location/Qualifiers
1. .36
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/notes="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1.7%; Score 30.2; DB 1; Length 36;
Best Local Similarity 91.4%; Pred. No. 0.91;
Matches 32; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1750 AAAAAAAAAAAAAAAAAAAAAACGGAATTC 1784
|||||
Db 1 AAAAAAAAAAAAAAAAAAAAAACGGAATTC 35

RESULT 3
CV066327 35 bp mRNA linear EST 24-AUG-2004
LOCUS WNEL32e2 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNEL32e2 5' similar to Unknown Function, mRNA sequence.
VERSION CV066327.1 GI:51529504
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Triticum.
1 (bases 1 to 35)
Ali, S., Holloway, B. and Taylor, W.C.
Normalisation of cereal endosperm EST libraries for structural and
functional genomic analysis
Plant Mol. Biol. Rep. 18, 123-132 (2000)
Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry.
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 35.
Location/Qualifiers
1. .35
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"

JOURNAL
COMMENT

FEATURES
source
1. .36
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/notes="Vector: Ziplox; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of Ziplox vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

JOURNAL
COMMENT

FEATURES
source
1. .30
/organism="Mus musculus"
/mol_type="mRNA"
/strain="129 ola"
/db_xref="taxon:10090"
/clone="A015.C10"
/sex="male"
/cell_type="Embryonic stem cell"
/cell_line="E14"
/clone_lib="TIGEM gene trap library"
/notes="Vector: pFLIP1"

Query Match 1.5%; Score 27; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 1.5;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1775
|||||

```

RESULT 1
CV064759 38 bp mRNA linear EST 24-AUG-2004
LOCUS WNEL1498 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNEL1498 5' similar to Unknown Function, mRNA sequence.
ACCESSION CV064759
VERSION CV064759.1 GI:51527936
KEYWORDS EST
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
REFERENCE Ali, S. Holloway, B. and Taylor, W.C.
AUTHORS Normalisation of cereal endosperm EST libraries for structural and
TITLE functional genomic analysis
JOURNAL Plant Mol. Biol. Rep. 18, 123-132 (2000)
COMMENT Contact: Bill Taylor
Commonwealth Scientific and Industrial Research Organisation
Division of Plant Industry
CSIRO Plant Industry, GPO Box 1600, Canberra, ACT 2601, Australia
Tel: 61 2 6246 5223
Fax: 61 2 6246 5000
Email: Bill.Taylor@csiro.au
Seq primer: M13 reverse primer
High quality sequence stop: 38.

FEATURES
source
1..38
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="Hartog"
/db_xref="taxon:4565"
/clone="WNEL1498"
/tissue_type="endosperm"
/dev_stage="developing endosperm tissue 6, 8, 10 dpa (days post anthesis)"
/lab_host="DH10B (Life Technology)"
/clone_lib="Wheat EST endosperm library"
/notes="Vector: ZiploX; Site 1: Sal I; Site 2: Not I; mRNA was prepared from endosperm tissues of the wheat cultivar Hartog. cDNA was synthesised from pooled 6, 8, and 10 dpa endosperm using Not I-oligo(dT)18 primer/adaptor (Pharmacia Biotech), and then ligated to the Sal I-Not I site of ZiploX vector (Life Technology) after adding a Sal I-Xho I adaptor (Stratagene). Constructed by Shahjahan Ali and Bill Taylor."

Query Match 1..7%; Score 31.2; DB 1; Length 38;
Best Local Similarity 91.7%; Pred. No. 0.77;
Matches 33; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAACGGAAATTC 1784
DB 2 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATTC 37

RESULT 2
CV066718 36 bp mRNA linear EST 24-AUG-2004
LOCUS WNEL7d3 Wheat EST endosperm library Triticum aestivum cDNA clone
DEFINITION WNEL7d3 5' similar to Unknown Function, mRNA sequence.
ACCESSION CV066718
VERSION CV066718.1 GI:51529895
KEYWORDS EST
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
REFERENCE Ali, S. Holloway, B. and Taylor, W.C.
AUTHORS Normalisation of cereal endosperm EST libraries for structural and
TITLE

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.
OM.nucleic - nucleic search, using sw model
Run on: May 13, 2005, 12:26:20 ; Search time 1 Seconds
(without alignments)
1.615 Million cell updates/sec
Title: US-10-619-906-2
Perfect score: 1790
Sequence: 1 atgaattttctcatgatg.....aaaaacgggaattcccgggga 1790
Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5
Searched: 21 seqs, 451 residues
Total number of hits satisfying chosen parameters: 42
Minimum DB seq length: 8
Maximum DB seq length: 50
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 28 summaries
Database : rst2.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	31.2	1.7	38	1	CV064759
2	30.2	1.7	36	1	CV066718
3	29.2	1.6	35	1	CV066327
C 4	27	1.5	30	1	CV020481
5	27	1.5	31	1	CV057897
C 6	24.4	1.4	28	1	CV091538
C 7	21.8	1.2	26	1	CV020478
C 8	19.2	1.1	24	1	AZ814559
C 9	17.8	1.0	21	1	AZ597932
C 10	17.4	1.0	35	1	CV066327
C 11	17.4	1.0	36	1	CV066718
C 12	17.4	1.0	38	1	CV064759
13	16.4	0.9	18	1	AJ725584
14	16.4	0.9	16	1	CR786637
15	16	0.9	16	1	CR786853
16	15	0.8	16	1	CR786609
17	14	0.8	15	1	CR789161
18	13.4	0.7	15	1	CF291030
C 19	13.4	0.7	31	1	CV057897
20	13	0.7	14	1	AJ588201
21	13	0.7	30	1	CV020481
C 22	12.8	0.7	16	1	AA937877
23	12.8	0.7	26	1	CV020478
24	12.4	0.7	14	1	CF301021
25	12.4	0.7	28	1	CV091538
26	12.2	0.7	24	1	AZ814559
27	12	0.7	12	1	AJ739036
28	12	0.7	15	1	AJ656714

ALIGNMENTS

THIS PAGE BLANK (USPTO)

KW dynamin axonemal light polypeptide chain 4; haplotyping; genotyping;
KW neuroprotective; neurological disorder; allele-specific oligonucleotide;
KW ASO; primer; ss.
OS Homo sapiens.
XX
XX WO200179235-A2.
PN
XX
XX PD
XX 25-OCT-2001.
XX
XX 16-APR-2001; 2001WO-US012304.
PF
XX 17-APR-2000; 2000US-0197460P.
PR
XX (GENA-) GENAISANCE PHARM INC.
XX
XX PA
XX Bentivegna SC, Chew A, Choi JY, Koshy B;
PI
XX WPI; 2002-075065/10.
DR
XX Genotyping human dynein, axonemal light polypeptide chain 4 gene of
PT individual, useful for determining haplotype of individual, comprises
PT determining identity of nucleotide pair at specific polymorphic sites for
PT two copies of gene.
XX
XX Claim 16; Page 13; 79pp; English.
PS
XX The present invention relates to novel single nucleotide polymorphisms
CC (SNPs) in the human dynein, axonemal light polypeptide chain 4 (DNAL4)
CC gene located on chromosome 22q13.1, and methods for haplotyping and/or
CC genotyping the DNAL4 gene. The methods of the invention make use of
CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
CC primer-extension oligonucleotides for detecting the DNAL4 gene
CC polymorphisms. The polynucleotides and screened compounds are useful for
CC the treatment of diseases associated with DNAL4 activity, such as
CC neurological disorders. AAS19921-AAS19948 represent ASO primers for
CC detecting human DNAL4 gene polymorphisms
XX
XX SQ Sequence 15 BP; 5 A; 1 C; 5 G; 3 T; 0 U; 1 Other;
Query Match 0.8%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 440 AGATGAGGCTGAC 453
Db 1 AGATGAGGCTGAY 14

Search completed: May 13, 2005, 12:20:44
Job time : 4 secs

PA (MORR/) MORRISSEY D.
 XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;
 XX WPI; 2004-247781/23.
 XX
 XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
 PT specifically cleaving RNA derived from hepatitis B virus and comprising
 PT one or more binding arms, useful for treating hepatitis and cirrhosis.
 XX
 XX Disclosure; SEQ ID NO 2466; 122pp; English.
 XX
 XX The invention relates to an enzymatic nucleic acid molecule that
 CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
 CC comprising one or more binding arms, without requiring the presence of a
 CC 2'-OH group within the molecule for activity. The nucleic acids are
 CC useful for treating hepatitis B virus infection, hepatitis,
 CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
 CC combination with other therapies such as lamivudine and interferons. The
 CC nucleic acids are useful as diagnostic tools to examine genetic drift and
 CC mutations within diseased cells, for detecting the presence of HBV RNA in
 CC a cell, for the study of RNA and for down-regulating gene expression of
 CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
 CC sequence represents an HBV RNA target sequence, used in the scope of the
 CC invention. Note: The sequence data for this patent is also available in
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 792 GACAAACCTAGCAGTC 808
 Db 17 GATAAAACCTAGCAGGC 1
 |||||
 |||||
 RESULT 227
 ACN73526/c
 ID ACN73526 standard; DNA; 17 BP.
 XX
 XX ACN73526;
 AC
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:10428.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 OS
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.

PR 30-JAN-2001; 2001WO-US0000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 XX (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 PI WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 PT
 XX Disclosure; SEQ ID NO 10428; Opp; English.
 PS
 XX The invention relates to a novel polypeptide (I) comprising a sequence
 CC of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 841 TTTGATGCTGTCAAC 857
 Db 17 TTTGATGCTGTCAAC 1
 |||||
 |||||
 RESULT 228
 ACN63972/c
 ID ACN63972 standard; DNA; 17 BP.
 XX
 XX ACN63972;
 AC
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:874.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 OS
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX 26-NOV-2003; 2003US-00723361.
 PF
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US0000661.
 PR 30-JAN-2001; 2001WO-US0000662.
 PR 30-JAN-2001; 2001WO-US0000663.
 PR 30-JAN-2001; 2001WO-US0000664.
 PR 30-JAN-2001; 2001WO-US0000665.
 PR 30-JAN-2001; 2001WO-US0000666.
 PR 30-JAN-2001; 2001WO-US0000667.
 PR 30-JAN-2001; 2001WO-US0000668.
 PR 30-JAN-2001; 2001WO-US0000669.

```

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 9; SEQ ID NO 789; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human NOGO
XX receptor zinzyme substrate sequence.
XX
XX Sequence 17 BP; 1 A; 8 C; 5 G; 0 T; 3 U; 0 Other;

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCC 1224
    :|||:|:|:|:|:|:|:|:|
Db 1 UGGGCCCGUGGACCCC 17

RESULT 225
ADL49748
ID ADL49748 standard; RNA; 17 BP.
XX
XX AC ADL49748;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human PKR substrate sequence #862.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
XX prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
XX protein kinase PKR; cerebrovascular accident;
XX central nervous system injury; CNS injury; spinal cord injury; cancer;
XX melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
XX restenosis; asthma; Crohn's disease; diabetes; obesity;
XX autoimmune disease; lupus; multiple sclerosis; transplant rejection;
XX graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
XX allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
XX substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
XX 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
XX
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.

```

```

XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 3281; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human PKR
XX substrate sequence.
XX
XX Sequence 17 BP; 9 A; 2 C; 2 G; 0 T; 4 U; 0 Other;

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.2e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 594 AAGTTTTCAGGCACAA 610
    |||:|:|:|:|:|:|:|
Db 1 AAGUUUUCRAGCAAA 17

RESULT 226
ADM60332/c
ID ADM60332 standard; RNA; 17 BP.
XX
XX AC ADM60332;
XX
XX 03-JUN-2004 (first entry)
XX
XX Hepatitis B virus (HBV) RNA target sequence #2466.
XX
XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX virucide; hepatotropic; antiinflammatory; cytostatic.
XX
XX Hepatitis B virus.
XX
XX US2004054156-A1.
XX
XX 18-MAR-2004.
XX
XX 15-JAN-2003; 2003US-00342902.
XX
XX 14-MAY-1992; 92US-00882712.
XX
XX 07-FEB-1994; 94US-00193627.
XX
XX 08-NOV-1999; 99US-00436430.
XX
XX 20-MAR-2000; 2000US-00531025.
XX
XX 09-AUG-2000; 2000US-00836385.
XX
XX 24-OCT-2000; 2000US-00696347.
XX
XX 08-JUN-2001; 2001US-00877478.
XX
XX (DRAP/) DRAPER K.
XX
XX (BLAT/) BLATT L.
XX
XX (MCSW/) MCSWIGGEN J A.

```

virus resistance; transgenic animals; Alzheimer's disease; schizophrenia; diagnosis.
 Homo sapiens.
 WO2003040369-A2.
 15-MAY-2003.
 17-SEP-2002; 2002WO-IB004219.
 17-SEP-2001; 2001FR-00011981.
 (MOLE-) MOLECULAR ENGINES LAB.
 Telerman A, Amson R, Tuijnder M;
 WPI; 2003-441574/41.
 New nucleic acid encoding human prostate membrane-specific antigen, useful e.g. for treatment of tumors and viral infection, also related polypeptide and antibodies.
 Disclosure; Page 392; 771pp; French.
 The invention relates to the isolation of 6327 nucleotide sequences, fragments of at least 15 consecutive nucleotides of these nucleotides, a sequence having at least 80% identity, after optimal alignment, with the nucleotides, a sequence that hybridizes under stringent conditions with the nucleotides, or the complement, or corresponding RNA, of the nucleotides. The nucleotides are used as probes or primers for detecting, identifying, quantifying and/or amplifying nucleic acids, as in vitro sense and antisense sequences, of nucleotides involved in tumour suppression or reversion, apoptosis and or viral resistance, to produce recombinant polypeptides, and to prepare transgenic animals, as experimental models. The nucleotides (also vectors containing them and cells containing the vectors), the encoded polypeptides and antibodies (Ab) against the polypeptide are useful for prevention and/or treatment of viral infections or diseases characterized by development of tumours or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 Analysis of the expression of the nucleotides can be used for diagnosis and/or prognosis of these diseases. The nucleotides and polypeptides can also be used to screen for their specific interactive molecules, potentially useful for treating diseases associated with abnormal expression of the nucleotides.
 Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1120 GATGACGCTGCTTTGA 1136
 ||| ||||| |||||
 Db 1 GATCCAGCTGCTCTGA 17
 RESULT 223
 ACC53133/c
 ID ACC53133 standard; DNA; 17 BP.
 XX
 AC ACC53133;
 XX
 DT 27-JUN-2003 (first entry)
 XX
 DE Human tumour suppressor sequence #1900.
 XX
 KW ss: tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX
 XX Homo sapiens.
 XX

FR2826373-A1.
 27-DEC-2002.
 20-JUN-2001; 2001FR-00008139.
 20-JUN-2001; 2001FR-00008139.
 (MOLE-) MOLECULAR ENGINES LAB SA.
 Tuijnder M, Telerman A, Amson R;
 WPI; 2003-250498/25.
 New nucleic acid sequences associated with tumor suppression, regression, apoptosis or virus resistance are useful to diagnose and treat viral disease, development of tumor cells and cell degeneration.
 Claim 1; Page 479; 798pp; French.
 This sequence represents an isolated nucleic acid sequence associated with tumor suppression or regression, apoptosis or virus resistance. The invention relates to these sequences or sequences having at least 80% identity to them, and polypeptides encoded by the sequences or polypeptides having 80% identity to the polypeptide sequences. The invention is used to diagnose or treat viral disease or disease characterized by development of tumour cells or cellular degeneration.
 Sequence 17 BP; 5 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1297 TACATCTTCCAGGAGC 1313
 ||| ||||| |||||
 Db 17 TACATCTTCCAGGATC 1
 RESULT 224
 ADL47256
 ID ADL47256 standard; RNA; 17 BP.
 XX
 AC ADL47256;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human NOGO receptor zymase substrate sequence #243.
 XX
 KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW proteoglycan D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;
 KW NOGO receptor zymase; substrate; ds.
 XX
 OS Unidentified.
 XX
 PN WO200281628-A2.
 XX
 PD 17-OCT-2002.
 XX
 PP 03-APR-2002; 2002WO-US010512.
 XX
 PR 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberzyme sequences
CC disclosed in the present invention

XX Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 792 GACAAAACCTAGCAGTC 808

Db 17 GATAAACCTAGCAGC 1

RESULT 220

ACC64538/c

ID ACC64538 standard; DNA; 17 BP.

XX

AC ACC64538;

XX 01-JUL-2003 (first entry)

XX Murine oligonucleotide associated with tumour suppression, SEQ ID 1785.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; ss.

XX

OS Mus musculus.

XX

PN WO2003025176-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004210.

XX

PR 17-SEP-2001; 2001FR-00011979.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

DR WPI; 2003-333167/31.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; Page 239; 738pp; French.

XX

CC The present invention relates to murine oligonucleotides (ACC62754-

CC ACC68806), which are associated with tumour suppression, tumour

CC reversion, apoptosis and virus resistance. The oligonucleotides are

CC useful as (1) as probes and primers for detecting, identifying,

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a

CC recombinant polypeptides. The oligonucleotides are useful for preparation

CC of pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 6 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1602 TTGAAGTGCATGCTC 1618

Db 17 TTGAAGTGTATGATC 1

RESULT 221

ACC65475

ID ACC65475 standard; DNA; 17 BP.

XX

AC ACC65475;

XX

DT 01-JUL-2003 (first entry)

XX

DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2722.

XX

KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; ss.

XX

OS Mus musculus.

XX

PN WO2003025176-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004210.

XX

PR 17-SEP-2001; 2001FR-00011979.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

DR WPI; 2003-333167/31.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; Page 349; 738pp; French.

XX

CC The present invention relates to murine oligonucleotides (ACC62754-

CC ACC68806), which are associated with tumour suppression, tumour

CC reversion, apoptosis and virus resistance. The oligonucleotides are

CC useful as (1) as probes and primers for detecting, identifying,

CC quantifying and/or amplifying nucleic acid, e.g. as one component of a

CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a

CC recombinant polypeptides. The oligonucleotides are useful for preparation

CC of pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration,

CC specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 7 A; 4 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 330 GATCTATAATTACATC 346

Db 1 GATCGAAAATTACATC 17

RESULT 222

ADB42757

ID ADB42757 standard; DNA; 17 BP.

XX

AC ADB42757;

XX

DT 18-DEC-2003 (revised)

DT

04-DEC-2003 (first entry)

XX

DE Tumour suppression/reversion associated nucleotide #3080.

XX

XX Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;

KW primer; probe; tumour suppression; tumour reversion; apoptosis;

CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.

SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 41 CCTGTGGGCTCTCC 57
 DB 17 CTTGTGGGCTCTCC 1

RESULT 218
 ID ABZ60033/c standard; RNA; 17 BP.

XX AC ABZ60033;

XX 21-MAR-2003 (first entry)

XX Human K-Ras DNzyme substrate #145.

XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.

XX Homo sapiens.

XX WO200297114-A2.

XX 05-DEC-2002.

XX 29-MAY-2002; 2002WO-US016840.

XX 29-MAY-2001; 2001US-0294140P.

PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318471P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J;

XX WPI; 2003-140484/13.

XX Novel short interfering RNA and enzymatic nucleic acid useful for

PT treating cancer, modulates the expression of a nucleic acid encoding

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

PS Claim 58; Page 87; 185pp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 CC ribozymes of the invention

SQ Sequence 17 BP; 9 A; 4 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1688 CTCTCTGTCTTACTG 1704

DB 17 CTGTCTGTCTTCTG 1

RESULT 219
 ACD55872/c

XX ACD55872 standard; RNA; 17 BP.

XX AC ACD55872;

XX 23-SEP-2003 (first entry)

XX HBV amberyne substrate sequence #271.

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 KW RNA stability; RNA expression; RNA synthesis; antisense;
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 KW HBV reverse transcriptase; Enhancer I region; viral replication;
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
 KW virucide; antiinflammatory; substrate; ss.

XX Hepatitis B virus.

XX WO200281494-A1.

XX 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

XX 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MACE/) MACEJAK D.

XX (MCSW/) MCSWIGGEN J.

XX (MORR/) MORRISSEY D.

XX (PAVC/) PAVCO P.

XX (LEEP/) LEE P.

XX (DRAP/) DRAPER K.

XX (ROBE/) ROBERTS E.

XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

XX WPI; 2003-229207/22.

XX Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus

PT infection.

PS Example 1; Page 209; 387pp; English.

XX The present invention relates to nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or

CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,

CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed

CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse

CC transcriptase and/or HBV reverse transcriptase primer sequences, as well

CC as oligonucleotides that specifically bind the Enhancer I region of HBV

CC DNA. The nucleic acids may be used to modulate the expression of HBV

CC genes and HBV viral replication. Also disclosed is a method for screening

CC compounds and/or potential therapies directed against HBV, and compounds

CC that modulate the expression and/or replication of HCV. The compounds and

CC methods of the invention are useful for the treatment of degenerative and

CC disease states related to HBV and HCV infection, replication and gene

CC expression such as cirrhosis, liver failure, and hepatocellular

PT MD24, MD27 or MD212, e.g. cancer.
 PS Example 8; SEQ ID NO 6361; 103pp; English.
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 824 GTCACAAAGCTTGAGT 840
 ||||| ||||| |||||
 Db 1 GTCACAAAGCTTCAGT 17
 RESULT 216
 ADB03208/c
 ID ADB03208 standard; DNA; 17 BP.
 AC ADB03208;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MD24 scanning oligonucleotide SEQ ID 4194.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 XX WPI; 2003-423107/40.
 DR
 XX
 PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MD23,
 PT MD24, MD27 or MD212, e.g. cancer.
 XX
 XX Example 8; SEQ ID NO 4194; 103pp; English.
 PS
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome

CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1296 CTACATCTTCCAGGAG 1312
 ||||| ||||| |||||
 Db 17 CTACCTGTTCAGGAG 1
 RESULT 217
 ADB00428/c
 ID ADB00428 standard; DNA; 17 BP.
 AC ADB00428;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human MD23 scanning oligonucleotide SEQ ID 1414.
 XX
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1281758-A2.
 XX
 PD 05-FEB-2003.
 XX
 PF 30-JUL-2002; 2002EP-00016874.
 XX
 PR 02-AUG-2001; 2001US-00922181.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Shannon M, Gu Y, Nguyen C;
 XX
 XX WPI; 2003-423107/40.
 DR
 XX
 PT New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 PT associated with decreased or increased expression or activity of MD23,
 PT MD24, MD27 or MD212, e.g. cancer.
 XX
 XX Example 8; SEQ ID NO 1414; 103pp; English.
 PS
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are

XX PD 05-FEB-2003.
 XX PF 30-JUL-2002; 2002EP-00016874.
 XX PR 02-AUG-2001; 2001US-00922181.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Shannon M, Gu Y, Nguyen C;
 XX PI WPI; 2003-423107/40.
 XX DR New zinc finger-containing proteins and nucleic acids, useful in
 XX PT manufacturing a medicament for treating or preventing a disorder
 XX PT associated with decreased or increased expression or activity of MDZ3,
 XX PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX PS Example 8; SEQ ID NO 6360; 103pp; English.
 XX CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
 CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
 CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MDZ3,
 CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX SQ Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 823 TGTACACAAAGCTTCAG 839
 DB 1 TGTACACAAAGCTTCAG 17
 RESULT 214
 ADB03207/c
 ID ADB03207 standard; DNA; 17 BP.
 XX AC ADB03207;
 XX DT 20-NOV-2003 (first entry)
 XX DE Human MDZ4 scanning oligonucleotide SEQ ID 4193.
 XX KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX OS Homo sapiens.
 XX PN EP1281758-A2.
 XX PD 05-FEB-2003.
 XX PF 30-JUL-2002; 2002EP-00016874.
 XX PR 02-AUG-2001; 2001US-00922181.
 XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M, Gu Y, Nguyen C;
 XX PI WPI; 2003-423107/40.
 XX DR New zinc finger-containing proteins and nucleic acids, useful in
 XX PT manufacturing a medicament for treating or preventing a disorder
 XX PT associated with decreased or increased expression or activity of MDZ3,
 XX PT MDZ4, MDZ7 or MDZ12, e.g. cancer.
 XX PS Example 8; SEQ ID NO 4193; 103pp; English.
 XX CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MDZ3, MDZ4, MDZ7, MDZ12. MDZ3 is
 CC encoded at chromosome 7q22.1, MDZ4 is encoded at chromosome 6p21.3-22.2,
 CC MDZ7 is encoded at chromosome 16p11.2 and MDZ12 is encoded at chromosome
 CC 15q26.1. The MDZ3, MDZ4, MDZ7, and MDZ12 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MDZ3,
 CC MDZ4, MDZ7, or MDZ12, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MDZ3, MDZ4, MDZ7, or MDZ12. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MDZ3, MDZ4, MDZ7, or MDZ12 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 XX SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1297 TACATCTTCCAAGGAGC 1313
 DB 17 TACCTGTCCAAAGGAGC 1
 RESULT 215
 ADB05375
 ID ADB05375 standard; DNA; 17 BP.
 XX AC ADB05375;
 XX DT 20-NOV-2003 (first entry)
 XX DE Human MDZ12 scanning oligonucleotide SEQ ID 6361.
 XX KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KW developmental disorder; ss.
 XX OS Homo sapiens.
 XX PN EP1281758-A2.
 XX PD 05-FEB-2003.
 XX PF 30-JUL-2002; 2002EP-00016874.
 XX PR 02-AUG-2001; 2001US-00922181.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Shannon M, Gu Y, Nguyen C;
 XX PI WPI; 2003-423107/40.
 XX DR New zinc finger-containing proteins and nucleic acids, useful in
 XX PT manufacturing a medicament for treating or preventing a disorder
 XX PT associated with decreased or increased expression or activity of MDZ3,

```
XX KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX OS
XX XX West Nile Virus.
XX PN WO200268637-A2.
XX XX
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX DR
XX PT New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX PS Claim 23; SEQ ID NO 1052; 495pp; English.
XX CC The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX SQ Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.2e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
QY 1467 GTGTAACCTATGTGGCAA 1483
Db 1 GUGUACUAUUGGCAA 17
|.:|.:|.:|.:|
RESULT 212
ABT35227
ID ABT35227 standard; DNA; 17 BP.
XX
XX AC ABT35227;
XX
XX DT 12-JUN-2003 (first entry)
XX
XX DE Tumour suppression related human fukutin oligo SEQ ID No 864.
XX KW Cytostatic; viricide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX OS
XX PN Homo sapiens.
```

```
XX PN WO2003025175-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004208.
XX PR 17-SEP-2001; 2001FR-00011978.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX PS Disclosure; Page 134; 720pp; French.
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX given in the specification, a sequence containing at least 15 consecutive
XX nucleotides from the 17 mer sequence, a sequence with, after optimal
XX alignment, at least 80 % identity to the 17 mer sequence, a sequence that
XX hybridizes to them under highly stringent conditions, or the complement
XX of any of them, or the corresponding RNA. The novel isolated nucleic
XX acids of the invention are useful as probes and primers for detecting,
XX identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
XX component of a gene chip, in vitro as (anti)sense reagents, and for
XX production of recombinant polypeptides. Any of the nucleic acids,
XX polypeptides, vectors containing the nucleic acids, cells containing the
XX vector or antibodies directed against the polypeptides are useful for
XX preparation of pharmaceuticals for prevention and/or treatment of viral
XX diseases that are characterised by development of tumours or cell
XX degeneration, specifically cancer but also Alzheimer's disease and
XX schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX patient samples is useful for diagnosis and/or prognosis of these
XX diseases. The polypeptides can also be used to generate antibodies, and
XX both the polypeptide and antibodies are useful as components of protein
XX chips. The nucleic acid sequences of the invention can be used in gene
XX therapy. This polynucleotide sequence represents a tumour suppression
XX related human fukutin oligonucleotide of the invention
XX SQ Sequence 17 BP; 4 A; 3 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1120 GATCCAGCTGTCTTTGA 1136
Db 1 GATCCAGATGCTTTGA 17
|.|.|.|.|.|.|.|.|.|.|.|.|.|.|
RESULT 213
ADB05374
ID ADB05374 standard; DNA; 17 BP.
XX
XX AC ADB05374;
XX
XX DT 20-NOV-2003 (first entry)
XX
XX DE Human MD212 scanning oligonucleotide SEQ ID 6360.
XX KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX OS
XX PN Homo sapiens.
XX PN EP1281758-A2.
```

RESULT 210
ACN08216/c

XX 09-AUG-2000; 2000US-0224383P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (SYNT) SYNTAX USA LLC.
XX (THOM) THOMPSON J.
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX WPI; 2002-217145/27.
XX Enzymatic polynucleotide that down regulates expression of chloride
XX channel calcium activated gene, useful for treating Chronic obstructive
XX pulmonary disease (COPD), chronic bronchitis and asthma.
XX Claim 4; Page 85; 152pp; English.
XX The invention relates to enzymatic nucleic acid molecules that down
XX regulate expression of chloride channel calcium activated 1 (ClCa1) genes
XX by cleaving RNA derived from the genes. The nucleic acid sequences are
XX useful as pharmaceutical agents for treating conditions such as chronic
XX obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX that are related to or will respond to the levels of ClCa1 in a cell or
XX tissue. The sequences are useful for reducing ClCa1 activity in a cell,
XX hence, are useful for treatment of a patient having a condition
XX associated with the level of ClCa1, where the invention further comprises
XX the use of one or more therapies under conditions suitable for the
XX treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
XX antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
XX nucleic acids of the invention are also used as diagnostic tools to
XX examine genetic drift and mutations within diseased cells or to detect
XX the presence of ClCa1 RNA in a cell. This sequence represents an
XX enzymatic nucleic acid molecule of the invention
XX Sequence 17 BP; 10 A; 1 C; 3 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 7 TTCTCATGATGATGT 23
DB 17 TTCTCATGATGATGT 1
RESULT 203
ACN07730/C
ID ACN07730 standard; RNA; 17 BP.
XX ACN07730;
XX 22-APR-2004 (first entry)
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7733.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX

PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT) BLATT L.
PA (MCSW) MCSWIGGEN J A.
PI Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX Claim 23; SEQ ID NO 7733; 495pp; English.
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;
XX
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 728 TCTCTGCTGATGACATA 744
DB 17 TCTATGCTGATGACACA 1
RESULT 204
ACN02884
ID ACN02884 standard; RNA; 17 BP.
XX ACN02884;
XX 22-APR-2004 (first entry)
XX WNV Inozyme substrate SEQ ID NO 2887.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT) BLATT L.
XX (MCSW) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
XX

XX PN WO200211674-A2.
 XX PD 14-FEB-2002.
 XX PF 09-AUG-2001; 2001WO-US024970.
 XX PR 09-AUG-2000; 2000US-0224383P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (SYNT) SYNTAX USA LLC.
 XX PA (THOM/) THOMPSON J.
 XX PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
 XX PI Grupe A;
 XX DR WPI; 2002-217145/27.
 XX PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX PS Claim 4; Page 58; 152pp; English.
 XX CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 298 TCAAGATGGATGAAGCG 314
 Db 17 TCAGCTGGATGAAGCG 1
 RESULT 201
 ABK56290
 ID ABK56290 standard; RNA; 17 BP.
 XX AC ABK56290;
 XX DT 02-JUL-2002 (first entry)
 XX DE Human CLCA1 gene enzymatic nucleic acid #661.
 XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX OS Homo sapiens.
 XX PN WO200211674-A2.

PD XX 14-FEB-2002.
 XX PF 09-AUG-2001; 2001WO-US024970.
 XX PR 09-AUG-2000; 2000US-0224383P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (SYNT) SYNTAX USA LLC.
 XX PA (THOM/) THOMPSON J.
 XX PI Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
 XX PI Grupe A;
 XX DR WPI; 2002-217145/27.
 XX PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX PS Claim 4; Page 66; 152pp; English.
 XX CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX SQ Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.2e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 1093 GGCTTCTCTGCATCTGT 1109
 Db 1 GGCAUCUCUGUAUCUGU 17
 RESULT 202
 ABK56882/c
 ID ABK56882 standard; RNA; 17 BP.
 XX AC ABK56882;
 XX DT 02-JUL-2002 (first entry)
 XX DE Human CLCA1 gene enzymatic nucleic acid #1253.
 XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX OS Homo sapiens.
 XX PN WO200211674-A2.
 XX PD 14-FEB-2002.
 XX PR 09-AUG-2001; 2001WO-US024970.

ID ABS75295 standard; DNA; 17 BP.
 XX AC ABS75295;
 XX DT 24-DEC-2002 (first entry)
 XX DE Human PAPP-Ea associated 17-mer SEQ ID 821.
 XX KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
 KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
 KW dysgenetic pregnancy; primer; ss.
 XX OS Homo sapiens.
 XX PN US2002102252-A1.
 XX PD 01-AUG-2002.
 XX PF 06-APR-2001; 2001US-00827998.
 XX PR 26-MAY-2000; 2000US-0207456P.
 XX PA (GUY/) GU Y.
 XX PA (SHAN/) SHANNON M E.
 XX PI Gu Y, Shannon ME;
 XX DR WPI; 2002-697817/75.
 XX PT New isolated nucleic acid encoding an isoform of human pregnancy
 PT associated plasma protein E, for preventing or aborting pregnancy.
 XX PS Example 2; Page 183; 353pp; English.
 CC This invention describes a novel isolated nucleic acid that encodes one
 CC of three new isoforms of human pregnancy associated plasma protein E,
 CC hPAPP-E. The products of the invention have abortive and contraceptive
 CC activity and can be used for gene therapy or in a vaccine. The nucleic
 CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
 CC used in pharmaceutical compositions or vaccines for preventing or
 CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
 CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
 CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
 CC antibodies can be used to assess the expression levels of PAPP-E isoform
 CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
 CC antenatally. This sequence represents an oligomer used in scanning the
 CC human PAPP-E genes described in the disclosure of the invention
 XX SQ Sequence 17 BP; 4 A; 1 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1176 CTACTGGAGGTATGATG 1192
 DB 1 CTAGGGGAGGTATGATG 17
 RESULT 199
 ABK57307/c
 ID ABK57307 standard; RNA; 17 BP.
 XX AC ABK57307;
 XX DT 02-JUL-2002 (first entry)
 XX DE Human CLCA1 gene enzymatic nucleic acid #1678.
 XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;

KW acetylcysteine.
 XX OS Homo sapiens.
 XX PN WO200211674-A2.
 XX PD 14-FEB-2002.
 XX PF 09-AUG-2001; 2001WO-US024970.
 XX PR 09-AUG-2000; 2000US-0224383P.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (SYNT) SYNTEX USA LLC.
 XX PA (THOM/) THOMPSON J.
 XX PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
 XX PI Grupe A;
 XX DR WPI; 2002-217145/27.
 XX PT Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma.
 XX PS Claim 4; Page 111; 152pp; English.
 XX CC The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention
 XX SQ Sequence 17 BP; 9 A; 1 C; 3 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 6 ATTTCTCATGATGATG 22
 DB 17 ATTTCTCATGATGATG 1
 RESULT 200
 ABK55934/c
 ID ABK55934 standard; RNA; 17 BP.
 XX AC ABK55934;
 XX DT 02-JUL-2002 (first entry)
 XX DE Human CLCA1 gene enzymatic nucleic acid #305.
 XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 XX acetylcysteine.
 XX OS Homo sapiens.

CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to scan
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)
XX
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1459 TGCTCAGGTTGTAACCTA 1475
DB 17 TGCTCAGGTTGGAACCA 1

RESULT 196
ABS74897
ID ABS74897 standard; DNA; 17 BP.
XX
AC ABS74897;
XX
DT 24-DEC-2002 (first entry)
DE Human PAPP-Ea associated 17-mer SEQ ID 423.
XX
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
XX contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dysgenetic pregnancy; primer; ss.
XX
OS Homo sapiens.

XX US2002102252-A1.
XX 01-AUG-2002.
XX 06-APR-2001; 2001US-00827998.
XX 26-MAY-2000; 2000US-0207456P.
XX (GUY/) GU Y.
XX (SHAN/) SHANNON M E.
XX Gu Y, Shannon ME;
XX WPI; 2002-697817/75.
XX
XX New isolated nucleic acid encoding an isoform of human pregnancy
XX associated plasma protein E, for preventing or aborting pregnancy.
XX Example 2; Page 130; 353pp; English.

XX This invention describes a novel isolated nucleic acid that encodes one
XX of three new isoforms of human pregnancy associated plasma protein E,
XX hPAPP-E. The products of the invention have abortive and contraceptive
XX activity and can be used for gene therapy or in a vaccine. The nucleic
XX acid, polypeptide encoded by it, or antibody to the polypeptide can be
XX used in pharmaceutical compositions or vaccines for preventing or
XX aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
XX dysgenetic pregnancies. The nucleic acids are used as probes to assess
XX the level of PAPP-E isoform mRNA in chorionic villus samples, and the
XX antibodies can be used to assess the expression levels of PAPP-E isoform
XX proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
XX antenatally. This sequence represents an oligomer used in scanning the
XX human PAPP-E genes described in the disclosure of the invention

XX Sequence 17 BP; 0 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 TGCTGTGGGGTGTCTC 55
DB 1 TGCTGTGGGGTGTCTC 17

RESULT 197
ABS75296
ID ABS75296 standard; DNA; 17 BP.
XX
AC ABS75296;
XX
DT 24-DEC-2002 (first entry)
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 822.
XX
KW PAPP-E; human; pregnancy associated plasma protein E; abortive;
XX contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dysgenetic pregnancy; primer; ss.
XX
OS Homo sapiens.

XX US2002102252-A1.
XX 01-AUG-2002.
XX 06-APR-2001; 2001US-00827998.
XX 26-MAY-2000; 2000US-0207456P.

XX (GUY/) GU Y.
XX (SHAN/) SHANNON M E.
XX Gu Y, Shannon ME;
XX WPI; 2002-697817/75.

XX New isolated nucleic acid encoding an isoform of human pregnancy
XX associated plasma protein E, for preventing or aborting pregnancy.
XX Example 2; Page 183; 353pp; English.
XX This invention describes a novel isolated nucleic acid that encodes one
XX of three new isoforms of human pregnancy associated plasma protein E,
XX hPAPP-E. The products of the invention have abortive and contraceptive
XX activity and can be used for gene therapy or in a vaccine. The nucleic
XX acid, polypeptide encoded by it, or antibody to the polypeptide can be
XX used in pharmaceutical compositions or vaccines for preventing or
XX aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
XX dysgenetic pregnancies. The nucleic acids are used as probes to assess
XX the level of PAPP-E isoform mRNA in chorionic villus samples, and the
XX antibodies can be used to assess the expression levels of PAPP-E isoform
XX proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
XX antenatally. This sequence represents an oligomer used in scanning the
XX human PAPP-E genes described in the disclosure of the invention

XX Sequence 17 BP; 4 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1177 TACTGGAGGTATGATGT 1193
DB 1 TAGGGGAGGTATGATGT 17

RESULT 198
ABS75295

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTGTGCTGTCACAC 857
DB 17 TTTGATGCTGTCAGC 1

RESULT 194
ABN10442/c
ID ABN10442 standard; DNA; 17 BP.
XX
AC ABN10442;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10434.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US016981.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
DR
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 10434; 214pp; English.
PS
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTGTGCTGT 851
DB 17 TCGACTTTTGTGCTGT 1

RESULT 195
ABQ64223/c
ID ABQ64223 standard; DNA; 17 BP.
XX
AC ABQ64223;
XX
DT 20-AUG-2002 (first entry)
XX
DE Human KTOM1a portion (ABQ63232) probe # 936.
XX
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200224750-A2.
XX
PD 28-MAR-2002.
XX
PF 21-SEP-2001; 2001WO-US029656.
XX
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhang J;
XX
XX WPI; 2002-479509/51.
DR
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT acids encoding the protein, useful for treating subjects having defects
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT e.g., liver or bone.
XX
XX Example 2; Page 280; 418pp; English.
PS
XX The invention relates to a novel isolated nucleic acid encoding human
CC

XX skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

PN 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption/ionization, comprises human myosin-like protein hGDMPLP-1. Disclosure; SEQ ID NO 874; 214pp; English.

XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterize and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 5 A; 2 C; 9 G; 1 T; 0 U; 0 Other;

XX Query March 0.8%; Score 13.8; DB 1; Length 17; Best Local Similarity 88.2%; Pred. No. 1.2e+02; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCACTTCGCC 1147

DB 17 CTTTGACCCCTCTCGCC 1

RESULT 193

ABN10436/c ID ABN10436 standard; DNA; 17 BP.

XX AC ABN10436;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10428.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart; muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease; skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption/ionization, comprises human myosin-like protein hGDMPLP-1. Disclosure; SEQ ID NO 10428; 214pp; English.

XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterize and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 U; 0 Other;

```
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1678.
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
KW anticancer; breast cancer; endometrium cancer; ss.
XX
OS Homo sapiens.
XX
PN WO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
XX
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
XX used to treat cancer.
XX
PS Claim 77; Page 71; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAA 1765
DB 17 AAAAAATAAACAAAAA 1
RESULT 191
ID AAA25555/c
XX AAA25555 standard; DNA; 17 BP.
XX
AC AAA25555;
XX
DT 19-JUL-2000 (first entry)
XX
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2053.
KW
```

```
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW gene expression modification; cancer; phosphorothioate; endonuclease;
XX anticancer; breast cancer; endometrium cancer; ss.
OS Homo sapiens.
XX
PN WO9954459-A2.
XX
PD 28-OCT-1999.
XX
PF 19-APR-1999; 99WO-US008547.
XX
PR 20-APR-1998; 98US-0082404P.
XX
PR 23-JUN-1998; 98US-00103636.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI Matulic-Adamic J;
XX
DR WPI; 2000-013248/01.
XX
XX New nucleic acids that interact, and optionally cleave, target sequences,
XX used to treat cancer.
XX
PS Claim 77; Page 83; 148pp; English.
XX
CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphoro(di)thioate
CC link, having endonuclease activity. (A), and more generally any catalytic
CC nucleic acid (A') that modulates expression of the oestrogen receptor
CC gene, are used to treat cancer (particularly of breast or endometrium),
CC in vivo or by transforming cells ex vivo and implanting treated cells, or
CC for other conditions associated with levels of oestrogen receptor.
CC Because of the high selectivity for targeted RNA, (A) can also be used to
CC correlate inhibition of gene expression with alterations in phenotype,
CC particularly for identification of therapeutic targets, and as research
CC reagents (for RNA, in the same way that restriction endonucleases are
CC used with DNA). The combination of modifications in (A) improves
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC AAA24748 to AAA25992 represent their corresponding target sequences.
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC sequences, and AAA26107 to AAA26218 represent their corresponding target
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC antisense oligonucleotides used in the exemplification of the present
CC invention
XX
SQ Sequence 17 BP; 13 A; 1 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1717 TTTTGTCTTTCTTAAAT 1733
DB 17 TTTTGTCTTTCTTAAAT 1
RESULT 192
ID ABN00882/c
XX ABN00882 standard; DNA; 17 BP.
XX
AC ABN00882;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:874.
KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
```

VT	19-JUL-2000	(first entry)	
XX	Oestrogen receptor	hammerhead ribozyme target sequence SEQ ID NO:1680.	
XX	Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;		
XX	hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;		
XX	gene expression modification; cancer; phosphorothioate; endonuclease;		
XX	anticancer; breast cancer; endometrium cancer; ss.		
XX	Homo sapiens.		
XX	WO9954459-A2.		
XX	28-OCT-1999.		
XX	19-APR-1999;	99WO-US008547.	
XX	20-APR-1998;	98US-0082404P.	
XX	23-JUN-1998;	98US-00103636.	
XX	(RIBO-) RIBOZYME PHARM INC.		
XX	Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;		
XX	Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;		
XX	Matulic-Adamic J;		
XX	WPI; 2000-013248/01.		
XX	New nucleic acids that interact, and optionally cleave, target sequences,		
XX	used to treat cancer.		
XX	Claim 77; Page 71; 148pp; English.		
XX	The present invention describes nucleic acids (A) that interact stably		
XX	with a target sequence and contain at least one phosphorodithioate		
XX	link, having endonuclease activity. (A), and more generally any catalytic		
XX	nucleic acid (A') that modulates expression of the oestrogen receptor		
XX	gene, are used to treat cancer (particularly of breast or endometrium), or		
XX	in vivo or by transforming cells ex vivo and implanting treated cells, or		
XX	for other conditions associated with levels of oestrogen receptor.		
XX	Because of the high selectivity for targeted RNA, (A) can also be used to		
XX	correlate inhibition of gene expression with alterations in phenotype,		
XX	particularly for identification of therapeutic targets, and as research		
XX	reagents (for RNA, in the same way that restriction endonucleases are		
XX	used with DNA). The combination of modifications in (A) improves		
XX	resistance to nucleases, binding affinity and/or activity. AAA23503 to		
XX	AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and		
XX	AAA24748 to AAA25992 represent their corresponding target sequences.		
XX	AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme		
XX	sequences, and AAA26107 to AAA26218 represent their corresponding target		
XX	sequences. AAA26219 to AAA26271 represent other ribozyme sequences and		
XX	antisense oligonucleotides used in the exemplification of the present		
XX	invention		
XX	Sequence 17 BP; 1 A; 0 C; 2 G; 14 T; 0 U; 0 Other;		
XX	Query Match	0.8%; Score 13.8; DB 1; Length 17;	
XX	Best Local Similarity	88.2%; Pred. No. 1.2e+02;	
XX	Matches 15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	
QY	130	ACAAAACAAACAAACAA 146	
DB	17	ACAAAATATAAACAAA 1	
RESULT 190			
AA25180/c			
ID	AAA25180 standard; DNA; 17 BP.		
XX	AAA25180;		
XX	19-JUL-2000 (first entry)		
XX			
XX			

KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS WO9950403-A2.
 PN 07-OCT-1999.
 XX 24-MAR-1999; 99WO-US006507.
 XX 27-MAR-1998; 98US-0079678P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 DR Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX Claim 56; Page 134; 305pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAL16775 to
 CC AAL17167 and AAL17561 to AAL17622 represent ribozyme sequences for ARNT,
 CC and AAL17168 to AAL17560 and AAL17623 to AAL17684 represent their
 CC corresponding target sequences; AAL17685 to AAL18385 and AAL19087 to
 CC AAL19154 represent ribozyme sequences for Tie-2, and AAL18386 to AAL19086
 CC and AAL19155 to AAL19222 represent their corresponding target sequences;
 CC AAL19223 to AAL20361 and AAL21501 to AAL21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAL20362 to AAL21500 and
 CC AAL21596 to AAL21688 represent their corresponding target sequences;
 CC AAL21689 to AAL22475 and AAL23263 to AAL23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAL22476 to AAL23262, AAL23343 to
 CC AAL23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX Sequence 17 BP; 5 A; 0 C; 3 G; 0 T; 9 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 1.2e-02;
 Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
 QY 830 AAAGCTTGAGTTTCAT 846
 DB 1 AAAGUUUUUUUUUGAU 17
 RESULT 187
 AAA18786/c
 ID AAA18786 standard; RNA; 17 BP.
 XX
 AC AAA18786;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human Tie-2 substrate sequence SEQ ID NO:2012.

XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX Homo sapiens.
 OS WO9950403-A2.
 PN 07-OCT-1999.
 XX 24-MAR-1999; 99WO-US006507.
 XX 27-MAR-1998; 98US-0079678P.
 PR (RIBO-) RIBOZYME PHARM INC.
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX WPI; 1999-591315/50.
 DR Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX Claim 56; Page 117; 305pp; English.
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAL16775 to
 CC AAL17167 and AAL17561 to AAL17622 represent ribozyme sequences for ARNT,
 CC and AAL17168 to AAL17560 and AAL17623 to AAL17684 represent their
 CC corresponding target sequences; AAL17685 to AAL18385 and AAL19087 to
 CC AAL19154 represent ribozyme sequences for Tie-2, and AAL18386 to AAL19086
 CC and AAL19155 to AAL19222 represent their corresponding target sequences;
 CC AAL19223 to AAL20361 and AAL21501 to AAL21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAL20362 to AAL21500 and
 CC AAL21596 to AAL21688 represent their corresponding target sequences;
 CC AAL21689 to AAL22475 and AAL23263 to AAL23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAL22476 to AAL23262, AAL23343 to
 CC AAL23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX Sequence 17 BP; 6 A; 2 C; 3 G; 0 T; 6 U; 0 Other;
 SQ
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e-02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1317 TCAATTGGATATGACC 1333
 DB 17 TCATTGCAATATGATC 1
 RESULT 188
 AAA25585
 ID AAA25585 standard; DNA; 17 BP.
 XX

Best Local Similarity 88.2%; Pred. NO. 1.2e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGCG 233
 ||||| |||||
 Db 17 GACAACTCAACTCTGCG 1

RESULT 184
 AAV85964/C
 ID AAV85964 standard; DNA; 17 BP.
 XX
 AC AAV85964;
 XX
 DT 10-FEB-1999 (first entry)
 XX
 DE Mouse LRP-3 cDNA PCR primer 83r (mues 1r).
 XX
 KW LRP5; LDL-receptor related protein; LRP-3; IDDM; diagnosis; endocytosis;
 KW insulin dependent diabetes mellitus; autoimmune disease;
 KW glomerulonephritis; inflammation; viral infection; osteoporosis;
 KW hypercholesterolemia; Alzheimer's disease; low density lipoprotein;
 KW PCR primer; ss.
 XX
 OS Synthetic.
 OS Mus sp.
 XX
 PN WO9846743-A1.
 XX
 PD 22-OCT-1998.
 XX
 PF 15-APR-1998; 98WO-GB001102.
 XX
 PR 15-APR-1997; 97US-0043553P.
 PR 05-JUN-1997; 97US-0048740P.
 XX
 PA (WELL) WELLCOME TRUST LTD.
 PA (MERI) MERCK & CO INC.
 XX
 PI Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H;
 PI Hey P, Kawaguchi Y, Merriman TR, Metzker ML, Nakagawa Y;
 PI Phillips MS, Twells RCJ;
 XX
 DR WPI; 1998-594573/50.
 XX
 PT New isolated LDL-receptor related protein - used to develop products for
 PT treating, e.g. elevated triglyceride levels, diabetes, autoimmune
 PT disorders, inflammation or Alzheimer's disease.
 XX
 PS Claim 12; Page 117; 200pp; English.
 XX
 CC The present invention describes LRP5 (low density lipoprotein (LDL)
 CC receptor related protein, previously designated LRP-3). Nucleic acid
 CC molecules (NAMS) encoding LRP5 can be used for determining if an
 CC individual is susceptible to insulin dependent diabetes mellitus (IDDM).
 CC The NAMS or proteins can be used for reducing triglyceride levels in the
 CC serum of an individual. Therapies that affect LRP5 may also be useful in
 CC the treatment of autoimmune diseases such as glomerulonephritis, diseases
 CC and disorders involving disruption of endocytosis and/or antigen
 CC presentation, cytokine clearance and/or inflammation, viral infection,
 CC pathogenic bacterial toxin contamination, elevation of free fatty acids
 CC or hypercholesterolemia, type 2 diabetes, osteoporosis, Alzheimer's
 CC disease and cardiovascular disease. Products from the present invention
 CC can also be used for detection, diagnosis and drug screening. AAV85917 to
 CC AAV86012 represent PCR primers for obtaining LRP-3 cDNA
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 CCTTGGGGCTGCAGCAT 663
 ||||| |||||
 Db 1 CCATGGGGCTGCAGCAT 17

RESULT 186
 AAA19065
 ID AAA19065 standard; RNA; 17 BP.
 XX
 AC AAA19065;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:2291.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;

QY 762 CTATGGAGCCCCAGTGA 778

Db 17 CCATGGAGCCCCAGTGA 1
 ||||| ||||| |||||

RESULT 185
 AAV26749
 ID AAV26749 standard; DNA; 17 BP.
 XX
 AC AAV26749;
 XX
 DT 17-SEP-1998 (first entry)
 XX
 DE Retroviral vector primer EPCS.
 XX
 KW ss; gag; gene delivery; pol; env; murine leukaemia virus; gene therapy;
 KW primer; PCR; amplification.
 XX
 OS Synthetic.
 XX
 PN WO9812338-A1.
 XX
 PD 26-MAR-1998.
 XX
 PF 22-SEP-1997; 97WO-KR000180.
 XX
 PR 21-SEP-1996; 96KR-00041438.
 XX
 PA (VIRO-) VIROMEDICA PACIFIC LTD.
 XX
 PI Kim S, Kim S, Robbins PD;
 XX
 WPI; 1998-217273/19.
 XX
 PT New retroviral vectors, particularly for gene therapy - which are free of
 PT the gag coding sequence, to provide for high levels of gene expression,
 PT viral titre and packaging efficiency.
 XX
 PS Example 6; Page 32; 79pp; English.
 XX
 CC The primers AAV26717-V26750 and AAV26752-V26753 were used in the
 CC production of two retroviral vectors (RV). The first is a RV that has no
 CC gag coding sequence is capable of delivering a gene of interest to a
 CC target cell when packaging functions of gag, pol and env are provided.
 CC The second is a RV based on murine leukaemia virus (MLV) where entire gag
 CC and env coding sequences are completely deleted. The vectors can be used
 CC for gene therapy, for example for the delivery of hormones, enzymes,
 CC receptors or drugs
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 CCTTGGGGCTGCAGCAT 663
 ||||| |||||
 Db 1 CCATGGGGCTGCAGCAT 17

RESULT 186
 AAA19065
 ID AAA19065 standard; RNA; 17 BP.
 XX
 AC AAA19065;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Human TIE-2 substrate sequence SEQ ID NO:2291.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;

DR WPI; 1997-259017/23.
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 149; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 1.2e+02;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 29 TACAGGTATCTGCCGTG 45
 DB 1 UACUGGUUUCGCGUGU 17
 RESULT 182
 AAX75069/c
 ID AAX75069 standard; RNA; 17 BP.
 XX AC AAX75069;
 XX DT 28-JUL-1999 (first entry)
 XX DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #597.
 XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Mus sp.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX PF Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 173; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAA 1765
 DB 17 AAAAAAAAAACAAAAA 1
 RESULT 183
 AAX69542/c
 ID AAX69542 standard; RNA; 17 BP.
 XX AC AAX69542;
 XX DT 28-JUL-1999 (first entry)
 XX DE Human flt1 VEGF receptor hammerhead ribozyme substrate #837.
 XX KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX OS Homo sapiens.
 XX PN WO9715662-A2.
 XX PD 01-MAY-1997.
 XX PF 25-OCT-1996; 96WO-US017480.
 XX PR 26-OCT-1995; 95US-0005974P.
 XX PR 11-JAN-1996; 96US-00584040.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (CHIR) CHIRON CORP.
 XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX Claim 4; Page 72; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 0.8%; Score 13.8; DB 1; Length 17;

XX	25-OCT-1996;	96WO-US017480.	
XX	PF		
XX	26-OCT-1995;	95US-0005974P.	
XX	PR		
XX	11-JAN-1996;	96US-00584040.	
XX	PR		
XX	(RIBO-) RIBOZYME PHARM INC.		
XX	(CHIR) CHIRON CORP.		
XX	Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;		
XX	PI		
XX	XX		
XX	DR		
XX	WPI; 1997-259017/23.		
XX			
XX	Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA		
XX	stability - useful for treating e.g. tumour angiogenesis, psoriasis,		
XX	rheumatoid arthritis, etc., in a human patient.		
XX	PT		
XX	Claim 4; Page 173; 218pp; English.		
XX			
XX	The present invention describes nucleic acid molecules which modulate the		
XX	synthesis, expression and/or stability of a mRNA encoding 1 or more		
XX	receptors of vascular endothelial growth factor (VEGF). A patient		
XX	(preferably human) having a condition associated with the level of the		
XX	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing		
XX	receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour		
XX	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be		
XX	treated by administering the nucleic acid molecule or the expression		
XX	vector to the patient. AAX67275 to AAX75752 represent specific examples		
XX	of nucleic acid molecules from the present invention		
XX	CC		
XX	Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;		
XX			
XX	Query Match	0.8%; Score 13.8; DB 1; Length 17;	
XX	Best Local Similarity	88.2%; Pred. No. 1.2e+02;	
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	1749 AAAAAAAAAAAAAAAAAA 1765		
DB	17 AAAAAAAAAAAAAAAAAA 1		
RESULT 181			
AAX73377			
ID	AAX73377 standard; RNA; 17 BP.		
XX	AC		
XX	AAX73377;		
XX			
XX	28-JUL-1999 (first entry)		
XX			
XX	Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #810.		
XX			
XX	Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;		
XX	KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;		
XX	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;		
XX	fms-like tyrosine kinase 1; kinase insert domain containing receptor;		
XX	foetal liver kinase 1; ss.		
XX			
XX	Mus sp.		
XX			
XX	WO9715662-A2.		
XX			
XX	01-MAY-1997.		
XX			
XX	25-OCT-1996; 96WO-US017480.		
XX			
XX	26-OCT-1995; 95US-0005974P.		
XX	11-JAN-1996; 96US-00584040.		
XX			
XX	(RIBO-) RIBOZYME PHARM INC.		
XX	(CHIR) CHIRON CORP.		
XX			
XX	Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;		
XX	PI		
XX	XX		

RESULT 178	
AAAT60238/C	
ID	AAAT60238 standard; DNA; 17 BP.
XX	
XX	AAAT60238;
DT	19-OCT-1997 (first entry)
XX	
DE	ASO Q493XM representing known cystic fibrosis mutation.
XX	
XX	Multiplex allele-specific diagnostic assay; MASDA;
KW	allele-specific oligonucleotide; ASO; polymorphism; genetic disease;
KW	diagnosis; cystic fibrosis; ss.
XX	
OS	Synthetic.
XX	
PN	WO9710366-A2.
XX	
PD	20-MAR-1997.
XX	
PF	13-SEP-1996; 96WO-US014842.
XX	
PR	15-SEP-1995; 95US-0003788P.
XX	
PA	(GENZ) GENZYME CORP.
PI	Shuber AP;
XX	
DR	WPI; 1997-202258/18.
XX	
PT	Identifying genetic alterations or target sequences in nucleic acid
PT	samples - useful for detecting genetic alterations associated with a
PT	disease, e.g. cystic fibrosis and sickle cell anaemia.
PS	Example 2; Page 40; 85pp; English.
XX	
CC	Allele-specific oligonucleotides (ASOs) (AAT60210-41) representing k
CC	cystic fibrosis mutations, and corresponding ASOs (AAT60242-70)
CC	representing wild-type sequences, are examples of ASOs that can be u
CC	in a multiplex allele-specific diagnostic assay (MASDA) that has the
CC	capacity to analyse over 300 samples of a large number of mutations
CC	100) in a single assay. Target DNA is immobilised to a solid support
CC	interrogated in combinatorial fashion with a mixture of mutation-sp
CC	ASOs in solution. The ASO(s) corresponding to the specific mutation
CC	present in the sample is hybrid-selected from the pool, and the
CC	mutation(s) is identified. MASDA can be used to detect genetic
CC	alterations associated with genetic disorders, to identify genetic
CC	polymorphisms, to determine the molecular basis of genetic diseases,
CC	for high-resolution identification of disease-causing microorganisms
XX	
SQ	Sequence 17 BP; 10 A; 2 C; 3 G; 2 T; 0 U; 0 Other;
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.2e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps
QY	1584 TTCATTCCTATCTTAAT 1600
DB	
	17 TTCATTCGTTCTTAGT 1
RESULT 179	
AAAT73378	
ID	AAAT73378 standard; RNA; 17 BP.
XX	
AC	AAAT73378;
XX	
DT	28-JUL-1999 (first entry)
XX	
XX	Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #811.
DE	

```

XX OS Oryctolagus cuniculus.
XX KW WO9618736-A2.
XX PD 20-JUN-1996.
XX PF 22-NOV-1995; 95WO-US015516.
XX PR 13-DEC-1994; 94US-00354920.
XX PR 23-DEC-1994; 94US-00363253.
XX PR 23-DEC-1994; 94US-00363254.
XX PR 17-FEB-1995; 95US-00390850.
XX PR 20-APR-1995; 95US-00426124.
XX PR 02-MAY-1995; 95US-00432874.
XX PR 04-MAY-1995; 95US-00434509.
XX PR 07-JUL-1995; 95US-0000951P.
XX PR 07-JUL-1995; 95US-0000974P.
XX PR 07-AUG-1995; 95US-00512861.
XX PR 05-OCT-1995; 95US-00541365.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
XX PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
XX PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX DR WPI; 1996-300653/30.
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
XX PT the treatment of arthritis, induction of graft tolerance or treatment of
XX PT auto-immune diseases.
XX PS Example 1; Page 154; 307pp; English.
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)
XX CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
XX CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
XX CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
XX CC can inhibit collagenase and stromelysin production in the synovial
XX CC membrane of joints for the treatment or prevention of arthritis,
XX CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
XX CC be used to treat antigen presenting cells of a donor to induce tolerance
XX CC in a recipient to an alloantigen of a donor. They can also be used for
XX CC enhancing graft tolerance or for treating autoimmune disease, and for
XX CC treating allergies and other inflammatory conditions. The ENA's can also
XX CC stromelysin without introducing the non-specific effects upon gene
XX CC expression which accompany treatment with retinoids and dexamethasone.
XX CC The concentration of ribozyme required to affect a therapeutic treatment
XX CC is lower than that required of antisense molecules, and is highly
XX CC specific. The present sequence is used in the exemplification of the
XX CC present invention
XX SQ Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 47.1%; Pred. No. 1.2e+02;
XX Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
OY 870 AATCCTTTTCTTTAAAG 886
DB 1 AAUUCUGUUCUUAAG 17
||| : : : : : |||
AAUUCUGUUCUUAAG 17
RESULT 176
ID AAX63884
XX AAX63884 standard; RNA; 17 BP.
XX AC AAX63884;
XX XX
XX DT 20-JUL-1999 (first entry)
XX XX

```

```

DE XX Rabbit stromelysin hammerhead target SEQ ID NO:516.
KW KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW KW diagnosis; ss.
OS Oryctolagus cuniculus.
XX PN WO9618736-A2.
XX PD 20-JUN-1996.
XX PF 22-NOV-1995; 95WO-US015516.
XX PR 13-DEC-1994; 94US-00354920.
XX PR 23-DEC-1994; 94US-00363253.
XX PR 23-DEC-1994; 94US-00363254.
XX PR 17-FEB-1995; 95US-00390850.
XX PR 20-APR-1995; 95US-00426124.
XX PR 02-MAY-1995; 95US-00432874.
XX PR 04-MAY-1995; 95US-00434509.
XX PR 07-JUL-1995; 95US-0000951P.
XX PR 07-JUL-1995; 95US-0000974P.
XX PR 07-AUG-1995; 95US-00512861.
XX PR 05-OCT-1995; 95US-00541365.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
XX PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
XX PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX DR WPI; 1996-300653/30.
XX PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
XX PT the treatment of arthritis, induction of graft tolerance or treatment of
XX PT auto-immune diseases.
XX PS Example 1; Page 154; 307pp; English.
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)
XX CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
XX CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
XX CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
XX CC can inhibit collagenase and stromelysin production in the synovial
XX CC membrane of joints for the treatment or prevention of arthritis,
XX CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
XX CC be used to treat antigen presenting cells of a donor to induce tolerance
XX CC in a recipient to an alloantigen of a donor. They can also be used for
XX CC enhancing graft tolerance or for treating autoimmune disease, and for
XX CC treating allergies and other inflammatory conditions. The ENA's can also
XX CC stromelysin without introducing the non-specific effects upon gene
XX CC expression which accompany treatment with retinoids and dexamethasone.
XX CC The concentration of ribozyme required to affect a therapeutic treatment
XX CC is lower than that required of antisense molecules, and is highly
XX CC specific. The present sequence is used in the exemplification of the
XX CC present invention
XX SQ Sequence 17 BP; 4 A; 7 C; 1 G; 0 T; 5 U; 0 Other;
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 58.8%; Pred. No. 1.2e+02;
XX Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
OY 750 CATTTCAGTCCCTCTATG 766
DB 1 CAUCCAUCCUUAUG 17
||| : : : : : |||
CAUCCAUCCUUAUG 17
RESULT 177

```


XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX Example 1; Page 154; 307pp; English.
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis.
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX Sequence 17 BP; 5 A; 2 C; 4 G; 0 T; 6 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.2e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 875 TTTTCTTTAAAGACGCG 891
DB 1 UGUUCUUUAAAGACAGG 17

RESULT 172
AX63885
ID AAX63885 standard; RNA; 17 BP.
AC AAX63885;
XX 20-JUL-1999 (first entry)
DE Rabbit stromelysin hammerhead target SEQ ID NO:517.
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX Oryctolagus cuniculus.
XX WO9618736-A2.
PN 20-JUN-1996.
XX 22-NOV-1995; 95WO-US015516.
XX 13-DEC-1994; 94US-00354920.
XX 23-DEC-1994; 94US-00363253.
XX 17-FEB-1995; 94US-00363254.
XX 20-APR-1995; 95US-00390850.
XX 02-MAY-1995; 95US-00432874.
XX 04-MAY-1995; 95US-00434509.
XX 07-JUL-1995; 95US-0009511P.
XX 07-JUL-1995; 95US-0000974P.
XX 07-AUG-1995; 95US-00512861.
XX 05-OCT-1995; 95US-00541365.

PA (RIBO-) RIBOZYME PHARM INC.
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX Example 1; Page 154; 307pp; English.
XX The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX Sequence 17 BP; 4 A; 7 C; 2 G; 0 T; 4 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.2e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 754 CAGTCCCTCTATGGAGC 770
DB 1 CAUCCCUUAUGGACC 17

RESULT 173
AX63908
ID AAX63908 standard; RNA; 17 BP.
AC AAX63908;
XX 20-JUL-1999 (first entry)
DE Rabbit stromelysin hammerhead target SEQ ID NO:540.
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX Oryctolagus cuniculus.
XX WO9618736-A2.
XX 20-JUN-1996.
XX 22-NOV-1995; 95WO-US015516.
XX 13-DEC-1994; 94US-00354920.
XX 23-DEC-1994; 94US-00363253.
XX 23-DEC-1994; 94US-00363254.
XX 17-FEB-1995; 95US-00390850.
XX 20-APR-1995; 95US-00426124.
XX 04-MAY-1995; 95US-00434509.
XX 07-JUL-1995; 95US-0009511P.
XX 07-JUL-1995; 95US-0000974P.
XX 07-AUG-1995; 95US-00512861.
XX 05-OCT-1995; 95US-00541365.

CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 17 BP; 4 A; 1 C; 7 G; 0 T; 5 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.2e+02;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGTGA 1195
 |:||||: :||: ||
 Db 1 CUGGAGGUUGAUGAGA 17

RESULT 170
 AAXG4062/c
 ID AAXG4062 standard; RNA; 17 BP.

AC AAXG4062;

DT 20-JUL-1999 (first entry)

DE Rabbit stromelysin hammerhead target SEQ ID NO:694.

KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

OS Oryctolagus cuniculus.

PN WO9618736-A2.

XX 20-JUN-1996.

XX 22-NOV-1995; 95WO-US015516.

PR 13-DEC-1994; 94US-00354920.

PR 23-DEC-1994; 94US-00363253.

PR 17-FEB-1995; 94US-00363254.

PR 17-FEB-1995; 95US-00390850.

PR 02-APR-1995; 95US-00426124.

PR 02-MAY-1995; 95US-00432874.

PR 04-MAY-1995; 95US-00434509.

PR 07-JUL-1995; 95US-0000951P.

PR 07-JUL-1995; 95US-0000974P.

PR 07-AUG-1995; 95US-00512861.

PR 05-OCT-1995; 95US-00541365.

XX (RIBO-) RIBOZYME PHARM INC.

XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

PI Karpeisky A, Thompson JD, Modak A, Burgin A;

XX WPI; 1996-300653/30.

XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

PS Example 1; Page 156; 307pp; English.

XX

CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX

SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 896 TCTGCTGGAAGCTTCCT 912
 ||| ||||| |||
 Db 17 TCTGCTGGAAGCTTCCT 1

RESULT 171

AAXG3909

ID AAXG3909 standard; RNA; 17 BP.

XX AC AAXG3909;

XX DT 20-JUL-1999 (first entry)

XX Rabbit stromelysin hammerhead target SEQ ID NO:541.

KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

OS Oryctolagus cuniculus.

PN WO9618736-A2.

XX 20-JUN-1996.

XX 22-NOV-1995; 95WO-US015516.

PR 13-DEC-1994; 94US-00354920.

PR 23-DEC-1994; 94US-00363253.

PR 17-FEB-1995; 94US-00363254.

PR 17-FEB-1995; 95US-00390850.

PR 20-APR-1995; 95US-00426124.

PR 02-MAY-1995; 95US-00432874.

PR 04-MAY-1995; 95US-00434509.

PR 07-JUL-1995; 95US-0000951P.

PR 07-JUL-1995; 95US-0000974P.

PR 07-AUG-1995; 95US-00512861.

PR 05-OCT-1995; 95US-00541365.

XX (RIBO-) RIBOZYME PHARM INC.

XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

PI Karpeisky A, Thompson JD, Modak A, Burgin A;

XX WPI; 1996-300653/30.

CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of anisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

XX
 SQ Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 47.1%; Pred. No. 1.2e+02;
 Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 871 ATCCTTTCTTTAAAGA 887
 | : : : : :
 Db 1 AUUCUGUUCUUAAGA 17

RESULT 169
 AAX63906
 ID AAX63906 standard; RNA; 17 BP.
 AC AAX63906;
 DT 20-JUL-1999 (first entry)
 DE Rabbit stromelysin hammerhead target SEQ ID NO:538.
 XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Oryctolagus cuniculus.
 XX
 PN WO9618736-A2.
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX
 XX WPI; 1996-300653/30.
 XX
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 XX Example 1; Page 154; 307pp; English.
 XX
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also

QY 631 CATGAACCTGGCCATTC 647
 | : : : : :
 Db 1 CAUGAGCUUGGCCACUC 17

RESULT 168
 AAX63906
 ID AAX63906 standard; RNA; 17 BP.
 AC AAX63906;
 DT 20-JUL-1999 (first entry)
 DE Rabbit stromelysin hammerhead target SEQ ID NO:538.
 XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Oryctolagus cuniculus.
 XX
 PN WO9618736-A2.
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US015516.
 XX
 PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00426124.
 PR 02-MAY-1995; 95US-00432874.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-JUL-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpeisky A, Thompson JD, Modak A, Burgin A;
 XX
 XX WPI; 1996-300653/30.
 XX
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX
 XX Example 1; Page 154; 307pp; English.
 XX
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.

Db 16 TTTTGATGCTGCA 3

RESULT 166
AAQ20006/c
ID AAQ20006 standard; DNA; 17 BP.
XX
AC AAQ20006;
XX
DT 01-APR-1992 (first entry)
XX
DE Oligonucleotide #2 able to covalently cross-link to target DNA.
XX
KW deoxyribonucleic acid; major groove; ethanamine group;
KW aziridinylcytosine; cross-linking group; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 8 /*tag= b
FT /*mod_base= m5c
FT modified_base 14 /*tag= c
FT /*mod_base= m5c
FT modified_base 17 /*tag= a
FT /*mod_base= OTHER
FT /*note= "N4N4-ethanocytosine"
XX WO9118997-A.
XX
PD 12-DEC-1991.
XX
PF 25-MAY-1990; 90US-00529346.
XX
PR 25-MAY-1990; 90US-00529346.
PR 14-JAN-1991; 91US-00640654.
XX
PA (GILE-) GILEAD SCITE INC.
XX
PI Matteucci MD, Krawczyk S;
XX
DR WPI; 1992-007480/01.
XX
PT New sequence-specific non-photo-activated crosslinking agents - bind to
PT the major groove of duplex DNA and are esp. useful for treating latent
PT infections e.g. HIV.
XX
PS Example 2; Page 20; 42pp; English.
XX
CC The 3' end of this oligonucleotide carries 1,3-propanediol. The oligo is
CC one of four oligonucleotides which were designed to specifically bind and
CC cross-link to the duplex target sequence AAQ20004. Oligo #2 has the
CC covalent cross-linking group, i.e. N4N4-ethanocytosine, at its 3' end. An
CC assay for crosslinked triple helix showed considerable reaction with
CC Oligo #2 and with Oligo #1 (see AAQ20005) which has the crosslinking
CC group at the 5' end. The most complete reaction was seen with Oligo #3
CC (see AAQ20007) having N4N4-ethanocytosine at both the 5' and 3' termini.
CC A control oligo with no cross-linking group showed no reaction. The half-
CC life of the cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);
CC Oligo #1 showed a rate four times slower. See also AAQ20008
XX
SQ Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1748 GAAAAAAAAAAAAAAAAA 1764
DB 17 GAAGAAAGAAAAAAAAA 1

RESULT 167
AAx63865
ID AAx63865 standard; RNA; 17 BP.
XX
AC AAx63865;
XX
DT 20-JUL-1999 (first entry)
XX
DE Rabbit stromelysin hammerhead target SEQ ID NO:497.
XX
KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
OS Oryctolagus cuniculus.
XX
FN WO9618736-A2.
XX
PD 20-JUN-1996.
XX
PF 22-NOV-1995; 95WO-US015516.
XX
PR 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 17-FEB-1995; 94US-00363254.
PR 20-APR-1995; 95US-00390850.
PR 02-MAY-1995; 95US-00426124.
PR 04-MAY-1995; 95US-00432874.
PR 07-JUL-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI Mcswigen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX
DR WPI; 1996-300653/30.
XX
PT Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX
PS Example 1; Page 154; 307pp; English.
XX
CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC having a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis,
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX
SQ Sequence 17 BP; 3 A; 6 C; 4 G; 0 T; 4 U; 0 Other;

Fri May 13 12:26:39 2005

chong906-2.rng

KW skeletal muscle function.

OS Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 30-JAN-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.

XX (JIY/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

XX (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder associated with decreased expression or activity of human genome-derived myosin-like protein-1 such as disorder of heart and/or skeletal muscle function.

XX Disclosure; SEQ ID NO 10429; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully defined in the specification, a fragment of at least 8 amino acids of (S1), 95% deviation from (S1) which are conservative substitutions, and 65% identity to (S1). A polypeptide of the invention acts as an agonist or antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A pharmaceutical composition of the invention is useful for treating or preventing a disorder associated with decreased expression or activity of hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function. The present sequence represents a 17-mer nucleotide, used in the invention for scanning the sequence represented in ACN63103

XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853

Db 17 TTTTGATGCTGTCA 4

RESULT 165

ACN73528/c

AC

XX

DT

XX

DE

XX

XX

KW

KW

KW

XX

XX

OS

XX

XX

PN

XX

XX

PD

XX

XX

PF

XX

XX

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

PR

ACN73528;

02-DEC-2004 (first entry)

Human GDMPLP-1 probe SEQ ID NO:10430.

Human; ss; probe; myosin-like protein-1; hGDMPLP-1;

hGDMPLP-1 agonist; hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

skeletal muscle function.

Homo sapiens.

US2004137589-A1.

15-JUL-2004.

26-NOV-2003; 2003US-00723361.

26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.

27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.

30-JAN-2001; 2001WO-US000661.

30-JAN-2001; 2001WO-US000662.

30-JAN-2001; 2001WO-US000663.

30-JAN-2001; 2001WO-US000664.

30-JAN-2001; 2001WO-US000665.

30-JAN-2001; 2001WO-US000666.

30-JAN-2001; 2001WO-US000667.

30-JAN-2001; 2001WO-US000668.

30-JAN-2001; 2001WO-US000669.

30-JAN-2001; 2001WO-US000670.

05-FEB-2001; 2001US-0266860P.

25-MAY-2001; 2001US-00866108.

(GUY/) GU Y.

(JIY/) JI Y.

(PENN/) PENN S G.

(HANZ/) HANZEL D K.

(RANK/) RANK D.

(CHEN/) CHEN W.

(SHAN/) SHANNON M E.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

WPI; 2004-533378/51.

Novel myosin-like protein-1, useful for treating or preventing disorder associated with decreased expression or activity of human genome-derived myosin-like protein-1 such as disorder of heart and/or skeletal muscle function.

Disclosure; SEQ ID NO 10430; Opp; English.

The invention relates to a novel polypeptide (I) comprising a sequence (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully defined in the specification, a fragment of at least 8 amino acids of (S1), 95% deviation from (S1) which are conservative substitutions, and 65% identity to (S1). A polypeptide of the invention acts as an agonist or antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A pharmaceutical composition of the invention is useful for treating or preventing a disorder associated with decreased expression or activity of hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function. The present sequence represents a 17-mer nucleotide, used in the invention for scanning the sequence represented in ACN63103

Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

Query Match

Best Local Similarity

Matches

14;

Conservative

0;

Mismatches

0;

Indels

0;

Gaps

0;

Length

17;

Pred. No.

1.2e+02;

840

TTTTGATGCTGTCA

853

```

ID ABZ61010 standard; RNA; 17 BP.
XX
AC ABZ61010;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNazyme substrate #1122.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
XX
PR 06-JUN-2001; 2001US-0296249P.
XX
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J;
XX
DR WPI; 2003-140484/13.
XX
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 106; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 6 A; 1 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.2e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1706 AATGTAACATGTTT 1719
Db ||:|||||:|:|
3 AAUGUAACAUGUUU 16
RESULT 163
AAD48153
ID AAD48153 standard; DNA; 17 BP.
XX
AC AAD48153;
XX
DT 24-FEB-2003 (first entry)
XX
DE PCR primer #1 used for single nucleotide polymorphism (SNP) analysis.
XX
KW Peptide nucleic acid; PNA; nucleic acid zygosity; genetic analysis;
KW scientific investigation; pharmacogenomic; pharmacogenetic; epigenomic;
KW PCR; primer; ss.

```

```

XX OS Unidentified.
XX PN WO200272865-A2.
XX PD 19-SEP-2002.
XX PF 09-MAR-2002; 2002WO-US007050.
XX PR 09-MAR-2001; 2001US-0274547P.
XX PA (BOST-) BOSTON PROBES INC.
XX PI Coull JM, Fiandaca MJ, Kristjansson MD, Hyldig-Nielsen JJ;
XX PI Creasey TW;
XX DR WPI; 2003-018741/01.
XX PF Composition for determining target sequence of contiguous nucleobases,
XX PT comprises polynucleobase strand and combination oligomer comprising first
XX PT and second oligomer blocks that are covalently linked to each other.
XX PS Example 5; Page 70; 149pp; English.
XX CC The present invention relates to combination oligomers, including block
XX CC synthesis of combination of oligomers in the absence of a template. The
XX CC invention relates to a composition comprising a polynucleobase strand and
XX CC a combination oligomer comprising first and second oligomer blocks that
XX CC are each independently a peptide nucleic acid (PNA) covalently linked to
XX CC each other by a linker of at least three atoms in length, where the
XX CC oligomer blocks are sequences specifically hybridised to a target
XX CC sequence of contiguous nucleobases in the polynucleobase strand, to form
XX CC a double stranded target sequence-oligomer complex. The composition is
XX CC used for determining a target sequence of contiguous nucleobases and for
XX CC determining the zygosity of a nucleic acid for a single nucleotide
XX CC polymorphism (SNP). The methods are useful in scientific investigation,
XX CC e.g., for detection, identification and/or enumeration of bacteria,
XX CC viruses and pathogens in food, beverages, water, pharmaceutical products,
XX CC personal care products, dairy products, in clinical samples or in samples
XX CC of plant, animal, human or environmental origin. They are also useful for
XX CC the analysis of raw materials, equipment, products or processes used to
XX CC manufacture or store food, beverages, water, pharmaceutical products,
XX CC personal care products dairy products or environmental samples. The
XX CC methods and materials are useful in areas such as expression analysis,
XX CC SNP analysis, genetic analysis of humans, animals, fungi, yeast viruses
XX CC and plants, therapy monitoring, pharmacogenomics, pharmacogenetics,
XX CC epigenomics and high throughput screening operations. The present
XX CC sequence is a PCR primer used for single nucleotide polymorphism (SNP)
XX CC analysis
XX SQ Sequence 17 BP; 5 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 394 CAAGTCTGGAGTGA 407
Db |||||
2 CAAGTCTGGAGTGA 15
RESULT 164
ACN73527/c
ID ACN73527 standard; DNA; 17 BP.
XX
AC ACN73527;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:10429.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

```

CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 3 A; 1 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
Db 3 GGAGGTATGATGTG 16

RESULT 160
ABS75300
ID ABS75300 standard; DNA; 17 BP.
XX
AC ABS75300;
XX
DT 24-DEC-2002 (first entry)
XX
DE Human PAPP-Ea associated 17-mer SEQ ID 826.
XX
XX PAPP-E; human; pregnancy associated plasma protein E; abortive;
KW contraceptive; gene therapy; vaccine; pregnancy; antenatal; diagnosis;
KW dysgenetic pregnancy; primer; ss.
XX
XX Homo sapiens.
XX
XX US2002102252-A1.
PN
XX
XX 01-AUG-2002.
PD
XX
XX 06-APR-2001; 2001US-00827998.
PF
XX
XX 26-MAY-2000; 2000US-0207456P.
PR
XX
XX (GUYX/) GU Y.
PA (SHAN/) SHANNON M E.
PA
XX Gu Y, Shannon ME;
XX
XX WPI; 2002-697817/75.
DR
XX
XX New isolated nucleic acid encoding an isoform of human pregnancy
PT associated plasma protein E, for preventing or aborting pregnancy.
PT
XX
XX Example 2; Page 183; 353pp; English.
PS
XX
XX This invention describes a novel isolated nucleic acid that encodes one
CC of three new isoforms of human pregnancy associated plasma protein E,
CC hPAPP-E. The products of the invention have abortive and contraceptive
CC activity and can be used for gene therapy or in a vaccine. The nucleic
CC acid, polypeptide encoded by it, or antibody to the polypeptide can be
CC used in pharmaceutical compositions or vaccines for preventing or
CC aborting pregnancy. PAPP-E is used in the antenatal diagnosis of
CC dysgenetic pregnancies. The nucleic acids are used as probes to assess
CC the level of PAPP-E isoform mRNA in chorionic villus samples, and the
CC antibodies can be used to assess the expression levels of PAPP-E isoform
CC proteins in chorionic villus samples, to diagnose dysgenetic pregnancies
CC antenatally. This sequence represents an oligomer used in scanning the
CC human PAPP-E genes described in the disclosure of the invention
XX
SQ Sequence 17 BP; 3 A; 1 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
Db 1 GGAGGTATGATGTG 14

RESULT 161
ABZ61011
ID ABZ61011 standard; RNA; 17 BP.
XX
AC ABZ61011;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNzyme substrate #1123.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS
XX WO200297114-A2.
PN
XX
XX 05-DEC-2002.
PD
XX
XX 29-MAY-2002; 2002WO-US016840.
PF
XX
XX 29-MAY-2001; 2001US-0294140P.
PR
XX 06-JUN-2001; 2001US-0296249P.
PR
XX 10-SEP-2001; 2001US-0318471P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcswiggen J;
PI
XX
XX WPI; 2003-140484/13.
DR
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
PT
XX
XX Claim 58; Page 106; 185pp; English.
PS
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytosstatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 6 A; 3 C; 2 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.2e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1706 AATGTAACATGTTT 1719
Db 1 AAUGUACAUGUUU 14

RESULT 162
ABZ61010


```

XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI Zhan J;
XX PI WPI; 2002-676582/73.
XX DR Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 241; 718pp; English.
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 1 A; 3 C; 3 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
DB 14 GAAAGCAGAAATCA 1

RESULT 156
ABV80108/C
ID ABV80108 standard; DNA; 17 BP.
XX AC ABV80108;
XX AC 03-JAN-2003 (first entry)
XX DT Human HTPL scanning oligonucleotide SEQ ID 1354.
XX DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX KW human testis expressed Patched like protein; testis; adrenal; liver;
XX KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX FN EP1229046-A2.

```

```

XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (AEOM-) AEOMICA INC.
XX PI Zhan J;
XX PI WPI; 2002-676582/73.
XX DR Novel isolated human testis expressed Patched like protein (HTPL), useful
XX PT for identifying agonist and antagonist and specific binding partners, and
XX PT for treating subjects having defects in HTPL.
XX PS Example 2; Page 241; 718pp; English.
XX CC The present invention relates to human testis expressed Patched like
XX CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
XX CC has two isoforms, with a few single base pair differences between the
XX CC two. One of the single base pair changes introduces a premature stop
XX CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX CC shares an overall structure organisation with the Patched protein. The
XX CC shared structural features strongly imply that HTPL plays a role similar
XX CC to that of Patched, and is a potential tumour suppressor. HTPL is
XX CC important in regulating male germ cell development, and the HTPL gene was
XX CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX CC useful for diagnosing a disorder caused by mutation in HTPL, and in
XX CC therapy and manufacture of a medicament for treatment or prevention of
XX CC such disorder associated with decreased expression or activity of human
XX CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX CC clinically useful diagnostic markers and potential therapeutic agents for
XX CC male infertility and cancer. The present oligonucleotide was used in an
XX CC example from the invention
XX SQ Sequence 17 BP; 2 A; 3 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
DB 16 GAAAGCAGAAATCA 3

RESULT 157
ABV75297
ID ABV75297 standard; DNA; 17 BP.
XX AC ABV75297;
XX AC 24-DEC-2002 (first entry)
XX DT Human PAPP-Ea associated 17-mer SEQ ID 823.
XX DE Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX KW human testis expressed Patched like protein; testis; adrenal; liver;
XX KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX FN EP1229046-A2.

```



```

PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 241; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 1 A; 3 C; 3 G; 10 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 994 GAAAGCAGAAATCA 1007
DB 15 GAAAGCAGAAATCA 2
RESULT 154
ABV80107/c
ID ABV80107 standard; DNA; 17 BP.
XX
AC ABV80107;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1353.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
FN EP1229046-A2.
XX
PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-00001167.

```

```

XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 23-MAY-2001; 2001US-00864761.
PR 09-OCT-2001; 2001US-0327898P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL), useful
PT for identifying agonist and antagonist and specific binding partners, and
PT for treating subjects having defects in HTPL.
XX
PS Example 2; Page 241; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 994 GAAAGCAGAAATCA 1007
DB 17 GAAAGCAGAAATCA 4
RESULT 155
ABV80110/c
ID ABV80110 standard; DNA; 17 BP.
XX
AC ABV80110;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 1356.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
FN EP1229046-A2.
XX
PD 07-AUG-2002.

```

Fri May 13 12:26:39 2005

chong906-2.rng

PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 10429; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 840 TTTTGATGCTGTCA 853
 DB 17 TTTTGATGCTGTCA 4
 RESULT 152
 ABN10438/C
 ID ABN10438 standard; DNA; 17 BP.
 XX
 AC ABN10438;
 XX 29-MAY-2002 (first entry)
 DT
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10430.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.

PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX Disclosure; SEQ ID NO 10430; 214pp; English.
 PS
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-
 CC -1 proteins, as standards in assays used to determine the concentration
 CC capture probes for surface-enhanced laser desorption/ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 840 TTTTGATGCTGTCA 853
 DB 16 TTTTGATGCTGTCA 3
 RESULT 153
 ABV80109/C
 ID ABV80109 standard; DNA; 17 BP.
 XX
 AC ABV80109;
 XX 03-JAN-2003 (first entry)
 DT
 DE Human HTPL scanning oligonucleotide SEQ ID 1355.
 XX
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1229046-A2.
 XX
 PD 07-AUG-2002.
 XX
 PF 28-JAN-2002; 2002EP-00001167.
 XX
 PR 30-JAN-2001; 2001WO-US000663.

CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1318 CAATTGGAATATGA 1331
 Db 15 CAATTGGAATATGA 2
 RESULT 150
 ID ABA78617
 XX ABA78617 standard; DNA; 17 BP.
 AC ABA78617;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE APC mutation correcting oligonucleotide SEQ ID NO: 1463.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antineoplastic; antianaemic; haemostatic;
 KW antilipemic; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 XX Kmiec EB, Gamper HB, Rice MC;
 PI
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 PS Claim 7; Page 133; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can

CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 7 A; 1 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1318 CAATTGGAATATGA 1331
 Db 3 CAATTGGAATATGA 16
 RESULT 151
 ID ABN10437/c
 XX ABN10437 standard; DNA; 17 BP.
 AC ABN10437;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10429.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US016981.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 XX Gu Y., Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser

XX 06-APR-2000.
 PD
 XX 24-SEP-1999; 99WO-US022283.
 PF
 XX 25-SEP-1998; 98US-0101757P.
 PR
 XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
 PA
 PI Landers JE, Jordan B, Housman DE, Charest A;
 PI WPI; 2000-293181/25.
 DR
 XX Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs.
 XX
 PS Disclosure; Page 60; 111pp; English.
 XX
 CC A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a SNP
 CC allele. The method can be used to characterise a tumour, to generate a
 CC genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be used
 CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences
 CC used in the exemplification of the present invention. AAA35948 to
 CC AAA36632 represent nucleotide sequences containing SNPs
 XX
 XX Sequence 17 BP; 9 A; 1 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1483 ATAAATGTAACAGCA 1496
 DB 4 ATAAATGTAACAGCA 17
 RESULT 148
 AAF02752/C
 ID AAF02752 standard; DNA; 17 BP.
 XX
 AC AAF02752;
 XX
 DT 16-FEB-2001 (first entry)
 XX
 XX Hammerhead ribozyme substrate #1047.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 XX interferon alpha; ss.
 KW
 KW Homo sapiens.
 OS
 XX WO200061729-A2.
 XX
 XX 19-OCT-2000.
 XX
 XX 11-APR-2000; 2000WO-US009721.
 XX
 XX 12-APR-1999; 99US-0129390P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Zwick M, Pavco P, Mcswiggen J;
 XX WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT

PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.
 XX
 PS Claim 37; Page 79; 164pp; English.
 XX
 CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha
 XX
 XX Sequence 17 BP; 7 A; 5 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 565 CATTITGATGAGGC 578
 DB 15 CATTITGATGAGGC 2
 RESULT 149
 ABA78618/C
 ID ABA78618 standard; DNA; 17 BP.
 XX
 AC ABA78618;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 XX APC mutation correcting oligonucleotide SEQ ID NO: 1464.
 DE
 XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antilipemic; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200173002-A2.
 XX
 XX 04-OCT-2001.
 PD
 XX 27-MAR-2001; 2001WO-US009761.
 XX
 XX 27-MAR-2000; 2000US-0192176P.
 PR
 XX 27-MAR-2000; 2000US-0192179P.
 PR
 XX 01-JUN-2000; 2000US-0208538P.
 PR
 XX 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 XX
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 133; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC

CC smooth muscle cell (SMC) proliferation in vascular tissue leading to
CC restenosis. The ribozymes can also directly block the production of
CC oncogenes and cell regulatory factors involved with SMC growth following
CC vascular injury
XX
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTCTGTGTCACCAA 832
Db 1 TTCTGTGTCACCAA 14

RESULT 143
AAH86559
ID AAH86559 standard; DNA; 16 BP.
XX
AC AAH86559;
XX
DT 04-DEC-2000 (first entry)
XX
DE PCNA hairpin ribozyme recognition site #7.
XX
XW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XW WPI; 2000-412314/35.
XX
PD New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Example 1; Page 16; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAH82415 to AAH86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTCTGTGTCACCAA 832
Db 1 TTCTGTGTCACCAA 14

RESULT 144
AAH86780
ID AAH86780 standard; DNA; 16 BP.

XX
AC AAH86780;
XX
DT 04-DEC-2000 (first entry)
XX
DE PCNA hammerhead ribozyme recognition site #5.
XX
XW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
OS Mammalia.
XX
FN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PF 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
XX
PA (IMMU-) IMMUSOL INC.
XX
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XW WPI; 2000-412314/35.
XX
PD New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
PS Example 1; Page 24; 109pp; English.
XX
CC The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAH82415 to AAH86787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
SQ Sequence 16 BP; 4 A; 4 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 819 TTCTGTGTCACCAA 832
Db 1 TTCTGTGTCACCAA 14

RESULT 145
AAH61725
ID AAH61725 standard; DNA; 16 BP.
XX
AC AAH61725;
XX
DT 10-SEP-2001 (first entry)
XX
DE PCNA hairpin/hammerhead ribozyme recognition site SEQ ID NO:4149.
XX
XW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
XW recognition site; target; ribozyme binding site; eye disease; vulnary;
XW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
XW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
XW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
XW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
XW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;
XW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
XW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
XW sickle cell retinopathy; ss.
XX
OS Homo sapiens.

orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The method has therapeutic applications, where gene expression is controlled by selective triple-helix formation within expression regulatory sequences of a target gene. The oligonucleotides can be used to form triple-helices, and are useful to detect the presence or absence of specific sequences within genomic DNA for diagnostic and therapeutic purposes. The oligonucleotides can be selected to specifically bind to pathogenic double-stranded DNA including specific sequences required by pathogenic bacteria or viruses for replication or virulence, reducing their pathogenicity. Alternatively, the oligonucleotide can be chosen to target a unique sequence of the pathogen which is not found in the genome of pathogen's host. The oligonucleotides can be used in cancer treatment by way of triple-helix suppression of specific oncogenes including those of endogenous or viral origin. Such therapeutic oligonucleotides are capable of forming triple-helices with such sequences in cancerous cells containing the activated oncogene, so preferentially killing or repressing the cancer causing cell. The present sequence represents an oligonucleotide used in the methods of the present invention

XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 96;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
||||| |||||
Db 15 AAAAAAAAAAAAAA 1

RESULT 141
ABK98186/c
ID ABK98186 standard; DNA; 15 BP.

AC ABK98186;

DT 07-OCT-2002 (first entry)

DE Triple helix forming associated oligonucleotide #50.

KW Triple-helix formation; purine-rich target sequence; double-helix DNA; gene expression; regulatory sequence; pathogenic double-stranded DNA; pathogenic bacteria; virus; replication; virulence; cancer; oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

OS Synthetic.

PN US6403302-B1.

PD 11-JUN-2002.

PF 16-DEC-1993; 93US-00168920.

PR 17-SEP-1992; 92US-00946976.

PA (CALY) CALIFORNIA INST OF TECHNOLOGY.

PI Dervan PB, Beal PA;

DR WPI; 2002-536030/57.

PT A triple-helix comprising a double helical nucleic acid (DHNA) and an oligonucleotide which binds in parallel and antiparallel orientation, respectively, for targeting sequences on alternate strands of DHNA to control gene expression.

PS Example 7; Fig 24A; 108pp; English.

CC The present invention relates to methods and oligonucleotides for forming a triple-helix comprising a double helical nucleic acid comprising first and second substantially complementary strands, and an oligonucleotide bound to a purine-rich target sequence within the double helical nucleic

acid, where the oligonucleotide binds in a parallel and antiparallel orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The method has therapeutic applications, where gene expression is controlled by selective triple-helix formation within expression regulatory sequences of a target gene. The oligonucleotides can be used to form triple-helices, and are useful to detect the presence or absence of specific sequences within genomic DNA for diagnostic and therapeutic purposes. The oligonucleotides can be selected to specifically bind to pathogenic double-stranded DNA including specific sequences required by pathogenic bacteria or viruses for replication or virulence, reducing their pathogenicity. Alternatively, the oligonucleotide can be chosen to target a unique sequence of the pathogen which is not found in the genome of pathogen's host. The oligonucleotides can be used in cancer treatment by way of triple-helix suppression of specific oncogenes including those of endogenous or viral origin. Such therapeutic oligonucleotides are capable of forming triple-helices with such sequences in cancerous cells containing the activated oncogene, so preferentially killing or repressing the cancer causing cell. The present sequence represents an oligonucleotide used in the methods of the present invention

XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 96;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
||||| |||||
Db 15 AAAAAAAAAAAAAA 1

RESULT 142
AAT60192

ID AAT60192 standard; DNA; 16 BP.

AC AAT60192;

DT 03-FEB-1998 (first entry)

DE Synthetic PCNA ribozyme recognition site #4.

KW Ribozyme; hairpin; hammerhead; proliferating cell nuclear antigen; growth factor; oncogene; vascular tissue; SMC; PCNA; recognition site; restenosis; smooth muscle cell proliferation; ss.

OS Synthetic.

PN WO9710334-A2.

PD 20-MAR-1997.

PF 12-SEP-1996; 96WO-US014838.

PR 12-SEP-1995; 95US-00527060.

PA (IMMU-) IMMUSOL INC.

PI Goldenberg T, Tritz R;

DR WPI; 1997-202230/18.

PT New hairpin and hammerhead ribozyme(s) - which inhibit abnormal smooth muscle cell proliferation in vascular tissue, partic. for preventing or treating restenosis.

PS Example 1; Page 15; 50pp; English.

CC This sequence represents a ribozyme recognition site for the proliferating cell nuclear antigen (PCNA) gene which is cleaved by a hairpin ribozyme at position 867 and by a hammerhead ribozyme at position 869. Novel ribozymes are being investigated for their ability to inhibit the activity of a growth factor (e.g. PCNA) responsible for abnormal

CC where gene expression is controlled by selective triple-helix formation
 CC within expression regulatory sequences of a target gene. The
 CC oligonucleotides can be used to form triple-helices, and are useful to
 CC detect the presence or absence of specific sequences within genomic DNA
 CC for diagnostic and therapeutic purposes. The oligonucleotides can be
 CC selected to specifically bind to pathogenic double-stranded DNA including
 CC specific sequences required by pathogenic bacteria or viruses for
 CC replication or virulence, reducing their pathogenicity. Alternatively,
 CC the oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or viral
 CC origin. Such therapeutic oligonucleotides are capable of forming triple-
 CC helices with such sequences in cancerous cells containing the activated
 CC oncogene, so preferentially killing or repressing the cancer causing
 CC cell. The present sequence represents an oligonucleotide used in the
 CC methods of the present invention
 XX
 XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 96;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
 ||||| |||||
 DB 15 AAAAAAAAAAAAAA 1

RESULT 139
 ABK98168/c
 ID, ABK98168 standard; DNA; 15 BP.
 XX
 AC ABK98168;
 DT 07-OCT-2002 (first entry)
 DE Triple helix forming associated oligonucleotide #38.
 XX
 KW Triple-helix formation; purine-rich target sequence; double-helix DNA;
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

OS Synthetic.
 XX US6403302-B1.
 PN 11-JUN-2002.
 PD 16-DEC-1993; 93US-00168920.
 PF 17-SEP-1992; 92US-00946976.
 PR (CALY) CALIFORNIA INST OF TECHNOLOGY.
 PA Dervan PB, Beal PA;
 PI WPI; 2002-536030/57.
 DR A triple-helix comprising a double helical nucleic acid (DHNA) and an
 XX oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.
 XX Example 6; Fig 20A; 108pp; English.

PS The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel
 CC orientation, respectively, to target sequences on alternate strands of

CC the double helical nucleic acid. The method has therapeutic applications,
 CC where gene expression is controlled by selective triple-helix formation
 CC within expression regulatory sequences of a target gene. The
 CC oligonucleotides can be used to form triple-helices, and are useful to
 CC detect the presence or absence of specific sequences within genomic DNA
 CC for diagnostic and therapeutic purposes. The oligonucleotides can be
 CC selected to specifically bind to pathogenic double-stranded DNA including
 CC specific sequences required by pathogenic bacteria or viruses for
 CC replication or virulence, reducing their pathogenicity. Alternatively,
 CC the oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or viral
 CC origin. Such therapeutic oligonucleotides are capable of forming triple-
 CC helices with such sequences in cancerous cells containing the activated
 CC oncogene, so preferentially killing or repressing the cancer causing
 CC cell. The present sequence represents an oligonucleotide used in the
 CC methods of the present invention
 XX
 XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 96;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
 ||||| |||||
 DB 15 AAAAAAAAAAAAAA 1

RESULT 140
 ABK98167/c
 ID, ABK98167 standard; DNA; 15 BP.

XX
 AC ABK98167;
 DT 07-OCT-2002 (first entry)
 DE Triple helix forming associated oligonucleotide #37.

XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.

OS Synthetic.
 XX US6403302-B1.
 PN 11-JUN-2002.
 PD 16-DEC-1993; 93US-00168920.
 PF 17-SEP-1992; 92US-00946976.
 PR (CALY) CALIFORNIA INST OF TECHNOLOGY.
 PA Dervan PB, Beal PA;
 PI WPI; 2002-536030/57.

XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
 PT oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.

XX Example 6; Fig 20A; 108pp; English.

PS The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel

CC which represents hybridisation conditions, and calculating HT including
 CC net HT based on the hybridisation information, TP, the correction data
 CC and the first set of data. Also described are: (1) a computer-readable
 CC storage medium having stored in it, a database of TP and a computer
 CC program which executes the above method; and (2) a system for predicting
 CC nucleic acid HT, comprising a database of TP, units for receiving
 CC hybridisation information which represents at least one sequence and for
 CC receiving correction data, receiving a first set of data which represents
 CC hybridisation conditions and unit for calculating HT. The method and
 CC system are useful to optimise and predict probe-target hybridisation. The
 CC method and system takes into account of single strand folding
 CC thermodynamics to calculate effective hybridisation thermodynamics not
 CC taken into account by prior art methods. ABL42498 to ABL42626 represent
 CC oligonucleotide sequences which are used in the exemplification of the
 CC present invention
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 96;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 131 CAAAAACCAAAACC 144
 DB 14 CAAAAACCAAAACC 1

RESULT 137
 ABK98169/C
 ID ABK98169 standard; DNA; 15 BP.
 XX
 AC ABK98169;
 DT 07-OCT-2002 (first entry)
 DE Triple helix forming associated oligonucleotide #39.
 XX
 KW Triple-helix formation; purine-rich target sequence; double-helix DNA;
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
 XX
 OS Synthetic.
 XX
 PN US6403302-B1.
 XX
 PD 11-JUN-2002.
 XX
 PF 16-DEC-1993; 93US-00168920.
 XX
 PR 17-SEP-1992; 92US-00946976.
 XX
 PA (CALY) CALIFORNIA INST OF TECHNOLOGY.
 XX
 PI Dervan PB, Beal PA;
 XX
 DR WPI; 2002-536030/57.
 XX
 PT A triple-helix comprising a double helical nucleic acid (DHNA) and an
 PT oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.
 XX
 PS Example 6; Fig 20A; 108pp; English.

CC The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel
 CC orientation, respectively, to target sequences on alternate strands of
 CC the double helical nucleic acid. The method has therapeutic applications,
 CC where gene expression is controlled by selective triple-helix formation

CC within expression regulatory sequences of a target gene. The
 CC oligonucleotides can be used to form triple-helices, and are useful to
 CC detect the presence or absence of specific sequences within genomic DNA
 CC for diagnostic and therapeutic purposes. The oligonucleotides can be
 CC selected to specifically bind to pathogenic double-stranded DNA including
 CC specific sequences required by pathogenic bacteria or viruses for
 CC replication or virulence, reducing their pathogenicity. Alternatively,
 CC the oligonucleotide can be chosen to target a unique sequence of the
 CC pathogen which is not found in the genome of pathogen's host. The
 CC oligonucleotides can be used in cancer treatment by way of triple-helix
 CC suppression of specific oncogenes including those of endogenous or viral
 CC origin. Such therapeutic oligonucleotides are capable of forming triple-
 CC helices with such sequences in cancerous cells containing the activated
 CC oncogene, so preferentially killing or repressing the cancer causing
 CC cell. The present sequence represents an oligonucleotide used in the
 CC methods of the present invention
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 96;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1749 AAAAAAAAAAAAAA 1763
 DB 15 AAAAAAAAAAAAAA 1

RESULT 138
 ABK98187/C
 ID ABK98187 standard; DNA; 15 BP.
 XX
 AC ABK98187;
 DT 07-OCT-2002 (first entry)
 DE Triple helix forming associated oligonucleotide #51.
 XX
 KW Triple-helix formation; purine-rich target sequence; double-helix DNA;
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
 KW pathogenic bacteria; virus; replication; virulence; cancer;
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
 XX
 OS Synthetic.
 XX
 PN US6403302-B1.
 XX
 PD 11-JUN-2002.
 XX
 PF 16-DEC-1993; 93US-00168920.
 XX
 PR 17-SEP-1992; 92US-00946976.
 XX
 PA (CALY) CALIFORNIA INST OF TECHNOLOGY.
 XX
 PI Dervan PB, Beal PA;
 XX
 DR WPI; 2002-536030/57.
 XX
 PT A triple-helix comprising a double helical nucleic acid (DHNA) and an
 PT oligonucleotide which binds in parallel and antiparallel orientation,
 PT respectively, for targeting sequences on alternate strands of DHNA to
 PT control gene expression.
 XX
 PS Example 7; Fig 24A; 108pp; English.

CC The present invention relates to methods and oligonucleotides for forming
 CC a triple-helix comprising a double helical nucleic acid comprising first
 CC and second substantially complementary strands, and an oligonucleotide
 CC bound to a purine-rich target sequence within the double helical nucleic
 CC acid, where the oligonucleotide binds in a parallel and antiparallel
 CC orientation, respectively, to target sequences on alternate strands of
 CC the double helical nucleic acid. The method has therapeutic applications,

Best Local Similarity 100.0%; Pred. No. 96;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 917 GTCCAGCCACCAAC 930
Db 2 GTCCAGCCACCAAC 15

RESULT 135
ABS97730
ID ABS97730 standard; DNA; 15 BP.
XX ABS97730;
AC ABS97730;
DT 23-DEC-2002 (first entry)
XX Human kelleikrin 2 (KLK2) gene sequencing primer #5.
XX Human; ss; primer; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
XX cytochrome P450 A2; CYP450A2; cytochrome P450 O2E; CYP450O2E1; LTF;
XX adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
XX aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
XX cyclooxigenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
XX HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
XX NADPH quinone oxidoreductase 2; NQO2; sulfoxidoreductase thermolabile; STM;
XX UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
XX UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
XX multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
XX multidrug resistance associated protein 3; Cancer; prostate;
XX acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
XX altered drug metabolism; cardiovascular function; colorectal tumour;
XX central nervous system; pulmonary; immunological; sequencing.
XX Homo sapiens.
XX OS
XX PN WO200257410-A2.
XX PD 25-JUL-2002.
XX PF 28-NOV-2001; 2001WO-US044838.
XX PR 28-NOV-2000; 2000US-00724389.
XX PA (DNAS-) DNA SCI LAB INC.
XX PI Guida M, Hall J;
XX PS WPI; 2002-698522/75.
XX PT Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX Example 14; Page 126; 714pp; English.
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
XX cytochrome P450 O2E1 (CYP450O2E1), adrenergic receptor beta1 (ADRB1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxigenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GSTI2), histamine-N-methyl
XX transferase (HNMT), NADPH quinone oxidoreductase 2 (NQO2),
XX sulfoxidoreductase thermolabile (STM), UDP-glucuronosyl transferase 2B4
XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
XX (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic

receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
XX The polymorphisms in the human genes cited in the invention are useful as
XX genetic linkage markers for locating and characterizing the genes that
XX are responsible for specific traits within the genome and eventually
XX identifying the genes responsible for a variety of disorder-related
XX traits as a result of their e.g., overexpression, constitutive
XX expression, mutation or underexpression. The nucleic acid molecules comprising the
XX and/or treating the disorders. The nucleic acid molecules comprising the
XX polymorphic sequences contained in CYP450A1, CYP450A2, CYP450O2E1,
XX ARNT, EPHX2, GSTI2, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
XX metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
XX used to screen for altered cardiovascular function, in COX2 for altered
XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
XX nervous system function, in FLAP and HNMT for altered pulmonary,
XX immunological or haematological function, in KLK2 for altered serine
XX protease activity in the prostate, in LTF for altered immunological or
XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
XX peripheral nervous system function. The present sequence represents a
XX sequencing primer used to sequence the polymorphic genes of the invention
SQ Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 917 GTCCAGCCACCAAC 930
Db 2 GTCCAGCCACCAAC 15
RESULT 136
ABL42626/c
ID ABL42626 standard; DNA; 15 BP.
XX ABL42626;
XX AC ABL42626;
XX DT 11-APR-2002 (first entry)
XX DE Hairpin beacon target hybridisation oligonucleotide #5.
XX KW Hybridisation; thermodynamic; computer readable storage medium; probe;
XX target; molecular beacon; duplex; hairpin; ss.
XX OS Synthetic.
XX PN WO200194611-A2.
XX PD 13-DEC-2001.
XX PF 07-JUN-2001; 2001WO-US018424.
XX PR 07-JUN-2000; 2000US-0209778P.
XX PS (UYWA-) UNIV WAYNE STATE.
XX PI Santalucia J, Peyret N;
XX WPI; 2002-122125/16.
XX PT Predicting nucleic acid hybridization thermodynamics based on
XX hybridization information, thermodynamic parameter, correction data and
XX first set of data which represents hybridization conditions.
XX Disclosure; Fig 8; 100pp; English.
XX The present invention describes a method for predicting nucleic acid
XX hybridisation thermodynamics (HT) comprising providing a database of
XX thermodynamic parameters (TP), receiving hybridisation information which
XX represents a sequence, receiving correction data, and a first set of data

e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers for locating, identifying and characterizing the genes responsible for disorder-related traits.

Example 14; Page 125; 714pp; English.

This invention relates to the sequence of an isolated nucleic acid molecule comprising at least one base variation from that of a known human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2), cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1), aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl transferase (HNMT), NADPH quinone oxidoreductase 2 (NQO2), sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3 (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence. The polymorphisms in the human genes cited in the invention are useful as genetic linkage markers for locating and characterizing the genes that are responsible for specific traits within the genome and eventually identifying the genes responsible for a variety of disorder-related traits as a result of their e.g., overexpression, constitutive expression, mutation or underexpression, which may be used in diagnosing and/or treating the disorders. The nucleic acid molecules comprising the polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function, in COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and HNMT for altered pulmonary, immunological or haematological function, in KLK2 for altered serine protease activity in the prostate, in LTF for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a PCR primer used to amplify the sequences of the invention

Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 96;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 917 GTCCAGCCACCAAC 930
|||||
Db 2 GTCCAGCCACCAAC 15

RESULT 134
ABS97731
ID ABS97731 standard; DNA; 15 BP.
XX AC ABS97731;
XX
XX
XX 23-DEC-2002 (first entry)
XX
XX Human kalleikrein 2 (KLK2) gene sequencing primer #6.
XX
XX Human; 88; primer; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;

NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7; UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; UPA; multidrug resistance 1; lactotransferrin; orphan nuclear receptor; multidrug resistance associated protein 3; cancer; prostate; acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5; altered drug metabolism; cardiovascular function; colorectal tumour; central nervous system; pulmonary; immunological; sequencing.

Homo sapiens.

WO200257410-A2.

25-JUL-2002.

28-NOV-2001; 2001WO-US044838.

28-NOV-2000; 2000US-00724389.

(DNAS-) DNA SCI LAB INC.

Guida M, Hall J;

WPI; 2002-698522/75.

Isolated nucleic acid molecules having polymorphisms in known human genes e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers for locating, identifying and characterizing the genes responsible for disorder-related traits.

Example 14; Page 126; 714pp; English.

This invention relates to the sequence of an isolated nucleic acid molecule comprising at least one base variation from that of a known human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2), cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1), aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl transferase (HNMT), kallikrein 2 KLK2, nicotinamide -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2), sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3 (MRP3), orphan nuclear receptor (NR112), or acetylcholine muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence. The polymorphisms in the human genes cited in the invention are useful as genetic linkage markers for locating and characterizing the genes that are responsible for specific traits within the genome and eventually identifying the genes responsible for a variety of disorder-related traits as a result of their e.g., overexpression, constitutive expression, mutation or underexpression, which may be used in diagnosing and/or treating the disorders. The nucleic acid molecules comprising the polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2, NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function, in COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and HNMT for altered pulmonary, immunological or haematological function, in KLK2 for altered serine protease activity in the prostate, in LTF for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a sequencing primer used to sequence the polymorphic genes of the invention

Sequence 15 BP; 4 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;

Fri May 13 12:26:39 2005

CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.2; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1723 TTCTTTAAATAATGAAA 1741
 ||||| ||||| ||||| |||||
 Db 19 TTCTTTCAACAATTAAA 1
 RESULT 133
 ABS97718
 ID ABS97718 standard; DNA; 15 BP.
 XX AC ABS97718;
 XX 23-DEC-2002 (first entry)
 DT Human kelleikrin 2 (KLK2) gene PCR primer #3.
 DE Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1; PCR;
 KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
 KW HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase; thermolabile; STM;
 KW UDP-glucuronosyl transferase 284; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological.
 XX Homo sapiens.
 OS WO200257410-A2.
 PN 25-JUL-2002.
 PD 28-NOV-2001; 2001WO-US044839.
 XX 28-NOV-2000; 2000US-00724389.
 PR (DNAS-) DNA SCI LAB INC.
 XX Guida M, Hall J;
 FI WPI; 2002-698522/75.
 DR Isolated nucleic acid molecules having polymorphisms in known human genes
 PT

QY 1723 TTCTTTAAATAATGAAA 1741
 ||||| ||||| ||||| |||||
 Db 19 TTCTTTCAACAATTAAA 1
 RESULT 132
 ADR78853/C
 ID ADR78853 standard; DNA; 19 BP.
 XX AC ADR78853;
 XX 16-DEC-2004 (first entry)
 DT Human apolipoprotein B (ApoB) oligonucleotide seqid 3338.
 DE antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytosolic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX Homo sapiens.
 OS WO2004080406-A2.
 PN 23-SEP-2004.
 PD 08-MAR-2004; 2004WO-US0007070.
 PF 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX (ALNY-) ALNYLAM PHARM.
 XX Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 DR Interference RNA agent useful for treating dyslipidaemias, coronary artery
 XX disease, diabetes, cancer or neurological disease, comprises sense
 XX sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 3338; 378pp; English.
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device

XX	Synthetic.
OS	Key
XX	misc_feature
FH	Location/Qualifiers
FT	17..18
FT	/tag= a
FT	/note= "2 deoxynucleotide overhang"
XX	
PN	WO2004063331-A2.
XX	
PD	29-JUL-2004.
XX	
PF	05-JAN-2004; 2004WO-US000128.
XX	
PR	03-JAN-2003; 2003US-0437842P.
XX	
PA	(GENC-) GENCIA CORP.
XX	
PI	Kahn S;
XX	
DR	WPI; 2004-561892/54.
XX	
PT	Inhibitory nucleic acid that inhibits expression of an androgen signal transduction pathway protein useful for treating hair loss, comprises a double stranded RNA having a partial sequence encoding a pathway protein in one strand.
PS	Claim 11; Page 59; 92pp; English.
XX	The present invention relates to novel small interfering RNAs (siRNAs), comprising a double stranded RNA, where one strand comprises a partial nucleic acid sequence of an androgen signal transduction pathway protein, and where the double-stranded RNA inhibits translation of mRNA encoding the nucleic acid sequence of the androgen signal transduction pathway protein thereby blocking the androgen signal transduction pathway. The androgen signal transduction pathway protein is chosen from isoforms I and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-hydroxysteroididehydrogenase (ADQ93182), 3-beta-hydroxysteroididehydrogenase (ADQ93360), 3-beta-hydroxysteroididehydrogenase-4-5-isomerase (ADQ93541), 17-beta-hydroxysteroididehydrogenase (ADQ93722), and steroid sulfatase (ADQ93770). The siRNAs of the invention are useful for reducing hair loss in a mammal which involves contacting several mammal's hair cells with the siRNA, where the siRNA interferes with the translation of mRNA of the androgen signal transduction protein. The siRNAs are useful for treating hyperandrogenic conditions of androgenic alopecia, including male pattern alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic hypertrophy. The present sequence is the antisense strand for one such siRNA of the invention.
XX	
SQ	Sequence 18 BP; 3 A; 4 C; 5 G; 2 T; 4 U; 0 Other;
	Query Match 0.8%; Score 14.4; DB 1; Length 18;
	Best Local Similarity 68.8%; Pred. No. 1.1e+02;
	Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
Qy	387 AGCTTCCCAAGTCGTG 402
Db	1 AGCTUUCCAAGGCTGG 16
	: :
	:: :
RESULT 129	
ADQ93225/c	
ID	ADQ93225 standard; DNA; 18 BP.
XX	
AC	ADQ93225;
XX	
DT	21-OCT-2004 (first entry)
XX	
DE	3-alpha-hydroxysteroididehydrogenase target oligonucleotide, SEQ ID 801.
XX	
KW	Endocrine; Antiseborrhoeic; Dermatological; Depilatory; RNA interference;

KW hybrid polypeptide/polyketide metabolite; Lnm production; cytostatic;
 KW PCR; primer; ss.
 XX Streptomyces atroolivaceus.
 OS WO200277179-A2.
 PN 03-OCT-2002.
 PD 22-MAR-2002; 2002WO-US008937.
 PF 26-MAR-2001; 2001US-0278935P.
 PR (REGC) UNIV CALIFORNIA.
 XX (KYOW) KYOWA HAKKO KOGYO KK.
 PA Shen B, Cheng Y, Tang G;
 PI WPI; 2003-018907/01.
 XX Novel gene cluster responsible for synthesis of leinamycin in
 PT Streptomyces atroolivaceus useful for making various peptide and/or
 PT polyketide, and/or hybrid polypeptide/polyketide metabolites.
 XX Claim 1; Page 29; 185pp; English.
 XX The present invention relates to the isolation of the Streptomyces
 CC atroolivaceus leinamycin (Lnm) biosynthesis gene cluster containing 71
 CC open reading frames (ORFs) (ORFs -35 through -1, ORFs lnmA through lnmZ,
 CC and ORFs +1 through +9). Leinamycin is a novel anti-tumour antibiotic
 CC produced by several Streptomyces species. It exhibits broad spectrum
 CC antimicrobial activity against Gram-positive and Gram-negative bacteria,
 CC but not against fungi. The polypeptides encoded by the lnm biosynthesis
 CC gene cluster ORFs are useful for chemically modifying a molecule in a
 CC host cell. The host cell is a bacterium or eukaryotic cell, including a
 CC mammalian, yeast, plant, fungal, or insect cell. The molecule is an
 CC endogenous metabolite produced by the host cell or exogenously supplied
 CC metabolite, or an amino acid, and the polypeptide is a peptide synthetase
 CC or amino transferase. The polypeptides encoded by the lnm gene cluster
 CC are useful for converting an apo-carrier protein to a holo-carrier
 CC protein. Lnm shows potent antitumour activity in tumour models in vivo.
 CC The lnm gene cluster modules and/or catalytic domains are useful for
 CC making various peptide and/or polyketide, and/or hybrid
 CC polypeptide/polyketide metabolites. The proteins encoded by the ORFs are
 CC useful alone, or in combination with other active domains to modify
 CC various target substrates. The lnm gene cluster is useful to upregulate
 CC endogenous lnm production to permit lnm production in cells and/or to
 CC make various modified lnm. Lnm, its analogue, or other polyketide,
 CC peptide or hybrid polyketide/peptide metabolites are useful as
 CC therapeutic agents, to treat a number of disorders, depending upon the
 CC type of metabolites. ABX34290-ABX34431 represent PCR primers used to
 CC amplify individual ORFs of the S. atroolivaceus leinamycin biosynthesis
 CC gene cluster
 XX Sequence 18 BP; 5 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 600 TCAGGCGCAACCTTC 615
 DB 1 TCAGGCGCAACCTTC 16
 RESULT 127
 ADK82331/c
 ID ADK82331 standard; DNA; 18 BP.
 XX
 AC ADK82331;
 XX
 DT 03-JUN-2004 (first entry)
 XX

DE Nucleic acid analysis method spacer oligonucleotide seqid 108.
 XX nucleic acid analysis; hepatitis C virus;
 KW non-contiguous single-stranded region; NCSR; cleavage structure;
 KW clinical; diagnostic; microorganism detection;
 KW microorganism identification; ss.
 XX Synthetic.
 XX US6709815-B1.
 PN 23-MAR-2004.
 PD 18-JUL-2000; 2000US-00402618.
 XX 05-MAY-1997; 97US-00851588.
 PR 19-SEP-1997; 97US-00934097.
 PR 03-MAR-1998; 98US-00034205.
 XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
 PA Dong F. Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
 PI Anderson TA, Dahlberg JE;
 DR WPI; 2004-256067/24.
 XX Analyzing nucleic acids, comprises mixing target nucleic acid such as
 PT hepatitis C virus nucleic acid, bridging oligonucleotide, second
 PT oligonucleotide and cleavage agent to form cleavage structure.
 XX Example 13; SEQ ID NO 108; 143pp; English.
 PS The invention describes a method of analysing nucleic acids comprising
 CC providing a target nucleic acid, e.g. hepatitis C virus nucleic acid
 CC having non-contiguous single-stranded regions (NCSR) separated by an
 CC intervening region, a bridging oligonucleotide capable of binding to the
 CC first and second NCSR; a second oligonucleotide capable of binding to the
 CC first NCSR and a cleavage agent, and mixing the contents to form a
 CC cleavage structure. The method is useful for analysing nucleic acids,
 CC e.g. hepatitis C virus nucleic acid useful for clinical diagnostic
 CC purposes and detection and identification of pathogenic microorganisms
 CC such as hepatitis C virus. This sequence represents a spacer
 CC oligonucleotide associated with the nucleic acid analysis method of the
 CC invention.
 XX Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 813 ATCAACTTTCGTGCAC 828
 DB 16 AACAACTTTCGTGCAC 1
 RESULT 128
 ADQ93227
 ID ADQ93227 standard; RNA; 18 BP.
 XX
 AC ADQ93227;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE 3-alpha-hydroxysteroiddehydrogenase siRNA antisense strand, SEQ ID 803.
 XX Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;
 KW small interfering RNA; siRNA;
 KW androgen signal transduction pathway protein;
 KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;
 KW hair loss; hyperandrogenic condition; androgenic alopecia;
 KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;
 KW prostatic hypertrophy; ds.

KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; immunological; sequencing.
 XX
 OS Homo sapiens.
 XX
 XX WO200257410-A2.
 XX
 XX 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.
 XX
 XX 28-NOV-2000; 2000US-00724389.
 XX
 XX (DNAS-) DNA SCI LAB INC.
 XX
 XX Guida M, Hall J;
 XX
 XX WPI; 2002-698522/75.
 XX
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 XX e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 XX for locating, identifying and characterizing the genes responsible for
 XX disorder-related traits.
 XX
 XX Example 2; Page 101; 714pp; English.
 XX
 XX This invention relates to the sequence of an isolated nucleic acid
 XX molecule comprising at least one base variation from that of a known
 XX human cytochrome p450 A1 (CYP450A1), cytochrome p450 A2 (CYP450A2),
 XX cytochrome p450 2E1 (CYP4502E1), adrenergic receptor beta1 (ADBR1),
 XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
 XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 XX transferase (HNMT), kallikrein 2 (KLK2), nicotinamide-N-methyl
 XX transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 XX sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 XX transferase (UGT2B15), uronkinase receptor (UPA), multidrug resistance 1
 XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 XX (MRP3), orphan nuclear receptor (NRI12), or acetylcholine muscarinic
 XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 XX The polymorphisms in the human genes cited in the invention are useful as
 XX genetic linkage markers for locating and characterizing the genes that
 XX are responsible for specific traits within the genome and eventually
 XX identifying the genes responsible for a variety of disorder-related
 XX traits as a result of their e.g., overexpression, constitutive
 XX expression, mutation or underexpression, which may be used in diagnosing
 XX and/or treating the disorders. The nucleic acid molecules comprising the
 XX polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1,
 XX ARNT, EPHX2, GST12, NNMT, NQO2, NRI12, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
 XX metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 XX used to screen for altered cardiovascular function. In COX2 for altered
 XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 XX nervous system function, in FLAP and HNMT for altered pulmonary,
 XX immunological or haematological function, in KLK2 for altered serine
 XX protease activity in the prostate, in LTF for altered immunological or
 XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 XX peripheral nervous system function. The present sequence represents a
 XX sequencing primer used to sequence the polymorphic genes of the invention
 XX
 XX Sequence 18 BP; 4 A; 1 C; 10 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 14.4; DB 1; Length 18;
 XX Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX 1504 GGAGGTGTACAGGTCA 1519

Db 1 GGAGGTGTACAGGTCA 16
 RESULT 125
 ABN83386
 ID ABN83386 standard; DNA; 18 BP.
 XX
 XX AC ABN83386;
 XX
 XX DT 15-AUG-2002 (first entry)
 XX
 XX DE Hepatocyte growth factor, HGF, sense RT-PCR primer.
 XX
 XX KW RT-PCR; primer; hepatotropic; antifibrotic; vulnery; fibrosis;
 XX KW hepatocyte growth factor; HGF; ss.
 XX
 XX OS Unidentified.
 XX
 XX XX WO200244393-A1.
 XX
 XX PD 06-JUN-2002.
 XX
 XX PF 30-NOV-2000; 2000WO-MX0000050.
 XX
 XX PR 28-NOV-2000; 2000MX-00011713.
 XX
 XX PA (TGT-) TGT LAB SA DE CV.
 XX
 XX PI Armendariz Borunda J, Aguilar Cordova E;
 XX
 XX DR WPI; 2002-471834/50.
 XX
 XX PT Preparing recombinant vector containing reporter and therapeutic genes,
 XX useful for treatment of fibrosis, particularly of liver, by inducing
 XX degradation of collagen.
 XX
 XX PS Example; Page 41; 75pp; Spanish.
 XX
 XX CC The present invention relates to a method for preparing recombinant
 XX vectors (A) by cloning a reporter gene, and modified cDNA of a
 XX therapeutic gene that encodes a protein useful for treating fibrosis
 XX (hepatic, pulmonary, renal, cardiac or pancreatic), keloids and
 XX hypertrophic scars. (A) are used to treat fibrosis in the cirrhotic
 XX liver, but more generally fibrosis in any organ. The present sequence is
 XX a RT-PCR primer for hepatocyte growth factor (HGF), which was used in the
 XX examples from the invention
 XX
 XX Sequence 18 BP; 3 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 14.4; DB 1; Length 18;
 XX Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 1203 GCTCATGGACCTGCT 1218
 XX
 XX DB 3 GCTCATGGACCTGCT 18
 XX
 XX RESULT 126
 ABX34397
 ID ABX34397 standard; DNA; 18 BP.
 XX
 XX AC ABX34397;
 XX
 XX DT 11-FEB-2003 (first entry)
 XX
 XX DE PCR primer #2 for S. atroolivaceus leinamycin gene cluster ORF lms.
 XX
 XX KW leinamycin biosynthesis gene cluster; lms; open reading frame; ORF;
 XX anti-tumour antibiotic; broad spectrum antimicrobial activity; metabolite;
 XX Gram-positive; Gram-negative bacteria; chemical modification; polyketide;
 KW apo-carrier protein; holo-carrier protein; tumour; polyketide;


```

XX ABL44181;
AC
XX
XX 11-APR-2002 (first entry)
XX
XX Human chromosome 1p36-35 PCR primer SEQ ID NO:1225.
DE
XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
KW
XX Homo sapiens.
OS
XX JP2001321190-A.
PN
XX
XX 20-NOV-2001.
PD
XX
XX 12-MAR-2001; 2001JP-00068285.
PF
XX
XX 10-MAR-2000; 2000JP-00066716.
PR
XX (RIKA ) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
PA
XX
XX WPI; 2002-144136/19.
DR
XX
XX Arraying genome clones.
PT
XX
XX Claim 4; Page 29; 528pp; Japanese.
PS
XX
XX The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
XX Sequence 18 BP; 4 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1243 TTCCAGGAATCAAGC 1258
DB 1 TTCCAGGAATCAGGC 16

RESULT 123
ABL46141/c
ID ABL46141 standard; DNA; 18 BP.
XX
XX ABL46141;
AC
XX
XX 26-APR-2002 (first entry)
DT
XX
XX Mycobacterium tuberculosis rpoB gene bridging probe SEQ ID NO:108.
DE
XX Nucleic acid accessible hybridisation site; detection; hybridisation;
KW

```

```

KW
KW characterisation; identification; nucleic acid structure; diagnosis;
KW PCR primer; probe; ss.
XX
OS Mycobacterium tuberculosis.
OS Synthetic.
XX
XX WO200198537-A2.
XX
XX 27-DEC-2001.
PD
XX
XX 15-JUN-2001; 2001WO-US019401.
PF
XX
XX 17-JUN-2000; 2000US-0212308P.
PR
XX 15-JUN-2001; 2001US-00212308.
XX
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
PA
XX
XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX
XX WPI; 2002-049698/06.
XX
XX Identifying oligonucleotides hybridizing to nucleic acids containing
XX secondary structure, useful in clinical diagnosis, comprises identifying
XX primers that interact with the target to form an extension product under
XX amplification conditions.
XX
XX Example 13; Fig 37C; 409pp; English.
XX
XX The present invention describes a method for identifying oligonucleotides
XX with desired hybridisation properties to nucleic acid targets containing
XX secondary structure. The method comprises amplifying a target nucleic
XX acid having at least one accessible and one inaccessible site. Primers
XX that form an extension product are identified as the oligonucleotides
XX which can interact with the folded target nucleic acid. Oligonucleotides
XX from the present invention can be used in novel detection methods for
XX clinical diagnostic purposes, including the detection and identification
XX of pathogenic organisms (e.g. HIV). The method allows the ability to
XX rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
XX sequences used in the exemplification of the present invention
XX
XX Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCGTGCAC 828
DB 16 AACAACTTTCGTGCAC 1

RESULT 124
ABS97172
ID ABS97172 standard; DNA; 18 BP.
XX
XX ABS97172;
AC
XX
XX 23-DEC-2002 (first entry)
DT
XX
XX Human CYP4501A2 Exon 2 sequencing primer #2.
XX
XX Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
XX cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
XX adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
XX aryl hydrocarbon receptor nuclear translocator; ARNT; catepsin S; CTSS;
XX cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
XX epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
XX glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
XX HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
XX NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
XX UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
XX UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
XX multidrug resistance 1; lactotransferrin; orphan nuclear receptor;

```

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCACTTTCTGTCTAC 828
 DB 16 AACAACTTCTGTCTAC 1

RESULT 120
 AAS06835
 ID AAS06835 standard; DNA; 18 BP.
 XX
 AC AAS06835;
 XX
 DT 12-SEP-2001 (first entry)
 XX
 DE SNP containing protein kinase DNA sequence #4.
 XX
 KW Human; protein kinase; PTK; STK; cancer; cardiovascular disease; SNP;
 KW metabolic disorder; immune related disease; neurological disorder;
 KW neurodegenerative disorder; inflammatory disorder; infectious disease;
 KW reproductive disorder; gene therapy; single nucleotide polymorphism; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200138503-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 22-NOV-2000; 2000WO-US032085.
 XX
 PR 24-NOV-1999; 99US-0167482P.
 XX
 PA (SUGS-) SUGEN INC.
 XX
 PI Plowman GD, Whyte D, Manning G, Sudarsanam S, Martinez R;
 PI Flanagan P, Clary D;
 XX
 DR WPI; 2001-343950/36.
 XX
 PT Nucleic acids encoding human kinase polypeptides, useful for preventing
 PT diagnosing and/or treating e.g. cancer, immune, cardiovascular and
 PT neuronal-associated diseases, and microbial infections.
 XX
 PS Example 8B; Page 329; 433pp; English.

AAS06832-AAS06897 represent part of a polynucleotide sequence encoding
 for novel human protein kinases where a single nucleotide polymorphism
 (SNP) has been identified. The SNP occurs at the last position of the
 present sequence. The sequences are described relating to the invention
 of novel human protein kinases #1-57 (AAU03501-AAU03557). The novel
 protein kinases have been identified as members of the tyrosine or
 serine/threonine kinase (PTK and STK) families. The polynucleotides
 encoding protein kinases and the polypeptides may be used in the
 prevention, diagnosis and treatment of diseases associated with
 inappropriate kinase expression. For example, they may be used to treat
 cancers (especially cancers of haematopoietic origin), cardiovascular
 disease (e.g. atherosclerosis), metabolic disorders (e.g. diabetes),
 immune related diseases (e.g. rheumatoid arthritis), neurological
 disorders (e.g. schizophrenia), neurodegenerative disorders (e.g.
 Parkinson's disease), inflammatory disorders (e.g. asthma), infectious
 disease (e.g. HIV) and reproductive disorders (e.g. infertility).
 Additionally, polynucleotides encoding protein kinases may be used for
 gene therapy and as DNA probes in diagnostic assays. The protein kinase
 polypeptides may be used as antigens in the production of antibodies
 against the protein kinases and in assays to identify modulators of
 protein kinase expression and activity

XX
 SQ Sequence 18 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 1 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 1.1e+02;

Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 351 CATCAACGCTGAGGATCT 368
 DB 1 CATGAGCCTGAGGATGK 18

RESULT 121
 ABK40971
 ID ABK40971 standard; DNA; 18 BP.
 XX
 AC ABK40971;
 XX
 DT 21-MAY-2002 (first entry)
 XX
 DE Human obesity-associated biallelic marker upstream PCR primer #48.
 XX
 KW Human; obesity associated biallelic marker; chromosome 10; obesity; ss;
 KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
 KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
 KW insulin disorder; atheromatous disease; cardiac insufficiency; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200206525-A2.
 XX
 PD 24-JAN-2002.
 XX
 PF 28-JUN-2001; 2001WO-IB001477.
 XX
 PR 18-JUL-2000; 2000US-0219704P.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
 XX
 DR WPI; 2002-155043/20.
 XX
 PT Set of novel map-related biallelic markers, preferably located on obesity
 PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,
 PT useful, for e.g. detecting statistical correlations between marker allele
 PT and a phenotype.
 XX
 PS Example 2; Page 237; 311pp; English.

The invention relates to a set of novel map-related biallelic markers,
 preferably located on obesity disorder-associated chromosomal regions on
 chromosomes 3, 10 and 19. The markers are useful for genotyping or
 estimating the frequency of an allele in a population, for detecting an
 association between a genotype or haplotype and a phenotype, e.g. a
 disease involving drug responses, obesity or disorders related to
 obesity, such as hyperuricaemia, digestive pathology, hepatic function
 disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
 insulin disorders, atheromatous disease and cardiac insufficiency. The
 markers are useful for detecting a statistical correlation between a
 biallelic marker allele and a phenotype and/or between a biallelic marker
 haplotype and a phenotype. This sequence represents a PCR primer used to
 amplify a human obesity-associated biallelic marker

XX
 SQ Sequence 18 BP; 5 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 CACACTTCCCGGAT 1253
 DB 1 CACACTTCCCTGGAAT 16

RESULT 122
 ABL44181
 ID ABL44181 standard; DNA; 18 BP.

ID ACN73531 standard; DNA; 17 BP.
 AC ACN73531;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:10433.
 XX
 DE Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 KW
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-0086610P.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 DR WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 10433; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTTCATGCTGTC 852
 DB 16 GACTTTTCATGCTGTC 1
 RESULT 119
 AAV70530/C
 ID AAV70530 standard; DNA; 18 BP.
 XX
 AC AAV70530;
 XX
 DT 08-APR-1999 (first entry)
 XX
 DE rpoB binding capture probe 62-114 d.
 XX
 KW Nucleic acid detection; nucleic acid characterisation; hybridisation;
 KW infection; disease; cancer; forensic; paternity; multiplexing; rpoB;
 KW probe; ss.
 XX
 OS Synthetic.
 OS Mycobacterium tuberculosis.
 XX
 PN WO9850403-A1.
 XX
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US003194.
 PR 05-MAY-1997; 97US-00851588.
 PR 19-SEP-1997; 97US-00934097.
 PR 03-MAR-1998; 98US-00034205.
 XX
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX
 PI Dong F. Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;
 PI Anderson TA, Dahlberg JE;
 DR WPI; 1998-610317/51.
 XX
 PT Detection and characterisation of nucleic acid sequences - by mixing a
 PT folded target and one or more probes to form a probe/folded target
 PT complex and detecting and characterising the complexes.
 XX
 PS Example 13; Fig 37C; 279pp; English.
 XX
 CC The invention relates to methods and compositions of detection and
 CC characterisation of nucleic acid sequences and sequence changes. One
 CC method of detection and characterisation comprises: (a) providing: (i) a
 CC folded target having a DNA sequence comprising at least 1 double stranded
 CC region and at least 1 single stranded region; and (ii) at least 1 probe
 CC complementary to at least a portion of the folded target; and (b) mixing
 CC the target and probes so that the probe hybridises to form a probe
 CC /folded target complex. Also provided are methods for determination of
 CC structure formation in nucleic acid targets; for analysing folded nucleic
 CC acids targets; and for analysis of nucleic acid structures. The methods
 CC can be used for the detection and characterisation of nucleic acid
 CC sequences to detect the presence of pathogenic nucleic acid sequences
 CC indicative of an infection, the presence of variants or alleles of
 CC mammalian genes associated with disease and cancers, and the
 CC identification of the source of nucleic acids found in forensic samples,
 CC as well as in paternity determinations. The methods allow simultaneous
 CC analysis of both strands (e.g. the sense and antisense strands) and are
 CC ideal for high-level multiplexing. The products produced are amenable to
 CC qualitative, quantitative and positional analysis. The methods may be
 CC performed in solution or in the solid phase (e.g. on a solid support).
 CC The methods are powerful in that they allow for analysis of longer
 CC fragments of nucleic acid than current methodologies. Sequences AAV70527
 CC -31 represent probes that can bind to rpoB truncated stem. These are used
 CC in rpoB capture experiments
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

AC ADN45011;
XX 15-JUL-2004 (first entry)
XX Mutant cell identification-related mutagenic oligonucleotide SeqIDI680.
DE
XX cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
XX Solanum tuberosum.
OS Synthetic.
OS W02004033708-A2.
XX
XX 22-APR-2004.
XX
XX 07-OCT-2003; 2003WO-US031862.
XX
XX 07-OCT-2002; 2002US-0416983P.
XX
XX 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX Kmiec EB, Van Brabant A;
XX
XX WPI; 2004-340941/31.
XX
XX Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX
XX Example 28; SEQ ID NO 1680; 303pp; English.
PS
XX This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
XX Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1478 TGGCAATAATCTACCA 1493
DB 17 TGGCAATAATCTACCA 2
RESULT 117
ACN73529/c
ID ACN73529 standard; DNA; 17 BP.
XX
AC ACN73529;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:10431.
DE
XX

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 05-FEB-2001; 2001WO-US000670.
XX
XX 25-MAY-2001; 2001US-0266860P.
XX
XX (GUYU/) GU Y.
PA (JIYU/) JI Y.
XX (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
PA (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 10431; Opp; English.
PS
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1 or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 838 AGTTTGTGATGCTGCA 853
DB 17 ACTTTTGTGCTGCTCA 2
RESULT 118
ACN73531/c

```
RESULT 114
ADL50592/c
ID ADL50592 standard; RNA; 17 BP.
XX
AC ADL50592;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1706.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX
PI Blatt L, Chowirza B, Haeberli P, Mowwigen J, Fosnaugh K;
XX WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 4125; 317bp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 10 A; 0 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 931 ATTACTTCTATTCTT 946
DB 16 ATTAATCTATTCTT 1
```

```
RESULT 115
ADN45010
ID ADN45010 standard; DNA; 17 BP.
XX
AC ADN45010;
XX
DT 15-JUL-2004 (first entry)
XX
DE Mutant cell identification-related mutagenic oligonucleotide SeqID1679.
XX
KW cell identification; oligonucleotide-directed sequence alteration;
KW selectable phenotype; transgenic plant; herbicide resistance;
KW sterile plant; abiotic stress tolerance; albino plant;
KW amino acid production; ss.
XX
OS Solanum tuberosum.
OS Synthetic.
XX
PN WO2004033708-A2.
XX
PD 22-APR-2004.
XX
PF 07-OCT-2003; 2003WO-US031862.
XX
PR 07-OCT-2002; 2002US-0416983P.
PR 07-MAR-2003; 2003US-0453360P.
XX
XX (UYDE ) UNIV DELAWARE.
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.
XX
XX Kmiec EB, Van Brabant A;
XX WPI; 2004-340941/31.
XX
PT Identifying a cell with a desired oligonucleotide-directed sequence
PT alteration at a nucleic acid target site within the cell by identifying
PT the desired sequence alteration in cells selected for the presence of a
PT selectable phenotype.
XX
PS Example 28; SEQ ID NO 1679; 303pp; English.
XX
CC This invention relates to a novel method of identifying a cell having a
CC desired oligonucleotide-directed sequence alteration at a first nucleic
CC acid target site within the cell. The method comprises identifying the
CC desired sequence alteration in cells that have been selected for the
CC presence of a selectable phenotype conferred by a concurrent
CC oligonucleotide-directed sequence alteration at a second nucleic acid
CC target site within the cells. The method is useful in identifying a cell
CC having a desired oligonucleotide-directed sequence alteration at a first
CC nucleic acid target site within the cell. The method may be useful for
CC the production of plants with herbicide resistance, male or female
CC sterile plants, abiotic stress tolerance, albino plants or plants with
CC altered amino acid production as well as for use in mammalian cell lines.
CC The present sequence is that of a mutagenic oligonucleotide which was
CC used in the exemplification of the invention.
XX
SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1478 TGGCAATAATGTACA 1493
DB 1 TGGCAATAATGTACA 16
RESULT 116
ADN45011/c
ID ADN45011 standard; DNA; 17 BP.
XX
```

RESULT 112
ADL49538
ID ADL49538 standard; RNA; 17 BP.
XX
AC ADL49538;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #652.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
FN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 3071; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 9 A; 4 C; 1 G; 0 T; 3 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 146 ATAGAACTTCCTAAA 161
DB 1 AAGAAACAUCCUAAA 16

RESULT 113
ADL49154/c
ID ADL49154 standard; RNA; 17 BP.
XX
AC ADL49154;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #268.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
FN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2687; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 11 A; 0 C; 2 G; 0 T; 4 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 931 ATTACTTCTATTCTT 946
DB 17 ATTAATTCCTATTCTT 2

CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration.
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGAATTTCTCATGAT 17
 |||||
 DB 17 TGAATTTCTCATGAT 2

RESULT 110
 ADI49691
 ID ADI49691 standard; DNA; 17 BP.
 AC ADI49691;
 DT 15-APR-2004 (first entry)
 DE Human tumour suppression/reversion-related DNA sequence SeqID2194.
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 XX Homo sapiens.
 OS
 PN WO2003025177-A2.
 PD 27-MAR-2003.
 PF 17-SEP-2002; 2002WO-IB004523.
 PR 17-SEP-2001; 2001PR-00011980.
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA Telerman A, Amson R, Tuijnder M;
 PI WPI; 2003-313354/30.
 DR New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX Disclosure; SEQ ID NO 2194; 30pp; French.
 PS
 CC This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC neurotropic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences

XX Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 871 ATCTTTTCTTAAAG 886
 |||||
 DB 2 ATCTTTTCTTAAAG 17

RESULT 111
 ACC51935/c
 ID ACC51935 standard; DNA; 17 BP.
 AC ACC51935;
 DT 27-JUN-2003 (first entry)
 DE Human tumour suppressor sequence #702.
 XX ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 KW tumour regression; apoptosis; virus resistance; diagnosis;
 KW cellular degeneration.
 XX Homo sapiens.
 OS
 PN FR2826373-A1.
 PD 27-DEC-2002.
 PF 20-JUN-2001; 2001FR-00008139.
 XX 20-JUN-2001; 2001FR-00008139.
 PR (MOLE-) MOLECULAR ENGINES LAB SA.
 PA Tuijnder M, Telerman A, Amson R;
 PI WPI; 2003-250498/25.
 DR New nucleic acid sequences associated with tumor suppression, regression,
 PT apoptosis or virus resistance are useful to diagnose and treat viral
 PT disease, development of tumor cells and cell degeneration.
 XX Claim 1; Page 202; 798pp; French.
 PS
 CC This sequence represents an isolated nucleic acid sequence associated
 CC with tumour suppression or regression, apoptosis or virus resistance. The
 CC invention relates to these sequences or sequences having at least 80%
 CC identity to them, and polypeptides encoded by the sequences or
 CC polypeptides having 80% identity to the polypeptide sequences. The
 CC invention is used to diagnose or treat viral disease or disease
 CC characterized by development of tumour cells or cellular degeneration

XX Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 TGAATTTCTCATGAT 17
 |||||
 DB 17 TGAATTTCTCATGAT 2

```

PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J;
XX WPI; 2003-140484/13.
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX Claim 59; Page 93; 185pp; English.
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889, ABZ62216, ABZ64544, ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX Sequence 17 BP; 10 A; 1 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;
QY 1576 TTTTTCATTCTTCCT 1591
Db 16 TTTTTCATTCTTCGT 1
RESULT 108
ADB40294
ID ADB40294 standard; DNA; 17 BP.
XX ADB40294;
XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
DE Tumour suppression/reversion associated nucleotide #617.
XX cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX Homo sapiens.
XX WO2003040369-A2.
XX 15-MAY-2003.
XX 17-SEP-2002; 2002WO-IB004219.
XX 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J;
XX WPI; 2003-140484/13.
XX Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX Claim 59; Page 93; 185pp; English.
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889, ABZ62216, ABZ64544, ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX Sequence 17 BP; 10 A; 1 C; 4 G; 0 T; 2 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;
QY 1576 TTTTTCATTCTTCCT 1591
Db 16 TTTTTCATTCTTCGT 1
RESULT 108
ADB40294
ID ADB40294 standard; DNA; 17 BP.
XX ADB40294;
XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
DE Tumour suppression/reversion associated nucleotide #617.
XX cytostatic; antiviral; neuroprotective; neurotropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX Homo sapiens.
XX WO2003040369-A2.
XX 15-MAY-2003.
XX 17-SEP-2002; 2002WO-IB004219.
XX 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT
PT polypeptide and antibodies.
XX Disclosure; Page 104; 771pp; French.
XX The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.
XX Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 0;
QY 1316 ATCAATTGGAATATGA 1331
Db 2 ATCAATTGGAATATGA 17
RESULT 109
ADI48529/C
ID ADI48529 standard; DNA; 17 BP.
XX ADI48529;
XX ADI48529;
XX 15-APR-2004 (first entry)
XX Human tumour suppression/reversion-related DNA sequence SeqID1032.
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;
XX primer; PCR; gene chip; antisense; viral disease; tumour;
XX cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX Homo sapiens.
XX WO2003025177-A2.
XX 27-MAR-2003.
XX 17-SEP-2002; 2002WO-IB004523.
XX 17-SEP-2001; 2001FR-00011980.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313354/30.
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX Disclosure; SEQ ID NO 1032; 30pp; French.
XX

```


KW Amberzyme; Zinzyne; ss.
 OS West Nile Virus.
 XX
 PN WO200268637-A2.
 XX
 XX 06-SEP-2002.
 PD
 XX
 PF 19-OCT-2001; 2001WO-US048350.
 XX
 XX 20-OCT-2000; 2000US-0242411P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J A.
 XX
 XX Blatt L, Mcswiggen JA;
 PI
 XX WPI; 2002-706994/76.
 DR
 XX
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
 PT
 PT
 XX Claim 23; SEQ ID NO 8220; 495pp; English.
 PS
 XX
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-Cleaver, DNazyme, Amberzyme and Zinzyne. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention
 XX
 XX Sequence 17 BP; 9 A; 3 C; 3 G; 0 T; 2 U; 0 Other;
 SQ
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 8 TTCTCATGATGATTGT 23
 DB 16 TTCTCTTGATGATTGT 1
 RESULT 106
 ABT34768
 ID ABT34768 standard; DNA; 17 BP.
 XX
 AC ABT34768;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 405.
 XX
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 XX WO2003025175-A2.
 PN
 XX 27-MAR-2003.
 PD
 XX

PF 17-SEP-2002; 2002WO-IB004208.
 XX
 PR 17-SEP-2001; 2001FR-00011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 XX WPI; 2003-313353/30.
 DR
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated with tumors and cell degeneration, also related polypeptides, antibodies and transfected cells.
 PT
 PT
 XX Disclosure; Page 81; 720pp; French.
 PS
 XX
 XX The invention relates to a novel isolated 17 mer nucleic acid sequence, given in the specification, a sequence containing at least 15 consecutive nucleotides from the 17 mer sequence, a sequence with, after optimal alignment, at least 80 % identity to the 17 mer sequence, a sequence that hybridizes to them under highly stringent conditions, or the complement of any of them, or the corresponding RNA. The novel isolated nucleic acids of the invention are useful as probes and primers for detecting, identifying, quantifying and/or amplifying a nucleic acid, e.g. as one component of a gene chip, in vitro as (anti)sense reagents, and for production of recombinant polypeptides. Any of the nucleic acids, polypeptides, vectors containing the nucleic acids, cells containing the vector or antibodies directed against the polypeptides are useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia. Analysis of the expression of the 17 mer nucleic acids in patient samples is useful for diagnosis and/or prognosis of these diseases. The polypeptides can also be used to generate antibodies, and both the polypeptide and antibodies are useful as components of protein chips. The nucleic acid sequences of the invention can be used in gene therapy. This polynucleotide sequence represents a tumour suppression related human fukutin oligonucleotide of the invention
 XX
 XX Sequence 17 BP; 4 A; 3 C; 3 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 871 ATCCTTTCTTTTAAAG 886
 DB 2 ATCCTTTCTTTTAAAG 17
 RESULT 107
 ABZ60344/C
 ID ABZ60344 standard; RNA; 17 BP.
 XX
 AC ABZ60344;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human K-Ras DNzyme substrate #456.
 XX
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200297114-A2.
 PN
 XX 05-DEC-2002.
 PD
 XX
 XX 29-MAY-2002; 2002WO-US016840.
 PF
 XX 29-MAY-2001; 2001US-0294140P.
 PR

KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

OS Solanum tuberosum.
 OS Synthetic.

PN WO200192512-A2.

XX 06-DEC-2001.

PF 01-JUN-2001; 2001WO-US017672.

PR 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

PR 27-MAR-2001; 2001US-00818875.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC, Kim J;

XX WPI; 2002-106307/14.

XX New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.

PS Claim 7; Page 144; 220pp; English.

XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention

XX Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493

DB 1 TGGCAATAATGTCACA 16

RESULT 102

ABK26320/c

ID ABK26320 standard; DNA; 17 BP.

XX ABK26320;

XX 09-APR-2002 (first entry)

XX Increased starch production genome altering oligonucleotide #172.

XX

KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin-B;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW modified fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX Solanum tuberosum.

OS Synthetic.

XX WO200192512-A2.

XX 06-DEC-2001.

XX 01-JUN-2001; 2001WO-US017672.

XX 01-JUN-2000; 2000US-0208538P.

PR 30-OCT-2000; 2000US-0244989P.

PR 27-MAR-2001; 2001US-00818875.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC, Kim J;

XX WPI; 2002-106307/14.

XX New oligonucleotides with modified nuclease-resistant termini, useful for
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved
 PT nutritional value, herbicide or disease resistance, or modified oil
 PT production.

PS Claim 7; Page 144; 220pp; English.

XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention

XX Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493

DB 1 TGGCAATAATGTCACA 2

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 10433; 214pp; English.

PS The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 7 A; 4 C; 4 G; 2 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGGATGCTGTC 852
DB 16 GACTTTTGATGCTGTC 1

RESULT 100
ABN10439/C
ID ABN10439 standard; DNA; 17 BP.
XX AC ABN10439;
XX 29-MAY-2002 (first entry)
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10431.
XX Human, genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
XX WO200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US016981.
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.

30-JAN-2001; 2001WO-US000666.
30-JAN-2001; 2001WO-US000667.
30-JAN-2001; 2001WO-US000668.
30-JAN-2001; 2001WO-US000669.
30-JAN-2001; 2001WO-US000670.
05-FEB-2001; 2001US-0266860P.
XX (ABOM-) ABOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.

XX Disclosure; SEQ ID NO 10431; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence

XX Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 838 AGTTTGGATGCTGTC 853
DB 17 ACTTTTGATGCTGTC 2

RESULT 101
ABK26319
ID ABK26319 standard; DNA; 17 BP.
XX AC ABK26319;
XX 09-APR-2002 (first entry)
XX Increased starch production genome altering oligonucleotide #171.
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
XX o-methyl modification; LNA modification; phosphorothioate linkage;
XX DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
XX abiotic stress tolerance; improved nutritional value; hygromycin; primer;
XX amino acid over production; herbicide resistance; glyphosate resistance;
XX imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
XX porphyric herbicide resistance; triazine resistance; disease resistance;
XX modified oil production; modified starch production; waxy starch;
XX altered floral morphology; male-sterile plant; albino mutant;
XX modified fatty acid content; reduced palmitate production; albino plant;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 62.5%; Pred. No. 1e+02;
 Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1672 ATTAGAAATTAGAAATTA 1687
 |:||||:||||:|
 Db 1 AUCAGAAUUGAAUUA 16

RESULT 98
 ABK03148
 ID ABK03148 standard; RNA; 17 BP.
 XX
 AC ABK03148;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Inozyme #99.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberyne; zinyne; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX
 DR WPI; 2001-607195/69.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 30; Page 147; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NTN motif) or
 CC an amberyne (cleaving RNA with an NGN triplet), a zinyne (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more

therapies. In particular, the CD20 targeting nucleic acid may be used to
 treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 nucleic acid may be contacted with a cell to reduce NOGO activity of the
 cell and treat a patient having a condition associated with the level of
 NOGO. The treatment may further comprise the use of one or more
 therapies. In particular, the NOGO-targeting nucleic acid may be used to
 treat central nervous system (CNS) injury and cerebrovascular accident
 (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 disease, muscular dystrophy, and/or other neurodegenerative disease
 states which respond to the modulation of NOGO expression. The present
 sequence is an inozyme of the invention

Sequence 17 BP; 7 A; 3 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 1e+02; Indels 0; Gaps 0;
 Matches 13; Conservative 2; Mismatches 1;

QY 165 AAAAATCCAGGAATG 180

||||:||||:|

Db 1 AAAACUCCAGGAUG 16

RESULT 99

ABN10441/c

ID ABN10441 standard; DNA; 17 BP.

XX

AC ABN10441;

XX

DT 29-MAY-2002 (first entry)

XX

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10433.

XX

KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX

OS Homo sapiens.

XX

PN WO200192524-A2.

XX

PD 06-DEC-2001.

XX

PF 25-MAY-2001; 2001WO-US016981.

XX

PR 26-MAY-2000; 2000US-0207456P.

XX

PR 21-SEP-2000; 2000US-0234687P.

XX

PR 27-SEP-2000; 2000US-0236359P.

XX

PR 04-OCT-2000; 2000GB-00024263.

XX

PR 30-JAN-2001; 2001WO-US000661.

XX

PR 30-JAN-2001; 2001WO-US000662.

XX

PR 30-JAN-2001; 2001WO-US000663.

XX

PR 30-JAN-2001; 2001WO-US000665.

XX

PR 30-JAN-2001; 2001WO-US000666.

XX

PR 30-JAN-2001; 2001WO-US000667.

XX

PR 30-JAN-2001; 2001WO-US000668.

XX

PR 30-JAN-2001; 2001WO-US000669.

XX

PR 05-FEB-2001; 2001US-0266860P.

XX

(AEOM-) AEOMICA INC.

XX

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX

CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention

XX SQ Sequence 17 BP; 6 A; 4 C; 2 G; 0 T; 5 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTCACTTACAGGAT 332
 |||: |||: |||: |||:
 Db 1 ACCUACUACAGGAU 16

RESULT 96
 AAX73080
 ID AAX73080 standard; RNA; 17 BP.
 XX AAX73080;
 AC AAX73080;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #513.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.

XX WO9715662-A2.
 XX 01-MAY-1997.
 XX 25-OCT-1996; 96WO-US017480.
 XX 26-OCT-1995; 95US-0005974P.
 XX 11-JAN-1996; 96US-00584040.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX Pavco P, Meswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.

XX Claim 4; Page 139; 218pp; English.
 XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX SQ Sequence 17 BP; 7 A; 1 C; 5 G; 0 T; 4 U; 0 Other;
 Query Match 0.8%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 1e+02;
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 297 GTCAGATGGATGAAG 312

Db 1 GUCAAGAUUGAUGAG 16

RESULT 97
 AAX21150
 ID AAX21150 standard; RNA; 17 BP.
 XX AAX21150;
 AC AAX21150;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4376.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIF-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiobroma;
 KW tuberculous sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US006507.

XX 27-MAR-1998; 98US-0079678P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Meswiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.

XX Claim 55; Page 190; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAX16775 to
 CC AAX17167 and AAX17561 to AAX17622 represent ribozyme sequences for ARNT,
 CC and AAX17168 to AAX17560 and AAX17623 to AAX17684 represent their
 CC corresponding target ribozyme sequences; AAX17685 to AAX18385 and AAX19087 to
 CC AAX19154 represent ribozyme sequences for Tie-2, and AAX18386 to AAX19086
 CC and AAX19155 to AAX19222 represent their corresponding target sequences;
 CC AAX19223 to AAX20361 and AAX21501 to AAX21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAX20362 to AAX21500 and
 CC AAX21596 to AAX21688 represent their corresponding target sequences;
 CC AAX21689 to AAX22475 and AAX23263 to AAX23262, AAX23343 to
 CC for integrin subunit beta 3, and AAX22476 to AAX23262, AAX23343 to
 CC AAX23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiobroma of tuberculous sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3

XX Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

CC macromolecules are specifically bound. The method of the invention may be
 CC used to detect hybridisation of RNA or, particularly DNA, especially for
 CC detecting the presence of particular sequences in samples, but also for
 CC studying reaction kinetics. The method allows the use of molecular
 CC beacons that are simple to prepare or synthesise, particularly because
 CC they do not require incorporation of a quencher. The current sequence is
 CC that of the control probe of the invention which is targeted to the
 CC fluorescent-labelled and bound DNA oligonucleotide in the binding
 CC analysis method.

SQ . Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 16;
 Best Local Similarity 93.8%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1748 GAAAAAAAAAAAAA 1763

Db 1 GAAAAAAAAAAAAA 16

RESULT 94

AAT81521/c
 ID AAT81521 standard; RNA; 17 BP.

XX AAT81521;

DT 14-DEC-1997 (first entry)

DE Human c-myb hammerhead ribozyme target sequence (nt. position 2738).

XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;

KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KW coronary angioplasty; ss.

OS Homo sapiens.

XX WO9531541-A2.

PN 23-NOV-1995.

PF 18-MAY-1995; 95WO-US006368.

XX 18-MAY-1994; 94US-00245466.

PR 13-JAN-1995; 95US-00373124.

XX (RIBO-) RIBOZYME PHARM INC.

PA Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;

DR WPI; 1996-010927/01.

XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.

XX Claim 1; Page 77; 128pp; English.

PS The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers

SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1545 GCTTTTACAAAATTAA 1560

Db 17 GCATTACAAAATTAA 2

RESULT 95

AA63814

ID AA63814 standard; RNA; 17 BP.

XX AA63814;

DT 20-JUL-1999 (first entry)

XX Rabbit stromelysin hammerhead target SEQ ID NO:446.

XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.

XX Oryctolagus cuniculus.

XX WO9618736-A2.

PN 20-JUN-1996.

PD 22-NOV-1995; 95WO-US015516.

XX 13-DEC-1994; 94US-00354920.

PR 23-DEC-1994; 94US-00363253.

PR 17-DEC-1994; 94US-00363254.

PR 17-FEB-1995; 95US-00390850.

PR 20-APR-1995; 95US-00426124.

PR 02-MAY-1995; 95US-00432874.

PR 04-MAY-1995; 95US-00434509.

PR 07-JUL-1995; 95US-0000951P.

PR 07-AUG-1995; 95US-00512861.

PR 05-OCT-1995; 95US-00541365.

XX (RIBO-) RIBOZYME PHARM INC.

PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

PI Mcswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;

PI Karpeisky A, Thompson JD, Modak A, Burgin A;

DR WPI; 1996-300653/30.

XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.

XX Example 1; Page 153; 307pp; English.

PS The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment or prevention of arthritis.
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment

KW Nonlinear optical technique; screening; ss.
XX Unidentified.
XX WO2003064991-A2.
XX 07-AUG-2003.
XX 17-JUL-2002; 2002WO-US022681.
XX 17-JUL-2001; 2001US-0306040P.
PR 23-OCT-2001; 2001US-0347821P.
PR 06-FEB-2002; 2002US-0354668P.
XX (SALA/) SALAFSKY J S.
XX Salafsky JS;
XX WPI; 2003-646172/61.
XX Screening candidate binding partner(s) for binding to test molecule by
PT applying external force field to sample in homogeneous phase.
PT illuminating sample with light beam(s) at fundamental frequencies; and
PT measuring physical properties.
XX Disclosure; Fig 20-B; 146pp; English.
PS The present invention relates to a method for detecting interactions
CC between biological components using a nonlinear optical technique. The
CC invention is used for screening candidate binding partner(s) for binding
CC to test molecule. It can also be used to detect changes in orientation or
CC conformation of the probe and/or target. The present sequence is a target
CC oligonucleotide used in nonlinear optical technique
XX
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1748 GAAAAAAAAAAAAA 1763
DB 1 GAAAAAAAACAAAAAA 16
RESULT 92
ADF23332
ID ADF23332 standard; DNA; 16 BP.
AC ADF23332;
XX 12-FEB-2004 (first entry)
DT Binding partner screening method molecular beacon analogue #3.
DE Binding partner screening; light beam; nonlinear optical light beam; ss;
KW molecular beacon analogue.
XX Synthetic.
OS
XX US2003148391-A1.
PN 07-AUG-2003.
PD 06-JUN-2002; 2002US-00164915.
PF 24-JAN-2002; 2002US-0351879P.
PR 06-FEB-2002; 2002US-0354668P.
PR 06-FEB-2002; 2002US-0354679P.
PR 05-MAR-2002; 2002US-0362003P.
XX (SALA/) SALAFSKY J S.
PA

PI Salafsky JS;
XX WPI; 2003-897567/82.
XX Screening of candidate binding partners for binding to test molecule
PT comprises illuminating sample with light beams and measuring physical
PT properties of nonlinear optical light beam emanating from sample.
XX Disclosure; SEQ ID NO 3; 58pp; English.
XX The invention describes screening a candidate binding partner by
CC illuminating the sample with light beams at fundamental frequencies to
CC binding partners, and measuring physical properties of a nonlinear
CC optical light beam emanating from sample. On binding to the test molecule
CC the properties change relative to that in absence of exposure of the test
CC molecule. The invention is used in the screening of candidate binding
CC partners for binding to test molecule. This sequence represents a
CC molecular beacon analogue, an exemplary test molecule of the invention.
XX
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1748 GAAAAAAAAAAAAA 1763
DB 1 GAAAAAAAACAAAAAA 16
RESULT 93
ADS15827
ID ADS15827 standard; DNA; 16 BP.
XX ADS15827;
AC ADS15827;
XX 02-DEC-2004 (first entry)
DT Control probe targeted to labelled/bound oligo in binding analysis.
DE binding; sequence detection; reaction kinetics; ss; probe.
KW Synthetic.
XX DE10307801-A1.
PN 09-SEP-2004.
PD 24-FEB-2003; 2003DE-01007801.
PF 24-FEB-2003; 2003DE-01007801.
PR (ADVA-) ADVALYTIX AG.
PA Kirchner R, Gauer C;
PI WPI; 2004-654186/64.
XX Analyzing binding between macromolecules, useful for detecting nucleic
PT acids by hybridization, where a labeled detector molecule is immobilized
PT and becomes fluorescent only after specific binding.
XX Example; Page 6; 11pp; German.
XX The invention relates to a novel analytical method for examining binding
CC events between first and second macromolecules. The method comprises
CC preparing a surface on which a fluorescently-labelled first macromolecule
CC is bound and which is at least partly fitted with a fluorescence-
CC suppressing layer. A sample liquid containing the second macromolecule is
CC applied and fluorescence is measured. The first macromolecule has a
CC secondary structure such that its fluorescence is suppressed by the
CC suppressing layer when it is not specifically bound to the second
CC macromolecule, but fluorescence is not suppressed when the two

Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 621 TGTCTGCTTCATCAACT 638
 :||:||||:||||:|
 Db 1 UGUUGCUGCUCAUGAGCU 18

RESULT 85
 AAV33107
 ID AAV33107 standard; DNA; 18 BP.
 AC AAV33107;
 XX
 DT 18-NOV-1998 (first entry)
 XX
 DE Stromelysin primer 1.
 XX
 KW Multiplex competitive PCR reaction; MC-PCR; reverse-transcriptase PCR;
 KW RT-PCR; tagging reaction; competitive amplification reaction; primer;
 KW housekeeping gene; Stromelysin; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9835058-A2.
 XX
 PD 13-AUG-1998.
 XX
 PF 27-JAN-1998; 98WO-US001471.
 XX
 PR 07-FEB-1997; 97US-0037841P.
 PR 18-DEC-1997; 97US-00993731.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Thompson JD;
 XX
 DR WPI; 1998-447252/38.
 XX
 XX Determining relative amounts of different nucleic acids by multiplex
 PT competitive polymerase chain reaction - involves tagging target and
 PT control sequences then amplification with generic primer pair
 PT corresponding to tagging sequences, used e.g. to determine response to
 PT drugs.
 XX
 PS Example 1; Page 23; 45pp; English.
 XX
 CC The present invention provides a method for determining the relative
 CC amounts of two or more different nucleic acid molecules by using the
 CC multiplex competitive PCR reaction (MC-PCR). A MC-PCR reaction involves a
 CC reverse-transcriptase (RT-PCR) reaction followed by a tagging reaction
 CC and a competitive amplification reaction. The RT-PCR reaction uses a
 CC primer #2 to convert target mRNA into cDNA. Primer #1 in combination with
 CC primer #2 is then used to convert the region of the resulting cDNA to be
 CC amplified during the MC-PCR reaction into a double-stranded molecule.
 CC Primers #3 and #4, nested relative to primers #1 and #2 respectively, are
 CC used as tagging primers in the tagging reaction. A forward tagging primer
 CC has a defined sequence at its 5' end (+TAG sequence) while a reverse
 CC tagging primer has a different defined sequence at its 3' end (-TAG
 CC sequence). The purpose of the tagging reaction is to introduce the two
 CC defined sequences at the correct ends of the sequence to be amplified.
 CC The competitive amplification reaction involves using a single pair of
 CC generic primers, whose sequences are complementary to the +TAG and -TAG
 CC sequences, to amplify the different products generated from the cDNAs
 CC during the tagging step. This amplification reaction is competitive due
 CC to the use of a single primer pair to amplify the different target RNAs.
 CC Probe #5, complementary to the region of target RNA being amplified, is
 CC used to specifically detect the amplified product. The MC-PCR reaction
 CC can amplify one or more target mRNAs in a sample using the primer set #1-
 CC #5 for each target mRNA. In the example given, primers #1, #2, #3, #4 and
 CC probe #5 are the Stromelysin primers 1, 2 (AAV33108), 3a (AAV33109) or 3b
 CC (AAV33110), 4 (AAV33111) and probe 5 (AAV33112) respectively. These
 CC primers/probes were used to illustrate the method of the invention. The

CC method claims to allow detection of low-abundance mRNA in small samples
 CC (e.g. 10 ng is sufficient) with high precision, and uses housekeeping
 CC genes as controls for RNA input and integrity. Also, a large number of
 CC samples may be processed simultaneously, making the process suitable for
 CC high throughput screening, and does not require continuous monitoring
 XX
 SQ Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 624 TGTCTGCTTCATCAACTTGG 641
 ||||| ||||| |||||
 Db 1 TGTCTGCTCATGAATTTGG 18

RESULT 86
 AAZ56071/c
 ID AAZ56071 standard; DNA; 18 BP.
 XX
 AC AAZ56071;
 XX
 DT 23-MAR-2000 (first entry)
 XX
 DE Phospholipase A2 group IV antisense molecule #36.
 XX
 KW Phospholipase A2 group IV; PLA2; antisense compound; inhibit; tumour;
 KW infection; inflammation; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key
 FT misc_feature 1..18
 FT Location/Qualifiers
 FT /*tag= a
 FT /note= "Phosphorothioate internucleoside linkage"
 FT modified_base 1..4
 FT /*tag= b
 FT /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides.
 FT Cytidine residues in the 2'-MOE wing are 5-
 FT methylcytidine"
 FT modified_base 15..18
 FT /*tag= c
 FT /note= "Optionally 2'-methoxyethyl (2'-MOE) nucleotides.
 FT Cytidine residues in the 2'-MOE wing are 5-
 FT methylcytidine"
 XX
 PN US6008344-A.
 XX
 PD 28-DEC-1999.
 XX
 PF 23-FEB-1999; 99US-00255893.
 XX
 PR 23-FEB-1999; 99US-00255893.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Cowsett LM;
 XX
 DR WPI; 2000-086226/07.
 XX
 XX Antisense oligonucleotides inhibit expression of human phospholipase A2
 PT Group IV, useful for diagnosis, treatment and prevention of tumors,
 PT infection and inflammation.
 XX
 PS Claim 11; Col 39; 32pp; English.
 XX
 CC This is an antisense phosphorothioate oligonucleotide, that binds to a
 CC region of human phospholipase A2 (PLA2) group IV. The oligonucleotide is
 CC used in the antisense compound of the invention. Phospholipase A2 group
 CC IV is activated in response to extracellular stimuli including growth
 CC factors, cytokines, and interferons. The invention relates to antisense
 CC compounds which are targeted to the coding region or 5' or 3'


```

XX PF 22-NOV-1995; 95WO-US015516.
XX PF 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI McSwiggan J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX Example 1; Page 165; 307pp; English.
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis.
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX SQ Sequence 18 BP; 6 A; 2 C; 2 G; 0 T; 8 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 1e+02;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
QY 869 AAATCCTTTCTTTTAAAG 886
DB 1 AAUUCUGUUCUUUAAAG 18
RESULT 82
AAAG63389
ID AAAG63389 standard; RNA; 18 BP.
XX AC AAAG63389;
XX DT 20-JUL-1999 (first entry)
XX DE Human stromelysin hammerhead target SEQ ID NO:21.
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;

```

```

KW diagnosis; ss.
XX OS Homo sapiens.
XX PN WO9618736-A2.
XX PD 20-JUN-1996.
XX PF 22-NOV-1995; 95WO-US015516.
PR 13-DEC-1994; 94US-00354920.
PR 23-DEC-1994; 94US-00363253.
PR 23-DEC-1994; 94US-00363254.
PR 17-FEB-1995; 95US-00390850.
PR 20-APR-1995; 95US-00426124.
PR 02-MAY-1995; 95US-00432874.
PR 04-MAY-1995; 95US-00434509.
PR 07-JUL-1995; 95US-0000951P.
PR 07-JUL-1995; 95US-0000974P.
PR 07-AUG-1995; 95US-00512861.
PR 05-OCT-1995; 95US-00541365.
XX (RIBO-) RIBOZYME PHARM INC.
XX PA Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
PI McSwiggan J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
PI Karpeisky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
PT the treatment of arthritis, induction of graft tolerance or treatment of
PT auto-immune diseases.
XX Example 1; Page 139; 307pp; English.
XX CC The present invention describes a novel enzymatic nucleic acid (ENA)
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
CC can inhibit collagenase and stromelysin production in the synovial
CC membrane of joints for the treatment or prevention of arthritis.
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
CC be used to treat antigen presenting cells of a donor to induce tolerance
CC in a recipient to an alloantigen of a donor. They can also be used for
CC enhancing graft tolerance or for treating autoimmune disease, and for
CC treating allergies and other inflammatory conditions. The ENA's can also
CC be used in diagnosis. Ribozyme therapy impacts on the expression of
CC stromelysin without introducing the non-specific effects upon gene
CC expression which accompany treatment with retinoids and dexamethasone.
CC The concentration of ribozyme required to affect a therapeutic treatment
CC is lower than that required of antisense molecules, and is highly
CC specific. The present sequence is used in the exemplification of the
CC present invention
XX SQ Sequence 18 BP; 7 A; 3 C; 2 G; 0 T; 6 U; 0 Other;
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 870 AATCCTTTTCTTTTAAAGA 887
DB 1 AAUCCUGAUCUUUAAAGA 18
RESULT 83
AAAG64436
ID AAAG64436 standard; RNA; 18 BP.
XX AC AAAG64436;
XX DT 20-JUL-1999 (first entry)

```

```
Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 87;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 629 TTCATGAACCTGGCC 643
DB. 1 UUCAUGAACUTGGCC 15

RESULT 79
AAQ57225
ID AAQ57225 standard; mRNA; 18 BP.
XX AC AAQ57225;
XX DT 25-MAR-2003 (revised)
XX DT 26-JUL-1994 (first entry)
XX DE Enzymatic RNA molecule stromelysin mRNA target sequence.
XX KW Specific; cleavage; target RNA; protein; prophylaxis; expression;
XX KW inhibitor; inhibition; ribozyme; treatment; prevention; psoriasis;
XX KW asthma; inflammatory diseases; restenosis; cardiovascular condition;
XX KW hypertension; arthritis; ss.
XX OS Synthetic.
XX PN WO9402595-A1.
XX PD 03-FEB-1994.
XX PF 02-JUL-1993; 93WO-US006316.
XX PR 17-JUL-1992; 92US-00916763.
XX PR 07-DEC-1992; 92US-00987132.
XX PR 07-DEC-1992; 92US-00989848.
XX PR 07-DEC-1992; 92US-00989849.
XX PR 19-JAN-1993; 93US-00008895.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Sullivan SM, Draper KG;
XX WPI; 1994-048853/06.
XX PT Enzymatic RNA molecules which cleave mRNA - used to treat or prevent
XX PT inflammatory, arthritic, stenotic or cardiovascular diseases or
XX PT conditions.
XX PS Claim 3; Page 18; 65pp; English.
XX CC This is a stromelysin mRNA target sequence (nucleotide no. 958) of an
XX CC enzymatic RNA molecule (ribozyme) which cleaves mRNA associated with the
XX CC development or maintenance of osteoarthritis or other pathological
XX CC conditions which are mediated by metalloproteinase activation. The concn.
XX CC of the ribozyme necessary to effect a therapeutic treatment is lower than
XX CC that of an antisense oligonucleotide and the specificity of action is
XX CC higher. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 18 BP; 7 A; 3 C; 2 G; 6 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTAAAGA 887
DB 1 AATCCTGAUCTTTAAAGA 18

RESULT 80
AAQ93482
ID AAQ93482 standard; RNA; 18 BP.

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTAAAGA 887
DB 1 AAUCCUGAUCUUUAAAGA 18

RESULT 81
AAQ64488
ID AAQ64488 standard; RNA; 18 BP.
XX AC AAQ64488;
XX DT 20-JUL-1999 (first entry)
XX DE Rabbit stromelysin hairpin target sequence SEQ ID NO:1120.
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;
XX KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
XX KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
XX KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX KW diagnosis; ss.
XX OS Oryctolagus cuniculus.
XX PN WO9618736-A2.
XX PD 20-JUN-1996.
```

```
XX AAQ93482;
XX AC 25-MAR-2003 (revised)
XX DT 06-DEC-1995 (first entry)
XX DE Hammerhead ribozyme target sequence #21.
XX KW Hammerhead ribozyme motif; arthritis; cancer; angiogenesis; hairpin;
XX KW hepatitis delta virus; group 1 intron; RNase P RNA; stromelysin; ss.
XX OS Synthetic.
XX PN WO9513380-A2.
XX PD 18-MAY-1995.
XX PF 10-NOV-1994; 94WO-US013129.
XX PR 12-NOV-1993; 93US-00152487.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Draper KG, Pavco P, Mcswiggen J, Gustofson J;
XX WPI; 1995-194099/25.
XX PT New enzymatic RNA molecules - which cleave mRNA of a gene encoding a
XX PT matrix metalloproteinase, for treating arthritis, cancer or angiogenesis.
XX PS Disclosure; Page 18; 70pp; English.
XX CC The sequences AAQ93462-Q93494 are examples of target cleavage sequences
XX CC for a hammerhead ribozyme with sequence motif AAQ90453. A ribozyme, pref.
XX CC hammerhead, hairpin, hepatitis delta virus, group 1 intron or RNase P RNA
XX CC motif can be used in a composition for the treatment of arthritis, cancer
XX CC or angiogenesis. The ribozyme comprises between 5-45 bases complementary
XX CC to the target mRNA. The ribozymes (see AAQ93830-51 for examples) were
XX CC synthesised based on putative stromelysin mRNA target cleavage sequences
XX CC (AAQ93496-Q93829). (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 18 BP; 7 A; 3 C; 2 G; 0 T; 6 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 1e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTAAAGA 887
DB 1 AAUCCUGAUCUUUAAAGA 18

RESULT 81
AAQ64488
ID AAQ64488 standard; RNA; 18 BP.
XX AC AAQ64488;
XX DT 20-JUL-1999 (first entry)
XX DE Rabbit stromelysin hairpin target sequence SEQ ID NO:1120.
XX KW Arthritic condition; graft tolerance; immune response; target; cleavage;
XX KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
XX KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
XX KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX KW diagnosis; ss.
XX OS Oryctolagus cuniculus.
XX PN WO9618736-A2.
XX PD 20-JUN-1996.
```

RESULT 77
ABK03571
ID ABK03571 standard; RNA; 17 BP.
XX
AC ABK03571;
XX
DT 12-MAR-2002 (first entry)
DE
DE Human CD20 DNazyme #25.
XX
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
PD 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
PR 28-FEB-2000; 2000US-0185516P.
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
PI WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
PT constructs, which down regulate expression of a CD20 gene or neurite
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
PT central nervous system injury.
XX
PS Claim 30; Page 159; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NVN motif) or
CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targeting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the

CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a DNazyme molecule of the invention

XX Sequence 17 BP; 8 A; 3 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 87;

Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 162 AGAAAACTCCAGGA 176

DB 3 AGAAAAACUCCAGGA 17

RESULT 78

ADI83540
ID ADI83540 standard; RNA; 17 BP.

XX

AC ADI83540;

XX

DT 03-JUN-2004 (first entry)

XX HCV DNazyme substrate sequence #786.

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;

XX HCV infection; type I interferon; DNazyme.

XX Hepatitis C virus.

XX US2003125270-A1.

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX 18-DEC-2000; 2000US-00740332.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J.

XX (ROBE/) ROBERTS E.

XX (PAVC/) PAVCO P A.

XX (MACE/) MACEJACK D.

XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from Hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.

PS Claim 1; SEQ ID NO 786; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.

XX Sequence 17 BP; 4 A; 5 C; 3 G; 1 T; 4 U; 0 Other;

PT pancreatic cancer.
 PS Claim 13; Page 56; 120pp; English.
 XX
 CC AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a
 CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 71;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 631 CATGAACCTGGCCAT 645
 DB 1 CATGAACCTGGCCAT 15
 RESULT 75
 ABK32457
 ID ABK32457 standard; DNA; 15 BP.
 XX
 AC ABK32457;
 XX
 DT 23-APR-2002 (first entry)
 XX
 DE Human pancreatic cancer SAGE tag #9.
 XX
 KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
 KW serial analysis of gene expression; diagnostic; prognostic; probe;
 KW cancer marker; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6333152-B1.
 XX
 PD 25-DEC-2001.
 XX
 PF 20-MAY-1998; 98US-00081646.
 XX
 PR 20-MAY-1998; 98US-00081646.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;
 XX
 DR WPI; 2002-153921/20.
 XX
 PT New human nucleic acid containing specific SAGE tags, useful as
 PT diagnostic markers for cancer, also derived probes.
 XX
 PS Disclosure; Col 62; 161pp; English.
 XX
 CC The invention relates to an isolated, purified human nucleic acid (I)
 CC that has the same sequence as a mRNA found in humans and is a SAGE
 CC (serial analysis of gene expression) tag comprising a single stranded
 CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 71;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 631 CATGAACCTGGCCAT 645
 DB 1 CATGAACCTGGCCAT 15
 RESULT 76
 ADQ81798/c
 ID ADQ81798 standard; DNA; 15 BP.
 XX
 AC ADQ81798;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE Oligonucleotide synthesis method polynucleotide #2.
 XX
 KW ss; primer; DNA synthesis; nucleotide chemistry.
 XX
 OS Synthetic.
 XX
 PN WO2004058794-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 31-DEC-2002; 2002WO-EP014905.
 XX
 PR 31-DEC-2002; 2002WO-EP014905.
 XX
 PA (PROL-) PROLIGO LLC.
 XX
 PI Arar K;
 XX
 DR WPI; 2004-553145/53.
 XX
 PT Synthesis of oligonucleotides in nucleotide chemistry involves providing
 PT solid support of anchor group protected by orthogonal protective group,
 PT removing the protective group, synthesizing an oligonucleotide followed
 PT by capping and cleaving.
 XX
 PS Example 9; SEQ ID NO 13; 77pp; English.
 XX
 CC The present invention relates to a method for the synthesis of at least
 CC two different oligonucleotides, which involves providing a solid support
 CC comprising anchor groups that are protected by at least two orthogonal
 CC protective groups, removing one of the protective groups from the anchor
 CC groups, synthesizing an oligonucleotide on the deprotected anchor groups,
 CC capping the synthesized oligonucleotide, repeating these steps until all
 CC of anchor groups are deprotected, and cleaving the synthesized
 CC oligonucleotides. The method can be used for the synthesis of at least
 CC two different oligonucleotides, in the field of nucleotide chemistry, in
 CC applying the required pairs of oligonucleotide primers, several probes at
 CC a time, duplexed nuclei acid fragments (including PCR, sequencing,
 CC multiplexed genotyping, cloning and RNA interference), for applying to
 CC any known methods for the solid phase synthesis of oligonucleotides
 CC (including phosphoramidite chemistry, H-phosphonate chemistry,
 CC phosphotriester chemistry, or any other synthetic chemistry used to
 CC prepare oligonucleotides on solid supports). The present sequence is a
 CC polynucleotide used to demonstrate the method of the invention.
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 15 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 71;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1749 AAAAAAAAAAAAAA 1763
 DB 15 AAAAAAAAAAAAAA 1

XX The invention relates to a DNA (I) encoding a protein (II) having
 CC juvenile-hormone acid transmethylease activity selected from the DNA from
 CC silkworm (*Bombyx mori*), *Drosophila melanogaster*, mosquito (*Anopheles*
 CC *gambiae*), *Spodoptera litura* and *Helicoverpa armigera*, their encoded
 CC proteins (S2), DNAs (D2) that hybridize under stringent conditions with
 CC the nucleic acids or an amino acid sequence (S3) comprising any one of
 CC (S2) in which one or more amino acids are substituted, deleted, inserted
 CC and/or added. (I) is useful for screening a compound that controls the
 CC expression level of (I), and as a controlling agent of molting and
 CC transformation, reproductive, diapause, blastogenesis, action,
 CC polymorphism or lifetime of arthropod. (II) is useful for screening a
 CC compound having binding affinity with respect to (II), which involves
 CC contacting test compound with (II), detecting the binding of (II) with
 CC test compound, and selecting the compound that binds with (II). (II) is
 CC useful for screening a compound that controls the activity of (II), which
 CC involves contacting test compound with (II), measuring the activity of
 CC (II), and selecting the compound that decreases or increases the activity
 CC of (II), based on comparison of the activity of (II) in absence of test
 CC compound. (II) is useful for manufacturing activated juvenile hormone.
 CC This sequence corresponds to a PCR primer used to amplify and isolate the
 CC transmethylease cDNA from the silkworm *Bombyx mori*.
 XX
 SQ Sequence 17 BP; 0 A; 1 C; 1 G; 15 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 77;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1748 GAAAAAAAAAAAAAAAAA 1764
 DB 17 GAAAAAAAAAAAAAAAAA 1

RESULT 73
 ACNT73530/c
 ID ACNT73530 standard; DNA; 17 BP.
 XX
 AC ACNT73530;
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:10432.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024283.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX

PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX WPI; 2004-533378/51.
 DR
 XX Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 10432; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 77;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 837 GAGTTTGTGATGCTGCTCA 853
 DB 17 GACTTTTGTGATGCTGCTCA 1
 RESULT 74
 AAX31503
 ID AAX31503 standard; DNA; 15 BP.
 XX
 AC AAX31503;
 XX
 DT 21-MAY-1999 (first entry)
 XX
 DE Tag sequence of a transcript increased in pancreatic cancer.
 XX
 KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KW diagnosis; prognosis; treatment; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9853319-A2.
 XX
 PD 26-NOV-1998.
 XX
 PF 20-MAY-1998; 98WO-US010277.
 XX
 PR 21-MAY-1997; 97US-0047352P.
 XX
 PA (UJJO) UNIV JOHNS HOPKINS.
 XX
 PI Vogelstein B, Kinzler KW;
 DR WPI; 1999-070161/06.
 XX
 PT Use of isolated gene transcripts - useful for developing products for the
 PT diagnosis, prognosis and treatment of cancers, particularly colon and

XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 5198; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Ambzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
XX Sequence 17 BP; 2 A; 2 C; 4 G; 0 T; 9 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 77;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
QY 8 TTCTCATGATGATGTG 24
DB 1 UUCUCUGAUGAUGUG 17

RESULT 71
AB222228
ID AB222228 standard; DNA; 17 BP.
XX
AC AB222228;
XX
DT 18-MAR-2003 (first entry)
XX
DE Transposon insertion site related oligonucleotide #4.
XX
KW Mouse; chromosome; transposon; transposon insertion site; adenovirus;
KW helper-dependent adenoviral vector; restriction endonuclease site;
KW stuffer region; packaging sequence; cytotatic; gene therapy;
KW genetic defect-based disease; cancer; ss.
XX
OS Synthetic.
XX
XX WO200292786-A2.
XX
XX 21-NOV-2002.
XX
XX 25-MAR-2002; 2002WO-US0009125.
XX
XX 26-MAR-2001; 2001US-0278972P.
XX
XX 16-APR-2001; 2001US-0284335P.
XX
XX (STRD) UNIV LELAND STANFORD JUNIOR.
XX
XX Ehrhardt A, Kay M;
XX
XX WPI; 2003-129286/12.
XX
XX New helper-dependent adenoviral vector for integrating endogenous or
XX exogenous nucleic acids into a target cell, comprises a restriction
XX endonuclease site, stuffer region and packaging sequence flanked by
XX adenoviral ITR sequences.
XX
XX Disclosure; Fig 18; 58pp; English.
XX
XX The present invention describes a helper-dependent adenoviral vector (I)

CC comprising at least one restriction endonuclease site, a stuffer region
CC and a packaging sequence, that are flanked by adenoviral ITR sequences.
CC Also described: (1) an adenoviral helper vector comprising an adenoviral
CC vector coding sequence or its portion positioned in a first region
CC between first and second recombinase recognition sites that recombine
CC with each other, and at least one endonuclease recognition site not found
CC in mammalian genomic sequences and that is located in a region that is
CC other than the first region; (2) a mammalian cell or a collection of
CC mammalian cells that stably expresses a recombinase, an adenoviral
CC preterminal protein, and an adenoviral polymerase; and (3) a system for
CC use in producing an adenoviral vector, comprising the helper-dependent
CC adenoviral vector, the adenoviral helper vector, and the mammalian cell.
CC (I) has cytostatic activity and can be used in gene therapy. The helper-
CC dependent adenoviral vector and/or the adenoviral helper vector are
CC useful in integrating a wide variety of endogenous and/or exogenous
CC nucleic acids into a target cell. The vectors and methods from the
CC present invention may also be used in research applications, in synthesis
CC of polypeptides, and in therapeutic applications (e.g. in treating
CC genetic defect-based disease conditions or cancers). The present sequence
CC represents a transposon insertion site related oligonucleotide which is
CC used in the exemplification of the present invention
XX
XX Sequence 17 BP; 3 A; 4 C; 1 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1576 TTTTTCATTCATTCTA 1592
DB 1 TTTTTCATTCATTCTA 17

RESULT 72
ADR05333/c
ID ADR05333 standard; DNA; 17 BP.
XX
AC ADR05333;
XX
DT 21-OCT-2004 (first entry)
XX
DE Silkworm juvenile hormone acid transmethylease cDNA PCR primer Fp1.
XX
KW ss; primer; insect repellent; insect attractant;
KW reproductive maturation regulator; imago; diapause inducer;
KW diapause inhibitor; larva; transformation regulator; pupa;
KW juvenile hormone acid transmethylease; silkworm; Bombyx mori;
KW Drosophila melanogaster; mosquito; Anopheles gambia; Spodoptera litura;
KW Helicoverpa armigera; molting; transformation; diapause; blastogenesis;
KW polymorphism; arthropod; cotton bollworm; PCR primer.
XX
OS Bombyx mori.
XX
XX WO2004065604-A1.
XX
XX 05-AUG-2004.
XX
XX 20-JAN-2003; 2003WO-JP000415.
XX
XX 20-JAN-2003; 2003WO-JP000415.
XX
XX (NAG-) NAT AGRIC RES ORG JAPAN.
XX
XX Shinoda T, Itoyama K, Hamamura T;
XX
XX WPI; 2004-580727/56.
XX
XX New DNA encoding protein having juvenile-hormone acid transmethylease
XX activity, useful for screening for a compound controlling the expression
XX level of juvenile-hormone acid transmethylease DNA.
XX
XX Example 1; SEQ ID NO 11; 118pp; Japanese.
PS

CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 8 A; 3 C; 4 G; 0 T; 2 U; 0 Other;
 Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 77;
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 163 GAAAAACTCCAGGAAT 179
 DB 1 GAAAAACUCCAGGAAGU 17
 RESULT 69
 ABN10440/c
 ID ABN10440 standard; DNA; 17 BP.
 AC ABN10440;
 XX
 XX 29-MAY-2002 (first entry)
 DT
 DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10432.
 KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200192524-A2.
 FN
 XX
 PD 06-DEC-2001.
 XX
 XX 25-MAY-2001; 2001WO-US016981.
 XX
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024283.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0265860P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI
 XX WPI; 2002-179446/23.
 DR
 XX

PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
 XX
 PS Disclosure; SEQ ID NO 10432; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
 CC nucleic acids can be used as probes to detect, characterise and quantify
 CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMLP
 CC -1 proteins, as standards in assays used to determine the concentration
 CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
 CC capture probes for surface-enhanced laser desorption ionisation, as
 CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
 CC production, and in vaccines or for replacement therapy. The
 CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
 CC disorder associated with the expression of hGDMLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence
 XX
 SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 77;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 837 GAGTTTGTGCTGCTCA 853
 DB 17 GACTTTGTGCTGCTCA 1
 RESULT 70
 ACN05195
 ID ACN05195 standard; RNA; 17 BP.
 XX
 AC ACN05195;
 XX
 XX 22-APR-2004 (first entry)
 DT
 XX
 DE WNV DNazyme substrate SEQ ID NO 5198.
 XX
 KW WNV; West Nile Virus; antinflammatory; cytostatic; hepatotropic;
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
 KW Amberyne; Zinzyme; ss.
 XX
 OS West Nile Virus.
 XX
 XX WO200268637-A2.
 PN
 XX
 PD 06-SEP-2002.
 XX
 XX 19-OCT-2001; 2001WO-US048350.
 PF
 XX 20-OCT-2000; 2000US-0242411P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J A.
 XX
 PI Blatt L, Mcswiggen JA;
 XX
 XX WPI; 2002-706994/76.
 DR

human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004273.
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
XX Claim 30; Page 147; 200pp; English.
XX The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is an inozyme of the invention
XX Sequence 17 BP; 8 A; 3 C; 4 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Fred. No. 77;

Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 164 AAAAATCTCCAGGAATG 180
DB 1 AAAAACUCCGGAAGUG 17
RESULT 68
ABK02767
ID ABK02767 standard; RNA; 17 BP.
XX AC ABK02767;
XX 12-MAR-2002 (first entry)
XX Human CD20 Hammerhead ribozyme #66.
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic; cerebroprotective; nootropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNzyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US004273.
XX 11-FEB-2000; 2000US-0181797P.
XX 28-FEB-2000; 2000US-0185516P.
XX 06-MAR-2000; 2000US-0187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX Blatt L, Mcswiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.
XX Claim 30; Page 141; 200pp; English.
XX The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-

```

XX PI Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX Example 5; SEQ ID NO 3338; 378pp; English.
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological diseases (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
XX can be used to control ApoB gene expression.
XX Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1727 TTTAAATTAATTCAGAGAA 1745
DB 1 TTTAAATGTTGAAGAAA 19
RESULT 66
AAK63863
ID AAK63863 standard; RNA; 17 BP.
XX AAK63863;
XX 20-JUL-1999 (first entry)
XX Rabbit stromelysin hammerhead target SEQ ID NO:495.
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
XX hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
XX stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
XX rheumatoid arthritis; autoimmune disease; allergy; inflammation;
XX diagnosis; ss.
XX Oryctolagus cuniculus.
XX OS
XX WO9618736-A2.
XX PN
XX 20-JUN-1996.
XX PD
XX

```

```

PF 22-NOV-1995; 95WO-US015516.
XX 13-DEC-1994; 94US-00354920.
XX 23-DEC-1994; 94US-00363253.
XX 23-DEC-1994; 94US-00363254.
XX 17-FEB-1995; 95US-00390850.
XX 20-APR-1995; 95US-00426124.
XX 02-MAY-1995; 95US-00432874.
XX 04-MAY-1995; 95US-00434509.
XX 07-JUL-1995; 95US-0000951P.
XX 07-JUL-1995; 95US-0000974P.
XX 07-AUG-1995; 95US-00512861.
XX 05-OCT-1995; 95US-00541365.
XX (RIBO-) RIBOZYME PHARM INC.
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
XX Mcswiggen J, Gustofson J, Uman N, Wincott F, Matulic-Adamic J;
XX Karpelsky A, Thompson JD, Modak A, Burgin A;
XX WPI; 1996-300653/30.
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
XX the treatment of arthritis, induction of graft tolerance or treatment of
XX auto-immune diseases.
XX Example 1; Page 154; 307pp; English.
XX The present invention describes a novel enzymatic nucleic acid (ENA)
XX having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
XX ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
XX ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
XX can inhibit collagenase and stromelysin production in the synovial
XX membrane of joints for the treatment or prevention of arthritis,
XX particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
XX be used to treat antigen presenting cells of a donor to induce tolerance
XX in a recipient to an alloantigen of a donor. They can also be used for
XX enhancing graft tolerance or for treating autoimmune disease, and for
XX treating allergies and other inflammatory conditions. The ENA's can also
XX be used in diagnosis. Ribozyme therapy impacts on the expression of
XX stromelysin without introducing the non-specific effects upon gene
XX expression which accompany treatment with retinoids and dexamethasone.
XX The concentration of ribozyme required to affect a therapeutic treatment
XX is lower than that required of antisense molecules, and is highly
XX specific. The present sequence is used in the exemplification of the
XX present invention
XX Sequence 17 BP; 1 A; 5 C; 3 G; 0 T; 8 U; 0 Other;
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 77;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;
QY 616 TTCCTTGTGTGCTGTCA 632
DB 1 UUCCTUGUGUCGUCUCA 17
RESULT 67
ABK03147
ID ABK03147 standard; RNA; 17 BP.
XX ABK03147;
XX 12-MAR-2002 (first entry)
XX Human CD20 Inozyme #98.
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOSO; hammerhead ribozyme;
XX DNzyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;

```

QY 175 GAAATGCAGCAGCTTCTTG 193
 Db 19 GAAATGCAGCAGCTTCTTG 1

RESULT 64
 ID ADR76235 standard; DNA; 19 BP.
 AC ADR76235;
 XX 16-DEC-2004 (first entry)
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 720.
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 OS Homo sapiens.
 XX WO2004080406-A2.
 PN 23-SEP-2004.
 PD 08-MAR-2004; 2004WO-US007070.
 PF 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-046565P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 25-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 11-AUG-2003; 2003US-0493986P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 PA (ALNY-) ALNYLAM PHARM.
 XX Manoharan M, Bumcrot D;
 PI WPI; 2004-677362/66.
 DR Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 720; 378pp; English.
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is

CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apoB-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human apolipoprotein B (ApoB) antisense oligonucleotide that can be used to control ApoB gene expression.

SQ Sequence 19 BP; 9 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1727 TTTAAATTAATTCGAAGAAA 1745
 Db 1 TTTAAATTAATTCGAAGAAA 19

RESULT 65
 ADR78853
 ID ADR78853 standard; DNA; 19 BP.
 XX ADR78853;
 AC 16-DEC-2004 (first entry)
 DT Human apolipoprotein B (ApoB) oligonucleotide seqid 3338.
 DE antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX Homo sapiens.
 OS WO2004080406-A2.
 XX 23-SEP-2004.
 PD 08-MAR-2004; 2004WO-US007070.
 PF 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-046565P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 25-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 11-AUG-2003; 2003US-0493986P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 PA (ALNY-) ALNYLAM PHARM.
 XX Manoharan M, Bumcrot D;
 PI WPI; 2004-677362/66.
 DR Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 720; 378pp; English.
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is

CC The invention relates to an isolated and purified protein of the
 CC hepatitis C virus (HCV) that is formed by expression of an overlapping
 CC open reading frame in the core protein gene sequence through an RNA frame
 CC shifting mechanism. The protein is termed p17 (the full length, unshifted
 CC protein being p21c). Also included are a vaccine (including a DNA
 CC vaccine) for immunising a mammal against hepatitis C (producing a
 CC protective antibody) comprising at least 1 protein of p17 (or a nucleic
 CC acid encoding p17), an anti-viral composition (used to treat hepatitis C)
 CC comprising a compound that binds to p17, antibodies directed against an
 CC HCV core protein which are elicited by immunising an animal using the
 CC partially purified protein p17, a method for analysing an HCV antigen in
 CC a sample using the anti-p17 antibodies and detection of anti-HCV
 CC antibodies in a sample using the p17 proteins. The HCV p17 and the DNA
 CC sequences that encode it may be used as vaccines for immunising patients
 CC against HCV infection. The antibodies and the antiviral compound may also
 CC be used for treating HCV infections. HCV p17 and the antibodies may also
 CC be used in immunoassays for detecting HCV antigens and/or antibodies in
 CC samples for the diagnosis of HCV infections. The present sequence
 CC represents part of the an HCV core protein DNA from the frameshift region
 XX
 SQ Sequence 19 BP; 15 A; 2 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 134 AAACAACCAACCAATAGAAA 152
 |||||
 Db 1 AAAGAACAACCAAGAAA 19

RESULT 62
 ADI53700/c
 ID ADI53700 standard; DNA; 19 BP.
 XX
 AC ADI53700;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human MMP-12 antisense oligonucleotide, SEQ ID 13.
 XX
 KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.

XX WO2004009098-A1.
 XX
 XX 29-JAN-2004.
 XX
 XX 17-JUL-2003; 2003WO-SE001223.
 XX
 XX 18-JUL-2002; 2002SE-00002253.
 XX
 XX 04-SEP-2002; 2002US-0407680P.
 XX
 XX (INDE-) INDEX PHARM AB.

XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;
 XX WPI; 2004-123288/12.
 XX
 XX New compound having a sequence targeted to a nucleic acid encoding
 XX metalloproteinase 12 (MMP-12), useful for preparing a composition for
 XX treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 XX asthma or psoriasis.

XX Claim 7; SEQ ID NO 13; 55pp; English.
 XX
 XX The present invention relates to antisense oligonucleotides (ADI53690-
 CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and

CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.

XX SQ Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 880 TTTAAAGACTGGTCTCTCT 898
 |||||
 Db 19 TTCAAGACAGGTTCTCTCT 1

RESULT 63
 ADI53698/c
 ID ADI53698 standard; DNA; 19 BP.
 XX
 AC ADI53698;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Human MMP-12 antisense oligonucleotide, SEQ ID 11.
 XX
 KW Antiinflammatory; Antipsoriatic; Antiasthmatic; Antiarthritic;
 KW Respiratory; antisense oligonucleotide; matrix metalloproteinase 12;
 KW MMP-12; inflammatory bowel disease; ulcerative colitis; Crohn's disease;
 KW rheumatoid arthritis; psoriasis; emphysema; asthma; human; ss.

XX Homo sapiens.
 XX Synthetic.

XX WO2004009098-A1.

XX 29-JAN-2004.

XX 17-JUL-2003; 2003WO-SE001223.

XX 18-JUL-2002; 2002SE-00002253.

XX 04-SEP-2002; 2002US-0407680P.

XX (INDE-) INDEX PHARM AB.

XX Dieckmann A, Loeffberg R, Von Stein O, Von Stein P, Good L;

XX WPI; 2004-123288/12.

XX New compound having a sequence targeted to a nucleic acid encoding
 XX metalloproteinase 12 (MMP-12), useful for preparing a composition for
 XX treating or preventing MMP-12 dependent disorder in a human patient e.g.,
 XX asthma or psoriasis.

XX Claim 7; SEQ ID NO 11; 55pp; English.

XX The present invention relates to antisense oligonucleotides (ADI53690-
 CC ADI53701) for matrix metalloproteinase 12 (MMP-12; ADI53688 and
 CC ADI53689), which specifically hybridise with the nucleic acid encoding
 CC MMP-12 and inhibiting the translation of MMP-12 protein. The antisense
 CC oligonucleotides are useful for preparing a composition for treating or
 CC preventing MMP-12 dependent disorder in a human patient e.g. inflammatory
 CC bowel disease, such as ulcerative colitis and Crohn's disease, rheumatoid
 CC arthritis, psoriasis, emphysema or asthma.

XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 81;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX
XX Example 1; Page 366; 408pp; English.
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antipapillary,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, anticaking,
CC ophthalmological, vulnary, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, seborrheic wart. They can
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 19 BP; 6 A; 1 C; 2 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1717 TTTTGTCTTCTTAATAA 1735
DB 1 TATTGTTTCTGTAATAA 19
RESULT 61
ACA62442
ID ACA62442 standard; DNA; 19 BP.
XX
XX ACA62442;
XX
XX 14-AUG-2003 (first entry)
XX
XX HCV core protein frameshift region DNA #4.
XX
XX HCV; hepatitis C infection; RNA frameshift; core protein; p17; virucide;
KW hepatotropic; overlapping open reading frame; p21c; vaccine; ds.
XX
XX Hepatitis C virus.
XX
XX US2002076415-A1.
XX
XX 20-JUN-2002.
XX
XX 14-DEC-2000; 2000US-00736959.
XX
XX 14-DEC-1999; 99US-0170835P.
XX
XX (OUJ/) OU J.
XX (XUZZ/) XU Z.
XX
XX Ou J, Xu Z;
XX
XX WPI; 2003-479366/45.
XX
XX Isolated hepatitis C virus (HCV) proteins formed by expression of
PT overlapping open reading frames in the core protein gene sequence through
PT a frame shifting mechanism, useful for vaccinating against, and detecting
PT HCV infections.
XX
XX Example 5; Fig 6B; 37pp; English.
XX

PR 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
XX
XX Disclosure; Page 108; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
CC Representative examples of ribozyme recognition sites are given in
CC AAH62415 to AAH6787. The ribozyme of the invention is useful for
CC inhibiting restenosis by introduction of the ribozyme into cells. The
CC ribozyme is resistant to endonuclease activity and hence is efficient in
CC restenosis treatment
XX
XX Sequence 19 BP; 6 A; 1 C; 2 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 81;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1717 TTTTGTCTTCTTAATAA 1735
DB 1 TATTGTTTCTGTAATAA 19
RESULT 60
AAH61620
ID AAH61620 standard; DNA; 19 BP.
XX
XX AAH61620;
XX
XX 10-SEP-2001 (first entry)
XX
XX PCNA HH ribozyme binding site SEQ ID NO:4044.
XX
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnary;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
KW antipapillary; dermatological; antiseborrheic; antidiabetic; virucide;
KW anticaking; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX WO200130362-A2.
XX
XX 03-MAY-2001.
XX
XX 26-OCT-2000; 2000WO-US029500.
XX
XX 26-OCT-1999; 99US-0161532P.
XX
XX (IMMU-) IMMUSOL INC.
XX
XX Robbins JM, Tritz R;
XX
XX WPI; 2001-300427/31.
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
XX

PI Cooper DN, Procter AM, Gregory J, Millar DS, Lewis M, Ulied A;
 DR WPI; 2003-449559/42.
 XX
 PT New polynucleotide comprising a variant of the human growth hormone
 PT nucleic acid sequence, GH1, useful for diagnosing or treating obesity,
 PT diabetes, infection, cancer or cardiac conditions.
 XX
 PS Example 3; Page 33; 62pp; English.
 XX
 CC The present sequence is that of primer GH2DF, which is one of a set of
 CC primers (see ACC58404-17) used for the denaturing high-pressure liquid
 CC chromatography (DHPLC) analysis and DNA sequencing of human growth
 CC hormone GH1 genes from a cohort of short stature patients. The primer
 CC corresponds to nucleotides -59 to -40 of the GH1 gene (see ACC58424).
 CC Novel GH1 gene mutations and polymorphisms were identified. The invention
 CC provides methods for detecting these variants of the GH1 gene, for
 CC screening patients for growth hormone irregularities, and for producing
 CC variant proteins for use in therapeutic, diagnostic or detection methods,
 CC e.g. for determination of susceptibility of an individual to diabetes,
 CC obesity, infection, cancer or a cardiac condition, and in gene therapy
 XX
 SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 83;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 854 CAACAGTGGGAGAGAA 869
 DB |||||
 4 CAACAGTGGGAGAGAA 19
 RESULT 58
 ADP19711
 ID ADP19711 standard; DNA; 20 BP.
 AC ADP19711;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human GH1 gene PCR primer GH2DF.
 XX
 KW human; growth hormone; growth hormone variant; GH; GH1;
 KW receptor-mediated cell signaling pathway activator;
 KW growth hormone dysfunction; growth hormone irregularity; chromosome 17;
 KW PCR; primer; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004044002-A1.
 XX
 PD 27-MAY-2004.
 XX
 PF 04-NOV-2003; 2003WO-GB004775.
 XX
 PR 12-NOV-2002; 2002GB-00026441.
 PR 12-NOV-2002; 2002WO-GB005112.
 PR 10-APR-2003; 2003GB-00008242.
 XX
 XX (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
 XX
 PI Cooper DN, Procter AM, Gregory J, Millar DS, Lewis M, Ulied A;
 XX
 DR WPI; 2004-411699/38.
 XX
 PT Isolated variant of human growth hormone nucleic acid molecule, GH1
 PT useful for diagnosing growth hormone dysfunction or development of
 PT suitable therapies, comprises altered nitrogenous bases.
 XX
 PS Example 3; Page 28; 66pp; English.
 XX

CC The present invention describes an isolated variant of a human growth
 CC hormone (GH) nucleic acid molecule (I), GH1, comprising the substitution:
 CC +1491 cytosine substituted by guanine, wherein 1491 refers to the
 CC position of the nucleotide with respect to this transcription initiation
 CC site which is designated 1 or comprises a nucleic acid molecule that
 CC encodes a protein, i.e. a GH protein, including the substitution
 CC Ile179Met. Also described: (1) a transcript of (I); (2) an isolated
 CC polypeptide encoded by (I); (3) an isolated polypeptide which is a
 CC variant of the growth hormone protein, GH, and which includes the
 CC substitution Ile179Met; (4) screening (M1) an individual suspected of
 CC having dysfunctional GH, involving: (a) obtaining a test sample
 CC comprising a nucleic acid molecule of human GH1 gene from an individual,
 CC sequencing the molecule, examining the sequence for a+1491 cytosine
 CC substituted by guanine, and where the substitution exists concluding
 CC there is GH dysfunction; (b) obtaining a test sample comprising a growth
 CC hormone, GH, polypeptide from the individual, sequencing the polypeptide,
 CC examining the sequence for a Ile179Met substitution, and where the
 CC substitution exists concluding there is a GH dysfunction; or (c)
 CC obtaining a test sample from the individual comprising the individual's
 CC endogenous growth mitogen-activated protein kinases (MAPK) hormone,
 CC examining the growth hormone to determine whether and to what extent it
 CC will activate the receptor-mediated cell signaling pathway, and where
 CC there is a reduction in MAPK cell signaling, with respect to wild-type
 CC GH, concluding there is a GH dysfunction; (5) a kit suitable for carrying
 CC out M1; (6) an oligonucleotide suitable for use in (M1) and optionally,
 CC provided in the kit; (7) an isolated growth hormone polypeptide or
 CC protein (II), containing an Ile179Met substitution and which further
 CC provides for differential activation of receptor-mediated cell signaling
 CC pathways or possessing a reduced ability to activate the MAP kinase
 CC pathway; (8) an antibody specific for (II); (9) pharmaceutical
 CC composition comprising (I) or (II) with a carrier; (10) vector (III)
 CC comprising (I); (II) host cell (IV) comprising (III); and (12) a
 CC polypeptide or protein produced by using (IV). (I) activates receptor-
 CC mediated cell signaling pathway. (I) and (II) are useful for the
 CC diagnosis of growth hormone dysfunction or the development of suitable
 CC therapies. (I) or (II) is useful as a pharmaceutical composition for
 CC treating growth hormone irregularities. (IV) is useful for preparing
 CC (II), by culturing (IV) and recovering from the culture medium the
 CC polypeptide or protein produced by the cell. The present sequence
 CC represents a PCR primer for human GH1, which is used in an example from
 CC the present invention. Human GH1 is located on chromosome 17q23.
 XX
 SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 83;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 854 CAACAGTGGGAGAGAA 869
 DB |||||
 4 CAACAGTGGGAGAGAA 19
 RESULT 59
 AAA86458
 ID AAA86458 standard; DNA; 19 BP.
 XX
 AC AAA86458;
 XX
 DT 04-DEC-2000 (first entry)
 XX
 DE PCBA HH ribozyme binding site #190.
 XX
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotrophic; restenosis; ss.
 XX
 OS Mammalia.
 XX
 PN WO200032765-A2.
 XX
 PD 08-JUN-2000.
 XX
 PF 06-DEC-1999; 99WO-US028772.
 XX

```

Db      |||||
        4 CAACAGTGGAGAGAA 19

RESULT 55
ABT15831
ID ABT15831 standard; DNA; 20 BP.
XX
AC ABT15831;
XX
DT 28-MAR-2003 (first entry)
XX
DE Human GU protein antisense oligonucleotide, SEQ ID No 80.
XX
KW Human; gene therapy; antisense oligonucleotide;
KW GU protein; autoimmune disorder; connective tissue disorder; ss;
KW hyperproliferative disorder; cancer; phosphorothioate backbone; 2-MOE;
KW 2'-methoxyethyl.
XX
OS Homo sapiens.
XX
PN WO200288392-A1.
XX
PD 07-NOV-2002.
XX
PF 22-APR-2002; 2002WO-US012904.
XX
PR 27-APR-2001; 2001US-00844521.
XX
PA (ISIS-) ISIS PHARM INC.
PA (BAYU) BAYLOR COLLEGE MEDICINE.
XX
PI Bennett FC, Busch H, Wyatt JR;
XX
DR WPI; 2003-111899/10.
XX
PT New antisense compound, particularly antisense oligonucleotide targeted
PT to a nucleic acid molecule that encodes GU protein, useful for treating
PT autoimmune, connective tissue or hyperproliferative disorder, e.g. cancer
PT in animal.
XX
PS Claim 3; Page 83; 112pp; English.
XX
CC The invention comprises antisense oligonucleotides designed to inhibit
CC expression of the human GU protein. The antisense oligonucleotides are
CC useful for treating autoimmune disorders, connective tissue disorders and
CC hyperproliferative disorders (e.g. cancer). The present DNA sequence
CC represents an antisense oligonucleotide of the invention. NOTE: The
CC present DNA sequence contains a phosphorothioate backbone, nucleotides 1-
CC 5 and 16-20 are 2'-methoxyethyl (2'-MOE) residues
XX
SQ Sequence 20 BP; 8 A; 6 C; 1 G; 5 T; 0 U; 0 Other;
Query Match 0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1294 TACTACATCTTCCAG 1309
DB 5 TACTACATCTTCCAG 20

RESULT 56
ADC61334
ID ADC61334 standard; DNA; 20 BP.
XX
AC ADC61334;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Growth Hormone 1, GH1, PCR primer GH2DF.
XX
KW Growth Hormone; GH1; human; PCR; primer; ss.

XX OS Homo sapiens.
XX PN WO2003042245-A2.
XX PD 22-MAY-2003.
XX PF 12-NOV-2002; 2002WO-GB005112.
XX PR 12-NOV-2001; 2001GB-00027214.
XX PA (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
XX PI Cooper DN, Procter AM, Gregory J, Millar DS;
XX PS WPI; 2003-449578/42.
XX PT Detecting a variation in pituitary-expressed growth hormone (GH1), useful
XX as an indicator of growth hormone (GH) dysfunction comprises comparing
XX the sequence obtained from the test sample with a standard sequence of
XX the human GH1 gene.
XX PS Example 3; Page 40; 70pp; English.
XX CC The present invention relates to a method for detecting a variation in
XX pituitary-expressed Growth Hormone (GH1) effective to act as an indicator
XX of Growth Hormone (GH) dysfunction in an individual. The method comprises
XX comparing the sequence obtained from the test sample with a standard
XX sequence of the human GH1 gene. The detection comprises PCR amplification
XX of the GH1 gene of the individual using a GH1 gene-specific fragment that
XX is unique to the GH1 gene whose sequence is not found in the four
XX paralogous (non-GH1) genes in the GH cluster, and one or more GH1-gene
XX specific primers that cannot bind to the homologous flanking regions in
XX the four other paralogous (non-GH1) genes in the GH cluster (ADC61308-
XX ADC61343).
XX SQ Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 83;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAACAGTGGAGAGAA 869
DB 4 CAACAGTGGAGAGAA 19

RESULT 57
ACC58406
ID ACC58406 standard; DNA; 20 BP.
XX
AC ACC58406;
XX
DT 26-AUG-2003 (first entry)
XX
DE Human growth hormone GH1 gene PCR primer GH2DF.
XX
KW Growth hormone; GH1 gene; human; cytostatic; antidiabetic; anorectic;
KW antimicrobial; cardiant; gene therapy; PCR; primer; ss.
XX
OS Homo sapiens.
XX PN WO2003042245-A2.
XX PD 22-MAY-2003.
XX PF 12-NOV-2002; 2002WO-GB005112.
XX PR 12-NOV-2001; 2001GB-00027214.
XX PA (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
XX

```

OS Synthetic.
 PN WO200159103-A2.
 XX
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001WO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 XX Blatt L, Mcswiggen J, Chowrira BM;
 PI WPI; 2001-607195/69.
 XX
 DR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 XX constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX Claim 30; Page 147; 200pp; English.
 PS
 XX The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a NYN motif) or
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zynzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 9 A; 3 C; 4 G; 0 T; 1 U; 0 Other;
 Query Match 0.9%; Score 16; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 64;
 Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 162 AGAAAACTCCAGGAA 177
 Db 1 AGAAAACTCCAGGAA 16
 RESULT 54
 AAS18855

AS18855 standard; DNA; 20 BP.
 AAS18855;
 12-MAR-2002 (first entry)
 Growth hormone 1 gene (GH1), specific primer GH2DF.
 Growth hormone 1; GH1; osteopathic; gene therapy; protein therapy;
 diabetes; obesity; infection; acromegaly; gigantism; sodium retention;
 water retention; metabolic syndrome; mood disorder; sleep disorder;
 Growth hormone dysfunction; familial growth hormone deficiency;
 short stature; pituitary storage defect; human; primer; GH2DF;
 denaturing high performance liquid chromatography; DHPLC; ss.
 Homo sapiens.
 WO200185993-A2.
 15-NOV-2001.
 14-MAY-2001; 2001WO-GB002126.
 12-MAY-2000; 2000GB-00011459.
 14-JUL-2000; 2000EP-00306004.
 (UYWA-) UNIV WALES COLLEGE OF MEDICINE.
 Cooper DN, Procter AM, Gregory J, Millar DS;
 WPI; 2002-089798/12.
 Detecting growth hormone variants (GH1), useful in screening patients for
 growth hormone irregularities, comprises comparing the nucleotide
 sequence of a GH1 gene from a test sample with that of a standard
 sequence of the human GH1.
 Claim 11; Page 76; 95pp; English.
 The invention described a method of detecting variation in growth hormone
 1 (GH1), and therefore GH dysfunction in an individual. The method
 comprises comparing the nucleotide sequence of GH1 gene obtained from the
 test sample with a standard human GH1 gene sequence, in order to identify
 variation (GH1 variant). The method is useful in screening patients for
 growth hormone irregularities or producing variant proteins for treating
 irregularities, and for the early detection and appropriate clinical
 management of familial GH deficiency. The GH1 variants are useful in
 therapeutic, diagnostic or detection method, particularly for determining
 binding defects and susceptibility to a disease such as diabetes, obesity
 or infection; for treating acromegaly or gigantism conditions associated
 with lactogenic, diabetogenic, lipolytic and protein anabolic effects,
 conditions associated with sodium and water retention, metabolic
 syndromes, mood and sleep disorders; diagnosing GH dysfunction and
 determining pituitary storage defects. The GH1 variants are especially
 useful in gene therapy or protein therapy. The GH1 or GH variant may also
 be used in the preparation of a medicament, diagnostics composition or
 kit, or detection kit. The method has the advantage of: expanding the
 know spectrum of GH1 gene mutations; evaluating the role of GH1 gene
 mutations in the etiology of short stature; identifying of the mode of
 inheritance of novel lesions; evaluation the effects of GH1 mutations on
 the structure and function of the GH molecule and development of rapid
 diagnostic tests for inherited GH deficiency. This sequence is the GH1
 gene specific primer, GH2DF, used in the denaturing high performance
 liquid chromatography (DHPLC) analysis of the GH1 gene to identify
 sequence variants, described in the method of the invention
 Sequence 20 BP; 7 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 83;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 854 CAACAGTGGAGAGAA 869

Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 74;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGGCCGATG 268
 Db 3 GATGTGGAGTGGCCAGATG 20

RESULT 51
 ACC57867/c
 ID ACC57867 standard; DNA; 20 BP.
 XX
 AC ACC57867;
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE Matrix metalloproteinase 12 antisense PCR primer.
 XX
 KW Matrix metalloproteinase 12; MMP-12; human; transcription;
 KW cis-acting element; transcription factor; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003033679-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 17-OCT-2002; 2002WO-US033579.
 XX
 PR 17-OCT-2001; 2001US-0329961P.
 XX
 PA (ADRE-) ADVANCED RES & TECHNOLOGY INST.
 XX
 XX Yokota H, Sun HB;
 XX WPI; 2003-393526/37.
 XX
 XX Predicting an expression level of a target gene or gene family comprises
 PT experimentally determining the number and type of cis-acting elements
 PT provided in 5' untranslated regulatory regions of the target gene.
 XX
 XX Example 4; Page 36; 78pp; English.

The present sequence is an antisense primer for the PCR amplification of
 human matrix metalloproteinase 12 (MMP-12) cDNA. A 369 bp product is
 obtained using this antisense primer with the sense primer given in
 ACC57866. RT-PCR was performed in an example from the invention to
 determine expression profiles of MMP genes in human synovial cells in
 response to mechanical shear. A model-based analysis was used to identify
 the role of transcription factor binding motifs in gene regulation. The
 results provide an example of the method of the invention for determining
 expression levels of target genes based on sequence elements present in
 untranslated regulatory regions

Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 74;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 358 CGTGAGGATGTAGACTAC 375
 Db 20 CGTGAGGATGTGACTAC 3

RESULT 52
 ADH14321/c
 ID ADH14321 standard; DNA; 20 BP.
 XX
 AC ADH14321;
 XX
 DT 11-MAR-2004 (first entry)

XX Human retinoblastoma 1 (RB1CC1) cDNA PCR primer RB1CC-R55.
 DE cell nucleus; transcription; gene expression; retinoblastoma-1; RB1CC1;
 KW diagnosis; cancer; primer; ss.
 KW Homo sapiens.
 OS WO2003102028-A1.
 PN 11-DEC-2003.
 XX
 PD 30-JAN-2003; 2003WO-JP000882.
 XX
 PF 03-JUN-2002; 2002JP-00161400.
 XX
 PR 24-JUL-2002; 2002JP-00214978.
 XX
 XX (OKAB/) OKABE H.
 PA (IKEG/) IKEGAWA S.
 PA (CHAN/) CHANO T.
 XX
 PI Chano T;
 XX
 DR WPI; 2004-081932/08.
 XX
 PT Protein in the nuclei of human and animal cells associated with
 PT expression of retinoblastoma-1 gene for diagnosis of cancer.
 XX
 PS Example 1; SEQ ID NO 35; 113pp; Japanese.
 XX
 CC The invention relates to a protein or polypeptide found in the nuclei of
 CC human and animal cells that are associated with transcription and/or
 CC induction of expression of retinoblastoma-1 gene (RB1CC1). The detection
 CC of RB1CC1 gene and its protein is useful for the diagnosis of cancer. The
 CC human RB1CC1 cDNA is 6.6 kb containing a 4782 bp ORF, encoding a 180 kD
 CC 1594 amino acid protein. This sequence corresponds to a PCR primer used
 CC to amplify and isolate the human RB1CC1 cDNA sequence (ADH14289).
 XX
 SQ Sequence 20 BP; 5 A; 1 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.9%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 74;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 CACACTTCCCGAATCA 1255
 Db 18 CACACTTCCCGAATCA 1

RESULT 53
 ABK03146
 ID ABK03146 standard; RNA; 17 BP.
 XX
 AC ABK03146;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Inozyme #97.
 XX
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 385 AAAGCTTCCAGTCTGG 402
DB 18 AAAGCTTCCAGGCTGG 1
|||||

RESULT 47
ADF36099/c
ID ADF36099 standard; RNA; 19 BP.
XX AC ADF36099;
XX 12-FEB-2004 (first entry)
XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:388.
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003070910-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005022.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX Example 3; SEQ ID NO 388; 207pp; English.
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,

CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.
XX SQ Sequence 19 BP; 2 A; 1 C; 7 G; 0 T; 9 U; 0 Other;
Query Match 0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 68;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTTACA 1535
DB 18 CACACACACAGTTACA 1
|||||

RESULT 48
ADF36526
ID ADF36526 standard; RNA; 19 BP.
XX AC ADF36526;
XX 12-FEB-2004 (first entry)
XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:815.
XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.
XX Synthetic.
OS Homo sapiens.
XX WO2003070910-A2.
XX 28-AUG-2003.
XX 20-FEB-2003; 2003WO-US005022.
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 29-MAY-2002; 2002WO-US017674.
PR 06-JUN-2002; 2002US-0386782P.
PR 03-JUL-2002; 2002US-0393796P.
PR 29-JUL-2002; 2002US-0399348P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 04-NOV-2002; 2002US-00287949.
PR 27-NOV-2002; 2002US-00306747.
PR 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J, Beigelman L, Pavco P;
XX WPI; 2003-679876/64.
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.
XX Example 3; SEQ ID NO 815; 207pp; English.
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a

CC developing Alzheimer's disease. Transgenic animals containing sequences
 CC from the Cp2/USF/LBP-1 gene are useful for screening for drugs capable of
 CC reducing or treating symptoms associated with Alzheimer's disease
 XX
 SQ Sequence 21 BP; 8 A; 2 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 71;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373
 ||||| ||||| ||||| |||||
 Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 45
 ACF04639
 ID ACF04639 standard; DNA; 21 BP.

XX ACF04639;
 AC
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Murine tumour chromatin immunoprecipitation promoter PCR primer #2.
 XX
 XX Mouse; tumour chromatin; immunoprecipitation; heterologous gene;
 KW transcription amplification system; molecular imaging; PCR; primer; ss.
 KW
 XX

OS Mus sp.
 XX
 FN WO2003066883-A2.
 XX
 PD 14-AUG-2003.
 XX
 PF 07-FEB-2003; 2003WO-US003847.
 XX
 PR 08-FEB-2002; 2002US-0355300P.
 PR
 XX (REGC) UNIV CALIFORNIA.
 PA

PI Carey MF, Wu L, Gambhir S, Iyer M, Zhang J;
 XX
 DR WPI; 2003-731506/59.

XX
 PT Expression vector comprising an effector nucleotide sequence having a
 PT modified tissue specific enhancer and promoter sequences, and a sequence
 PT encoding a chimeric transactivator, useful for detecting heterologous
 PT gene product.

XX Example 5; Page 103; Opp; English.

XX The present invention relates to an expression vector comprising an
 CC effector nucleotide sequence comprising a modified tissue specific
 CC enhancer sequence, a tissue specific promoter sequence, and a nucleotide
 CC sequence encoding a chimeric transactivator operably linked to the
 CC modified tissue specific promoter sequence, where the encoded
 CC transactivator comprises a DNA binding domain and at least one viral
 CC transcription activation domain. The expression vector and vector system
 CC can be used for producing, detecting, imaging, and monitoring the
 CC heterologous gene product in a cell or in a subject. The present sequence
 CC is a PCR primer used to monitor the gene activity in a murine tumour cell
 CC in the exemplification of the invention

XX Sequence 21 BP; 5 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 71;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 478 GCTCAGGAGACTTCAACTA 497
 ||||| ||||| ||||| |||||
 Db 1 GCTCATGGAGACTTCTCTA 20.

RESULT 46
 ADQ93226/c
 ID ADQ93226 standard; RNA; 18 BP.

XX ADQ93226;
 AC

XX 21-OCT-2004 (first entry)
 DT

XX 3-alpha-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 802.
 DE

XX Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;
 KW small interfering RNA; siRNA;
 KW androgen signal transduction pathway protein;
 KW androgen signal transduction; 3-alpha-hydroxysteroiddehydrogenase;
 KW hair loss; hyperandrogenic condition; androgenic alopecia;
 KW male pattern alopecia; acne vulgaris; seborrhea; female hirsutism;
 KW prostatic hypertrophy; ds.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT misc_feature 17..18
 FT /*tag= a
 FT /note= "2 deoxynucleotide overhang"

XX WO2004063331-A2.

XX 29-JUL-2004.

XX 05-JAN-2004; 2004WO-US000128.

XX 03-JAN-2003; 2003US-0437842P.

XX (GENC-) GENCIA CORP.

XX Kahn S;

XX WPI; 2004-561892/54.

XX Inhibitory nucleic acid that inhibits expression of an androgen signal
 PT transduction pathway protein useful for treating hair loss, comprises a
 PT double stranded RNA having a partial sequence encoding a pathway protein
 PT in one strand.

XX Claim 11; Page 59; 92pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs),
 CC comprising a double stranded RNA, where one strand comprises a partial
 CC nucleic acid sequence of an androgen signal transduction of mRNA encoding
 CC and where the double-stranded RNA inhibits translation of pathway protein,
 CC the nucleic acid sequence of the androgen signal transduction pathway
 CC protein thereby blocking the androgen signal transduction pathway. The
 CC androgen signal transduction pathway protein is chosen from isozymes I
 CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen
 CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
 CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-
 CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-
 CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
 CC hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase
 CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss
 CC in a mammal which involves contacting several mammal's hair cells with
 CC the siRNA, where the siRNA interferes with the translation of mRNA of the
 CC androgen signal transduction protein. The siRNAs are useful for treating
 CC hyperandrogenic conditions of androgenic alopecia, including male pattern
 CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic
 CC hypertrophy. The present sequence is the sense strand for one such siRNA
 CC of the invention.

XX Sequence 18 BP; 4 A; 5 C; 4 G; 2 T; 3 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 62;

XX PR 14-AUG-2002; 2002US-0403416P.
XX PA (PHAA) PHARMACIA CORP.
XX PI Roberds SL;
XX XX WPI; 1994-169331/21.
XX DR WPI; 2004-203785/19.
XX XX New antisense compound targeted to a nucleic acid molecule encoding
PT Navi1.3, useful for treating a disease or condition associated
PT with Navi1.3, e.g. pain, seizure disorder such as childhood seizure
PT disorder, or ataxia.
XX PT Claim 4; SEQ ID NO 8124; 417pp; English.
XX XX The present invention relates to an antisense compound targeted to a
CC nucleic acid molecule encoding Navi1.3, where the antisense compound
CC specifically hybridizes with and inhibits the expression of Navi1.3. The
CC compound and composition are useful for treating a disease or condition
CC associated with Navi1.3, e.g. pain including but not limited to
CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,
CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,
CC pain from burns, migraines headache, cluster headache, mild-to-moderate
CC headache; seizure disorder such as childhood seizure disorder, including
CC but not limited to neonatal or infantile epilepsy; or ataxia. The present
CC sequence represents a chimeric phosphorothioate oligonucleotide with
CC 2'MOE wings and a deoxy gap. Used during the antisense inhibition of
CC human Navi1.3 expression, the oligonucleotides are designed to target
CC different regions of the human Navi1.3 RNA.
XX XX Sequence 20 BP; 17 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
SQ Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 65;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1757 AAAAAAAAAAAAAAAAAA 1776
DB 1 AAAAAAAAAAAAAAAAAA 20
RESULT 43
ID AAQ65723 standard; DNA; 21 BP.
XX AC AAQ65723;
XX XX 25-MAR-2003 (revised)
DT 18-JAN-1995 (first entry)
XX DE HIV-1 antisense RNA expression vector PCR primer.
XX XX PCR; polymerase chain reaction amplification; hybrid promoter;
XX KW expression vector; antisense sequence; anti-viral; HIV-1;
XX KW human immunodeficiency virus; inhibition; viral replication; ss.
XX OS Synthetic.
XX OS EP598935-A1.
XX PN 01-JUN-1994.
PD 24-NOV-1992; 92EP-00119963.
XX PF 24-NOV-1992; 92EP-00119963.
XX PR (FARB) BAYER AG.
XX PA Kretschmer A, Antonicek H, Baumgarten J, Loebberding A, Mielke B;
XX PI Springer W, Stropp U, Struck M, Biesert L, Ruebsamen-Waigmann H;
XX PI Suhartono H, Hausner T;
XX

DR XX WPI; 1994-169331/21.
XX XX Vectors for expressing anti-sense RNA for HIV-1 pro-viral DNA - in
PT haematopoietic cells, providing complete blockage of HIV-1 replication.
XX PS Example 9; Page 9; 28pp; German.
XX XX Expression vectors were prepared for the expression of HIV-1 antisense
CC RNA. The antisense sequences are designed to hybridise to proviral RNA
CC and to thereby inhibit (block) viral replication. The vector constructs
CC contain a constitutive promoter or a promoter which is inducible in
CC haematopoietic cells. The promoter may be fused to a sequence which
CC enhances expression following exposure to the virus, e.g. cytomegalovirus
CC immediate early promoter/ metallothionein promoter fragment and the HIV-1
CC long terminal repeat. Polyadenylation signals are also included in the
CC constructs to ensure stability of antisense transcripts. Primers AAQ65721
CC -Q65725 were used to amplify regions of expression vector constructs to
CC verify the cloning procedure. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX SQ Sequence 21 BP; 3 A; 5 C; 1 G; 12 T; 0 U; 0 Other;
Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 71;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1575 TTTTTCACCTTCATTCTATT 1594
DB 1 TTTTTCACCTTCATTCTACT 20
RESULT 44
ID AAQ67025 standard; DNA; 21 BP.
XX AC AAQ67025;
XX XX 18-SEP-2001 (first entry)
DT Sequencing primer for Human CP2/LSF/LBP-1 ARNm sequence.
XX DE LBP-1; human; intron; Alzheimer's disease; diagnosis; ADN sequence;
XX KW CP2/LSF/LBP-1 gene; sequencing primer; ss.
XX OS Homo sapiens.
XX XX EP1113081-A1.
XX PN 04-JUL-2001.
PD 28-DEC-1999; 99EP-00403304.
XX PF 28-DEC-1999; 99EP-00403304.
XX PR (INSP) INST PASTEUR LITTLE.
XX PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
XX PI Chartier-Harlin M, Amouyel P, Lambert J;
XX XX WPI; 2001-427121/46.
XX DR Predicting increased risk of human developing Alzheimer's disease,
XX PT comprises identifying polymorphisms located at untranslated regions of
XX CP2/LSF/LBP-1 gene.
XX PS Example 1; Page 10; 35pp; English.
XX CC This sequence is a sequencing primer for the human CP2/LSF/LBP-1 gene
CC ARNm. The invention relates to a method for predicting an increased risk
CC of a human subject of developing Alzheimer's disease, comprising assaying
CC for a mutation within the ADN sequence of the CP2/LSF/LBP-1 gene
CC including the region controlling the expression of the gene. The method
CC is useful for predicting an increased risk of a human subject of


```
FT FT /*tag= a
XX FT /note= "phosphorothioate linkage"
PN WO200144455-A2.
XX 21-JUN-2001.
PD
XX
XX 12-DEC-2000; 2000WO-GB004741.
XX
XX 15-DEC-1999; 99GB-00029487.
XX
XX (ASTR ) ASTRAZENECA AB.
XX (ASTR ) ASTRAZENECA UK LTD.
XX
XX Beri R;
XX
XX WPI; 2001-398145/42.
XX
XX Novel antisense DNA oligonucleotide useful for inhibiting the expression
PT of wild type COL1A1 gene, for treating, reducing the risk of, and
PT preventing collagen disorders.
XX
XX Claim 10; Page 8; 30pp; English.
XX
XX The present sequence is that of 1 of 12 claimed antisense
CC oligonucleotides (ASOs, see AAF90492-503) of the invention. These ASOs
CC are complementary to regions of the human gene (see AAF90491) for the pro
CC -alpha-1 chain of type I procollagen. They are capable of inhibiting the
CC expression of type I procollagen pro-alpha-1 chain in a cell that
CC expresses it. The ASO, or a pharmaceutical composition including it, is
CC used in a claimed method of treating, or reducing a risk of, a collagen
CC disorder. Such disorders may include those caused by overproduction of
CC collagen fibres, such as liver cirrhosis, kidney, liver and heart
CC fibrosis, scleroderma, hypertrophic scars and keloids. The present ASO,
CC when administered to human WI-26 cells, inhibited type I collagen
CC production by 50%
XX
XX Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 65;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1194 GAGGCGAGCTCATGGACC 1213
Db ||||| ||||| |||||
20 GAGGCTGGAGCTCAGGACC 1
RESULT 41
AD127533
ID AD127533 standard; DNA; 20 BP.
XX
XX AD127533;
XX
XX 22-APR-2004 (first entry)
XX
XX Human DRK1 DNA, antisense oligonucleotide #11.
DE
XX Antisense therapy; human;
KW death-associated protein kinase-related apoptosis-inducing;
KW protein kinase 1; DRK1; hyperproliferative disorder; cancer;
KW neurological disorder; infection; inflammation; tumour formation;
KW cytostatic; antiinflammatory; neuroprotective; antimicrobial;
KW phosphorothioate; ss.
XX
XX Homo sapiens.
OS
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5',
and 3' ends, which are 5 nucleotides in length at each
end. All cytidine residues are 5-methylcytidines"
FT
XX US2003232773-A1.
XX 18-DEC-2003.
XX
XX 17-JUN-2002; 2002US-00174559.
XX
XX 17-JUN-2002; 2002US-00174559.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Freier SM, Dobie KW;
XX WPI; 2004-061310/06.
XX
XX New antisense compound targeted to a nucleic acid molecule encoding death
PT -associated protein kinase-related apoptosis-inducing protein kinase 1
PT (DRK1), useful for modulating expression of DRK1 or for treating
PT cancer.
XX
XX Example 15; SEQ ID NO 25; 56pp; English.
XX
XX The present invention relates to antisense compounds targeted to a
CC nucleic acid encoding death-associated protein kinase-related apoptosis-
CC inducing protein kinase 1 (DRK1). The antisense compound comprises an
CC antisense oligonucleotide that specifically hybridises with the nucleic
CC acid and inhibits the expression of DRK1. The antisense oligonucleotide
CC is a chimeric oligonucleotide. The antisense oligonucleotide comprises at
CC least one modified internucleoside linkage, preferably a phosphorothioate
CC linkage. It also comprises at least one modified sugar moiety, preferably
CC a 2'-O-methoxyethyl (2'-MOE) sugar moiety. The antisense oligonucleotide
CC further comprises at least one modified nucleobase, preferably a 5-
CC methylcytosine. The antisense oligonucleotides are useful for the
CC treatment of diseases such as hyperproliferative disorders, preferably
CC cancer, and neurological disorders. The antisense compound can also be
CC used as prophylaxis, e.g. to prevent or delay infection, inflammation or
CC tumour formation. The present sequence represents an antisense
CC oligonucleotide used in the examples of the present invention.
XX
XX Sequence 20 BP; 6 A; 3 C; 2 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 65;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 867 GAAATCCTTTCTTTAAAG 886
Db ||||| ||||| ||||| |||||
1 GAACATCTTTTCTTTAAAG 20
RESULT 42
ADK80790
ID ADK80790 standard; DNA; 20 BP.
XX
XX ADK80790;
XX
XX 20-MAY-2004 (first entry)
XX
XX Chimeric phosphorothioate oligonucleotide to target Nav1.3 #8124.
DE
XX Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;
KW diabetic neuropathy; arthritic pain; migraine headache;
KW infantile epilepsy; ataxia; ss.
XX
XX Synthetic.
OS
XX WO2004016754-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025465.
```


KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 OS Hepatitis C virus.
 XX

PN WO2004080406-A2.

XX 23-SEP-2004.

XX 08-MAR-2004; 2004WO-US007070.

XX 07-MAR-2003; 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.

PR 13-MAR-2003; 2003US-0454962P.

PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.

PR 08-AUG-2003; 2003US-0493986P.

PR 11-AUG-2003; 2003US-0494597P.

PR 26-SEP-2003; 2003US-0506341P.

PR 09-OCT-2003; 2003US-0510248P.

PR 10-OCT-2003; 2003US-0510318P.

PR 07-NOV-2003; 2003US-0518453P.

XX (ALNY-) ALNYLAM PHARM.

XX Manoharan M, Buncrot D;

XX WPI; 2004-677362/66.

XX

DR

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.

Example 5; SEQ ID NO 6180; 378pp; English.

The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apoB-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a hepatitis C virus (HCV) antisense oligonucleotide that can be used to control HCV gene expression.

Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 56;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1760 AAAAAAAAAAAAAAAC 1776
 |||||
 Db 19 AAAAAAAAAAAAAAAC 3

RESULT 36

AAZ90012

ID AAZ90012 standard; DNA; 20 BP.

XX

AC AAZ90012;

XX

DT 05-MAY-2000 (first entry)

XX

DE PCR primer corresponding to MMP preservative amino acid sequence.

XX

KW Metalloprotease in the female reproductive tract; MIFR; MMP; PCR primer;

KW matrix metalloprotease; ss.

XX

OS Synthetic.

XX

PN JP2000014387-A.

XX

PD 18-JAN-2000.

XX

PF 06-JUL-1998; 98JP-00190869.

XX

PR 06-JUL-1998; 98JP-00190869.

XX

PA (TAKA/) TAKAHASHI T.

PA

PA (SDIS-) SDI KK.

XX

DR WPI; 2000-154341/14.

XX

PT A new metalloprotease and a DNA coding it.

XX

PS Example 3; Page 8; 21pp; Japanese.

XX

CC This sequence represents a PCR primer corresponding to the preservative amino acid sequence of the matrix metalloprotease MMP family of proteins. The PCR primer is used in the detection of the MMP of the invention. The invention relates to the human metalloprotease in the female reproductive tract (MIFR) protein which is 390 amino acids in length. A recombinant vector containing the MIFR gene can be used to create transformants which produce the metalloprotease in culture

XX

SQ Sequence 20 BP; 1 A; 2 C; 7 G; 5 T; 0 U; 5 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;

Best Local Similarity 75.0%; Pred. No. 65;

Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 250 CGATGTGGAGTGCCCGATGT 269

|||

Db 1 MGVTGTGGWGTBCCGATGT 20

RESULT 37

AAZ90013/c

ID AAZ90013 standard; DNA; 20 BP.

XX

AC AAZ90013;

XX

DT 05-MAY-2000 (first entry)

XX

DE PCR primer corresponding to MMP preservative amino acid sequence.

XX

KW Metalloprotease in the female reproductive tract; MIFR; MMP; PCR primer;

KW matrix metalloprotease; ss.

XX

OS Synthetic.

XX

PN JP2000014387-A.

XX 03-JAN-2003; 2003US-0437842P.
 XX (GENC-) GENCIA CORP.
 XX Kahn S;
 XX WPI; 2004-561892/54.
 XX Inhibitory nucleic acid that inhibits expression of an androgen signal
 PT transduction pathway protein useful for treating hair loss, comprises a
 PT double stranded RNA having a partial sequence encoding a pathway protein
 PT in one strand.
 XX Claim 11; Page 70; 92pp; English.
 XX The present invention relates to novel small interfering RNAs (siRNAs),
 CC comprising a double stranded RNA, where one strand comprises a partial
 CC nucleic acid sequence of an androgen signal transduction pathway protein,
 CC and where the double-stranded RNA inhibits translation of mRNA encoding
 CC the nucleic acid sequence of the androgen signal transduction pathway
 CC protein thereby blocking the androgen signal transduction pathway. The
 CC androgen signal transduction pathway protein is chosen from isoforms I
 CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen
 CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
 CC hydroxysteroid dehydrogenase (ADQ93182), 3-beta-
 CC hydroxysteroid dehydrogenase (ADQ93360), 3-beta-
 CC hydroxysteroid dehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
 CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss
 CC in a mammal which involves contacting several mammal's hair cells with
 CC the siRNA, where the siRNA interferes with the translation of mRNA of the
 CC androgen signal transduction protein. The siRNAs are useful for treating
 CC hyperandrogenic conditions of androgenic alopecia, including male pattern
 CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic
 CC hypertrophy. The present sequence is the antisense strand for one such
 CC siRNA of the invention.
 XX Sequence 21 BP; 3 A; 4 C; 5 G; 2 T; 7 U; 0 Other;
 SQ
 Query Match 1.0%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 61.9%; Pred. No. 52;
 Matches 13; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
 QY 1454 CTCATGCTCAGGCTCAACT 1474
 Db 1 CUCUUGCUCAGGGUGUAATT 21
 RESULT 34
 AAX64428
 ID AAX64428 standard; RNA; 18 BP.
 XX AC
 XX AAX64428;
 XX 20-JUL-1999 (first entry)
 XX Human stromelysin hairpin target sequence SEQ ID NO:1060.
 XX Arthritic condition; graft tolerance; immune response; target; cleavage;
 XX hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 XX stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 XX rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 XX diagnosis; ss.
 XX Homo sapiens.
 XX WO9618736-A2.
 XX 20-JUN-1996.
 XX 22-NOV-1995; 95WO-US015516.
 XX

PR 13-DEC-1994; 94US-00354920.
 PR 23-DEC-1994; 94US-00363253.
 PR 23-DEC-1994; 94US-00363254.
 PR 17-FEB-1995; 95US-00390850.
 PR 20-APR-1995; 95US-00428124.
 PR 02-MAY-1995; 95US-00432874.
 PR 04-MAY-1995; 95US-00434509.
 PR 07-JUL-1995; 95US-0000951P.
 PR 07-AUG-1995; 95US-0000974P.
 PR 07-AUG-1995; 95US-00512861.
 PR 05-OCT-1995; 95US-00541365.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;
 PI Meswiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;
 PI Karpelsky A, Thompson JD, Modak A, Burgin A;
 XX WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used for
 PT the treatment of arthritis, induction of graft tolerance or treatment of
 PT auto-immune diseases.
 XX Example 1; Page 164; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues
 CC ; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least
 CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's
 CC can inhibit collagenase and stromelysin production in the synovial
 CC membrane of joints for the treatment of arthritis. The ENA's can also
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention
 XX Sequence 18 BP; 3 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
 SQ
 Query Match 0.9%; Score 17; DB 1; Length 18;
 Best Local Similarity 64.7%; Pred. No. 51;
 Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
 QY 750 CATTGAGTCCCTCTATG 766
 Db 2 CAUUCAGUCCUUAUG 18
 RESULT 35
 ADR81681/c
 ID ADR81681 standard; DNA; 19 BP.
 XX AC ADR81681;
 XX 16-DEC-2004 (first entry)
 XX Hepatitis C virus (HCV) oligonucleotide seqid 6180.
 XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 XX cytosolic; anticonvulsant; nootropic; muscula; anti-HIV;
 XX RNA interference; RNA; antisense technology; lipid metabolism;
 XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 XX coronary artery disease; CAD; coronary heart disease; CHD;
 XX atherosclerosis; hepatic glucose production;
 XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW

KW 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase; hair loss;
 KW hyperandrogenic condition; androgenic alopecia; male pattern alopecia;
 KW acne vulgaris; seborrhea; female hirsutism; prostatic hypertrophy; ds.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 20..21
 FT /*tag= a
 FT /note= "2 deoxynucleotide overhang"
 XX
 XX
 PN WO2004063331-A2.
 XX
 XX
 PD 29-JUL-2004.
 XX
 XX
 PF 05-JAN-2004; 2004WO-US000128.
 XX
 PR 03-JAN-2003; 2003US-0437842P.
 XX
 PA (GENC-) GENCIA CORP.
 XX
 XX
 PI Kahn S;
 XX
 XX
 DR WPI; 2004-561892/54.
 XX
 XX Inhibitory nucleic acid that inhibits expression of an androgen signal
 PT transduction pathway protein useful for treating hair loss, comprises a
 PT double stranded RNA having a partial sequence encoding a pathway protein
 PT in one strand.
 XX
 PS Claim 11; Page 77; 92pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs),
 CC comprising a double stranded RNA, where one strand comprises a partial
 CC nucleic acid sequence of an androgen signal transduction pathway protein,
 CC and where the double-stranded RNA inhibits translation of mRNA encoding
 CC the nucleic acid sequence of the androgen signal transduction pathway
 CC protein thereby blocking the androgen signal transduction pathway. The
 CC androgen signal transduction pathway protein is chosen from isozymes I
 CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen
 CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
 CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-
 CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-
 CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
 CC hydroxysteroidoxidoreductase (ADQ93722), and steroid sulfatase
 CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss
 CC in a mammal which involves contacting several mammal's hair cells with
 CC the siRNA where the siRNA interferes with the translation of mRNA of the
 CC androgen signal transduction protein. The siRNAs are useful for treating
 CC hyperandrogenic conditions of androgenic alopecia, including male pattern
 CC alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic
 CC hypertrophy. The present sequence, SEQ ID 1257, is the sense strand for
 CC one such siRNA of the invention.
 XX
 SQ Sequence 21 BP; 7 A; 5 C; 4 G; 2 T; 3 U; 0 Other;
 Query Match 1.0%; Score 18.4; DB 1; Length 21;
 Best Local Similarity 95.0%; Pred. No. 43;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1453 ACTCTATGCTCGGGTGTA 1472
 DB 20 ACTCTTTGCTCAGGGTGTA 1
 RESULT 28
 ADR32355/c
 ID ADR32355 standard; DNA; 18 BP.
 XX
 AC ADR32355;
 XX
 XX 04-NOV-2004 (first entry)
 DT
 XX

DE Rat KDR cytosolic domain cloning RT-PCR primer.
 XX
 KW Rat; receptor tyrosine kinase; KDR; therapy; cancer;
 KW ischaemic ocular disease; proliferative retinopathy; inflammation;
 KW reverse transcription; RT; PCR; primer; ss.
 XX
 OS Rattus norvegicus.
 XX
 PN WO2004070004-A2.
 XX
 PD 19-AUG-2004.
 XX
 XX
 PF 23-JAN-2004; 2004WO-US001928.
 XX
 PR 29-JAN-2003; 2003US-0443335P.
 XX
 PA (MERI) MERCK & CO INC.
 XX
 XX Thomas RA, Pan B, Mcgaughey GB;
 PI
 XX
 DR WPI; 2004-604429/58.
 XX
 XX New nucleic acid molecules encoding rat KDR protein, useful for
 PT identifying inhibitors of KDR activity for treating cancer, ischemic
 PT ocular diseases, and inflammation.
 XX
 PS Example 2; Page 30; 77pp; English.
 XX
 CC The invention relates to rat receptor tyrosine kinase (KDR) and its
 CC corresponding nucleic acid sequence. The nucleic acid molecules of the
 CC invention are useful for identifying compounds that modulate wild-type
 CC rat KDR activity to evaluate the safety and efficacy of specific
 CC inhibitors of KDR in rats. KDR inhibitors are useful for treating cancer,
 CC ischaemic ocular diseases such as proliferative retinopathy and
 CC inflammation. The present sequence is a reverse transcription (RT) PCR
 CC primer used for cloning rat KDR cytosolic domain. This sequence is used
 CC in the exemplification of the invention.
 XX
 SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;
 Query Match 1.0%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAA 1766
 DB 18 AAAAAAAAAAAAAAAAAA 1
 RESULT 29
 ADR57967/c
 ID ADR57967 standard; DNA; 18 BP.
 XX
 AC ADR57967;
 XX
 DT 18-NOV-2004 (first entry)
 XX
 DE Nucleotide #4 for signal amplification method.
 XX
 KW ss; signal amplification method; gene expression; reverse transcription;
 KW self-assembly reaction; DNA chip.
 XX
 OS Unidentified.
 XX
 PN WO2004072302-A1.
 XX
 PD 26-AUG-2004.
 XX
 PF 13-FEB-2004; 2004WO-JP001588.
 XX
 PR 14-FEB-2003; 2003JP-00037212.
 XX
 XX (PALM-) PALMA BEEZ RES INST CO LTD.

DE Antisense primer to amplify DNA encoding human IQGAP1.
XX
KW IQGAP1; human GTPase-activating protein; IQ motif; diagnosis; treatment;
KW tumour; suppressor; ras; cancer; p21-ras; neoplastic cell; primer; PCR;
KW polymerase chain reaction; matrix metalloproteinase; ss.
XX
OS Synthetic.
XX
PN US5639651-A.
XX
PD 17-JUN-1997.
XX
PF 09-AUG-1994; 94US-00287959.
XX
PR 09-AUG-1994; 94US-00287959.
XX
PA (GEO) GEN HOSPITAL CORP.
XX
PI Settleman J, Weissbach L, Bernards A;
XX
DR WPI; 1997-332049/30.
XX
PT DNA encoding GTPase-activating protein IQGAP1 - for producing recombinant
PT protein useful for tumour diagnosis and therapy.
XX
PS Disclosure; Col 4; 35pp; English.
XX
CC AAT58682 and AAT70486 are degenerate primers designed based on conserved
CC peptides in matrix metalloproteinases. They were used to amplify a human
CC IQGAP1 (a GTPase-activating protein) DNA probe using total RNA from human
CC metastatic osteosarcoma tissue as a template. IQGAP1 (AAW18822) has an
CC "IQ motif" which is defined as an amino acid sequence of 20-40 amino
CC acids in length containing an isoleucine residue immediately followed by
CC a glutamine residue which has at least 50 percent sequence similarity to
CC the consensus sequence shown in AAW18823. The DNA sequence (AAT58681) is
CC used for production of recombinant IQGAP1, which is useful in the
CC diagnosis and treatment of tumours characterised by aberrant ras
CC expression. Detection of mutations in the IQGAP1 gene is diagnostic of
CC cancer. The IQGAP1 protein can be used for treatment of cancer to reduce
CC the activity of p21-ras. Detection of neoplastic cells can be achieved by
CC measuring IQGAP1 expression
XX
SQ Sequence 23 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 5 Other;
Query Match 1.0%; Score 18.6; DB 1; Length 23;
Best Local Similarity 73.9%; Pred. No. 47;
Matches 17; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 631 CATGAACCTGGCCATCCTTGGG 653
DB 23 CATGAATTTGGCCAYKBTGGG 1
RESULT 26
ADQ93500/C
ID ADQ93500 standard; RNA; 21 BP.
XX
AC ADQ93500;
XX
DT 21-OCT-2004 (first entry)
XX
DE 3-beta-hydroxysteroiddehydrogenase siRNA sense strand, SEQ ID 1076.
XX
KW Endocrine; Antisecretory; Dermatological; Depilatory; RNA interference;
KW small interfering RNA; siRNA;
KW androgen signal transduction pathway protein;
KW androgen signal transduction; 3-beta-hydroxysteroiddehydrogenase;
KW hair loss; hyperandrogenic condition; androgenic alopecia;
KW male pattern alopecia; acne vulgaris; seborrhoea; female hirsutism;
KW prostatic hypertrophy; ds.
XX
OS Synthetic.
XX

PH Key Location/Qualifiers
FT misc_feature 20..21
FT /*tag= a
XX /note= "2 deoxynucleotide overhang"
PN WO2004063331-A2.
XX
PD 29-JUL-2004.
XX
PF 05-JAN-2004; 2004WO-US000128.
XX
PR 03-JAN-2003; 2003US-0437842P.
XX
PA (GENC-) GENCIA CORP.
XX
PI Kahn S;
XX
DR WPI; 2004-561892/54.
XX
PT Inhibitory nucleic acid that inhibits expression of an androgen signal
PT transduction pathway protein useful for treating hair loss, comprises a
PT double stranded RNA having a partial sequence encoding a pathway protein
PT in one strand.
XX
PS Claim 11; Page 70; 92pp; English.
XX
CC The present invention relates to novel small interfering RNAs (siRNAs),
CC comprising a double stranded RNA, where one strand comprises a partial
CC nucleic acid sequence of an androgen signal transduction pathway protein,
CC and where the double-stranded RNA inhibits translation of mRNA encoding
CC the nucleic acid sequence of the androgen signal transduction pathway
CC protein thereby blocking the androgen signal transduction pathway. The
CC androgen signal transduction pathway protein is chosen from isozymes I
CC and II of 5-alpha reductase (ADQ92425 and ADQ92516), the androgen
CC receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-
CC hydroxysteroiddehydrogenase (ADQ93182), 3-beta-
CC hydroxysteroiddehydrogenase (ADQ93360), 3-beta-
CC hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-
CC hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase
CC (ADQ93770). The siRNAs of the invention are useful for reducing hair loss
CC in a mammal which involves contacting several mammal's hair cells with
CC the siRNA, where the siRNA interferes with the translation of mRNA of the
CC androgen signal transduction protein. The siRNAs are useful for treating
CC hyperandrogenic conditions of androgenic alopecia, including male pattern
CC alopecia, acne vulgaris, seborrhoea, and female hirsutism and prostatic
CC hypertrophy. The present sequence is the sense strand for one such siRNA
CC of the invention.
XX
SQ Sequence 21 BP; 7 A; 5 C; 4 G; 2 T; 3 U; 0 Other;
Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 43;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1453 ACTCTATGCTCAGGCTGTA 1472
DB 20 ACTCTTTGCTCAGGCTGTA 1
RESULT 27
ADQ93681/C
ID ADQ93681 standard; RNA; 21 BP.
XX
AC ADQ93681;
XX
DT 21-OCT-2004 (first entry)
XX
DE 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase siRNA sense strand.
KW Endocrine; Antisecretory; Dermatological; Depilatory; RNA interference;
KW small interfering RNA; siRNA;
KW androgen signal transduction pathway protein;
KW androgen signal transduction;
XX


```

PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 09-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493988P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
PA
XX
XX Manoharan M, Buncrot D;
PI
XX
XX WPI; 2004-677362/66.
DR
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
PT
XX
XX Example 5; SEQ ID NO 6758; 378pp; English.
PS
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
DB 19 AAAAAAAAAAAAAAAAAA 1

RESULT 24
AAH62035
ID AAH62035 standard; DNA; 21 BP.
XX
XX AAH62035;
XX
XX 10-SEP-2001 (first entry)
XX
XX MMP3 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4459.
XX

```

```

KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
KW recognition site; target; ribozyme binding site; eye disease; vulnery;
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
KW matrix metalloproteinase; growth factor; reductase; scarring; cytosatic;
KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
KW antiskinning; ophthalmological; keratolytic; gene therapy; viral wart;
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
KW sickle cell retinopathy; ss.
XX
XX Homo sapiens.
OS Synthetic.
OS
XX
XX WO200130362-A2.
PN
XX
XX 03-MAY-2001.
PD
XX
XX 26-OCT-2000; 2000WO-US029500.
PF
XX
XX 26-OCT-1999; 99US-0161532P.
PR
XX
XX (IMMU-) IMMUSOL INC.
PA
XX
XX Robbins JM, Tritz R;
PI
XX
XX WPI; 2001-300427/31.
DR
XX
XX Treating proliferative skin or eye diseases and scarring, using ribozymes
PT that cleave RNA encoding cytokines involved in inflammation, matrix
PT metalloproteinases, growth factors and cell-cycle dependent kinases.
XX
XX Example 1; Page 23; 408pp; English.
PS
XX
XX The present invention describes a method for treating a proliferative
CC skin or eye disease and scarring. The method involves administering a
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
CC dependent kinase, growth factor or a reductase, or administering a
CC nucleic acid molecule (II) comprising a promoter operably linked to a
CC nucleic acid segment encoding (I). (I) can have antiproliferative,
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiskinning,
CC ophthalmological, vulnery, keratolytic and virucide activities, and
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
CC in gene therapy. (I) and (II) are useful for treating proliferative skin
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
CC also be used for treating proliferative eye diseases such as diabetic
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
CC prematurity and retinal detachment, and for treating and preventing
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
CC scar. AAH57577 to AAH62099 represent sequences used in the
CC exemplification of the present invention
XX
XX Sequence 21 BP; 4 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATGGA 768
DB 3 CATTGAGTCCCTCTATGGA 21

RESULT 25
AAH70486/c
ID AAH70486 standard; DNA; 23 BP.
XX
XX AAH70486;
XX
XX 05-JAN-1998 (first entry)
XX

```

```

CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match      1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 22
ADR82256/c
ID ADR82256 standard; DNA; 19 BP.
XX
AC ADR82256;
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6755.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; RNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
XX
PR 12-MAR-2003; 2003US-0454265P.
XX
PR 13-MAR-2003; 2003US-0454962P.
XX
PR 14-APR-2003; 2003US-0455050P.
XX
PR 17-APR-2003; 2003US-0462894P.
XX
PR 25-APR-2003; 2003US-0463772P.
XX
PR 25-APR-2003; 2003US-0465665P.
XX
PR 09-MAY-2003; 2003US-0465802P.
XX
PR 09-MAY-2003; 2003US-0469612P.
XX
PR 08-AUG-2003; 2003US-0493986P.
XX
PR 11-AUG-2003; 2003US-0494597P.
XX
PR 26-SEP-2003; 2003US-0506341P.
XX
PR 09-OCT-2003; 2003US-0510246P.
XX
PR 10-OCT-2003; 2003US-0510318P.
XX
PR 07-NOV-2003; 2003US-0518453P.
XX
(PALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 6755; 378pp; English.
XX

```

The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1) The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apob-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a hepatitis C virus (HCV) antisense oligonucleotide that can be used to control HCV gene expression.

Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 23
ADR82259/c
ID ADR82259 standard; DNA; 19 BP.
XX
AC ADR82259;
XX
DT 16-DEC-2004 (first entry)
XX
DE Hepatitis C virus (HCV) oligonucleotide seqid 6758.
XX
KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; RNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
OS Hepatitis C virus.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
XX
PR 12-MAR-2003; 2003US-0454265P.
XX
PR 13-MAR-2003; 2003US-0454962P.
XX
PR 14-APR-2003; 2003US-0455050P.
XX
PR 17-APR-2003; 2003US-0462894P.
XX
PR 25-APR-2003; 2003US-0463772P.
XX
PR 25-APR-2003; 2003US-0465665P.
XX
PR 09-MAY-2003; 2003US-0465802P.
XX
PR 09-MAY-2003; 2003US-0469612P.
XX
PR 08-AUG-2003; 2003US-0493986P.
XX
PR 11-AUG-2003; 2003US-0494597P.
XX
PR 26-SEP-2003; 2003US-0506341P.
XX
PR 09-OCT-2003; 2003US-0510246P.
XX
PR 10-OCT-2003; 2003US-0510318P.
XX
PR 07-NOV-2003; 2003US-0518453P.
XX
(ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR WPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 6755; 378pp; English.
XX

```

PR 12-MAR-2003; 2003US-0454265P.
PR 13-MAR-2003; 2003US-0454962P.
PR 13-MAR-2003; 2003US-0455050P.
PR 14-APR-2003; 2003US-0462894P.
PR 17-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 25-APR-2003; 2003US-0465802P.
PR 25-MAY-2003; 2003US-0469612P.
PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
PA
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
DR
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6760; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX
XX Query Match 1.1%; Score 19; DB 1; Length 19;
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1749 AAAAAAAAAAAAAAAAAA 1767
Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 21
ADR82258/c
ID ADR82258 standard; DNA; 19 BP.
XX
XX ADR82258;
AC
XX
```

```

DT 16-DEC-2004 (first entry)
XX Hepatitis C virus (HCV) oligonucleotide seqid 6757.
DE
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cyostatic; anticonvulsant; nootropic; muscular; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
OS
XX Hepatitis C virus.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
PD
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454265P.
XX 13-MAR-2003; 2003US-0454982P.
XX 13-MAR-2003; 2003US-0455050P.
XX 14-APR-2003; 2003US-0462894P.
XX 17-APR-2003; 2003US-0463772P.
XX 25-APR-2003; 2003US-0465665P.
XX 25-APR-2003; 2003US-0465802P.
XX 09-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
PA
XX Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6757; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX
```

CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX
 SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
 |||||
 Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 19
 ADR82257/c
 ID ADR82257 standard; DNA; 19 BP.
 XX
 AC ADR82257;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Hepatitis C virus (HCV) oligonucleotide seqid 6756.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 PI Mancharan M, Bumcrot D;
 XX
 XX WPI; 2004-677362/66.
 DR
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 FT disease, diabetes, cancer or neurological disease, comprises sense
 PT

sequence and antisense sequence which has specific modifications.

Example 5; SEQ ID NO 6756; 378pp; English.

XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 1.1%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
 |||||
 Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 20

ADR82261/c

ID ADR82261 standard; DNA; 19 BP.

XX
 AC ADR82261;

XX
 DT 16-DEC-2004 (first entry)

XX
 DE Hepatitis C virus (HCV) oligonucleotide seqid 6760.

XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.

XX Hepatitis C virus.

XX WO2004080406-A2.

XX
 PD 23-SEP-2004.

XX
 PF 08-MAR-2004; 2004WO-US007070.

XX
 PR 07-MAR-2003; 2003US-0452682P.

```
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
Query Match      1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAAAAAAACAAAAAACAA 1

RESULT 17
ADIS3690/c
ID ADIS3690 standard; DNA; 19 BP.
XX AC
XX DT
XX DE
XX KW antileptic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX KW cytosolic; anticonvulsant; nootropic; muscula; anti-HIV;
XX KW RNA interference; iRNA; antisense technology; lipid metabolism;
XX KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX KW coronary artery disease; CAD; coronary heart disease; CHD;
XX KW atherosclerosis; hepatic glucose production;
XX KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX KW colon cancer; lung cancer; neurological disease; Huntington disease;
XX KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX OS Hepatitis C virus.
XX FN WO2004080406-A2.
XX PD 23-SEP-2004.
XX PF 08-MAR-2004; 2004WO-US007070.
XX PR 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX PR 13-MAR-2003; 2003US-0455050P.
XX PR 14-APR-2003; 2003US-0462894P.
XX PR 17-APR-2003; 2003US-0463772P.
XX PR 25-APR-2003; 2003US-0465665P.
XX PR 09-MAY-2003; 2003US-0469612P.
XX PR 08-AUG-2003; 2003US-0493986P.
XX PR 11-AUG-2003; 2003US-0494597P.
XX PR 26-SEP-2003; 2003US-0506341P.
XX PR 09-OCT-2003; 2003US-0510246P.
XX PR 10-OCT-2003; 2003US-0510318P.
XX PR 07-NOV-2003; 2003US-0518453P.
XX PA (ALNY-) ALNYLAM PHARM.
XX PI Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX PT disease, diabetes, cancer or neurological disease, comprises sense
XX PT sequence and antisense sequence which has specific modifications.
XX PS Example 5; SEQ ID NO 6759; 378pp; English.
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX CC sense sequence and an antisense sequence, where the sense sequences have
XX CC one or more asymmetrical 2'-O alkyl modifications, the antisense
XX CC sequences have one or more asymmetrical phosphorothioate modifications
XX CC and the antisense sequence targets a human gene sequence. Also described
XX CC are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX CC levels or glucose-6-phosphatase levels in a subject; producing (I);
XX CC stabilising (I), involves selecting a sequence with activity and
XX CC introducing one or more asymmetrical modification in the sequence, where
XX CC the modification decreases nuclease sensitivity while not decreasing its
XX CC activity; a kit comprising (I) and instruction for its use; and a device
XX CC that can be dispense or administer a composition comprising (I). (I) is
XX CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX CC The subject is suffering from a disorder characterised by elevated or
XX CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX CC disorder is chosen from the HDL/LDL cholesterol imbalance,
XX CC dyslipidaemias, hypercholesterolaemia, statin-resistant
```

XX The present invention describes a method for predicting, diagnosing or
 CC prognosing chronic lung disease by detecting a chronic obstructive
 CC pulmonary disease (COPD) gene related polynucleotide (see ACC46750 to
 CC ACC46777, which encode the COPD related proteins in ABP96779 to
 CC ABP96806). The method is useful for predicting, diagnosing or prognosing
 CC chronic lung disease in a biological sample. The COPD genes and proteins
 CC encoded by them from the present invention (I) can be used for treating
 CC or preventing chronic lung disease in a mammal. (I) can be used in an
 CC animal model for determining the efficacy, toxicity, or side effects of
 CC treatment with (I), and determining the mechanism of action of (I).
 CC ACC46778 to ACC46903 represent COPD related PCR primers and probes used
 CC in an example from the present invention

XX Sequence 24 BP; 6 A; 5 C; 3 G; 10 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 42;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 981 TGCATTACGAATTTGAACGAGAAA 1004
 DB 24 TGCATTACGAATTTGAACGAGAAA 1
 ||||| ||||| ||||| ||||| |||||

RESULT 15
 ADG76001/C
 ID ADG76001 standard; DNA; 24 BP.
 AC ADG76001;
 DT 11-MAR-2004 (first entry)
 XX Non-CpG DNA oligonucleotide 2.
 DE ss; non-CpG; immunostimulatory; non-palindromic; immune response;
 KW proliferation; differentiation; cytokine; antibody production; B-cell;
 KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
 KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
 KW renal cell carcinoma.
 XX Synthetic.
 OS WO2003101375-A2.
 PN 11-DEC-2003.
 XX 30-MAY-2003; 2003WO-EF005691.
 XX 30-MAY-2002; 2002CA-02388049.
 PR (IMMU-) IMMUNOTECH SA.
 XX Lopez RA;
 PI WPI; 2004-053333/05.
 DR New immunostimulatory oligonucleotide comprising non-palindromic nucleic
 XX acid sequence motif, useful for inducing B-cell activation, treating,
 PT preventing or ameliorating immune system disorder or tumoral disease e.g.
 PT melanoma.
 PS Example 17; Page 80; 139pp; English.
 XX This invention relates to novel immunostimulatory oligonucleotides that
 CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
 CC oligonucleotides (without a CpG motif), which can stimulate an immune
 CC response in animals of the order of primate, including humans. The immune
 CC response is characterised by the proliferation, differentiation, cytokine
 CC and antibody production in B-cells, as well as cell differentiation and
 CC cytokine production in plasmacytoid dendritic cells. The present
 CC invention describes immunomodulator compositions that also comprise an
 CC antigen selected from, for example, viruses, bacteria, parasites, tumour
 CC cells and glycolipids. As such, these DNA oligos can be used in gene
 CC therapy for inducing B-cell activation, treating, preventing or
 CC ameliorating an immune system disorder or a tumoral disease including
 CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
 CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the
 CC invention.

CC cells and glycolipids. As such, these DNA oligos can be used in gene
 CC therapy for inducing B-cell activation, treating, preventing or
 CC ameliorating an immune system disorder or a tumoral disease including
 CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
 CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the
 CC invention.

XX Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
 SQ Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 42;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAA 1772
 DB 24 AAAAAAAAAAAAAAAAAAAAAAA 1
 ||||| ||||| ||||| ||||| |||||

RESULT 16
 ADG76035/C
 ID ADG76035 standard; DNA; 24 BP.
 XX AC ADG76035;
 XX 11-MAR-2004 (first entry)
 XX Non-CpG DNA oligonucleotide 36.
 DE ss; non-CpG; immunostimulatory; non-palindromic; immune response;
 KW proliferation; differentiation; cytokine; antibody production; B-cell;
 KW plasmacytoid dendritic cell; immunomodulator; gene therapy;
 KW chronic myelogenous leukaemia; melanoma; Kaposi's sarcoma;
 KW renal cell carcinoma.
 XX Synthetic.
 OS WO2003101375-A2.
 PN 11-DEC-2003.
 XX 30-MAY-2003; 2003WO-EF005691.
 XX 30-MAY-2002; 2002CA-02388049.
 PR (IMMU-) IMMUNOTECH SA.
 XX Lopez RA;
 PI WPI; 2004-053333/05.
 DR New immunostimulatory oligonucleotide comprising non-palindromic nucleic
 XX acid sequence motif, useful for inducing B-cell activation, treating,
 PT preventing or ameliorating immune system disorder or tumoral disease e.g.
 PT melanoma.
 PS Example 17; Page 81; 139pp; English.
 XX This invention relates to novel immunostimulatory oligonucleotides that
 CC contain a non-palindromic sequence motif. Specifically, it refers to DNA
 CC oligonucleotides (without a CpG motif), which can stimulate an immune
 CC response in animals of the order of primate, including humans. The immune
 CC response is characterised by the proliferation, differentiation, cytokine
 CC and antibody production in B-cells, as well as cell differentiation and
 CC cytokine production in plasmacytoid dendritic cells. The present
 CC invention describes immunomodulator compositions that also comprise an
 CC antigen selected from, for example, viruses, bacteria, parasites, tumour
 CC cells and glycolipids. As such, these DNA oligos can be used in gene
 CC therapy for inducing B-cell activation, treating, preventing or
 CC ameliorating an immune system disorder or a tumoral disease including
 CC chronic myelogenous leukaemia, melanoma, Kaposi's sarcoma, and renal cell
 CC carcinoma. This oligonucleotide sequence is a non-CpG DNA oligo of the
 CC invention.

```

RESULT 12
ACD99368/c
ID ACD99368 standard; DNA; 24 BP.
XX
AC ACD99368;
XX
DT 25-SEP-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #54.
XX
KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW antilucer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
OS Synthetic.
XX
PN US2003050268-A1.
XX
PD 13-MAR-2003.
XX
PF 29-MAR-2002; 2002US-00112653.
XX
PR 29-MAR-2001; 2001US-0279642P.
XX
PA (KRIE/) KRIEG A M.
PA (BERG/) BERG D J.
XX
PI Krieg AM, Berg DJ;
XX
DR WPI; 2003-521815/49.
XX
PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
PS Disclosure; Page 10; 229pp; English.
XX
CC The invention describes a method of treating non-allergic inflammatory
CC disease comprising administering to a subject having or at risk of
CC developing a non-allergic inflammatory disease an immunostimulatory
CC nucleic acid for prevention or treatment of the disease. The method is
CC useful for treating non-allergic inflammatory diseases, such as
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
CC This sequence represents an immunostimulatory nucleic acid
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAAAAAACAAAAACAA 1
RESULT 13
ADB36437/c
ID ADB36437 standard; DNA; 24 BP.
XX
AC ADB36437;
XX
DT 04-DEC-2003 (first entry)
XX
DE Immunostimulatory nucleic acid #51.
XX
KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
OS Synthetic.
XX
PN US2003087848-A1.
XX
PD 08-MAY-2003.
XX
PF 02-FEB-2001; 2001US-00776479.
XX
PR 03-FEB-2000; 2000US-0179991P.
XX
PA (BRAT/) BRATZLER R L.
PA (PETE/) PETERSEN D M.
XX
PI Bratzler RL, Petersen DM, Pouron Y;
XX
DR WPI; 2003-657977/62.
XX
PT Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
PS Disclosure; Page 6; 221pp; English.
XX
CC The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.
XX
SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 42;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAAAAAACAAAAACAA 1
RESULT 14
ACC46843/c
ID ACC46843 standard; DNA; 24 BP.
XX
AC ACC46843;
XX
DT 05-JUN-2003 (first entry)
XX
DE Human COPD related gene reverse PCR primer SEQ ID NO:122.
XX
KW Human; chronic obstructive pulmonary disease; COPD; chronic lung disease;
KW PCR primer; ss.
OS Homo sapiens.
OS Synthetic.
XX
PN WO200297127-A2.
XX
PD 05-DEC-2002.
XX
PF 28-MAY-2002; 2002WO-EP005835.
XX
PR 31-MAY-2001; 2001GB-00013266.
XX
PA (FARB ) BAYER AG.
XX
PI Oellers N, Gehrman M, Kallabis H, Hall R, Schulze T, Kroegel C;
XX
DR WPI; 2003-140492/13.
XX
PT Predicting, diagnosing or prognosing chronic lung disease, by detecting a
PT chronic obstructive pulmonary disease (COPD) gene in a biological sample.
XX
PS Example 1; Page 212; 214pp; English.

```

CC behaviour in a non turbulent flow, in a micro flow path, where a large
 CC number of samples can be processed. This polynucleotide sequence
 CC represents an oligo used in the exemplification of the invention.
 XX
 SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 24;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
 DB 1 AAAAAAAAAAAAAAAAAAAAAA 20
 RESULT 10
 AAF98935/c
 ID AAF98935 standard; DNA; 24 BP.
 AC AAF98935;
 XX
 DT 12-JUN-2001 (first entry)
 DE Immunostimulatory nucleic acid #51.
 KW Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
 KW immunostimulatory; tumour; viral infection; bacterial infection;
 KW fungal infection; parasitic infection; cancer; asthma;
 KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
 OS Synthetic.
 XX
 PN WO200122972-A2.
 XX
 PD 05-APR-2001.
 PF 25-SEP-2000; 2000WO-US026383.
 XX
 PR 25-SEP-1999; 99US-0156113P.
 PR 27-SEP-1999; 99US-0156135P.
 PR 23-AUG-2000; 2000US-0227436P.
 XX
 PA (IOWA) UNIV IOWA RES FOUND.
 PA (COLE-) COLEY PHARM GMBH.
 XX
 PI Krieg AM, Schetter C, Vollmer J;
 XX
 DR WPI; 2001-273485/28.
 XX
 PT Vaccinating against tumors, infectious diseases, allergies and asthma
 PT using immunostimulatory Py-rich and TG nucleic acids.
 XX
 PS Disclosure; Page 39; 338pp; English.
 XX
 CC The present invention relates to a method for stimulating an immune
 CC response. The method comprises administering an immunostimulatory nucleic
 CC acid to a non-rodent subject in sufficient quantity to stimulate an
 CC immune response. The present sequence is one such immunostimulatory
 CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
 CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
 CC against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
 CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
 CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
 CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
 CC also useful for preventing cancer, asthma, infectious disease, allergy or
 CC immune deficiency. The present sequence can also be used to redirect a
 CC Th2 to a Th1 immune response and to activate immune cells. Note: the
 CC present sequence may have a phosphorothioate backbone
 XX
 SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
 Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 42;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 DB 24 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 11
 ABS77576/c
 ID ABS77576 standard; DNA; 24 BP.
 AC ABS77576;
 XX
 DT 13-DEC-2002 (first entry)
 DE Angiogenesis inhibitory oligonucleotide #60.
 XX
 KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
 KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
 KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
 KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
 KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
 KW plaque neovascularisation; telangiectasia; haemophilic joint;
 KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
 KW scleroderma; hypertrophic scar.
 OS Synthetic.
 XX
 PN WO200253141-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 14-DEC-2001; 2001WO-US048458.
 XX
 PR 14-DEC-2000; 2000US-0255534P.
 XX
 PA (COLE-) COLEY PHARM GROUP INC.
 XX
 PI Bratzler RL;
 XX
 DR WPI; 2002-566690/60.
 XX
 PT Inhibiting angiogenesis in a subject, involves administering at least one
 PT antiangiogenic nucleic acid molecule to the subject.
 XX
 PS Claim 2; Page 20; 276pp; English.
 XX
 CC The invention relates to inhibiting angiogenesis in a subject, comprising
 CC administering at least one antiangiogenic nucleic acid molecule. Also
 CC included is a kit comprising a first container housing the antiangiogenic
 CC nucleic acids, and instructions for administering them to a subject
 CC having a condition characterised by unwanted angiogenesis. The method is
 CC useful for inhibiting angiogenesis associated with solid tumour growth,
 CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
 CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
 CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
 CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
 CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
 CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
 CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
 CC acid of the invention
 XX
 SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
 Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 42;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 DB 24 AAAAAAAAAAAAAAAAAAAAAA 1

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 DB 24 AAAAAAAAAAAAAAAAAAAAAA 1
 RESULT 11
 ABS77576/c
 ID ABS77576 standard; DNA; 24 BP.
 AC ABS77576;
 XX
 DT 13-DEC-2002 (first entry)
 DE Angiogenesis inhibitory oligonucleotide #60.
 XX
 KW Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
 KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
 KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;
 KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
 KW rubeosis; Osler-Webber Syndrome; myocardial angiogenesis;
 KW plaque neovascularisation; telangiectasia; haemophilic joint;
 KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
 KW scleroderma; hypertrophic scar.
 OS Synthetic.
 XX
 PN WO200253141-A2.
 XX
 PD 11-JUL-2002.
 XX
 PF 14-DEC-2001; 2001WO-US048458.
 XX
 PR 14-DEC-2000; 2000US-0255534P.
 XX
 PA (COLE-) COLEY PHARM GROUP INC.
 XX
 PI Bratzler RL;
 XX
 DR WPI; 2002-566690/60.
 XX
 PT Inhibiting angiogenesis in a subject, involves administering at least one
 PT antiangiogenic nucleic acid molecule to the subject.
 XX
 PS Claim 2; Page 20; 276pp; English.
 XX
 CC The invention relates to inhibiting angiogenesis in a subject, comprising
 CC administering at least one antiangiogenic nucleic acid molecule. Also
 CC included is a kit comprising a first container housing the antiangiogenic
 CC nucleic acids, and instructions for administering them to a subject
 CC having a condition characterised by unwanted angiogenesis. The method is
 CC useful for inhibiting angiogenesis associated with solid tumour growth,
 CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
 CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
 CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
 CC rubeosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque
 CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
 CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
 CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
 CC acid of the invention
 XX
 SQ Sequence 24 BP; 0 A; 0 C; 3 G; 21 T; 0 U; 0 Other;
 Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 42;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 DB 24 AAAAAAAAAAAAAAAAAAAAAA 1

CC from the genes corresponding to the partial sequences given in ABZ82842
 CC to ABZ84764, or their fragments of at least 20 nucleotides, or homologues
 CC ; and (2) determining if a gene putatively identified to be a toxic
 CC response gene plays a role on toxic response pathways by determining the
 CC expression profile of the gene after exposure of cells or a human subject
 CC to a known toxic pharmaceutical or industrial agent, comprising: (a)
 CC exposing cells to an agent or isolating cells from a human subject who
 CC was exposed to an agent; (b) obtaining the test gene expression profile
 CC for a putatively identified toxic response gene after exposure to a known
 CC toxic pharmaceutical or industrial agent; and (c) comparing the test
 CC profile to the expression profile of a gene with a similar function or
 CC comparing the test profile to the expression profile of that gene after
 CC exposure to other known toxic compounds. The methods are useful for
 CC predicting and determining toxicological responses on a cellular, organ
 CC or system level. The arrays comprising the human genes are useful for
 CC toxicological screening of drugs, pharmaceutical compounds and chemicals
 XX

Sequence 26 BP; 7 A; 10 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 1.3%; Score 22.8; DB 1; Length 26;
 Best Local Similarity 92.3%; Pred. No. 15;
 Matches 24; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1370 CAAGCTGGTTGGTTGGTTAGGAAGAA 1395
 DB 26 CGAGCTGGTTGGTTGGTTAGGAAGAA 1

RESULT 6
 ADR44220
 ID ADR44220 standard; DNA; 25 BP.
 XX
 AC ADR44220;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE Caenorhabditis elegans heat-shock promoter DNA #1.
 DE Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.
 KW Caenorhabditis elegans.

FT Key Location/Qualifiers
 FT misc_feature 4 /tag= a
 FT /note= "N can be repeated X times"
 FT misc_feature 22 /tag= b
 FT /note= "N can be repeated Y times"

US2004161782-A1.
 PD 19-AUG-2004.
 XX
 PF 21-NOV-2003; 2003US-00719995.
 XX
 PR 22-MAY-2001; 2001EP-00201936.
 PR 22-MAY-2002; 2002WO-NL000322.
 PR 28-NOV-2002; 2002WO-WO095071.

(TIJS/) TIJSTERMAN M.
 (PLAS/) PLASTERK R H A.

PI Tijsterman M, Plasterk RHA;

DR WPI; 2004-603554/58.

Determining if a gene product/compound is involved in preventing
 PT replication error in a cell, useful for treating cancer, comprises
 PT determining expression level of a marker gene in a cell treated with a
 PT gene product inhibitor/compound.

PS Disclosure; Fig 3; 25pp; English.

XX The present invention relates to a method for determining if a gene
 CC product or compound is involved in preventing replication error in a
 CC cell. The method involves providing a cell with a specific inhibitor for
 CC a gene product or with a compound and determining the expression level of
 CC a marker gene in the cell, where the expression level of the marker gene
 CC is dependent on the occurrence of a replication error. The invention is
 CC useful in gene therapy and for treating a subject having tumours or
 CC cancer. The present sequence is a Caenorhabditis elegans heat-shock
 CC promoter DNA. This sequence is used to illustrate the method of
 CC invention.

Sequence 25 BP; 21 A; 0 C; 1 G; 1 T; 0 U; 2 Other;

Query Match 1.2%; Score 22; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 18;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1747 TGAAGAAAAA 1770
 DB 2 TGAAGAAAAA 25

RESULT 7
 ADR44221
 ID ADR44221 standard; DNA; 24 BP.
 XX
 AC ADR44221;
 XX

DT 04-NOV-2004 (first entry)

DE Caenorhabditis elegans heat-shock promoter DNA #2.

KW Nematode; gene therapy; tumour; cancer; heat-shock promoter; ss.

OS Caenorhabditis elegans.

FT Key Location/Qualifiers

FT misc_feature 4 /tag= a
 FT /note= "N can be repeated X times"
 FT misc_feature 21 /tag= b
 FT /note= "N can be repeated Y times"

US2004161782-A1.

PD 19-AUG-2004.

PF 21-NOV-2003; 2003US-00719995.

XX 22-MAY-2001; 2001EP-00201936.

PR 22-MAY-2002; 2002WO-NL000322.

PR 28-NOV-2002; 2002WO-WO095071.

(TIJS/) TIJSTERMAN M.

(PLAS/) PLASTERK R H A.

PI Tijsterman M, Plasterk RHA;

DR WPI; 2004-603554/58.

Determining if a gene product/compound is involved in preventing
 PT replication error in a cell, useful for treating cancer, comprises
 PT determining expression level of a marker gene in a cell treated with a
 PT gene product inhibitor/compound.

PS Disclosure; Fig 3; 25pp; English.

XX The present invention relates to a method for determining if a gene
 CC product or compound is involved in preventing replication error in a
 CC cell. The method involves providing a cell with a specific inhibitor for
 CC a gene product or with a compound and determining the expression level of

```

PA (KRON/) KRONICK M N.
PI Leproust EM, Amorese DA, Kronick MN;
XX
XX
DR WPI; 2004-634540/61.
XX
XX Detection of deposition unit misalignment of in situ polymeric array
PT synthesis device, by contacting test probe feature with different
PT distinguishably labeled targets, and evaluating binding of labeled
PT targets to test probe feature.
XX
XX
XX Example 2; Page 16; 36pp; English.
XX
XX The invention relates to a method of detection of deposition unit
CC misalignment of an in situ polymeric array synthesis device which
CC comprises synthesising test probe feature(s) on substrate using in situ
CC polymeric array synthesis device, contacting test probe feature with at
CC least two different distinguishably labelled targets and evaluating
CC binding of labelled targets to test probe feature to detect any pulse jet
CC misalignment of polymeric array synthesis device. The method is useful
CC for detecting deposition unit misalignment e.g. printhead misalignment,
CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
CC method is easy to use, cost effective, effective at detecting printhead
CC misalignments and may enable immediate detection and/or adjustments of
CC one or more printheads of an in situ nucleic acid array synthesis fluid
CC deposition device if misalignment is detected. The present sequence
CC represents an oligonucleotide synthesised on a microarray.
XX
SQ Sequence 24 BP; 24 A; 0 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 1 AAAAAAAAAAAAAAAAAAAAAA 24
RESULT 4
ADR48249/c
ID ADR48249 standard; DNA; 24 BP.
XX
XX ADR48249;
XX
XX 18-NOV-2004 (first entry)
XX
XX Microarray synthesised oligonucleotide #13.
XX
XX ss; deposition unit misalignment; polymeric array synthesis;
KW pulse jet misalignment; printhead misalignment; microarray.
XX
XX Synthetic.
XX
XX US2004170984-A1.
XX
XX 02-SEP-2004.
XX
XX 25-FEB-2003; 2003US-00374307.
XX
XX 25-FEB-2003; 2003US-00374307.
XX
XX (LEPR/) LEPROUST E M.
PA (AMOR/) AMORESE D A.
PA (KRON/) KRONICK M N.
XX
XX Leproust EM, Amorese DA, Kronick MN;
XX
XX WPI; 2004-634540/61.
XX
XX Detection of deposition unit misalignment of in situ polymeric array
PT synthesis device, by contacting test probe feature with different
PT distinguishably labeled targets, and evaluating binding of labeled
PT targets to test probe feature.

```

```

PT targets to test probe feature.
XX
XX Example 2; Page 16; 36pp; English.
XX
XX The invention relates to a method of detection of deposition unit
CC misalignment of an in situ polymeric array synthesis device which
CC comprises synthesising test probe feature(s) on substrate using in situ
CC polymeric array synthesis device, contacting test probe feature with at
CC least two different distinguishably labelled targets and evaluating
CC binding of labelled targets to test probe feature to detect any pulse jet
CC misalignment of polymeric array synthesis device. The method is useful
CC for detecting deposition unit misalignment e.g. printhead misalignment,
CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
CC method is easy to use, cost effective, effective at detecting printhead
CC misalignments and may enable immediate detection and/or adjustments of
CC one or more printheads of an in situ nucleic acid array synthesis fluid
CC deposition device if misalignment is detected. The present sequence
CC represents an oligonucleotide synthesised on a microarray.
XX
SQ Sequence 24 BP; 0 A; 0 C; 0 G; 24 T; 0 U; 0 Other;
Query Match 1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAAAAAAAAAAAAAAAAAA 1
RESULT 5
ABZ84111/c
ID ABZ84111 standard; DNA; 26 BP.
XX
XX AC ABZ84111;
XX
XX 14-MAY-2003 (first entry)
XX
XX Toxicologically relevant rat PCR primer #1270.
XX
XX Toxicologically relevant gene; toxicological response; PCR primer; ss.
XX
XX Rattus sp.
XX Synthetic.
XX
XX WO2003016500-A2.
XX
XX 27-FEB-2003.
XX
XX 16-AUG-2002; 2002WO-US026514.
XX
XX 16-AUG-2001; 2001US-0313080P.
XX
XX (PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.
XX
XX Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schweiser K;
PI Alen P;
XX
XX WPI; 2003-268322/26.
XX
XX Determining a toxicological response to an agent, useful for screening of
PT drugs, comprises comparing the expression profile of one or more human
PT toxic response genes to a reference gene expression profile indicative of
PT toxicity.
XX
XX Claim 1; Page 332; 455pp; English.
XX
XX The present invention describes a method (M1) for determining a
CC toxicological response to an agent, which comprises comparing the
CC expression profile of one or more human toxic response genes to a
CC reference gene expression profile indicative of toxicity, and so
CC determining the presence of a toxic response to the agent. Also
CC described: (1) an array comprising one or more polynucleotides selected

```

27-FEB-2003.

16-AUG-2002; 2002WO-US026514.

16-AUG-2001; 2001US-0313080P.

(PHAS-) PHASE-1 MOLECULAR TOXICOLOGY INC.

Neft RE, Dunn RT, Adkins K, Pickett GG, Kier LD, Schmeiser K; Alen P;

WPI; 2003-268322/26.

Determining a toxicological response to an agent, useful for screening of drugs, comprises comparing the expression profile of one or more human toxic response genes to a reference gene expression profile indicative of toxicity.

Claim 1; Page 332; 455pp; English.

The present invention describes a method (M1) for determining a toxicological response to an agent, which comprises comparing the expression profile of one or more human toxic response genes to a reference gene expression profile indicative of toxicity, and so determining the presence of a toxic response to the agent. Also described: (1) an array comprising one or more polynucleotides selected from the genes corresponding to the partial sequences given in AB282842 to AB284764, or their fragments of at least 20 nucleotides, or homologues; and (2) determining if a gene putatively identified to be a toxic response gene plays a role on toxic response pathways by determining the expression profile of the gene after exposure of cells or a human subject to a known toxic pharmaceutical or industrial agent, comprising: (a) exposing cells to an agent or isolating cells from a human subject who was exposed to an agent; (b) obtaining the test gene expression profile for a putatively identified toxic response gene after exposure to a known toxic pharmaceutical or industrial agent; and (c) comparing the test profile to the expression profile of a gene with a similar function or comparing the test profile to the expression profile of that gene after exposure to other known toxic compounds. The methods are useful for predicting and determining toxicological responses on a cellular, organ or system level. The arrays comprising the human genes are useful for toxicological screening of drugs, pharmaceutical compounds and chemicals

Sequence 26 BP; 7 A; 8 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.08; Pred. No. 5.3;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0

912 TGGGAGTCCAGCCACCACTACTT 937
 |||||
 1 TGGGAGTCCAGCCACCACTACTT 26

RESULT 2
 ADR51048/c
 ID ADR51048 standard; DNA; 27 BP.
 XX
 AC ADR51048;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 XX Duo binding moiety multivalent compound associated primer #1.
 XX
 KW ss; primer; antiarthritic; cytostatic; ophthalmological;
 KW angiogenesis inhibitor; Kdr tyrosine kinase inhibitor; VEGF antagonist;
 KW hepatocyte growth factor antagonist; multivalent compound;
 KW binding moiety; euplastic tumour growth; angiogenesis;
 KW hyperproliferation; arthritis; atherosclerotic plaque;
 KW corneal graft neovascularization; ocular disease.
 XX
 XX Synthetic.
 OS
 XX

c 107	14.4	0.8	17	1	AB260344	Human K-Ras DNazym
c 108	14.4	0.8	17	1	ADB40294	Tumour suppression
c 109	14.4	0.8	17	1	ADI48529	Human tumour suppress
c 110	14.4	0.8	17	1	ADI49691	Human tumour suppress
c 111	14.4	0.8	17	1	ACC51935	Human tumour suppress
c 112	14.4	0.8	17	1	ADI49338	Human PKR substrat
c 113	14.4	0.8	17	1	ADL49154	Human PKR substrat
c 114	14.4	0.8	17	1	ADL50592	Human PKR substrat
c 115	14.4	0.8	17	1	ADN45010	Mutant cell identi
c 116	14.4	0.8	17	1	ADN45011	Mutant cell identi
c 117	14.4	0.8	17	1	ACN73529	Human GDMPLP-1 prob
c 118	14.4	0.8	17	1	ACN73531	Human GDMPLP-1 prob
c 119	14.4	0.8	18	1	AAV70530	rpob binding capu
c 120	14.4	0.8	18	1	AA506835	SNP containing pro
c 121	14.4	0.8	18	1	ABK40971	Human obesity-asso
c 122	14.4	0.8	18	1	ABL44181	Human chromosome 1
c 123	14.4	0.8	18	1	ABL46141	Mycobacterium tube
c 124	14.4	0.8	18	1	AB597172	Human CYP4501A2 Ex
c 125	14.4	0.8	18	1	ABN83386	Hepatocyte growth
c 126	14.4	0.8	18	1	ABX34397	PCR primer #2 for
c 127	14.4	0.8	18	1	ADK82331	Nucleic acid analy
c 128	14.4	0.8	18	1	ADQ93227	3-alpha-hydroxyste
c 129	14.4	0.8	18	1	ADQ93225	3-alpha-hydroxyste
c 130	14.4	0.8	18	1	AD590092	Oligonucleotide of
c 131	14.2	0.8	19	1	ADR76235	Human apolipoprote
c 132	14.2	0.8	19	1	ADR78853	Human apolipoprote
c 133	14	0.8	15	1	AB597718	Human kelleikrin 2
c 134	14	0.8	15	1	AB597731	Human kelleikrin 2
c 135	14	0.8	15	1	AB597730	Human kelleikrin 2
c 136	14	0.8	15	1	ABL42626	Hairpin beacon tar
c 137	14	0.8	15	1	ABK98169	Triple helix formi
c 138	14	0.8	15	1	ABK98187	Triple helix formi
c 139	14	0.8	15	1	ABK98168	Triple helix formi
c 140	14	0.8	15	1	ABK98167	Triple helix formi
c 141	14	0.8	15	1	ABK98186	Triple helix formi
c 142	14	0.8	16	1	AAT60192	Synthetic PCNA rib
c 143	14	0.8	16	1	AA866559	PCNA hairpin riboz
c 144	14	0.8	16	1	AA866780	PCNA hammerhead ri
c 145	14	0.8	16	1	AAH61725	PCNA hairpin/hamme
c 146	14	0.8	16	1	AAH61946	PCNA hammerhead ri
c 147	14	0.8	17	1	AAA36162	Human genomic SNP
c 148	14	0.8	17	1	RAF02752	Hammerhead ribozym
c 149	14	0.8	17	1	ABA78618	APC mutation corre
c 150	14	0.8	17	1	ABA78617	APC mutation corre
c 151	14	0.8	17	1	ABN10437	Human GDMPLP-1 17-m
c 152	14	0.8	17	1	ABN10438	Human GDMPLP-1 17-m
c 153	14	0.8	17	1	ABV80109	Human HTPL scannin
c 154	14	0.8	17	1	ABV80107	Human HTPL scannin
c 155	14	0.8	17	1	ABV80110	Human HTPL scannin
c 156	14	0.8	17	1	ABV80108	Human HTPL scannin
c 157	14	0.8	17	1	AB575297	Human PAPP-Ea asso
c 158	14	0.8	17	1	AB575299	Human PAPP-Ea asso
c 159	14	0.8	17	1	AB575298	Human PAPP-Ea asso
c 160	14	0.8	17	1	AB575300	Human PAPP-Ea asso
c 161	14	0.8	17	1	AB261011	Human K-Ras DNazym
c 162	14	0.8	17	1	AB261010	Human K-Ras DNazym
c 163	14	0.8	17	1	AAD48153	PCR primer #1 used
c 164	14	0.8	17	1	ACN73527	Human GDMPLP-1 prob
c 165	14	0.8	17	1	ACN73528	Human GDMPLP-1 prob
c 166	13.8	0.8	17	1	AAQ20006	Oligonucleotide #2
c 167	13.8	0.8	17	1	AAK63865	Rabbit stromelysin
c 168	13.8	0.8	17	1	AAK63906	Rabbit stromelysin
c 169	13.8	0.8	17	1	AAK63977	Rabbit stromelysin
c 170	13.8	0.8	17	1	AAK64062	Rabbit stromelysin
c 171	13.8	0.8	17	1	AAK63909	Rabbit stromelysin
c 172	13.8	0.8	17	1	AAK63885	Rabbit stromelysin
c 173	13.8	0.8	17	1	AAK63908	Rabbit stromelysin
c 174	13.8	0.8	17	1	AAK63864	Rabbit stromelysin
c 175	13.8	0.8	17	1	AAK63905	Rabbit stromelysin
c 176	13.8	0.8	17	1	AAK63884	Rabbit stromelysin
c 177	13.8	0.8	17	1	AAV25258	Primer R3 for H.py
c 178	13.8	0.8	17	1	AAT60238	ASO Q493XM represe
c 179	13.8	0.8	17	1	AAK73378	Mouse flk-1 VEGF r
c 180	13.8	0.8	17	1	AAK75068	Mouse flt-1 VEGF r
c 181	13.8	0.8	17	1	AAK73377	Mouse flk-1 VEGF r
c 182	13.8	0.8	17	1	AAK75069	Mouse flt-1 VEGF r
c 183	13.8	0.8	17	1	AAK69542	Human flt1 VEGF re
c 184	13.8	0.8	17	1	AAV85964	Mouse LRP-3 cDNA P
c 185	13.8	0.8	17	1	AAV26749	Retroviral vector
c 186	13.8	0.8	17	1	AAA19065	Human TIE-2 substr
c 187	13.8	0.8	17	1	AAA18786	Human TIE-2 substr
c 188	13.8	0.8	17	1	AAA25585	Oestrogen receptor
c 189	13.8	0.8	17	1	AAA25182	Oestrogen receptor
c 190	13.8	0.8	17	1	AAA25180	Oestrogen receptor
c 191	13.8	0.8	17	1	AAA25185	Oestrogen receptor
c 192	13.8	0.8	17	1	ABN00882	Human GDMPLP-1 17-m
c 193	13.8	0.8	17	1	ABN10436	Human GDMPLP-1 17-m
c 194	13.8	0.8	17	1	ABN10442	Human GDMPLP-1 17-m
c 195	13.8	0.8	17	1	ABQ64223	Human KtOM1a porti
c 196	13.8	0.8	17	1	AB574897	Human PAPP-Ea asso
c 197	13.8	0.8	17	1	AB575296	Human PAPP-Ea asso
c 198	13.8	0.8	17	1	AB575295	Human PAPP-Ea asso
c 199	13.8	0.8	17	1	ABK57307	Human CLCA1 gene e
c 200	13.8	0.8	17	1	ABK55934	Human CLCA1 gene e
c 201	13.8	0.8	17	1	ABK56290	Human CLCA1 gene e
c 202	13.8	0.8	17	1	ABK56882	Human CLCA1 gene e
c 203	13.8	0.8	17	1	ACN07730	WNV minus strand H
c 204	13.8	0.8	17	1	ACN02884	WNV inozyme subatr
c 205	13.8	0.8	17	1	ACN06635	WNV Amberzyme subs
c 206	13.8	0.8	17	1	ACN07069	WNV Amberzyme subs
c 207	13.8	0.8	17	1	ACN07020	WNV Amberzyme subs
c 208	13.8	0.8	17	1	ACN07773	WNV minus strand H
c 209	13.8	0.8	17	1	ACN08010	WNV minus strand H
c 210	13.8	0.8	17	1	ACN08216	WNV Hammerhead Rib
c 211	13.8	0.8	17	1	ACN01062	Tumour suppression
c 212	13.8	0.8	17	1	ABT35227	Human MD212 scanni
c 213	13.8	0.8	17	1	ADB05374	Human MD212 scanni
c 214	13.8	0.8	17	1	ADB03207	Human MD24 scanni
c 215	13.8	0.8	17	1	ADB05375	Human MD24 scanni
c 216	13.8	0.8	17	1	ADB03208	Human MD23 scanni
c 217	13.8	0.8	17	1	ADB00428	Human K-Ras DNazym
c 218	13.8	0.8	17	1	ABZ60033	HBV amberzyme subs
c 219	13.8	0.8	17	1	ACD55872	Murine oligonucleo
c 220	13.8	0.8	17	1	ACC64538	Murine oligonucleo
c 221	13.8	0.8	17	1	ACC65475	Tumour suppression
c 222	13.8	0.8	17	1	ADB42757	Human tumour suppr
c 223	13.8	0.8	17	1	ACC53133	Human NOGO recepto
c 224	13.8	0.8	17	1	ADL47256	Human PKR substrat
c 225	13.8	0.8	17	1	ADL49748	Hepatitis B virus
c 226	13.8	0.8	17	1	ADM60332	Human GDMPLP-1 prob
c 227	13.8	0.8	17	1	ACN73526	Human GDMPLP-1 prob
c 228	13.8	0.8	17	1	ACN63972	Human GDMPLP-1 prob
c 229	13.8	0.8	17	1	ACN73532	ASO primer #15 to
c 230	13.6	0.8	15	1	AA519935	

ALIGNMENTS

RESULT 1

AB284116
ID AB284116 standard; DNA; 26 BP.

XX AB284116;

XX 14-MAY-2003 (first entry)

XX Toxicologically relevant rat PCR primer #1275.

XX Toxicologically relevant gene; toxicological response; PCR primer; ss.

XX Rattus sp.

XX Synthetic.

XX WO2003016500-A2.

XX

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:20:39 ; Search time 3.2 seconds
(without alignments)
4.905 Million cell updates/sec

Title: US-10-619-906-2
Perfect score: 1790
Sequence: 1 atgaatttcctcatgat.....aaaacggaattccgggga 1790

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 228 seqs, 4110 residues

Total number of hits satisfying chosen parameters: 456

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 230 summaries

Database : rng2.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	26	1.5	26	1	AB284116
2	25.4	1.4	27	1	ADRS1048
3	24	1.3	24	1	ADRA48246
4	24	1.3	24	1	ADRA48249
5	22.8	1.3	26	1	AB284111
6	22	1.2	25	1	ADRA4220
7	21	1.2	24	1	ADRA4221
8	20.2	1.1	22	1	ADRS13095
9	20	1.1	20	1	ADRG9805
10	19.2	1.1	24	1	AAFG98935
11	19.2	1.1	24	1	ABS77576
12	19.2	1.1	24	1	ACD93368
13	19.2	1.1	24	1	ACC468437
14	19.2	1.1	24	1	ADG76001
15	19.2	1.1	24	1	ADG76035
16	19.2	1.1	24	1	ADIS3690
17	19	1.1	19	1	ADRS2260
18	19	1.1	19	1	ADRS2257
19	19	1.1	19	1	ADRS2261
20	19	1.1	19	1	ADRS2258
21	19	1.1	19	1	ADRS2256
22	19	1.1	19	1	ADRS2259
23	19	1.1	21	1	AAH62035
24	19	1.1	21	1	AAH70486
25	18.6	1.0	23	1	ADQ93500
26	18.4	1.0	21	1	ADQ93501
27	18.4	1.0	21	1	ADQ93681
28	18	1.0	18	1	ADQ932355
29	18	1.0	18	1	ADQ93499
30	17.8	1.0	21	1	ADQ93682
31	17.8	1.0	21	1	ADQ93680
32	17.8	1.0	21	1	ADQ93501
33	17.8	1.0	21	1	ADQ93501

34	17	0.9	18	1	AAK64428	Human stromelysin
35	17	0.9	19	1	ADR81681	Hepatitis C virus
36	16.8	0.9	20	1	AAZ90012	PCR primer corresp
37	16.8	0.9	20	1	AAZ90013	PCR primer corresp
38	16.8	0.9	20	1	AAZ88394	Metalloproteinase
39	16.8	0.9	20	1	AAZ88395	Metalloproteinase
40	16.8	0.9	20	1	AAZ90500	COL1A1 gene antisense
41	16.8	0.9	20	1	ADI27533	Human DRK1 DNA, a
42	16.8	0.9	20	1	ADK80790	Chimeric phosphoro
43	16.8	0.9	21	1	AAQ65723	HIV-1 antisense RN
44	16.8	0.9	21	1	AAQ67025	Sequencing primer
45	16.8	0.9	21	1	ACF04639	Murine tumour chro
46	16.4	0.9	18	1	ADQ93226	3-alpha-hydroxyste
47	16.4	0.9	19	1	ADF36099	Human VEGFR1 short
48	16.4	0.9	19	1	ADF36526	Human VEGFR1 short
49	16.4	0.9	20	1	AAQ95937	Primer A (Group 13
50	16.4	0.9	20	1	AAQ95937	Human matrilysin P
51	16.4	0.9	20	1	ACCS7867	Matrix metalloprot
52	16.4	0.9	20	1	ADH14321	Human retinoblasto
53	16	0.9	17	1	ABK03146	Human CD20 Inozyme
54	16	0.9	20	1	AAQ95937	Growth hormone 1 9
55	16	0.9	20	1	AAQ95937	Human GU protein a
56	16	0.9	20	1	ADG61334	Human Growth Hormo
57	16	0.9	20	1	ACCS8406	Human growth hormo
58	16	0.9	20	1	ADP19711	Human GH1 gene PCR
59	15.8	0.9	19	1	AAH86458	PCBA HH ribozyme b
60	15.8	0.9	19	1	AAH86458	PCNA HH ribozyme b
61	15.8	0.9	19	1	ACAG2442	HCV core protein f
62	15.8	0.9	19	1	ADI53700	Human MMP-12 antis
63	15.8	0.9	19	1	ADI53698	Human MMP-12 antis
64	15.8	0.9	19	1	ADP76235	Human apolipoprote
65	15.8	0.9	19	1	ADP76235	Human apolipoprote
66	15.4	0.9	17	1	AAK63863	Rabbit stromelysin
67	15.4	0.9	17	1	ABK03147	Human CD20 Inozyme
68	15.4	0.9	17	1	ABK02767	Human CD20 Hammer
69	15.4	0.9	17	1	ABN10440	Human GDMPL-1 17-m
70	15.4	0.9	17	1	ACN05195	WNV DNAzyme substr
71	15.4	0.9	17	1	ABZ22228	Transposon inserti
72	15.4	0.9	17	1	ADP05333	Silkworm juvenile
73	15.4	0.9	17	1	ACN73530	Human GDMPL-1 prob
74	15	0.8	15	1	AAK31503	Tag sequence of a
75	15	0.8	15	1	ABK32457	Human pancreatic c
76	15	0.8	15	1	ADQ81798	Oligonucleotide sy
77	15	0.8	17	1	ABK03571	Human CD20 DNzyme
78	15	0.8	17	1	ADH83540	HCV DNzyme subutr
79	14.8	0.8	18	1	AAQ57225	Enzymatic RNA mole
80	14.8	0.8	18	1	AAQ93482	Hammerhead ribozym
81	14.8	0.8	18	1	AAK64488	Rabbit stromelysin
82	14.8	0.8	18	1	AAK63389	Human stromelysin
83	14.8	0.8	18	1	AAK64436	Human stromelysin
84	14.8	0.8	18	1	AAK64464	Rabbit stromelysin
85	14.8	0.8	18	1	AAV33107	Stromelysin primer
86	14.8	0.8	18	1	AAZ56071	Phospholipase A2 9
87	14.8	0.8	18	1	AAZ71138	Human biallelic ma
88	14.8	0.8	18	1	ADQ78196	PCR primer used to
89	14.8	0.8	18	1	ADQ90796	Oligonucleotide of
90	14.4	0.8	16	1	ADH57076	Molecular beacon t
91	14.4	0.8	16	1	AAH57846	Target oligonucleo
92	14.4	0.8	16	1	ADP23332	Binding partner sc
93	14.4	0.8	16	1	ADP23332	Control probe targ
94	14.4	0.8	17	1	AAH1521	Human c-myc hamme
95	14.4	0.8	17	1	AAK63814	Rabbit stromelysin
96	14.4	0.8	17	1	AAK73080	Mouse flk-1 VEGF r
97	14.4	0.8	17	1	AAZ21150	Integrin alpha 6 s
98	14.4	0.8	17	1	ABK03148	Human CD20 Inozyme
99	14.4	0.8	17	1	ABN10441	Human GDMPL-1 17-m
100	14.4	0.8	17	1	ABN10439	Human GDMPL-1 17-m
101	14.4	0.8	17	1	ABK26319	Increased starch p
102	14.4	0.8	17	1	ABK26320	Increased starch p
103	14.4	0.8	17	1	ACN06634	WNV Amberzyme subs
104	14.4	0.8	17	1	ACN10573	WNV minus strand I
105	14.4	0.8	17	1	ACN08217	WNV minus strand H
106	14.4	0.8	17	1	ABT34768	Tumour suppression

Job time : 3 secs

```
FEATURES
source
  FT Location/Qualifiers
  1..15 /organism='Artificial Sequence'
  /organism='synthetic construct'
  /mol_type='genomic DNA'
  /db_xref='taxon:32630'

Query Match
  0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 1 AAAAAAAAAAAAAA 15

RESULT 180
AX632930
LOCUS AX632930 15 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 69 from Patent EP1260586.
ACCESSION AX632930
VERSION AX632930.1 GI:28468544
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweidler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 69 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
  1..15 /organism='unidentified'
  /mol_type='unassigned RNA'
  /db_xref='taxon:32644'

Query Match
  0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGTGC 983
Db 1 TGCTATTCAAGTGC 15

RESULT 181
CQ831855
LOCUS CQ831855 16 bp DNA linear PAT 29-JUL-2004
DEFINITION Sequence 30 from Patent WO2004057029.
ACCESSION CQ831855
VERSION CQ831855.1 GI:50831730
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Cooper,D.N., Krawczak,M. and Hedderich,J.
TITLE Haplotype partitioning
JOURNAL Patent: WO 2004057029-A 30 08-JUL-2004;
University of Wales College of Medicine (GB)
FEATURES
source
  1..16 /organism='Homo sapiens'
  /mol_type='unassigned DNA'
  /db_xref='taxon:9606'
  misc_feature 3

/organism='Artificial Sequence'
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

Query Match
  0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 GGTGTAGGAAGAAT 1396
Db 1 GGCGTTAGGAAGAAT 16

RESULT 182
AR328665
LOCUS AR328665 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6067 from patent US 6566127.
ACCESSION AR328665
VERSION AR328665.1 GI:33714473
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6067 20-MAY-2003;
FEATURES
source
  1..16 /organism='unknown'
  /mol_type='unassigned RNA'

Query Match
  0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTT 1532
Db 15 CACACACACACAGTT 1

RESULT 183
AX458441
LOCUS AX458441 16 bp DNA linear PAT 08-JUL-2002
DEFINITION Sequence 26 from Patent WO0246457.
ACCESSION AX458441
VERSION AX458441.1 GI:21725107
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Fischer,A. and Newrzella,D.
TITLE Method for encoding hybridization probes
JOURNAL Patent: WO 0246457-A 26 13-JUN-2002;
Axaron Bioscience AG (DE)
FEATURES
source
  1..16 /organism='synthetic construct'
  /mol_type='unassigned DNA'
  /db_xref='taxon:32630'
  /note='Oligonukleotid 1-TACG- zur Herstellung des Encoders
1-TACG (Beispiel 2)'

Query Match
  0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 94;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1402 GAAGGCTGCTTCTG 1416
Db 15 GAAGGATGCTTCTG 1

Search completed: May 13, 2005, 12:18:38
```


JOURNAL Patent: JP 2002501376-A 326 15-JAN-2002;
THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO
INC
COMMENT PN JP 2002501376-A/326
PD 15-JAN-2002
PF 15-APR-1998 JP 1998543635
PR 15-APR-1997 US 60/043553,05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES
THOMAS CASKEY,ROGER
PI DAVID COX,
PI DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY
PC C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,
PC A61K39/395,
PC A61K48/00
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.
FEATURES source
1..17
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGAGCCCGAGTGA 778
Db 17 CCATGAGCCCGAGTGA 1

RESULT 176
AR055837
LOCUS AR055837 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 41 from patent US 5837542.
ACCESSION AR055837
VERSION AR055837.1 GI:5981414
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 41 17-NOV-1998;
FEATURES source
1..15
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGCTGC 983
Db 1 TGCTATTCAAACTGC 15

RESULT 177
AR113595
LOCUS AR113595 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 41 from patent US 6132967.
ACCESSION AR113595
VERSION AR113595.1 GI:14093917
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and

Draper,K.G.
Ribozyme treatment of diseases or conditions related to levels of
intercellular adhesion molecule-1 (ICAM-1)
Patent: US 6132967-A 41 17-OCT-2000;
FEATURES source
1..15
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 TGCTATTCAAGCTGC 983
Db 1 TGCTATTCAAACTGC 15

RESULT 178
AR133315
LOCUS AR133315 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1740 from patent US 6194150.
ACCESSION AR133315
VERSION AR133315.1 GI:14122220
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.,
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 1740 27-FEB-2001;
FEATURES source
1..15
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 84;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1483 ATAAATGTAACAGGAA 1497
Db 1 AGAATGTAACAGGAA 15

RESULT 179
BD244856
LOCUS BD244856 15 bp DNA linear PAT 17-JUL-2003
DEFINITION Oligonucleotide primer capable of making the non-specific double
strand formation unstable.
ACCESSION BD244856
VERSION BD244856.1 GI:33054626
KEYWORDS JP 2002532063-A/1.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 15)
AUTHORS Pelletier,J. and Das,M.
TITLE Oligonucleotide primer capable of making the non-specific double
strand formation unstable
JOURNAL Patent: JP 2002532063-A 1 02-OCT-2002;
COMMENT MCGILL UNIVERSITY
OS Artificial Sequence
PN JP 2002532063-A/1
PD 02-OCT-2002
PF 06-OCT-1999 JP 2000574722
PR 07-OCT-1998 CA 2246623
PI JERRY PELLETIER,MANJULA DAS
PC C12N15/09,C12Q1/68,C12N15/00
CC Description of Artificial Sequence: synthetic oligonucleotide
FH Key Location/Qualifiers
FT source 1..15

RESULT 171
AX724098/c
LOCUS AX724098 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1785 from Patent WO03025176.
ACCESSION AX724098
VERSION AX724098.1 GI:30503441
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 1785 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1602 TTGAAGTGCATGGTTC 1618
Db 17 TTGAAGTGTATGGATC 1
|||||
|||||
RESULT 172
AX725035
LOCUS AX725035 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2722 from Patent WO03025176.
ACCESSION AX725035
VERSION AX725035.1 GI:30504378
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 2722 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 330 GATCTATAATTACACTC 346
Db 1 GATCGAAATTACACTC 17
|||||
|||||
RESULT 173
AX729230
LOCUS AX729230 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 864 from Patent WO03025175.
ACCESSION AX729230
VERSION AX729230.1 GI:30508573
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 864 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1120 GATCAGCTGCTTTGA 1136
Db 1 GATCCAGATGCTTTGA 17
|||||
|||||
RESULT 174
AX759759
LOCUS AX759759 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 3080 from Patent WO03040369.
ACCESSION AX759759
VERSION AX759759.1 GI:32254375
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3080 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1.17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1120 GATCAGCTGCTTTGA 1136
Db 1 GATCCAGCTGCTCTGA 17
|||||
|||||
RESULT 175
BD106311/c
LOCUS BD106311 Novel LDL-receptor.
DEFINITION BD106311
ACCESSION BD106311
VERSION BD106311.1 GI:23201129
KEYWORDS JP 2002501376-A/326.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
1 (bases 1 to 17)
REFERENCE
AUTHORS Todd, J.A., Hess, J.W., Caskey, C.T., Cox, R.D., Gerhold, D., Hammond, H.
and Hey, P.
TITLE Novel LDL-receptor

```
mdz12
JOURNAL Patent: EP 1281758-A 1414 05-FEB-2003;
FEATURES   Aecomica, Inc. (US)
SOURCE     Location/Qualifiers
1. 17
/organism="Homo sapiens"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 41 CCTGTGGGCTCTCC 57
Db 17 CTTGTGGGCTTCTCC 1

RESULT 167
AX691461/c
LOCUS AX691461 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4193 from Patent EP1281758.
ACCESSION AX691461
VERSION AX691461.1 GI:29414397
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 4193 05-FEB-2003;
FEATURES Aecomica, Inc. (US)
SOURCE Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAAGGAGC 1313
Db 17 TACCTGTTCCAAGGAGC 1

RESULT 168
AX691462/c
LOCUS AX691462 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 4194 from Patent EP1281758.
ACCESSION AX691462
VERSION AX691462.1 GI:29414398
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 4194 05-FEB-2003;
FEATURES Aecomica, Inc. (US)
SOURCE Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

mdz12
JOURNAL Patent: EP 1281758-A 1414 05-FEB-2003;
FEATURES   Aecomica, Inc. (US)
SOURCE     Location/Qualifiers
1. 17
/organism="Homo sapiens"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1296 CTACATCTTCCAAGGAG 1312
Db 17 CTACCTGTTCCAAGGAG 1

RESULT 169
AX693628
LOCUS AX693628 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6360 from Patent EP1281758.
ACCESSION AX693628
VERSION AX693628.1 GI:29416677
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6360 05-FEB-2003;
FEATURES Aecomica, Inc. (US)
SOURCE Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 TGTCAACCAAGCTTGAG 839
Db 1 TGTCAACAAAGCTTCAG 17

RESULT 170
AX693629
LOCUS AX693629 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 6361 from Patent EP1281758.
ACCESSION AX693629
VERSION AX693629.1 GI:29416678
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 6361 05-FEB-2003;
FEATURES Aecomica, Inc. (US)
SOURCE Location/Qualifiers
1. 17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 824 CTCACCAAGCTTGAGT 840
Db 1 GTCACAAAGCTTCAGT 17
```

```

DEFINITION Sequence 661 from Patent WO0211674.
ACCESSION AX578823
VERSION AX578823.1 GI:27648025
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1 Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 661 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1093 GGCTTCTCTGCATCTGT 1109
|||||
Db 1 GGCATCTCTGTATCTGT 17

RESULT 163
AX579415/c
LOCUS AX579415 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1253 from Patent WO0211674.
ACCESSION AX579415
VERSION AX579415.1 GI:27648617
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1 Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 1253 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 7 TTTCATCATGATTTGT 23
|||||
Db 17 TTTCATCATATTATTTG 1

RESULT 164
AX579840/c
LOCUS AX579840 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1678 from Patent WO0211674.
ACCESSION AX579840
VERSION AX579840.1 GI:27649042
KEYWORDS
SOURCE Homo sapiens (human)

```

```

ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1 Thompson, J., Mcswiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL Patent: WO 0211674-A 1678 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 ATTTCTCATGATGATTG 22
|||||
Db 17 ATTTCATCATATTG 1

RESULT 165
AX673455/c
LOCUS AX673455 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1900 from Patent WO03004526.
ACCESSION AX673455
VERSION AX673455.1 GI:29331803
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1 Teller, A., Amson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 1900 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAGGAGC 1313
|||||
Db 17 TACATCTTCCAGGATC 1

RESULT 166
AX688682/c
LOCUS AX688682 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1414 from Patent EP1281758.
ACCESSION AX688682
VERSION AX688682.1 GI:29411384
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1 Shannon, M., Gu, Y. and Nguyen, C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and

```

```

predominantly in heart and muscle
Patent: US 6686188-A 10428 03-FEB-2004;
LOCATION/Qualifiers
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      841 TTTGATGCTGTCAACAC 857
DB      17 TTTGATGCTGTCAACAC 1

RESULT 158
AR466757/c
LOCUS      AR466757      17 bp      DNA      linear      PAT 20-FEB-2004
DEFINITION Sequence 10434 from patent US 6686188.
ACCESSION AR466757
VERSION AR466757.1 GI:42701814
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS      Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
              Shannon,M.E.
TITLE      Polynucleotide encoding a human myosin-like polypeptide expressed
              predominantly in heart and muscle
JOURNAL      Predominantly in heart and muscle
PATENT: US 6686188-A 10434 03-FEB-2004;
FEATURES      Location/Qualifiers
source      1. .17
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 17; Gaps 0;

QY      835 TTGACTTTTGATGCTGT 851
DB      17 TCGACTTTTGATGCTGT 1

RESULT 159
AX166715
LOCUS      AX166715      17 bp      DNA      linear      PAT 22-JUN-2001
DEFINITION Sequence 206 from Patent WO0138503.
ACCESSION AX166715
VERSION AX166715.1 GI:14546990
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Plowman,G.D., Whyte,D., Manning,G.S., Sudarsanam,S., Martinez,R.,
              Flanagan,P. and Clary,D.S.
TITLE      Novel human protein kinases and protein kinase-like enzymes
JOURNAL      Patent: WO 0138503-A 206 31-MAY-2001;
              Sugen, Inc. (US)
FEATURES      Location/Qualifiers
source      1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      351 CATGAAGCGTCAGGATG 367
DB      1 CATGAAGCGTCAGGATG 17

RESULT 160
AX475778/c
LOCUS      AX475778      17 bp      DNA      linear      PAT 12-AUG-2002
DEFINITION Sequence 999 from Patent WO0224750.
ACCESSION AX475778
VERSION AX475778.1 GI:22215063
KEYWORDS      Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Zhang,J.
TITLE      Human kidney tumor overexpressed membrane protein 1
JOURNAL      Patent: WO 0224750-A 999 28-MAR-2002;
              Aeomica, Inc. (US)
FEATURES      Location/Qualifiers
source      1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1459 TGCTCAGGTCGTAACTA 1475
DB      17 TGCTCAGGTCGTAACTA 1

RESULT 161
AX578467/c
LOCUS      AX578467      17 bp      RNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 305 from Patent WO0211674.
ACCESSION AX578467
VERSION AX578467.1 GI:27647669
KEYWORDS      Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Thompson,J., Mcswigen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
              and Grupe,A.
TITLE      Method and reagent for the inhibition of calcium activated chloride
              channel-1 (clca-1)
JOURNAL      Patent: WO 0211674-A 305 14-FEB-2002;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
              Thompson, James (US)
FEATURES      Location/Qualifiers
source      1. .17
              /organism="Homo sapiens"
              /mol_type="unassigned RNA"
              /db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      298 TCAAGATGGATGAAGCG 314
DB      17 TCAAGCTGGATGGAGCG 1

RESULT 162
AX578823
LOCUS      AX578823      17 bp      RNA      linear      PAT 10-JAN-2003

```

AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3603 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAA 1765
Db 17 AAAAAAAAAACAAAAA 1

RESULT 153
AR434000 17 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 423 from patent US 6656700.
DEFINITION AR434000
ACCESSION AR434000
VERSION AR434000.1 GI:40196843
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y. and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 423 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 TGCCTGTGGGCTGCTC 55
Db 1 TGCCTGTGGGCTCTCTC 17

RESULT 154
AR434398 17 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 821 from patent US 6656700.
DEFINITION AR434398
ACCESSION AR434398
VERSION AR434398.1 GI:40197241
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y. and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 821 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CTACTGAGGTATGATG 1192
Db 1 CTAGGGGAGGTATGATG 17

RESULT 155
AR434399 17 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 822 from patent US 6656700.
DEFINITION AR434399
ACCESSION AR434399
VERSION AR434399.1 GI:40197242
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y. and Shannon, M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 822 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1177 TACTGAGGTATGATGT 1193
Db 1 TAGGGGAGGTATGATGT 17

RESULT 156
AR457197 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 874 from patent US 6686188.
DEFINITION AR457197
ACCESSION AR457197
VERSION AR457197.1 GI:42692254
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 874 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCACTTCGCC 1147
Db 17 CTTTGACCCCTCTCGCC 1

RESULT 157
AR466751 17 bp DNA linear PAT 20-FEB-2004
LOCUS Sequence 10428 from patent US 6686188.
DEFINITION AR466751
ACCESSION AR466751
VERSION AR466751.1 GI:42701808
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed

AUTHORS Todd, J.A., Hess, J.W., Caskey, C.T., Cox, R.D., Gerhold, D., Hammond, H., Hey, P., Kawaguchi, Y., Merriman, T.R., Metzker, M.L., Nakagawa, Y., Phillips, M.S. and Twells, R.C.J.
TITLE LDL-receptor
JOURNAL Patent: US 6556654-A 354 29-APR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 762 CTATGAGCCCGAGTGA 778
Db 17 CCATGGAGCCCGAGTGA 1
RESULT 148
AR323435/c
LOCUS AR323435 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 837 from patent US 6566127.
ACCESSION AR323435
VERSION AR323435.1 GI:33709243
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 837 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 217 GACAACTCAACTCTGCG 233
Db 17 GACAACTCAACTCTGCG 1
RESULT 149
AR325562
LOCUS AR325562 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2964 from patent US 6566127.
ACCESSION AR325562
VERSION AR325562.1 GI:33711370
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2964 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 TACAGGTATCTGCCTGT 45

Db 1 TACTGGTTTCTGCCTGT 17
RESULT 150
AR325563
LOCUS AR325563 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2965 from patent US 6566127.
ACCESSION AR325563
VERSION AR325563.1 GI:33711371
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2965 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 30 ACAGGTATCTGCCTGTG 46
Db 1 ACTGGTTTCTGCCCTGTG 17
RESULT 151
AR326200/c
LOCUS AR326200 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3602 from patent US 6566127.
ACCESSION AR326200
VERSION AR326200.1 GI:33712008
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAA 1765
Db 17 AACACAAACACAAAAA 1
RESULT 152
AR326201/c
LOCUS AR326201 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3603 from patent US 6566127.
ACCESSION AR326201
VERSION AR326201.1 GI:33712009
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)

Db	17	AAACAAACCAAAAAA	1
RESULT 145			
AR192331/c			
LOCUS	AR192331	17 bp	DNA
DEFINITION	Sequence 7819 from patent US 6346398.		linear
ACCESSION	AR192331		
VERSION	AR192331.1	GI:20238296	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Pavco P., McSwiggen J., Stinchcomb, D. and Escobedo, J.		
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor		
JOURNAL	Patent: US 6346398-A 7819 12-FEB-2002;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="unassigned DNA"		
Query Match	0.8%;	Score 13.8;	DB 1; Length 17;
Best Local Similarity	88.2%;	Pred. No. 93;	
Matches	15;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	1749	AAAAAAAAAAAAAAAA 1765	
DB	17	AAACAAACCAAAAAA 1	
RESULT 146			
AR305400/c			
LOCUS	AR305400	17 bp	DNA
DEFINITION	Sequence 354 from patent US 6545137.		linear
ACCESSION	AR305400		
VERSION	AR305400.1	GI:31694710	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		
AUTHORS	Todd, J.A., Hess, J.W., Caskey, C.T., Cox, R.D., Gerhold, D., Hammond, H., Hey, P., Kawaguchi, Y., Merriman, T.R., Metzker, M.L., Nakagawa, Y., Phillips, M.S. and Twells, R.C.J.		
TITLE	Receptor		
JOURNAL	Patent: US 6545137-A 354 08-APR-2003;		
FEATURES	Location/Qualifiers		
source	1..17		
	/organism="unknown"		
	/mol_type="genomic DNA"		
Query Match	0.8%;	Score 13.8;	DB 1; Length 17;
Best Local Similarity	88.2%;	Pred. No. 93;	
Matches	15;	Conservative 0;	Mismatches 2; Indels 0; Gaps 0;
QY	762	CTATGGAGCCCGAGTGA 778	
DB	17	CCATGGAGCCCGAGTGA 1	
RESULT 147			
AR309504/c			
LOCUS	AR309504	17 bp	DNA
DEFINITION	Sequence 354 from patent US 6555654.		linear
ACCESSION	AR309504		
VERSION	AR309504.1	GI:31701509	
KEYWORDS			
SOURCE	Unknown.		
ORGANISM	Unknown.		
REFERENCE	1 (bases 1 to 17)		


```
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 540 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 874 CTTTCTTTAAAGACTG 890
Db 1 CTGTTCTTTAAAGACAG 17

RESULT 138
LOCUS 194378 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 541 from patent US 5731295.
ACCESSION 194378
VERSION 194378.1 GI:3938848
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 541 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 875 TTTTCTTTAAAGACTGG 891
Db 1 TGTCTCTTTAAAGACAGG 17

RESULT 139
LOCUS 194446 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 609 from patent US 5731295.
ACCESSION 194446
VERSION 194446.1 GI:3938916
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 609 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGTGA 1195

REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 540 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 876 TCTGTGTGGAGCTTCCT 912
Db 1 TCTGTGTGGAGCTCCCT 1

RESULT 141
LOCUS AR186804/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2292 from patent US 6346398.
ACCESSION AR186804
VERSION AR186804.1 GI:20232769
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
          related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 2292 12-FEB-2002;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGGC 233
Db 17 GACAACTCAACTCTGGC 1

RESULT 142
LOCUS AR190639 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 6127 from patent US 6346398.
ACCESSION AR190639
VERSION AR190639.1 GI:20236604
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 6127 12-FEB-2002;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGTGA 1195
```

```
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 497 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCATC 647
Db 1 CATGAGCTGGCCACTC 17

RESULT 133
LOCUS I94353 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 516 from patent US 5731295.
ACCESSION I94353
VERSION I94353.1 GI:3938823
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 516 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 750 CATTCACTCCCTCTATG 766
Db 1 CATCCATCCCTCTATG 17

RESULT 134
LOCUS I94354 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 517 from patent US 5731295.
ACCESSION I94354
VERSION I94354.1 GI:3938824
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 517 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 537 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCTTTTCTTTAAAG 886
Db 1 AATCTGTCTTTAAAG 17

RESULT 136
LOCUS I94375 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 538 from patent US 5731295.
ACCESSION I94375
VERSION I94375.1 GI:3938845
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
          Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 538 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..17
              /organism="unknown"
              /mol_type="unassigned DNA"
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 871 ATCCTTTTCTTTAAAGA 887
Db 1 ATTCTGTCTTTAAAGA 17

RESULT 137
LOCUS I94377 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 540 from patent US 5731295.
ACCESSION I94377
VERSION I94377.1 GI:3938847
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
```

```
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 540 18-MAR-1997;
FEATURES Location/Qualifiers
source
1..17
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 874 TTTTCTTTAAAGACTG 890
Db 1 CTGTTCTTTAAAGACAG 17

RESULT 128
LOCUS I37528 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 541 from patent US 5612215.
ACCESSION I37528
VERSION I37528.1 GI:2085488
KEYWORDS Unknown.
SOURCE ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 541 18-MAR-1997;
FEATURES Location/Qualifiers
source
1..17
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 875 TTTTCTTTAAAGACTGG 891
Db 1 TGTTCCTTTAAAGACAGG 17

RESULT 129
LOCUS I37596 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 609 from patent US 5612215.
ACCESSION I37596
VERSION I37596.1 GI:2085556
KEYWORDS Unknown.
SOURCE ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 609 18-MAR-1997;
FEATURES Location/Qualifiers
source
1..17
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 876 TTTTCTTTAAAGACTG 891
Db 1 TGTTCCTTTAAAGACAGG 17

RESULT 130
LOCUS I37681/c 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 694 from patent US 5612215.
ACCESSION I37681
VERSION I37681.1 GI:2085641
KEYWORDS Unknown.
SOURCE ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 694 18-MAR-1997;
FEATURES Location/Qualifiers
source
1..17
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 896 TCTGCTGGAGCTTCCT 912
Db 17 TCTGCTGGAGCTCCCT 1

RESULT 131
LOCUS I94333 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 496 from patent US 5731295.
ACCESSION I94333
VERSION I94333.1 GI:3938803
KEYWORDS Unknown.
SOURCE ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Method of reducing stomelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 496 24-MAR-1998;
FEATURES Location/Qualifiers
source
1..17
/mol_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 623 TTGCTGTTTCATGAACCTT 639
Db 1 TTGCTGTTTCATGAGCTT 17

RESULT 132
LOCUS I94334 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 497 from patent US 5731295.
ACCESSION I94334
VERSION I94334.1 GI:3938804
KEYWORDS Unknown.
SOURCE ORGANISM Unknown.
```

```

SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE        Stromelysin targeted ribozymes
JOURNAL      Patent: US 5612215-A 497 18-MAR-1997;
FEATURES     Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      631 CATGAACCTGGCCATC 647
Db      1 CATGAGCTTGGCCACTC 17

RESULT 123
LOCUS    I37503                      17 bp      DNA
DEFINITION Sequence 516 from patent US 5612215.
ACCESSION I37503
VERSION   I37503.1 GI:2085463
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE     Stromelysin targeted ribozymes
JOURNAL   Patent: US 5612215-A 516 18-MAR-1997;
FEATURES  Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      750 CATTCAGTCCCTCTATG 766
Db      1 CATCCAATCCCTCTATG 17

RESULT 124
LOCUS    I37504                      17 bp      DNA
DEFINITION Sequence 517 from patent US 5612215.
ACCESSION I37504
VERSION   I37504.1 GI:2085464
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE     Stromelysin targeted ribozymes
JOURNAL   Patent: US 5612215-A 517 18-MAR-1997;
FEATURES  Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;

SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE        Stromelysin targeted ribozymes
JOURNAL      Patent: US 5612215-A 497 18-MAR-1997;
FEATURES     Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      754 CAGTCCCTCTATGGAGC 770
Db      1 CAATCCCTCTATGGACC 17

RESULT 125
LOCUS    I37524                      17 bp      DNA
DEFINITION Sequence 537 from patent US 5612215.
ACCESSION I37524
VERSION   I37524.1 GI:2085484
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE     Stromelysin targeted ribozymes
JOURNAL   Patent: US 5612215-A 537 18-MAR-1997;
FEATURES  Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      870 AATCCTTTTCTTTAAAG 886
Db      1 AATCTGTTCTTTAAAG 17

RESULT 126
LOCUS    I37525                      17 bp      DNA
DEFINITION Sequence 538 from patent US 5612215.
ACCESSION I37525
VERSION   I37525.1 GI:2085485
KEYWORDS
SOURCE    Unknown.
ORGANISM  Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS   Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE     Stromelysin targeted ribozymes
JOURNAL   Patent: US 5612215-A 538 18-MAR-1997;
FEATURES  Location/Qualifiers
              source
                1..17
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      871 ATCCTTTTCTTTAAAGA 887
Db      1 ATTCTGTTCTTTAAAGA 17

RESULT 127
LOCUS    I37527                      17 bp      DNA
DEFINITION Sequence 540 from patent US 5612215.
ACCESSION I37527
VERSION   I37527.1 GI:2085487
KEYWORDS
SOURCE    Unknown.

```

```
FEATURES
  source
    Aeonica, Inc. (US)
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1131 CTTTGACCCCTCTCGCC 1147
Db 17 CTTTGACCCCTCTCGCC 1

RESULT 118
LOCUS CQ625688/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10428 from Patent WO0192524.
ACCESSION CQ625688
VERSION CQ625688.1 GI:41675906
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 10428 06-DEC-2001;
  Aeonica, Inc. (US)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 841 TTTGATGCTGCACAC 857
Db 17 TTTGATGCTGCAGCAC 1

RESULT 119
LOCUS CQ625694/c 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10434 from Patent WO0192524.
ACCESSION CQ625694
VERSION CQ625694.1 GI:41675912
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu.Y., Ji.Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
  Shannon,M.E.
  TITLE Myosin-like gene expressed in human heart and muscle
  JOURNAL Patent: WO 0192524-A 10434 06-DEC-2001;
  Aeonica, Inc. (US)
FEATURES
  source
    1..17
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match
  Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 835 TTGAGTTTGTGCTGT 851
Db 17 TCGACTTTTGTGCTGT 1

RESULT 120
LOCUS I32565/c 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 29 from patent US 5589330.
ACCESSION I32565
VERSION I32565.1 GI:1823356
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  AUTHORS Shuber,A.P.
  TITLE High-throughput screening method for sequence or genetic
  alterations in nucleic acids using elution and sequencing of
  complementary oligonucleotides
  JOURNAL Patent: US 5589330-A 29 31-DEC-1996;
  FEATURES
    Location/Qualifiers
      1..17
        source
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1584 TTCATTCTATTCTTAAT 1600
Db 17 TTCATTCTGTTCTTAGT 1

RESULT 121
LOCUS I37483 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 496 from patent US 5612215.
ACCESSION I37483
VERSION I37483.1 GI:2085443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
  1 (bases 1 to 17)
  AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
  Stinchcomb,D.T.
  TITLE Stromelysin targeted ribozymes
  JOURNAL Patent: US 5612215-A 496 18-MAR-1997;
  FEATURES
    Location/Qualifiers
      1..17
        source
          /organism="unknown"
          /mol_type="unassigned DNA"

Query Match
  Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
  Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 623 TTGCTGTTTCATGAACCTT 639
Db 1 TTGCTGCTCATGAGCTT 17

RESULT 122
LOCUS I37484 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 497 from patent US 5612215.
ACCESSION I37484
VERSION I37484.1 GI:2085444
KEYWORDS
```

```

RESULT 114
LOCUS       AR131042
DEFINITION  Sequence 35 from patent US 6190907.
ACCESSION  AR131042
VERSION    AR131042.1 GI:14119367
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1. (bases 1 to 17)
AUTHORS   Kim,S.-Y., Kim,S.-H. and Robbins,P.D.
TITLE     Retroviral vectors for gene therapy
JOURNAL   Patent: US 6190907-A 35 20-FEB-2001;
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="unknown"
            /mol_type="unasigned DNA"
            Query Match      0.8%; Score 13.8; DB 1; Length 17;
            Best Local Similarity 88.2%; Pred. No. 93;
            Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 CCTGGGGCTGCAGCAT 663
Db 1 CCATGGGGCTGCAGAA 17

RESULT 115
LOCUS       BD198986/c
DEFINITION  Method and reagent for treating diseases or conditions concerning
ACCESSION  BD198986
VERSION    BD198986.1 GI:33008756
KEYWORDS   JP 2002509721-A/2012.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1. (bases 1 to 17)
            Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
            Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
            Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
            Patent: JP 2002509721-A 2012 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
            OS Homo sapiens (human)
            PN JP 2002509721-A/2012
            PD 02-APR-2002
            PF 24-MAR-1999 JP 2000541291
            PR 27-MAR-1998 US 60/079678
            PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
            JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
            A61P29/00,A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
            C12N5/00
            CC Method and reagent for treating diseases or conditions CC
            concerning molecule
            CC participating in vasculogenic response
            FH Key Location/Qualifiers
            FT source 1..17
            /organism="Homo sapiens (human)"
            /mol_type="genomic RNA"
            /db_xref="taxon:9606"
            JOURNAL
            COMMENT
            Query Match      0.8%; Score 13.8; DB 1; Length 17;
            Best Local Similarity 88.2%; Pred. No. 93;
            Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 116
LOCUS       BD199265
DEFINITION  Method and reagent for treating diseases or conditions concerning
ACCESSION  BD199265
VERSION    BD199265.1 GI:33009035
KEYWORDS   JP 2002509721-A/2291.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1. (bases 1 to 17)
            Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
            Patent: JP 2002509721-A 2291 02-APR-2002;
            RIBOZYME PHARMACEUTICALS INC
            OS Homo sapiens (human)
            PN JP 2002509721-A/2291
            PD 02-APR-2002
            PF 24-MAR-1999 JP 2000541291
            PR 27-MAR-1998 US 60/079678
            PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,
            JAMES A MCSWIGGEN
            PC
            C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
            A61P29/00,A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
            C12N5/00
            CC Method and reagent for treating diseases or conditions CC
            concerning molecule
            CC participating in vasculogenic response
            FH Key Location/Qualifiers
            FT source 1..17
            /organism="Homo sapiens (human)"
            /mol_type="genomic RNA"
            /db_xref="taxon:9606"
            JOURNAL
            COMMENT
            Query Match      0.8%; Score 13.8; DB 1; Length 17;
            Best Local Similarity 88.2%; Pred. No. 93;
            Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 830 AAAGCTTGAGTTTGTAT 846
Db 1 AAAGTTTGTAGTTTGTAT 17

RESULT 117
LOCUS       CQ616134/c
DEFINITION  Sequence 874 from Patent WO0192524.
ACCESSION  CQ616134
VERSION    CQ616134.1 GI:41666352
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
            1. (bases 1 to 17)
            Method and reagent for treating diseases or conditions concerning
            molecule participating in vasculogenic response
            Patent: WO 0192524-A 874 06-DEC-2001;
            Myosin-like gene expressed in human heart and muscle
            Patent: WO 0192524-A 874 06-DEC-2001;
            Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,W.E.
            TITLE     Myosin-like gene expressed in human heart and muscle
            JOURNAL   Patent: WO 0192524-A 874 06-DEC-2001;

```

```

VERSION      AX500047.1  GI:23382340
KEYWORDS
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Zhan, J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 1354 07-AUG-2002;
             Aeomica, Inc. (US)
FEATURES
source       1..17
             Location/Qualifiers
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      994  GAAAGCAGAAATCA 1007
         |||||
Db       16  GAAAGCAGAAATCA 3

RESULT 110
AX500048/c
LOCUS      AX500048
DEFINITION Sequence 1355 from Patent EP1229046.
ACCESSION  AX500048
VERSION     AX500048.1  GI:23382341
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Zhan, J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 1355 07-AUG-2002;
             Aeomica, Inc. (US)
FEATURES
source       1..17
             Location/Qualifiers
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      994  GAAAGCAGAAATCA 1007
         |||||
Db       16  GAAAGCAGAAATCA 3

RESULT 111
AX500049/c
LOCUS      AX500049
DEFINITION Sequence 1356 from Patent EP1229046.
ACCESSION  AX500049
VERSION     AX500049.1  GI:23382342
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
             Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Zhan, J.
TITLE        Human testis expressed patched like protein
JOURNAL      Patent: EP 1229046-A 1356 07-AUG-2002;
             Aeomica, Inc. (US)

FEATURES
source       1..17
             Location/Qualifiers
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      994  GAAAGCAGAAATCA 1007
         |||||
Db       15  GAAAGCAGAAATCA 2

RESULT 112
AX053059/c
LOCUS      AR053059
DEFINITION Sequence 29 from patent US 5834181.
ACCESSION  AR053059
VERSION     AR053059.1  GI:5977921
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Shuber, A.P.
TITLE        High throughput screening method for sequences or genetic
             alterations in nucleic acids
JOURNAL      Patent: US 5834181-A 29 10-NOV-1998;
             Location/Qualifiers
FEATURES
source       1..17
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1584  TTCATTCTGTTCTTAAT 1600
         |||||
Db       17  TTCATTCTGTTCTTAAT 1

RESULT 113
AR065020/c
LOCUS      AR065020
DEFINITION Sequence 29 from patent US 5849483.
ACCESSION  AR065020
VERSION     AR065020.1  GI:5995236
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE    1 (bases 1 to 17)
AUTHORS      Shuber, A.P.
TITLE        High throughput screening method for sequences or genetic
             alterations in nucleic acids
JOURNAL      Patent: US 5849483-A 29 15-DEC-1998;
             Location/Qualifiers
FEATURES
source       1..17
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1584  TTCATTCTGTTCTTAAT 1600
         |||||
Db       17  TTCATTCTGTTCTTAAT 1
```

Shannon,M.E.
 Polynucleotide encoding a human myosin-like polypeptide expressed
 predominantly in heart and muscle
 Patent: US 6686188-A 10430 03-FEB-2004;
 JOURNAL
 FEATURES
 source
 1. .17
 Location/Qualifiers
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 840 TTTTGATGCTGCA 853
 Db 16 TTTTGATGCTGCA 3

RESULT 105
 AR482773
 LOCUS
 DEFINITION Sequence 219 from patent US 6703228.
 ACCESSION AR482773
 VERSION AR482773.1 GI:47245296
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE
 1 (bases 1 to 17)
 AUTHORS Landers,J., Jordan,B., Houseman,D.E. and Charest,A.
 TITLE Methods and products related to genotyping and DNA analysis
 JOURNAL Patent: US 6703228-A 219 09-MAR-2004;
 FEATURES
 Location/Qualifiers
 source
 1. .17
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1483 ATAATGTAACAGGA 1496
 Db 4 ATAATGTAACAGGA 17

RESULT 106
 AX264072
 LOCUS
 DEFINITION Sequence 1463 from Patent WO0173002.
 ACCESSION AX264072
 VERSION AX264072.1 GI:16512871
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE
 1
 AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 1463 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES
 Location/Qualifiers
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
 Db 3 CAATTGGAATATGA 16

RESULT 107
 AX264073/c
 LOCUS
 DEFINITION Sequence 1464 from Patent WO0173002.
 ACCESSION AX264073
 VERSION AX264073.1 GI:16512872
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE
 1
 AUTHORS Kmiec,E.B., Gamper,H.B. and Rice,M.C.
 TITLE Targeted chromosomal genomic alterations with modified single
 stranded oligonucleotides
 JOURNAL Patent: WO 0173002-A 1464 04-OCT-2001;
 UNIVERSITY OF DELAWARE (US)
 FEATURES
 Location/Qualifiers
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1318 CAATTGGAATATGA 1331
 Db 15 CAATTGGAATATGA 2

RESULT 108
 AX500046/c
 LOCUS
 DEFINITION Sequence 1353 from Patent EP1229046.
 ACCESSION AX500046
 VERSION AX500046.1 GI:23382339
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE
 1
 AUTHORS Zhan,J.
 TITLE Human testis expressed patched like protein
 JOURNAL Patent: EP 1229046-A 1353 07-AUG-2002;
 Aeomica, Inc. (US)
 FEATURES
 Location/Qualifiers
 source
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 994 GAAAGCAGAAATCA 1007
 Db 17 GAAAGCAGAAATCA 4

RESULT 109
 AX500047/c
 LOCUS
 DEFINITION Sequence 1354 from Patent EP1229046.
 ACCESSION AX500047


```
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 823 02-DEC-2003;
FEATURES
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
      |||||
Db 4 GGAGGTATGATGTG 17

RESULT 100
AR434401
LOCUS AR434401 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 824 from patent US 6656700.
ACCESSION AR434401
VERSION AR434401.1 GI:40197244
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 824 02-DEC-2003;
FEATURES
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
      |||||
Db 3 GGAGGTATGATGTG 16

RESULT 101
AR434402
LOCUS AR434402 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 825 from patent US 6656700.
ACCESSION AR434402
VERSION AR434402.1 GI:40197245
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 825 02-DEC-2003;
FEATURES
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
      |||||
Db 3 GGAGGTATGATGTG 16

RESULT 102
AR434403
LOCUS AR434403 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 826 from patent US 6656700.
ACCESSION AR434403
VERSION AR434403.1 GI:40197246
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y. and Shannon,M.E.
TITLE Isoforms of human pregnancy-associated protein-E
JOURNAL Patent: US 6656700-A 826 02-DEC-2003;
FEATURES
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1181 GGAGGTATGATGTG 1194
      |||||
Db 1 GGAGGTATGATGTG 14

RESULT 103
AR466752/c
LOCUS AR466752 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10429 from patent US 6686188.
ACCESSION AR466752
VERSION AR466752.1 GI:42701809
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10429 03-FEB-2004;
FEATURES
    source
        1..17
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 840 TTTTGATGCTGTCA 853
      |||||
Db 17 TTTTGATGCTGTCA 4

RESULT 104
AR466753/c
LOCUS AR466753 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10430 from patent US 6686188.
ACCESSION AR466753
VERSION AR466753.1 GI:42701810
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
```

PD 13-AUG-2002
 PF 24-SEP-1999 JP 2000572407
 PR 25-SEP-1998 US 60/101757
 PI JOHN E LANDERS, BARBARA JORDAN, DAVID E HOUSMAN, ALAIN CHAREST PC
 C12N15/09, C12Q1/68, G01N33/53, G01N33/566, G01N33/58, G01N37/00, PC
 G01N37/00,
 PC C12N15/00
 CC Methods and products related to genotyping and DNA analysis FH
 Key Location/Qualifiers
 FT source 1..17
 FT /organism='Homo sapiens (human)'.
 FEATURES
 source
 1..17
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGA 1496
 |||||
 Db 4 ATAATGTAACAGGA 17

RESULT 96
 BD254950/c
 LOCUS
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254950
 VERSION BD254950.1 GI:33064720
 KEYWORDS JP 2002541795-A/2743.
 SOURCE unidentified
 ORGANISM unclassified.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswiggen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 2743 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC
 COMMENT
 OS Eukaryote
 PN JP 2002541795-A/2743
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1..17
 FT /organism='Eukaryote'.
 FEATURES
 source
 1..17
 Location/Qualifiers
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 CATTGATGAGGC 578
 |||||
 Db 15 CATTGATGAGGC 2

RESULT 97
 CQ625689/c
 LOCUS
 DEFINITION Sequence 10429 from Patent WO0192524.
 ACCESSION CQ625689
 VERSION CQ625689.1 GI:41675907
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 10429 06-DEC-2001;
 Aeonica, Inc. (US)
 FEATURES
 source
 1..17
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
 |||||
 Db 17 TTTTGATGCTGTCA 4

RESULT 98
 CQ625690/c
 LOCUS
 DEFINITION Sequence 10430 from Patent WO0192524.
 ACCESSION CQ625690
 VERSION CQ625690.1 GI:41675908
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
 Shannon, M.E.
 TITLE Myosin-like gene expressed in human heart and muscle
 JOURNAL Patent: WO 0192524-A 10430 06-DEC-2001;
 Aeonica, Inc. (US)
 FEATURES
 source
 1..17
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
 |||||
 Db 16 TTTTGATGCTGTCA 3

RESULT 99
 AR434400
 LOCUS
 DEFINITION Sequence 823 from patent US 6656700.
 ACCESSION AR434400
 VERSION AR434400.1 GI:40197243
 KEYWORDS Unknown.
 SOURCE

Qy 1243 TTCCAGGAATCAGC 1258
|||||
Db 1 TTCCAGGAATCAGC 16

RESULT 91
AR054087 AR054087 16 bp DNA linear PAT 29-SEP-1999
LOCUS Sequence 14 from patent US 5834440.
DEFINITION AR054087
ACCESSION AR054087
VERSION AR054087.1 GI:5978949
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
1 (bases 1 to 16)
AUTHORS Goldenberg, T. and Tritz, R.
TITLE Ribozyme therapy for the inhibition of restenosis
JOURNAL Patent: US 5834440-A 14 10-NOV-1998;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 819 TTCTGTCAACAAA 832
|||||
Db 1 TTCTGTCAACAAA 14

RESULT 92
AR436182 AR436182 16 bp RNA linear PAT 18-DEC-2003
LOCUS Sequence 441 from patent US 6656731.
DEFINITION AR436182
ACCESSION AR436182
VERSION AR436182.1 GI:40199266
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE
1 (bases 1 to 16)
AUTHORS Eckstein, F., Ludwig, J. and Beigelman, L.
TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6656731-A 441 02-DEC-2003;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1706 AATGTAACATGTTT 1719
|||||
Db 1 AATGTAACATGTTT 14

RESULT 93
AX132931 AX132931 16 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 4149 from Patent WO0130362.
DEFINITION AX132931
ACCESSION AX132931
VERSION AX132931.1 GI:14139241
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
1 (bases 1 to 16)
AUTHORS Landers, J.E., Jordan, B., Housman, D.E. and Charest, A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 219 13-AUG-2002;
COMMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY
OS Homo sapiens (human)
PN JP 2002525127-A/219

REFERENCE
1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4149 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)
LOCATION/Qualifiers
source
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Hairpin ribozyme recognition site for PCNA"

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 819 TTCTGTCAACAAA 832
|||||
Db 1 TTCTGTCAACAAA 14

RESULT 94
AX133152 AX133152 16 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 4370 from Patent WO0130362.
DEFINITION AX133152
ACCESSION AX133152
VERSION AX133152.1 GI:14139462
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
1
AUTHORS Robbins, J.M. and Tritz, R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4370 03-MAY-2001;
FEATURES IMMUSOL, INC. (US)
LOCATION/Qualifiers
source
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Hammerhead ribozyme recognition site for PCNA"

Query Match 0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 819 TTCTGTCAACAAA 832
|||||
Db 1 TTCTGTCAACAAA 14

RESULT 95
BD241272 BD241272 17 bp DNA linear PAT 17-JUL-2003
LOCUS Methods and products related to genotyping and DNA analysis.
DEFINITION BD241272
ACCESSION BD241272
VERSION BD241272.1 GI:33051042
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
1 (bases 1 to 17)
AUTHORS Landers, J.E., Jordan, B., Housman, D.E. and Charest, A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: JP 2002525127-A 219 13-AUG-2002;
COMMENT MASSACHUSETTS INSTITUTE OF TECHNOLOGY
OS Homo sapiens (human)
PN JP 2002525127-A/219

```

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCGTGCAC 828
Db 16 AACAACTTTCGTGCAC 1

RESULT 88
BD085033/c
LOCUS          18 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION    Target-dependent reactions using structure-bridging
              oligonucleotides.
ACCESSION    BD085033
VERSION      BD085033.1 GI:22630643
KEYWORDS     JP 2001523111-A/108.
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Dong,F., Lyamichev,V.I., Prudent,J.R., Fors,L., Neri,B.P.,
              Brow,M.A.D., Anderson,T.A. and Dahlberg,J.E.
TITLE        Target-dependent reactions using structure-bridging
              oligonucleotides
JOURNAL      Patent: JP 2001523111-A 108 20-NOV-2001;
              THIRD WAVE TECHNOLOGIES INC
COMMENT      OS Unidentified
              PN JP 2001523111-A/108
              PD 20-NOV-2001
              PF 05-MAY-1998 JP 1998548047
              PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR
              03-MAR-1998 US 09/034205
              PI FANG DONG,VICTOR I LYAMICHEV,JAMES R PRUDENT,LANCE FORS,BRUCE
              PI P NERI.
              PI MARY ANN D BROW,TODD A ANDERSON,JAMES E DAHLBERG PC
              CO7H21/04,C07H21/02,C12Q1/68
              CC Strandedness: Single;
              CC Topology: Linear;
              CC /desc = 'DNA'
              FH Key
              FT source
              FT Location/Qualifiers
FEATURES      source
              1..18
              /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCGTGCAC 828
Db 16 AACAACTTTCGTGCAC 1

RESULT 89
BD088981
LOCUS          18 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION    A method of arraying genome clone.
ACCESSION    BD088981
VERSION      BD088981.1 GI:22634591
KEYWORDS     JP 2001321190-A/1225.
SOURCE       synthetic construct
ORGANISM     synthetic construct
              other sequences; artificial sequences.
REFERENCE    1 (bases 1 to 18)
AUTHORS      Soeda,E.
              A method of arraying genome clone
              Patent: JP 2001321190-A 1225 20-NOV-2001;
              THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
              GENOTECHS
              OS Artificial Sequence
              PN JP 2001321190-A/1225
              PD 20-NOV-2001
              PF 12-MAR-2001 JP 2001068285
              PI EIICHI SOEDA
              PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
              PC C12N15/00
              CC Description of Artificial Sequence:Synthetic DNA FH Key
              FT source
              FT Location/Qualifiers
FEATURES      source
              1..18
              /organism="Artificial Sequence".
              Location/Qualifiers
              1..18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1243 TTCCAGGATCAAGC 1258
Db 1 TTCCAGGATCAAGC 16

RESULT 90
AB068916
LOCUS          18 bp      DNA      linear      SYN 21-MAY-2003
DEFINITION    Synthetic construct DNA, forward primer for human STS sts-R164D21F
              at 1p36.
ACCESSION    AB068916
VERSION      AB068916.1 GI:15129720
KEYWORDS     synthetic construct
SOURCE       synthetic construct
              other sequences; artificial sequences.
REFERENCE    1
AUTHORS      Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
              Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
              Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
              and Soeda,E.
              A BAC-based STS-content map spanning a 35-Mb region of human
              chromosome 1p35-p36
              Genomics 74 (1), 55-70 (2001)
              21269192
              PUBMED 11374902
              2 (bases 1 to 18)
              Direct Submission
              Horii,A.
              Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
              Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
              Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
              Tel:81-22-717-8042, Fax:81-22-717-8047)
              Location/Qualifiers
FEATURES      source
              1..18
              /organism="synthetic construct"
              /mol_type="genomic DNA"
              /db_xref="taxon:32630"
              misc_feature
              1..18
              /note="forward primer for human STS sts-R164D21F at 1p36
              sts-R164D21F obtained from clones B31A4, B354N13, B330C5,
              260018, B145C4, B164D21, B27A6, Human BAC library RPCI-11"

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

AX757296
LOCUS AX757296 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 617 from Patent WO03040369.
ACCESSION AX757296
VERSION AX757296.1 GI:32251912
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Telleran, A., Amson, R. and Tuijinder, M.
AUTHORS
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 617 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1316 ATCAATTGGAATATGA 1331
||||| |||||||||
Db 2 ATCAATGGAATATGA 17
RESULT 84
CQ807658
LOCUS CQ807658 18 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 1108 from Patent WO2004035803.
ACCESSION CQ807658
VERSION CQ807658.1 GI:47113052
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Fokens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,
AUTHORS Nimrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and
Marx, A.
TITLE Method and nucleic acids for the improved treatment of breast cell
proliferative disorders
JOURNAL Patent: WO 2004035803-A 1108 29-APR-2004;
Epigenomics AG (DE)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for BCL2"
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1376 GGTGGTGGTTAGGA 1391
||||| |||||||||
Db 2 GATTGGTGGTTAGGA 17
RESULT 85
AR488779/c
LOCUS AR488779 18 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 108 from patent US 6709815.
ACCESSION AR488779
VERSION AR488779.1 GI:47254977
KEYWORDS

Unknown.
ORGANISM Unknown.
REFERENCE 1 (Bases 1 to 18)
AUTHORS Dong, F., Lyamichev, V.I., Prudent, J.R., Fors, L., Neri, B.P.,
Brow, M.A.D., Anderson, T.A. and Dahlberg, J.E.
TITLE target-dependent reactions using structure-bridging
oligonucleotides
JOURNAL Patent: US 6709815-A 108 23-MAR-2004;
FEATURES
source
1..18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 813 ATCAACTTCTGTCAC 828
||||| |||||||||
Db 16 AACAACTTCTGTCAC 1
RESULT 86
AX378430
LOCUS AX378430 18 bp DNA linear PAT 18-MAR-2002
DEFINITION Sequence 219 from Patent WO0206525.
ACCESSION AX378430
VERSION AX378430.1 GI:19574283
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Cohen, D., Blumenfeld, M., Chumakov, I., Abderrahim, H. and Bihaï, B.
AUTHORS Obesity associated biallelic marker maps
TITLE Patent: WO 0206525-A 219 24-JAN-2002;
JOURNAL GENSET (FR)
FEATURES
source
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
primer_bind
1..18
/note="upstream amplification primer 99-32165 for SEQ 48"
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1238 CACACTTCCCAGGAAT 1253
||||| |||||||||
Db 1 CACACTTCCCTGGAAT 16
RESULT 87
AX419771/c
LOCUS AX419771 18 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 108 from Patent WO0198537.
ACCESSION AX419771
VERSION AX419771.1 GI:21524138
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
AUTHORS Nucleic acid accessible hybridization sites
TITLE Patent: WO 0198537-A 108 27-DEC-2001;
JOURNAL THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1..18
Location/Qualifiers

Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1478 TGGCAATAATGTAACA 1493	
Db	17 TGGCAATAATGTCACA 2	
RESULT 79	AX672257/c	
LOCUS	AX672257	17 bp DNA linear PAT 27-MAR-2003
DEFINITION	Sequence 702 from Patent WO03004526.	
ACCESSION	AX672257	
VERSION	AX672257.1 GI:29330605	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman,A., Amson,R. and Tuijnder,M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines	
JOURNAL	Patent: WO 03004526-A 702 16-JAN-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	2 TGAATTTCTCATGAT 17	
Db	17 TGAATTTCTCATGAT 2	
RESULT 80	AX728771	
LOCUS	AX728771	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 405 from Patent WO03025175.	
ACCESSION	AX728771	
VERSION	AX728771.1 GI:30508114	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman,A., Amson,R. and Tuijnder,M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines	
JOURNAL	Patent: WO 03025175-A 405 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	871 ATCCTTTTCTTTAAAG 886	
Db	2 ATCCTTTTCTTTGAAAG 17	
RESULT 81	AX735442/c	
LOCUS	AX735442	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 1032 from Patent WO03025177.	
ACCESSION	AX735442	
VERSION	AX735442.1 GI:30514719	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman,A., Amson,R. and Tuijnder,M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments	
JOURNAL	Patent: WO 03025177-A 1032 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	2 TGAATTTCTCATGAT 17	
Db	17 TGAATTTCTCATGAT 2	
RESULT 82	AX736604	
LOCUS	AX736604	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 2194 from Patent WO03025177.	
ACCESSION	AX736604	
VERSION	AX736604.1 GI:30515892	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman,A., Amson,R. and Tuijnder,M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments	
JOURNAL	Patent: WO 03025177-A 2194 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1..17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	871 ATCCTTTTCTTTAAAG 886	
Db	2 ATCCTTTTCTTTGAAAG 17	
RESULT 83		

Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1478 TGGCAATAATGTAACA 1493	
Db	17 TGGCAATAATGTCACA 2	
RESULT 79	AX672257/c	
LOCUS	AX672257	17 bp DNA linear PAT 27-MAR-2003
DEFINITION	Sequence 702 from Patent WO03004526.	
ACCESSION	AX672257	
VERSION	AX672257.1 GI:29330605	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman, A., Anson, R. and Tuijnder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines	
JOURNAL	Patent: WO 03004526-A 702 16-JAN-2003;	
FEATURES	source	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	2 TGAATTTCTCATGAT 17	
Db	17 TGAATTTCTCATGAT 2	
RESULT 80	AX728771	
LOCUS	AX728771	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 405 from Patent WO03025175.	
ACCESSION	AX728771	
VERSION	AX728771.1 GI:30508114	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman, A., Anson, R. and Tuijnder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines	
JOURNAL	Patent: WO 03025175-A 405 27-MAR-2003;	
FEATURES	source	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	871 ATCCTTTCTTTAAAG 886	
Db	2 ATCCTTTCTTTGAAAG 17	
RESULT 81	AX735442/c	
LOCUS	AX735442	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 1032 from Patent WO03025177.	
ACCESSION	AX735442	
VERSION	AX735442.1 GI:30514719	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman, A., Anson, R. and Tuijnder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments	
JOURNAL	Patent: WO 03025177-A 1032 27-MAR-2003;	
FEATURES	source	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	2 TGAATTTCTCATGAT 17	
Db	17 TGAATTTCTCATGAT 2	
RESULT 82	AX736604	
LOCUS	AX736604	17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 2194 from Patent WO03025177.	
ACCESSION	AX736604	
VERSION	AX736604.1 GI:30515892	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE	1	
AUTHORS	Tejerman, A., Anson, R. and Tuijnder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments	
JOURNAL	Patent: WO 03025177-A 2194 27-MAR-2003;	
FEATURES	source	
Query Match	0.8%; Score 14.4; DB 1; Length 17;	
Best Local Similarity	93.8%; Pred. No. 78;	
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	871 ATCCTTTCTTTAAAG 886	
Db	2 ATCCTTTCTTTGAAAG 17	
RESULT 83		

RESULT 74	AR466754/c	17 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	AR466754	Sequence	10431	from patent US 6686188.	
DEFINITION	AR466754	Sequence	10431	from patent US 6686188.	
ACCESSION	AR466754	Sequence	10431	from patent US 6686188.	
VERSION	AR466754.1	GI:42701811			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,W.E.				
TITLE	Poly-nucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle				
JOURNAL	Patent: US 6686188-A 10431 03-FEB-2004;				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	0.8%; Score 14.4; DB 1; Length 17;				
Best Local Similarity	93.8%; Pred. No. 78;				
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
Qy	838 AGTTTGGATGCTGTC A 853				
Db	17 ACTTTTGATGCTGTC A 2				
RESULT 75	AR466756/c	17 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	AR466756	Sequence	10433	from patent US 6686188.	
DEFINITION	AR466756	Sequence	10433	from patent US 6686188.	
ACCESSION	AR466756	Sequence	10433	from patent US 6686188.	
VERSION	AR466756.1	GI:42701813			
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	1 (bases 1 to 17)				
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,W.E.				
TITLE	Poly-nucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle				
JOURNAL	Patent: US 6686188-A 10433 03-FEB-2004;				
FEATURES	Location/Qualifiers				
source	1..17				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	0.8%; Score 14.4; DB 1; Length 17;				
Best Local Similarity	93.8%; Pred. No. 78;				
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
Qy	837 GAGTTTGGATGCTGTC 852				
Db	16 GACTTTTGATGCTGTC 1				
RESULT 76	AX217706	17 bp	RNA	linear	PAT 07-SEP-2001
LOCUS	AX217706	Sequence	3148	from Patent WO0159103.	
DEFINITION	AX217706	Sequence	3148	from Patent WO0159103.	
ACCESSION	AX217706	Sequence	3148	from Patent WO0159103.	
VERSION	AX217706.1	GI:15527767			
KEYWORDS	synthetic construct				
SOURCE	synthetic construct				
ORGANISM	other sequences; artificial sequences.				
REFERENCE	1				
AUTHORS	Blatt,L., Mcswiggen,J. and Chowira,B.M.				
TITLE	Method and reagent for the modulation and diagnosis of cd20 and				

RESULT 69
I54342/c
LOCUS 154342 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 2083 from patent US 5646042.
ACCESSION I54342
VERSION I54342.1 GI:2475545
KEYWORDS
SOURCE
ORGANISM
Unassigned.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 2083 08-JUL-1997;
FEATURES
source
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTACAAATTAA 1560
Db 17 GCATTACAAATTAA 2
|||||

RESULT 70
I94283
LOCUS 194283 17 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 446 from patent US 5731295.
ACCESSION I94283
VERSION I94283.1 GI:3938753
KEYWORDS
SOURCE
ORGANISM
Unassigned.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 446 24-MAR-1998;
FEATURES
source
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTCACTTACAGGAT 332
Db 1 ACCTCACTTACAGGAT 16
|||||

RESULT 71
AR190342
LOCUS AR190342 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5830 from patent US 6346398.
ACCESSION AR190342
VERSION AR190342.1 GI:20236307
KEYWORDS
SOURCE
ORGANISM
Unassigned.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 5830 12-FEB-2002;
FEATURES
source
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 GTCAGATGATGAAG 312
Db 1 GTCAGATGATGAAG 16
|||||

RESULT 72
AR325288
LOCUS AR325288 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2690 from patent US 6566127.
ACCESSION AR325288
VERSION AR325288.1 GI:33711096
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2690 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 297 GTCAGATGATGAAG 312
Db 1 GTCAGATGATGAAG 16
|||||

RESULT 73
AR328139/c
LOCUS AR328139 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5541 from patent US 6566127.
ACCESSION AR328139
VERSION AR328139.1 GI:33713947
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5541 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATAGTTACAC 1536
Db 17 ACACACATAGTTACAC 2
|||||

PI JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC C12N5/00
CC Method and reagent for treating diseases or conditions CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT Location/Qualifiers
FEATURES source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1672 ATTGAATAGAGATTA 1687
Db 1 ATCAGATTAGATTA 16
RESULT 65
CQ625691/c
LOCUS CQ625691 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10431 from Patent WO0192524.
ACCESSION CQ625691
VERSION CQ625691.1 GI:41675909
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10431 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 838 AGTTTGTGCTGCTCA 853
Db 17 ACTTTTGTGCTGCTCA 2
RESULT 66
CQ625693/c
LOCUS CQ625693 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10433 from Patent WO0192524.
ACCESSION CQ625693
VERSION CQ625693.1 GI:41675911
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10433 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 837 GAGTTTGTGCTGCTC 852
Db 16 GACTTTTGTGCTGCTC 1
RESULT 67
I37433
LOCUS I37433 17 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 446 from patent US 5612215.
ACCESSION I37433
VERSION I37433.1 GI:2085393
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 446 18-MAR-1997;
Aeomica, Inc. (US)
FEATURES source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 317 ACCTCACTTACAGGAT 332
Db 1 ACCTCACTTACAGGAT 16
RESULT 68
I53259/c
LOCUS I53259 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1000 from patent US 5646042.
ACCESSION I53259
VERSION I53259.1 GI:2474462
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1000 08-JUL-1997;
Aeomica, Inc. (US)
FEATURES source
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1545 GCTTTTACAAAATTAA 1560
Db 17 GCATTTACAAAATTAA 2

```

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATGTTACAC 1536
Db 16 ACACACACATGTTACAC 1

RESULT 60
AR328664/c
LOCUS AR328664 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6066 from patent US 6566127.
ACCESSION AR328664
VERSION AR328664.1 GI:33714472
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6066 20-MAY-2003;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 ACACACATAGTTAC 1534
Db 16 ACACACACATGTTAC 1

RESULT 61
AR435918/c
LOCUS AR435918 16 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 177 from patent US 6656731.
ACCESSION AR435918
VERSION AR435918.1 GI:40199002
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.
TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6656731-A 177 02-DEC-2003;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match      0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 70;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCATTCATTC 1591
Db 16 TTTTTCATTCATTC 1

RESULT 62
AR046207/c
LOCUS AR046207 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1000 from patent US 5817796.
ACCESSION AR046207
VERSION AR046207.1 GI:5967672
KEYWORDS

```

```

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 1000 06-OCT-1998;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAAATTAA 1560
Db 17 GCATTTACAAAATTAA 2

RESULT 63
AR047290/c
LOCUS AR047290 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2083 from patent US 5817796.
ACCESSION AR047290
VERSION AR047290.1 GI:5968755
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 2083 06-OCT-1998;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAAATTAA 1560
Db 17 GCATTTACAAAATTAA 2

RESULT 64
BD201350
LOCUS BD201350 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions
concerning molecule participating in vasculogenic response.
ACCESSION BD201350
VERSION BD201350.1 GI:33011120
KEYWORDS JP 2002509721-A/4376.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and McSwiggen,J.A.
TITLE Method and reagent for treating diseases or conditions
concerning molecule participating in vasculogenic response
JOURNAL Patent: JP 2002509721-A 4376 02-APR-2002;
COMMENT
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4376
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,

```

```
Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887
      ||||| ||||| |||||
DB 1 AATCCTGATCTTTAAAGA 18

RESULT 55
LOCUS 194911 18 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 1074 from patent US 5731295.
ACCESSION I94911
VERSION I94911.1 GI:3939381
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
        Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 1074 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886
      ||||| ||||| |||||
DB 1 AAATCTGTCCTTTAAAG 18

RESULT 56
LOCUS 194954 18 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 1117 from patent US 5731295.
ACCESSION I94954
VERSION I94954.1 GI:3939424
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
        Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 1117 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886
      ||||| ||||| |||||
DB 1 AAATCCTGATCTTTAAAG 18

RESULT 57
LOCUS 194966 18 bp DNA PAT 01-DEC-1998
DEFINITION Sequence 1129 from patent US 5731295.
ACCESSION I94966
VERSION I94966.1 GI:3939436
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
        Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 1129 24-MAR-1998;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886
      ||||| ||||| |||||
DB 1 AAATCTGTCCTTTAAAG 18

RESULT 58
LOCUS 194959 18 bp DNA PAT 12-JUN-2003
DEFINITION Sequence 5494 from patent US 6537751.
ACCESSION AR293759
VERSION AR293759.1 GI:31681043
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
        disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 5494 25-MAR-2003;
FEATURES Location/Qualifiers
          source
            1..18
              /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 CCCACCTACAGATACCTT 708
      ||||| ||||| |||||
DB 18 CCCACCTTGAGATACCTT 1

RESULT 59
LOCUS 194963 16 bp RNA PAT 17-AUG-2003
DEFINITION Sequence 6065 from patent US 6566127.
ACCESSION AR328663
VERSION AR328663.1 GI:33714471
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
        related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6065 20-MAY-2003;
FEATURES Location/Qualifiers
          source
            1..16
              /organism="unknown"
              /mol_type="unassigned RNA"
```

/note="Detection oligonucleotide for EBBP"

```
Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1042 ATAAACAACTTAGTACCA 1059
Db 18 ATAAACAACTCAATACCA 1

RESULT 50
I37008
LOCUS I37008 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 21 from patent US 5612215.
ACCESSION I37008
VERSION I37008.1 GI:2084968
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 21 18-MAR-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887
Db 1 AATCCTGATCTTTAAAGA 18

RESULT 51
I38061
LOCUS I38061 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 1074 from patent US 5612215.
ACCESSION I38061
VERSION I38061.1 GI:2086051
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 1074 18-MAR-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886
Db 1 AAATCCTGATCTTTAAAG 18

RESULT 52
I38104
LOCUS I38104 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 1117 from patent US 5612215.

Accession I38104.1 GI:2086094
Version I38104.1
Source Unknown.
Organism Unclassified.
Reference 1 (bases 1 to 18)
Authors Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
Title Stromelysin targeted ribozymes
Journal Patent: US 5612215-A 1117 18-MAR-1997;
Features Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 621 TGTTCCTGCTTCATGAAC 638
Db 1 TGTTCCTGCTCATGAGCT 18

RESULT 53
I38116
LOCUS I38116 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 1129 from patent US 5612215.
ACCESSION I38116
VERSION I38116.1 GI:2086106
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 1129 18-MAR-1997;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTTCTTTAAAG 886
Db 1 AAATCCTGCTTTTAAAG 18

RESULT 54
I93858
LOCUS I93858 18 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 21 from patent US 5731295.
ACCESSION I93858
VERSION I93858.1 GI:3938328
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Method of reducing stromelysin RNA via ribozymes
JOURNAL Patent: US 5731295-A 21 24-MAR-1998;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
```

```

RESULT 45
AX217705
LOCUS AX217705 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3147 from Patent WO0159103.
ACCESSION AX217705
VERSION AX217705.1 GI:15527766
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3147 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
MCSwigen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 164 AAAAATCCAGGAATG 180
Db 1 AAAAATCCAGGAAGTG 17

RESULT 46
AX180490
LOCUS AR180490 15 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 558 from patent US 6333152.
ACCESSION AR180490
VERSION AR180490.1 GI:20222523
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 15)
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE Gene expression profiles in normal and cancer cells
JOURNAL Patent: US 6333152-A 558 25-DEC-2001;
FEATURES
source
1..15
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 CATGAACCTGGCCAT 645
Db 1 CATGAACCTGGCCAT 15

RESULT 47
AX218129
LOCUS AX218129 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3571 from Patent WO0159103.
ACCESSION AX218129
VERSION AX218129.1 GI:15528190
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1

AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 3147 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
MCSwigen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 162 AGAATAACTCCAGGA 176
Db 3 AGAATAACTCCAGGA 17

RESULT 48
AR096838/c
LOCUS AR096838 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 36 from patent US 6008344.
ACCESSION AR096838
VERSION AR096838.1 GI:10025996
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Cowsett,L.M.
TITLE Antisense modulation of phospholipase A2 group IV expression
JOURNAL Patent: US 6008344-A 36 28-DEC-1999;
FEATURES
source
1..18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 98.9%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 577 GCAGAAACGTGGACTAAA 594
Db 18 GCAGAAAGTGGGCTAAA 1

RESULT 49
CO808362/c
LOCUS CO808362 18 bp DNA linear PAT 10-MAY-2004
DEFINITION Sequence 1812 from Patent WO2004035803.
ACCESSION CO808362
VERSION CO808362.1 GI:47113756
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Foekens,J., Harbeck,N., Koenig,T., Maier,S., Martens,J., Model,F.,
Nimmrich,I., Rujan,T., Schmitt,A., Schmitt,M., Look,M.P. and
Marx,A.
TITLE Method and nucleic acids for the improved treatment of breast cell
proliferative disorders
JOURNAL Patent: WO 2004035803-A 1812 29-APR-2004;
Epigenomics AG (DE)
FEATURES
source
1..18
Location/Qualifiers
/organism="synthetic construct"
/db_xref="taxon:32630"

```

[illegible]

```
FEATURES
  source
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 16; DB 1; Length 16;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1764
Db 16 AAAAAAAAAAAAAA 1

RESULT 36
LOCUS AX217704 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 3146 from Patent WO0159103.
ACCESSION AX217704
VERSION AX217704.1 GI:15527765
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
  AUTHORS Blatt, B., McSwiggen, J. and Chowrira, B. M.
  TITLE Method and reagent for the modulation and diagnosis of cd20 and
  JOURNAL nogo gene expression
  PATENT: WO 0159103-A 3146 16-AUG-2001; Blatt, Lawrence (US);
  RIBOZYNE PHARMACEUTICALS, INC. (US); Chowrira, Bharat M. (US)
  McSwiggen, James (US); Chowrira, Bharat M. (US)
  Location/Qualifiers
    1..17
    /organism="synthetic construct"
    /mol_type="unassigned RNA"
    /db_xref="taxon:32630"
    /note="Nucleic Acid"

FEATURES
  source
    Query Match
    Best Local Similarity 0.9%; Score 16; DB 1; Length 17;
    Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 162 AGAAAACTCCAGAA 177
Db 1 AGAAAACTCCAGAA 16

RESULT 37
LOCUS AR266181 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 80 from patent US 6492172.
ACCESSION AR266181
VERSION AR266181.1 GI:29695027
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
  AUTHORS Bennett, C. F., Busch, H. and Wyatt, J.
  TITLE Antisense modulation of GU protein expression
  JOURNAL Patent: US 6492172-A 80 10-DEC-2002;
  Location/Qualifiers
    1..20
    /organism="unknown"
    /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 16; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1294 TACTACATCTTCCAG 1309
Db 5 TACTACATCTTCCAG 20

FEATURES
  source
    Location/Qualifiers
      1..16
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAA 1764
Db 16 AAAAAAAAAAAAAA 1

RESULT 38
LOCUS AX300803 20 bp DNA linear PAT 30-NOV-2001
DEFINITION Sequence 5 from Patent WO0185993.
ACCESSION AX300803
VERSION AX300803.1 GI:17382083
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Cooper, D. N., Procter, A. M., Gregory, J. D. and Millar, D. S.
  TITLE Method for detecting growth hormone variations in humans, the
  JOURNAL variations and their uses
  PATENT: WO 0185993-A 5 15-NOV-2001;
  UNIVERSITY OF WALES COLLEGE OF MEDICINE (GB)
  Location/Qualifiers
    1..20
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
Best Local Similarity 100.0%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 854 CAACAGTCGGAGAGAA 869
Db 4 CAACAGTCGGAGAGAA 19

RESULT 39
LOCUS AX132826 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4044 from Patent WO0130362.
ACCESSION AX132826
VERSION AX132826.1 GI:14139136
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Robbins, J. M. and Tritz, R.
  TITLE Ribozyme therapy for the treatment of proliferative skin and eye
  JOURNAL diseases
  PATENT: WO 0130362-A 4044 03-MAY-2001;
  IMMUSOL, INC. (US)
  Location/Qualifiers
    1..19
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
    /note="PCNA HH ribozyme binding site"

Query Match
Best Local Similarity 89.5%; Pred. No. 63;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1717 TTTTGTTCCTTTAAATAA 1735
Db 1 TATTGTTTCCTGTAATAA 19

RESULT 40
LOCUS CQ625692 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10432 from Patent WO0192524.
ACCESSION CQ625692
VERSION CQ625692.1 GI:41675910
```

```
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373
||||| ||||||| |||||
Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 31
AX189740
LOCUS AX189740
DEFINITION Sequence 42 from Patent WO0148240.
ACCESSION AX189740
VERSION AX189740.1 GI:15143116
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Chartier-Harlin,M.C., Amouyel,P., Lambert,J.C. and Ataria,L.
JOURNAL Implication of a known gene named cp2/lst-lbp-1 in Alzheimer's
PATENT: WO 0148240-A 42 05-JUL-2001;
INSTITUT PASTEUR DE LILLE (FR) ; INSTITUT NATIONAL DE LA SANTE ET
DE LA RECHERCHE MEDICALE (INSERM) (FR)
FEATURES
source
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 56;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373
||||| ||||||| |||||
Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 32
AX021121
LOCUS AX021121
DEFINITION Sequence 5 from Patent WO9930730.
ACCESSION AX021121
VERSION AX021121.1 GI:10044774
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE Tremblay,J.P.
AUTHORS Methods and compositions for improving the success of cell
TITLE transplantation in a host
JOURNAL Patent: WO 9930730-A 5 24-JUN-1999;
UNIV LAVAL (CA); TREMBLAY JACQUES P (CA)
FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTCCCGATG 268
||||| ||||||| |||||
Db 3 GATGTGGAGTCCAGATG 20

RESULT 33
```

```
AX613732/c
LOCUS AX613732
DEFINITION Sequence 4757 from Patent WO02072882.
ACCESSION AX613732
VERSION AX613732.1 GI:28409161
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Cullen,P. and Seedorf,U.
JOURNAL Coronary chip
PATENT: WO 02072882-A 4757 19-SEP-2002;
OGHAM GmbH (DE)
FEATURES
source
Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 58;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 799 CCTAGCAGTCCACCATCA 816
||||| ||||||| |||||
Db 20 CTTGCAGTCCACCATCA 3

RESULT 34
AR561628
LOCUS AR561628
DEFINITION Sequence 1 from patent US 6756492.
ACCESSION AR561628
VERSION AR561628.1 GI:53974736
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Beier,M. and Honeisel,J.
TITLE Nucleoside derivatives with photo-unstable protective groups
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;
FEATURES
source
Location/Qualifiers
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAA 1764
||||| ||||||| |||||
Db 1 AAAAAAAAAAAAAAAA 16

RESULT 35
AR561693/c
LOCUS AR561693
DEFINITION Sequence 9 from patent US 6759039.
ACCESSION AR561693
VERSION AR561693.1 GI:53974843
KEYWORDS Location/Qualifiers
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Tsang,W.-G., Zheng,T. and Huang,C.J.
TITLE Culturing pancreatic stem cells having a specified, intermediate
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;
```


[illegible]

```

194907
LOCUS           194907               18 bp      DNA          linear          PAT 01-DEC-1998
DEFINITION     Sequence 1070 from patent US 5731295.
ACCESSION     194907
VERSION       194907.1  GI:3939377
KEYWORDS      Unknown.
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE        Method of reducing stromelysin RNA via ribozymes
JOURNAL      Patent: US 5731295-A 1070 24-MAR-1998;
FEATURES     Location/Qualifiers
             1..18
             /organism="unknown"
             /mol_type="unassigned DNA"
Query Match      0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATG 766
DB 2 CATTGAGTCCCTCTATG 18

RESULT 24
E31760
LOCUS           E31760               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31760
VERSION       E31760.1  GI:13018609
KEYWORDS      JP 2000014386-A/2.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Takayuki,T. and Yoshiyuki,O.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014386-A 2 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014386-A/2
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190868
              PR TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI
              PI C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC
              PC (C12N1/21,C12R1:19), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19),
              PC (C12P21/08,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91),
              CC (C12N5/00,C12R1:91)
              FT source

Query Match      0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATG 766
DB 2 CATTGAGTCCCTCTATG 18

RESULT 24
E31760
LOCUS           E31760               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31760
VERSION       E31760.1  GI:13018609
KEYWORDS      JP 2000014386-A/2.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Takayuki,T. and Yoshiyuki,O.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014386-A 2 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014386-A/2
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190868
              PR TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI
              PI C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC
              PC (C12N1/21,C12R1:19), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19),
              PC (C12P21/08,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91),
              CC (C12N5/00,C12R1:91)
              FT source

Query Match      0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 51;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 250 CGATGTGGAGTCCCGATGT 269
DB 1 MGVTTGGGWTBCCGATGT 20

194907
LOCUS           194907               18 bp      DNA          linear          PAT 01-DEC-1998
DEFINITION     Sequence 1070 from patent US 5731295.
ACCESSION     194907
VERSION       194907.1  GI:3939377
KEYWORDS      Unknown.
SOURCE        Unknown.
ORGANISM      Unclassified.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
              Stinchcomb,D.T.
TITLE        Method of reducing stromelysin RNA via ribozymes
JOURNAL      Patent: US 5731295-A 1070 24-MAR-1998;
FEATURES     Location/Qualifiers
             1..18
             /organism="unknown"
             /mol_type="unassigned DNA"
Query Match      0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATG 766
DB 2 CATTGAGTCCCTCTATG 18

RESULT 24
E31760
LOCUS           E31760               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31760
VERSION       E31760.1  GI:13018609
KEYWORDS      JP 2000014386-A/2.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Takayuki,T. and Yoshiyuki,O.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014386-A 2 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014386-A/2
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190868
              PR TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI
              PI C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC
              PC (C12N1/21,C12R1:19), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19),
              PC (C12P21/08,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91),
              CC (C12N5/00,C12R1:91)
              FT source

Query Match      0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 51;
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 250 CGATGTGGAGTCCCGATGT 269
DB 1 MGVTTGGGWTBCCGATGT 20

```

```

RESULT 25
E31761/c
LOCUS           E31761               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31761
VERSION       E31761.1  GI:13018610
KEYWORDS      JP 2000014386-A/3.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Takayuki,T. and Yoshiyuki,O.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014386-A 3 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014386-A/3
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190868
              PR TAKAYUKI TAKAHASHI,YOSHIYUKI ONISHI
              PI C12N15/09,C12N1/21,C12N5/10,C12N9/50,C12P21/08//(C12N15/09, PC
              PC (C12N1/21,C12R1:19), (C12N5/10,C12R1:91), (C12N9/50,C12R1:19),
              PC (C12P21/08,C12R1:91),C12N15/00,C12N5/00,(C12N15/00,C12R1:91),
              CC (C12N5/00,C12R1:91)
              FT source

Query Match      0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 51;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGCCCATTCCTT 650
DB 20 CATGARVTTGGCCAYKCCT 1

RESULT 26
E31765
LOCUS           E31765               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31765
VERSION       E31765.1  GI:13018614
KEYWORDS      JP 2000014387-A/3.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Yoshiyuki,O. and Takayuki,T.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014387-A 3 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014387-A/3
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190869
              PR YOSHIYUKI ONISHI,TAKAYUKI TAKAHASHI
              PI C12N15/09,C12N1/21,C12N9/50//(C12N1/21,C12R1:19), (C12N9/50, PC
              PC (C12R1:19),
              CC C12N15/00
              FT source

Query Match      0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 51;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGCCCATTCCTT 650
DB 20 CATGARVTTGGCCAYKCCT 1

RESULT 26
E31765
LOCUS           E31765               20 bp      DNA          linear          PAT 18-JUN-2001
DEFINITION     Novel metaprotease and DNA encoding the same.
ACCESSION     E31765
VERSION       E31765.1  GI:13018614
KEYWORDS      JP 2000014387-A/3.
SOURCE        synthetic construct
ORGANISM      other sequences; artificial sequences.
REFERENCE     1 (bases 1 to 20)
AUTHORS      Yoshiyuki,O. and Takayuki,T.
TITLE        Novel metaprotease and DNA encoding the same
JOURNAL      Patent: JP 2000014387-A 3 18-JAN-2000;
COMMENT      TAKAYUKI TAKAHASHI,KK SDI
              OS Artificial Sequence
              PN JP 2000014387-A/3
              PD 18-JAN-2000
              PF 06-JUL-1998 JP 1998190869
              PR YOSHIYUKI ONISHI,TAKAYUKI TAKAHASHI
              PI C12N15/09,C12N1/21,C12N9/50//(C12N1/21,C12R1:19), (C12N9/50, PC
              PC (C12R1:19),
              CC C12N15/00
              FT source

Query Match      0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 51;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGCCCATTCCTT 650
DB 20 CATGARVTTGGCCAYKCCT 1

```

```
Db 3 CATTGAGTCCCTCTATGGA 21
RESULT 18
LOCUS 146905 23 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 25 from patent US 5639651.
ACCESSION I46905
VERSION I46905.1 GI:2470870
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 23)
AUTHORS Weisbach,L., Bernards,A. and Settleman,J.
TITLE Gap-related gene, human IQGAP1
JOURNAL Patent: US 5639651-A 25 17-JUN-1997;
FEATURES
source
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.0%; Score 18.6; DB 1; Length 23;
Best Local Similarity 73.9%; Pred. No. 38;
Matches 17; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
QY 631 CATGAACCTGGCCATTCCTTGGG 653
Db 23 CATGAHTTGGCCAYKBTGGG 1
RESULT 19
LOCUS AR528447/c 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 85 from patent US 6723897.
ACCESSION AR528447
VERSION AR528447.1 GI:53916512
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brown,S.M., Elich,T.D., Heck,G.R., Kishore,G.M., Logusch,E.W.,
Logusch,S.J., Piller,K.J., Rao,S., Ream,J.E. and Baerson,S.R.
TITLE Methods for controlling gibberellin levels
JOURNAL Patent: US 6723897-A 85 20-APR-2004;
FEATURES
source
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.0%; Score 18.2; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 30;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1748 GAAAAAAGAAAAA 1766
Db 19 BAAAAAAGAAAAA 1
RESULT 20
LOCUS AR562156/c 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 32 from patent US 6759215.
ACCESSION AR562156
VERSION AR562156.1 GI:53976019
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 33 06-JUL-2004;
FEATURES
source
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1
RESULT 21
LOCUS AR562157/c 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 33 from patent US 6759215.
ACCESSION AR562157
VERSION AR562157.1 GI:53976020
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 33 06-JUL-2004;
FEATURES
source
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1
RESULT 22
LOCUS I38057 18 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 1070 from patent US 5612215.
ACCESSION I38057
VERSION I38057.1 GI:2086047
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and
Stinchcomb,D.T.
TITLE Stromelysin targeted ribozymes
JOURNAL Patent: US 5612215-A 1070 18-MAR-1997;
FEATURES
source
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 750 CATTGAGTCCCTCTATG 766
Db 2 CATTGAGTCCCTCTATG 18
RESULT 23
```

RESULT 13
AR541352/c
LOCUS AR541352 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 17 from patent US 6737520.
ACCESSION AR541352
VERSION AR541352.1 GI:53932999
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 17 18-MAY-2004;
FEATURES
source Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1
|||||
RESULT 14
AR541353/c
LOCUS AR541353 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 18 from patent-US 6737520.
ACCESSION AR541353
VERSION AR541353.1 GI:53933000
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;
FEATURES
source Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1
|||||
RESULT 15
AR541361/c
LOCUS AR541361 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 26 from patent US 6737520.
ACCESSION AR541361
VERSION AR541361.1 GI:53933008
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry

JOURNAL Patent: US 6737520-A 26 18-MAY-2004;
FEATURES
source Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
|||||
Db 19 AAAAAAAAAAAAAAAAAAAAAA 1
|||||
RESULT 16
AR562158/c
LOCUS AR562158 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION AR562158.1 GI:53976021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 34 06-JUL-2004;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1766
|||||
Db 19 GAAAAAAAAAAAAAAAAAAAAA 1
|||||
RESULT 17
AX133241
LOCUS AX133241 21 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4459 from Patent WO0130362.
ACCESSION AX133241
VERSION AX133241.1 GI:14139551
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases
JOURNAL Patent: WO 0130362-A 4459 03-MAY-2001;
FEATURES
source Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="MMP-3 ribozyme recognition site"
Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 750 CATTCACTCCCTCATCGA 768
|||||

FEATURES	Location/Qualifiers
source	1..24
	/organism="synthetic construct"
	/mol_type="unassigned DNA"
	/db_xref="taxon:32630"
	/note="L23808 reverse primer"
Query Match	1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity	87.5%; Pred. No. 35;
Matches	21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	981 TGCTTACGAAATTGAAGCAGAAA 1004
DB	24 TGCTTTATGAAATTGAAGCCAGAAA 1
RESULT 11	
AR541350/c	
LOCUS	AR541350 19 bp DNA linear PAT 08-OCT-2004
DEFINITION	Sequence 15 from patent US 6737520.
ACCESSION	AR541350
VERSION	AR541350.1 GI:53932997
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 19)
TITLE	Manoharan,M. and Mohan,V.
	Oligonucleotides having A-DNA form and B-DNA form conformational
JOURNAL	geometry
PATENT:	US 6737520-A 15 18-MAY-2004;
FEATURES	
source	Location/Qualifiers
	1..19
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 23;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1749 AAAAAAAAAAAAAAAAAAAAAA 1767
DB	19 AAAAAAAAAAAAAAAAAAAAAA 1
RESULT 12	
AR541351/c	
LOCUS	AR541351 19 bp DNA linear PAT 08-OCT-2004
DEFINITION	Sequence 16 from patent US 6737520.
ACCESSION	AR541351
VERSION	AR541351.1 GI:53932998
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 19)
TITLE	Manoharan,M. and Mohan,V.
	Oligonucleotides having A-DNA form and B-DNA form conformational
JOURNAL	geometry
PATENT:	US 6737520-A 16 18-MAY-2004;
FEATURES	
source	Location/Qualifiers
	1..19
	/organism="unknown"
	/mol_type="genomic DNA"
Query Match	1.1%; Score 19; DB 1; Length 19;
Best Local Similarity	100.0%; Pred. No. 23;
Matches	19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1749 AAAAAAAAAAAAAAAAAAAAAA 1767
DB	19 AAAAAAAAAAAAAAAAAAAAAA 1

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6730269-A 55 04-MAY-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 4
LOCUS AR559396 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6750016.
ACCESSION AR559396
VERSION AR559396.1 GI:53968812
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6750016-A 55 15-JUN-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 5
LOCUS AR559411 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 70 from patent US 6750016.
ACCESSION AR559411
VERSION AR559411.1 GI:53968827
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6750016-A 70 15-JUN-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 6
LOCUS AR561993 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6759199.
ACCESSION AR561993
VERSION AR561993.1 GI:53975645
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6759199-A 55 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 7
LOCUS AR565165 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6767702.
ACCESSION AR565165
VERSION AR565165.1 GI:53981003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6767702-A 55 27-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 8
LOCUS AX103868/c 24 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 60 from Patent WO0122972.
ACCESSION AX103868
VERSION AX103868.1 GI:13920065

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 6
LOCUS AR561993 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6759199.
ACCESSION AR561993
VERSION AR561993.1 GI:53975645
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6759199-A 55 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 7
LOCUS AR565165 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6767702.
ACCESSION AR565165
VERSION AR565165.1 GI:53981003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J.,
Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses
therefor
JOURNAL Patent: US 6767702-A 55 27-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20
RESULT 8
LOCUS AX103868/c 24 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 60 from Patent WO0122972.
ACCESSION AX103868
VERSION AX103868.1 GI:13920065

GenCore version 5.1.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:18:34 ; Search time 3 seconds
(without alignments)
3.868 Million cell updates/sec

Title: US-10-619-906-2

Perfect score: 1790

Sequence: 1 atgaattctcatgatg.....aaaacgggaattccgggga 1790

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 183 seqs, 3241 residues

Total number of hits satisfying chosen parameters: 366

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 183 summaries

Database : rge2.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	27	1.5	30	1	AR541545
C 2	27	1.5	30	1	AR541546
C 3	20	1.1	20	1	AR532682
C 4	20	1.1	20	1	AR532682
C 5	20	1.1	20	1	AR559396
C 6	20	1.1	20	1	AR559411
C 7	20	1.1	20	1	AR561993
C 8	19.2	1.1	24	1	AR565165
C 9	19.2	1.1	24	1	AR565165
C 10	19.2	1.1	24	1	AR565165
C 11	19	1.1	19	1	AR541350
C 12	19	1.1	19	1	AR541351
C 13	19	1.1	19	1	AR541352
C 14	19	1.1	19	1	AR541353
C 15	19	1.1	19	1	AR541361
C 16	19	1.1	20	1	AR562158
C 17	19	1.1	21	1	AR53241
C 18	18.6	1.0	23	1	I46905
C 19	18.2	1.0	19	1	AR528447
C 20	18	1.0	20	1	AR562156
C 21	18	1.0	20	1	AR562157
C 22	17	0.9	18	1	I38057
C 23	17	0.9	18	1	I38057
C 24	16.8	0.9	20	1	E31760
C 25	16.8	0.9	20	1	E31761
C 26	16.8	0.9	20	1	E31765
C 27	16.8	0.9	20	1	E31766
C 28	16.8	0.9	20	1	AR562157
C 29	16.8	0.9	21	1	AR562157
C 30	16.8	0.9	21	1	AR562157
C 31	16.8	0.9	21	1	AR562157
C 32	16.4	0.9	20	1	AR562157
C 33	16.4	0.9	20	1	AR562157

34	16	0.9	16	1	AR561628	ACCESSION:AR561628
35	16	0.9	16	1	AR561693	ACCESSION:AR561693
36	16	0.9	17	1	AR217704	ACCESSION:AR217704
37	16	0.9	20	1	AR266181	ACCESSION:AR266181
38	16	0.9	20	1	AR300803	ACCESSION:AR300803
39	15.8	0.9	19	1	AR132826	ACCESSION:AR132826
C 40	15.4	0.9	17	1	CO625692	ACCESSION:CO625692
C 41	15.4	0.9	17	1	I37482	ACCESSION:I37482
C 42	15.4	0.9	17	1	I94332	ACCESSION:I94332
C 43	15.4	0.9	17	1	AR466755	ACCESSION:AR466755
C 44	15.4	0.9	17	1	AR217325	ACCESSION:AR217325
C 45	15.4	0.9	17	1	AR217705	ACCESSION:AR217705
C 46	15	0.8	15	1	AR180490	ACCESSION:AR180490
C 47	15	0.8	17	1	AR218129	ACCESSION:AR218129
C 48	14.8	0.8	18	1	AR096838	ACCESSION:AR096838
C 49	14.8	0.8	18	1	CO808362	ACCESSION:CO808362
C 50	14.8	0.8	18	1	I37008	ACCESSION:I37008
C 51	14.8	0.8	18	1	I38061	ACCESSION:I38061
C 52	14.8	0.8	18	1	I38104	ACCESSION:I38104
C 53	14.8	0.8	18	1	I38116	ACCESSION:I38116
C 54	14.8	0.8	18	1	I93858	ACCESSION:I93858
C 55	14.8	0.8	18	1	I94911	ACCESSION:I94911
C 56	14.8	0.8	18	1	I94954	ACCESSION:I94954
C 57	14.8	0.8	18	1	I94966	ACCESSION:I94966
C 58	14.8	0.8	18	1	AR293759	ACCESSION:AR293759
C 59	14.4	0.8	16	1	AR328663	ACCESSION:AR328663
C 60	14.4	0.8	16	1	AR328664	ACCESSION:AR328664
C 61	14.4	0.8	16	1	AR435918	ACCESSION:AR435918
C 62	14.4	0.8	17	1	AR046207	ACCESSION:AR046207
C 63	14.4	0.8	17	1	AR047290	ACCESSION:AR047290
C 64	14.4	0.8	17	1	BD201350	ACCESSION:BD201350
C 65	14.4	0.8	17	1	CO625691	ACCESSION:CO625691
C 66	14.4	0.8	17	1	CO625693	ACCESSION:CO625693
C 67	14.4	0.8	17	1	I37433	ACCESSION:I37433
C 68	14.4	0.8	17	1	I53259	ACCESSION:I53259
C 69	14.4	0.8	17	1	I54342	ACCESSION:I54342
C 70	14.4	0.8	17	1	I94283	ACCESSION:I94283
C 71	14.4	0.8	17	1	AR190342	ACCESSION:AR190342
C 72	14.4	0.8	17	1	AR325288	ACCESSION:AR325288
C 73	14.4	0.8	17	1	AR328139	ACCESSION:AR328139
C 74	14.4	0.8	17	1	AR466754	ACCESSION:AR466754
C 75	14.4	0.8	17	1	AR466756	ACCESSION:AR466756
C 76	14.4	0.8	17	1	AR217706	ACCESSION:AR217706
C 77	14.4	0.8	17	1	AR325541	ACCESSION:AR325541
C 78	14.4	0.8	17	1	AR325542	ACCESSION:AR325542
C 79	14.4	0.8	17	1	AR672257	ACCESSION:AR672257
C 80	14.4	0.8	17	1	AR728771	ACCESSION:AR728771
C 81	14.4	0.8	17	1	AR735442	ACCESSION:AR735442
C 82	14.4	0.8	17	1	AR736604	ACCESSION:AR736604
C 83	14.4	0.8	17	1	AR757296	ACCESSION:AR757296
C 84	14.4	0.8	18	1	CO807658	ACCESSION:CO807658
C 85	14.4	0.8	18	1	AR488779	ACCESSION:AR488779
C 86	14.4	0.8	18	1	AR378430	ACCESSION:AR378430
C 87	14.4	0.8	18	1	AR419771	ACCESSION:AR419771
C 88	14.4	0.8	18	1	BD085033	ACCESSION:BD085033
C 89	14.4	0.8	18	1	BD089981	ACCESSION:BD089981
C 90	14.4	0.8	18	1	AR068916	ACCESSION:AR068916
C 91	14	0.8	16	1	AR054087	ACCESSION:AR054087
C 92	14	0.8	16	1	AR436182	ACCESSION:AR436182
C 93	14	0.8	16	1	AR132931	ACCESSION:AR132931
C 94	14	0.8	16	1	AR133152	ACCESSION:AR133152
C 95	14	0.8	17	1	BD241272	ACCESSION:BD241272
C 96	14	0.8	17	1	BD254950	ACCESSION:BD254950
C 97	14	0.8	17	1	CO625689	ACCESSION:CO625689
C 98	14	0.8	17	1	CO625690	ACCESSION:CO625690
C 99	14	0.8	17	1	AR434400	ACCESSION:AR434400
C 100	14	0.8	17	1	AR434401	ACCESSION:AR434401
C 101	14	0.8	17	1	AR434402	ACCESSION:AR434402
C 102	14	0.8	17	1	AR434403	ACCESSION:AR434403
C 103	14	0.8	17	1	AR466752	ACCESSION:AR466752
C 104	14	0.8	17	1	AR466753	ACCESSION:AR466753
C 105	14	0.8	17	1	AR482773	ACCESSION:AR482773
C 106	14	0.8	17	1	AR264072	ACCESSION:AR264072


```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10434

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTTCATGCTGT 851
Db 17 TCGACTTTTGATGCTGT 1

RESULT 372
US-10-724-270-145/c
; Sequence 145, Application US/10724270
; Publication No. US2005080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MEHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 145
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-145

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1688 CTCCTTGTCTTACTG 1704
Db 17 CTGCTTGTCTTACTG 1

Search completed: May 13, 2005, 12:24:30
Job time : 6 secs

```

```
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 874
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-723-361-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCCTCCGCC 1147
Db 17 CTTTGACCCCTCCGCC 1

RESULT 370
US-10-723-361-10428/c
/ Sequence 10428, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 874
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-723-361-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCCCTCCGCC 1147
Db 17 CTTTGACCCCTCCGCC 1

RESULT 370
US-10-723-361-10428/c
/ Sequence 10428, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 874
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-723-361-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTTGATGCTGTCCACAC 857
Db 17 TTTGATGCTGTCCACAC 1

RESULT 371
US-10-723-361-10434/c
/ Sequence 10434, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 10434
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-723-361-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 841 TTTGATGCTGTCCACAC 857
Db 17 TTTGATGCTGTCCACAC 1

RESULT 371
US-10-723-361-10434/c
/ Sequence 10434, Application US/10723361
/ Publication No. US20040137589A1
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
/ FILE REFERENCE: PB0105
/ CURRENT APPLICATION NUMBER: US/10/723,361
/ CURRENT FILING DATE: 2003-11-26
/ PRIOR APPLICATION NUMBER: US 09/866,108
/ PRIOR FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 10434
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ US-10-723-361-10428
```

```
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2965

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.2%; Pred. No. 2.5e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCTGTG 46
DB 1 ACUGGUUUCGCCUGUG 17

RESULT 366
US-10-287-949A-3602/c
; Sequence 3602, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3602

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
DB 17 AAACAAAAAACAAAAA 1

RESULT 367
US-10-287-949A-3603/c
; Sequence 3603, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-3603

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
DB 17 AAACAAAAAACAAAAA 1

RESULT 368
US-10-669-841-2269/c
; Sequence 2269, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2269
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-2269

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 792 GACAAAACCTAGCAGTC 808
DB 17 GATAAAACCTAGCAGGC 1

RESULT 369
US-10-723-361-874/c
; Sequence 874, Application US/10723361
```

```

US-10-287-949A-837/c
; Sequence 837, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-837

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      217  GACAACTCAACTCTGGC 233
DB      17  GACAACTCAACTCTGGC 1

RESULT 364
US-10-287-949A-2964
; Sequence 2964, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2964

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.5e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY      29  TACAGGTATCTGCTGT 45
DB      1  UACUGGUUCUGCCUG 17

RESULT 365
US-10-287-949A-2965
; Sequence 2965, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime

```

```

; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 821
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-821

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1176 C T A C T G G A G G T A T G A T G 1192
||| ||| ||| ||| ||| ||| |||
Db 1 C T A G G G G A G G T A T G A T G 17

```

RESULT 357
US-10-675-685-822
; Sequence 822, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-822

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1177 TACTGGAGGTATGATGT 1193
pb 1 TAGGGGAGGTATGATGT 17

RESULT 358
US-10-138-674-837/c
; Sequence 837, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03

```

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 837
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-837

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels

Qy 217 GACAACTCAACTCTGGC 233
|||
Db 17 GACAACTCAACTCTGGC 1

```

RESULT 359
US-10-138-674-2964
; Sequence 2964, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular E
; FILE REFERENCE: MHH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2964
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
; US-10-138-674-2964

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.5e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCCCTGT 45
:
:| | : : : | | :
Db 1 UACUGGUUUCUGCCUGU 17

```

RESULT 360
US-10-138-674-2965
; Sequence 2965, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular E
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674/2965
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2965

```

Query Match 0.88; Score 13.8; DB 1; Length 17;

```
RESULT 353
US-10-335-977-9894
; Sequence 9894, Application US/10335977
; Publication No. US20040052799A1
; GENERAL INFORMATION:
; APPLICANT: DOUGLAS SMITH et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES
; RELATING TO HELICOBACTER PYLORI FOR
; DIAGNOSTICS AND THERAPEUTICS
; NUMBER OF SEQUENCES: 10031
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875
; COMPUTER READABLE FORM:
; MEDIUM TYPE: CD-ROM ISO9660
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: Windows NT 4.0
; SOFTWARE: UNIX
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/335,977
; FILING DATE: 30-Dec-2002
; PRIOR APPLICATION NUMBER: 08/993,002
; FILING DATE: 17-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandragouras, Amy E.
; REGISTRATION NUMBER: 36,207
; REFERENCE/DOCKET NUMBER: GTN-018
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 9894:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: circular
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Helicobacter pylori
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (B) LOCATION 1..17
; SEQUENCE DESCRIPTION: SEQ ID NO: 9894:
US-10-335-977-9894
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 713 CCAGCACATTTCGCCTC 729
Db 1 CCATTACATTTCGCCTC 17

RESULT 354
US-10-342-902-2466/c
; Sequence 2466, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave

TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2466
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
; US-10-342-902-2466
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 792 GACAAACCTAGCAGTC 808
Db 17 GATAAAACCTAGCAGGC 1

RESULT 355
US-10-675-685-423
; Sequence 423, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-675-685-423
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 TGCCTGTGGGCTGCTC 55
Db 1 TGCCTGTGGGCTTCTC 17

RESULT 356
US-10-675-685-821
; Sequence 821, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 594 AAGTTTCAAGGCACAA 610
Db 1 AAGUUUCAAAGCAAA 17

RESULT 350
US-10-238-700-145/c
; Sequence 145, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 145
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-145

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1688 CTCTCTGTGCTTACTG 1704
Db 17 CTGCTGTGCTTGTCTG 1

RESULT 351
US-10-331-907-354/c
; Sequence 354, Application US/10331907
; Publication No. US20030181660A1
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. US20030181660A1e1 LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. US20030181660A1th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/331,907
; FILING DATE: 31-Dec-2002
```

```
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J. Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 354:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 354:
US-10-331-907-354

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGAGCCCGAGTGA 778
Db 17 CCATGGAGCCCGAGTGA 1

RESULT 352
US-10-430-882-789
; Sequence 789, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haerberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-789

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1208 TGGACCCCTGCTTACCCC 1224
Db 1 UGGGCCCCUGCUGACCCC 17
```

QY 1254 CAAGCCTAAATTTGATG 1270
Db 1 CAAGCCUACAUUGGUG 17

RESULT 345

US-09-827-395A-789
; Sequence 789, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBHB00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 789
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-789

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1208 TGGACCTGCTTACCCC 1224
Db 1 UGGCCCCGUGACCCC 17

RESULT 346

US-09-745-237A-952
; Sequence 952, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-952

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.5e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1251 AATCAAGCCTTAAATTTG 1267
Db 1 AAACAAGCCUACAUUG 17

RESULT 347

US-09-745-237A-954
; Sequence 954, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-954

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1256 AGCCTAAATTTGATGCA 1272
Db 1 AGCCUACAUUGGUGCA 17

RESULT 348

US-09-745-237A-1445
; Sequence 1445, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBHB00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1445
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-1445

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.5e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1254 CAAGCCTAAATTTGATG 1270
Db 1 CAAGCCUACAUUGGUG 17

RESULT 349

US-10-156-306-1493
; Sequence 1493, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1493
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1493


```

; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-952

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1251 AATCAAGCCTAAATTTG 1267
Db 1 AAACAAGCCUAAUAUUG 17

RESULT 343
US-09-930-423-954
; Sequence 954, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-954

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1256 AGCCTAAATTTGATGCA 1272
Db 1 AGCCUACAUUGUGCA 17

RESULT 344
US-09-930-423-1445
; Sequence 1445, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1445
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1445

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1512 ACAGGTCACACACAT 1528
Db 17 ACAGGTCACACACAGAT 1

RESULT 342
US-09-930-423-952
; Sequence 952, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease

```

```

; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 952
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-952

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1251 AATCAAGCCTAAATTTG 1267
Db 1 AAACAAGCCUAAUAUUG 17

RESULT 343
US-09-930-423-954
; Sequence 954, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 954
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-954

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1256 AGCCTAAATTTGATGCA 1272
Db 1 AGCCUACAUUGUGCA 17

RESULT 344
US-09-930-423-1445
; Sequence 1445, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBH00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1445
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-1445

Query Match
Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1512 ACAGGTCACACACAT 1528
Db 17 ACAGGTCACACACAGAT 1

RESULT 342
US-09-930-423-952
; Sequence 952, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease

```

```
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1253
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1253

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      7 TTTCATCATGATTTCT 23
        ||||| |||||
Db      17 TTTCATCATGATTTCT 1

RESULT 336
US-09-927-046-1678/c
; Sequence 1678, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Avers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1678
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1678

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      6 ATTCTCATCATGATTTG 22
        ||||| |||||
Db      17 ATTCTCATCATGATTTG 1

RESULT 337
US-09-877-478-2466/c
; Sequence 2466, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH900-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; CURRENT FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
```

```
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2466
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2466

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      792 GACAAAACCTAGCAGTC 808
        ||||| |||||
Db      17 GATAAAACCTAGCAGGC 1

RESULT 338
US-09-848-754A-1292/c
; Sequence 1292, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH900-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1292
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1292

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      503 ATGGCAAGGTGGTGACA 519
        ||||| |||||
Db      17 ATGGCACAGGTGGCACCA 1

RESULT 339
US-09-848-754A-1293/c
; Sequence 1293, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH900-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1293
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1293

Query Match      0.8%; Score 13.8; DB 1; Length 17;
```

```
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMPF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 821
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-821

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CTACTGGAGGTATGATG 1192
Db 1 CTAGGGGAGGTATGATG 17

RESULT 332
US-09-827-998-822
; Sequence 822, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMPF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 822
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-827-998-822

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1177 TACTGGAGGTATGATG 1193
Db 1 TAGGGGAGGTATGATG 17

RESULT 333
US-09-927-046-305/c
; Sequence 305, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
```

```
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 305
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-927-046-305

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 298 TCAGATGGATGAAGCG 314
Db 17 TCAAGCTGGATGGAGCG 1

RESULT 334
US-09-927-046-661
; Sequence 661, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 661
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-927-046-661

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.5e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1093 GGCTTCTCTGCATCTGT 1109
Db 1 GGCAUCUCUGAUCUGU 17

RESULT 335
US-09-927-046-1253/c
; Sequence 1253, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
```

; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10428

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 841 TTTCATGCTGTCACAC 857
Db 17 TTTCATGCTGTCACAC 1

RESULT 329
US-09-866-108-10434/c
; Sequence 10434, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10434
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10434

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 835 TTCAGTTTTCATGCTCT 851
Db 17 TCGACTTTTCATGCTCT 1

RESULT 330
US-09-827-998-423
; Sequence 423, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 423
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-423

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 39 TCCCTGTGGGCTGCTC 55
Db 1 TGCCTGTGGGCTTCTC 17

RESULT 331
US-09-827-998-821
; Sequence 821, Application US/09827998

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1122
; LENGTH: 17

; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1122

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719
||:|||||:|:
Db 3 AAUGUACAUGUUU 16

RESULT 326

US-10-724-270-1123
; Sequence 1123, Application US/10724270
; Publication No. US2005008031A1

; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MHB02-326-A)

; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10

; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06

; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29

; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10

; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1123

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens
US-10-724-270-1123

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719
||:|||||:|:
Db 1 AAUGUACAUGUUU 14

RESULT 327

US-09-866-108-874/c

; Sequence 874, Application US/09866108
; Patent No. US20020048800A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 874

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1131 CTTTGACCACTTCGCC 1147

|||||||

Db 17 CTTTGACCACTTCGCC 1

RESULT 328

US-09-866-108-10428/c

; Sequence 10428, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108

; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; NUMBER OF SEQ ID NOS: 1881
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; SEQ ID NO 825
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-675-685-825

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
 Db 2 GGAGGTATGATGTG 15

RESULT 319

US-10-675-685-826
 ; Sequence 826, Application US/10675685
 ; Publication No. US20040063134A1
 ; GENERAL INFORMATION:

; APPLICANT: Gu, Yizhong
 ; APPLICANT: Shannon, Mark
 ; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
 ; FILE REFERENCE: PB0114
 ; CURRENT APPLICATION NUMBER: US/10/675,685

; CURRENT FILING DATE: 2003-09-30
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; NUMBER OF SEQ ID NOS: 1881
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; SEQ ID NO 826

; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-675-685-826

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
 Db 1 GGAGGTATGATGTG 14

RESULT 320

US-10-676-154-219
 ; Sequence 219, Application US/10676154
 ; Publication No. US20040081996A1
 ; GENERAL INFORMATION:

; APPLICANT: John Landers
 ; APPLICANT: David Houseman
 ; APPLICANT: Barbara Jordan
 ; APPLICANT: Alain Charest

; TITLE OF INVENTION: Methods and Products Related to
 ; FILE REFERENCE: M0656/7045(HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/10/676,154

; CURRENT FILING DATE: 2003-09-29
 ; PRIOR APPLICATION NUMBER: US 60/101,757
 ; PRIOR FILING DATE: 1998-09-25
 ; PRIOR APPLICATION NUMBER: PCT/US99/22283
 ; PRIOR FILING DATE: 1999-09-24
 ; NUMBER OF SEQ ID NOS: 691
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 219

; LENGTH: 17

; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-676-154-219

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGA 1496
 Db 4 ATAATGTAACAGGA 17

RESULT 321

US-10-723-361-10429/c
 ; Sequence 10429, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI

; FILE REFERENCE: PB0105
 ; CURRENT APPLICATION NUMBER: US/10/723,361
 ; CURRENT FILING DATE: 2003-11-26
 ; PRIOR APPLICATION NUMBER: US 09/866,108

; PRIOR FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669
 ; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668
 ; PRIOR FILING DATE: 2001-01-30
 ; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
 ; SOFTWARE: Acomica Sequence Listing Engine
 ; SEQ ID NO 10429
 ; LENGTH: 17

; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; US-10-723-361-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGCA 853
 Db 17 TTTTGATGCTGCA 4

RESULT 322

US-10-723-361-10430/c
 ; Sequence 10430, Application US/10723361
 ; Publication No. US20040137589A1
 ; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

```
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR FILING DATE: 2001-03-27 PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27 US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR FILING DATE: 2000-03-27 US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR FILING DATE: 2000-06-01 US 60/208,538
; PRIOR FILING DATE: 2000-10-30
; PRIOR FILING DATE: 2000-10-30 US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1463
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1463

Query Match      0.8%  Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 3 CAATTGGAATATGA 16

RESULT 315
US-10-261-185-1464/c
; Sequence 1464, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR FILING DATE: 2001-03-27 PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27 US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR FILING DATE: 2000-03-27 US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR FILING DATE: 2000-06-01 US 60/208,538
; PRIOR FILING DATE: 2000-10-30
; PRIOR FILING DATE: 2000-10-30 US 60/244,989
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-1464

Query Match      0.8%  Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 316
US-10-675-685-823
; Sequence 823, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR FILING DATE: 2000-05-26 US 60/207,456
; PRIOR FILING DATE: 2000-09-27 US 60/236,359
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-823
```

```
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR FILING DATE: 2000-05-26 US 60/207,456
; PRIOR FILING DATE: 2000-05-26 US 60/236,359
; PRIOR FILING DATE: 2000-09-27 US 60/236,359
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-823

Query Match      0.8%  Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 4 GGAGGTATGATGTG 17

RESULT 317
US-10-675-685-824
; Sequence 824, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR FILING DATE: 2000-05-26 US 60/207,456
; PRIOR FILING DATE: 2000-05-26 US 60/236,359
; PRIOR FILING DATE: 2000-09-27 US 60/236,359
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-675-685-824

Query Match      0.8%  Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 3 GGAGGTATGATGTG 16

RESULT 318
US-10-675-685-825
; Sequence 825, Application US/10675685
; Publication No. US20040063134A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: PB0114
; CURRENT APPLICATION NUMBER: US/10/675,685
; CURRENT FILING DATE: 2003-09-30
; PRIOR FILING DATE: 2000-05-26 US 60/207,456
; PRIOR FILING DATE: 2000-05-26 US 60/236,359
```



```

; CURRENT APPLICATION NUMBER: US/10/238,700
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1122
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1123

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719
Db 3 AAGUAAACAUGUUU 16

RESULT 311
US-10-238-700-1123
; Sequence 1123, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1123.
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1123

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 2.4e+02;
Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1706 AATGTAACATGTTT 1719
Db 1 AAGUAAACAUGUUU 14

RESULT 312
US-10-238-700-1123
; Sequence 1463, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1464

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 314
US-10-261-185-1463
; Sequence 1463, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US 60/192,179

```

```

; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1463
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1463

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 3 CAATTGGAATATGA 16

RESULT 313
US-10-209-787-1464/c
; Sequence 1464, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; CURRENT FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-1464

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 15 CAATTGGAATATGA 2

RESULT 314
US-10-261-185-1463
; Sequence 1463, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US 60/192,179

```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1354

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
    |||||
Db 16 GAAAGCAGAAATCA 3

RESULT 307
US-10-060-756A-1355/c
; Sequence 1355, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1355

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
    |||||
Db 15 GAAAGCAGAAATCA 2

RESULT 308
US-10-060-756A-1356/c
; Sequence 1356, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1356
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1356

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
    |||||
Db 14 GAAAGCAGAAATCA 1

RESULT 309
US-10-096-125-8
; Sequence 8, Application US/10096125
; Publication No. US20030077608A1
; GENERAL INFORMATION:
; APPLICANT: Coull, James M.
; APPLICANT: Elandaca, Mark J.
; APPLICANT: Kristjanson, Mark D.
; APPLICANT: Hyldig-Nielsen, Jens J.
; APPLICANT: Creasey, Theresa S.
; TITLE OF INVENTION: Methods, Kits And Compositions Pertaining To
; TITLE OF INVENTION: Combination Oligomers And Libraries For Their
; FILE REFERENCE: BP0102-US
; CURRENT APPLICATION NUMBER: US/10/096,125
; CURRENT FILING DATE: 2002-03-09
; PRIOR APPLICATION NUMBER: 60/274,547
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: Oligonucleotide Primer
US-10-096-125-8

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 394 CAAAGTCTGGAGTGA 407
    |||||
Db 2 CAAAGTCTGGAGTGA 15

RESULT 310
US-10-238-700-1122
; Sequence 1122, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels
; FILE REFERENCE: 400/057 (MBH01-1158-A)
```

; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1464

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATCA 1331
|:|||||
Db 15 CAATTGGAATATCA 2

RESULT 303
US-09-848-754A-2095
; Sequence 2095, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2095
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2095

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1516 GTCACACACACATA 1529
|:|||||
Db 4 GUCACACACACAU 17

RESULT 304
US-09-848-754A-2096
; Sequence 2096, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2096
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2096

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 2.4e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1516 GTCACACACACATA 1529
|:|||||
Db 2 GUCACACACACAU 15

RESULT 305
US-10-060-756A-1353/c
; Sequence 1353, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-1353

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 GAAAGCAGAAATCA 1007
|:|||||
Db 17 GAAAGCAGAAATCA 4

RESULT 306
US-10-060-756A-1354/c
; Sequence 1354, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1354
; LENGTH: 17

; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-824

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 3 GGAGGTATGATGTG 16
|||||

RESULT 299

US-09-827-998-825
; Sequence 825, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 825
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-825

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 2 GGAGGTATGATGTG 15
|||||

RESULT 300

US-09-827-998-826
; Sequence 826, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDHMOF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 826

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-826

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 1 GGAGGTATGATGTG 14
|||||

RESULT 301

US-09-818-875-1463
; Sequence 1463, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1463
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-1463

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1318 CAATTGGAATATGA 1331
Db 3 CAATTGGAATATGA 16
|||||

RESULT 302

US-09-818-875-1464/c
; Sequence 1464, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10429
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
Db 17 TTTTGATGCTGTCA 4

RESULT 296
US-09-866-108-10430/c
; Sequence 10430, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10430
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10430

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
Db 16 TTTTGATGCTGTCA 3

RESULT 297
US-09-827-998-823
; Sequence 823, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORE-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-823

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 4 GGAGGTATGATGTG 17

RESULT 298
US-09-827-998-824
; Sequence 824, Application US/09827998
; Patent No. US20020102252A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORE-8

;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/10/855,532
;/ FILING DATE: 28-May-2004
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: US/09/668,482
;/ FILING DATE: 25-Sep-2000
;/ APPLICATION NUMBER: 08/882,164
;/ FILING DATE: June 25, 1997
;/ APPLICATION NUMBER: 08/667,546
;/ FILING DATE: June 21, 1996
;/ APPLICATION NUMBER: 08/724,466
;/ FILING DATE: October 1, 1996
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Hunt, John C.
;/ REGISTRATION NUMBER: 36,424
;/ REFERENCE/DOCKET NUMBER: 50767/00010
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (416) 863-4344
;/ TELEFAX: (416) 863-2653
;/ INFORMATION FOR SEQ ID NO: 21
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 14 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 21
;/
;/ US-10-855-532-21

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 TGAATAAAAAAAAAA 1760
|||||
Db 14 TGAATAAAAAAAAAA 1

RESULT 293
US-10-764-388-11
;/ Sequence 11, Application US/10764388
;/ Publication No. US20050004350A1
;/ GENERAL INFORMATION:
;/ APPLICANT: STAVRIANOPOULOS, JANNIS G.
;/ APPLICANT: RABBANI, ELAZAR
;/ TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
;/ TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
;/ TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
;/ FILE REFERENCE: ENZ-61
;/ CURRENT APPLICATION NUMBER: US/10/764,388
;/ CURRENT FILING DATE: 2004-01-23
;/ PRIOR APPLICATION NUMBER: US/10/096,075
;/ PRIOR FILING DATE: 2002-03-12
;/ NUMBER OF SEQ ID NOS: 12
;/ SOFTWARE: PatentIn Ver. 2.1
;/ SEQ ID NO 11
;/ LENGTH: 14
;/ TYPE: RNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Description of Artificial Sequence: Primer
;/ US-10-764-388-11

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
|||||
Db 1 AAAAAAAAAAAAAA 14

RESULT 294
US-10-601-140A-21/c

;/ Sequence 21, Application US/10601140A
;/ Publication No. US20050053942A1
;/ GENERAL INFORMATION:
;/ APPLICANT: KAUPPINEN, SAKARI
;/ APPLICANT: JACOBSEN, NANA
;/ TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
;/ TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
;/ FILE REFERENCE: 57764(71994)
;/ CURRENT APPLICATION NUMBER: US/10/601,140A
;/ CURRENT FILING DATE: 2003-06-20
;/ PRIOR APPLICATION NUMBER: US 60/390,928
;/ PRIOR FILING DATE: 2002-06-24
;/ NUMBER OF SEQ ID NOS: 45
;/ SOFTWARE: PatentIn Ver. 3.2
;/ SEQ ID NO 21
;/ LENGTH: 15
;/ TYPE: DNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;/ OTHER INFORMATION: oligonucleotide
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: (1)
;/ OTHER INFORMATION: LNA monomer
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: (4)
;/ OTHER INFORMATION: LNA monomer
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: (7)
;/ OTHER INFORMATION: LNA monomer
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: (10)
;/ OTHER INFORMATION: LNA monomer
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: (13)
;/ OTHER INFORMATION: LNA monomer
;/ US-10-601-140A-21

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1763 AAAAAAAAAAAC 1776
|||||
Db 14 AAAAAAAAAAAC 1

RESULT 295
US-09-866-108-10429/c
;/ Sequence 10429, Application US/09866108
;/ Patent No. US20020048800A1
;/ GENERAL INFORMATION:
;/ APPLICANT: GU, Yizhong
;/ APPLICANT: .JI, Yonggang
;/ APPLICANT: PENN, Sharron G.
;/ APPLICANT: HANZEL, David K.
;/ APPLICANT: RANK, David R.
;/ APPLICANT: CHEN, Wensheng
;/ APPLICANT: SHANNON, Mark
;/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;/ FILE REFERENCE: AEOMICA-7
;/ CURRENT APPLICATION NUMBER: US/09/866,108
;/ CURRENT FILING DATE: 2001-05-25
;/ PRIOR APPLICATION NUMBER: US 60/207,456
;/ PRIOR FILING DATE: 2000-05-26
;/ PRIOR APPLICATION NUMBER: GB 24263.6
;/ PRIOR FILING DATE: 2000-10-04
;/ PRIOR APPLICATION NUMBER: US 60/236,359

```
US-10-764-389-11
; Sequence 11, Application US/10764389
; Publication No. US20040230036A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,389
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-389-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 TGAAGAAAAA 1762
DB 1 TGAAGAAAAA 14

RESULT 290
US-10-855-595-21/c
; Sequence 21, Application US/10855595
; Publication No. US2004023057A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,595
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/668,482
; FILING DATE: 25-Sep-2000
; APPLICATION NUMBER: 08/882,164
; FILING DATE: June 25, 1997
; APPLICATION NUMBER: 08/667,546
; FILING DATE: June 21, 1996
; APPLICATION NUMBER: 08/724,466
; FILING DATE: October 1, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunt, John C.
; REGISTRATION NUMBER: 36,424
; REFERENCE/DOCKET NUMBER: 50767/00010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 863-4344
; TELEFAX: (416) 863-2653
```

```
; INFORMATION FOR SEQ ID NO: 21
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 21
US-10-855-595-21

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 TGAAGAAAAA 1760
DB 1 TGAAGAAAAA 14

RESULT 291
US-10-763-076-11
; Sequence 11, Application US/10763076
; Publication No. US20040254355A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/763,076
; CURRENT FILING DATE: 2004-01-22
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-763-076-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA 1762
DB 1 AAAAAA 14

RESULT 292
US-10-855-532-21/c
; Sequence 21, Application US/1085532
; Publication No. US2004025907A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,595
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/882,164
; FILING DATE: June 25, 1997
; APPLICATION NUMBER: 08/667,546
; FILING DATE: June 21, 1996
; APPLICATION NUMBER: 08/724,466
; FILING DATE: October 1, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunt, John C.
; REGISTRATION NUMBER: 36,424
; REFERENCE/DOCKET NUMBER: 50767/00010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 863-4344
; TELEFAX: (416) 863-2653
```

US-10-655-362-108/c
; Sequence 108, Application US/10655362
; Publication No. US20050014163A1
; GENERAL INFORMATION:
; APPLICANT: Dong, Fang
; APPLICANT: Lyamichev, Victor
; APPLICANT: Prudent, James
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce
; APPLICANT: Brow, Mary Ann
; APPLICANT: Anderson, Todd
; APPLICANT: Dahlberg, James
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides
; FILE REFERENCE: FORS-04012
; CURRENT APPLICATION NUMBER: US/10/655,362
; CURRENT FILING DATE: 2003-09-04
; PRIOR APPLICATION NUMBER: US/09/402,618B
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/US98/03194
; PRIOR FILING DATE: 1998-05-05
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-655-362-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTCTGTGCAC 828
DB 16 AACAACTTCTGTGCAC 1

RESULT 286
US-10-473-193-180
; Sequence 180, Application US/10473193
; Publication No. US20050080247A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, BEN
; APPLICANT: TANG, YI-QIANG
; APPLICANT: CHEN, GONG-LI
; TITLE OF INVENTION: LEINAMYCIN BIOSYNTHESIS GENE CLUSTER AND ITS COMPONENTS AND THEIR
; TITLE OF INVENTION: USES
; FILE REFERENCE: 309T-0001100S
; CURRENT APPLICATION NUMBER: US/10/473,193
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; NUMBER OF SEQ ID NOS: 222
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 180
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide PCR primer.
US-10-473-193-180

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 600 TCAAGGCACAACTTC 615
DB 1 TCAAGGCACAACTTC 16

RESULT 287
US-10-830-484-3/c
; Sequence 3, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides
; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
; NAME/KEY: misc feature
; LOCATION: (1)-(14)
; OTHER INFORMATION: 3' NH2
US-10-830-484-3

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
DB 14 AAAAAAAAAAAAAA 1

RESULT 288
US-10-764-393-11
; Sequence 11, Application US/10764393
; Publication No. US20040229248A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABERANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,393
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-393-11

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
DB 1 AAAAAAAAAAAAAA 14

RESULT 289

Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1191 TGTGAGGACGAGCTC 1206
Db 1 TGTGAGGACGAGCTC 16

RESULT 281

US-09-882-945A-108/c
; Sequence 108, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-108

Query Match 0.8%; Score 14.4; DB 1; Length: 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCTGTGCAC 828
Db 16 AACAACTTTCTGTGCAC 1

RESULT 282

US-10-314-657-180
; Sequence 180, Application US/10314657
; Publication No. US20030175888A1
; GENERAL INFORMATION:
; APPLICANT: SHEN, Ben
; APPLICANT: CHENG, Yi-Qiang
; APPLICANT: TANG, Gong-Li
; TITLE OF INVENTION: Discrete Acyltransferases Associated with Type I Polyketide
; FILE REFERENCE: 054030-0021
; CURRENT APPLICATION NUMBER: US/10/314,657
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: PCT/US02/08937
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US 60/278,935
; PRIOR FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 214
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 180
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Streptomyces atroolivaceus
US-10-314-657-180

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 600 TCAAGGCACAACTC 615
Db 1 TCAAGGCACGAGCTC 16

RESULT 283

US-10-333-429-219
; Sequence 219, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-083US02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pn
; SEQ ID NO 219
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-32165 for SEQ 48,
US-10-333-429-219

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 CACACTTCCCGAAT 1253
Db 1 CACACTTCCCGAAT 16

RESULT 284

US-10-807-114-108/c
; Sequence 108, Application US/10807114
; Publication No. US2004023024A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/10/807,114
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/882,945
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-807-114-108

Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 813 ATCAACTTTCTGTGCAC 828
Db 16 AACAACTTTCTGTGCAC 1

RESULT 285

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 838 AGTTTGATGCTGTC 853
| | | | | | | | | | | | | | | | | | | | |
Db 17 ACTTTTGATGCTGTC 2

RESULT 278

US-10-723-361-10433/c
; Sequence 10433, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN

; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10433

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGATGCTGTC 852
| | | | | | | | | | | | | | | | | | | | |
Db 16 GACTTTTGATGCTGTC 1

RESULT 279

US-10-724-270-456/c

; Sequence 456, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-456

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCATTCATTCCT 1591
| | | | | | | | | | | | | | | | | | | | |
Db 16 TTTTTCATTCATTCGT 1

RESULT 280

US-09-969-373-1693
; Sequence 1693, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1693
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1693

Query Match 0.8%; Score 14.4; DB 1; Length 18;

; SEQ ID NO 3637
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3637

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 ATTACTCTATTCTT 946
|||||
Db 16 ATTAATTCATTCTT 1

RESULT 270

US-10-238-700-456/c
; Sequence 456, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:

; APPLICANT: McSwiggen, James
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 456
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-456

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCACCTTCATCT 1591
|||||
Db 16 TTTTTCATCTCATGT 1

RESULT 271

US-10-307-005-1679
; Sequence 1679, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:

; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1679

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1679

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
|||||
Db 1 TGGCAATAATGTCACA 16

RESULT 272

US-10-307-005-1680/c
; Sequence 1680, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:

; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 1680
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Solanum tuberosum
US-10-307-005-1680

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1478 TGGCAATAATGTAACA 1493
|||||
Db 17 TGGCAATAATGTCACA 2

RESULT 273

US-10-138-674-2690
; Sequence 2690, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stichcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17

RESULT 267
US-10-156-306-268/c
; Sequence 268, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 268
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-268

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 931 ATTACTTCTATTCTT 946
|||||
Db 17 ATTAATCTATTCTT 2

RESULT 268
US-10-156-306-1283
; Sequence 1283, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1283
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1283

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGTC 852
|||||
Db 16 GACTTTGTGCTGTC 1

RESULT 266
US-09-780-164-447
; Sequence 447, Application US/09780164
; Publication No. US2003002646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 447
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-447

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 165 AAAACTCCAGGAATG 180
|||||
Db 1 AAAACUCCAGGAAGUG 16

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 146 ATAGAACTTCCTAAA 161
|||||
Db 1 AUAGAAACAUCUAAA 16

RESULT 269
US-10-156-306-3637/c
; Sequence 3637, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0

```

; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, MYOSIN
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-10431

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps

Qy 838 AGTTTGATGCTGTCA 853
Db 17 ACTTTTGATGCTGTCA 2

RESULT 265
US-09-866-108-10433/c
; Sequence 10433, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

```

Db 3 AGAAAAAUCUCCAGGA 17

RESULT 258

US-10-349-143-5494/c

; Sequence 5494, Application US/10349143

; Publication No. US20040005584A1

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET.020C91

; CURRENT APPLICATION NUMBER: US/10/349,143

; CURRENT FILING DATE: 2003-01-21

; PRIOR APPLICATION NUMBER: US/09/422,978

; PRIOR FILING DATE: 1999-10-20

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850

; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732

; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23

; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614

; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 5494

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: primer_bind

; LOCATION: 1..18

; OTHER INFORMATION: upstream amplification primer 99-4676 for SEQ 1560,

US-10-349-143-5494

Query Match 0.8%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 2.2e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 CCCACCTACAGATACCTT 708

Db 18 CCCACCTTGAGATACCTT 1

RESULT 259

US-10-164-915-3

; Sequence 3, Application US/10164915

; Publication No. US20030148391A1

; GENERAL INFORMATION:

; APPLICANT: Salafsky, Joshua S.

; TITLE OF INVENTION: Method Using a Surface-Selective No. US20030148391A1linear Optica

; TITLE OF INVENTION: for Detection of Interactions Involving a Conformational Change

; FILE REFERENCE: 11100-035-999

; CURRENT APPLICATION NUMBER: US/10/164,915

; CURRENT FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: 60/253,862

; PRIOR FILING DATE: 2000-11-29

; PRIOR APPLICATION NUMBER: 60/260,249

; PRIOR FILING DATE: 2001-01-08

; PRIOR APPLICATION NUMBER: 60/265,775

; PRIOR FILING DATE: 2001-02-01

; PRIOR APPLICATION NUMBER: 60/278,941

; PRIOR FILING DATE: 2001-01-27

; NUMBER OF SEQ ID NOS: 6

; SEQ ID NO 3

; LENGTH: 16

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Oligonucleotide structure fo

US-10-164-915-3

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 GAAAAAATACAAAAA 1763

Db 1 GAAAAAATACAAAAA 16

RESULT 260

US-10-138-674-6065/c

; Sequence 6065, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MEHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6065

; LENGTH: 16

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-6065

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATAGTTACAC 1536

Db 16 ACACACATAGTTACAC 1

RESULT 261

US-10-138-674-6066/c

; Sequence 6066, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MEHB00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 6066

; LENGTH: 16

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-6066

Query Match 0.8%; Score 14.4; DB 1; Length 16;

Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 ACACACATAGTTAC 1534

Db 16 ACACACATAGTTAC 1

RESULT 262

```
; Sequence 16, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; US-10-601-140A-16

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAA 1763
Db      15 AAAAAAAAAAAAAA 1

RESULT 255
US-10-601-140A-19/c
; Sequence 19, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; US-10-601-140A-19/c

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAA 1763
Db      15 AAAAAAAAAAAAAA 1

RESULT 256
US-10-938-661A-22/c
; Sequence 22, Application US/10938661A
; Publication No. US20050070000A1
; GENERAL INFORMATION:
; APPLICANT: PECKER, IRIS
; APPLICANT: MICHAL, ISRAEL
; APPLICANT: ITZHAKI, HANAN
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY DISTANTLY
; FILE REFERENCE: 28567
; CURRENT APPLICATION NUMBER: US/10/938,661A
; CURRENT FILING DATE: 2004-09-13
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; US-10-938-661A-22

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAA 1763
Db      15 AAAAAAAAAAAAAA 1

RESULT 257
US-09-780-164-870
; Sequence 870, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: RIBOZYME PHARMACEUTICALS, INC.
; APPLICANT: BLATT, LARRY
; APPLICANT: MCSWIGGEN, JIM
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 870
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-780-164-870

Query Match      0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.9e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      162 AGAAAACTCCAGGA 176
Db      15 AAAAAAAAAAAAAA 1
```



```
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 54
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-54

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 251
US-10-939-214-55/c
; Sequence 55, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 55
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-55

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 252
US-10-239-919A-4/c
; Sequence 4, Application US/10239919A
; Publication No. US20050054831A1
```

```
; GENERAL INFORMATION:
; APPLICANT: HWANG, IN-HWAN
; APPLICANT: LIM, JEONG-HWA
; APPLICANT: PIH, KYOUNG-TAE
; TITLE OF INVENTION: AN OSMOTIC STRESS-INDUCIBLE PROTEIN FUNCTIONING AS A
; TITLE OF INVENTION: NEGATIVE REGULATOR IN OSMOTIC STRESS SIGNALING PATHWAY
; FILE REFERENCE: 7022-0004
; CURRENT APPLICATION NUMBER: US/10/239,919A
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/KR02/00152
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: KR 2001/5097
; PRIOR FILING DATE: 2001-02-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-239-919A-4

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 253
US-10-601-140A-5/c
; Sequence 5, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)-(15)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-5

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 254
US-10-601-140A-16/c
```

Matches	15;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

Qy 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

Db 15 AAAAAAAAAAAAAAAAAA 1

RESULT 247

US-10-755-118-49/c
; Sequence 49, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49

QY · 1749 AAAAAAAAAAAAAA 1763
 |||||
Db · 15 AAAAAAAAAAAAAA 1

Db . 15 AAAAAAAAAAAAAA 1

RESIT.T 248

US-10-770-989-9/c
; Sequence 9, Application US/10770989
; Publication NO. US20050019789A1
; GENERAL INFORMATION:
; APPLICANT: Ankenbauer, Waltraud
; APPLICANT: Schmitz-Aghaghian, Gudrun
; APPLICANT: Bonch-Osmolovskaya, Elizaveta
; APPLICANT: Svetlichny, Vitaly
; APPLICANT: Markau, Ursula
; APPLICANT:

```

; APPLICANT: Angerer, Bernard
; APPLICANT: Reiser, Astrid
; APPLICANT: Roche Molecular Systems, Inc.
; TITLE OF INVENTION: Thermostable DNA Polymerase from Anaerocellum
; TITLE OF INVENTION: Thermophilum
; FILE REFERENCE: 022101-000610US
; CURRENT APPLICATION NUMBER: US/10/770,989
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: EP 96115877.1
; PRIOR FILING DATE: 1996-10-03
; PRIOR APPLICATION NUMBER: WO PCT/EP97/05390
; PRIOR FILING DATE: 1997-10-01
; PRIOR APPLICATION NUMBER: US 09/269,858
; PRIOR FILING DATE: 1999-06-10
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: (dt) -15,
; OTHER INFORMATION: oligo dt primer
; US-10-770-989-9

```

Qy 1749 AAAAAAAAAAAAAA 1763
|||
Db 15 AAAAAAAAAAAAAA 1

Db 15 AAAAAAAAAAAAAA 1

RESULT 249

```

US-10-833-502-9/c
; Sequence 9, Application US/10833502
; Publication No. US20050026279A1
; GENERAL INFORMATION:
; APPLICANT: TSENG, SCHEFFER C.G.
; APPLICANT: ESPANA, EDGAR M.
; TITLE OF INVENTION: SURGICAL GRAFTS AND METHODS OF PREPARATION
; FILE REFERENCE: TIS-107
; CURRENT APPLICATION NUMBER: US/10/833,502
; CURRENT FILING DATE: 2002-04-28
; PRIOR APPLICATION NUMBER: 60/465,989
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/473,007
; PRIOR FILING DATE: 2003-05-22
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-833-502-9

```

Qy 1749 AAAAAAAAAAAAAA 1763
 Dp 15 AAAAAAAAAAAAAA 1

Db 15 AAAAAAAAAAAAAAAAAA 1

RESULT 250

US-10-939-214-54/c
; Sequence 54, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:

```

; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 44
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys-NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; US-10-755-118-44

```

Query Match 0.8%; Score 15; DB 1; Length 15; ~
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

```

```

RESULT 245
US-10-755-118-45/c
; Sequence 45, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 45
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

```

; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Clz)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
; US-10-755-118-45

```

Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

```

```

RESULT 246
US-10-755-118-48/c
; Sequence 48, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Clz)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; US-10-755-118-48

```

Query Match 0.8%; Score 15; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;

```

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
US-10-755-118-39

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 242
US-10-755-118-40/c
; Sequence 40, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-43

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 244
US-10-755-118-44/c
; Sequence 44, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-40

Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1
```

```

; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; FEATURE:
; OTHER INFORMATION: BHA resin
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; FEATURE:
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; FEATURE:
; OTHER INFORMATION: BHA resin
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
; US-10-755-118-36

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 240
US-10-755-118-38/c
; Sequence 38, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin

```

```

; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; FEATURE:
; OTHER INFORMATION: BHA resins
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; FEATURE:
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; US-10-755-118-38

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
Db 15 AAAAAAAAAAAAAA 1

RESULT 241
US-10-755-118-39/c
; Sequence 39, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin

```

Db 15 AAAAAAAAAAAAAA 1

RESULT 236

US-10-755-118-4/c
; Sequence 4, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
US-10-755-118-4

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763

Db 15 AAAAAAAAAAAAAA 1

RESULT 237

US-10-755-118-31/c
; Sequence 31, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219

; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligodeoxyribonucleotide
US-10-755-118-31

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763

Db 15 AAAAAAAAAAAAAA 1

RESULT 238

US-10-755-118-32
; Sequence 32, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligodeoxyribonucleotide
US-10-755-118-32

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763

Db 1 AAAAAAAAAAAAAA 15

RESULT 239

US-10-755-118-36/c
; Sequence 36, Application US/10755118

; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; CURRENT APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1533
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1533

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATGTTAC 1534
|||||
DB 17 CACACACACACATGTTAC 1

RESULT 233

US-10-848-922-98/c
; Sequence 98, Application US/10848922
; Publication No. US20040235138A1
; GENERAL INFORMATION:
; APPLICANT: Weisburg, William G.
; APPLICANT: Bungo, Jennifer J.
; TITLE OF INVENTION: Compositions, Methods and Kits for Determining the Presence of
; TITLE OF INVENTION: Trichomonas Vaginalis in a Test Sample
; FILE REFERENCE: GP142-02.UT
; CURRENT APPLICATION NUMBER: US/10/848,922
; CURRENT FILING DATE: 2004-05-18
; PRIOR APPLICATION NUMBER: 60/472,028
; PRIOR FILING DATE: 2003-05-19
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 98
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Polynucleotide having a 3' poly (dA)30 tail and a 5' poly (dT)3
; OTHER INFORMATION: flexible linker for use in a capture probe
US-10-848-922-98

Query Match 0.9%; Score 15.4; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1575 TTTTTCACATTCATCTTAAATTTGAAA 1607
|||||
DB 33 TTTTTCACATTCATCTTAAATTTTAAAA 1

RESULT 234

US-10-830-484-4/c
; Sequence 4, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides

; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-830-484-4

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
|||||
DB 15 AAAAAAAAAAAAAA 1

RESULT 235

US-10-755-118-3/c
; Sequence 3, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)-(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)-(15)
; OTHER INFORMATION: Hydrogen
US-10-755-118-3

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
|||||

GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Reomica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 837 GAGTTTGTGCTGCTCA 853
DB 17 GACTTTGTGCTGCTCA 1

RESULT 230
US-10-753-962-23
; Sequence 23, Application US/10753962
; Publication No. US20040203133A1
; GENERAL INFORMATION:
; APPLICANT: Ehrhardt, Anja
; APPLICANT: Kay, Mark
; TITLE OF INVENTION: Helper Dependent Adenoviral Vector
; FILE REFERENCE: STAN-215US2
; CURRENT APPLICATION NUMBER: US/10/753,962
; CURRENT FILING DATE: 2004-01-07
; PRIOR APPLICATION NUMBER: 60/438,715
; PRIOR FILING DATE: 2003-01-07
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-753-962-23

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCATTCTCTA 1592
DB 1 TTTTTCATTCTCTA 17

RESULT 231
US-10-712-633-1532/c
; Sequence 1532, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; FILE REFERENCE: MEHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1532
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1532

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CACACATAGTTACAC 1536
DB 17 CACACATAGTTACAC 1

RESULT 232
US-10-712-633-1533/c
; Sequence 1533, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTO
; FILE REFERENCE: MEHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-106-831-23

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTTCACCTTCATTCTA 1592
Db 1 TTTTTCACGCACTCTA 17

RESULT 225
US-10-138-674-8254/c
; Sequence 8254, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8254
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8254

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CACACACATAGTTACAC 1536
Db 17 CACACACACAGTTACAC 1

RESULT 226
US-10-138-674-8255/c
; Sequence 8255, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8255
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8255

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACATAGTTAC 1534
Db 17 CACACACACAGTTAC 1

RESULT 227
US-10-287-949A-8254/c
; Sequence 8254, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8254
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8254

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CACACACATAGTTACAC 1536
Db 17 CACACACACAGTTACAC 1

RESULT 228
US-10-287-949A-8255/c
; Sequence 8255, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8255
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8255

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACATAGTTAC 1534
Db 17 CACACACACAGTTAC 1

RESULT 229
US-10-723-361-10432/c
; Sequence 10432, Application US/10723361
; Publication No. US20040137589A1

```
RESULT 221
US-09-866-108-10432/c
; Sequence 10432, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10432

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      837 GACCTTTGATGCTGTCA 853
DB      17 GACCTTTGATGCTGTCA 1

RESULT 222
US-09-780-164-66
; Sequence 66, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-446

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      163 GAAAACTCCAGGAAT 179
DB      1 GAAAACTCCAGGAAGU 17

RESULT 223
US-09-780-164-446
; Sequence 446, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 446
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-446

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.7e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      164 AAAAATCTCCAGGAATG 180
DB      1 AAAAATCTCCAGGAAGU 17

RESULT 224
US-10-106-831-23
; Sequence 23, Application US/10106831
; Publication No. US20030022378A1
; GENERAL INFORMATION:
; APPLICANT: Ehrhardt, Anja
; APPLICANT: Kay, Mark
; TITLE OF INVENTION: Helper Dependent Adenoviral Vector
; TITLE OF INVENTION: System and Methods for Using the Same
; FILE REFERENCE: STAN-215
; CURRENT APPLICATION NUMBER: US/10/106,831
; CURRENT FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/278,972
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: 60/284,335
; PRIOR FILING DATE: 2001-04-16
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 17
; TYPE: DNA
```

; CURRENT APPLICATION NUMBER: US/09/853,688
 ; CURRENT FILING DATE: 2001-05-14
 ; NUMBER OF SEQ ID NOS: 66
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 39
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-853-688-39

Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAACAGTGGGAGAGAA 869
 Db 4 CAACAGTGGGAGAGAA 19

RESULT 217
 US-10-788-318-39
 ; Sequence 39, Application US/10788318
 ; Publication No. US20040137510A1
 ; GENERAL INFORMATION:
 ; APPLICANT: COOPER, DAVID N.
 ; APPLICANT: PROCTER, ANNIE M.
 ; APPLICANT: GREGORY, JOHN
 ; APPLICANT: MILLAR, DAVID S.
 ; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN
 ; TITLE OF INVENTION: HUMANS, THE VARIATIONS AND THEIR USES
 ; FILE REFERENCE: WCM78
 ; CURRENT APPLICATION NUMBER: US/10/788,318
 ; CURRENT FILING DATE: 2004-03-01
 ; NUMBER OF SEQ ID NOS: 66
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 39
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-10-788-318-39

Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CAACAGTGGGAGAGAA 869
 Db 4 CAACAGTGGGAGAGAA 19

RESULT 218
 US-10-831-778-431/C
 ; Sequence 431, Application US/10831778
 ; Publication No. US20040235774A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bratzler, Robert L.
 ; APPLICANT: Petersen, Deanna M.
 ; APPLICANT: Fouron, Yves
 ; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
 ; TITLE OF INVENTION: Treatment of Asthma and Allergy
 ; FILE REFERENCE: C1037/7013 (HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/10/831,778
 ; CURRENT FILING DATE: 2004-04-23
 ; PRIOR APPLICATION NUMBER: US 60/179,991
 ; PRIOR FILING DATE: 2000-02-03
 ; NUMBER OF SEQ ID NOS: 1093
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 431
 ; LENGTH: 20
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence

US-10-831-778-431

Query Match 0.9%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1762 AAAAAAAAAAAAAACG 1777
 Db 20 AAAAAAAAAAAAAACG 5

RESULT 219
 US-10-619-906-11/c
 ; Sequence 11, Application US/10619906
 ; Publication No. US20040087533A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Index Pharmaceuticals
 ; TITLE OF INVENTION: New Compound
 ; FILE REFERENCE: 50299
 ; CURRENT APPLICATION NUMBER: US/10/619,906
 ; CURRENT FILING DATE: 2003-07-16
 ; NUMBER OF SEQ ID NOS: 23
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 11
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Artificial
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (1)..(19)
 ; OTHER INFORMATION: SEQ ID NO. 11, antisense oligonucleotide
 US-10-619-906-11

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 175 GAAATGCAGCAGTCTTTG 193
 Db 19 GAAATGCAGCAGTCTTTG 1

RESULT 220
 US-10-619-906-13/c
 ; Sequence 13, Application US/10619906
 ; Publication No. US20040087533A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Index Pharmaceuticals
 ; TITLE OF INVENTION: New Compound
 ; FILE REFERENCE: 50299
 ; CURRENT APPLICATION NUMBER: US/10/619,906
 ; CURRENT FILING DATE: 2003-07-16
 ; NUMBER OF SEQ ID NOS: 23
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 13
 ; LENGTH: 19
 ; TYPE: DNA
 ; ORGANISM: Artificial
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (1)..(19)
 ; OTHER INFORMATION: SEQ ID NO. 13, antisense oligonucleotide
 US-10-619-906-13

Query Match 0.9%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.9e+02;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 880 TTAAAGACTGGTCTTCT 898
 Db 19 TTCAAGACAGGTTCTTCT 1

;
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 445
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-445

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 162 AGAAAACTCCAGGAA 177
|||||||:|||||||
Db 1 AGAAAAACUCCAGGAA 16

RESULT 213
US-10-608-863-3/c
; Sequence 3, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-3

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
|||||||:|||||||
Db 16 AAAAAAAAAAAAAAC 1

RESULT 214
US-10-608-863-4/c
; Sequence 4, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000

;
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-4

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAA 1763
|||||||:|||||||
Db 17 GAAAAAAAAAAAAA 2

RESULT 215
US-10-608-863-5/c
; Sequence 5, Application US/10608863
; Publication No. US20040214192A1
; GENERAL INFORMATION:
; APPLICANT: Hashida, Ryoichi
; APPLICANT: Kagaya, Shinji
; APPLICANT: Yayoi, Yoshihiro
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREATING ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608,863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-5

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
|||||||:|||||||
Db 16 AAAAAAAAAAAAAAC 1

RESULT 216
US-09-853-688-39
; Sequence 39, Application US/09853688
; Patent No. US20020081605A1
; GENERAL INFORMATION:
; APPLICANT: COOPER, DAVID N.
; APPLICANT: PROCTER, ANNIE M.
; APPLICANT: GREGORY, JOHN
; APPLICANT: MILLAR, DAVID S.
; TITLE OF INVENTION: METHOD FOR DETECTING GROWTH HORMONE VARIATIONS IN HUMANS, THE VARIATIONS AND THEIR USES
; FILE REFERENCE: WCM78

```

; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-758-155-815

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTTACA 1535
DB 2 CACACACACACAGUUACA 19

RESULT 209
US-10-238-011-36
; Sequence 36, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
; APPLICANT: Frey Jorgen
; APPLICANT: Frey, Jorgen
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
; FILE REFERENCE: 516326-2002
; CURRENT APPLICATION NUMBER: US/10/238,011
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: EP 00 107 515.9
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/827,406
; PRIOR FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-238-011-36

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATG 268
DB 3 GATGTGGAGTGCCAGATG 20

RESULT 210
US-10-274-095-36/c
; Sequence 36, Application US/10274095
; Publication No. US20030120433A1
; GENERAL INFORMATION:
; APPLICANT: Yokota, Hiroki
; APPLICANT: Sun, Hui Bin
; TITLE OF INVENTION: Methods for Predicting Transcription
; FILE REFERENCE: ARTI.0137US
; CURRENT APPLICATION NUMBER: US/10/274,095
; CURRENT FILING DATE: 2002-10-17

```

```

; PRIOR APPLICATION NUMBER: 60/329,961
; PRIOR FILING DATE: 2001-10-17
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-274-095-36

Query Match      0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 358 CGTGAGGATGTAGACTAC 375
DB 20 CGTGAGGATGTAGACTAC 3

RESULT 211
US-10-755-118-94/c
; Sequence 94, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Bigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-755-118-94

Query Match      0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1764
DB 16 AAAAAAAAAAAAAAAAAA 1

RESULT 212
US-09-780-164-445
; Sequence 445, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim

```

```

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1518 CACACACATAGTTACA 1535
    |||||
Db 18 CACACACACAGTTACA 1

RESULT 206
US-10-665-951-815
; Sequence 815, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MEHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-815

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1518 CACACACATAGTTACA 1535
    |||||
Db 2 CACACACACAGUACA 19

RESULT 207
US-10-758-155-388/c
; Sequence 388, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid

```

```

; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MEHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 388
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-758-155-388

Query Match      0.9%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1518 CACACACATAGTTACA 1535
    |||||
Db 18 CACACACACAGTTACA 1

RESULT 208
US-10-758-155-815
; Sequence 815, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MEHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 815
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-665-951-815

```

APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
PRIOR FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 12929
LENGTH: 21
TYPE: RNA
ORGANISM: RNAi
US-10-751-736-12929

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. NO. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1687 ACTCTGTGCTTTACTGAA 1706
DB 20 ACTCTGTGCTTTGCTGAA 1

RESULT 203

US-10-872-984-5/C
Sequence 5, Application US/10872984
Publication No. US20040265888A1
GENERAL INFORMATION:
APPLICANT: Kaufman, Joseph C.
APPLICANT: Roth, Matthew E.
APPLICANT: Lizardi, Paul M.
APPLICANT: Feng, Li
APPLICANT: Latimer, Darin R.
TITLE OF INVENTION: Binary Encoded Sequence Tags
FILE REFERENCE: AGL 100
CURRENT APPLICATION NUMBER: US/10/872,984
CURRENT FILING DATE: 2004-06-21
PRIOR APPLICATION NUMBER: US/09/994,311
PRIOR FILING DATE: 2001-11-26
PRIOR APPLICATION NUMBER: US/09/637,751
PRIOR FILING DATE: 2000-08-11
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5

Query Match 0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. NO. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 GAAAAA 1765
DB 18 GCAAAAAA 1

RESULT 204

US-10-872-984-6/C
Sequence 6, Application US/10872984
Publication No. US20040265888A1
GENERAL INFORMATION:
APPLICANT: Kaufman, Joseph C.
APPLICANT: Roth, Matthew E.
APPLICANT: Lizardi, Paul M.
APPLICANT: Feng, Li

APPLICANT: Latimer, Darin R.
TITLE OF INVENTION: Binary Encoded Sequence Tags
FILE REFERENCE: AGL 100
CURRENT APPLICATION NUMBER: US/10/872,984
CURRENT FILING DATE: 2004-06-21
PRIOR APPLICATION NUMBER: US/09/994,311
PRIOR FILING DATE: 2001-11-26
PRIOR APPLICATION NUMBER: US/09/637,751
PRIOR FILING DATE: 2000-08-11
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6

Query Match 0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. NO. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1749 AAAAAA 1766
DB 18 AAAAAA 1

RESULT 205

US-10-665-951-388/c
Sequence 388, Application US/10665951
Publication No. US20040138163A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Beigelman, Leonid
APPLICANT: Favco, Pamela
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
Growth Factor and Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/131 (MEHB02-742-F)
CURRENT APPLICATION NUMBER: US/10/665,951
CURRENT FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/664,668
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: PCT/US 03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29
PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/287,949
PRIOR FILING DATE: 2002-11-04
PRIOR APPLICATION NUMBER: US 10/306,747
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: PCT/US 02/17674
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 2455
SOFTWARE: PatentIn version 3.2
SEQ ID NO 388
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-665-951-388

```
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 973 ATTCAAGCTGCTTACGAAAT 992
   ||| ||||| ||||| |||||
Db 2 ATTGAAGCTGCTTATGAAAT 21

RESULT 198
US-10-751-736-11042
; Sequence 11042, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11042
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11042

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 55.0%; Pred. No. 1.7e+02;
Matches 11; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 974 TTCAAGCTGCTTACGAAAT 993
   :: ||||| :: |||||
Db 1 UUGAGCUGCUUGAUAUU 20

RESULT 199
US-10-751-736-11177
; Sequence 11177, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11177
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11177

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 738 TGACATACGCTTAACATTCAGT 757
   : ||||| : |||||
Db 1 UGACAUACGUGGCAUUCAGU 20
```

```
RESULT 200
US-10-751-736-11332
; Sequence 11332, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11332
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11332

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 ACTACTACATCTTCCAAGGA 1311
   ||||| ||||| |||||
Db 2 ACTACTATTCTTCCAAGGA 21

RESULT 201
US-10-751-736-11381
; Sequence 11381, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11381
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11381

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 358 CGTGAGGATGTAGACTACAT 377
   ||: ||||| :: |||||
Db 2 CGUGAGGAGUGUGACUACUU 21

RESULT 202
US-10-751-736-12929/c
; Sequence 12929, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```


Query Match 0.9%; Score 16.8; DB 1; Length 21;

Db 21 AATGACAAGGAATTGCTGA 2

RESULT 189

US-10-751-736-8632
; Sequence 8632, Application US/10751736
; Publication No. US20040265230A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8632
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8632

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 386 AAGCTTTCCAAGTCTGGAGT 405

Db 1 AAGCTTTCCAAGTCTGGAGT 20

RESULT 190

US-10-751-736-9055
; Sequence 9055, Application US/10751736
; Publication No. US20040265230A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9055
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9055

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 383 AGAAGCTTTCCAAGTCTGG 402

Db 2 AGAAGCTTTCCAAGTCTGG 21

RESULT 191

US-10-751-736-9059
; Sequence 9059, Application US/10751736
; Publication No. US20040265230A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9059
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-9059

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 65.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 386 AAGCTTTCCAAGTCTGGAGT 405

Db 1 AAGCTTTCCAAGTCTGGAGT 20

RESULT 192

US-10-751-736-10780
; Sequence 10780, Application US/10751736
; Publication No. US20040265230A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10780
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10780

Query Match 0.9%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 335 ATAATTACACTCCGACATG 354

Db 2 ATAATTACACTCCGACATG 21

RESULT 193

US-10-751-736-10783
; Sequence 10783, Application US/10751736
; Publication No. US20040265230A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10783
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10783

```
; ORGANISM: Homo sapiens
US-10-168-989-42

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAAGCGTGAGGATGTAGACT 373
Db 2 GAAGCATGAGGATGGAGACT 21

RESULT 185
US-10-842-142-10
; Sequence 10, Application US/10842142
; Publication No. US20040259136A1
; GENERAL INFORMATION:
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER
; TITLE OF INVENTION: INFLAMMATORY DISEASES
; FILE REFERENCE: 01997.026800
; CURRENT APPLICATION NUMBER: US/10/842,142
; CURRENT FILING DATE: 2004-05-10
; PRIOR APPLICATION NUMBER: US 60/468,987
; PRIOR FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/491,274
; PRIOR FILING DATE: 2003-07-31
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-842-142-10

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 300 AAGATGATGAAGCGGTACC 319
Db 1 AAGATGAGGAGCGTGTACC 20

RESULT 186
US-10-842-142-94
; Sequence 94, Application US/10842142
; Publication No. US20040259136A1
; GENERAL INFORMATION:
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER
; TITLE OF INVENTION: INFLAMMATORY DISEASES
; FILE REFERENCE: 01997.026800
; CURRENT APPLICATION NUMBER: US/10/842,142
; CURRENT FILING DATE: 2004-05-10
; PRIOR APPLICATION NUMBER: US 60/468,987
; PRIOR FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/491,274
; PRIOR FILING DATE: 2003-07-31
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 94
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-842-142-94

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 300 AAGATGATGAAGCGGTACC 319
Db 1 AAGATGAGGAGCGTGTACC 20

RESULT 187
US-10-842-142-114
; Sequence 114, Application US/10842142
; Publication No. US20040259136A1
; GENERAL INFORMATION:
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER
; TITLE OF INVENTION: INFLAMMATORY DISEASES
; FILE REFERENCE: 01997.026800
; CURRENT APPLICATION NUMBER: US/10/842,142
; CURRENT FILING DATE: 2004-05-10
; PRIOR APPLICATION NUMBER: US 60/468,987
; PRIOR FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/491,274
; PRIOR FILING DATE: 2003-07-31
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: siRNA polynucleotide, synthesized
US-10-842-142-114

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.7e+02;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 301 AGATGATGAAGCGGTACC 320
Db 1 AGAUGGAGGAGCGUGUACCU 20

RESULT 188
US-10-751-736-2282/c
; Sequence 2282, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AMI00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-2282

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 61 AATGACAGTGAATTCGTGA 80
```

```
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 300 AAGATGATGAAGCGGTACC 319
Db 2 AAGATGAGGAGCGTGTACC 21

RESULT 187
US-10-842-142-114
; Sequence 114, Application US/10842142
; Publication No. US20040259136A1
; GENERAL INFORMATION:
; APPLICANT: LaVallie, Edward R.
; APPLICANT: Collins-Racie, Lisa A.
; TITLE OF INVENTION: PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER
; TITLE OF INVENTION: INFLAMMATORY DISEASES
; FILE REFERENCE: 01997.026800
; CURRENT APPLICATION NUMBER: US/10/842,142
; CURRENT FILING DATE: 2004-05-10
; PRIOR APPLICATION NUMBER: US 60/468,987
; PRIOR FILING DATE: 2003-05-08
; PRIOR APPLICATION NUMBER: US 60/491,274
; PRIOR FILING DATE: 2003-07-31
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 114
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: siRNA polynucleotide, synthesized
US-10-842-142-114

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 1.7e+02;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 301 AGATGATGAAGCGGTACC 320
Db 1 AGAUGGAGGAGCGUGUACCU 20

RESULT 188
US-10-751-736-2282/c
; Sequence 2282, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AMI00927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2282
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-2282

Query Match          0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 61 AATGACAGTGAATTCGTGA 80
```

```
RESULT 180
US-10-751-736-11059
; Sequence 11059, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11059
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11059
Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1372 AGCTGGTTTGGTTGTTA 1388
Db 5 AGCTGGTTTGGTTGTTA 21

RESULT 181
US-10-751-736-11060
; Sequence 11060, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11060
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNA1
US-10-751-736-11060
Query Match 0.9%; Score 17; DB 1; Length 21;
Best Local Similarity 52.9%; Pred. No. 1.7e+02;
Matches 9; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1372 AGCTGGTTTGGTTGTTA 1388
Db 3 AGCUGGUUGUUGUUA 19

RESULT 182
US-10-149-352-11/c
; Sequence 11, Application US/10149352
; Publication No. US20030105050A1
; GENERAL INFORMATION:
; APPLICANT: Beri, Rajinder
```

```
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES
; FILE REFERENCE: 06275-254US1
; CURRENT APPLICATION NUMBER: US/10/149,352
; CURRENT FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: PCT/GB00/04741
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: GB 9929487.8
; PRIOR FILING DATE: 1999-12-15
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 4.0
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-149-352-11
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1194 GAGCGAGGAGCTCATGACC 1213
Db 20 GAGGCTGGAGCTCAGGACC 1

RESULT 183
US-10-174-559-25
; Sequence 25, Application US/10174559
; Publication No. US20030232773A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF DRAK1 EXPRESSION
; FILE REFERENCE: PFS-0006
; CURRENT APPLICATION NUMBER: US/10/174,559
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 112
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-559-25
Query Match 0.9%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.6e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 867 GAAATCCTTTCTTTTAAAG 886
Db 1 GAACATCTTTTCTTTAAAG 20

RESULT 184
US-10-168-989-42
; Sequence 42, Application US/10168989
; Publication No. US20030190631A1
; GENERAL INFORMATION:
; APPLICANT: Chartier-Harlin et al.
; TITLE OF INVENTION: Implication of a known gene named CP2/LSP-LBP-1 in
; FILE REFERENCE: P07666US00/BAS
; CURRENT APPLICATION NUMBER: US/10/168,989
; CURRENT FILING DATE: 2002-06-26
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
```

```
Best Local Similarity 100.0%; Pred. No. 1.4e+02; DB 1; Length 19;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1764
DB 19 GAAAAAAAAAAAAAAAAA 3

RESULT 177
US-10-800-487-328
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-328

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAA 1764
DB 1 GAAAAAAAAAAAAAAAAA 17

RESULT 178
US-10-644-052A-376/c
; Sequence 376, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marion
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 377
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAACG 1777
DB 20 AAAAAAAAAAAAAACG 4
```

```
US-10-644-052A-376/c
; Sequence 377, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marion
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-376

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAACG 1777
DB 20 AAAAAAAAAAAAAACG 4
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11449
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29/c
Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 559 GATGCACATTTTGATGAGG 577
| | | | | | | | | | | | | | | | | | | | |
Db 1 GATGCACATTTTGATGAGG 19

RESULT 174
US-10-669-962-27/c
; Sequence 27, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Bruggiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1765
| | | | | | | | | | | | | | | | | | | | |
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 175
US-10-669-962-29/c
; Sequence 29, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Bruggiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-27
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1765
| | | | | | | | | | | | | | | | | | | | |
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 176
US-10-800-487-162/c
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-800-487-162
Query Match 0.9%; Score 17; DB 1; Length 19;
```

```
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1765
| | | | | | | | | | | | | | | | | | | | |
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 176
US-10-800-487-162/c
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-800-487-162
Query Match 0.9%; Score 17; DB 1; Length 19;
```

```
Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.5e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 978 AGCTGTTAGCAATGCA 996
|||:|:|:|:|:|:|:|:|:|
Db 1 AGCGCUAUGAAUUGAA 19

RESULT 169
US-10-751-736-11296
; Sequence 11296, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11296
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11296

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 940 ATTTCTTCCATATGGCAA 958
|||||:|:|:|:|:|:|:|
Db 3 ATTTCTTCTATGGCCAA 21

RESULT 170
US-10-751-736-11297
; Sequence 11297, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11297
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11297

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 1.5e+02;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 940 ATTTCTTCCATATGGCAA 958
|:|:|:|:|:|:|:|:|:|
```

```
Db 1 AUUUCUCCUAUGGCCAA 19

RESULT 171
US-10-751-736-11345
; Sequence 11345, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11345
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11345

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 52.6%; Pred. No. 1.5e+02;
Matches 10; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 1373 GCTGTTTGGTTGTAGGA 1391
|||:|:|:|:|:|:|:|
Db 1 GCUGGUUUGUUGUUGAA 19

RESULT 172
US-10-751-736-11432
; Sequence 11432, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 11432
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11432

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 714 CAGCACATTTGCGCTCTCT 732
|||:|:|:|:|:|:|:|
Db 2 CAACACAUUUGCCUCUCU 20

RESULT 173
US-10-751-736-11449
; Sequence 11449, Application US/10751736
; Publication No. US20040265230A1
```

```
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10793
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-10793

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 387 AGCTTCCAAAGTCTGGAGT 405
      |||::|||:::||||:
Db 1 AGCUUCCAAGUAGGAGU 19

RESULT 165
US-10-751-736-10855
; Sequence 10855, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10855
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10855

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 940 ATTTCTTCATATGCGCAA 958
      |||::|||:::||||:
Db 2 ATTTCTTCATATGCGCAA 20

RESULT 166
US-10-751-736-11006
; Sequence 11006, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
```

```
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11006
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11006

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 1.5e+02;
Matches 12; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 714 CAGCACATTTGCGCTCTCT 732
      |||::|||:::||||:
Db 2 CAACACAUUGGCCUCUCU 20

RESULT 167
US-10-751-736-11143
; Sequence 11143, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11143
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11143

Query Match      1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 559 GATGCACATTTTCATGAGG 577
      |||::|||:::||||:
Db 1 GATGCACATTTTCATGAGG 19

RESULT 168
US-10-751-736-11207
; Sequence 11207, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11207
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAI
US-10-751-736-11207
```



```
QY 739 GACATACGTAAACATTAGTCC 759
      |||||
Db 1 GACATACGTGGCATTAGTCC 21

RESULT 160
US-10-238-011-32
; Sequence 32, Application US/10238011
; Publication No. US20030091568A1
; GENERAL INFORMATION:
; APPLICANT: Frey Jorgen
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; TITLE OF INVENTION: Inhibitors for the Formation of Soluble Human CD23
; FILE REFERENCE: 516326-2002
; CURRENT APPLICATION NUMBER: US/10/238,011
; CURRENT FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: EP 00 107 515.9
; PRIOR FILING DATE: 2000-04-07
; PRIOR APPLICATION NUMBER: 09/827,406
; PRIOR FILING DATE: 2000-04-05
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-238-011-32

Query Match 1.0%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269
      |||||
Db 1 GATGTGGAGTGCCCTGATGT 19

RESULT 161
US-10-751-736-8824
; Sequence 8824, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8824
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-8824

Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269
      |||||
Db 3 GATGTGGAGTGCCCTGATGT 21

RESULT 162
US-10-751-736-8825
; Sequence 8825, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8825
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-8825

Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 1.5e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269
      |||||
Db 1 GAUGUGGAGUGCCUGAUGU 19

RESULT 163
US-10-751-736-9031
; Sequence 9031, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9031
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-9031

Query Match 1.0%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 251 GATGTGGAGTGCCCGATGT 269
      |||||
Db 1 GATGTGGAGTGCCCTGATGT 19

RESULT 164
US-10-751-736-10793
; Sequence 10793, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
```

; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11269
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11269

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 336 TAATTACACTCCGACATGAA 356
Db 1 TAATTACACCTGACATGAA 21

RESULT 156
US-10-751-736-11380
; Sequence 11380, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11380
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11380

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 AACCGTGAGGATGTAGTACTAC 375
Db 1 AACCGTGAGGATGTAGTACTAC 21

RESULT 157
US-10-751-736-11404
; Sequence 11404, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11404
; LENGTH: 21

; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11404

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 351 CATGAACCGTGAGGATGTAGA 371
Db 1 CATGAACCGTGAGGATGTGA 21

RESULT 158
US-10-751-736-11437
; Sequence 11437, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11437
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11437

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAACGCTGAGGATGTAGCTA 374
Db 1 GAACGCTGAGGATGTAGCTA 21

RESULT 159
US-10-751-736-11464
; Sequence 11464, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11464
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11464

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 151

US-10-751-736-11113
; Sequence 11113, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11113
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11113

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 354 GAACGCTGAGGATGTAGCTA 374
DB 1 GAACGCTGAGGATGTAGCTA 21

RESULT 152

US-10-751-736-11176
; Sequence 11176, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11176
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11176

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 736 GATGACATACGTAACTTCAG 756
DB 1 GATGACATACGTAACTTCAG 21

RESULT 153

US-10-751-736-11179
; Sequence 11179, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11179
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11179

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 739 GACATACGTAACTTCAGTCC 759
DB 1 GACATACGTAACTTCAGTCC 21

RESULT 154

US-10-751-736-11209
; Sequence 11209, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11209
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11209

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 988 GAAATTGAAAGCAGAAATCAA 1008
DB 1 GAAATTGAAAGCAGAAATCAA 21

RESULT 155

US-10-751-736-11269
; Sequence 11269, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736

; SEQ ID NO 10901
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-10901

Query Match 1.0%; Score 18; DB 1; Length 21;
Best Local Similarity 55.6%; Pred. No. 1.3e+02;
Matches 10; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1372 AGCTGGTTTGGTTCTTAG 1389
|||:||||:||||:|
Db 2 AGCGUUUGGUUGUAG 19

RESULT 147

US-10-751-736-8629
; Sequence 8629, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8629
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

US-10-751-736-8629

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 385 AAAGCTTTCCAAGTCTGGAGT 405
|||||:|||||:|||||
Db 1 AAAGCTTTCCAAGTCTGGAGT 21

RESULT 148

US-10-751-736-9058
; Sequence 9058, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9058
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

US-10-751-736-9058

Query Match 1.0%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 384 GAAAGCTTTCCAAGTCTGGAG 404
|||||:|||||:|||||
Db 1 GAAAGCTTTCCAAGTCTGGAG 21

RESULT 149

US-10-751-736-10786
; Sequence 10786, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10786
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

US-10-751-736-10786

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 355 AAGCGTGAGGATGTGACTAC 375
|||||:|||||:|||||
Db 1 AAGCGTGAGGATGTGACTAC 21

RESULT 150

US-10-751-736-10951
; Sequence 10951, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10951
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

US-10-751-736-10951

Query Match 1.0%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 351 CATGAGCGTGAGGATGTAGA 371
|||||:|||||:|||||
Db 1 CATGAGCGTGAGGATGTAGA 21

```
;
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32
;
; Query Match 1.0%; Score 18; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 1.2e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1749 AAAAAAAAAAAAAAAAAA 1766
DB 18 AAAAAAAAAAAAAAAAAA 1

;
; RESULT 144
; US-10-620-642-33/c
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
;
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33
;
; Query Match 1.0%; Score 18; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 1.2e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1749 AAAAAAAAAAAAAAAAAA 1766
DB 18 AAAAAAAAAAAAAAAAAA 1

;
; RESULT 145
; US-10-751-736-10900
; Sequence 10900, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 10900
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
; US-10-751-736-10900
;
; Query Match 1.0%; Score 18; DB 1; Length 21;
; Best Local Similarity 100.0%; Pred. No. 1.3e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1372 AGCTGTTTGGTTGTTAG 1389
DB 4 AGCTGTTTGGTTGTTAG 21

;
; RESULT 146
; US-10-751-736-10901
; Sequence 10901, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-669-962-28

Query Match 1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1748 GAAAAAAAAAAAAAAAAA 1765
Db 18 GAAAAAAAAAAAAAAAAA 1

RESULT 141

US-10-913-246-22
; Sequence 22, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR FILING DATE: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19

; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

Query Match 1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 142

US-10-934-890-22
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR FILING DATE: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

Query Match 1.0%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 2 AAAAAAAAAAAAAAAAAA 19

RESULT 143

US-10-620-642-32/c
; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION NUMBER: US/10/620,642
FILING DATE: 16-Jul-2003
CLASSIFICATION: <Unknown>
APPLICATION NUMBER: US/10/175,608
FILING DATE: 16-Oct-2002
APPLICATION NUMBER: 09/635,249
FILING DATE: 07-AUG-2000
APPLICATION NUMBER: 09/486,546
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 10-APR-1991
APPLICATION NUMBER: 09/589,701
FILING DATE: 10-OCT-1991
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448

RESULT 137
US-10-776-934-741/c
; Sequence 741, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: 58610(71432)
; CURRENT APPLICATION NUMBER: US/10/776,934
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,372
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: 60/523,591
; PRIOR FILING DATE: 2003-11-19
; NUMBER OF SEQ ID NOS: 741
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 741
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-934-741

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 138
US-10-601-140A-24/c
; Sequence 24, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; NAME/KEY: misc feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 139
US-10-884-617-2/c
; Sequence 2, Application US/10884617
; Publication No. US20050054730A1
; GENERAL INFORMATION:
; APPLICANT: Fu, Jin
; APPLICANT: Gaetani, Silvana
; APPLICANT: Piomelli, Daniele
; TITLE OF INVENTION: The Regents of the University of California
; TITLE OF INVENTION: Compounds, Compositions and Treatments of
; FILE REFERENCE: 02307E-133310US
; CURRENT APPLICATION NUMBER: US/10/884,617
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US 60/279,542
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/336,289
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: US 10/112,509
; PRIOR FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: US 60/485,062
; PRIOR FILING DATE: 2003-07-02
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Oligo(dT)-12-18
; OTHER INFORMATION: primer for reverse transcription of total RNA
; NAME/KEY: modified base
; LOCATION: (13)..(18)
; OTHER INFORMATION: t at positions 13-18 may be present or absent
US-10-884-617-2

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 140
US-10-669-962-28/c
; Sequence 28, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brughiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: FN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18

; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-917-141

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 134

US-10-766-096-9/c
; Sequence 9, Application US/10766096
; Publication No. US20040265786A1

GENERAL INFORMATION:

APPLICANT: Lin, Ching-I Patsy
Wallace, Robert Bruce
Cosman, Jeffrey
French, Cynthia

TITLE OF INVENTION: Lympholization of Cultured Human Cells
to Preserve RNA and DNA

NUMBER OF SEQUENCES: 9

CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA

ZIP: 94111-3834

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/766,096

FILING DATE: 27-Jan-2004

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US/08/884,029

FILING DATE: 27-JUN-1997

ATTORNEY/AGENT INFORMATION:

NAME: Parent, Annette S.

REGISTRATION NUMBER: 42,058

REFERENCE/DOCKET NUMBER: 02558B-059100US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 9:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

FEATURE:

NAME/KEY: modified_base

LOCATION: 13..18

OTHER INFORMATION: /mod_base= OTHER

/note= "t at positions 13-18 may be

present or absent"

SEQUENCE DESCRIPTION: SEQ ID NO: 9:

US-10-766-096-9

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766

Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 135

US-10-872-984-7/c

; Sequence 7, Application US/10872984

; Publication No. US20040265888A1

GENERAL INFORMATION:

APPLICANT: Kaufman, Joseph C.

APPLICANT: Roth, Matthew E.

APPLICANT: Lizardi, Paul M.

APPLICANT: Feng, Li

APPLICANT: Latimer, Darin R.

TITLE OF INVENTION: Binary Encoded Sequence Tags

FILE REFERENCE: AGL 100

CURRENT APPLICATION NUMBER: US/10/872,984

CURRENT FILING DATE: 2004-06-21

PRIOR APPLICATION NUMBER: US/09/994,311

PRIOR FILING DATE: 2001-11-26

PRIOR APPLICATION NUMBER: US/09/637,751

PRIOR FILING DATE: 2000-08-11

NUMBER OF SEQ ID NOS: 10

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 7

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Primer

US-10-872-984-7

Query Match 1.0%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 95;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 TGAATAAAAAAAAAAAAAA 1764

Db 18 TGAATAAAAAAAAAAAAAA 1

RESULT 136

US-10-638-141-10/c

; Sequence 10, Application US/10638141

; Publication No. US2005000364A1

GENERAL INFORMATION:

APPLICANT: Stanton, Lawrence W.

APPLICANT: Kapoun, Ann Marie

TITLE OF INVENTION: SECRETED FACTORS

FILE REFERENCE: SCIOS.013A

CURRENT APPLICATION NUMBER: US/10/638,141

CURRENT FILING DATE: 2003-08-07

PRIOR APPLICATION NUMBER: US/09/665,728

PRIOR FILING DATE: 2000-09-20

PRIOR APPLICATION NUMBER: 60/156,277

PRIOR FILING DATE: 1999-09-27

NUMBER OF SEQ ID NOS: 19

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 10

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: synthetic

US-10-638-141-10

Query Match 1.0%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 95;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766

Db 18 AAAAAAAAAAAAAAAAAA 1


```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 130
US-10-831-778-939/c
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 939
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-939

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 131
US-10-776-933-150/c
; Sequence 150, Application US/10776933
; Publication No. US2004024171A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBAACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDIN
; FILE REFERENCE: 58614(71432)
; CURRENT APPLICATION NUMBER: US/10/776,933
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,374
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 150
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-776-933-150/c

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 132
US-10-674-159A-112/c
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Jianzhu
; APPLICANT: Ge, Qing
; APPLICANT: Eisen, Herman
; TITLE OF INVENTION: Influenza Therapeutic
; FILE REFERENCE: 0492611-0506
; CURRENT APPLICATION NUMBER: US/10/674,159A
; CURRENT FILING DATE: 2003-09-29
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 112
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mRNA
US-10-674-159A-112

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 133
US-10-776-917-141/c
; Sequence 141, Application US/10776917
; Publication No. US20040248840A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBAACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION
; FILE REFERENCE: 58609(71432)
; CURRENT APPLICATION NUMBER: US/10/776,917
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,363
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: DK 2003-01539
; PRIOR FILING DATE: 2003-10-20
; NUMBER OF SEQ ID NOS: 201
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 141
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
```

```
/ Publication No. US20040265230A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Martinez, Robert
/ APPLICANT: Brown, Eugene
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
/ FILE REFERENCE: AM100927 (031896-002000)
/ CURRENT APPLICATION NUMBER: US/10/751,736
/ CURRENT FILING DATE: 2003-01-06
/ PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
/ PRIOR FILING DATE: 2003-01-06
/ NUMBER OF SEQ ID NOS: 54873
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 11383
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: homo sapiens
US-10-751-736-11383

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 386 AAGCTTTCACAGTCTGGAGT 405
DB 1 AAGCTTTCACAGTATGGAGT 20

RESULT 126
US-10-751-736-11434
/ Sequence 11434, Application US/10751736
/ Publication No. US20040265230A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Martinez, Robert
/ APPLICANT: Brown, Eugene
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
/ FILE REFERENCE: AM100927 (031896-002000)
/ CURRENT APPLICATION NUMBER: US/10/751,736
/ CURRENT FILING DATE: 2003-01-06
/ PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
/ PRIOR FILING DATE: 2003-01-06
/ NUMBER OF SEQ ID NOS: 54873
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 11434
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: homo sapiens
US-10-751-736-11434

Query Match          1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 349 GACATGAACCGTGAGGATGT 368
DB 1 GACATGAACCGTGAGGATGT 20

RESULT 127
US-10-849-072-21
/ Sequence 21, Application US/10849072
/ Publication No. US20040214221A1
/ GENERAL INFORMATION:
/ APPLICANT: Roche Diagnostics GmbH
/ TITLE OF INVENTION: High density labeling of DNA with modified or
/ TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
/ FILE REFERENCE: 4780/00/WO
```

```
/ CURRENT APPLICATION NUMBER: US/10/849,072
/ CURRENT FILING DATE: 2004-05-19
/ NUMBER OF SEQ ID NOS: 26
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 21
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: second
/ OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAA 1766
DB 1 AAAAAAAAAAAAAAAAAAAA 18

RESULT 128
US-10-849-072-23/c
/ Sequence 23, Application US/10849072
/ Publication No. US20040214221A1
/ GENERAL INFORMATION:
/ APPLICANT: Roche Diagnostics GmbH
/ TITLE OF INVENTION: High density labeling of DNA with modified or
/ TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
/ FILE REFERENCE: 4780/00/WO
/ CURRENT APPLICATION NUMBER: US/10/849,072
/ CURRENT FILING DATE: 2004-05-19
/ NUMBER OF SEQ ID NOS: 26
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 23
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: second
/ OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

Query Match          1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAA 1766
DB 18 AAAAAAAAAAAAAAAAAAAA 1

RESULT 129
US-10-831-778-913/c
/ Sequence 913, Application US/10831778
/ Publication No. US20040235774A1
/ GENERAL INFORMATION:
/ APPLICANT: Bratzler, Robert L.
/ APPLICANT: Petersen, Deanna M.
/ APPLICANT: Fouron, Yves
/ TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
/ TITLE OF INVENTION: Treatment of Asthma and Allergy
/ FILE REFERENCE: C1037/7013 (HCL/MAT)
/ CURRENT APPLICATION NUMBER: US/10/831,778
/ CURRENT FILING DATE: 2004-04-23
/ PRIOR APPLICATION NUMBER: US 60/179,991
/ PRIOR FILING DATE: 2000-02-03
/ NUMBER OF SEQ ID NOS: 1093
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 913
/ LENGTH: 18
```

US-10-751-736-10888

Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1263 AATTGATGAGTCTCTATT 1282

DB 1 AATTGATGAGTCTCTATT 20

RESULT 121

US-10-751-736-11110
; Sequence 11110, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11110
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11110

Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 349 GACATGAAGCGTGAGGATGT 368

DB 1 GACATGAAGCGTGAGGATGT 20

RESULT 122

US-10-751-736-11126
; Sequence 11126, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11126
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-11126

Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 386 AAGCTTTCCAAGTCTGGAGT 405

DB 1 AAGCUUCCAGUAGGAGU 20

RESULT 123

US-10-751-736-11206
; Sequence 11206, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11206
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11206

Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 977 AAGCTGCTTACGAAATTGAA 996

DB 2 AAGCTGCTTACGAAATTGAA 21

RESULT 124

US-10-751-736-11344
; Sequence 11344, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11344
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11344

Query Match 1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1372 AGCTGGTTGCTGTAGGA 1391

DB 2 AGCTGGTTGCTGTAGGA 21

RESULT 125

US-10-751-736-11383
; Sequence 11383, Application US/10751736

```

; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10795
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10795

Query Match
  1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 386 AAGCTTTCCCAAGTCTGGAGT 405
      |||||
Db 1 AAGCTTTCCCAAGTATGGAGT 20

RESULT 119
US-10-751-736-10861
; Sequence 10861, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10861
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10861

Query Match
  1.0%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 1.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 977 AAGCTGCTTACGAAATTGAA 996
      |||||
Db 1 AAGCTGCTTATGAAATTGAA 20

RESULT 120
US-10-751-736-10888
; Sequence 10888, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10888
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens

```

```

; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34
;
; Query Match 1.1%; Score 19; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 90;
; Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1766
DB 19 GAAAAAAAAAAAAAAAAAAAAA 1
;
; RESULT 114
; US-10-751-736-10823
;
; Sequence 10823, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10823
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
; US-10-751-736-10823
;
; Query Match 1.1%; Score 19; DB 1; Length 21;
; Best Local Similarity 63.2%; Pred. No. 99;
; Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
;
QY 717 CACATTTCGCTCTCTGCT 735
DB 1 CACAUUUGCCUCUCUCU 19
;
; RESULT 115
; US-10-751-736-11009
; Sequence 11009, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11009
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
; US-10-751-736-11009
;
; Query Match 1.1%; Score 19; DB 1; Length 21;
; Best Local Similarity 63.2%; Pred. No. 99;
; Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;
;
QY 717 CACATTTCGCTCTCTGCT 735
DB 2 CACAUUUGCCUCUCUCU 20
;
; RESULT 116
; US-10-751-736-11015
; Sequence 11015, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei

```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-913-246-24

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
Db 1 AAAAAAAAAAAAAAAAAA 19

RESULT 110
US-10-934-890-24
; Sequence 24, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-934-890-24

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
Db 1 AAAAAAAAAAAAAAAAAA 19

RESULT 111
US-10-700-884-23/c
; Sequence 23, Application US/10700884
; Publication No. US20050037370A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Thazha P.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
; FILE REFERENCE: ISIS-5317
; CURRENT APPLICATION NUMBER: US/10/700,884
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/635,380
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match          1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1767
Db 19 AAAAAAAAAAAAAAAAAA 1

RESULT 112
US-10-728-078-14
; Sequence 14, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14

Query Match          1.1%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1758 AAAAAAAAAAAAAAAAAA 1776
Db 1 AAAAAAAAAAAAAAAAAA 19

RESULT 113
US-10-620-642-34/c
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
```

; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAACAAAAACAAAAACAA 1

RESULT 106
US-10-831-778-60/c
; Sequence 60, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
DB 24 AAAAAACAAAAACAAAAACAA 1

RESULT 107
US-10-619-906-3/c
; Sequence 3, Application US/10619906
; Publication No. US20040087533A1
; GENERAL INFORMATION:
; APPLICANT: Index Pharmaceuticals
; TITLE OF INVENTION: New Compound
; FILE REFERENCE: 50299
; CURRENT APPLICATION NUMBER: US/10/619,906
; CURRENT FILING DATE: 2003-07-16
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (1)..(19)
; OTHER INFORMATION: SEQ ID NO.3, antisense oligonucleotide
US-10-619-906-3

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 ACATTTCGCTCTCTGCTG 736
DB 19 ACATTTCGCTCTCTGCTG 1

RESULT 108

US-10-760-940-1/c
; Sequence 1, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel C.
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas L.
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
; FILE REFERENCE: ISIS-5422
; CURRENT APPLICATION NUMBER: US/10/760,940
; CURRENT FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US 10/232,881
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: US 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-760-940-1

Query Match 1.1%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1767
DB 19 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 109

US-10-913-246-24
; Sequence 24, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA

; Sequence 60, Application US/09776479
 ; Publication No. US20030087848A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bratzler, Robert L.
 ; APPLICANT: Petersen, Deanna M.
 ; APPLICANT: Fouron, Yves
 ; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
 ; TITLE OF INVENTION: Treatment of Asthma and Allergy
 ; FILE REFERENCE: C1037/7013 (HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/09/776,479
 ; CURRENT FILING DATE: 2001-02-02
 ; PRIOR APPLICATION NUMBER: US 60/179,991
 ; PRIOR FILING DATE: 2000-02-03
 ; NUMBER OF SEQ ID NOS: 1093
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 60
 ; LENGTH: 24
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence
 US-09-776-479-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 102
 US-09-776-479-60/c
 ; Sequence 60, Application US/09776479
 ; Publication No. US20040067902A9
 ; GENERAL INFORMATION:
 ; APPLICANT: Bratzler, Robert L.
 ; APPLICANT: Petersen, Deanna M.
 ; APPLICANT: Fouron, Yves
 ; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
 ; TITLE OF INVENTION: Treatment of Asthma and Allergy
 ; FILE REFERENCE: C1037/7013 (HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/09/776,479
 ; CURRENT FILING DATE: 2001-02-02
 ; PRIOR APPLICATION NUMBER: US 60/179,991
 ; PRIOR FILING DATE: 2000-02-03
 ; NUMBER OF SEQ ID NOS: 1093
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 60
 ; LENGTH: 24
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence
 US-09-776-479-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 103
 US-10-112-653-54/c
 ; Sequence 54, Application US/10112653
 ; Publication No. US20030050268A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Krieg, Arthur M.
 ; APPLICANT: Berg, Daniel J.

; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
 ; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
 ; FILE REFERENCE: C01039/70060(AWS)
 ; CURRENT APPLICATION NUMBER: US/10/112,653
 ; CURRENT FILING DATE: 2002-03-29
 ; PRIOR APPLICATION NUMBER: US 60/279,642
 ; PRIOR FILING DATE: 2001-03-29
 ; NUMBER OF SEQ ID NOS: 1040
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 54
 ; LENGTH: 24
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Oligonucleotide
 US-10-112-653-54

Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 104
 US-10-017-995-60/c
 ; Sequence 60, Application US/10017995
 ; Publication No. US20030055014A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bratzler, Robert L.
 ; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
 ; FILE REFERENCE: C1037/7025 (HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/10/017,995
 ; CURRENT FILING DATE: 2001-12-18
 ; PRIOR APPLICATION NUMBER: US 60/255,534
 ; PRIOR FILING DATE: 2000-12-14
 ; NUMBER OF SEQ ID NOS: 1093
 ; SOFTWARE: FastSEQ for Windows Version 3.0
 ; SEQ ID NO 60
 ; LENGTH: 24
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic Sequence
 US-10-017-995-60

Query Match 1.1%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
 Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 105
 US-10-314-578-60/c
 ; Sequence 60, Application US/10314578
 ; Publication No. US20030212026A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Krieg, Arthur M.
 ; APPLICANT: Schetter, Christian
 ; APPLICANT: Vollmer, Jorg
 ; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
 ; FILE REFERENCE: C1039/7035 (HCL/MAT)
 ; CURRENT APPLICATION NUMBER: US/10/314,578
 ; CURRENT FILING DATE: 2002-12-09
 ; PRIOR APPLICATION NUMBER: US 60/156,113
 ; PRIOR FILING DATE: 1999-09-25
 ; PRIOR APPLICATION NUMBER: US 60/156,135
 ; PRIOR FILING DATE: 1999-09-27

; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-23

Query Match 1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
DB 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 97

US-10-751-736-10792
; Sequence 10792, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10792
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10792

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 385 AAAGCTTCCAGTCTGGAGT 405
DB 1 AAAGCTTCCAGTATGGAGT 21

RESULT 98

US-10-751-736-10822
; Sequence 10822, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10822
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-10822

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 AGCACATTCGCTCTCTGCT 735
DB 1 AAACATTCGCTCTCTGCT 21

RESULT 99

US-10-751-736-11008
; Sequence 11008, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11008
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11008

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 CAGCACATTCGCTCTCTGCG 734
DB 1 CAACATTCGCTCTCTGCG 21

RESULT 100

US-10-751-736-11125
; Sequence 11125, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11125
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11125

Query Match 1.1%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 89;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 384 GAAAGCTTCCAGTCTGGAG 404
DB 1 GAAAGCTTCCAGTATGGAG 21

RESULT 101

US-09-776-479-60/c

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-44

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 93
US-10-876-086-49/c
; Sequence 49, Application US/10876086
; Publication No. US20050066389A1
; GENERAL INFORMATION:
; APPLICANT: Gallie, Daniel R.
; APPLICANT: Young, Todd E.
; TITLE OF INVENTION: The Regents of the University of California
; TITLE OF INVENTION: Genes Which Produce Staygreen Characteristics in Maize
; FILE REFERENCE: 023070-137010US
; CURRENT APPLICATION NUMBER: US/10/876,086
; CURRENT FILING DATE: 2004-06-23
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligo-dT (20)
US-10-876-086-49

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 94
US-10-751-736-11012
; Sequence 11012, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11012
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-11012
```

```
Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 60.0%; Pred. No. 76;
Matches 12; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 719 CATTTCGCTCTCTGCTGAT 738
Db 1 CAUUGCGCCUCUCGCGAU 20

RESULT 95
US-10-913-246-23
; Sequence 23, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-23

Query Match      1.1%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 2 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 96
US-10-934-890-23
; Sequence 23, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-23
```

```
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide capture probe
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-23

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 90
US-10-601-140A-34
; Sequence 34, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
```

```
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide linker
; US-10-601-140A-34

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 91
US-10-601-140A-40/c
; Sequence 40, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; US-10-601-140A-40

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 92
US-10-601-140A-44
; Sequence 44, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; LENGTH: 20
```

```
RESULT 86
US-10-601-140A-8/c
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 87
US-10-601-140A-9/c
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (8)..(9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (13)..(14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (18)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-9
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 88
US-10-601-140A-10/c
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)..(5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)..(12)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-10
Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 89
US-10-601-140A-23/c
; Sequence 23, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-4

```

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 69;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 84
US-10-601-140A-6/c
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base

```

```

; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-6

```

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

RESULT 85
US-10-601-140A-7/c
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-7

```

Query Match 1.1%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 68;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
    |||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

```

```

; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-601-140A-1
; LOCATION: (15)
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-2

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   1749 AAAAAAAAAAAAAAAAAAAAAA 1768
     |||||||
Db    20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 81
US-10-601-140A-2/c
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified base

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   1749 AAAAAAAAAAAAAAAAAAAAAA 1768
     |||||||
Db    20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 82
US-10-601-140A-3/c
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-3

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   1749 AAAAAAAAAAAAAAAAAAAAAA 1768
     |||||||
Db    20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 83
US-10-601-140A-4/c
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20

```

; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 226
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-226

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 77
US-10-831-778-556/c
; Sequence 556, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Fouron, Yves
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 556
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-556

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 78
US-10-831-778-560
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Fouron, Yves
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23

; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 560
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||||
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 79
US-10-728-078-23/c
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
|||||
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 80
US-10-601-140A-1/c
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24

```
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-45

Query Match      1.1%  Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 79;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAA... 1768
Db 21 BAAAAA... 1

RESULT 73
US-09-976-900A-55
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elgharian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-976-900A-55

Query Match      1.1%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA... 1768
Db 1 AAAAAA... 20

RESULT 74
US-10-661-415-12
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205

Query Match      1.1%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA... 1768
Db 1 AAAAAA... 20

RESULT 75
US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-15

Query Match      1.1%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA... 1768
Db 20 AAAAAA... 1

RESULT 76
US-10-831-778-226/c
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
```

```
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-12

Query Match      1.1%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA... 1768
Db 1 AAAAAA... 20

RESULT 75
US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-15

Query Match      1.1%  Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 68;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAA... 1768
Db 20 AAAAAA... 1

RESULT 76
US-10-831-778-226/c
; Sequence 226, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
```


Db 24 GAGTTTGTGCTGTCTACTACCGT 1

RESULT 70
US-10-664-000-3/c
; Sequence 3, Application US/10664000
; Publication No. US20040248144A1
; GENERAL INFORMATION:
; APPLICANT: Mir, Kalim
; TITLE OF INVENTION: Arrays and Methods of Use
; FILE REFERENCE: 8654/2182
; CURRENT APPLICATION NUMBER: US/10/664,000
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/GB02/01245
; PRIOR FILING DATE: 2002-03-18
; PRIOR APPLICATION NUMBER: GB0106635.6
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: GB0118879.6
; PRIOR FILING DATE: 2001-08-02
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Anchored capture oligonucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (22)..(22)
; OTHER INFORMATION: n is a, c, g, or t
US-10-664-000-3

Query Match 1.1%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 79;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1768
:|||||
Db 21 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 71
US-10-601-140A-32/c
; Sequence 32, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 32
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer

; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-32

Query Match 1.1%; Score 20.2; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 79;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAA 1768
:|||||
Db 21 BAAAAAAAAAAAAAAAAAAAAA 1

RESULT 72
US-10-601-140A-45/c
; Sequence 45, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 45
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)

```
; SEQ ID NO 11011
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11011

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 717 CACATTCGCCTCTCTCTGTA 737
Db 1 CACATTCGCCTCTCTCTGTA 21

RESULT 56
US-10-751-736-11014
; Sequence 1014, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11014
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-11014

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 719 CATTTCGCCTCTCTCTGTGATG 739
Db 1 CATTTCGCCTCTCTCTGTGATG 21

RESULT 67
US-10-830-287A-7/c
; Sequence 7, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-7

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 719 CATTTCGCCTCTCTCTGTGATG 739
Db 1 CATTTCGCCTCTCTCTGTGATG 21

RESULT 68
US-10-601-140A-43
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match      1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
Db 1 AAAAAAAAAAAAAAAAAAAAAA 21

RESULT 69
US-10-872-063-161/c
; Sequence 161, Application US/10872063
; Publication No. US20050079518A1
; GENERAL INFORMATION:
; APPLICANT: BAKER, Joffre
; APPLICANT: BRYANT, John L.
; APPLICANT: PAIK, Soonmyung
; APPLICANT: SHAK, Steven
; TITLE OF INVENTION: Prediction of Likelihood of Cancer
; FILE REFERENCE: 39740-0012 US
; CURRENT APPLICATION NUMBER: US/10/872,063
; CURRENT FILING DATE: 2004-06-17
; PRIOR APPLICATION NUMBER: US 60/482,339
; PRIOR FILING DATE: 2003-06-24
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 161
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer-probe
US-10-872-063-161

Query Match      1.2%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 80;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 837 GAGTTTGTGCTGCTCACAACAGT 860
Db 1 GAGTTTGTGCTGCTCACAACAGT 860
```

```
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 908158
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-908158
```

```
Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1164 TGTGGATAAACAAGTCTGAGGTAT 1188
DB 1 TGTGGATAAACAAGTCTGAGGTAT 25
```

```
RESULT 62
US-10-719-900-962530
; Sequence 962530, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 962530
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-962530
```

```
Query Match 1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1644 TTGTTTCTTAACACCTTCAAGTAG 1668
DB 1 TTGTTTCTTAACACCTTCAAGTAG 25
```

```
RESULT 63
US-10-721-793-285/c
; Sequence 285, Application US/10721793
; Publication No. US20050065331A1
; GENERAL INFORMATION:
; APPLICANT: Corona Villegas, Miguel
; APPLICANT: Garcia Rodriguez, Ma Consuelo
; APPLICANT: Valdez Cruz, Norma Adriana
; APPLICANT: Gurrola Briones, Georgina
; APPLICANT: Becerra Lujan, Baltazar
; APPLICANT: Possani Postay, Lourival Domingos
; TITLE OF INVENTION: Recombinant Immunogens for the Generation of Antivenoms to the
; FILE REFERENCE: Venom of Scorpions of the Genus Centruroides
; CURRENT APPLICATION NUMBER: US/10/721,793
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 60/430,067
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 294
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 285
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: PCR Reverse oligonucleotide primer
; NAME/KEY: misc_feature
```

```
; LOCATION: (23)..(23)
; OTHER INFORMATION: n is a, t, g, or c
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(24)
; OTHER INFORMATION: oligonucleotide T22NN
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (24)..(24)
; OTHER INFORMATION: n is a, t, g, or c
US-10-721-793-285
```

```
Query Match 1.2%; Score 22; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1770
DB 22 AAAAAAAAAAAAAAAAAAAAAA 1
```

```
RESULT 64
US-10-831-778-912/c
; Sequence 912, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 912
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-912
```

```
Query Match 1.2%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1769
DB 21 AAAAAAAAAAAAAAAAAAAAAA 1
```

```
RESULT 65
US-10-751-736-11011
; Sequence 11011, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
```

```
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 512976
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-512976

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1267 GATGAGTCTCTTATTTCAAAGAC 1291
      |||||||
Db 1 GATGAGTCTCTCAATTTCAAAGAC 25

RESULT 57
US-10-719-900-611610
; Sequence 611610, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 611610
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-611610

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1196 GGCAGGAGCTCAGGAGCCCTGCTTA 1220
      |||||||
Db 1 GGCAGGAGCTCAAGGAGCCCTGCTTA 25

RESULT 58
US-10-719-900-761328
; Sequence 761328, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-761328

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1297 TACATCTTCCAGGAGCCTATCAAT 1321
      |||||||
Db 1 TACATCTTCCAGGAGCCTATCAAT 25
```

```
RESULT 59
US-10-719-900-860596
; Sequence 860596, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 860596
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-860596

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1229 TGATTTCCACACACTTCCCGAGGAAT 1253
      |||||||
Db 1 TGATTTCCACACTCTTCCCGAGGAAT 25

RESULT 60
US-10-719-900-879472
; Sequence 879472, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 879472
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-879472

Query Match      1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1208 TGGACCCCTGCTTACCCCAAGCTGAT 1232
      |||||||
Db 1 TGGACCCCTGCTTCCCAAGCTGAT 25

RESULT 61
US-10-719-900-908158
; Sequence 908158, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-3

Query Match          1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
      |||||
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 52
US-10-719-900-174230
; Sequence 174230, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 174230
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-174230

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1256 AGCTAAATGTGAGCTCTCTA 1280
      |||||
Db 1 AGCTAAATGTGAGCTCTCTA 25

RESULT 53
US-10-719-900-309853
; Sequence 309853, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 309853
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-309853

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1240 CACTTCCAGGATCAAGCCTAAAA 1264
      |||||
Db 1 CACTTCCAGGATCAAGCCTAAAA 25

RESULT 54
US-10-719-900-446212
; Sequence 446212, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 446212
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-446212

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1289 GACACTACTACATCTTCCAAGGAGC 1313
      |||||
Db 1 GACACTACTACATCTTCCAAGGAGC 25

RESULT 55
US-10-719-900-480520
; Sequence 480520, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 480520
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-480520

Query Match          1.3%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 43;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1310 GAGCCTATCAATTTGGAATATGACCC 1334
      |||||
Db 1 GAGCCTATCAATTTGGAATATGACCC 25

RESULT 56
US-10-719-900-512976
; Sequence 512976, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
```

```
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 433
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-433

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 48
US-10-831-778-961/c
; Sequence 961, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 961
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-961

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 49
US-10-831-778-962
; Sequence 962, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 962
; LENGTH: 24
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-962

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 1 AAAAAAAAAAAAAAAAAAAAAA 24

RESULT 50
US-10-357-930-14833/c
; Sequence 14833, Application US/10357930
; Publication No. US20040259086A1
; GENERAL INFORMATION:
; APPLICANT: Schlegel, Robert
; APPLICANT: Endegge, Wilson
; APPLICANT: Monahan, John
; TITLE OF INVENTION: NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR
; TITLE OF INVENTION: IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF
; FILE REFERENCE: MRI-007BCN
; CURRENT APPLICATION NUMBER: US/10/357,930
; CURRENT FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 09/785,276
; PRIOR FILING DATE: 2003-02-16
; PRIOR APPLICATION NUMBER: 60/183,319
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: 60/189,862
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/207,454
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 60/211,314
; PRIOR FILING DATE: 2000-06-09
; PRIOR APPLICATION NUMBER: 60/219,007
; PRIOR FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: 60/255,281
; PRIOR FILING DATE: 2000-12-13
; NUMBER OF SEQ ID NOS: 62232
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14833
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-357-930-14833

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 51
US-10-942-251-3/c
; Sequence 3, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
```

RESULT 43

US-10-969-164-7/c
; Sequence 7, Application US/10969164
; Publication No. US20050065322A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/10/969,164
; PRIOR FILING DATE: 2004-10-20
; PRIOR APPLICATION NUMBER: US/09/527,345
; PRIOR FILING DATE: 1999-03-17
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-10-969-164-7

Query Match 1.4%; Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAAAAAA 1773
DB 25 AAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 44

US-10-942-251-8/c
; Sequence 8, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-8

Query Match 1.4%; Score 25; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 35;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAAAAAA 1776
DB 28 AAAAAAAAAAAAAAAAAAAAAAAAAA 4

RESULT 45

US-10-942-251-9/c
; Sequence 9, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri

; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-9

Query Match 1.4%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 31;
Matches 24; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAAAAAA 1776
DB 25 AAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 46

US-10-942-251-12/c
; Sequence 12, Application US/10942251
; Publication No. US20050069524A1
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/10/942,251
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US/09/213,834
; PRIOR FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-10-942-251-12

Query Match 1.4%; Score 24.4; DB 1; Length 28;
Best Local Similarity 96.2%; Pred. No. 42;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAAAAAA 1777
DB 28 AAAAAAAAAAAAAAAAAAAAAAAAAA 3

RESULT 47

US-10-831-778-433/c
; Sequence 433, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/NAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03

US-10-809-189-125382
 ; Sequence 125382, Application US/10809189
 ; Publication No. US20050048531A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Michael Mittmann
 ; APPLICANT: David Lockhart
 ; APPLICANT: Affymetrix, Inc.
 ; TITLE OF INVENTION: Methods of Genetic Analysis
 ; FILE REFERENCE: 3101.1
 ; CURRENT APPLICATION NUMBER: US/10/809,189
 ; CURRENT FILING DATE: 2004-03-25
 ; PRIOR APPLICATION NUMBER: US/09/396,196
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: 60/100,678
 ; PRIOR FILING DATE: 1998-09-17
 ; NUMBER OF SEQ ID NOS: 127806
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 125382
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: mus musculus
 ; US-10-809-189-125382

Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1324 GAATATGACCCCTGTTCCCTCGTG 1348
 Db 1 GAATATGACCCCTGTTCCCTCGTG 25

RESULT 40
 US-10-809-189-125383
 ; Sequence 125383, Application US/10809189
 ; Publication No. US20050048531A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Michael Mittmann
 ; APPLICANT: David Lockhart
 ; APPLICANT: Affymetrix, Inc.
 ; TITLE OF INVENTION: Methods of Genetic Analysis
 ; FILE REFERENCE: 3101.1
 ; CURRENT APPLICATION NUMBER: US/10/809,189
 ; CURRENT FILING DATE: 2004-03-25
 ; PRIOR APPLICATION NUMBER: US/09/396,196
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: 60/100,678
 ; PRIOR FILING DATE: 1998-09-17
 ; NUMBER OF SEQ ID NOS: 127806
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 125383
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: mus musculus
 ; US-10-809-189-125383

Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1336 CTGTCGTCGTGTACCAAAACAT 1360
 Db 1 CTGTCGTCGTGTACCAAAACAT 25

RESULT 41
 US-10-809-189-125384
 ; Sequence 125384, Application US/10809189
 ; Publication No. US20050048531A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Michael Mittmann

; APPLICANT: David Mack
 ; APPLICANT: David Lockhart
 ; APPLICANT: Affymetrix, Inc.
 ; TITLE OF INVENTION: Methods of Genetic Analysis
 ; FILE REFERENCE: 3101.1
 ; CURRENT APPLICATION NUMBER: US/10/809,189
 ; CURRENT FILING DATE: 2004-03-25
 ; PRIOR APPLICATION NUMBER: US/09/396,196
 ; PRIOR FILING DATE: 1999-09-15
 ; PRIOR APPLICATION NUMBER: 60/100,678
 ; PRIOR FILING DATE: 1998-09-17
 ; NUMBER OF SEQ ID NOS: 127806
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 125384
 ; LENGTH: 25
 ; TYPE: DNA
 ; ORGANISM: mus musculus
 ; US-10-809-189-125384

Query Match 1.4%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 28;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1339 TTCGTCGTGTACCAAAACATTGA 1363
 Db 1 TTCGTCGTGTACCAAAACATTGA 25

RESULT 42
 US-10-787-442-38/c
 ; Sequence 38, Application US/10787442
 ; Publication No. US2004026065A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Novak, Julia E.
 ; APPLICANT: Presnell, Scott R.
 ; APPLICANT: Sprecher, Cindy A.
 ; APPLICANT: Foster, Donald C.
 ; APPLICANT: Holly, Richard D.
 ; APPLICANT: Gross, Jane A.
 ; APPLICANT: Johnston, Janet V.
 ; APPLICANT: Neilson, Andrew J.
 ; APPLICANT: Dillon, Stacey R.
 ; APPLICANT: Hammond, Angela K.
 ; TITLE OF INVENTION: NOVEL CVTOKINE ZALPHA11 LIGAND
 ; FILE REFERENCE: 99-16
 ; CURRENT APPLICATION NUMBER: US/10/787,442
 ; CURRENT FILING DATE: 2004-02-26
 ; PRIOR APPLICATION NUMBER: US/09/522,217
 ; PRIOR FILING DATE: 2000-03-09
 ; PRIOR APPLICATION NUMBER: US 60/123,547
 ; PRIOR FILING DATE: 1999-03-09
 ; PRIOR APPLICATION NUMBER: US 60/123,904
 ; PRIOR FILING DATE: 1999-03-11
 ; PRIOR APPLICATION NUMBER: US 60/142,013
 ; PRIOR FILING DATE: 1999-07-01
 ; NUMBER OF SEQ ID NOS: 115
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 38
 ; LENGTH: 26
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Oligonucleotide primer ZC7764a
 ; US-10-787-442-38

Query Match 1.4%; Score 25; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
 Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1273 GTCTCTATTTCAAAAGACACTACT 1297
Db 1 GTCTCTATTTCAAAAGACACTACT 25

RESULT 35
US-10-809-189-125378
; Sequence 125378, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 2004-03-25
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125378
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125378

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1276 CTCTATTTCAAAAGACACTACTACA 1300
Db 1 CTCTATTTCAAAAGACACTACTACA 25

RESULT 36
US-10-809-189-125379
; Sequence 125379, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 2004-03-25
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125379
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125379

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1279 TATTTCAAAAGACACTACTACTACT 1303

Db 1 TATTTCAAAAGACACTACTACTACT 25

RESULT 37
US-10-809-189-125380
; Sequence 125380, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 2004-03-25
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125380
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125380

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1297 TACATCTTCCAGGAGCCTATCAAT 1321
Db 1 TACATCTTCCAGGAGCCTATCAAT 25

RESULT 38
US-10-809-189-125381
; Sequence 125381, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 2004-03-25
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125381
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125381

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1303 TTCCAAGGAGCCTATCAATTGGAAT 1327
Db 1 TTCCAAGGAGCCTATCAATTGGAAT 25

RESULT 39

; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125373
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125373

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1588 TTCTATTCTTAATTTGAAAGTGCA 1612
|||||
Db 1 TTCTATTCTTAATTTGAAAGTGCA 25
|||||

RESULT 31
US-10-809-189-125374
; Sequence 125374, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125374
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125374

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1612 ATGTTTCAGAGGCCAACTGGTTTAT 1636
|||||
Db 1 ATGTTTCAGAGGCCAACTGGTTTAT 25
|||||

RESULT 32
US-10-809-189-125375
; Sequence 125375, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125375

; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125375

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1681 AGAATTACTCTCTGTCTTTACTGA 1705
|||||
Db 1 AGAATTACTCTCTGTCTTTACTGA 25
|||||

RESULT 33
US-10-809-189-125376
; Sequence 125376, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125376
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125376

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1684 ATTACTCTCTGTCTTTACTGAAAT 1708
|||||
Db 1 ATTACTCTCTGTCTTTACTGAAAT 25
|||||

RESULT 34
US-10-809-189-125377
; Sequence 125377, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125377
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125377

```
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125369
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-125369

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1447 ATATTCACCTATGCTCAGGGTGTGA 1471
Db      1 ATATTCACCTATGCTCAGGGTGTGA 25

RESULT 27
US-10-809-189-125370
; Sequence 125370, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125370
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-125370

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1453 ACTCTATGCTCAGGGTCTAACTATG 1477
Db      1 ACTCTATGCTCAGGGTCTAACTATG 25

RESULT 28
US-10-809-189-125371
; Sequence 125371, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125371
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-125371

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1513 CAGGTCACACACATAGTTACACA 1537
Db      1 CAGGTCACACACATAGTTACACA 25

RESULT 29
US-10-809-189-125372
; Sequence 125372, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125372
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-10-809-189-125372

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 GTCACACACACATAGTTACACAGAA 1540
Db      1 GTCACACACACATAGTTACACAGAA 25

RESULT 30
US-10-809-189-125373
; Sequence 125373, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
```

QY 1644 TTGTTTCTAACAACTTCAAGTAG 1668
|||||
Db 1 TTGTTTCTAACAACTTCAAGTAG 25

RESULT 22
US-10-809-189-125365
; Sequence 125365, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125365

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1237 ACACACTTCCAGGAATCAAGCCTA 1261
|||||
Db 1 ACACACTTCCAGGAATCAAGCCTA 25

RESULT 23
US-10-809-189-125366
; Sequence 125366, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125366
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125366

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1243 TTCCAGGAATCAAGCCTAAATTTG 1267
|||||
Db 1 TTCCAGGAATCAAGCCTAAATTTG 25

RESULT 24
US-10-809-189-125367
; Sequence 125367, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125367
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125367

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 TATTACATATTCACCTCTATGCTCAG 1465
|||||
Db 1 TATTACATATTCACCTCTATGCTCAG 25

RESULT 25
US-10-809-189-125368
; Sequence 125368, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125368
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-125368

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1444 TACATATTCACCTCTATGCTCAGGGT 1468
|||||
Db 1 TACATATTCACCTCTATGCTCAGGGT 25

RESULT 26
US-10-809-189-125369
; Sequence 125369, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:

```
OY 1196 GGCAGGAGCTCATGGACCTCGTTA 1220
      |||||||
Db 1 GGCAGGAGCTCATGGACCTCGTTA 25

RESULT 17
US-10-719-900-761329
; Sequence 761329, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761329
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-761329

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1297 TACATCTTCCAAGGAGCCTATCAAT 1321
      |||||||
Db 1 TACATCTTCCAAGGAGCCTATCAAT 25

RESULT 18
US-10-719-900-860595
; Sequence 860595, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 860595
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-860595

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1229 TGATTTCCACACACTTCCAGGAAT 1253
      |||||||
Db 1 TGATTTCCACACACTTCCAGGAAT 25

RESULT 19
US-10-719-900-879471
; Sequence 879471, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
```

```
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 879471
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-879471

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1208 TGGACCTGCTTACCCCAAGCTGAT 1232
      |||||||
Db 1 TGGACCTGCTTACCCCAAGCTGAT 25

RESULT 20
US-10-719-900-908157
; Sequence 908157, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 908157
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-908157

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1164 TGTGGATAAACACTACTGGAGGTAT 1188
      |||||||
Db 1 TGTGGATAAACACTACTGGAGGTAT 25

RESULT 21
US-10-719-900-962529
; Sequence 962529, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 962529
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-962529

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1256 AGCTAAATTTGATGAGTCTCTTA 1280
|||||
Db 1 AGCTAAATTTGATGAGTCTCTTA 25

RESULT 12

US-10-719-900-309852
; Sequence 309852, Application US/10719900
; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 309852

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-309852

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1240 CACTTCCAGGATCAAGCTTAAAA 1264
|||||
Db 1 CACTTCCAGGATCAAGCTTAAAA 25

RESULT 13

US-10-719-900-446213

; Sequence 446213, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 446213

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-446213

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1289 GACACTACTACATCTTCCAGGAGC 1313
|||||
Db 1 GACACTACTACATCTTCCAGGAGC 25

RESULT 14

US-10-719-900-480521

; Sequence 480521, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 480521
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-480521

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1310 GAGCCTATCAATTTGGAATATGACCC 1334
|||||
Db 1 GAGCCTATCAATTTGGAATATGACCC 25

RESULT 15

US-10-719-900-512977

; Sequence 512977, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 512977

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-512977

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1267 GATGAGTCTCTCTATTTCAAAAGAC 1291
|||||
Db 1 GATGAGTCTCTCTATTTCAAAAGAC 25

RESULT 16

US-10-719-900-611611

; Sequence 611611, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 611611

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-611611

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 28;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match	1.4%	Score 25;	DB 1;	Length 25;
Best Local Similarity	100.0%	Pred. No. 28;		


```
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Polynucleotide having a 3' poly (dA)30 tail and a 5' poly (dT)3
US-10-848-922-98
;
Query Match          1.5%; Score 27.4; DB 1; Length 33;
Best Local Similarity 96.6%; Pred. No. 26;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
Qy 1747 TGAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1775
Db 2 TTAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 30

RESULT 5
US-10-831-778-911/c
; Sequence 911, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT FILING DATE: 2004-04-23
; PRIOR FILING DATE: 2004-04-23
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0.
; SEQ ID NO 911
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-911

Query Match          1.5%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1749 AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1775
Db 27 AAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1

RESULT 6
US-10-787-442-39/c
; Sequence 39, Application US/10787442
; Publication No. US20040260065A1
; GENERAL INFORMATION:
; APPLICANT: Novak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Foster, Donald C.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/10787,442
; CURRENT FILING DATE: 2004-02-26
; PRIOR APPLICATION NUMBER: US/09/522,217
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: US 60/123,547
; PRIOR FILING DATE: 1999-03-09
; PRIOR APPLICATION NUMBER: US 60/123,904
```

```
; PRIOR FILING DATE: 1999-03-11
; PRIOR APPLICATION NUMBER: US 60/142,013
; PRIOR FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 39
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764b
US-10-787-442-39

Query Match          1.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
Qy 1748 GAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1773
Db 26 GAAAAAAGAAAAAAGAAAAAAGAAAAAAGAAAAA 1

RESULT 7
US-10-925-448-10/c
; Sequence 10, Application US/10925448
; Publication No. US20050019820A1
; GENERAL INFORMATION:
; APPLICANT: BILLING-MEDEL, PATRICIA
; APPLICANT: COHEN, MAURICE
; APPLICANT: COLPITS, TRACEY L.
; APPLICANT: FRIEDMAN, PAULA N.
; APPLICANT: KLASS, MICHAEL R.
; APPLICANT: RUSSELL, JOHN C.
; APPLICANT: STROUPE, STEPHEN D.
; TITLE OF INVENTION: REAGENTS AND METHODS USEFUL
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Abbott Laboratories
; STREET: 100 Abbott Park Road
; CITY: Abbott Park
; STATE: IL
; COUNTRY: USA
; ZIP: 60064-3500
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/925,448
; FILING DATE: 25-Aug-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,296
; FILING DATE: 05-JUNE-1998
; APPLICATION NUMBER: 60/048,810
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Becker, Cheryl L.
; REGISTRATION NUMBER: 35,441
; REFERENCE/DOCKET NUMBER: 6104.US.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 847/935-1729
; TELEFAX: 847/938-2623
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 10:
```

```

RESULT 4
US-10-848-922-98
; Sequence 98, Application US/10848922
; Publication No. US20040235138A1
; GENERAL INFORMATION:
; APPLICANT: Weisburg, William G.
; APPLICANT: Bungo, Jennifer J.
; TITLE OF INVENTION: Compositions, Methods and Kits for Determining the Presence of
; TITLE OF INVENTION: Trichomonas Vaginalis in a Test Sample
; FILE REFERENCE: GP142-02.UT
; CURRENT APPLICATION NUMBER: US/10/848,922
; CURRENT FILING DATE: 2004-05-18
; PRIOR APPLICATION NUMBER: 60/472,028
; PRIOR FILING DATE: 2003-05-19
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 98
; LENGTH: 33
; TYPE: DNA

```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:24:23 ; Search time 5 Seconds
(without alignments)
5.228 Million cell updates/sec

Title: US-10-619-906-2
Perfect score: 1790
Sequence: 1 atgaatttctcatgatg.....aaaacggaattccgggga 1790

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 371 seqs, 7301 residues

Total number of hits satisfying chosen parameters: 742

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 372 summaries

Database : rnpb2.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	28.6	1.6	35	1	US-10-601-140A-11
2	28.6	1.6	35	1	US-10-601-140A-12
3	28	1.6	29	1	US-10-764-799-8
4	27.4	1.5	33	1	US-10-848-922-98
5	27	1.5	27	1	US-10-831-778-911
6	26	1.5	26	1	US-10-787-442-39
7	26	1.5	26	1	US-10-925-448-10
8	25.2	1.4	26	1	US-10-969-164-6
9	25.2	1.4	27	1	US-09-859-012-37
10	25.2	1.4	27	1	US-10-838-122-51
11	25	1.4	25	1	US-10-719-900-174229
12	25	1.4	25	1	US-10-719-900-309852
13	25	1.4	25	1	US-10-719-900-446213
14	25	1.4	25	1	US-10-719-900-480521
15	25	1.4	25	1	US-10-719-900-512977
16	25	1.4	25	1	US-10-719-900-611611
17	25	1.4	25	1	US-10-719-900-761329
18	25	1.4	25	1	US-10-719-900-860595
19	25	1.4	25	1	US-10-719-900-879471
20	25	1.4	25	1	US-10-719-900-908157
21	25	1.4	25	1	US-10-719-900-962529
22	25	1.4	25	1	US-10-809-189-125365
23	25	1.4	25	1	US-10-809-189-125366
24	25	1.4	25	1	US-10-809-189-125367
25	25	1.4	25	1	US-10-809-189-125368
26	25	1.4	25	1	US-10-809-189-125369
27	25	1.4	25	1	US-10-809-189-125370
28	25	1.4	25	1	US-10-809-189-125371
29	25	1.4	25	1	US-10-809-189-125372
30	25	1.4	25	1	US-10-809-189-125373
31	25	1.4	25	1	US-10-809-189-125374
32	25	1.4	25	1	US-10-809-189-125375
33	25	1.4	25	1	US-10-809-189-125376

34	25	1.4	25	1	US-10-809-189-125377	Sequence 125377,
35	25	1.4	25	1	US-10-809-189-125378	Sequence 125378,
36	25	1.4	25	1	US-10-809-189-125379	Sequence 125379,
37	25	1.4	25	1	US-10-809-189-125380	Sequence 125380,
38	25	1.4	25	1	US-10-809-189-125381	Sequence 125381,
39	25	1.4	25	1	US-10-809-189-125382	Sequence 125382,
40	25	1.4	25	1	US-10-809-189-125383	Sequence 125383,
41	25	1.4	25	1	US-10-809-189-125384	Sequence 125384,
42	25	1.4	26	1	US-10-787-442-38	Sequence 38, Appl
43	25	1.4	26	1	US-10-969-164-7	Sequence 7, Appl
44	25	1.4	28	1	US-10-942-251-8	Sequence 8, Appl
45	24.6	1.4	25	1	US-10-942-251-9	Sequence 9, Appl
46	24.4	1.4	28	1	US-10-942-251-12	Sequence 12, Appl
47	24	1.3	24	1	US-10-831-778-433	Sequence 433, App
48	24	1.3	24	1	US-10-831-778-961	Sequence 961, App
49	24	1.3	24	1	US-10-831-778-962	Sequence 962, App
50	24	1.3	24	1	US-10-357-930-14833	Sequence 14833, A
51	24	1.3	24	1	US-10-942-251-3	Sequence 3, Appl
52	23.4	1.3	25	1	US-10-719-900-174230	Sequence 174230,
53	23.4	1.3	25	1	US-10-719-900-309853	Sequence 309853,
54	23.4	1.3	25	1	US-10-719-900-446212	Sequence 446212,
55	23.4	1.3	25	1	US-10-719-900-480520	Sequence 480520,
56	23.4	1.3	25	1	US-10-719-900-512976	Sequence 512976,
57	23.4	1.3	25	1	US-10-719-900-611610	Sequence 611610,
58	23.4	1.3	25	1	US-10-719-900-761328	Sequence 761328,
59	23.4	1.3	25	1	US-10-719-900-860596	Sequence 860596,
60	23.4	1.3	25	1	US-10-719-900-879472	Sequence 879472,
61	23.4	1.3	25	1	US-10-719-900-908158	Sequence 908158,
62	23.4	1.3	25	1	US-10-719-900-962530	Sequence 962530,
63	22	1.2	24	1	US-10-721-793-285	Sequence 285, App
64	21	1.2	21	1	US-10-831-778-912	Sequence 912, App
65	21	1.2	21	1	US-10-751-736-11011	Sequence 11011, A
66	21	1.2	21	1	US-10-751-736-11014	Sequence 11014, A
67	21	1.2	21	1	US-10-830-287A-7	Sequence 7, Appl
68	21	1.2	21	1	US-10-601-140A-43	Sequence 43, Appl
69	20.8	1.2	24	1	US-10-872-063-161	Sequence 161, App
70	20.2	1.1	22	1	US-10-664-000-3	Sequence 3, Appl
71	20.2	1.1	22	1	US-10-601-140A-32	Sequence 32, Appl
72	20.2	1.1	22	1	US-10-601-140A-45	Sequence 45, Appl
73	20	1.1	20	1	US-09-976-900A-55	Sequence 55, Appl
74	20	1.1	20	1	US-10-661-415-12	Sequence 12, Appl
75	20	1.1	20	1	US-10-661-415-15	Sequence 15, Appl
76	20	1.1	20	1	US-10-831-778-236	Sequence 226, App
77	20	1.1	20	1	US-10-831-778-556	Sequence 556, App
78	20	1.1	20	1	US-10-831-778-560	Sequence 560, App
79	20	1.1	20	1	US-10-728-078-23	Sequence 23, Appl
80	20	1.1	20	1	US-10-601-140A-1	Sequence 1, Appl
81	20	1.1	20	1	US-10-601-140A-2	Sequence 2, Appl
82	20	1.1	20	1	US-10-601-140A-3	Sequence 3, Appl
83	20	1.1	20	1	US-10-601-140A-4	Sequence 4, Appl
84	20	1.1	20	1	US-10-601-140A-5	Sequence 5, Appl
85	20	1.1	20	1	US-10-601-140A-6	Sequence 6, Appl
86	20	1.1	20	1	US-10-601-140A-7	Sequence 7, Appl
87	20	1.1	20	1	US-10-601-140A-8	Sequence 8, Appl
88	20	1.1	20	1	US-10-601-140A-9	Sequence 9, Appl
89	20	1.1	20	1	US-10-601-140A-10	Sequence 10, Appl
90	20	1.1	20	1	US-10-601-140A-23	Sequence 23, Appl
91	20	1.1	20	1	US-10-601-140A-34	Sequence 34, Appl
92	20	1.1	20	1	US-10-601-140A-44	Sequence 44, Appl
93	20	1.1	20	1	US-10-876-086-49	Sequence 49, Appl
94	20	1.1	21	1	US-10-751-736-11012	Sequence 11012, A
95	20	1.1	21	1	US-10-913-246-23	Sequence 23, Appl
96	20	1.1	21	1	US-10-934-890-23	Sequence 23, Appl
97	19.4	1.1	21	1	US-10-751-736-10792	Sequence 10792, A
98	19.4	1.1	21	1	US-10-751-736-10822	Sequence 10822, A
99	19.4	1.1	21	1	US-10-751-736-11008	Sequence 11008, A
100	19.4	1.1	21	1	US-10-751-736-11125	Sequence 11125, A
101	19.2	1.1	24	1	US-09-776-479-60	Sequence 60, Appl
102	19.2	1.1	24	1	US-09-776-479-60	Sequence 60, Appl
103	19.2	1.1	24	1	US-10-112-653-54	Sequence 54, Appl
104	19.2	1.1	24	1	US-10-017-955-60	Sequence 60, Appl
105	19.2	1.1	24	1	US-10-314-578-60	Sequence 60, Appl
106	19.2	1.1	24	1	US-10-831-778-60	Sequence 60, Appl

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: May 13, 2005, 12:22:17 ; Search time 2 Seconds
(without alignments)
5.665 Million cell updates/sec

Title: US-10-619-906-2
Perfect score: 1790
Sequence: 1 agaaattctcatgatg.....aaaaacgggaattccgggga 1790

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 169 seqs, 3165 residues

Total number of hits satisfying chosen parameters: 338

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 172 summaries

Database : rn12.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	25.2	1.4	26	1	US-09-923-236-6
2	25	1.4	25	1	US-09-396-196G-125365
3	25	1.4	25	1	US-09-396-196G-125366
4	25	1.4	25	1	US-09-396-196G-125367
5	25	1.4	25	1	US-09-396-196G-125368
6	25	1.4	25	1	US-09-396-196G-125369
7	25	1.4	25	1	US-09-396-196G-125370
8	25	1.4	25	1	US-09-396-196G-125371
9	25	1.4	25	1	US-09-396-196G-125372
10	25	1.4	25	1	US-09-396-196G-125373
11	25	1.4	25	1	US-09-396-196G-125374
12	25	1.4	25	1	US-09-396-196G-125375
13	25	1.4	25	1	US-09-396-196G-125376
14	25	1.4	25	1	US-09-396-196G-125377
15	25	1.4	25	1	US-09-396-196G-125378
16	25	1.4	25	1	US-09-396-196G-125379
17	25	1.4	25	1	US-09-396-196G-125380
18	25	1.4	25	1	US-09-396-196G-125381
19	25	1.4	25	1	US-09-396-196G-125382
20	25	1.4	25	1	US-09-396-196G-125383
21	25	1.4	25	1	US-09-396-196G-125384
C 22	25	1.4	25	1	US-09-859-736-2
C 23	25	1.4	25	1	US-09-859-736-7
C 24	25	1.4	26	1	US-09-923-236-7
C 25	25	1.4	28	1	US-09-213-834B-8
C 26	24.6	1.4	25	1	US-09-213-834B-9
C 27	24.4	1.4	28	1	US-09-213-834B-12
C 28	24	1.3	24	1	US-09-926-028-28
C 29	24	1.3	24	1	US-09-213-834B-3
C 30	24	1.3	24	1	US-10-009-962-10
C 31	24	1.3	24	1	US-09-859-736-5
C 32	21.8	1.2	26	1	US-09-853-646A-3
C 33	21	1.2	21	1	US-09-859-736-6

Sequence 4, Appli	1	US-09-853-646A-4	25	1.2	20.8	34
Sequence 55, Appl	20	US-09-976-618A-55	20	1.1	20	35
Sequence 55, Appl	20	US-09-976-968A-55	20	1.1	20	36
Sequence 10, Appl	20	US-10-234-764-10	20	1.1	20	37
Sequence 55, Appl	20	US-09-975-059A-55	20	1.1	20	38
Sequence 3, Appli	20	US-09-859-736-3	20	1.1	20	39
Sequence 4, Appli	20	US-09-859-736-4	20	1.1	20	40
Sequence 4459, Ap	21	US-09-696-791-4459	21	1.1	19	41
Sequence 25, Appl	23	US-08-287-959-25	23	1.0	18.6	42
Sequence 84, Appl	18	US-09-809-545A-84	18	1.0	18	43
Sequence 12, Appl	18	US-10-352-704-12	18	1.0	18	44
Sequence 18, Appl	18	US-10-352-704-18	18	1.0	18	45
Sequence 132, App	17	US-09-766-253-132	17	0.9	17	46
Sequence 1075, Ap	17	US-09-685-664B-1075	17	0.9	17	47
Sequence 1070, Ap	18	US-08-390-850-1070	18	0.9	17	48
Sequence 1070, Ap	18	US-08-435-634-1070	18	0.9	17	49
Sequence 3, Appli	21	US-08-338-355-3	21	0.9	16.8	50
Sequence 1, Appli	18	US-09-904-744-1	18	0.9	16.4	51
Sequence 131, App	16	US-09-766-253-131	16	0.9	16	52
Sequence 1074, Ap	17	US-09-685-664B-1074	17	0.9	16	53
Sequence 1076, Ap	17	US-09-685-664B-1076	17	0.9	16	54
Sequence 105, App	17	US-09-090-672B-105	17	0.9	16	55
Sequence 106, App	17	US-09-090-672B-106	17	0.9	16	56
Sequence 107, App	17	US-09-090-672B-107	17	0.9	16	57
Sequence 2, Appli	18	US-09-304-744-2	18	0.9	16	58
Sequence 80, Appl	20	US-09-844-521-80	20	0.9	16	59
Sequence 4044, Ap	19	US-09-696-791-4044	19	0.9	15.8	60
Sequence 495, App	17	US-08-390-850-495	17	0.9	15.4	61
Sequence 495, App	17	US-08-435-634-495	17	0.9	15.4	62
Sequence 10432, A	17	US-09-866-108A-10432	17	0.9	15.4	63
Sequence 1077, Ap	17	US-09-685-664B-1077	17	0.9	15.4	64
Sequence 558, App	15	US-09-081-646-558	15	0.8	15	65
Sequence 10, Appl	15	US-10-352-704-10	15	0.8	15	66
Sequence 16, Appl	15	US-10-352-704-16	15	0.8	15	67
Sequence 1073, Ap	17	US-09-685-664B-1073	17	0.8	15	68
Sequence 21, Appl	18	US-08-390-850-21	18	0.8	14.8	69
Sequence 1074, Ap	18	US-08-390-850-1074	18	0.8	14.8	70
Sequence 1117, Ap	18	US-08-390-850-1117	18	0.8	14.8	71
Sequence 1129, Ap	18	US-08-390-850-1129	18	0.8	14.8	72
Sequence 21, Appl	18	US-08-435-634-21	18	0.8	14.8	73
Sequence 1074, Ap	18	US-08-435-634-1074	18	0.8	14.8	74
Sequence 1117, Ap	18	US-08-435-634-1117	18	0.8	14.8	75
Sequence 1129, Ap	18	US-08-435-634-1129	18	0.8	14.8	76
Sequence 36, Appl	18	US-09-255-893-36	18	0.8	14.8	77
Sequence 5494, Ap	18	US-09-422-978-5494	18	0.8	14.8	78
Sequence 6065, Ap	16	US-09-371-772B-6065	16	0.8	14.4	79
Sequence 6066, Ap	16	US-09-371-772B-6066	16	0.8	14.4	80
Sequence 177, App	16	US-09-479-005A-177	16	0.8	14.4	81
Sequence 446, App	17	US-08-390-850-446	17	0.8	14.4	82
Sequence 2083, Ap	17	US-08-373-124A-2083	17	0.8	14.4	83
Sequence 446, App	17	US-08-435-634-446	17	0.8	14.4	84
Sequence 2083, Ap	17	US-08-435-634-2083	17	0.8	14.4	85
Sequence 2690, Ap	17	US-08-584-040-2690	17	0.8	14.4	86
Sequence 2690, Ap	17	US-09-371-772B-2690	17	0.8	14.4	87
Sequence 5541, Ap	17	US-09-371-772B-5541	17	0.8	14.4	88
Sequence 10431, A	17	US-09-866-108A-10431	17	0.8	14.4	89
Sequence 10433, A	17	US-09-866-108A-10433	17	0.8	14.4	90
Sequence 1078, Ap	17	US-09-685-664B-1078	17	0.8	14.4	91
Sequence 2690, Ap	17	US-09-685-664B-2690	17	0.8	14.4	92
Sequence 108, App	18	US-09-402-618B-108	18	0.8	14.4	93
Sequence 7, Appli	14	US-09-859-736-7	14	0.8	14	94
Sequence 14, Appl	16	US-08-527-060-14	16	0.8	14	95
Sequence 441, App	16	US-09-479-005A-441	16	0.8	14	96
Sequence 4149, Ap	16	US-09-696-791-4149	16	0.8	14	97
Sequence 4370, Ap	16	US-09-696-791-4370	16	0.8	14	98
Sequence 823, App	17	US-09-827-998-823	17	0.8	14	99
Sequence 824, App	17	US-09-827-998-824	17	0.8	14	100
Sequence 825, App	17	US-09-827-998-825	17	0.8	14	101
Sequence 826, App	17	US-09-827-998-826	17	0.8	14	102
Sequence 10439, A	17	US-09-866-108A-10439	17	0.8	14	103
Sequence 10430, A	17	US-09-866-108A-10430	17	0.8	14	104
						105
						106

```
107 14 0.8 17 1 US-09-404-912-219 Sequence 219, App
108 14 0.8 17 1 US-09-685-664B-1072 Sequence 1072, Ap
109 13.8 0.8 17 1 US-08-281-940-29 Sequence 29, Appl
110 13.8 0.8 17 1 US-08-390-850-496 Sequence 496, App
111 13.8 0.8 17 1 US-08-390-850-497 Sequence 497, App
112 13.8 0.8 17 1 US-08-390-850-516 Sequence 516, App
113 13.8 0.8 17 1 US-08-390-850-517 Sequence 517, App
114 13.8 0.8 17 1 US-08-390-850-537 Sequence 537, App
115 13.8 0.8 17 1 US-08-390-850-538 Sequence 538, App
116 13.8 0.8 17 1 US-08-390-850-540 Sequence 540, App
117 13.8 0.8 17 1 US-08-390-850-541 Sequence 541, App
118 13.8 0.8 17 1 US-08-390-850-609 Sequence 609, App
119 13.8 0.8 17 1 US-08-390-850-694 Sequence 694, App
120 13.8 0.8 17 1 US-08-435-634-496 Sequence 496, App
121 13.8 0.8 17 1 US-08-435-634-497 Sequence 497, App
122 13.8 0.8 17 1 US-08-435-634-516 Sequence 516, App
123 13.8 0.8 17 1 US-08-435-634-517 Sequence 517, App
124 13.8 0.8 17 1 US-08-435-634-537 Sequence 537, App
125 13.8 0.8 17 1 US-08-435-634-538 Sequence 538, App
126 13.8 0.8 17 1 US-08-435-634-540 Sequence 540, App
127 13.8 0.8 17 1 US-08-435-634-541 Sequence 541, App
128 13.8 0.8 17 1 US-08-435-634-609 Sequence 609, App
129 13.8 0.8 17 1 US-08-435-634-694 Sequence 694, App
130 13.8 0.8 17 1 US-08-710-134-29 Sequence 29, Appl
131 13.8 0.8 17 1 US-08-485-885-29 Sequence 35, Appl
132 13.8 0.8 17 1 US-09-077-205-35 Sequence 2292, Ap
133 13.8 0.8 17 1 US-08-584-040-2292 Sequence 6127, Ap
134 13.8 0.8 17 1 US-08-584-040-6127 Sequence 6128, Ap
135 13.8 0.8 17 1 US-08-584-040-7818 Sequence 7818, Ap
136 13.8 0.8 17 1 US-08-584-040-7819 Sequence 7819, Ap
137 13.8 0.8 17 1 US-09-060-299-354 Sequence 354, App
138 13.8 0.8 17 1 US-09-402-923A-354 Sequence 354, App
139 13.8 0.8 17 1 US-09-371-772B-837 Sequence 837, App
140 13.8 0.8 17 1 US-09-371-772B-2964 Sequence 2964, Ap
141 13.8 0.8 17 1 US-09-371-772B-2965 Sequence 2965, Ap
142 13.8 0.8 17 1 US-09-371-772B-2965 Sequence 3602, Ap
143 13.8 0.8 17 1 US-09-371-772B-3602 Sequence 3603, Ap
144 13.8 0.8 17 1 US-09-371-772B-3603 Sequence 423, App
145 13.8 0.8 17 1 US-09-827-998-423 Sequence 821, App
146 13.8 0.8 17 1 US-09-827-998-821 Sequence 822, App
147 13.8 0.8 17 1 US-09-827-998-822 Sequence 822, App
148 13.8 0.8 17 1 US-09-866-108A-874 Sequence 10428, A
149 13.8 0.8 17 1 US-09-866-108A-10428 Sequence 10434, A
150 13.8 0.8 17 1 US-09-866-108A-10434 Sequence 837, App
151 13.8 0.8 17 1 US-09-685-664B-837 Sequence 2964, Ap
152 13.8 0.8 17 1 US-09-685-664B-2964 Sequence 2965, Ap
153 13.8 0.8 17 1 US-09-685-664B-2965 Sequence 3602, Ap
154 13.8 0.8 17 1 US-09-685-664B-3602 Sequence 3603, Ap
155 13.8 0.8 17 1 US-09-685-664B-3603 Sequence 41, Appl
156 13.4 0.7 15 1 US-08-292-620A-41 Sequence 1740, Ap
157 13.4 0.7 15 1 US-08-595-684B-1740 Sequence 41, Appl
158 13.4 0.7 15 1 US-09-071-845-41 Sequence 1740, Ap
159 13.4 0.7 15 1 US-09-038-073-1740 Sequence 134, App
160 13.4 0.7 16 1 US-08-753-147-134 Sequence 6067, Ap
161 13.4 0.7 16 1 US-09-371-772B-6067 Sequence 93, Appl
162 13 0.7 16 1 US-08-291-932A-93 Sequence 2, Appli
163 13 0.7 16 1 US-08-864-224-2 Sequence 125371,
164 13 0.7 16 1 US-09-122-384-2 Sequence 125372,
165 13 0.7 25 1 US-09-386-196G-125371 Sequence 134, App
166 13 0.7 25 1 US-09-396-196G-125372 Sequence 5, Appli
167 12.8 0.7 16 1 US-08-753-147-134 Sequence 5, Appli
168 12.8 0.7 16 1 US-08-667-338B-5 Sequence 7106, Ap
169 12.8 0.7 16 1 US-09-179-665-5 Sequence 185, App
170 12.8 0.7 16 1 US-09-371-772B-7106 Sequence 7, Appli
171 12.8 0.7 16 1 US-09-479-005A-185
172 12.8 0.7 16 1 US-09-931-381A-7
```

Sequence 219, App
Sequence 1072, Ap
Sequence 29, Appl
Sequence 496, App
Sequence 497, App
Sequence 516, App
Sequence 517, App
Sequence 537, App
Sequence 538, App
Sequence 540, App
Sequence 541, App
Sequence 609, App
Sequence 694, App
Sequence 694, App
Sequence 496, App
Sequence 497, App
Sequence 516, App
Sequence 517, App
Sequence 537, App
Sequence 538, App
Sequence 540, App
Sequence 541, App
Sequence 609, App
Sequence 694, App
Sequence 694, App
Sequence 496, App
Sequence 497, App
Sequence 516, App
Sequence 517, App
Sequence 537, App
Sequence 538, App
Sequence 540, App
Sequence 541, App
Sequence 609, App
Sequence 694, App
Sequence 694, App
Sequence 29, Appl
Sequence 35, Appl
Sequence 2292, Ap
Sequence 6127, Ap
Sequence 6128, Ap
Sequence 7818, Ap
Sequence 7819, Ap
Sequence 354, App
Sequence 354, App
Sequence 837, App
Sequence 2964, Ap
Sequence 2965, Ap
Sequence 3602, Ap
Sequence 3603, Ap
Sequence 423, App
Sequence 821, App
Sequence 822, App
Sequence 822, App
Sequence 10428, A
Sequence 10434, A
Sequence 837, App
Sequence 2964, Ap
Sequence 2965, Ap
Sequence 3602, Ap
Sequence 3603, Ap
Sequence 41, Appl
Sequence 1740, Ap
Sequence 41, Appl
Sequence 1740, Ap
Sequence 134, App
Sequence 6067, Ap
Sequence 93, Appl
Sequence 2, Appli
Sequence 125371,
Sequence 125372,
Sequence 134, App
Sequence 5, Appli
Sequence 5, Appli
Sequence 7106, Ap
Sequence 185, App
Sequence 7, Appli

Sequence 6, Application US/09923236
Patent No. 6828419
GENERAL INFORMATION:
APPLICANT: Sheppard, Paul O.
APPLICANT: Adler, David A.
TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
FILE REFERENCE: 97-71
CURRENT APPLICATION NUMBER: US/09/923,236
CURRENT FILING DATE: 2001-08-03
PRIOR APPLICATION NUMBER: US 60/124,820
PRIOR FILING DATE: 1999-03-17
NUMBER OF SEQ ID NOS: 9
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 6
LENGTH: 26
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer ZC7231
US-09-923-236-6

Query Match 1.4%; Score 25.2; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 12;
Matches 25; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1773
:|||||
Db 26 BAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 2
US-09-396-196G-125365
Sequence 125365, Application US/09396196G
Patent No. 6821724
GENERAL INFORMATION:
APPLICANT: Michael Mittmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1
CURRENT APPLICATION NUMBER: US/09/396,196G
CURRENT FILING DATE: 1999-09-15
PRIOR APPLICATION NUMBER: 60/100,678
PRIOR FILING DATE: 1998-09-17
NUMBER OF SEQ ID NOS: 127806
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 125365
LENGTH: 25
TYPE: DNA
ORGANISM: mus musculus
US-09-396-196G-125365

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1237 ACACACTTCCAGGATCAAGCCTA 1261
|||||
Db 1 ACACACTTCCAGGATCAAGCCTA 25

RESULT 3
US-09-396-196G-125366
Sequence 125366, Application US/09396196G
Patent No. 6821724
GENERAL INFORMATION:
APPLICANT: Michael Mittmann
APPLICANT: David Mack
APPLICANT: David Lockhart
APPLICANT: Affymetrix, Inc.
TITLE OF INVENTION: Methods of Genetic Analysis
FILE REFERENCE: 3101.1

Query Match 1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Db      1 ACTCTATGCTCAGGGTGTAACATG 25

RESULT 8
US-09-396-196G-125371
; Sequence 125371, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125371
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125371

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1513 CAGGTCACACACATAGTTACACA 1537
Db      1 CAGGTCACACACATAGTTACACA 25

RESULT 9
US-09-396-196G-125372
; Sequence 125372, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125372
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125372

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1516 GTCACACACACATAGTTACACAGAA 1540
Db      1 GTCACACACACATAGTTACACAGAA 25

RESULT 10
US-09-396-196G-125373
; Sequence 125373, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
```

```
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125373
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125373

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1588 TTCTATTCTTAATTTGAAAGTGCA 1612
Db      1 TTCTATTCTTAATTTGAAAGTGCA 25

RESULT 11
US-09-396-196G-125374
; Sequence 125374, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125374
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125374

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1612 ATGGTTCAGAGGCCCACTGGTTTAT 1636
Db      1 ATGGTTCAGAGGCCCACTGGTTTAT 25

RESULT 12
US-09-396-196G-125375
; Sequence 125375, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
```

```
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125375
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125375

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1681 AGAATTACTCTCTGTCTTACTGCA 1705
      |||||
Db 1 AGAATTACTCTCTGTCTTACTGCA 25

RESULT 13
US-09-396-196G-125376
; Sequence 125376, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125376
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125376

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1684 ATTACTCTCTGTCTTACTGAAAT 1708
      |||||
Db 1 ATTACTCTCTGTCTTACTGAAAT 25

RESULT 14
US-09-396-196G-125377
; Sequence 125377, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125377
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125377

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1684 ATTACTCTCTGTCTTACTGAAAT 1708
      |||||
Db 1 ATTACTCTCTGTCTTACTGAAAT 25

RESULT 15
US-09-396-196G-125378
; Sequence 125378, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125378
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125378

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1273 GTCTCTATTTCAAAAGACACTACT 1297
      |||||
Db 1 GTCTCTATTTCAAAAGACACTACT 25

RESULT 16
US-09-396-196G-125379
; Sequence 125379, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 125379
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125379

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1279 TATTTCAAAAGACACTACTACTCT 1303
      |||||
Db 1 TATTTCAAAAGACACTACTACTCT 25

RESULT 17
```

File Reference	Score	DB	Length	Indels	Gaps
US-09-396-196G-125380	1.4%	25	25	0	0
Sequence 125380, Application US/09396196G					
Patent No. 6821724					
GENERAL INFORMATION:					
APPLICANT: Michael Mittmann					
APPLICANT: David Mack					
APPLICANT: David Lockhart					
APPLICANT: Affymetrix, Inc.					
TITLE OF INVENTION: Methods of Genetic Analysis					
FILE REFERENCE: 3101.1					
CURRENT APPLICATION NUMBER: US/09/396,196G					
CURRENT FILING DATE: 1999-09-15					
PRIOR FILING DATE: 1998-09-17					
NUMBER OF SEQ ID NOS: 127806					
SOFTWARE: FastSEQ for Windows Version 4.0					
SEQ ID NO 125380					
LENGTH: 25					
TYPE: DNA					
ORGANISM: mus musculus					
US-09-396-196G-125380					
Query Match	1.4%	25	25	0	0
Best Local Similarity	100.0%	Pred. No. 11			
Matches	25	Conservative	0	Mismatches	0
Db					
1					
TACATCTTCCAGGAGCCTATCAAT					
1					
TACATCTTCCAGGAGCCTATCAAT					
RESULT 18					
US-09-396-196G-125381					
Sequence 125381, Application US/09396196G					
Patent No. 6821724					
GENERAL INFORMATION:					
APPLICANT: Michael Mittmann					
APPLICANT: David Mack					
APPLICANT: David Lockhart					
APPLICANT: Affymetrix, Inc.					
TITLE OF INVENTION: Methods of Genetic Analysis					
FILE REFERENCE: 3101.1					
CURRENT APPLICATION NUMBER: US/09/396,196G					
CURRENT FILING DATE: 1999-09-15					
PRIOR FILING DATE: 1998-09-17					
NUMBER OF SEQ ID NOS: 127806					
SOFTWARE: FastSEQ for Windows Version 4.0					
SEQ ID NO 125381					
LENGTH: 25					
TYPE: DNA					
ORGANISM: mus musculus					
US-09-396-196G-125381					
Query Match	1.4%	25	25	0	0
Best Local Similarity	100.0%	Pred. No. 11			
Matches	25	Conservative	0	Mismatches	0
Db					
1					
TTCAGGAGCCTATCAATGGAAT					
1					
TTCAGGAGCCTATCAATGGAAT					
RESULT 19					
US-09-396-196G-125382					
Sequence 125382, Application US/09396196G					
Patent No. 6821724					
GENERAL INFORMATION:					
APPLICANT: Michael Mittmann					
APPLICANT: David Mack					
APPLICANT: David Lockhart					
APPLICANT: Affymetrix, Inc.					
TITLE OF INVENTION: Methods of Genetic Analysis					
FILE REFERENCE: 3101.1					
CURRENT APPLICATION NUMBER: US/09/396,196G					
CURRENT FILING DATE: 1999-09-15					
PRIOR FILING DATE: 1998-09-17					
NUMBER OF SEQ ID NOS: 127806					
SOFTWARE: FastSEQ for Windows Version 4.0					
SEQ ID NO 125382					
LENGTH: 25					
TYPE: DNA					
ORGANISM: mus musculus					
US-09-396-196G-125382					
Query Match	1.4%	25	25	0	0
Best Local Similarity	100.0%	Pred. No. 11			
Matches	25	Conservative	0	Mismatches	0
Db					
1					

```
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-125384

Query Match      1.4%  Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1339 TTCGGTGTGTCACCAAAACATTGA 1363
Db 1 TTCGGTGTGTCACCAAAACATTGA 25

RESULT 22
US-09-859-736-1/c
; Sequence 1, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATB oligonucleotide
US-09-859-736-1

Query Match      1.4%  Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 23
US-09-859-736-2/c
; Sequence 2, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CATB oligonucleotide
US-09-859-736-2

Query Match      1.4%  Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 24
US-09-923-236-7/c
; Sequence 7, Application US/09923236
; Patent No. 6828419
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Adler, David A.
; TITLE OF INVENTION: SECRETED SALIVARY ZSIG63 POLYPEPTIDE
; FILE REFERENCE: 97-71
; CURRENT APPLICATION NUMBER: US/09/923,236
; CURRENT FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: US 60/124,820
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC7764a
US-09-923-236-7

Query Match      1.4%  Score 25; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1773
Db 25 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 25
US-09-213-834B-8/c
; Sequence 8, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; TITLE OF INVENTION: NUCLEIC ACIDS INTO CIRCULAR VECTORS
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
US-09-213-834B-8

Query Match      1.4%  Score 25; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1752 AAAAAAAAAAAAAAAAAAAAAA 1776
Db 28 AAAAAAAAAAAAAAAAAAAAAA 4

RESULT 26
US-09-213-834B-9/c
; Sequence 9, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
```

```
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
;
US-09-213-834B-9

Query Match      1.4%; Score 24.6; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 13;
Matches 24; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1752 AAAAAAAAAAAAAAAAAAAAAAC 1776
Db 25 AAAAAAAAAAAAAAAAAAAAAAA 1

RESULT 27
US-09-213-834B-12/c
; Sequence 12, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
;
US-09-213-834B-12

Query Match      1.4%; Score 24.4; DB 1; Length 28;
Best Local Similarity 96.2%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1752 AAAAAAAAAAAAAAAAAAAAAACG 1777
Db 28 AAAAAAAAAAAAAAAAAAAAAAG 3

RESULT 28
US-09-926-028-28
; Sequence 28, Application US/09926028
; Patent No. 6806049
; GENERAL INFORMATION:
; APPLICANT: MAEKAWA, TAKAMI
; APPLICANT: MITSUI, AKIRA
; APPLICANT: DATE, MASAYO
; APPLICANT: FUKUDA, HISAO
; APPLICANT: TAKAHARA, YOSHIYUKI
; TITLE OF INVENTION: METHOD FOR ANALYZING EXPRESSION FREQUENCIES OF GENES
; FILE REFERENCE: 212833USOPCT
; CURRENT APPLICATION NUMBER: US/09/926,028
; CURRENT FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: PCT/JP00/00902
; PRIOR FILING DATE: 2000-02-17
; PRIOR APPLICATION NUMBER: JP 11-038538
; PRIOR FILING DATE: 1999-02-17

; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic DNA
;
US-09-926-028-28

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAA 1772
Db 1 AAAAAAAAAAAAAAAAAAAAA 24

RESULT 29
US-09-213-834B-3/c
; Sequence 3, Application US/09213834B
; Patent No. 6825011
; GENERAL INFORMATION:
; APPLICANT: Romantchikov, Yuri
; TITLE OF INVENTION: IMPROVED METHODS FOR INSERTION OF
; FILE REFERENCE: 11639/1
; CURRENT APPLICATION NUMBER: US/09/213,834B
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cloning Vector
;
US-09-213-834B-3

Query Match      1.3%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAAAAAAA 1772
Db 24 AAAAAAAAAAAAAAAAAAAAA 1

RESULT 30
US-10-009-962-10/c
; Sequence 10, Application US/10009962
; Patent No. 6825321
; GENERAL INFORMATION:
; APPLICANT: ITO, KIKUKATSU
; TITLE OF INVENTION: Plant Thermogenic Genes and Proteins
; FILE REFERENCE: 2001-1838A/LC/00653
; CURRENT APPLICATION NUMBER: US/10/009,962
; CURRENT FILING DATE: 2002-01-23
; PRIOR APPLICATION NUMBER: PCT/JP00/03806
; PRIOR FILING DATE: 2000-06-12
; PRIOR APPLICATION NUMBER: JP11-167439
; PRIOR FILING DATE: 1999-06-14
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 10
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

Query Match 1.2%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 39;..
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-976-968A-55

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.25;
Matches 20; Conservative 0; Mismatches 0; Indels

Qy      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
      |||||
Db      1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 37
US-10-234-764-10/c
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lomborg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-10

Query Match      1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.25;
Matches 20; Conservative 0; Mismatches 0; Indels

Qy      1749 AAAAAAAAAAAAAAAAAAAAAA 1768
      |||||
Db      20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 38
US-09-975-059A-55
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.

```


; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-115
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 1 AAAAAAAAAAAAAAAAAAAAAA 20

RESULT 39
US-09-859-736-3/c
; Sequence 3, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CAT1 oligonucleotide
US-09-859-736-3

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 40

US-09-859-736-4/c
; Sequence 4, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: CAT2 oligonucleotide
US-09-859-736-4

Query Match 1.1%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAAAAAA 1768
Db 20 AAAAAAAAAAAAAAAAAAAAAA 1

RESULT 41
US-09-696-791-4459
; Sequence 4459, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4459
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; OTHER INFORMATION: MMP-3 ribozyme recognition site
US-09-696-791-4459

Query Match 1.1%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATGGA 768
Db 3 CATTGAGTCCCTCTATGGA 21

RESULT 42
US-08-287-959-25/c
; Sequence 25, Application US/08287959
; Patent No. 5639651
; GENERAL INFORMATION:
; APPLICANT: Weissbach, Lawrence
; APPLICANT: Bernards, Andre
; APPLICANT: Settleman, Jeffrey
; TITLE OF INVENTION: GAP-RELATED GENE
; NUMBER OF SEQUENCES: 26

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: U.S.A.
; ZIP: 02110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/287,959
; FILING DATE: August 9, 1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul C.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 00786/181001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-287-959-25

Query Match 1.0%; Score 18.6; DB 1; Length 23;
Best Local Similarity 73.9%; Pred. No. 57;
Matches 17; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 631 CATGAACCTTGGCCATTCCTTGGG 653
Db 23 CATGAATTTGGCCAYKVBCTGGG 1

RESULT 43
US-09-809-545A-84/c
; Sequence 84, Application US/09809545A
; Patent No. 6800455
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.017A
; CURRENT APPLICATION NUMBER: US/09/809,545A
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 44
US-09-809-545A-84

US-10-352-704-12/c
; Sequence 12, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; Kumarev, Viktor
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
; APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
Db 18 AAAAAAAAAAAAAAAAAA 1

RESULT 45
US-10-352-704-18
; Sequence 18, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; Kumarev, Viktor
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its

```

;
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; STATE: D.C
; COUNTRY: U.S.A.
; ZIP: 20004
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William B.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 638-6666
; TELEFAX: (202) 393-5350
; TELE: RCA 248593 IDEA UR
;
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18

Query Match 1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1766
DB 1 AAAAAAAAAAAAAAAAAA 18

RESULT 46
US-09-766-253-132/c
; Sequence 132, Application US/09766253
; Patent No. 6808880
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; LINGNER, Joachim
; Nakamura, Toru
; Chapman, Karen B.
; Morin, Gregg B.
; Harley, Calvin
; Andrews, William H.
; TITLE OF INVENTION: No. 6808880el Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor

```

```

;
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/766,253
; FILING DATE: 19-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,017
; FILING DATE: 1997-04-25
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002920US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
;
; INFORMATION FOR SEQ ID NO: 132:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 132:
US-09-766-253-132

Query Match 0.9%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAAAAAA 1765
DB 17 AAAAAAAAAAAAAAAAAA 1

RESULT 47
US-09-685-664B-1075/c
; Sequence 1075, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1075

Query Match 0.9%; Score 17; DB 1; Length 17;

```

Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAA1764
Db 17 GAAAAA1

RESULT 48

US-08-390-850-1070
; Sequence 1070, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1070:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-1070

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 44;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATG 766
Db 2 CAUCAGUCCCUAUG 18

RESULT 49

US-08-435-634-1070
; Sequence 1070, Application US/08435634

; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1070:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-1070

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 44;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 750 CATTGAGTCCCTCTATG 766
Db 2 CAUCAGUCCCUAUG 18

RESULT 50

US-08-338-355-3
; Sequence 3, Application US/08338355
; Patent No. 5583035
; GENERAL INFORMATION:
; APPLICANT: Kretschmer, Axel; Antonicek, Horst-
; APPLICANT: Peter; Baumgarten, Jorg; Loebberding,
; APPLICANT: Antonius; Mielke, Burkhard; Springer,
; APPLICANT: Wolfgang; Stropp, Udo; Struck, Mark-
; APPLICANT: Michael; Biesent, Lothar; Rubsamen-
; APPLICANT: Walmann, Helga; Sunartono, Hary;

```

; APPLICANT: Hausner, Thomas-Peter
; TITLE OF INVENTION: EXPRESSION VECTORS AND THEIR
; TITLE OF INVENTION: USE IN THE PREPARATION OF HIV-
; TITLE OF INVENTION: RESISTANT HUMAN CELLS FOR
; TITLE OF INVENTION: THERAPEUTIC APPLICATIONS
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SPRUNG HORN KRAMER & WOODS
; STREET: 660 White Plains Road
; CITY: Tarrytown
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10591-5144
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 720 KB storage
; COMPUTER: Sharp PC-4600
; OPERATING SYSTEM: DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/338,355
; FILING DATE: 14-NOV-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/987,506
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Kurt G. Briscoe
; REGISTRATION NUMBER: 33,141
; REFERENCE/DOCKET NUMBER: Bayer 8638-KGB
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (914) 332-1700
; TELEFAX: (914) 332-1844
; TELEX:
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-338-355-3

```

```

Query Match 0.9%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 72;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1575 TTTTTCACCTTCATTCTACT 1594
DB 1 TTTTTCACCTGCATTCTACT 20

```

```

RESULT 51
US-09-904-744-1
; Sequence 1, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbra-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; TITLE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: synthesized
; US-09-904-744-1
;
Query Match 0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
;
QY 1746 GTGAAAAAAAAAAAAAAAAA 1763
DB 1 GCGAAAAAAAAAAAAAAAAA 18
;
RESULT 52
US-09-766-253-131
; Sequence 131, Application US/09766253
; Patent No. 6808880
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; Liringer, Joachim
; Nakamura, Toru
; Chapman, Karen B.
; Morin, Gregg B.
; Harley, Calvin
; Andrews, William H.
; TITLE OF INVENTION: No. 6808880el Telomerase
; NUMBER OF SEQUENCES: 171
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/766,253
; FILING DATE: 19-Jan-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/846,017
; FILING DATE: 1997-04-25
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002920US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 131:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 131:
;
US-09-766-253-131

```

```

Query Match 0.9%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY 1749 AAAAAAAAAAAAAAAAAA 1764
DB 1 AAAAAAAAAAAAAAAAAA 16

```

RESULT 53
US-09-685-664B-1074/c
; Sequence 1074, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1074

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1749 AAAAAAAAAAAAAA 1764
Db 17 AAAAAAAAAAAAAA 2

RESULT 54
US-09-685-664B-1076/c
; Sequence 1076, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1076
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1076

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1748 AAAAAAAAAAAAAA 1763
Db 17 AAAAAAAAAAAAAA 2

Db 16 GAAAAAAAAAAAAA 1

RESULT 55
US-09-090-672B-105/c
; Sequence 105, Application US/09090672B
; Patent No. 6828428
; GENERAL INFORMATION:
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Masami
; APPLICANT: Shigemasa, Takei, Masami
; TITLE OF INVENTION: IGA Nephropathy-Related Genes
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; ZIP: 10112-3801
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: Compaq PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/090,672B
; FILING DATE: 04-JUNE-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP97/04468
; FILING DATE: 05-DEC-1997
; APPLICATION NUMBER: JP-8-325763
; FILING DATE: 05-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; REFERENCE/DOCKET NUMBER: 766.21
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 218-2100
; TELEFAX: (212) 218-2200
; INFORMATION FOR SEQ ID NO: 105:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-105

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1761 AAAAAAAAAAAAAA 1776
Db 16 AAAAAAAAAAAAAA 1

RESULT 56
US-09-090-672B-106/c
; Sequence 106, Application US/09090672B
; Patent No. 6828428
; GENERAL INFORMATION:
; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Masami
; APPLICANT: Shigemasa, Takei, Masami
; TITLE OF INVENTION: IGA Nephropathy-Related Genes
; NUMBER OF SEQUENCES: 111
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York

ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Compaq PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Wordperfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/090,672B
FILING DATE: 04-JUNE-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP97/04468
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: JP-8-325763
FILING DATE: 05-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
REFERENCE/DOCKET NUMBER: 766.21
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 218-2100
TELEFAX: (212) 218-2200
INFORMATION FOR SEQ ID NO: 106:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-106

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1761 AAAAAAAAAAAAAAC 1776
DB 16 AAAAAAAAAAAAAAC 1

RESULT 57
US-09-090-672B-107/c
Sequence 107, Application US/09090672B
Patent No. 6828428
GENERAL INFORMATION:
APPLICANT: Ishiwa, Tetsuyoshi; Sakurada, Mikiko; Nishimura,
APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,
APPLICANT: Shigemasa; Takeda, Masami
TITLE OF INVENTION: Iga Nephropathy-Related Genes
NUMBER OF SEQUENCES: 111
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
COMPUTER: Compaq PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Wordperfect 8.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/090,672B
FILING DATE: 04-JUNE-1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/JP97/04468
FILING DATE: 05-DEC-1997
APPLICATION NUMBER: JP-8-325763
FILING DATE: 05-DEC-1996
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865

REFERENCE/DOCKET NUMBER: 766.21
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 218-2100
TELEFAX: (212) 218-2200
INFORMATION FOR SEQ ID NO: 107:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-107

Query Match 0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1748 GAAAAAAAAAAAAA 1763
DB 17 GAAAAAAAAAAAAA 2

RESULT 58
US-09-904-744-2/c
Sequence 2, Application US/09904744
Patent No. 6828142
GENERAL INFORMATION:
APPLICANT: Barbera-Guillem, Emilio
APPLICANT: Nelson, M. Bud
APPLICANT: Castro, Stephanie
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
FILE REFERENCE: B-73
CURRENT APPLICATION NUMBER: US/09/904,744
CURRENT FILING DATE: 2001-07-13
PRIOR APPLICATION NUMBER: 09/437076
PRIOR FILING DATE: 1999-11-09
PRIOR APPLICATION NUMBER: 60/107828
PRIOR FILING DATE: 1998-11-10
NUMBER OF SEQ ID NOS: 6
SOFTWARE: PatentIn version 3.0
SEQ ID NO 2
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: synthesized
US-09-904-744-2

Query Match 0.9%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
DB 18 AAAAAAAAAAAAAAC 3

RESULT 59
US-09-844-521-80
Sequence 80, Application US/09844521
Patent No. 6492172
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Harris Busch
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF GU PROTEIN EXPRESSION
FILE REFERENCE: RTS-0163
CURRENT APPLICATION NUMBER: US/09/844,521
CURRENT FILING DATE: 2001-04-27
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 80
LENGTH: 20

```
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-09-844-521-80

Query Match          0.9%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1294 TACTACATCTTCAAG 1309
Db      |||||
5 TACTACATCTTCAAG 20

RESULT 60
US-09-696-791-4044
; Sequence 4044, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4044
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: PCNA HH ribozyme binding site
US-09-696-791-4044

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1717 TTTTGTCTTCTTTAAATAA 1735
Db      |||||
1 TATTGTTTCTGTAAATAA 19

RESULT 61
US-08-390-850-495
; Sequence 495, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: December 12, 1993
```

```
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/390,850
/ FILING DATE: February 17, 1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5612215ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 495:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-390-850-495

Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 60;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 616 TTCTTGTGCTGTCA 632
Db      |||||
1 UUUUUUUUGUGUCUCA 17

RESULT 62
US-08-435-634-495
; Sequence 495, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
```


; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 495:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-495

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 60;
Matches 8; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

QY 616 TTCTTGTGCTGTCA 632
DB 1 UCCUUGUUCGUCUCA 17

RESULT 63
US-09-866-108A-10432/c
; Sequence 10432, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10432
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10432

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 837 GAGTTTGTGCTGTCA 853
DB 17 GACTTTGTGCTGTCA 1

RESULT 64
US-09-685-664B-1077/c
; Sequence 1077, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1077
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1077

Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 60;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1747 TGAATAAAAAAAAAA 1763
DB 17 TGAATAAAAAAAAAA 1

RESULT 65
US-09-081-646-558
; Sequence 558, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 558
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-558

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 46;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CATGAACCTGGCCAT 645
|||||
Db 1 CATGAACCTGGCCAT 15

RESULT 66

US-10-352-704-10/c
; Sequence 10, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; Kumarev, Viktor
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation

NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman & Stern
STREET: 400 Seventh St. N.W.
CITY: Washington D.C.
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/352,704
FILING DATE: 28-Jan-2003
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/358,556A
FILING DATE: 14-DEC-1994
APPLICATION NUMBER: FR 9315164
FILING DATE: 16-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELEPHONE: (202) 638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDEA UR

INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
FEATURE:

NAME/KEY: CDS
LOCATION: 1..15
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-10-352-704-10

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
|||||
Db 15 AAAAAAAAAAAAAA 1

RESULT 67

US-10-352-704-16
; Sequence 16, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; Kumarev, Viktor
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation

NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: Jacobson, Price, Holman & Stern
STREET: 400 Seventh St. N.W.
CITY: Washington D.C.
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20004

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/352,704
FILING DATE: 28-Jan-2003
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/358,556A
FILING DATE: 14-DEC-1994
APPLICATION NUMBER: FR 9315164
FILING DATE: 16-DEC-1993
ATTORNEY/AGENT INFORMATION:
NAME: Player, William E.
REGISTRATION NUMBER: 31,409
REFERENCE/DOCKET NUMBER: 10577/P58418
TELEPHONE: (202) 638-6666
TELEFAX: (202) 393-5350
TELEX: RCA 248593 IDEA UR

INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE: N-terminal
FEATURE:

NAME/KEY: CDS
LOCATION: 1..15
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-352-704-16

Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
|||||
Db 1 AAAAAAAAAAAAAA 15

RESULT 68

US-09-685-664B-1073/c
; Sequence 1073, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```

; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1073

Query Match 0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1763
DB 17 AAAAAAAAAAAAAA 3

RESULT 69
US-08-390-850-21
; Sequence 21, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1073:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-1074

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```

```

; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-21

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTTAAAGA 887
DB 1 AAUCCUGAUUUUAAAGA 18

RESULT 70
US-08-390-850-1074
; Sequence 1074, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1074:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-1074

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;

```


STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-21

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAGA 887
DB 1 AAUCCUGAUCUUAAGA 18

RESULT 74
US-08-435-634-1074
Sequence 1074, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1074:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-1074
Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 55.6%; Pred. No. 82;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 869 AATCCTTTTCTTTAAAG 886
DB 1 AAUCCUGAUCUUAAGA 18

RESULT 75
US-08-435-634-1117
Sequence 1117, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/390,850
;; FILING DATE: February 17, 1995
;; APPLICATION NUMBER: 08/354,920
;; FILING DATE: December 13, 1994
;; APPLICATION NUMBER: 08/152,487
;; FILING DATE: No. 5731295ember 12, 1993
;; APPLICATION NUMBER: 07/989,848
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 211/084
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1117:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-634-1117

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 82;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 621 TGTTCCTTCATGAACT 638
Db 1 UGUUGCUCGCAUGACU 18

RESULT 76
US-08-435-634-1129
; Sequence 1129, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; APPLICATION NUMBER: 07/989,848

;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 211/084
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1129:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-634-1129

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 82;
Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 869 AAATCCTTTCTTTAAAG 886
Db 1 AAAUUCUGUCUUAAG 18

RESULT 77
US-09-255-893-36/c
; Sequence 36, Application US/09255893A
; Patent No. 6008344
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP IV EXPRESSION
; FILE REFERENCE: RTS-0055
; CURRENT APPLICATION NUMBER: US/09/255,893A
; CURRENT FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 36
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-255-893-36

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 82;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 577 GCAGAAACGTGGACTAAA 594
Db 18 GCAGAAAGTGGCTAAA 1

RESULT 78
US-09-422-978-5494/c
; Sequence 5494, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density....
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 5494
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-4676 for SEQ 1560,
US-09-422-978-5494

Query Match 0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 82;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 691 CCCACCTACAGATACCTT 708
Db 18 CCCACCTTGATACCTT 1

RESULT 79
US-09-371-772B-6065/c
; Sequence 6065, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6065
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6065

Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1521 ACACACATAGTTACAC 1536
Db 16 ACACACAGTTACAC 1

RESULT 80
US-09-371-772B-6066/c
; Sequence 6066, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6066
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6066

Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1519 ACACACATAGTTAC 1534
Db 16 ACACACACAGTTAC 1

RESULT 81
US-09-479-005A-177/c
; Sequence 177, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MEHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 177
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-177

Query Match 0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1576 TTTTCACCTTCATTCT 1591
Db 16 TTTTCACCTTCATTGT 1

RESULT 82
US-08-390-850-446
; Sequence 446, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 446:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-446

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 79;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTACTTACAGGT 332
Db 1 ACCUACUACAGAU 16
||||:||||:|

RESULT 83
US-08-373-124A-1000/c
Sequence 1000, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/245,466

FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1000:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-1000

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTTTTACAAATTA 1560
Db 17 GCATTACAAATTA 2
||||:||||:|

RESULT 84
US-08-373-124A-2083/c
Sequence 2083, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2083:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2083

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCATTACAAATTA 1560
DB 17 GCATTACAAATTA 2

RESULT 85

US-08-435-634-446
Sequence 446, Application US/08435634
Patent No. 5731295

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995

CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295, September 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 446:
SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-446

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 79;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 317 ACCTCATTACAGGAT 332
DB 1 ACCUACUACAGAU 16

RESULT 86

US-08-435-628-1000/c
Sequence 1000, Application US/08435628
Patent No. 5817796

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995

CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1000:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-1000

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCATTACAAATTA 1560
DB 17 GCATTACAAATTA 2

RESULT 87
US-08-435-628-2083/c
; Sequence 2083, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2083:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-435-628-2083

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCATTACAAATTA 1560
DB 17 GCATTACAAATTA 2

Db 17 GCATTACAAATTA 2

RESULT 88
US-08-584-040-5830
; Sequence 5830, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5830:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5830

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 297 GTCAGATGATGAAG 312
DB 1 GUCAGAUGAUGAAG 16

RESULT 89
US-09-371-7728-2690
; Sequence 2690, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2690

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      297  GTCAAGTGTGATGAG 312
DB      1  GUCAGAGTGAUGAG 16
      |:|||||: |:|||||
      1  GUCAGAGTGAUGAG 16

RESULT 90
US-09-371-772B-5541/c
; Sequence 5541, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5541

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1521 ACACACAGTGTACAC 1536
DB      17 ACACACAGTGTACAC 2
      ||||| ||||| |||||
      17 ACACACAGTGTACAC 2

RESULT 91
US-09-866-108A-10431/c
; Sequence 10431, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10431

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      838  AGTTTGTGATGCTGTCA 853
DB      17  AGTTTGTGATGCTGTCA 2
      | ||||| ||||| |||||
      17  AGTTTGTGATGCTGTCA 2

RESULT 92
US-09-866-108A-10433/c
; Sequence 10433, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10431
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10431

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      838  AGTTTGTGATGCTGTCA 853
DB      17  AGTTTGTGATGCTGTCA 2
      | ||||| ||||| |||||
      17  AGTTTGTGATGCTGTCA 2

RESULT 92
US-09-866-108A-10433/c
; Sequence 10433, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6886188
; SEQ ID NO 10433
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10433

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      837 GAGTTTGTGCTGTC 852
DB      16 GACTTTGTGCTGTC 1

RESULT 93
US-09-685-664B-1078/c
; Sequence 1078, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1078
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1078

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1747 TGAAGAAAAA 1762
DB      16 TGAAGAAAAA 1

RESULT 94
US-09-685-664B-2690
; Sequence 2690, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim

```

```

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2690
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2690

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 79;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY      297 GTCAAGATCGATCAAG 312
DB      1 GUCAGAGUUGAUGAAG 16

RESULT 95
US-09-402-618B-108/c
; Sequence 108, Application US/09402618B
; Patent No. 6709815
; GENERAL INFORMATION:
; APPLICANT: Dong, Fang
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Prudent, James
; APPLICANT: Fors, Lance
; APPLICANT: Neri, Bruce
; APPLICANT: Brow, Mary Ann
; APPLICANT: Anderson, Todd
; APPLICANT: Dahlberg, James
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides
; FILE REFERENCE: FORS-04012
; CURRENT APPLICATION NUMBER: US/09/402,618B
; CURRENT FILING DATE: 2000-07-18
; PRIOR APPLICATION NUMBER: PCT/US98/03194
; PRIOR FILING DATE: 1998-03-05
; NUMBER OF SEQ ID NOS: 128
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 108
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-402-618B-108

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      813 ATCAACTTCTGTCAC 828
DB      16 AACAACTTCTGTCAC 1

RESULT 96
US-09-859-736-7/c
; Sequence 7, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:

```

; APPLICANT: LI, WAN-LIANG ROBERT
 ; APPLICANT: ZHOU, JIAN S.
 ; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
 ; FILE REFERENCE: 16517.248
 ; CURRENT APPLICATION NUMBER: US/09/859,736
 ; CURRENT FILING DATE: 2001-05-18
 ; PRIOR APPLICATION NUMBER: 60/205,452
 ; PRIOR FILING DATE: 2000-05-19
 ; NUMBER OF SEQ ID NOS: 7
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 7
 ; LENGTH: 14
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 ; OTHER INFORMATION: dt oligonucleotide
 US-09-859-736-7

 Query Match 0.8%; Score 14; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 51;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 Qy 1749 AAAAAAAAAAAAAA 1762
 Db 14 AAAAAAAAAAAAAA 1

 RESULT 97
 US-08-527-060-14
 ; Sequence 14, Application US/08527060
 ; Patent No. 5834440
 ; GENERAL INFORMATION:
 ; APPLICANT: Goldenberg, Tsvi
 ; APPLICANT: Tritz, Richard
 ; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
 ; TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
 ; NUMBER OF SEQUENCES: 35
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: SEED AND BERRY
 ; STREET: 6300 Columbia Center, 701 Fifth Avenue
 ; CITY: Seattle
 ; STATE: Washington
 ; COUNTRY: USA
 ; ZIP: 98104-7092
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/527,060
 ; FILING DATE: 12-SEP-1995
 ; CLASSIFICATION: 514
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: McWaters, David D.
 ; REGISTRATION NUMBER: 33,963
 ; REFERENCE/DOCKET NUMBER: 480124.402C1
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (206) 622-4900
 ; TELEFAX: (206) 682-6031
 ; INFORMATION FOR SEQ ID NO: 14:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-08-527-060-14

Query Match 0.8%; Score 14; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 74;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 819 TTTCTGTCCACAAA 832
 Db 1 TTTCTGTCCACAAA 14

 RESULT 98
 US-09-479-005A-441
 ; Sequence 441, Application US/09479005A
 ; Patent No. 6656731
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
 ; FILE REFERENCE: MHB00-884-C
 ; CURRENT APPLICATION NUMBER: US/09/479,005A
 ; CURRENT FILING DATE: 2000-01-07
 ; PRIOR APPLICATION NUMBER: US 09/444,209
 ; PRIOR FILING DATE: 1999-11-19
 ; PRIOR APPLICATION NUMBER: US 09/159,274
 ; PRIOR FILING DATE: 1998-09-22
 ; PRIOR APPLICATION NUMBER: US 60/059,473
 ; PRIOR FILING DATE: 1997-09-22
 ; NUMBER OF SEQ ID NOS: 1208
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 441
 ; LENGTH: 16
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-479-005A-441

Query Match 0.8%; Score 14; DB 1; Length 16;
 Best Local Similarity 57.1%; Pred. No. 74;
 Matches 8; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1706 AATGTAACATGTTT 1719
 Db 1 AUGUACACUGUUU 14

 RESULT 99
 US-09-696-791-4149
 ; Sequence 4149, Application US/09696791
 ; Patent No. 6770633
 ; GENERAL INFORMATION:
 ; APPLICANT: Robbins, Joan M.
 ; APPLICANT: Tritz, Richard
 ; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
 ; TITLE OF INVENTION: SKIN AND EYE DISEASES
 ; FILE REFERENCE: 480124.407
 ; CURRENT APPLICATION NUMBER: US/09/696,791
 ; CURRENT FILING DATE: 2000-10-25
 ; NUMBER OF SEQ ID NOS: 4523
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 4149
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: Hairpin ribozyme recognition site for PCNA
 US-09-696-791-4149

Query Match 0.8%; Score 14; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 74;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 819 TTTCTGTCCACAAA 832
 Db 1 TTTCTGTCCACAAA 14

 RESULT 100
 US-09-696-791-4370
 ; Sequence 4370, Application US/09696791
 ; Patent No. 6770633

```
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 4370
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hammerhead ribozyme recognition site for PCNA
US-09-696-791-4370

Query Match          0.8%; Score 14; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 74;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      819 TTTTCTGTCCACAA 832
Db      1 TTTTCTGTCCACAA 14

RESULT 101
US-09-827-998-823
; Sequence 823, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 823
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-823

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      4 GGAGGTATGATGTG 17

RESULT 102
US-09-827-998-824
; Sequence 824, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 824
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-824

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      3 GGAGGTATGATGTG 16

RESULT 103
US-09-827-998-825
; Sequence 825, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 825
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-825

Query Match          0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1181 GGAGGTATGATGTG 1194
Db      2 GGAGGTATGATGTG 15

RESULT 104
US-09-827-998-826
; Sequence 826, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 826
; LENGTH: 17
```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-826

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 GGAGGTATGATGTG 1194
Db 1 GGAGGTATGATGTG 14

RESULT 105

US-09-866-108A-10429/c
; Sequence 10429, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 10429

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-10429

Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
Db 17 TTTTGATGCTGTCA 4

RESULT 106

US-09-866-108A-10430/c
; Sequence 10430, Application US/09866108A

; Patent No. 6686188

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 10430

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-10430

Query Match 0.8%; Score 14; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 88;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 TTTTGATGCTGTCA 853
Db 16 TTTTGATGCTGTCA 3

RESULT 107

US-09-404-912-219

; Sequence 219, Application US/09404912

; Patent No. 6703228

; GENERAL INFORMATION:

; APPLICANT: John Landers

; APPLICANT: David Houseman

; APPLICANT: Barbara Jordan

; APPLICANT: Alain Charest

; TITLE OF INVENTION: Methods and Products Related to

; FILE REFERENCE: M0656/7045(HCL/MAT)

; CURRENT APPLICATION NUMBER: US/09/404,912

; CURRENT FILING DATE: 1999-09-24

; PRIOR APPLICATION NUMBER: US 60/101,757

; PRIOR FILING DATE: 1998-09-25

; PRIOR APPLICATION NUMBER: PCT/US99/22283

; PRIOR FILING DATE: 1999-09-24

; NUMBER OF SEQ ID NOS: 691

; SOFTWARE: FastSEQ for Windows Version 3.0

; SEQ ID NO 219

; LENGTH: 17

; TYPE: DNA

```
; ORGANISM: Homo Sapiens
US-09-404-912-219

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1483 ATAAATGTAACAGGA 1496
   |||||
Db 4 ATAAATGTAACAGGA 17

RESULT 108
US-09-685-664B-1072/c
; Sequence 1072, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1072
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1072

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1762
   |||||
Db 17 AAAAAAAAAAAAAA 4

RESULT 109
US-08-281-940-29/c
; Sequence 29, Application US/08281940
; Patent No. 5589330
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
; TITLE OF INVENTION: DISEASE ANALYSIS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,940
```

```
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: LUDWIG, S. PETER
; REGISTRATION/DOCKET NUMBER: 25351
; REFERENCE/DOCKET NUMBER: 0372/09696
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212/527-7700
; TELEFAX: 212/753-6237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapien
; IMMEDIATE SOURCE:
; CLONE: Q493XM
US-08-281-940-29

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCATTCCTATCTTAAT 1600
   |||||
Db 17 TTCATTCCTATCTTAAT 1

RESULT 110
US-08-390-850-496
; Sequence 496, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
```


TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 496:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-496

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 623 TTGCTGTTTCATGACTT 639
DB 1 UUGCUGCUCAUGAGCUU 17

RESULT 111
US-08-390-850-497
Sequence 497, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 497:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-497

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 93;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 631 CATGACTTGGCCATTC 647
DB 1 CAUGAGCUUGGCCACUC 17

RESULT 112
US-08-390-850-516
Sequence 516, Application US/08390850
Patent No. 5612215
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 516:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-516

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 750 CATTCAGTCCCTCATG 766
DB 1 CAUCCAAUCCCUCAUG 17

RESULT 113

US-08-390-850-517
; Sequence 517, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: December 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 517:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-517

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 93;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 754 CAGTCCCTCTATGGAC 770
Db 1 CAAUCCUUAUGGACC 17

RESULT 114

US-08-390-850-537
; Sequence 537, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: December 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 537:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-390-850-537

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 870 AATCCTTTCTTTAAAG 886
Db 1 AAUUCUGUUCUUAAAG 17

RESULT 115

US-08-390-850-538
; Sequence 538, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 538:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-538

```

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 871 ATCTTTCTTTTAAAGA 887
DB 1 AUUCUGUUCUUUAAAGA 17

```

```

RESULT 116
US-08-390-850-540
; Sequence 540, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

```

```

; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 540:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-540

```

```

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 874 CTTTCTTTTAAAGACTG 890
DB 1 CUGUUCUUUAAAGACAG 17

```

```

RESULT 117
US-08-390-850-541
; Sequence 541, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

```


APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 496:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-496

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 93;

Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 93;

Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 47.1%; Pred. No. 93;

Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

RESULT 121

US-08-435-634-497

Sequence 497, Application US/08435634

Patent No. 5731295

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/435,634

FILING DATE: 05-MAY-1995

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/390,850

FILING DATE: February 17, 1995

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5731295ember 12, 1993

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 497:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-435-634-497

Query Match

Best Local Similarity 64.7%; Pred. No. 93;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 631 CATGAACCTTGCCCATTC 647

Db 1 CAUGAGCUGGCCACUC 17

RESULT 122

US-08-435-634-516

Sequence 516, Application US/08435634

Patent No. 5731295

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela

APPLICANT: McSwiggen, James

APPLICANT: Gustofson, John

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

```
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 516:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-516
/
/ Query Match 0.8%; Score 13.8; DB 1; Length 17;
/ Best Local Similarity 58.8%; Pred. No. 93;
/ Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 750 CATTGCTCCTCTATG 766
/ DB 1 CAUCCAAUCCUUAUG 17
/
/ RESULT 123
/ US-08-435-634-517
/ Sequence 517, Application US/08435634
/ Patent No. 5731295
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ OF ARTHRITIC CONDITIONS
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 516:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-516
/
/ Query Match 0.8%; Score 13.8; DB 1; Length 17;
/ Best Local Similarity 58.8%; Pred. No. 93;
/ Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 750 CATTGCTCCTCTATG 766
/ DB 1 CAUCCAAUCCUUAUG 17
/
/ RESULT 123
/ US-08-435-634-517
/ Sequence 517, Application US/08435634
/ Patent No. 5731295
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ OF ARTHRITIC CONDITIONS
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 517:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-517
/
/ Query Match 0.8%; Score 13.8; DB 1; Length 17;
/ Best Local Similarity 64.7%; Pred. No. 93;
/ Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 754 CAGTCCTCTATGAGC 770
/ DB 1 CAUCCUUAUGACC 17
/
/ RESULT 124
/ US-08-435-634-537
/ Sequence 537, Application US/08435634
/ Patent No. 5731295
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ OF ARTHRITIC CONDITIONS
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 517:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-517
```

/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 537:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-537

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 870 AATCCTTTTCTTTAAAG 886
||: |:|:|:|:|
Db 1 AAUCUGUUCUUAAG 17

RESULT 125
US-08-435-634-538
/ Sequence 538, Application US/08435634
/ Patent No. 5731295
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 540:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single

/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 538:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-435-634-538

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 93;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 871 ATCCTTTTCTTTAAAGA 887
||: |:|:|:|:|
Db 1 AAUCUGUUCUUAAGA 17

RESULT 126
US-08-435-634-540
/ Sequence 540, Application US/08435634
/ Patent No. 5731295
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/435,634
/ FILING DATE: 05-MAY-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/390,850
/ FILING DATE: February 17, 1995
/ APPLICATION NUMBER: 08/354,920
/ FILING DATE: December 13, 1994
/ APPLICATION NUMBER: 08/152,487
/ FILING DATE: No. 5731295ember 12, 1993
/ APPLICATION NUMBER: 07/989,848
/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 211/084
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 540:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single

TOPOLOGY: linear
US-08-435-634-540

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 874 CTTTCTTTAAAGACTG 890
| : : : : : |||||
Db 1 CUGUUCUUAAAGACAG 17

RESULT 127
US-08-435-634-541
; Sequence 541, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; FILING DATE: 07/989,848
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-541

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 875 TTTTCTTTAAAGACTG 891

Db 1 UGUUCUUAAAGACAG 17
| : : : : : |||||

RESULT 128
US-08-435-634-609
; Sequence 609, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295ember 12, 1993
; FILING DATE: 07/989,848
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-609

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 93;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1179 CTGGAGGTATGATGCA 1195
| : : : : : |||||
Db 1 CUGGAGGUUGAUGAGA 17

RESULT 129
US-08-435-634-694/c
; Sequence 694, Application US/08435634
; Patent No. 5731295

GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Gustafson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 694:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-694

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 896 TCTGTGGAGCTTCT 912
DB 17 TCTGTGGAGCTCCCT 1

RESULT 130
US-08-710-134-29/c
Sequence 29, Application US/08710134
Patent No. 5834181
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road

CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/710,134
FILING DATE: 13-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IGS-8.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotides"
US-08-710-134-29

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCATTCCTTCTTAAT 1600
DB 17 TTCATTCCTTCTTAGT 1

RESULT 131
US-08-485-885-29/c
Sequence 29, Application US/08485885
Patent No. 5849483
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,885
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: GEN4-12.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:

```
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "Oligonucleotides"
US-08-485-885-29

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1584 TTCAATCTATTCTTAAT 1600
Db 17 TTCAATCTATTCTTACT 1

RESULT 132
US-09-077-205-35
; Sequence 35, Application US/09077205
; Patent No. 6190907
; GENERAL INFORMATION:
; APPLICANT: Viromedica Pacific Limited
; APPLICANT: Kim, S.Y
; APPLICANT: Kim, S.H
; APPLICANT: Robbins, P.D.
; TITLE OF INVENTION: IMPROVED RETROVIRAL VECTORS FOR GENE
; TITLE OF INVENTION: THERAPY
; FILE REFERENCE: 0136/0E292
; CURRENT APPLICATION NUMBER: US/09/077,205
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: PCT/KR97/00180
; EARLIER FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: EPC5, single-stranded oligonucleotide
US-09-077-205-35

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 647 CCTGGGGCTGCAGCAT 663
Db 1 CCATGGGGCTGCAGAAAT 17

RESULT 133
US-08-584-040-2292/c
; Sequence 2292, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
```

```
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/584,040
/ FILING DATE: January 11, 1996
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/005,974
/ FILING DATE: October 26, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/064
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 2292:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-584-040-2292

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGCG 233
Db 17 GACAACTCAACTCTGCG 1

RESULT 134
US-08-584-040-6127
; Sequence 6127, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071-2066
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: Word Perfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/584,040
/ FILING DATE: January 11, 1996
/ CLASSIFICATION: 514
```

```
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6127:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-6127

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 29 TACAGGTATCTGCTGT 45
Db 1 UACUGGUUCUGCCUG 17

RESULT 135
US-08-584-040-6128
; Sequence 6128, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 6128:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-6128

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 29 TACAGGTATCTGCTGT 45
Db 1 UACUGGUUCUGCCUG 17

RESULT 136
US-08-584-040-7818/c
; Sequence 7818, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7818:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7818

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAA 1765
```

```
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-6128

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 30 ACAGGTATCTGCTGTG 46
Db 1 ACUGGUUCUGCCUG 17

RESULT 136
US-08-584-040-7818/c
; Sequence 7818, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7818:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7818

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1749 AAAAAAAAAAAAAAAA 1765
```


STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
 CITY: Arlington
 STATE: Virginia
 COUNTRY: US
 ZIP: VA 22201-4714
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25 (BPO)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/402,923A
 FILING DATE: 14-Feb-2001
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/GB98/01102
 FILING DATE: 15-APR-1998
 APPLICATION NUMBER: US 60/043,553
 FILING DATE: 15-APR-1997
 APPLICATION NUMBER: US 60/048,740
 FILING DATE: 05-JUN-1997
 ATTORNEY/AGENT INFORMATION:
 NAME: B.J. Sadoff
 REGISTRATION NUMBER: 36,663
 REFERENCE/DOCKET NUMBER: 620-81
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (703)816-4091
 TELEFAX: (703)816-4100
 INFORMATION FOR SEQ ID NO: 354:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 17 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 SEQUENCE DESCRIPTION: SEQ ID NO: 354:
 US-09-402-923A-354

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 762 CTATGGAGCCCCAGTGA 778
 DB 17 CCATGGAGCCCGAGTGA 1

RESULT 140
 US-09-371-772B-837/c
 ; Sequence 837, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 837
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-837

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 217 GACAACTCAACTCTGGC 233
 DB 17 GACAACTCAACTCTGGC 1
 RESULT 141
 US-09-371-772B-2964
 ; Sequence 2964, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2964
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus sp.
 US-09-371-772B-2964

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 52.9%; Pred. No. 93;
 Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCTGT 45
 DB 1 UACUGGUUCUGCCUGU 17

RESULT 142
 US-09-371-772B-2965
 ; Sequence 2965, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2965
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus sp.
 US-09-371-772B-2965

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 93;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCTCTG 46
 |||:::|:|:|:|:
 Db 1 ACUGGUUCUGCCUG 17

RESULT 143
 US-09-371-772B-3602/c
 ; Sequence 3602, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MBH00,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 3602
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus sp.
 US-09-371-772B-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
 |||:::|:|:|:|:
 Db 17 AACACAAAAACAAAAA 1

RESULT 144
 US-09-371-772B-3603/c
 ; Sequence 3603, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MBH00,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 3603
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus sp.
 US-09-371-772B-3603

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
 |||:::|:|:|:|:
 Db 17 AACACAAAAACAAAAA 1

RESULT 145
 US-09-827-998-423
 ; Sequence 423, Application US/09827998
 ; Patent No. 6656700
 ; GENERAL INFORMATION:
 ; APPLICANT: Gu, Yizhong
 ; APPLICANT: Shannon, Mark
 ; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
 ; FILE REFERENCE: MDHMORE-8
 ; CURRENT APPLICATION NUMBER: US/09/827,998
 ; CURRENT FILING DATE: 2001-04-06
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; NUMBER OF SEQ ID NOS: 1881
 ; SOFTWARE: Aemica Sequence Listing Engine
 ; Patent No. 6656700
 ; SEQ ID NO 423
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-827-998-423

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 39 TGCCTGTGGGTCTC 55
 |||:::|:|:|:|:
 Db 1 TGCCTGTGGGTCTCTC 17

RESULT 146
 US-09-827-998-821
 ; Sequence 821, Application US/09827998
 ; Patent No. 6656700
 ; GENERAL INFORMATION:
 ; APPLICANT: Gu, Yizhong
 ; APPLICANT: Shannon, Mark
 ; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
 ; FILE REFERENCE: MDHMORE-8
 ; CURRENT APPLICATION NUMBER: US/09/827,998
 ; CURRENT FILING DATE: 2001-04-06
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: US 60/236,359
 ; PRIOR FILING DATE: 2000-09-27
 ; NUMBER OF SEQ ID NOS: 1881
 ; SOFTWARE: Aemica Sequence Listing Engine
 ; Patent No. 6656700
 ; SEQ ID NO 821
 ; LENGTH: 17
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 US-09-827-998-821

Query Match 0.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 93;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1176 CTACTGAGGTATGATG 1192
 |||:::|:|:|:|:
 Db 1 CTAGGGGAGGTATGATG 17

RESULT 147

```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-874

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1131 CTTTGACCCACTTCGCC 1147
          |||||
Db       17 CTTTGACCCCTCTCGCC 1

RESULT 149
US-09-866-108A-10428/c
; Sequence 10428, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A6MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10428
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10428

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      841 TTTGATGCTGTCAAC 857
          |||||
Db       17 TTTGATGCTGTCAAC 1

RESULT 150
US-09-866-108A-10434/c
; Sequence 10434, Application US/09866108A
; Patent No. 6686188

```

```
/ GENERAL INFORMATION:
/ APPLICANT: GU, Yizhong
/ APPLICANT: JI, Yonggang
/ APPLICANT: PENN, Sharron G.
/ APPLICANT: HANZEL, David K.
/ APPLICANT: RANK, David R.
/ APPLICANT: CHEN, Wensheng
/ APPLICANT: SHANNON, Mark
/ TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
/ FILE REFERENCE: AEOMICA-7
/ CURRENT APPLICATION NUMBER: US/09/866,108A
/ CURRENT FILING DATE: 2001-05-25
/ PRIOR APPLICATION NUMBER: US 60/207,456
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: GB 24263.6
/ PRIOR FILING DATE: 2000-10-04
/ PRIOR APPLICATION NUMBER: US 60/236,359
/ PRIOR FILING DATE: 2000-09-27
/ PRIOR APPLICATION NUMBER: PCT/US01/00666
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00667
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00664
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00669
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00665
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00668
/ PRIOR FILING DATE: 2001-01-30
/ PRIOR APPLICATION NUMBER: PCT/US01/00663
/ PRIOR FILING DATE: 2001-01-30
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 15755
/ SOFTWARE: Aecomica Sequence Listing Engine
/ Patent No. 6686188
/ SEQ ID NO 10434
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/
/
/ US-09-866-108A-10434

Query Match ( 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 TTGAGTTTTCATGCTCT 851
Db 17 TCGACTTTTCATGCTGT 1

RESULT 151
US-09-685-664B-837/c
/ Sequence 837, Application US/09685664B
/ Patent No. 6818447
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
/ FILE REFERENCE: MBH00-876-K (400/021)
/ CURRENT APPLICATION NUMBER: US/09/685,664B
/ CURRENT FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ PRIOR APPLICATION NUMBER: US 09/371,772
/ PRIOR FILING DATE: 1999-08-10
/ NUMBER OF SEQ ID NOS: 8231
/
```

```
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 837
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
/
/ US-09-685-664B-837

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 217 GACAACTCAACTCTGGC 233
Db 17 GACAACTCAACTCTGGC 1

RESULT 152
US-09-685-664B-2964
/ Sequence 2964, Application US/09685664B
/ Patent No. 6818447
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
/ FILE REFERENCE: MBH00-876-K (400/021)
/ CURRENT APPLICATION NUMBER: US/09/685,664B
/ CURRENT FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ PRIOR APPLICATION NUMBER: US 09/371,772
/ PRIOR FILING DATE: 1999-08-10
/ NUMBER OF SEQ ID NOS: 8231
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 2964
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Mus musculus
/
/ US-09-685-664B-2964

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 93;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 29 TACAGGTATCTGCCTGT 45
Db 1 UACUGGUUCUGCCUGU 17

RESULT 153
US-09-685-664B-2965
/ Sequence 2965, Application US/09685664B
/ Patent No. 6818447
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
/ FILE REFERENCE: MBH00-876-K (400/021)
/ CURRENT APPLICATION NUMBER: US/09/685,664B
/ CURRENT FILING DATE: 2000-10-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1999-08-10
/ NUMBER OF SEQ ID NOS: 8231
/
```


; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2965
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2965

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 93;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 30 ACAGGTATCTGCTGTG 46
|||:|:|:|:|:
DB 1 ACUGGUUCUGCCUGUG 17

RESULT 154

US-09-685-664B-3602/c
; Sequence 3602, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3602

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
|||:|:|:|:|:
DB 17 AAAAAAAAAAAAAA 1

RESULT 155

US-09-685-664B-3603/c
; Sequence 3603, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3603

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1749 AAAAAAAAAAAAAA 1765
|||:|:|:|:|:
DB 17 AAAAAAAAAAAAAA 1

RESULT 156

US-08-292-620A-41
; Sequence 41, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:

two


```

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; APPLICATION NUMBER: 08/585,684
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1740:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-1740

Query Match 0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 73;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1483 ATAATGTAACAGGAA 1497
Db 1 AGAAGUACAGGAA 15

RESULT 160
US-08-753-147-134
; Sequence 134, Application US/08/753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:
; CLASSIFICATION: 435

```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: VMRC-1-9714
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 743-4387
; TELEFAX: (206) 224 0779
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; US-08-753-147-134

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1562 CTCCTTTAGGAAGTT 1576
Db 2 CTCCTTTAGGAAGTT 16

RESULT 161
US-09-371-772B-6067/c
; Sequence 6067, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Receptor
; FILE REFERENCE: MEH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6067
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6067

Query Match 0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1518 CACACACACATAGTT 1532
Db 15 CACACACACATAGTT 1

RESULT 162
US-08-291-932A-93
; Sequence 93, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James

```

;; TITLE OF INVENTION: RIBOZYME TREATMENT OF
;; TITLE OF INVENTION: DISEASES OR CONDITIONS
;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: NF-KB
;; NUMBER OF SEQUENCES: 830
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: Storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/291,932A
;; FILING DATE: August 15, 1994
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION DATA: including application
;; PRIOR APPLICATION DATA: described below:
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/157
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 93:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-291-932A-93

Query Match 0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 69.2%; Pred. No. 82;
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 809 CACCATCAACTTT 821
Db 2 CACCAUACUUU 14
|||||:|||||

RESULT 163
US-08-864-224-2/c
; Sequence 2, Application US/08864224
; Patent No. 5851808
; GENERAL INFORMATION:
; APPLICANT: Elledge, Stephen J.
; APPLICANT: Liu, Qinghua
; TITLE OF INVENTION: Rapid Subcloning Using Site-Specific
; TITLE OF INVENTION: Recombination
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medien & Carroll, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94104
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/864,224
;; FILING DATE:
;; CLASSIFICATION: 435
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Ingolia, Diane E.
;; REGISTRATION NUMBER: 40,027
;; REFERENCE/DOCKET NUMBER: BCM-02681
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (415) 705-8410
;; TELEFAX: (415) 397-8338
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: double
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "DNA"
;; US-08-864-224-2

Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1778 GAATTCCTCCGGGA 1790
Db 16 GAATTCCTCCGGGA 4
|||||:|||||

RESULT 164
US-09-122-384-2/c
; Sequence 2, Application US/09122384A
; Patent No. 6828093
; GENERAL INFORMATION:
; APPLICANT: Elledge, Stephen J.
; APPLICANT: Liu, Qinghua
; TITLE OF INVENTION: Improved Rapid Subcloning Using Site-Specific
; TITLE OF INVENTION: Recombination
; FILE REFERENCE: 120541-1005
; CURRENT APPLICATION NUMBER: US/09/122,384A
; CURRENT FILING DATE: 1998-07-24
; EARLIER APPLICATION NUMBER: 08/864,224
; EARLIER FILING DATE: 1997-02-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
;; US-09-122-384-2

Query Match 0.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1778 GAATTCCTCCGGGA 1790
Db 16 GAATTCCTCCGGGA 4
|||||:|||||

RESULT 165
US-09-396-196G-125371/c
; Sequence 125371, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann


```
/ FILING DATE: 27-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Sibley, Kenneth D.
/ REGISTRATION NUMBER: 31,665
/ REFERENCE/DOCKET NUMBER: 5470-107B
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 919-854-1400
/ TELEFAX: 919-854-1401
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ HYPOTHETICAL: YES
/ ANTI-SENSE: NO
/ US-08-667-338B-5

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1426 TTTTATAAGTATATTT 1441
Db 16 TTTTATACCTATATTT 1

RESULT 169
US-09-179-665-5/c
/ Sequence 5, Application US/09179665
/ Patent No. 6132971
/ GENERAL INFORMATION:
/ APPLICANT: Thorpe, H. H.
/ APPLICANT: Johnston, Dean H.
/ APPLICANT: Napier, Mary E.
/ APPLICANT: Loomis, Carson R.
/ APPLICANT: Sistare, Mark F.
/ APPLICANT: Kim, Jinheung
/ TITLE OF INVENTION: Electrochemical Detection of Nucleic
/ TITLE OF INVENTION: Acid Hybridization
/ NUMBER OF SEQUENCES: 11
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Kenneth D. Sibley
/ STREET: PO Box 37428
/ CITY: Raleigh
/ STATE: NC
/ COUNTRY: US
/ ZIP: 27627
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/179,665
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/667,338
/ FILING DATE: 20-JUN-1996
/ APPLICATION NUMBER: US 60/016,625
/ FILING DATE: 19-APR-1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 60/060,949
/ FILING DATE: 27-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Sibley, Kenneth D.
/ REGISTRATION NUMBER: 31,665
/ REFERENCE/DOCKET NUMBER: 5470-107B
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 919-854-1400
/ TELEFAX: 919-854-1401
```

```
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ HYPOTHETICAL: YES
/ ANTI-SENSE: NO
/ US-09-179-665-5

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1426 TTTTATAAGTATATTT 1441
Db 16 TTTTATACCTATATTT 1

RESULT 170
US-09-371-772B-7106
/ Sequence 7106, Application US/09371772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: MCSwigen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
/ FILE REFERENCE: MBHB00.876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ CURRENT FILING DATE: 1999-08-10
/ PRIOR APPLICATION NUMBER: US 60/005,974
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1996-01-08
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 7106
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
/ US-09-371-772B-7106

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 296 GGTCAGATGGATGAA 311
Db 1 GGUAAGAUGAUGAA 16

RESULT 171
US-09-479-005A-185
/ Sequence 185, Application US/09479005A
/ Patent No. 6656731
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
/ FILE REFERENCE: MBHB00-884-C
/ CURRENT APPLICATION NUMBER: US/09/479,005A
/ CURRENT FILING DATE: 2000-01-07
/ PRIOR APPLICATION NUMBER: US 09/444,209
/ PRIOR FILING DATE: 1999-11-19
/ PRIOR APPLICATION NUMBER: US 09/159,274
/ PRIOR FILING DATE: 1998-09-22
/ PRIOR APPLICATION NUMBER: US 60/059,473
/ PRIOR FILING DATE: 1997-09-22
/ NUMBER OF SEQ ID NOS: 1208
```

```

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 185
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-185

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1761 AAAAAAAAAAAAAAC 1776
Db 1 AAAAAAAAAAAAAAC 16

RESULT 172
US-09-931-381A-7
; Sequence 7, Application US/09931381A
; Patent No. 6692922
; GENERAL INFORMATION:
; APPLICANT: Butcher, Eugene C.
; APPLICANT: Kunkel, Eric J.
; APPLICANT: Pan, Junliang
; APPLICANT: Soler-Ferran, Dulce
; TITLE OF INVENTION: Method for Identifying Agents Which
; TITLE OF INVENTION: Modulate Chemokine "Mec"-Induced Functions of CCR3 and/or
; TITLE OF INVENTION: CCR10
; FILE REFERENCE: 1855.2010-003
; CURRENT APPLICATION NUMBER: US/09/931,381A
; CURRENT FILING DATE: 2001-08-15
; PRIOR APPLICATION NUMBER: U.S. 09/638,914
; PRIOR FILING DATE: 2000-08-15
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: intron
; LOCATION: (1)...(8)
; NAME/KEY: exon
; LOCATION: (9)...(16)
; OTHER INFORMATION: 16
US-09-931-381A-7

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1650 TCTAACACCTTCAAG 1665
Db 1 TCTAACACCTTCAAG 16

Search completed: May 13, 2005, 12:22:21
Job time : 3 secs

```

THIS PAGE BLANK (USPTO)